<SEC-DOCUMENT>0001493152-19-003143.txt : 20190312
<SEC-HEADER>0001493152-19-003143.hdr.sgml : 20190312
<ACCEPTANCE-DATETIME>20190312092637
ACCESSION NUMBER:		0001493152-19-003143
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		98
CONFORMED PERIOD OF REPORT:	20181231
FILED AS OF DATE:		20190312
DATE AS OF CHANGE:		20190312

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Corbus Pharmaceuticals Holdings, Inc.
		CENTRAL INDEX KEY:			0001595097
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				464348039
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37348
		FILM NUMBER:		19674125

	BUSINESS ADDRESS:	
		STREET 1:		100 RIVER RIDGE DRIVE
		CITY:			NORWOOD
		STATE:			MA
		ZIP:			02062
		BUSINESS PHONE:		617-963-0103

	MAIL ADDRESS:	
		STREET 1:		100 RIVER RIDGE DRIVE
		CITY:			NORWOOD
		STATE:			MA
		ZIP:			02062

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SAV Acquisition Corp
		DATE OF NAME CHANGE:	20131220
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>form10-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>WASHINGTON,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[X]</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE FISCAL YEAR ENDED DECEMBER 31, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>[&nbsp;&nbsp;]</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TRANSITION
    REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE TRANSITION PERIOD FROM ________ TO ________.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMISSION
FILE NUMBER: 001-37348</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Exact
name of registrant as specified in its charter)</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-4348039</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(State
                                         or other jurisdiction of</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>incorporation
        or organization)</B></FONT></P></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(I.R.S.
                                         Employer</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Identification
        No.)</B></FONT></P></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>500
                                         River Ridge Drive</B></FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Norwood,
        Massachusetts</B></FONT></P></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>02062</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Address
    of principal executive offices)</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(Zip
    Code)</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(617)
963-0100</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Registrant&rsquo;s
telephone number, including area code:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(b) of the Act:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Title
    of each class</U></B></FONT></TD>
    <TD STYLE="width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Common
    Stock, par value $0.0001 per share</B></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NASDAQ
    Global Market</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<!-- Field: Rule-Page --><DIV ALIGN="CENTER" STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; width: 25%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Securities
registered pursuant to Section 12(g) of the Act: None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes [&nbsp;&nbsp;]
No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes [&nbsp;&nbsp;]
No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports),
and (2) has been subject to such filing requirements for the past 90 days. Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant
to Rule 405 of Regulation S-T (&sect;232.405 of this chapter) during the preceding 12 months (or for such shorter period that
the registrant was required to submit such files). Yes [X] No [&nbsp;&nbsp;]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K is not contained herein, and will not
be contained, to the best of the registrant&rsquo;s knowledge, in definitive proxy or information statements incorporated by reference
in Part III of this Form 10-K or any amendment to this Form 10-K. [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting
company, or an emerging growth company. See the definitions of &ldquo;large accelerated filer,&rdquo; &ldquo;accelerated filer,&rdquo;
&ldquo;smaller reporting company,&rdquo; and &ldquo;emerging growth company&rdquo; in Rule 12b-2 of the Exchange Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 30%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Large
    accelerated filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="width: 40%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 30%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accelerated
    filer [X]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Non-accelerated
    filer [&nbsp;&nbsp;]</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Smaller
    reporting company [X]</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
    growth company [X]</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.25in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for
complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes [&nbsp;&nbsp;] No [X]</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of June 30, 2018, the last business day of the registrant&rsquo;s most recently completed second fiscal quarter, the aggregate
market value of the common stock held by non-affiliates of the registrant was approximately $271,269,436, based on the closing
price of the registrant&rsquo;s common stock on June 30, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 6, 2019, the number of shares outstanding of the registrant&rsquo;s common stock, $0.0001 par value per share, was 64,395,221.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Documents
incorporated by reference</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Portions
of the registrant&rsquo;s proxy statement for the 2019 annual meeting of stockholders to be filed pursuant to Regulation 14A within
120 days after the registrant&rsquo;s fiscal year ended December 31, 2018, are incorporated by reference in Part III of this Form
10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Rule-Page --><DIV ALIGN="LEFT" STYLE="font-family: Times New Roman, Times, Serif"><DIV STYLE="font: 1pt Times New Roman, Times, Serif; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid; width: 100%"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ANNUAL
REPORT ON FORM 10-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FOR
THE YEAR ENDED DECEMBER 31, 2018</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TABLE
OF CONTENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ITEM</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    </B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_001"><FONT STYLE="font-size: 10pt"><B>PART
    I</B></FONT></A></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center; vertical-align: bottom"></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_002"><FONT STYLE="font-size: 10pt">Business</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_003"><FONT STYLE="font-size: 10pt">Risk
    Factors</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">36</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_004"><FONT STYLE="font-size: 10pt">Unresolved
    Staff Comments</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_005"><FONT STYLE="font-size: 10pt">Properties</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">64</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_006"><FONT STYLE="font-size: 10pt">Legal
    Proceedings</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_007"><FONT STYLE="font-size: 10pt">Mine
    Safety Disclosures</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">65</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_008"><FONT STYLE="font-size: 10pt"><B>PART
    II</B></FONT></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_009"><FONT STYLE="font-size: 10pt">Market
    for Registrant&rsquo;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">66</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_010"><FONT STYLE="font-size: 10pt">Selected
    Financial Data</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_011"><FONT STYLE="font-size: 10pt">Management&rsquo;s
    Discussion and Analysis of Financial Condition and Results of Operations</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">67</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_012"><FONT STYLE="font-size: 10pt">Quantitative
    and Qualitative Disclosures About Market Risk</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_013"><FONT STYLE="font-size: 10pt">Financial
    Statements and Supplementary Data</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_014"><FONT STYLE="font-size: 10pt">Changes
    in and Disagreements with Accountants on Accounting and Financial Disclosure</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9A.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_015"><FONT STYLE="font-size: 10pt">Controls
    and Procedures</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">79</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9B.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_016"><FONT STYLE="font-size: 10pt">Other
    Information</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">80</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_017"><FONT STYLE="font-size: 10pt"><B>PART
    III</B></FONT></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_018"><FONT STYLE="font-size: 10pt">Directors,
    Executive Officers and Corporate Governance</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_019"><FONT STYLE="font-size: 10pt">Executive
    Compensation</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_020"><FONT STYLE="font-size: 10pt">Security
    Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_021"><FONT STYLE="font-size: 10pt">Certain
    Relationships and Related Transactions, and Director Independence</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_022"><FONT STYLE="font-size: 10pt">Principal
    Accounting Fees and Services</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">81</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_023"><FONT STYLE="font-size: 10pt"><B>PART
    IV</B></FONT></A></FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_024"><FONT STYLE="font-size: 10pt">Exhibits,
    Financial Statement Schedules</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">82</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="white-space: nowrap; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">16.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_025"><FONT STYLE="font-size: 10pt">Form
    10-K Summary</FONT></A></FONT></TD>
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">85</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_001"></A><FONT STYLE="font-size: 10pt"><B>PART
I</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SPECIAL
NOTE REGARDING FORWARD-LOOKING STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report on Form 10-K contains forward-looking statements made pursuant to the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995 under Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange
Act of 1934, as amended. Forward-looking statements include statements with respect to our beliefs, plans, objectives, goals,
expectations, anticipations, assumptions, estimates, intentions and future performance, and involve known and unknown risks, uncertainties
and other factors, which may be beyond our control, and which may cause our actual results, performance or achievements to be
materially different from future results, performance or achievements expressed or implied by such forward-looking statements.
All statements other than statements of historical fact are statements that could be forward-looking statements. You can identify
these forward-looking statements through our use of words such as &ldquo;may,&rdquo; &ldquo;can,&rdquo; &ldquo;anticipate,&rdquo;
&ldquo;assume,&rdquo; &ldquo;should,&rdquo; &ldquo;indicate,&rdquo; &ldquo;would,&rdquo; &ldquo;believe,&rdquo; &ldquo;contemplate,&rdquo;
&ldquo;expect,&rdquo; &ldquo;seek,&rdquo; &ldquo;estimate,&rdquo; &ldquo;continue,&rdquo; &ldquo;plan,&rdquo; &ldquo;point to,&rdquo;
&ldquo;project,&rdquo; &ldquo;predict,&rdquo; &ldquo;could,&rdquo; &ldquo;intend,&rdquo; &ldquo;target,&rdquo; &ldquo;potential&rdquo;
and other similar words and expressions of the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are a number of important factors that could cause the actual results to differ materially from those expressed in any forward-looking
statement made by us. These factors include, but are not limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    lack of operating history and history of operating losses;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    current and future capital requirements and our ability to satisfy our capital needs;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to complete required clinical trials of our product and obtain approval from the FDA or other regulatory agents in
    different jurisdictions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to maintain or protect the validity of our patents and other intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to retain key executive members;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to internally develop new inventions and intellectual property;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
    </FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">interpretations
    of current laws and the passages of future laws;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">acceptance
    of our business model by investors;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">the
    accuracy of our estimates regarding expenses and capital requirements; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">our
    ability to adequately support growth.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 30.95pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
foregoing does not represent an exhaustive list of matters that may be covered by the forward-looking statements contained herein
or risk factors that we are faced with that may cause our actual results to differ from those anticipate in our forward-looking
statements. Please see &ldquo;Risk Factors&rdquo; for additional risks which could adversely impact our business and financial
performance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
forward-looking statements are expressly qualified in their entirety by this cautionary notice. You are cautioned not to place
undue reliance on any forward-looking statements, which speak only as of the date of this report or the date of the document incorporated
by reference into this report. We have no obligation, and expressly disclaim any obligation, to update, revise or correct any
of the forward-looking statements, whether as a result of new information, future events or otherwise. We have expressed our expectations,
beliefs and projections in good faith and we believe they have a reasonable basis. However, we cannot assure you that our expectations,
beliefs or projections will result or be achieved or accomplished.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 3; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_002"></A><FONT STYLE="font-size: 10pt"><B>Item
1. BUSINESS</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
references in this report to &ldquo;Corbus,&rdquo; the &ldquo;Company,&rdquo; &ldquo;we,&rdquo; &ldquo;us,&rdquo; or &ldquo;our&rdquo;
mean Corbus Pharmaceuticals Holdings, Inc. and its subsidiaries unless we state otherwise or the context otherwise indicates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Phase 3, clinical-stage pharmaceutical company focused on the development and commercialization of novel therapeutics to
treat chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs by targeting the human endocannabinoid
system (ECS). We are developing a pipeline of cannabinoid drug candidates which are rationally designed, synthetic, small molecule
drugs which target the ECS to treat inflammatory and fibrotic diseases. Our focus on the ECS is backed by an ever-expanding body
of knowledge on the biology of the ECS and its role as being a master regulator of inflammation and fibrosis. Our lead investigational
drug candidate, lenabasum, is a novel, synthetic, oral, cannabinoid (CB2 agonist) designed to resolve chronic inflammation and
halt fibrotic processes. We are currently developing lenabasum to treat four serious and rare chronic inflammatory diseases: systemic
sclerosis (SSc), dermatomyositis (DM), cystic fibrosis (CF) and systemic lupus erythematosus (SLE). In addition, we are developing
a pipeline of experimental drug candidates from our library of more than 600 novel cannabinoids targeting the ECS. Our pipeline
also includes CRB-4001, a 2nd generation, peripherally-restricted, CB1 inverse agonist designed to treat organ specific fibrotic
liver diseases, such as nonalcoholic steatohepatitis (NASH). We expect to initiate a Phase 1 study for CRB-4001 by the end of
2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
selectively binds to CB2 in the periphery, which is preferentially expressed on activated immune cells, fibroblasts and other
cell types, including muscle and bone cells. Lenabasum stimulates the production of Specialized Pro-Resolving Lipid Mediators
(SPMs) that act to resolve inflammation and halt fibrosis without immunosuppression by activating endogenous pathways. These pathways
are activated in healthy individuals during the course of normal immune responses but are dysfunctional in patients with chronic
inflammatory and fibrotic diseases. By its binding to CB2, lenabasum drives innate immune responses from the activation phase
into the resolution phase. CB2 plays a central role in modulating and resolving inflammation by, in effect, turning heightened
inflammation &ldquo;off&rdquo; and restoring homeostasis. This has been demonstrated in animal models lacking CB2 as well as humans
with genetic polymorphism in the CB2 gene, as these exhibit excessive inflammation and fibrosis in response to activators of the
innate immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is currently being evaluated in a Phase 3 SSc study, expected to enroll 354 patients and be completed in 2020, a Phase 2b CF study
expected to enroll 415 patients and be completed in 2020, and a Phase 3 study in DM that commenced in December 2018 and is expected
to enroll 150 patients. In addition, we are conducting a Phase 2 SLE study funded by a grant through the National Institutes of
Health (NIH) which is expected to enroll 100 patients. Open-label extension studies are ongoing in SSc and DM following the completion
of the Phase 2 studies in these indications. Lenabasum has generated positive clinical data in three consecutive Phase 2 studies
in diffuse cutaneous SSc, CF and skin-predominant DM. Lenabasum has demonstrated acceptable safety and tolerability profiles in
clinical studies to date.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration, or the FDA, has granted lenabasum Orphan Drug Designation as well as Fast Track Status for
SSc and CF, and Orphan Drug Designation for DM. The European Medicines Authority, or the EMA, has granted lenabasum Orphan Designation
for SSc, CF and DM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Developments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, we entered into a collaboration and license agreement with Kaken Pharmaceutical Co., Ltd. (Kaken), pursuant to
which we granted Kaken an exclusive license to commercialize lenabasum in Japan for the treatment of SSc and DM. In consideration
for the license, we will receive a $27 million upfront payment and have the potential to receive approximately $173 million in
additional milestone payments. In addition, Kaken is obligated to pay us double digit royalties upon the sale of
lenabasum in Japan for SSc and DM. As a result of the $27 million upfront payment, we will owe a $2.7 million royalty (which
is 10% of such payment) to CFF pursuant to the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2018, we licensed the exclusive worldwide rights to develop, manufacture and market drug candidates from more than
600 compounds targeting the ECS from Jenrin Discovery LLC. In consideration for the license rights, Jenrin was paid $250,000 upfront
and is entitled to receive potential milestone payments totaling up to $18,400,000 for each compound Corbus elects to develop
based upon the achievement of specified development and regulatory milestones. In addition, Corbus is obligated to pay Jenrin
royalty rates in the mid, single digits based on net sales of the licensed compounds.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have devoted substantially all of our efforts to business planning, research and development, recruiting management
and technical staff, acquiring operating assets, licensing lenabasum to marketing partners and raising capital. Our research and
development activities have included conducting pre-clinical studies, developing manufacturing methods, and the manufacturing
of our drug lenabasum for clinical trials and conducting clinical studies in patients. Two of the four clinical programs for lenabasum
are being supported by non-dilutive awards and grants. The NIH funded the majority of the clinical development costs for the DM
Phase 2 clinical trial and is funding the SLE Phase 2 clinical trials. In cystic fibrosis, the Phase 2b clinical trial is being
funded in part by a development award for up to $25 million from the Cystic Fibrosis Foundation, while the previously completed
Phase 2 clinical trial in CF was partially funded by a $5 million award from the Cystic Fibrosis Foundation Therapeutics, Inc.,
a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
development status of Corbus pipeline is summarized below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
1-: Clinical development pipeline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><IMG SRC="figure_001.jpg" ALT="" STYLE="height: 290; width: 650"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt"><B></B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Development-Lenabasum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Sclerosis (SSc)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ongoing
Phase 3 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017, we initiated a Phase 3 double-blind placebo-controlled multi-center international clinical study (&ldquo;RESOLVE-1)
in diffuse cutaneous SSc which is expected to be completed in 2020. The RESOLVE-1 is a multi-national study expected to enroll
approximately 354 subjects. The planned duration of treatment with study drug is 52 weeks. Subjects will be randomized 1:1:1 to
receive lenabasum 5 mg twice per day, lenabasum 20 mg twice per day or placebo twice per day.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary efficacy outcome of the RESOLVE-1 study will be change from baseline in modified Rodnan Skin Score (&ldquo;mRSS&rdquo;),
a measure of skin fibrosis and a standard clinical trial outcome in SSc. Secondary outcomes of the RESOLVE-1 study include patient
reported outcome of Health Assessment Questionnaire-Disability Index, the American College of Rheumatology Combined Response Index
in diffuse cutaneous Systemic Sclerosis (&ldquo;ACR CRISS&rdquo;) score, a novel composite measure of clinical improvement from
baseline that incorporates change from baseline in mRSS, and lung function and forced vital capacity, % predicted. These same
outcomes were evaluated in the Phase 2 study and are also outcomes for the ongoing open-label extension study.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Encouraging
Data from Ongoing Open-Label Extension Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thirty-six
subjects with diffuse cutaneous SSc received open-label dosing with lenabasum at 20 mg twice per day following 16 weeks participation
in the preceding double-blinded placebo-controlled part of the lenabasum Phase 2 study. Patients had a mean of about 20 weeks
off treatment from the end of lenabasum dosing during the placebo-controlled period before starting open-label dosing. Lenabasum
was administered in addition to standard-of-care treatments for SSc, including concomitant immunosuppressive drugs in 92% of subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Efficacy
Outcomes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
modified Rodnan Skin Score (mRSS), the primary outcome for the Phase 3 study of lenabasum in SSc, improved by a mean (SD) of -10.7
in the 29 subjects who had completed 76 weeks open-label dosing at the time of data analyses, compared to baseline at the start
of the Phase 2 double-blind placebo-controlled portion of the study. 87% of the subjects who received open-label dosing with lenabasum
achieved a degree of improvement in mRSS (reduction &ge; 5 points) at eighteen months that has been previously associated with
improved survival in SSc and 47% of subjects reached a mRSS &le; 10 points.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
ACR CRISS score steadily increased steadily over time with lenabasum open-label dosing and reached a median of 99% at 76 weeks,
with 50% of subjects achieving an ACR CRISS score of 100%. Patient-reported disability, function, skin symptoms and global assessment
of health all improved from study start and start of open-label dosing. Forced vital capacity (FVC) % predicted was stable during
lenabasum treatment through month nine and a small decrease in mean FVC% predicted was seen after month nine in contrast to the
natural history of a decline in FVC in the disease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 7; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
2 and 3: mRSS Results from Phase 2 Study-Primary Outcome Measure for Phase 3 RESOLVE -1 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
are shown for subjects who received lenabasum during double-blinded placebo-controlled dosing (N= 29) and during open-label dosing
(N = 36 at the start of open-label dosing). Data are change from the study start at the beginning of the double-blinded placebo-controlled
dosing period through week 76 of the open-lapel extension study</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_002.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_003.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 8; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4 &amp; 5: ACR CRISS Results from Phase 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_004.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_005.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>


<!-- Field: Page; Sequence: 9; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Safety</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
have been no severe or serious adverse events (AEs) and no clinically significant laboratory abnormalities related to lenabasum
in the Phase 2 study, and the safety and tolerability profile of lenabasum remains favorable after 18 months of dosing in the
open label extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
Data from Double-blinded, Placebo-Controlled Part of Phase 2 Systemic Sclerosis Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2016, the Company reported positive results from the double-blind, randomized placebo-controlled portion of the Phase
2 study in diffuse cutaneous SSc. This part of the multi-center Phase 2 study evaluated lenabasum&rsquo;s clinical benefit and
safety in 27 subjects who received lenabasum and 15 who received placebo. Subjects had disease duration up to 6 years and were
allowed to receive stable doses of immunosuppressive drugs during this study. Subjects were randomized in a 2 to 1 overall lenabasum
to placebo ratio. Subjects randomized to lenabasum received 5 mg once a day (n = 9), 20 mg once a day (n = 9), or 20 mg twice
a day (n = 9) for the first four weeks, then all lenabasum subjects received 20 mg twice a day for the next 8 weeks. Subjects
randomized to placebo received placebo twice a day for 12 weeks. All subjects were followed off study drug from weeks 13 through
16.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
primary efficacy objective was to evaluate clinical benefit in all subjects who received lenabasum versus subjects who received
placebo using the ACR CRISS score. Lenabasum out-performed placebo in the ACR CRISS reaching 33% at week 16 (p = 0.044, 1-sided
mixed model repeated measures using rank transformed data) versus 1% for placebo. Lenabasum also outperformed placebo in the mRSS,
the primary outcome for the Phase 3 study, with a mean improvement (reduction) of 4.8 points in mRSS at sixteen weeks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
4-mRSS Primary Endpoint in Phase 3 RESOLVE-1 Improved from Baseline</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_006.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-right: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 10; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cystic
Fibrosis (CF)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ongoing
Phase 2B Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2018, the Company initiated a Phase 2b study in CF which is being funded in part by a development award for up to $25
million from the Cystic Fibrosis Foundation (CFF) and is expected to be completed in 2020. The Phase 2b multicenter, double-blinded,
randomized, placebo-controlled study is expected to enroll CF subjects who are at least 12 years of age and at increased risk
for pulmonary exacerbations. The primary outcome is the event rate of pulmonary exacerbations which is the average number of pulmonary
exacerbations per subject per time period. Secondary efficacy outcomes include other measures of pulmonary exacerbations, change
in Cystic Fibrosis Questionnaire-Revised Respiratory domain score and change in forced expiratory volume in 1 second (FEV1), %
predicted. The study is a multi-center international study expected to enroll 415 patients. Subjects will be centrally randomized
to one of three cohorts to receive lenabasum 20 mg twice per day, lenabasum 5 mg twice per day, or placebo twice per day for 28
weeks, with 4 weeks follow-up off active treatment. This Phase 2b CF study was designed with input from the Therapeutic Development
Network of the Cystic Fibrosis Foundation and the European Cystic Fibrosis Society Clinical Trials Network.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
Data from Phase 2 Cystic Fibrosis Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
March 2017, the Company completed a double-blind placebo-controlled Phase 2 study in CF and reported positive results. The Phase
2 study evaluated multiple doses of lenabasum compared to placebo for the treatment of patients with CF. The 16-week study dosed
85 adult CF patients with baseline (FEV1) percent predicted &ge; 40%, who were enrolled without regard to their specific CFTR
mutation or infecting pathogens and continued with all baseline treatment regimens.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
successfully achieved the primary objective of the study by demonstrating an acceptable safety and tolerability profile at all
doses with no serious or severe adverse events related to the study drug. Lenabasum cohorts showed a dose-dependent reduction
in a number of acute pulmonary exacerbations defined as those requiring intravenous (IV) antibiotics compared to placebo. Additionally,
lenabasum caused a consistent reduction in multiple inflammatory cell types in sputum, including total leukocytes, neutrophils,
eosinophils, and macrophages. Inflammatory mediators, including interleukin-8, neutrophil elastase, and immunoglobulin G, were
also reduced in sputum by lenabasum in a dose-dependent manner. These patient data provide evidence of biological activity of
lenabasum in resolving ongoing innate immune responses in lungs of CF patients and support the observed reduction in pulmonary
exacerbations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 11; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
5-Lenabasum Reduced Pulmonary Exacerbations in Completed Phase 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_007.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_008.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; text-indent: 0.5in"></P>


<!-- Field: Page; Sequence: 12; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
6-Lenabasum Reduced Inflammation in the Sputum in Completed Phase 2 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_009.jpg" ALT="" STYLE="height: 287; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Cystic Fibrosis Foundation Therapeutics, Inc. (&ldquo;CFFT&rdquo;), the non-profit drug discovery and development affiliate of
the Cystic Fibrosis Foundation supported the prior Phase 2 study with a $5 million development award. To date, the Company has
received two development awards with total potential payments of up to $30 million from the CFF to support the clinical development
of lenabasum in CF.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dermatomyositis
(DM)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Ongoing
Phase 3 Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2018, we initiated a Phase 3 double-blind placebo-controlled multi-center international clinical study titled <B>D</B>ETER<B>M</B>INE
in DM. The <B>D</B>ETER<B>M</B>INE study is a multi-center international trial expected to enroll approximately 150 subjects.
The planned duration of treatment with study drug is 52 weeks. Subjects will be randomized to receive lenabasum 20 mg twice per
day, lenabasum 5 mg twice per day, or placebo twice per day in a 2:1:2 ratio. The primary efficacy outcome at Week 52 will be
American College of Rheumatology/European League Against Rheumatism 2016 Total Improvement Score (TIS), which is a weighted composite
measure of improvement from baseline in six endpoints, including Physician Global Assessment of Disease Activity, Physician Global
Assessment of Extramuscular Disease Activity, Patient Global Assessment of Disease Activity, Health Assessment Questionnaire (patient-reported
disability), Manual Muscle Testing, and muscle enzymes. Evaluation of key organ involvement &ndash; muscle, skin, and lungs, will
be included in secondary efficacy outcomes. Change from Baseline in the Cutaneous Dermatomyositis Activity and Severity index
(&ldquo;CDASI&rdquo;) composite activity score will be a secondary efficacy outcome.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 13; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Encouraging
Data from Ongoing Open Label Extension Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Twenty
subjects with skin-predominant DM received open-label dosing with lenabasum at 20 mg twice per day following 16 weeks participation
in the preceding double-blinded placebo-controlled part of the lenabasum Phase 2 study. Patients had a mean of about 31 weeks
off treatment from the end of lenabasum dosing during the placebo-controlled period before starting open-label dosing. Lenabasum
was administered in addition to standard-of-care treatments for DM, including concomitant immunosuppressive drugs in 85% of subjects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Efficacy
Outcomes</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CDASI activity score improved from study start by to -17.6 points at 12 months in the open label extension study (OLE). An improvement
of -4 to -5 points in CDASI activity score is considered medically important, and 84% of subjects had improvement in CDASI activity
score exceeding -10 points at 12 months in the OLE. Continued improvement was observed during the OLE in patient-reported global
assessments of skin activity, skin symptoms, itch and hair loss and physician-reported global disease activity, physician assessment
of extramuscular disease activity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 14; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
7: CDASI Activity Score During Open Label Extension</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_010.jpg" ALT="" STYLE="height: 417; width: 650"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Positive
Data from Phase 2 Dermatomyositis Study</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2017, the Company completed the double-blind, placebo-controlled portion of the Phase 2 study in skin-predominant DM and
reported positive results. The mean improvement (reduction) in the primary efficacy outcome, the CDASI activity score, an, was
9.3 points for lenabasum treatment versus a reduction of 3.7 points for placebo treatment (p = 0.04,2-sided MMRM) at sixteen weeks.
Lenabasum also outperformed placebo in multiple secondary efficacy outcomes studied. Lenabasum was well tolerated with no severe
or serious side effects associated with the drug. No subjects dropped out. The dermatomyositis trial was funded by a grant from
the National Institute of Arthritis and Musculoskeletal and Skin Diseases of the National Institutes of Health to the University
of Pennsylvania Perelman School of Medicine.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
single center trial enrolled 22 adults at a 1 to 1 ratio of lenabasum to placebo cohorts. At baseline, subjects in each cohort
had a mean CDASI activity score in the severe range and skin symptoms in the extremely severe range despite background treatment
with immunosuppressive drugs in 19 of the 22 subjects. Demographic parameters, CDASI activity scores, patient-reported outcomes,
and use of immunosuppressive drugs at baseline were similar for lenabasum and placebo cohorts. Subjects received lenabasum 20
mg QD through week 4, then lenabasum 20 mg BID through week 12 with safety and efficacy follow-up thereafter through week 16.
All subjects remained on their background standard-of-care therapy throughout the study in DM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 15; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
8-Lenabasum Demonstrated Clinically Meaningful Improvement in CDASI</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_011.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Lupus Erythematosus (SLE)</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
December 2017 a Phase 2 clinical study of lenabasum was initiated for the treatment of systemic lupus erythematosus and patient
dosing commenced in February 2018. The Phase 2 SLE clinical trial is being conducted by the Autoimmunity Centers of Excellence
(ACE) program, which is funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes
of Health (NIH).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
randomized, double-blind, placebo-controlled, Phase 2 trial is being conducted in the U.S. and is expected to enroll 100 adult
SLE patients with active musculoskeletal disease, which is the most common disease manifestation of SLE. Subjects will be randomized
in a 1:1:1:1 ratio to one of four cohorts to receive placebo or three different doses of lenabasum for 3 months, with 1-month
follow-up. The primary efficacy outcome assesses pain from active musculoskeletal disease, and secondary efficacy outcomes include
other assessments of active musculoskeletal disease, overall disease activity using SLE Responder Index, SLE Disease Activity
Index (&ldquo;SLEDAI&rdquo;) and British Isles Lupus Activity Group (&ldquo;BILAG&rdquo;) scoring systems, and patient-reported
outcomes.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 16; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lenabasum&rsquo;s
Unique and Novel Mechanism of Action as a Pro-Resolving Drug</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is a synthetic, rationally-designed, oral small-molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2,
found on activated immune cells, fibroblasts and other cell types including muscle and bone cells. Lenabasum stimulates the production
of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation and halt fibrosis by activating endogenous
pathways. These pathways are activated in healthy individuals during the course of normal immune responses but are dysfunctional
in patients with chronic inflammatory and fibrotic diseases. By its binding to the CB2 receptor, lenabasum drives innate immune
responses from the activation phase through completion of the resolution phase. The CB2 receptor plays a central role in modulating
and resolving inflammation by, in effect, turning heightened inflammation &ldquo;off&rdquo; and restoring homeostasis. This has
been demonstrated in animal models lacking CB2 as well as humans suffering from polymorphism in the CB2 gene, as these exhibit
abnormal immune responses and a propensity for chronic inflammation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
key aspect of the body&rsquo;s innate immune response is its activation phase when inflammatory cells are recruited to the site
of tissue infection/injury whereupon these cells act to destroy the infection and/or repair tissue damage. The next phase in a
normal innate immune response is its resolution phase, during which the nature of the infiltrating immune cells changes from pro-inflammatory
to pro-resolving, the infectious pathogens are eliminated, residual cellular debris and immune cells are cleared from the tissue,
and tissue repair processes are eventually halted when they are no longer needed. In chronic inflammatory and fibrotic diseases,
the innate immune responses are &ldquo;stuck&rdquo; in the initial activation phase. This failure to progress through the resolution
phase causes chronic tissue infiltration with inflammatory cells and chronic activation of healing processes that cause tissue
scarring, or fibrosis. The key event that propels an innate immune response from its activation phase to its resolution phase
is a &ldquo;class switch&rdquo; from production of pro-inflammatory lipid mediators such as prostaglandins and leukotrienes to
a family of SPMs (Figure 1) which include lipoxins, resolvins, protectins, and marescins. If an innate immune response persists
in the activation phase and does not progress through resolution, chronic inflammation and fibrosis can result, causing organ
dysfunction, organ failure, severe morbidity and even death. There are hundreds of life-long chronic and incurable inflammatory
diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 17; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
9-Lenabasum&rsquo;s Mechanism of Action</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_012.jpg" ALT="" STYLE="height: 280; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is designed to restore immune system homeostasis, by harnessing the body&rsquo;s own physiologic pathways to transition the innate
immune response from the activation phase to the resolution phase. If the innate immune response is &ldquo;stuck&rdquo; in the
activation phase, tissue damage, fibrosis and persistent infection are expected consequences. Endogenous progression of the innate
immune response through its resolution phase has been shown to clear inflammation, stop fibrosis, and promote pathogen clearance.
Lenabasum&rsquo;s unique mechanism of action is different than anti-inflammatory drugs that inhibit the production or functions
of distinct pro-inflammatory mediators that initiate or are active during the activation phase. Activation of an innate immune
response is necessary to clear infections, however drugs that interfere with the activation phase carry the risk of immunosuppression
and may have other undesirable side effects. In contrast, lenabasum is designed to transition an innate immune response from its
activation phase to resolution phase. Lenabasum&rsquo;s CB2 agonist activity initiates a class switch in bioactive lipid mediators
from inflammation-activating mediators to pro-resolving mediators. Lenabasum acts to impact and activate multiple pathways including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in production of SPMs and anti-inflammatory eicosanoids, with a concomitant decrease in production of pro-inflammatory eicosanoids.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in production of anti-inflammatory cytokines, coupled with a decrease in production of pro-inflammatory cytokines and pro-fibrotic
    growth factors.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in influx of non-inflammatory macrophages with a decrease in influx and accumulation of inflammatory cells and pro-fibrotic
    myofibroblasts.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in bacterial clearance. SPMs stimulate production of bactericidal peptides, enhance phagocytosis and killing of bacteria by
    neutrophils and macrophages.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in apoptosis of inflammatory cells, including neutrophil and pro-fibrotic cells, including fibroblasts.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Increase
    in clearance of apoptotic cells and cellular debris by non-inflammatory macrophages.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 18; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Effect
of Lenabasum in a Human Model of Inflammatory Resolution</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dr.
Derek Gilroy, Professor of Experimental Inflammation and Pharmacology at University College of London evaluated the effects of
lenabasum in a clinical research model of inflammation and its resolution in healthy volunteers. In this model, inflammation was
triggered in healthy individuals by the subcutaneous injection of heat-killed E. coli. Blood flow to the site of inflammation
was measured with laser Doppler techniques. Suction blisters were generated over the site of inflammation, and cells and inflammatory
mediators were measured in the blister fluid at different times after the injection of E. coli. In this study 22 subjects received
either lenabasum at 5 mg or 20 mg twice a day or placebo prior to the procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
data demonstrated that both doses of lenabasum exerted potent anti-inflammatory effects by inhibiting neutrophil infiltration
and increased the clearance of bacteria as measured by local endotoxin levels, both key determinants of inflammation. Controlling
neutrophils is considered highly important for treating many diseases driven by chronic inflammation. In addition to inhibiting
neutrophil accumulation, lenabasum also enhanced clearance of the injected bacteria. The data were published in January 2018 in
the peer-reviewed &ldquo;Clinical Pharmacology &amp; Therapeutics&rdquo; journal in a paper entitled: &ldquo;Potent anti-inflammatory
and pro-resolving effects of lenabasum in a human model of self-resolving acute inflammation. The findings in this paper provide
additional evidence for lenabasum&rsquo;s unique mechanism of action to modulate the trafficking of key harmful effector cells
to the site of infection and injury without compromising internal host defense mechanisms, and instead enhancing it. This dual
mechanism of action of lenabasum combines the inhibition of lipid mediators that normally reduce the immune system&rsquo;s ability
to clear bacteria with the inhibition of pro-inflammatory lipid mediators. This unique activity of lenabasum ultimately drives
the inflammatory response down the pro-resolution pathway.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 19; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
10- Lenabasum Increases Pro-Resolving Lipid Mediators in Humans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_013.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
10- Lenabasum also Decreases Inflammatory Lipid Mediators in Humans</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_014.jpg" ALT="" STYLE="height: 317; width: 670"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Data
from this human clinical model demonstrated that lenabasum activates the resolution of innate immune responses and is the first
experimental therapeutic shown to activate the &ldquo;pro-resolution&rdquo; pathway in humans. These results are consistent with
previous findings from experiments that evaluated lenabasum&rsquo;s effects in animal models of inflammation and support lenabasum&rsquo;s
potential to deliver therapeutic benefit in chronic inflammatory diseases as a first-in-class pro-resolution drug. The results
identify the CB2 receptor, the therapeutic target of lenabasum, as a key link between the innate immune response and the endocannabinoid
system acting as an upstream activator of the resolution of innate immunity. The top dose of lenabasum in this study at 20 mg
twice a day is the same as the highest dose in the Phase 3 SSc clinical trial and the Phase 2b CF trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 20; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Clinical
Development-CRB-4001 and other synthetic cannabinoid drugs</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
is developing CRB-4001, a 2<SUP>nd</SUP> generation peripherally-restricted, CB1 inverse agonist for NASH and other fibrotic diseases.
CRB-4001 was developed in collaboration with and financial support from the National Institutes of Health (NIH). CRB-4001 was
specifically designed to eliminate blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric
issues associated with first-generation CB1 inverse agonists, such as rimonabant. Corbus also has a pre-clinical library of more
than 600 molecules targeting the ECS for the treatment of fibrotic diseases. Corbus expects to commence a Phase 1 study for CRB-4001
by the end of 2019, intended to be followed by a NIH-funded Phase 2 study in NASH. We are also evaluating and characterizing
our library of more than 600 compounds to select additional clinical candidates to move forward into clinical studies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Market
Opportunity for Lenabasum in Inflammatory and Fibrotic Diseases</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are many different chronic, serious inflammatory and fibrotic diseases that could be addressed by treatment with lenabasum. Some
examples of chronic, serious diseases characterized by inflammation with variable degrees of fibrosis include genetic diseases
such as cystic fibrosis, nonalcoholic steatohepatitis (&ldquo;NASH&rdquo;), myelofibrosis, lung diseases including idiopathic
pulmonary fibrosis, bronchiolitis obliterans, and sarcoidosis and autoimmune diseases including systemic sclerosis, systemic lupus
erythematosus, myositis, rheumatoid arthritis, vasculitis, primary biliary cirrhosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
autoimmune diseases, four out of the five top selling drugs in the U.S. are anti-inflammatory biologic drugs which had total sales
of $42 billion in 2016. These drugs however suppress the immune systems and thus leave patients susceptible to serious infections.
Lenabasum, on the other hand, is designed to resolve inflammation without immunosuppression and is an oral pill, which potentially
positions it as a front-line, first choice for autoimmune and other serious inflammatory and fibrotic diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lenabasum
Market Opportunity for Current Indications Being Developed</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Autoimmune
Disorders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Sclerosis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
sclerosis (SSc) is a chronic, systemic autoimmune disease characterized by activation of innate and adaptive immune systems, an
obliterative, proliferative vasculopathy of small blood vessels, and fibrosis of the skin and multiple internal organs. Approximately
200,000 people in the U.S., Europe and Japan have SSc. The disease affects mainly adults (80% of SSc patients are women) with
mean age of onset about 46 years of age in the United States and the majority of patients between 45-64 years of age.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 21; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
commonly used system classifies SSc patients into those with more wide-spread skin thickening (diffuse cutaneous SSc, about 45%
of patients) and those with more restricted skin thickening (limited cutaneous SSc, about 55% of patients). There is significant
overlap in the clinical manifestations for these two groups of SSc patients and no known significant differences in disease pathogenesis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SSc
can affect multiple internal organs in the body, including the lungs, heart, kidneys, joints, muscles, esophagus, stomach and
intestines. Clinically apparent organ involvement that occurs in more than a third of these patients includes thickened skin,
Raynaud&rsquo;s phenomenon, esophageal symptoms, pulmonary fibrosis, restrictive lung disease, edematous skin, joint contractures,
digital ulcers, and muscle weakness. Less frequently occurring, yet life-threatening manifestations include pulmonary artery hypertension
(about 1 in 5 patients), cardiac conduction blocks (about 1 in 10 patients), and renal crisis (about 1 in 50 patients). In the
U.S., SSc is the deadliest of the systemic autoimmune diseases. The median disease duration for an individual who dies of SSc
is 7.1 years from the onset of symptoms. About 85% of deaths caused by SSc are the result of pulmonary fibrosis, pulmonary artery
hypertension, or cardiovascular disease, such as sudden death.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
SSc the innate immune system fails to transition from the activation phase to the resolution phase. Individuals with SSc who have
interstitial lung disease have an imbalance of bioactive lipid mediators, causing a predominance of inflammatory mediators versus
resolving mediators. The preponderance of inflammatory mediators correlates positively with the degree of inflammation in the
lungs and negatively with forced vital capacity, a measure of lung fibrosis. Excessive activation of the pathways which cause
fibrosis including TGF&beta;, myofibroblast accumulation, and production of collagen and other extracellular matrix proteins are
all present in SSc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no cure for systemic sclerosis, and there are no FDA-approved treatments for this disease. Other drugs that suppress the immune
system but are not specifically FDA approved for SSc are prescribed by some doctors, such as methotrexate, mycophenolate and cyclophosphamide.
These treatments may be associated with significant side effects, such as serious infections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there is general agreement in the SSc community that an effective anti-inflammatory and anti-fibrotic drug would address
a significant unmet medical need in SSc, especially a drug that is orally administered, can be used chronically with other commonly
prescribed medications for SSc, and is not immunosuppressive. We believe such a therapy would be positively received by the market.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Dermatomyositis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dermatomyositis
(DM) is a serious and rare autoimmune idiopathic inflammatory myopathy with characteristic cutaneous findings. About 80,000 individuals
in the U.S., Europe and Japan suffer from dermatomyositis. DM usually strikes adults, with most common age of adult onset between
50-60 years.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 22; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
systemic disorder most frequently affects the skin and muscles, and DM can also include interstitial lung disease/restrictive
lung disease, arthritis, gastrointestinal and cardiac involvement. Inflammatory muscle disease associated with DM can cause discomfort
and significant weakness of the proximal muscles of the arms and legs and of the trunk. Dermatomyositis can include damaging inflammation
elsewhere in the body, for example: lung inflammation that leads to lung fibrosis and restrictive lung disease; heart inflammation
that causes arrhythmia, congestive heart failure, and pericarditis, inflammation of muscles in the esophagus that causes swallowing
problems or aspiration pneumonia, and arthritis. DM patients may have active skin disease despite successful treatment of their
muscle and/or lung disease. The skin findings in DM can be disfiguring and are inflammatory rashes characterized by redness and
itching in exposed areas of the skin, around the eyes, on the hands, and in a &ldquo;shawl&rdquo; distribution on the scalp, hands,
upper back, and photo-exposed areas. Due to this chronic inflammation, patients with DM have an increased risk of malignancy,
most commonly in older patients. By itself, skin involvement in DM has a large negative impact on quality of life, comparable
to that of cutaneous lupus erythematosus and vulvodynia, and much higher than those of many dermatologic diseases. The pathophysiology
of DM is consistent with a patient&rsquo;s inherent inability to adequately resolve innate immune responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no cure for DM, a disease that continues to progressively worsen over time. Typically, people with DM are prescribed drugs
that suppress the immune system. These treatments may be associated with significant side effects, such as serious infections.
FDA-approved treatments for DM include systemic corticosteroids and adrenocorticotropic hormone analogue.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that an effective drug that controls inflammation in the skin, muscles, and other organs will address a significant unmet
medical need in <FONT STYLE="background-color: white">DM</FONT>, particularly a drug that is orally administered, can be used
chronically with other commonly prescribed medications for the disease, and is not immunosuppressive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Lupus Erythematosus</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
lupus erythematosus (SLE) is a prototypical autoimmune disease with a wide array of clinical manifestations, including arthritis,
rash, photosensitivity, oral ulcers, pleuritis, pericarditis, kidney problems, seizures and psychosis and blood cell abnormalities.
About 550,000 individuals in the U.S., Europe and Japan suffer from SLE. The musculoskeletal system is the most commonly involved
system in SLE. Patients with SLE have an increased frequency of related autoimmune problems, such as Sjogren&rsquo;s syndrome
and antiphospholipid syndrome that require additional treatments. SLE may occur with other autoimmune conditions, such as thyroiditis,
hemolytic anemia, and idiopathic thrombocytopenia purpura. Accelerated atherosclerosis among SLE patients is responsible for premature
mortality.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
pathology of SLE involves chronic activation of the innate immune system by immune complexes, with activation of the complement
cascade, increased production of type 1 interferons and other mediators of inflammation and resultant tissue inflammation and
damage.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 23; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Medicines
specifically approved by the FDA for treatment of SLE are aspirin, hydroxychloroquine, corticosteroids (for example, prednisone),
the corticotropin injection Acthar&reg; and the immunosuppressive drug Benlysta&reg;. Other drugs that are not specifically FDA
approved for SLE but are often prescribed by physicians include methotrexate, mycophenolate, azathioprine and cyclophosphamide.
These treatments may be associated with significant side effects, such as serious infections.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that an effective drug that controls inflammation in the joints and skin as well as improves overall disease activity
will address a significant unmet medical need in <FONT STYLE="background-color: white">SLE</FONT>, particularly a drug that is
orally administered, can be used chronically with other commonly prescribed medications for the disease, and is not immunosuppressive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Cystic
Fibrosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cystic
fibrosis (CF) is a life-long, progressive, debilitating, and life-threatening autosomal recessive disease. Cystic fibrosis is
caused by mutations in the gene Cystic Fibrosis Transmembrane Conductance Regulator (CFTR). <FONT STYLE="background-color: white">The
CFTR serves as a central hub to modulate transport, trafficking, and signaling in cells. </FONT>Given multiple roles of CFTR in
cellular activation and homeostasis, mutation of the CFTR give rise to multiple disorders in respiratory, digestive and reproductive
organs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
current median life expectancy of cystic fibrosis patients is about 40 years. According to the Cystic Fibrosis Foundation, 30,000
Americans and a total of 70,000 people in the U.S. and Europe suffer from cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CFTR mutations lead to defective ion transport, with reduced chloride and bicarbonate secretion and sodium hyper-absorption, followed
by water hyper-absorption, by airway epithelia and other cell types. The resultant reduced height of epithelial lining fluid and
decreased hydration of mucus results in abnormally thick and sticky mucus, which obstructs the lumen into which the mucus is secreted
and reduces mucociliary clearance of bacteria. The dysfunction in ion transport in CF patients is reflected in abnormal sweat
chloride levels.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
negative effects caused by CFTR gene mutations are not restricted to ion channels, but also extend to dysfunction of the innate
immune system. The nature of the abnormalities in CF are consistent with inability of innate immune responses to make the transition
out of the activation phase and into and through the resolution phase. Bioactive lipid mediators (SPMs) that initiate the transition
to resolution phase of innate immune responses have been found to be deficient relative to pro-inflammatory lipid mediators that
initiate its activation phase, and this reduction correlates with poor recovery of lung function following an acute pulmonary
exacerbation in children. The preponderance of activated neutrophils and pro-inflammatory macrophages in inflamed tissue, reduced
neutrophil apoptosis, high levels of neutrophil proteases that reflect persistent neutrophil activation, reduced clearance of
neutrophils by macrophages, ineffective clearance of certain bacteria such as <I>P. aeruginosa</I>, and excessive activation of
fibrotic pathways all show the inability of individuals with CF to resolve their innate immune responses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">An
overview of the disease progression in cystic fibrosis is provided in Figure 3.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 24; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Figure
11: Factors involved in cystic fibrosis progression</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><IMG SRC="figure_015.jpg" ALT=""></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of obstructing secretions, recurrent infections, hyper-inflammation, and activated fibrotic pathways in the lungs, individuals
with CF develop bronchiectasis, pulmonary fibrosis, mixed obstructive/restrictive lung disease, and, eventually, respiratory failure.
They may also have chronic sinusitis and nasal polyps. The same pathophysiologic events of obstruction, infection, chronic inflammation,
and tissue damage/fibrosis occur in the gastrointestinal system, which can lead to bowel obstructions, fat malabsorption, bacterial
overgrowth, gut dysmotility, malnutrition, growth retardation, low weight, pancreatic insufficiency, cystic fibrosis-related diabetes,
gallstones, and liver failure including cirrhosis. Adult males with cystic fibrosis have degeneration of the ductus deferens and
sterility. End-stage organ involvement in cystic fibrosis is sometimes treated with transplantation, especially lung transplantation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
therapies for cystic fibrosis include mucolytics to breakdown mucus, antibiotics to fight bacterial infection, and drugs that
act to restore some functionality to the faulty CFTR protein in patients, including Kalydeco&reg; Orkambi&reg; and the Symdeco&reg;.
Drugs that are designed to partially restore ion channel functions of mutant CFTR protein are not necessarily able to correct
the dysfunction of the innate immune system. For example, ivacaftor treatment has not been associated with reduction in sputum
neutrophils or neutrophil derived proteases in CF patients.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
CF patients appear to have dysfunction in resolution of the innate immune system, no matter which CFTR mutations a given patient
has. This is borne out by the incidence of pulmonary exacerbations which according to the CF registry occur at an annual rate
of 17,000 case per year and an event rate of 0.70 times per patient per year. A pulmonary exacerbation is acute worsening of the
patient&rsquo;s day-to-day signs and symptoms of lung disease and is associated with worsening of inflammation at the start of
the exacerbation. Failure to resolve lung inflammation during a pulmonary exacerbation is associated with treatment failure, such
as need to change antibiotics, prolonged antibiotic therapy, early recurrent of pulmonary exacerbation, and failure to recover
lung function lost during the exacerbation. Pulmonary exacerbations in CF are associated with reduced survival, lung function,
and patient quality of life and increased health-care burden. The annual average pulmonary exacerbation hospitalization related
costs in the U.S. vary from $30,000 for a &ldquo;mild&rdquo; exacerbation to as high as $120,000 in patients with severe lung
disease. Currently, there are no approved drugs used to address pulmonary exacerbations, a key driver of morbidity and mortality
in cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe there is general agreement in the CF community that an effective drug that will reduce hyper-inflammation and help reduce
the rate of pulmonary exacerbations would address a significant unmet medical need in CF, especially a drug that is orally administered,
can be used chronically with other prescribed medications for CF, is not immunosuppressive, and has anti-fibrotic effects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 25; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Current
Treatment Alternatives for Chronic, Serious Diseases Characterized by Chronic Inflammation and Fibrosis</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Drugs
currently used to treat chronic serious inflammatory and fibrotic diseases are divided broadly into several groups: non-steroidal
anti-inflammatory drugs (NSAIDS), anti-malarial agents, systemic corticosteroids, and other immunosuppressive agents. The choice
of agent or combination generally depends upon the underlying disease, and physician and patient preferences.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
potency of NSAIDs in the treatment of chronic, serious diseases, inflammatory and fibrotic diseases is often too limited to control
disease activity, requiring patients to receive additional treatment with anti-malarial drugs, systemic corticosteroids or immunosuppressive
agents. Anti-malarial therapy is used as a baseline treatment for chronic inflammation in certain autoimmune diseases, typically
SLE and DM, especially in patients with milder manifestations of disease. Anti-malarial therapy is frequently ineffective in controlling
chronic, serious inflammation, or can cause adverse drug reactions. Antimalarial-refractory disease is then treated with systemic
therapies that may cause additional toxicity, including systemic corticosteroids and immunosuppressive agents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Systemic
corticosteroids are commonly prescribed for treatment of chronic, serious diseases characterized by chronic inflammation and fibrosis,
such as cystic fibrosis, SSc, and DM. Chronic corticosteroid use is limited by toxicities that include growth retardation, iatrogenic
Cushings&rsquo;s Disease, hypertension, high glucose levels/diabetes, obesity, brittle bones/osteoporosis, aseptic necrosis of
bone, immunosuppression/increased infection, glaucoma, depression, and psychosis. Thus, safer yet potent alternatives to steroids
have long been sought.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Multiple
other immunosuppressive drugs are used to treat chronic, serious, inflammatory diseases, to achieve disease control and to curtail
the need for corticosteroids. These include biological agents, such as monoclonal antibodies or fusion proteins, which target
a very specific molecule in a key disease pathway. These drugs have several disadvantages including parental administration and
increased associated incidence of malignancy and infection. Non-biologic immunosuppressive agents that are used to treat chronic,
serious inflammation include methotrexate, mycophenolate, leflunomide, cyclophosphamide, and azathioprine, among others. Intravenous
immunoglobulin is used occasionally to treat refractory chronic, serious inflammatory diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Lenabasum
As a Pro Resolving Drug with a Novel Mechanism of Action Has Safety Advantages versus Anti-Inflammatory Drugs, Steroids and Immunosuppressive
Agents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corticosteroids
and NSAIDs exert their effect by inhibiting the activation of inflammation. In simple terms, both classes of drugs inhibit inflammation
by &ldquo;interfering&rdquo; with the biochemical pathways in the cell that promote and sustain inflammation. For example, NSAIDs
directly inhibit the activity of the COX 1 and COX 2 enzymes that are responsible for generating pro-inflammatory eicosanoids.
A drawback of this approach is that it one arm of the eicosanoid pathway (e.g. COX but not LOX) is inhibited resulting in a build-up
in LOX-derived inflammatory mediators which leads to gastrointestinal and cardiovascular side effects (termed &ldquo;molecular
shunting&rdquo;). Lenabasum on the other hand triggers endogenous pathways that resolves inflammation and halts fibrosis without
immunosuppression Therefore lenabasum potentially offers a new and unique mechanism to treat a spectrum of rare, chronic, serious
inflammatory and fibrotic diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 26; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Autoimmune
Disorders</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Sclerosis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cytotoxic
and immunosuppressive medications are used to control overall disease activity in SSc. In a one-year study of 2,739 SSc patients
in the U.S., 44.3% received corticosteroids, 4.8% received mycophenolate mofetil, 2.7% received cyclophosphamide, and 0.5% received
cyclosporine. In a report of 7,655 patients in the European Scleroderma Trials and Research Group database, the percentage of
SSc patients receiving immunosuppressant treatments were: prednisone (43.5%) with median dose of 8 mg/day; cyclophosphamide (15.9%);
methotrexate (13.7%); azathioprine (6.4%); mycophenolate mofetil (4.2%), d-penicillamine (2.1%), and rituximab (1%).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>DM</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Current
medications for DM involve both treatments to reduce overall disease activity and specific treatments to control the muscle disease
and the skin disease. The muscle component is treated by administering corticosteroids, typically with an immunosuppressive agent.
The skin component of the disease is treated by avoiding sun exposure and by using sunscreens and photoprotective clothing, as
well as with topical corticosteroids, antimalarial agents such as hydroxychloroquine and immunosuppressive medications such as
methotrexate, azathioprine, mycophenolate mofetil, or intravenous immunoglobulin.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Systemic
Lupus Erythematosus</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Similar
to DM, current medications for SLE involve treatments to reduce overall disease activity and specific treatments for a given organ
involvement. Commonly used medications include NSAIDs, topical corticosteroids, antimalarial agents, prednisone, belimumab, and
other immunosuppressive medications such as mycophenolate, methotrexate, azathioprine, and cyclophosphamide.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cystic
Fibrosis</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
importance of treating inflammation in cystic fibrosis is confirmed in the Cystic Fibrosis Foundation&rsquo;s Strategic Plan,
2014-2018. While treatment with systemic corticosteroids and ibuprofen are effective in improving the symptoms of cystic fibrosis,
the side effects associated with chronic treatment using these drugs are significant. Specifically, long term usage of oral corticosteroids
in children are associated with glucose intolerance, cataract formation, multiple bone fractures secondary to osteoporosis or
osteopenia, Cushing disease effects, and anorexia nervosa as well as growth retardation. The use of high dose ibuprofen is limited
by the years of treatment it takes to show benefit, a need to monitor levels closely in the patient, and the increased risk of
gastrointestinal bleeding. As a result, these drugs have limited long-term use in cystic fibrosis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 27; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
therapies routinely used by cystic fibrosis patients routinely include antibiotics, such as Cayston from Gilead and TOBI from
Novartis, and mucolytics, such as Pulmozyme from Genentech. In addition, Vertex currently markets the only approved drugs that
specifically target the defective CFTR protein, Kalydeco, Orkambi and Symdeko.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Competition</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
autoimmune disorders such as SSc, DM and SLE, physicians treat patients with a number of drugs including potent immunosuppressants
and cytotoxics to try to reduce the autoimmune response characteristic of the disease. These drugs have not proven to be very
effective thus there remains a high unmet need for safe and effective drugs to treat these autoimmune disorders. Several companies,
including Boehringer Ingelheim, Galapagos, GlaxoSmithkline, Bristol Myers and Sanofi, are actively working to develop new drugs
for treating the inflammation and/or fibrosis in SSc. To the best of our knowledge, lenabasum offers a unique mode of action to
treat SSc being one of the few oral drugs with the potential to resolve inflammation and halt fibrosis without immunosuppression.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are numerous drug therapies currently used to treat CF patients, targeting different aspects of this complex disease. Inhaled
and oral antibiotics address the pulmonary microbial infection. Mucolytics address the accumulation of mucus in the lungs. Bronchodilators
and hydration agents are also used to help improve pulmonary function. Targeting of the inflammatory component of the disease
is currently done by high dose Ibuprofen and oral corticosteroids. While these offer some clinical benefit, they are not used
chronically due to their adverse side effects which include immunosuppression and metabolic changes (steroids) as well as the
risk of gastrointestinal bleeding (ibuprofen). Thus, there is a clear and urgent unmet medical need for safe and effective inflammation-targeting
drugs for the chronic treatment of CF that could potentially have a beneficial impact on morbidity and mortality. An emerging
and growing area of CF therapy has been the development and commercialization of correctors and potentiators of CFTR by Vertex.
Celtaxsys is developing an anti-inflammatory drug to treat CF which completed a Phase 2b study in 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
incurred expenses of approximately $48,614,000 $ and $26,039,000 for research and development activities for the years ended December
31, 2018 and 2017, respectively. These expenses include cash and non-cash expenses relating to the development of our clinical
and pre-clinical programs for lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 28; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->26<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Intellectual
Property</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have filed patent applications directed to lenabasum, compositions and methods for treating disease using lenabasum. If granted,
the resulting patents would expire on dates ranging from 2031 to 2034, subject to extension under certain circumstances. The patent
application filings are directed to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Compositions
    including an improved ultrapure version of lenabasum and uses of the compositions for the treatment of fibrotic conditions
    and inflammatory conditions;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    use of lenabasum in the treatment of fibrotic diseases; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
    formulations and uses of the formulations for the treatment of disease.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Issued
Patents</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 10pt">On
December 18, 2018, the Company announced that the U.S. Patent and Trademark Office (&ldquo;USPTO&rdquo;) issued U.S. Patent No.
10,154,986 to the Company. This patent includes claims covering pharmaceutical compositions of lenabasum and provides exclusivity
in the U.S. for the use of lenabasum through 2034.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 3, 2018, the Company announced that the USPTO issued U.S. Patent No. 10,085,964 to the Company. This patent includes claims
covering the use of pharmaceutical compositions comprising lenabasum for the treatment of all fibrotic diseases, including Corbus&rsquo;
lead indications systemic sclerosis, dermatomyositis, cystic fibrosis and others. The patent provides exclusivity in the U.S.
for the use of lenabasum through 2034.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 31, 2017, the Company announced that the USPTO issued U.S. Patent No. 9,801,849 to the Company with claims covering the
use of pharmaceutical compositions comprising lenabasum, Corbus&rsquo; lead product in development for the treatment of inflammatory
diseases. The patent provides intellectual property protection for Corbus&rsquo; use of lenabasum to treat inflammatory diseases
in the United States to February 12, 2034.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
November 27, 2017, the Company announced that the USPTO issued U.S. Patent No. 9,820,964 to the Company with claims covering the
use of pharmaceutical compositions comprising lenabasum for the treatment of fibrotic diseases, encompassing the Company&rsquo;s
lead indications: systemic sclerosis, DM, cystic fibrosis as well as others. The patent provides intellectual property protection
in the United States for the use of lenabasum through February 12, 2034.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2018, we entered in an exclusive license agreement with Jenrin Discovery, LLC which provides us with an exclusive
worldwide license to develop and market cannabinoid compounds covered by the Jenrin issued patents and patent applications that
cover the composition and method of use of selective cannabinoid receptor modulators. The Jenrin intellectual property portfolio
includes fifteen granted U.S. patents and 23 granted or pending foreign patents and applications. This
portfolio includes U.S. Patent No 9,987,253, which granted with claims covering the cannabinoid receptor blocker
CRB-4001 and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders,
hepatic disorders, and/or cancers. The licensed intellectual property portfolio provides intellectual property protection in the
United States for CRB-4001 to July of 2033, not including any potential patent term extension.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
has been granted Orphan Drug Designation for cystic fibrosis, dermatomyositis and systemic sclerosis in the U.S. and in the European
Union. In addition, in systemic sclerosis and in cystic fibrosis, Lenabasum has been granted a Fast Track Designation by the FDA.
We will be seeking orphan drug status for lenabasum in Japan for systemic sclerosis and eventually in DM. Orphan designation for
lenabasum may be pursued for other inflammatory diseases in the U.S. and in Europe. Orphan drug status provides seven years of
market exclusivity in the U.S. and ten years in Europe and Japan beginning on the date of drug approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 29; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->27<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection for lenabasum
and to operate without infringing the proprietary right of others and to prevent others from infringing our proprietary rights.
We strive to protect our intellectual property through a combination of patents and trademarks as well as through the confidentiality
provisions in our contracts. With respect to lenabasum, we endeavor to obtain and maintain patent protection in the U.S. and internationally
on all patentable aspects of the drug. We cannot be sure that the patents will be granted with respect to any patent applications
we may own or license in the future, nor can we be sure that any patents issued or licensed to us in the future will be useful
in protecting our technology. For this and more comprehensive risks related to our intellectual property, please see &ldquo;Risk
Factors&mdash;Risks Relating to Our Intellectual Property Rights.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition to patent protection, we rely on trade secrets and know-how to develop and maintain our competitive position. For example,
aspects of our proprietary technology platform are based on unpatented trade secrets and know-how related to the manufacturing
of lenabasum. Trade secrets and know-how can be difficult to protect. We seek to protect our proprietary technology and processes,
in part, by confidentiality agreements and invention assignment agreements with our employees, consultants, scientific advisors,
contractors and commercial partners. These agreements are designed to protect our proprietary information and, in the case of
the invention assignment agreements, to grant us ownership of technologies that are developed through a relationship with a third
party. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security
of our premises and physical and electronic security of our information technology systems. While we have confidence in these
individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies
for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors. To the
extent that our contractors use intellectual property owned by others in their work for us, disputes may arise as to the rights
in related or resulting know-how and inventions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also plan to seek trademark protection in the U.S. and outside of the U.S. where available and when appropriate. We intend to
use these registered marks in connection with our pharmaceutical research and development as well as our product candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Manufacturing
and Supply for Lenabasum</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have developed and validated a good manufacturing practice, or GMP, process to manufacture lenabasum active pharmaceutical ingredient
(&ldquo;API&rdquo;) and drug product through our contract manufacturers. Our existing API contract manufacturer has produced multi-Kg
scale bulk batches under GMP for our on-going clinical studies and is under agreement to produce sufficient API required prior
to submitting an NDA filing with the FDA. We do not own or operate manufacturing facilities for the production of lenabasum. We
expect to depend on third-party suppliers and manufacturing organizations for all of our clinical trial quantities of raw materials
and drug substance. Lenabasum is a synthetic molecule and there are readily available supplies of all raw materials necessary
for the manufacture of lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 30; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->28<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Regulatory
Matters</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Government
Regulation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local and foreign statutes
and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable requirements
at any time during the product development process, approval process or after approval, may subject an applicant to administrative
or judicial sanctions. These sanctions could include the US FDA&rsquo;s refusal to approve pending applications, withdrawal of
an approval, a clinical hold, warning letters, product recalls or withdrawals from the market, product seizures, total or partial
suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement, or
civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
product development activities related to lenabasum or products that we may develop or acquire in the future will be subject to
extensive regulation by various government authorities, including the FDA, other federal, state and local agencies and comparable
regulatory authorities in other countries, which regulate the design, research, clinical and non-clinical development, testing,
manufacturing, storage, distribution, import, export, labeling, advertising and marketing of pharmaceutical products and devices.
Generally, before a new drug can be sold, considerable data demonstrating its quality, safety and efficacy must be obtained, organized
into a format specific to each regulatory authority, submitted for review and approved by the regulatory authority. The data are
often generated in two distinct development states: pre-clinical and clinical.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Development
of Drugs in the U.S.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
or other products that we may develop or acquire in the future must be approved by the FDA before they may be legally marketed
in the United States. For new chemical entities, the pre-clinical development stage generally involves synthesizing the active
component, developing the formulation and determining the manufacturing process, as well as carrying out non-human toxicology,
pharmacology and drug metabolism studies that support subsequent clinical testing. These pre-clinical laboratory and animal tests
are often performed under the FDA&rsquo;s Good Laboratory Practices regulations. A drug&rsquo;s sponsor must submit the result
of the pre-clinical tests, together with manufacturing information, analytical data and any available clinical data or literature
and a proposed clinical protocol to the FDA as part of an IND application, which is a request for authorization from the FDA to
administer an investigational drug or biological product to humans. Similar filings are required in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 31; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->29<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
clinical stage of development can generally be divided into three sequential phases that may overlap, Phase 1, Phase 2 and Phase
3 clinical trials. In Phase 1, generally, small numbers of healthy volunteers are initially exposed to single escalating doses
and then multiple escalating doses of the product candidate. The primary purpose of these studies is to assess the metabolism,
pharmacologic action and general safety of the drug. Phase 2 trials typically involve studies in disease-affected patients to
determine the dose required to produce the desired benefits, common short-term side effects and risks. Phase 2 studies are typically
well-controlled, closely monitored, and conducted in a relatively small number of patients, usually involving no more than several
hundred subjects. Phase 3 trials are intended to gather the additional information about effectiveness and safety that is needed
to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling. Phase 3
studies usually include from several hundred to several thousand subjects and are closely controlled and monitored. In addition
to these Phase 1-3 trials, other trials may be conducted to gather additional safety, pharmacokinetic and pharmacodynamic information.,
Pharmaceutical products with active ingredients equal or similar to those already approved by the FDA often have more streamlined
development programs than compounds entirely new to the agency, often skipping Phase 1 and 2 trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
clinical plan must be submitted to the FDA prior to commencement of a clinical trial. If the FDA has concerns about the clinical
plan or the safety of the proposed studies, they may suspend or terminate the study at any time. Studies must be conducted in
accordance with good clinical practice and reporting of study progress and any adverse experiences is required. Studies are also
subject to review by independent institutional review boards responsible for overseeing studies at particular sites and protecting
human research study subjects. An independent institutional review board may also suspend or terminate a study once initiated.
Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that once
begun, issues will not arise that could cause the trial to be suspended or terminated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Post-approval
studies, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. Sometimes, these
studies are used to gain additional experience from the treatment of patients in the intended therapeutic condition. In certain
instances, the FDA may mandate the performance of Phase 4 studies. In other situations, post-approval studies aim to gain additional
indications for a medication.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Special
Protocol Assessment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Federal Food, Drug, and Cosmetic Act directs the FDA to meet with sponsors, pursuant to a sponsor&rsquo;s written request, for
the purpose of reaching agreement on the design and size of clinical trials intended to form the primary basis of an efficacy
claim in an NDA. If an agreement is reached, the FDA will reduce the agreement to writing and make it part of the administrative
record. This agreement is called a special protocol assessment, or SPA. While the FDA&rsquo;s guidance on SPAs states that documented
SPAs should be considered binding on the review division, the FDA has latitude to change its assessment if certain exceptions
apply. Exceptions include public health concerns emerging that were unrecognized at the time of the protocol assessment, identification
of a substantial scientific issue essential to the safety or efficacy testing that later comes to light, a sponsor&rsquo;s failure
to follow the protocol agreed upon, or the FDA&rsquo;s reliance on data, assumptions or information that are determined to be
wrong.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Review
and Approval in the U.S.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
pivotal or Phase 3 trial completion, data are analyzed to determine safety and efficacy. Data are then filed with the FDA in a
New Drug Application, or an NDA, along with proposed labeling for the product and information about the manufacturing and testing
processes and facilities that will be used to ensure product quality. In the United States, FDA approval of an NDA must be obtained
before marketing a pharmaceutical product. The NDA must contain proof of safety, purity, potency and efficacy, which entails extensive
pre-clinical and clinical testing.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA will likely re-analyze the clinical trial data, which could result in extensive discussions between the FDA and us during
the review process. The review and evaluation of applications by the FDA is extensive and time consuming and may take several
years to complete. The FDA may conduct a pre-approval inspection of the manufacturing facilities for the new product to determine
whether they comply with current good manufacturing practice requirements and may also audit data from clinical and pre-clinical
trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
is no assurance that the FDA will act favorably or quickly in making such reviews and significant difficulties or costs may be
encountered in our efforts to obtain FDA approvals. The FDA may require that certain contraindications, warnings or precautions
be including in the product labeling, or may condition the approval of the NDA on other changes to the proposed labeling, development
of adequate controls and specifications, or a commitment to conduct post-marketing testing or clinical trials and surveillance
programs to monitor the safety of approved products that have been commercialized. Further, the FDA may place conditions on approvals
including the requirement for a risk evaluation and mitigation strategy, or REMS, to assure the safe use of the drug. If the FDA
concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS; the FDA will not approve the NDA without an approved
REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such
as restricted distribution methods, patient registries and other risk minimization tools. Any of these limitations on approval
or marketing could restrict the commercial promotion, distribution, prescription or dispensing of products. Product approvals
may be withdrawn for non-compliance with regulatory standards or if problems occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 32; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->30<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Orphan
Drug Designation</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the United States. Orphan product designation
must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent
and its potential orphan use are disclosed publicly by the FDA. Orphan product designation does not convey any advantage in or
shorten the duration of regulatory review and approval process. In addition to the potential period of exclusivity, orphan designation
makes a company eligible for grant funding of up to $500,000 per year for four years to defray costs of clinical trial expenses,
tax credits for clinical research expenses and potential exemption from the FDA application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications
to market the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&rsquo;s
orphan designation is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval
of another applicant&rsquo;s product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient
quantity of drug; or (v) a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If
a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not
be entitled to orphan drug exclusivity. We have received orphan drug designation for lenabasum for cystic fibrosis and systemic
sclerosis. There can be no assurance that we will receive orphan drug designation for lenabasum for DM, or additional orphan diseases.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Drug
Development in Europe</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, our future products may also be subject to extensive regulatory requirements. Similar to the U.S., the marketing
of medicinal products is subject to the granting of marketing authorizations by regulatory agencies. Also, as in the U.S., the
various phases of pre-clinical and clinical research in the European Union are subject to significant regulatory controls.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Review
and Approval in the European Union</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the European Union, approval of new medicinal products can be obtained through one of three processes: the mutual recognition
procedure, the centralized procedure and the decentralized procedure. We intend to determine which process we will follow, if
any, in the future.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mutual
Recognition Procedure: An applicant submits an application in one European Union member state, known as the reference member state.
Once the reference member state has granted the marketing authorization, the applicant may choose to submit applications in other
concerned member states, requesting them to mutually recognize the marketing authorizations already granted. Under this mutual
recognition process, authorities in other concerned member states have 55 days to raise objections, which must then be resolved
by discussion among the concerned member states, the reference member state and the applicant within 90 days of the commencement
of the mutual recognition procedure. If any disagreement remains, all considerations by authorities in the concerned member states
are suspended and the disagreement is resolved through an arbitration process. The mutual recognition procedure results in separate
national marketing authorizations in the reference member state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Centralized
Procedure: This procedure is currently mandatory for products developed by means of a biotechnological process and optional for
new active substances and other &ldquo;innovative medicinal products with novel characteristics.&rdquo; Under this procedure,
an application is submitted to the European Agency for the Evaluation of Medical Products. Two European Union member states are
appointed to conduct an initial evaluation of each application. These countries each prepare an assessment report that is then
used as the basis of a scientific opinion of the Committee on Proprietary Medical Products. If this opinion is favorable, it is
sent to the European Commission, which drafts a decision. After consulting with the member states, the European Commission adopts
a decision and grants a marketing authorization, which is valid throughout the European Union and confers the same rights and
obligations in each of the member states as a marketing authorization granted by that member state.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 33; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->31<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Decentralized
Procedure: The most recently introduced of the three processes for obtaining approval of new medicinal processes in the European
Union, the decentralized procedure is similar to the mutual recognition procedure described above, but with differences in the
timing that key documents are provided to concerned member states by the reference member state, the overall timing of the procedure
and the possibility of, among other things, &ldquo;clock stops&rdquo; during the procedure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Post-Marketing
Requirements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Following
approval of a new product, a pharmaceutical company and the approved product are subject to continuing regulation by the FDA and
other federal and state regulatory authorities, including, among other things, monitoring and recordkeeping activities, reporting
to applicable regulatory authorities of adverse experiences with the product, providing the regulatory authorities with updated
safety and efficacy information, product sampling and distribution requirements, and complying with promotion and advertising
requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses
or in patient populations not described in the drug&rsquo;s approved labeling (known as &ldquo;off-label use&rdquo;), and limitations
on industry-sponsored scientific and educational activities. Although physicians may prescribe legally available drugs for off-label
uses, manufacturers may not market or promote such off-label uses. Modifications or enhancements to the products or labeling or
changes of site of manufacture are often subject to the approval of the FDA and other regulators, which may or may not be received
or may result in a lengthy review process. The FDA regulations require the products be manufactured in specific approved facilities
and in accordance with current good manufacturing practices, and NDA holders must list their products and register their manufacturing
establishments with the FDA. These regulations also impose certain organizational, procedural and documentation requirements with
respect to manufacturing and quality assurance activities. Drug manufacturers and other entities involved in the manufacture and
distribution of approved drugs are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance
with current good manufacturing practice and other laws. NDA holders using contract manufacturers, laboratories or packagers are
responsible for the selection and monitoring of qualified firms. These firms are subject to inspections by the FDA at any time,
and the discovery of violative conditions could result in enforcement actions that interrupt the operation of any such facilities
or the ability to distribute products manufactured, processed or tested by them.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Other
Regulatory Matters</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manufacturing,
sales, promotion and other activities following product approval are also subject to regulation by numerous regulatory authorities
in addition to the FDA, including, in the United States, the Centers for Medicare &amp; Medicaid Services, or CMS, other divisions
of the Department of Health and Human Services, the Drug Enforcement Administration, the Consumer Product Safety Commission, the
Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state
and local governments. These regulations include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the federal healthcare program anti-kickback law which prohibits, among other things, persons from soliciting, receiving or providing
remuneration, directly or indirectly, to induce either the referral of an individual, for an item or service or the purchasing
or ordering of a good or service, for which payment may be made under federal healthcare programs such as the Medicare and Medicaid
programs;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
federal false claims laws which prohibit, among other things, individuals or entities from knowingly presenting, or causing to
be presented, claims for payment from Medicare, Medicaid, or other government reimbursement programs that are false or fraudulent.
The government may assert that a claim including items or services resulting from a violation of the federal healthcare program
anti-kickback law or related to off-label promotion constitutes a false or fraudulent claim for purposes of the federal false
claims laws;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the Federal Physician Payments Sunshine Act within the ACA, and its implementing regulations, require that certain manufacturers
of drugs, devices, biological and medical supplies for which payment is available under Medicare, Medicaid or the Children&rsquo;s
Health Insurance Program (with certain exceptions) to report information related to certain payments or other transfers of value
made or distributed to physicians and teaching hospitals, or to entities or individuals at the request of, or designated on behalf
of, the physicians and teaching hospitals and to report annually certain ownership and investment interests held by physicians
and their immediate family members; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 34; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->32<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the Health Insurance Portability and Accountability Act, or HIPAA, as amended by the Health Information Technology for Economic
and Clinical Health Act, or HITECH, and its implementing regulations, imposes certain requirements relating to the privacy, security
and transmission of individually identifiable health information. Among other things, HITECH makes HIPAA&rsquo;s privacy and security
standards directly applicable to &ldquo;business associates&rdquo;&mdash;independent contractors or agents of covered entities
that receive or obtain protected health information in connection with providing a service on behalf of a covered entity. HITECH
also created four new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable
to business associates and possibly other persons, and gave state attorneys general new authority to file civil actions for damages
or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&rsquo; fees and costs associated with pursuing
federal civil actions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
The Lanham Act and federal antitrust laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items
or services reimbursed by any third party payer, including commercial insurers, and state laws governing the privacy and security
of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted
by federal laws, thus complicating compliance efforts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Distribution
of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing,
traceability, and storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
handling of any controlled substances must comply with the U.S. Controlled Substances Act and the Controlled Substances Import
and Export Act. In the U.S., our product candidate, lenabasum, is currently classified as Schedule I controlled substance as defined
in the Controlled Substance Act (&ldquo;CSA&rdquo;). This designation is based on lenabasum&rsquo;s chemical structure and pharmacology
(namely, it being a synthetic endocannabinoid mimetic that binds to the CB2 receptor). Even though lenabasum&rsquo;s mechanism
of action is to modulate the immune system and results to date from clinical studies have demonstrated the drug has no psychotropic
effects (which we believe is unlike other members of its chemical class), the DEA classifies lenabasum as a Schedule I substance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I controlled substances are pharmaceutical products subject to specific regulations under the CSA, that establishes, among other
things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements
administered by the DEA. All parties responsible for the manufacturing, distribution and testing the drug in clinical studies
must apply for and obtain a license from the DEA before they are permitted to perform these activities with lenabasum. Furthermore,
these parties must have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent
drug loss and diversion. All licensed facilities are required to renew their registrations annually if they intend to continue
to work with our drug. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances.
We have been working with our manufacturers, distributors, exporters and clinical sites to obtain the necessary licenses to work
with lenabasum. The parties responsible for the manufacturing, distribution and export of lenabasum have already applied for and
have been granted DEA licenses and a number of institutions responsible for conducting our current clinical studies have also
been granted DEA licenses</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal
law, because the states are separate jurisdictions, they may separately schedule drugs, as well. While some states automatically
schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. The requirement
for state registrations could also result in delay of the manufacturing, distribution of lenabasum or in the completion of our
current clinical studies. We and our manufacturing vendors and clinical sites must also obtain separate state registrations, permits
or licenses in order to be able to obtain, handle, and distribute controlled substances for clinical trials or commercial sale,
and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those
from the DEA or otherwise arising under federal law.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 35; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->33<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-Party
Payer Coverage and Reimbursement</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
uncertainty exists as to the coverage and reimbursement status of any of our drug candidates that ultimately may obtain regulatory
approval. In both the United States and foreign markets, our ability to commercialize our product candidates successfully, and
to attract commercialization partners for our product candidates, depends in significant part on the availability of adequate
financial coverage and reimbursement from third-party payers, including, in the United States, governmental payers such as the
Medicare and Medicaid programs, managed care organizations, and private health insurers. Medicare is a federally funded program
managed by the CMS, through local fiscal intermediaries and carriers that administer coverage and reimbursement for certain healthcare
items and services furnished to the elderly and disabled. Medicaid is an insurance program for certain categories of patients
whose income and assets fall below state defined levels and who are otherwise uninsured that is both federally and state funded
and managed by each state. The federal government sets general guidelines for Medicaid and each state creates specific regulations
that govern its individual program. Each payer has its own process and standards for determining whether it will cover and reimburse
a procedure or particular product. Private payers often rely on the lead of the governmental payers in rendering coverage and
reimbursement determinations. Therefore, achieving favorable CMS coverage and reimbursement is usually a significant gating issue
for successful introduction of a new product. The competitive position of some of our products will depend, in part, upon the
extent of coverage and adequate reimbursement for such products and for the procedures in which such products are used. Prices
at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by
the government and other payers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
United States Congress and state legislatures may, from time to time, propose and adopt initiatives aimed at cost containment,
which could impact our ability to sell our product candidates profitably. For example, the two-year spending law signed by the
President of United States on February 9, 2018 includes a provision raising the manufacturer discount to 70% in 2019 in the Medicare
Part D coverage gap, also known as the &ldquo;donut hole.&rdquo; Under prior law, manufacturers were required to provide a 50%
discount on prescription drugs purchased in the donut hole. Manufacturers of branded drugs will face much higher liabilities from
donut hole payments beginning in 2019, estimated at multiple billions of dollars for some of the largest companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
cost of pharmaceuticals continues to generate substantial governmental and third-party payer interest. We expect that the pharmaceutical
industry will experience pricing pressures due to the trend toward managed healthcare, the increasing influence of managed care
organizations and additional legislative proposals. Our results of operations could be adversely affected by current and future
healthcare reforms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Some
third-party payers also require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse
healthcare providers that use such therapies. While we cannot predict whether any proposed cost-containment measures will be adopted
or otherwise implemented in the future, the announcement or adoption of these proposals could have a material adverse effect on
our ability to obtain adequate prices for our product candidates and operate profitably.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The
requirements governing drug pricing vary widely from country to country. For example, the European Union provides options for
its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement
and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product
or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product
on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical
products will allow favorable reimbursement and pricing arrangements for any of our products. Historically, products launched
in the European Union do not follow price structures of the United States and generally tend to be significantly lower.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 36; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->34<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Employees</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
had 77 full-time employees at December 31, 2018. All of our employees are engaged in administration, finance, clinical, manufacturing,
regulatory and business development functions. We believe our relations with our employees are good. We anticipate that the number
of employees will grow as we continue to develop our product candidates. In addition, we utilize and will continue to utilize
consultants, clinical research organizations and third parties to perform our pre-clinical studies, clinical studies, manufacturing
and regulatory functions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Emerging
Growth Company</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or the JOBS Act.
We will remain an emerging growth company until the earlier of (1) December 31, 2019, (2) the last day of the first fiscal year
in which our annual gross revenues exceed $1.07 billion, (3) the date on which we become a &ldquo;large accelerated filer&rdquo;
as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if the market value of our common
stock that is held by non-affiliates exceeds $700 million as of the last business day of our most recently completed second fiscal
quarter or (4) the date on which we have issued more than $1 billion in non-convertible debt during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
as long as we remain an &ldquo;emerging growth company,&rdquo; we may take advantage of certain exemptions from various reporting
requirements that are applicable to public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited
to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, reduced disclosure
obligations regarding executive compensation and financial statements in our periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote to approve executive compensation and shareholder approval of any
golden parachute payments not previously approved. We are choosing to &ldquo;opt out&rdquo; of the extended transition periods
available under the JOBS Act for complying with new or revised accounting standards, and intend to take advantage of the other
reporting exemptions until we are no longer an &ldquo;emerging growth company.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corporate
Information</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
Pharmaceuticals, Inc. (formerly known as JB Therapeutics Inc.), was incorporated on April 24, 2009 under the laws of the State
of Delaware. On April 11, 2014, JB Therapeutics, Inc. completed a merger with Corbus Pharmaceuticals Holdings, Inc. and changed
its name to Corbus Pharmaceuticals, Inc. Upon the consummation of the merger, Corbus Pharmaceuticals, Inc. became a wholly owned
subsidiary of Corbus Pharmaceuticals Holdings, Inc. which continues to operate the business of Corbus Pharmaceuticals, Inc. Our
principal executive offices are located at 500 River Ridge Drive, Norwood, Massachusetts 02062, and our telephone number is (619)
963-0100. Our website address is <U>www.corbuspharma.com</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
make available free of charge on or through the Investor Relations link on our website, <U>www.corbuspharma.com</U>, access to
press releases and investor presentations, as well as all materials that we file electronically with the SEC, including our annual
report on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and amendments to those reports, filed or furnished
pursuant to Section 13(a) or 15(d) of the Exchange Act as soon as reasonably practicable after electronically filing such materials
with, or furnishing them to, the SEC. During the period covered by this Form 10-K, we made all such materials available through
our website as soon as reasonably practicable after filing such materials with the SEC. In addition, the SEC maintains an Internet
website, <U>www.sec.gov</U>, that contains reports, proxy and information statements and other information that we file electronically
with the SEC.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
report and the information incorporated herein by reference contain references to trademarks, service marks and trade names owned
by us or other companies. Solely for convenience, trademarks, service marks and trade names referred to in this report and the
information incorporated herein, including logos, artwork, and other visual displays, may appear without the &reg; or &trade;
symbols, but such references are not intended to indicate, in any way, that we will not assert, to the fullest extent under applicable
law, our rights or the rights of the applicable licensor to these trademarks, service marks and trade names. We do not intend
our use or display of other companies&rsquo; trade names, service marks or trademarks to imply a relationship with, or endorsement
or sponsorship of us by, any other companies. Other trademarks, trade names and service marks appearing in this report are the
property of their respective owners.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 37; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->35<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_003"></A><FONT STYLE="font-size: 10pt"><B>Item
    1A.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RISK
    FACTORS </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>An
investment in our common stock is speculative and illiquid and involves a high degree of risk including the risk of a loss of
your entire investment. You should carefully consider the risks and uncertainties described below and the other information contained
in this report and our other reports filed with the Securities and Exchange Commission. The risks set forth below are not the
only ones facing us. Additional risks and uncertainties may exist that could also adversely affect our business, operations and
financial condition. If any of the following risks actually materialize, our business, financial condition and/or operations could
suffer. In such event, the value of our common stock could decline, and you could lose all or a substantial portion of the money
that you pay for our common stock.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risk
Related to our Company and our Business</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Our Financial Position and Need for Capital</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are a clinical stage pharmaceutical company with a limited operating history</I>.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company with a limited operating history. We must complete clinical studies and receive regulatory
approval of a New Drug Application, or NDA, before commercial sales of a product can commence. The likelihood of success of our
business plan must be considered in light of the problems, substantial expenses, difficulties, complications and delays frequently
encountered in connection with developing and expanding early-stage businesses and the regulatory and competitive environment
in which we operate. Pharmaceutical product development is a highly speculative undertaking, involves a substantial degree of
risk and is a capital-intensive business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accordingly,
you should consider our prospects in light of the costs, uncertainties, delays and difficulties frequently encountered by companies
in the early stages of development, especially clinical pharmaceutical companies such as ours. Potential investors should carefully
consider the risks and uncertainties that a company with a limited operating history will face. In particular, potential investors
should consider that we cannot assure you that we will be able to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully implement or execute our current business plan, and we cannot assure you that our business plan is sound;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully manufacture our clinical products and establish commercial drug supply;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtain Drug Enforcement Administration, or DEA, licenses necessary for the manufacturing of lenabasum and for evaluating lenabasum
in our clinical trials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
successfully complete the clinical trials necessary to obtain regulatory approval for the marketing of our drug candidates, including
lenabasum and CRB-4001;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 38; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->36<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
secure market exclusivity and/or adequate intellectual property protection for our drug candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
attract and retain an experienced management and advisory team;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
secure acceptance of our drug candidates in the medical community and with third party payors and consumers;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
launch commercial sales of our drug candidates, whether alone or in collaboration with others; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
raise sufficient funds in the capital markets to effectuate our business plan.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we cannot successfully execute any one of the foregoing, our business may not succeed and your investment will be adversely affected.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have incurred operating losses in each year since our inception and expect to continue to incur substantial losses for the foreseeable
future. We may never become profitable or, if we achieve profitability, be able to sustain profitability.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to incur substantial expenses without corresponding revenues unless and until we are able to obtain regulatory approval
and successfully commercialize any of our drug candidates. We have been engaged in developing lenabasum since 2009, and we licensed
the exclusive worldwide rights to develop, manufacture and market drug candidates from Jenrin in the third quarter of 2018. To
date, we have not generated any revenue from our drug candidates and we expect to incur significant expense to complete our clinical
program for our drug candidates in the United States and elsewhere. We may never be able to obtain regulatory approval for the
marketing of our drug candidates in any indication in the United States or internationally. Even if we are able to commercialize
our drug candidates, there can be no assurance that we will generate significant revenues or ever achieve profitability. Our net
losses for the years ended December 31, 2018 and December 31, 2017 were approximately $55,672,000 and $32,422,000, respectively.
As of December 31, 2018, we had an accumulated deficit of approximately $121,370,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to obtain FDA approval for lenabasum, we would expect that our research and development expenses will continue to increase
as we advance clinical trials for additional indications. We may elect to pursue FDA approval for lenabasum in other indications
and for other drug candidates, which will result in significant additional research and development expenses. As a result, we
expect to continue to incur substantial losses for the foreseeable future, and these losses will increase. We are uncertain when
or if we will be able to achieve or sustain profitability. If we achieve profitability in the future, we may not be able to sustain
profitability in subsequent periods. Failure to become and remain profitable would impair our ability to sustain operations and
adversely affect the price of our common stock and our ability to raise capital.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
cash or cash equivalents will only fund our operations for a limited time and we will need to raise additional capital to support
our development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are currently operating at a loss and expect our operating costs will increase significantly as we incur further costs related
to the clinical trials for our drug candidates. As of December 31, 2018, we held cash and cash equivalents of approximately $41.7
million.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2018, we entered into the Cystic Fibrosis Program Related Investment Agreement (the &ldquo;Investment Agreement&rdquo;)
with the Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;), a non-profit drug discovery and development corporation, pursuant to
which we received a development award for up to $25 million in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b
clinical trial (the &ldquo;Phase 2b Clinical Trial&rdquo;) of lenabasum in patients with cystic fibrosis, of which we received
$12.5 million to date. The remainder of the 2018 CFF Award is payable to us incrementally upon the achievement of the remaining
milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 39; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->37<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, the Company entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (&ldquo;Kaken&rdquo;)
for the development and commercialization in Japan of the Company&rsquo;s investigational drug lenabasum for the treatment of
systemic sclerosis (&ldquo;SSc&rdquo;) and dermatomyositis (&ldquo;DM&rdquo;), two rare and serious autoimmune diseases. Under
the terms of the agreement, Kaken receives an exclusive license to commercialize and market lenabasum in Japan for SSc and DM.
Kaken will make an upfront payment to Corbus of $27 million. Corbus will be eligible to receive in addition up to $173 million
upon achievement of certain regulatory, development and sales milestones as well as double-digit royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2019, the Company consummated an underwritten public offering of shares of its common stock pursuant to which the
Company sold an aggregate of 6,198,500 shares of its common stock at a purchase price of $6.50 per share with gross proceeds to
the Company totaling $40,290,250, less estimated issuance costs incurred of approximately $2,667,000 (&ldquo;January 2019 Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect the cash and cash equivalents of approximately $41.7 million at December 31, 2018 together with the  $27 million upfront
payment to be received from Kaken, less the $2.7 million royalty (which is 10% of such upfront payment) that we will owe to CFF
pursuant to the Investment Agreement, and the approximately $37.6 million of net proceeds from the January 2019 Offering, to be
sufficient to meet our operating and capital requirements into the fourth quarter of 2020, based on planned expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
than the Investment Agreement, we do not currently have any arrangements or credit facilities in place as a source of funds, and
there can be no assurance that we will be able to raise sufficient additional capital on acceptable terms, or at all, including
pursuant to the Investment Agreement due to the dependency of our receiving future payments thereunder on our achieving certain
milestones described therein. If we are not successful in raising additional capital, we may not be able to continue as a going
concern. We may seek additional capital through a combination of private and public equity offerings, debt financings and strategic
collaborations. Debt financing, if obtained, may involve agreements that include covenants limiting or restricting our ability
to take specific actions, such as incurring additional debt, and could increase our expenses and require that our assets secure
such debt.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Equity
financing, if obtained, could result in dilution to our then existing stockholders and/or require such stockholders to waive certain
rights and preferences. If such financing is not available on satisfactory terms, or is not available at all, we may be required
to delay, scale back or eliminate the development of business opportunities and our operations and financial condition may be
materially adversely affected. We can provide no assurances that any additional sources of financing will be available to us on
favorable terms, if at all. In addition, if we are unable to secure sufficient capital to fund our operations, we may choose to
pursue, as an alternative, strategic collaborations that could require us to share commercial rights to our drug candidates with
third parties in ways that we currently do not intend or on terms that may not be favorable to us. If we choose to pursue additional
indications and/or geographies for our drug candidates or otherwise expand more rapidly than we presently anticipate we may also
need to raise additional capital sooner than expected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to Product Development, Regulatory Approval, Manufacturing and Commercialization</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
depend heavily on the success of lenabasum. If we are unable to generate revenues from lenabasum, our ability to create stockholder
value will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
most advanced product candidate currently is lenabasum, for which we have completed Phase 1 safety studies and Phase 2 clinical
studies and which we are evaluating in subsequent clinical studies. We do not generate revenues from any FDA approved drug products
and have no other product candidates in development other than CRB-4001 and the other compounds we licensed from Jenrin, which
are in the early stages of development. There is no guarantee that our clinical trials will be successful or that we will continue
with clinical studies to support an approval from the FDA of any of our product candidates for any indication. We note that most
drug candidates never reach the clinical development stage and even those that do have only a small chance of successfully completing
clinical development and gaining regulatory approval. Therefore, our business currently depends heavily on the successful development,
regulatory approval and commercialization of lenabasum, which may never occur.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 40; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->38<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not able to obtain any required regulatory approvals for our drug candidates, we will not be able to commercialize our
product candidates and our ability to generate revenue will be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
clinical trials may be unsuccessful, which would materially harm our business. Even if our ongoing clinical trials are successful,
we will be required to conduct additional clinical trials to establish the safety and efficacy of our drug candidates, before
a New Drug Application, or NDA, can be filed with the FDA for marketing approval of any of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive, is difficult to design and implement, can take many years to complete and is uncertain as to outcome. Success
in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim
results of a clinical trial do not necessarily predict final results. A failure of one or more of our clinical trials can occur
at any stage of testing. We may experience numerous unforeseen events during, or as a result of, the clinical trial process that
could delay or prevent our ability to receive regulatory approval or commercialize our drug candidates. The research, testing,
manufacturing, labeling, packaging, storage, approval, sale, marketing, advertising and promotion, pricing, export, import and
distribution of drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States
and other countries, which regulations differ from country to country. We are not permitted to market any of our drug candidates
as prescription pharmaceutical products in the United States until we receive approval of an NDA from the FDA or in foreign markets
until we receive the requisite approval from comparable regulatory authorities in such countries. In the United States, the FDA
generally requires the completion of clinical trials of each drug to establish its safety and efficacy and extensive pharmaceutical
development to ensure its quality before an NDA is approved. Regulatory authorities in other jurisdictions impose similar requirements.
Of the large number of drugs in development, only a small percentage result in the submission of an NDA to the FDA and even fewer
are eventually approved for commercialization. We have never submitted an NDA to the FDA or any comparable applications to other
regulatory authorities. If our development efforts for our drug candidates, including regulatory approval, are not successful
for our planned indications, or if adequate demand for our drug candidates is not generated, our business will be harmed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Receipt
of necessary regulatory approval is subject to a number of risks, including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the FDA or comparable foreign regulatory authorities or institutional review boards, or IRBs, may disagree with the design or
implementation of our clinical trials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
we may not be able to provide acceptable evidence of the safety and efficacy of our drug candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the results of our clinical trials may not be satisfactory or may not meet the level of statistical or clinical significance required
by the FDA, the European Medicines Agency, or EMA, or other comparable foreign regulatory authorities for marketing approval;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the dosing of our drug candidates in a particular clinical trial may not be at an optimal level;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
patients in our clinical trials may suffer adverse effects for reasons that may or may not be related to our drug candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the data collected from clinical trials may not be sufficient to support the submission of an NDA or other submission or to obtain
regulatory approval in the United States or elsewhere;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the FDA or comparable foreign regulatory authorities may fail to approve the manufacturing processes or facilities of third-party
manufacturers with which we contract for clinical and commercial supplies; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner
rendering our clinical data insufficient for approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 41; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->39<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Failure
to obtain regulatory approval for any of our drug candidates for the foregoing or any other reasons will prevent us from commercializing
such product candidate as a prescription product, and our ability to generate revenue will be materially impaired. We cannot guarantee
that regulators will agree with our assessment of the results of our clinical trials or that such trials will be considered by
regulators to have shown safety or efficacy of our product candidates. The FDA, EMA and other regulators have substantial discretion
in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and
require additional clinical trials, or pre-clinical or other studies. In addition, varying interpretations of the data obtained
from pre-clinical and clinical testing could delay, limit or prevent regulatory approval of a product candidate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have only limited experience in filing the applications necessary to gain regulatory approvals and expect to rely on consultants
and third party contract research organizations, or CROs, with expertise in this area to assist us in this process. Securing FDA
approval requires the submission of pre-clinical, clinical and/or pharmacokinetic data, information about product manufacturing
processes and inspection of facilities and supporting information to the FDA for each therapeutic indication to establish a product
candidate&rsquo;s safety and efficacy for each indication. Our drug candidates may prove to have undesirable or unintended side
effects, toxicities or other characteristics that may preclude our obtaining regulatory approval or prevent or limit commercial
use with respect to one or all intended indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of obtaining regulatory approvals is expensive, often takes many years, if approval is obtained at all, and can vary substantially
based upon, among other things, the type, complexity and novelty of the product candidates involved, the jurisdiction in which
regulatory approval is sought and the substantial discretion of regulatory authorities. Changes in the regulatory approval policy
during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review
for a submitted product application may cause delays in the approval or rejection of an application. Regulatory approval obtained
in one jurisdiction does not necessarily mean that a product candidate will receive regulatory approval in all jurisdictions in
which we may seek approval, but the failure to obtain approval in one jurisdiction may negatively impact our ability to seek approval
in a different jurisdiction. Failure to obtain regulatory marketing approval for any of our drug candidates in any indication
will prevent us from commercializing such product candidates, and our ability to generate revenue will be materially impaired.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Clinical
drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials
may not be predictive of future trial results.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Clinical
testing is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time
during the clinical trial process. The results of pre-clinical studies and early clinical trials may not be predictive of the
results of later-stage clinical trials. We cannot assure you that the FDA will view the results as we do or that any future trials
of our drug candidates will achieve positive results. Product candidates in later stages of clinical trials may fail to show the
desired safety and efficacy traits despite having progressed through pre-clinical studies and initial clinical trials. A number
of companies in the pharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy
or adverse safety profiles, notwithstanding promising results in earlier trials. Any future clinical trial results for our drug
candidates may not be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, a number of factors could contribute to a lack of favorable safety and efficacy results for our drug candidates. For
example, such trials could result in increased variability due to varying site characteristics, such as local standards of care,
differences in evaluation period and surgical technique, and due to varying patient characteristics, including demographic factors
and health status.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we receive regulatory approval for </I></B>our drug candidates<B><I>, we still may not be able to successfully commercialize
any of our products, and the revenue that we generate from sales, if any, may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
approved for marketing, the commercial success of our drug candidates will depend upon their acceptance by the medical community,
including physicians, patients and health care payors. The degree of market acceptance of our drug candidates will depend on a
number of factors, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
demonstration of clinical safety and efficacy;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
relative convenience, pill burden and ease of administration;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the prevalence and severity of any adverse effects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 55.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 42; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->40<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 55.6pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the willingness of physicians to prescribe our drug candidates and of the target patient population to try new therapies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
safety, tolerability and efficacy of our drug candidates compared to competing products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the introduction of any new products that may in the future become available to treat indications for which our drug candidates
may be approved;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
new procedures or methods of treatment that may reduce the incidences of any of the indications in which our drug candidates may
show utility;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
pricing and cost-effectiveness;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inclusion or omission of our drug candidates in applicable treatment guidelines;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the effectiveness of our or any future collaborators&rsquo; sales and marketing strategies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
limitations or warnings contained in FDA-approved labeling;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain and maintain sufficient third-party coverage or reimbursement from government health care programs, including
Medicare and Medicaid, private health insurers and other third-party payors; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the willingness of patients to pay out-of-pocket in the absence of third-party coverage or reimbursement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our drug candidates are approved, but do not achieve an adequate level of acceptance by physicians, health care payors
and patients, we may not generate sufficient revenue and we may not be able to achieve or sustain profitability. Our efforts to
educate the medical community and third-party payors on the benefits of our drug candidates may require significant resources
and may never be successful.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, even if we obtain regulatory approvals, the timing or scope of any approvals may prohibit or reduce our ability to commercialize
our drug candidates successfully. For example, if the approval process takes too long, we may miss market opportunities and give
other companies the ability to develop competing products or establish market dominance. Any regulatory approval we ultimately
obtain may be limited or subject to restrictions or post-approval commitments that render our drug candidates not commercially
viable. For example, regulatory authorities may approve our drug candidates for fewer or more limited indications than we request,
may not approve the prices we intend to charge for our drug candidates, may grant approval contingent on the performance of costly
post-marketing clinical trials, or may approve our drug candidates with labels that do not include the labeling claims necessary
or desirable for the successful commercialization of a particular indication. Further, the FDA or comparable foreign regulatory
authorities may place conditions on approvals, such as risk management plans and a Risk Evaluation and Mitigation Strategy, or
REMS, to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed
REMS; the FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician
communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries and other risk
minimization tools. The FDA may also require a REMS for an approved product when new safety information emerges. Any of these
limitations on approval or marketing could restrict the commercial promotion, distribution, prescription or dispensing of our
drug candidates. Moreover, product approvals may be withdrawn for non-compliance with regulatory standards or if problems occur
following the initial marketing of the product. Any of the foregoing scenarios could materially harm the commercial success of
our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 43; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->41<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Even
if we obtain marketing approval for our drug candidates, we will be subject to ongoing obligations and continued regulatory review,
which may result in significant additional expense. Additionally, our drug candidates could be subject to labeling and other restrictions
and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience
unanticipated problems with our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Even
if we obtain United States regulatory approval of our drug candidates for an indication, the FDA may still impose significant
restrictions on their indicated uses or marketing or the conditions of approval, or impose ongoing requirements for potentially
costly and time-consuming post-approval studies, including Phase 4 clinical trials, and post-market surveillance to monitor safety
and efficacy. Our drug candidates will also be subject to ongoing regulatory requirements governing the manufacturing, labeling,
packaging, storage, distribution, safety surveillance, advertising, promotion, recordkeeping and reporting of adverse events and
other post-market information. These requirements include registration with the FDA, continued compliance with current Good Clinical
Practices regulations, or cGCPs, for any clinical trials that we conduct post-approval, continued compliance with the CSA and
ongoing review by the DEA. In addition, manufacturers of drug products and their facilities are subject to continual review and
periodic inspections by the FDA and other regulatory authorities for compliance with current Good Manufacturing Practices, or
cGMP, requirements relating to quality control, quality assurance and corresponding maintenance of records and documents.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">With
respect to sales and marketing activities by us or any future partner, advertising and promotional materials must comply with
FDA rules in addition to other applicable federal, state and local laws in the United States and similar legal requirements in
other countries. In the United States, the distribution of product samples to physicians must comply with the requirements of
the U.S. Prescription Drug Marketing Act. Application holders must obtain FDA approval for product and manufacturing changes,
depending on the nature of the change. We may also be subject, directly or indirectly through our customers and partners, to various
fraud and abuse laws, including, without limitation, the U.S. Anti-Kickback Statute, U.S. False Claims Act, and similar state
laws, which impact, among other things, our proposed sales, marketing, and scientific/educational grant programs. If we participate
in the U.S. Medicaid Drug Rebate Program, the Federal Supply Schedule of the U.S. Department of Veterans Affairs, or other government
drug programs, we will be subject to complex laws and regulations regarding reporting and payment obligations. All of these activities
are also potentially subject to U.S. federal and state consumer protection and unfair competition laws. Similar requirements exist
in many of these areas in other countries.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, if any of our drug candidates are approved for an indication, our product labeling, advertising and promotion would
be subject to regulatory requirements and continuing regulatory review. The FDA strictly regulates the promotional claims that
may be made about prescription products. In particular, a product may not be promoted for uses that are not approved by the FDA
as reflected in the product&rsquo;s approved labeling. If we receive marketing approval for any of our drug candidates, physicians
may nevertheless legally prescribe such products to their patients in a manner that is inconsistent with the approved label. However,
if we are found to have promoted such off-label uses, we may become subject to significant liability and government fines. The
federal government has levied large civil and criminal fines against companies for alleged improper promotion and has enjoined
several companies from engaging in off-label promotion. The FDA has also requested that companies enter into consent decrees of
permanent injunctions under which specified promotional conduct is changed or curtailed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we or a regulatory agency discover previously unknown problems with a product, such as adverse events of unanticipated severity
or frequency or problems with the facility where the product is manufactured, or if we or our manufacturers fail to comply with
applicable regulatory requirements, we may be subject to the following administrative or judicial sanctions:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
restrictions on the marketing or manufacturing of the product, withdrawal of the product from the market, or voluntary or mandatory
product recalls;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
issuance of warning letters or untitled letters;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 44; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->42<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
injunctions or the imposition of civil or criminal penalties or monetary fines;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension of any ongoing clinical trials;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusal to approve pending applications or supplements to approved applications filed by us, or suspension or revocation of product
license approvals;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
suspension of, or imposition of restrictions on, operations, including costly new manufacturing requirements; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product seizure or detention or refusal to permit the import or export of product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
occurrence of any event or penalty described above may inhibit our ability to commercialize our drug candidates and generate revenue.
Adverse regulatory action, whether pre- or post-approval, can also potentially lead to product liability claims and increase our
product liability exposure.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
collaboration and license agreement, or the Collaboration Agreement, with Kaken Pharmaceuticals Co., Ltd., or Kaken, is important
to our business. If we or Kaken fail to adequately perform under the Collaboration Agreement, or if we or Kaken terminate the
Collaboration Agreement, the development and commercialization of lenabasum for the treatment of SSc and DM in Japan would be
delayed or terminated and our business would be adversely affected.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, we entered into the Collaboration Agreement with Kaken, pursuant to which we granted to Kaken an exclusive license
to commercialize and market lenabasum for the prevention and treatment of DM and SSc in Japan. Our ability to generate revenue
under the Collaboration Agreement will depend in large part on our success in further clinical development of lenabasum and Kaken&rsquo;s
success in achieving regulatory approval for, and commercializing lenabasum, in Japan. Such efforts are subject to significant
uncertainty. We have no control over the resources, time and effort that Kaken may devote to the commercialization of lenabasum.
Any of several events or factors could have a material adverse effect on our ability to generate revenue from Kaken&rsquo;s commercialization
of lenabasum in Japan. For example, Kaken:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may not achieve satisfactory levels of market acceptance and reimbursement by physicians, patients and third-party payers for
lenabasum for the treatment of DM and SSc;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may not compete successfully against other products and therapies for DM and SSc&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may have to comply with additional requests and recommendations from foreign regulatory authorities;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may not make all regulatory filings and obtain all necessary approvals from foreign regulatory agencies and all commercially necessary
reimbursement approvals&#894;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may not commit sufficient resources to the marketing and distribution of lenabasum, whether for competitive or strategic reasons
or otherwise due to a change in business priorities&#894; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
may cease to perform its obligations under the terms of the Collaboration Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, pursuant to the Collaboration Agreement, we and Kaken have agreed to negotiate in good faith to enter into a supply
agreement and a quality agreement. There can be no assurance that we will be able to reach mutually agreeable terms on such agreements
with Kaken, and the absence of agreement on such terms would prevent us from gaining the expected benefit of the Collaboration
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Further,
we and Kaken agreed to provide mutual indemnification against losses in connection with third-party claims arising out of breaches
of or inaccuracies in the Collaboration Agreement, gross negligence or willful misconduct, and the development or commercialization
of lenabasum pursuant to the Collaboration Agreement. Conflicts may arise in connection with these indemnification obligations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 45; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->43<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">After
a specified period of time, Kaken may unilaterally terminate the Collaboration Agreement on 180 days&rsquo; prior written notice
without any reason and without any further commitment. Kaken may also terminate in the event of certain safety concerns and clinical
failures, and either we or Kaken may terminate in the case of the other party&rsquo;s material breach or insolvency. Termination
of the Collaboration Agreement could cause significant delays in our product candidate development and commercialization efforts,
which could prevent us from commercializing lenabasum without first expanding our internal capabilities or entering into another
agreement with a third party. Any suitable alternative collaboration or license agreement would take considerable time to negotiate
and could also be on less favorable terms to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have entered into, and may in the future enter into, collaboration agreements for the licensing, development and ultimate commercialization
of some of our drug candidates. In such cases, we will depend greatly on our third-party collaborators to license, develop and
commercialize such drug candidates, and they may not meet our expectations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may enter into further co-development and commercialization partnerships for our drug candidates where appropriate. The process
of identifying collaborators and negotiating collaboration agreements for the licensing, development and ultimate commercialization
of some of our drug candidates may cause delays and increased costs. We may not be able to enter into collaboration agreements
on terms favorable to us or at all. Furthermore, some of those agreements may give substantial responsibility over our drug candidates
to the collaborator. Some collaborators may be unable or unwilling to devote sufficient resources to develop our drug candidates
as their agreements require. They often face business risks similar to ours, and this could interfere with their efforts. Also,
collaborators may choose to devote their resources to products that compete with ours. If a collaborator does not successfully
develop any one of our products, we will need to find another collaborator to do so. The success of our search for a new collaborator
will depend on our legal right to do so at the time and whether the product remains commercially viable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we enter into collaboration agreements for one or more of our drug candidates, the success of such drug candidates will depend
in great part upon our and our collaborators&rsquo; success in promoting them as superior to other treatment alternatives. We
believe that our drug candidates can be proven to offer disease treatment with notable advantages over drugs in terms of patient
compliance and effectiveness. However, there can be no assurance that we will be able to prove these advantages or that the advantages
will be sufficient to support the successful commercialization of our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
currently have no sales and marketing organization. If we are unable to secure a sales and marketing partner or establish satisfactory
sales and marketing capabilities, we may not successfully commercialize our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
present, we have just started building a commercial organization in order to commercialize products that are approved for commercial
sales. We must either collaborate with third parties that have such commercial infrastructure or continue to develop our own sales
and marketing infrastructure. If we are not successful in entering into appropriate collaboration arrangements, or recruiting
sales and marketing personnel or in building a sales and marketing infrastructure, we will have difficulty successfully commercializing
our drug candidates, which would adversely affect our business, operating results and financial condition.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to enter into collaboration agreements on terms acceptable to us or at all. In addition, even if we enter into
such relationships, we may have limited or no control over the sales, marketing and distribution activities of these third parties.
Our future revenues may depend heavily on the success of the efforts of these third parties. If we elect to establish a sales
and marketing infrastructure we may not realize a positive return on this investment. In addition, we will have to compete with
established and well-funded pharmaceutical and biotechnology companies to recruit, hire, train and retain sales and marketing
personnel. Factors that may inhibit our efforts to commercialize our drug candidates without strategic partners or licensees include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our inability to recruit and retain adequate numbers of effective sales and marketing personnel;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability of sales personnel to obtain access to or persuade adequate numbers of physicians to prescribe our drug candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to
companies with more extensive product lines; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
unforeseen costs and expenses associated with creating an independent sales and marketing organization.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 46; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->44<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
face competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete
effectively.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
biotechnology and pharmaceutical industries are intensely competitive and subject to rapid and significant technological change.
We have competitors in a number of jurisdictions, many of which have substantially greater name recognition, commercial infrastructures
and financial, technical and personnel resources than we have. Established competitors may invest heavily to quickly discover
and develop novel compounds that could make our drug candidates obsolete or uneconomical. Any new product that competes with an
approved product may need to demonstrate compelling advantages in efficacy, cost, convenience, tolerability and safety to be commercially
successful. Other competitive factors, including generic competition, could force us to lower prices or could result in reduced
sales. In addition, new products developed by others could emerge as competitors to our drug candidates. If we are not able to
compete effectively against our current and future competitors, our business will not grow and our financial condition and operations
will suffer.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Recently
enacted and future legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our
drug candidates and affect the prices we may obtain.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed
changes regarding the healthcare system that could prevent or delay marketing approval for our drug candidates, restrict or regulate
post-approval activities and affect our ability to profitably sell our drug candidates. Legislative and regulatory proposals have
been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We do
not know whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will
be changed, or what the impact of such changes on the marketing approvals of our drug candidates, if any, may be. In addition,
increased scrutiny by the U.S. Congress of the FDA&rsquo;s approval process may significantly delay or prevent marketing approval,
as well as subject us to more stringent product labeling and post-marketing testing and other requirements.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, under the Medicare Modernization Act, or MMA, Medicare Part D provides coverage to the elderly and disabled
for outpatient prescription drugs by approving and subsidizing prescription drug plans offered by private insurers. The MMA also
authorizes Medicare Part D prescription drug plans to use formularies where they can limit the number of drugs that will be covered
in any therapeutic class. The Part D plans use their formulary leverage to negotiate rebates and other price concessions from
drug manufacturers. Also under the MMA, Medicare Part B provides coverage to the elderly and disabled for physician-administered
drugs on the basis of the drug&rsquo;s average sales price, a price that is calculated according to regulatory requirements and
that the manufacturer reports to Medicare quarterly.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Both
Congress and the Centers for Medicare &amp; Medicaid Services (CMS), the agency that administers the Medicare program, from time
to time consider legislation, regulations, or other initiatives to reduce drug costs under Medicare Parts B and D. For example,
under the 2010 Affordable Care Act, drug manufacturers are required to provide a 50% discount on prescriptions for branded drugs
filled while the beneficiary is in the Medicare Part D coverage gap, also known as the &ldquo;donut hole.&rdquo; There have been
legislative proposals to repeal the &lsquo;non-interference&rdquo; provision of the MMA to allow CMS to leverage the Medicare
market share to negotiate larger Part D rebates. Further cost reduction efforts could decrease the coverage and price that we
receive for our drug candidates and could seriously harm our business. Private payors often follow Medicare coverage policy and
payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under the Medicare program may
result in a similar reduction in payments from private payors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
2010 Affordable Care Act is intended to broaden access to health insurance and reduce or constrain the growth of healthcare spending.
Further, the Affordable Care Act imposes a significant annual fee on companies that manufacture or import branded prescription
drug products. It also increased the amount of the rebates drug manufacturers must pay to state Medicaid programs, required that
Medicaid rebates be paid on managed Medicaid utilization, and increased the additional rebate on &ldquo;line extensions&rdquo;
(such as extended release formulations) of solid oral dosage forms of branded products. The law also contains substantial provisions
affecting fraud and abuse compliance and transparency, which may require us to modify our business practices with healthcare practitioners,
and incur substantial costs to ensure compliance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 47; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->45<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
President and the majority party in both Houses of the U.S. Congress have indicated their desire to repeal the Affordable Care
Act. It is unclear whether, when and how that repeal will be effectuated and what the effect on the healthcare sector will be.
In addition to the potential repeal of the Affordable Care Act, there are indications that the Medicaid program may be restructured,
which could lead to revisions in Medicaid coverage for prescription drugs. While we are unable to predict what legislation, if
any, may potentially be enacted, to the extent that future changes affect how our product candidates could be paid for and/or
reimbursed by the government and private payers, our business could be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example,
the Budget Control Act of 2011 included, among other things, provisions that have led to 2% across-the-board reductions in Medicare
payment amounts. Several states have adopted or are considering adopting laws that require pharmaceutical companies to provide
notice prior to raising prices and to justify price increases. We expect that additional healthcare reform measures will be adopted
in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services,
and in turn could significantly reduce the projected value of certain development projects and reduce our profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
future growth depends, in part, on our ability to enter into and succeed in markets outside of the United States, where we may
choose to rely on third party collaborations and will be subject to additional regulatory and commercial burdens, risks and other
uncertainties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
future profitability will depend, in part, on our ability to gain approval of and commercialize our drug candidates in non-U.S.
markets. In some or all of these non-U.S. markets, we intend to enter into licensing and contractual collaborations with third
parties, such as Kaken, to handle some or all of the tasks and responsibilities necessary to succeed. Our activities in non-U.S.
markets are subject to additional risks and uncertainties, including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to enter into favorable licensing and contractual arrangements with our partners;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to select partners who are capable of achieving success at the tasks they agree to perform;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtaining timely and sufficient favorable approval terms for our drug candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
obtaining favorable pricing and reimbursement;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our inability to directly control commercial activities because we are relying on third parties;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the burden of complying with complex and changing foreign regulatory, tax, accounting and legal requirements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
different medical practices and customs in foreign countries affecting acceptance in the marketplace;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
import or export licensing requirements;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
longer accounts receivable collection times;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
longer lead times for shipping;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
language barriers for technical training;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reduced protection of intellectual property rights in some foreign countries;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
foreign currency exchange rate fluctuations; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the interpretation of contractual provisions governed by foreign laws in the event of a contract dispute.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 48; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->46<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">International
sales of our drug candidates could also be adversely affected by the imposition of governmental controls, political and economic
instability, and trade restrictions and changes in tariffs, any of which may adversely affect our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we market our drug candidates in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting
laws, we may be subject to civil or criminal penalties.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
FDA enforces laws and regulations which require that the promotion of pharmaceutical products be consistent with the approved
prescribing information. While physicians may prescribe an approved product for a so-called &ldquo;off label&rdquo; use, it is
unlawful for a pharmaceutical company to promote its products in a manner that is inconsistent with its approved label and any
company which engages in such conduct may be subject to significant liability. Similarly, industry codes in the European Union
and other foreign jurisdictions prohibit companies from engaging in off-label promotion and regulatory agencies in various countries
enforce violations of the code with civil penalties. While we intend to ensure that our promotional materials are consistent with
our label, regulatory agencies may disagree with our assessment and may issue untitled letters, warning letters or may institute
other civil or criminal enforcement proceedings. In addition to FDA restrictions on marketing of pharmaceutical products, several
other types of state and federal healthcare fraud and abuse laws have been applied in recent years to restrict certain marketing
practices in the pharmaceutical industry. These laws include the U.S. Anti-Kickback Statute, U.S. False Claims Act and similar
state laws. Because of the breadth of these laws and the narrowness of the safe harbors, it is possible that some of our business
activities could be subject to challenge under one or more of these laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Anti-Kickback Statute prohibits, among other things, knowingly and willfully offering, paying, soliciting or receiving remuneration
to induce, or in return for, purchasing, leasing, ordering or arranging for the purchase, lease or order of any healthcare item
or service reimbursable under Medicare, Medicaid or other federally financed healthcare programs. This statute has been interpreted
broadly to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary
managers on the other. Although there are several statutory exemptions and regulatory safe harbors protecting certain common activities
from prosecution, the exemptions and safe harbors are drawn narrowly, and practices that involve remuneration intended to induce
prescribing, purchasing or recommending may be subject to scrutiny if they do not qualify for an exemption or safe harbor. Our
practices may not, in all cases, meet all of the criteria for safe harbor protection from anti-kickback liability. Moreover, recent
health care reform legislation has strengthened these laws. For example, the Health Care Reform Law, among other things, amends
the intent requirement of the U.S. Anti-Kickback Statute and criminal health care fraud statutes; a person or entity no longer
needs to have actual knowledge of this statute or specific intent to violate it. In addition, the Health Care Reform Law provides
that the government may assert that a claim including items or services resulting from a violation of the U.S. Anti-Kickback Statute
constitutes a false or fraudulent claim for purposes of the U.S. False Claims Act. Federal false claims laws prohibit any person
from knowingly presenting, or causing to be presented, a false claim for payment to the federal government or knowingly making,
or causing to be made, a false statement to get a false claim paid.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Over
the past few years, pharmaceutical and other healthcare companies have been prosecuted under these laws for a variety of alleged
promotional and marketing activities, such as: allegedly providing free trips, free goods, sham consulting fees and grants and
other monetary benefits to prescribers; reporting to pricing services inflated average wholesale prices that were then used by
federal programs to set reimbursement rates; engaging in off-label promotion that caused claims to be submitted to Medicare or
Medicaid for non-covered, off-label uses; and submitting inflated best price information to the Medicaid Rebate Program to reduce
liability for Medicaid rebates. Most states also have statutes or regulations similar to the U.S. Anti-Kickback Statute and the
U.S. False Claims Act, which apply to items and services reimbursed under Medicaid and other state programs, or, in several states,
apply regardless of the payor. Sanctions under these federal and state laws may include substantial civil monetary penalties,
exclusion of a manufacturer&rsquo;s products from reimbursement under government programs, substantial criminal fines and imprisonment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 49; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->47<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are, and will be, completely dependent on third parties to manufacture our drug candidates, and our commercialization of our drug
candidates could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from
the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of our drug candidates or
fail to do so at acceptable quality levels or prices.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not currently have, nor do we plan to acquire, the capability or infrastructure to manufacture the active pharmaceutical ingredients
of our drug candidates, or the finished drug products, for use in our clinical trials or for commercial product, if any. As a
result, we will be obligated to rely on contract manufacturers if and when our drug candidates are approved for commercialization.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
currently rely on a single foreign supplier for manufacturing the starting chemical intermediates and finished bulk drug product
for lenabasum. We also rely on a single foreign supplier for the manufacturing of the finished lenabasum capsules. The facilities
used by our two contract manufacturers to manufacture lenabasum must be approved by the FDA pursuant to inspections that will
be conducted after we submit our NDAs to the FDA. We do not control the manufacturing processes of, and are completely dependent
on, our two contract manufacturing partners for compliance with cGMPs for manufacture of all active drug substances and finished
drug products. These cGMP regulations cover all aspects of the manufacturing, testing, quality control and record keeping relating
to our drug candidates. If our contract manufacturers cannot successfully manufacture material that conforms to our specifications
and the strict regulatory requirements of the FDA or others, they will not be able to secure and/or maintain regulatory approval
for their manufacturing facilities. If the FDA or a comparable foreign regulatory authority does not approve these facilities
for the manufacture of lenabasum or our other product candidates or if it withdraws any such approval in the future, we may need
to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval
for or market our drug candidates, if approved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
contract manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign
agencies for compliance with cGMPs and similar regulatory requirements. We will not have control over our contract manufacturers&rsquo;
compliance with these regulations and standards. Failure by any of our contract manufacturers to comply with applicable regulations
could result in sanctions being imposed on us, including fines, injunctions, civil penalties, failure to grant approval to market
our drug candidates, delays, suspensions or withdrawals of approvals, operating restrictions and criminal prosecutions, any of
which could significantly and adversely affect our business. In addition, we will not have control over the ability of our contract
manufacturers to maintain adequate quality control, quality assurance and qualified personnel. Failure by our contract manufacturers
to comply with or maintain any of these standards could adversely affect our ability to develop, obtain regulatory approval for
or market our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
for any reason, these third parties are unable or unwilling to perform, we may not be able to terminate our agreements with them,
and we may not be able to locate alternative manufacturers or formulators or enter into favorable agreements with them and we
cannot be certain that any such third parties will have the manufacturing capacity to meet future requirements. If these manufacturers
or any alternate manufacturer of finished drug product experiences any significant difficulties in its respective manufacturing
processes for our active pharmaceutical ingredient, or API, or our finished products or should cease doing business with us, we
could experience significant interruptions in the supply of our drug candidates or may not be able to create a supply of our drug
candidates at all. Were we to encounter manufacturing issues, our ability to produce a sufficient supply of our drug candidates
might be negatively affected. Our inability to coordinate the efforts of our third party manufacturing partners, or the lack of
capacity available at our third party manufacturing partners, could impair our ability to supply our drug candidates at required
levels. Because of the significant regulatory requirements that we would need to satisfy in order to qualify a new bulk or finished
product manufacturer, if we face these or other difficulties with our current manufacturing partners, we could experience significant
interruptions in the supply of our drug candidates if we decided to transfer the manufacture of our drug candidates to one or
more alternative manufacturers in an effort to deal with the difficulties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 50; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->48<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
manufacturing problem or the loss of a contract manufacturer could be disruptive to our operations and result in lost sales. Additionally,
we rely on third parties to supply the raw materials needed to manufacture our potential products. Any reliance on suppliers may
involve several risks, including a potential inability to obtain critical materials and reduced control over production costs,
delivery schedules, reliability and quality. Any unanticipated disruption to a future contract manufacturer caused by problems
at suppliers could delay shipment of our drug candidates, increase our cost of goods sold and result in lost sales.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot guarantee that our manufacturing and supply partners will be able to manufacture our drug candidates at commercial scale
on a cost-effective basis. If the commercial-scale manufacturing costs of our drug candidates are higher than expected, these
costs may significantly impact our operating results. In order to reduce costs, we may need to develop and implement process improvements.
However, in order to do so, we will need, from time to time, to notify or make submissions with regulatory authorities, and the
improvements may be subject to approval by such regulatory authorities. We cannot be sure that we will receive these necessary
approvals or that these approvals will be granted in a timely fashion. We also cannot guarantee that we will be able to enhance
and optimize output in our commercial manufacturing process. If we cannot enhance and optimize output, we may not be able to reduce
our costs over time.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
are risks associated with scaling up manufacturing to commercial scale. If our contract manufacturers are unable to manufacture
our drug candidates on a commercial scale, this could potentially delay regulatory approval and commercialization or materially
adversely affect our results of operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">There
are risks associated with scaling up manufacturing to commercial volumes including, among others, cost overruns, technical problems
with process scale-up, process reproducibility, stability issues, and lot consistency. Even if we obtain regulatory approval for
our drug candidates, there is no assurance that our contract manufacturers will be able to manufacture the approved products to
specifications acceptable to the FDA or other regulatory authorities, to produce them in sufficient quantities to meet the requirements
for the potential launch of the product or to meet potential future demand. If our manufacturers are unable to produce sufficient
quantities of approved products for commercialization, either on a timely basis or at all, our commercialization efforts would
be impaired, which would have a material adverse effect on our business, financial condition, results of operations and growth
prospects.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
lead product candidate, lenabasum, is currently classified as a Schedule I controlled substance subject to U.S. controlled substance
laws and regulations, including regulations of the Drug Enforcement Agency and the U.S. Food and Drug Administration. Failure
to obtain the necessary licenses and registrations and failure to comply with these laws could result in the delay in the manufacturing
and distribution of lenabasum and could delay the completion of clinical studies. Such delays and the cost of compliance with
these laws and regulations, could adversely affect our business operations and our financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the United States, our lead product candidate, lenabasum, is currently classified as a Schedule I controlled substance as defined
in the Controlled Substance Act (&ldquo;CSA&rdquo;). This designation is based on lenabasum&rsquo;s chemical structure and pharmacology
(namely, it being a synthetic endocannabinoid mimetic that binds to the CB2 receptor). Even though lenabasum&rsquo;s mechanism
of action is to modulate the immune system and results to date from clinical trials indicate that the drug has no psychotropic
effects (which we believe is unlike other members of its chemical class), the DEA classifies lenabasum as a Schedule I substance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedule
I controlled substances are pharmaceutical products subject to specific regulations under the CSA, which establishes, among other
things, certain registration, manufacturing quotas, security, recordkeeping, reporting, import, export and other requirements
administered by the DEA. All parties responsible for the manufacturing, distribution and testing of the drug in clinical studies
must apply for and obtain a license from the DEA before they are permitted to perform these activities with lenabasum. Furthermore,
these parties must have the security, control, recordkeeping, reporting and inventory mechanisms required by the DEA to prevent
drug loss and diversion. All licensed facilities are required to renew their registrations annually if they intend to continue
to work with our drug. The DEA conducts periodic inspections of certain registered establishments that handle controlled substances.
We have been working with our manufacturers, distributors, exporters and clinical sites to obtain the necessary licenses to work
with lenabasum. The parties responsible for the manufacturing, distribution and export of lenabasum have already applied for and
have been granted DEA licenses and a number of institutions responsible for conducting our current clinical studies have also
been granted DEA licenses. However, the failure to maintain the necessary registrations, and the delay or failure of additional
clinical sites to obtain DEA registrations, could delay the manufacturing, distribution and export of lenabasum and could delay
the completion of the clinical studies. Furthermore, failure to maintain compliance with the CSA, particularly non-compliance
resulting in loss or diversion, could result in regulatory action that could have a material adverse effect on our business, financial
condition and results of operations. The DEA may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings
to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal proceedings. In
addition, if the FDA, DEA, or any foreign regulatory authority determines that lenabasum may have potential for abuse, it may
require us to generate more clinical or other data than we currently anticipate to establish whether or to what extent the substance
has an abuse potential, which could increase the cost and/or delay the launch of lenabasum.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 51; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->49<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Individual
states have also established controlled substance laws and regulations. Though state-controlled substances laws often mirror federal
law, because the states are separate jurisdictions, they may separately schedule drugs, as well. While some states automatically
schedule a drug based on federal action, other states schedule drugs through rulemaking or a legislative action. The requirement
for state registrations could also result in delay of the manufacturing and distribution of lenabasum or in the completion of
our clinical studies. We and our manufacturing vendors and clinical sites must also obtain separate state registrations, permits
or licenses in order to be able to obtain, handle and distribute controlled substances for clinical trials or commercial sale,
and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those
from the DEA or otherwise arising under federal law.&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
manufacturing and distribution of lenabasum is subject to the DEA&rsquo;s annual manufacturing and procurement quota requirements.
The annual quota allocated to us or our contract manufacturers for the controlled substances in lenabasum may not be sufficient
to complete clinical trials. Consequently, any delay or refusal by the DEA in establishing our, or our contract manufacturers&rsquo;,
procurement and/or production quota for controlled substances could delay or stop our clinical trials or product launches, which
could have a material adverse effect on our business, financial position and operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
lenabasum is a Schedule I controlled substance, if lenabasum is approved for medical use by the FDA, it will have satisfied the
&ldquo;accepted medical use&rdquo; requirement of the CSA. If and when lenabasum receives FDA approval, the DEA will make a scheduling
determination and place lenabasum in a schedule other than Schedule I or declassify it in order for it to be prescribed to patients
in the United States. As part of the scheduling determination, FDA will assess the abuse and dependence potential of lenabasum
and make a scheduling recommendation to DEA. If approved by the FDA, the length of time the DEA takes to complete the rescheduling
or declassification of lenabasum is uncertain and could be lengthy and we will not be able to sell the drug until the rescheduling
is complete. Any delays in the rescheduling could have a material adverse impact on our results of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Delays
in shipping our drug candidates could have a material adverse effect on our business, results of operations and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
import and export of our drug candidates requires import and export licenses. In addition, because lenabasum is currently a Schedule
I controlled substance in the United States, in addition to the FDA and U.S. Customs and Border Protection, its import and export
is also regulated by the DEA. We may not be granted, or if granted, maintain, such licenses for import or export from the authorities
these regulatory agencies. Even if we obtain the relevant licenses, shipments of our drug candidates may be held up in transit
by any of these authorities, which could cause significant delays and may lead to product batches which no longer meet specifications
for use in clinical trials or commercial distribution. Such events could result in delayed development timelines, increased expenses
and partial or total loss of revenue from our drug candidates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 52; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->50<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
expect that we will rely on third parties to assist us in conducting clinical trials for our drug candidates. If these third parties
do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval
for or commercialize our drug candidates and our business would be substantially harmed.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to enter into agreements with third-party CROs to assist us in conducting and managing our clinical programs, including
contracting with clinical sites to perform our clinical studies. We plan to rely on these parties for execution of clinical studies
for our drug candidates and we will control only certain aspects of conducting the clinical studies. Nevertheless, we will be
responsible for ensuring that each of our studies is conducted in accordance with the applicable protocol, legal, regulatory and
scientific standards, and our reliance on CROs and clinical sites will not relieve us of our regulatory responsibilities. We and
our CROs will be required to comply with cGCPs, which are regulations and guidelines enforced by the FDA, the Competent Authorities
of the Member States of the European Economic Area and comparable foreign regulatory authorities for any products in clinical
development. The FDA enforces these cGCP regulations through periodic inspections of trial sponsors, principal investigators and
trial sites. If we or our CROs fail to comply with applicable cGCPs, the clinical data generated in our clinical trials may be
deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials
before approving our marketing applications. We cannot assure you that, upon inspection, the FDA will determine that any of our
clinical trials comply with cGCPs. In addition, our clinical trials must be conducted with products produced under cGMP regulations
and will require a large number of test subjects. Our failure or the failure of our CROs or clinical sites to comply with these
regulations may require us to repeat clinical trials, which would delay the regulatory approval process and could also subject
us to enforcement action up to and including civil and criminal penalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we intend to design the clinical trials for our drug candidates in consultation with CROs, we expect that the CROs will manage
all of the clinical trials conducted at contracted clinical sites. As a result, many important aspects of our drug development
programs would be outside of our direct control. In addition, the CROs and clinical sites may not perform all of their obligations
under arrangements with us or in compliance with regulatory requirements. If the CROs or clinical sites do not perform clinical
trials in a satisfactory manner, or if they breach their obligations to us or fail to comply with regulatory requirements, the
development and commercialization of our drug candidates for the subject indications may be delayed or our development program
materially and irreversibly harmed. We cannot control the amount and timing of resources these CROs and clinical sites will devote
to our program or our drug candidates. If we are unable to rely on clinical data collected by our CROs, we could be required to
repeat, extend the duration of, or increase the size of our clinical trials, which could significantly delay commercialization
and require significantly greater expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
any of our relationships with these third-party CROs or clinical sites terminate, we may not be able to enter into arrangements
with alternative CROs or clinical sites. If CROs do not successfully carry out their contractual duties or obligations or meet
expected deadlines, if they need to be replaced or if the quality or accuracy of the clinical data they obtain is compromised
due to the failure to adhere to our clinical protocols, regulatory requirements or for other reasons, any such clinical trials
may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for or successfully commercialize
our drug candidates. As a result, our financial results and the commercial prospects for our drug candidates would be harmed,
our costs could increase and our ability to generate revenue could be delayed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
termination or suspension of or delays in the commencement or completion of any necessary studies of our drug candidates for any
indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial
prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
commencement and completion of clinical studies can be delayed for a number of reasons, including delays related to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the FDA failing to grant permission to proceed and placing the clinical study on hold;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subjects failing to enroll or remain in our trials at the rate we expect;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 55.6pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a facility manufacturing any of our drug candidates being ordered by the FDA or other government or regulatory authorities to
temporarily or permanently shut down due to violations of cGMP requirements or other applicable requirements, or cross-contaminations
of product in the manufacturing process;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 53; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->51<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
                                         any changes to our manufacturing process that may be necessary or desired;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subjects choosing an alternative treatment for the indications for which we are developing our drug candidates, or participating
in competing clinical studies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
subjects experiencing severe or unexpected drug-related adverse effects;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
reports of similar technologies and products raising safety and/or efficacy concerns;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
third-party clinical investigators losing their license or permits necessary to perform our clinical trials, not performing our
clinical trials on our anticipated schedule or employing methods consistent with the clinical trial protocol, cGCP requirements,
or other third parties not performing data collection and analysis in a timely or accurate manner;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
inspections of clinical study sites by the FDA or IRBs finding regulatory violations that require us to undertake corrective action,
result in suspension or termination of one or more sites or the imposition of a clinical hold on the entire study, or that prohibit
us from using some or all of the data in support of our marketing applications;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
third-party contractors becoming debarred or suspended or otherwise penalized by the FDA or other government or regulatory authorities
for violations of regulatory requirements, in which case we may need to find a substitute contractor, and we may not be able to
use some or any of the data produced by such contractors in support of our marketing applications;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
one or more IRBs refusing to approve, suspending or terminating the study at an investigational site precluding enrollment of
additional subjects, or withdrawing its approval of the trial; reaching agreement on acceptable terms with prospective CROs and
clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs
and trial sites;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
deviations of the clinical sites from trial protocols or dropping out of a trial;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
adding new clinical trial sites;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability of the CRO to execute any clinical trials for any reason; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
government or regulatory delays or &ldquo;clinical holds&rdquo; requiring suspension or termination of a trial.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Product
development costs for our drug candidates will increase if we have delays in testing or approval or if we need to perform more
or larger clinical studies than planned. Additionally, changes in regulatory requirements and policies may occur and we may need
to amend study protocols to reflect these changes. Amendments may require us to resubmit our study protocols to the FDA and IRBs
for reexamination, which may impact the costs, timing or successful completion of that study. If we experience delays in completion
of, or if we, the FDA or other regulatory authorities, any IRBs, or other reviewing entities, or any of our clinical study sites
suspend or terminate any of our clinical studies of our drug candidates, our commercial prospects may be materially harmed and
our ability to generate product revenues will be delayed. Any delays in completing our clinical trials will increase our costs,
slow down our development and approval process and jeopardize our ability to commence product sales and generate revenues. Any
of these occurrences may harm our business, financial condition and prospects significantly. In addition, many of the factors
that cause, or lead to, termination or suspension of, or a delay in the commencement or completion of, clinical studies may also
ultimately lead to the denial of regulatory approval of our drug candidates. In addition, if one or more clinical studies are
delayed, our competitors may be able to bring products to market before we do, and the commercial viability of our drug candidates
could be significantly reduced.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 54; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->52<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may not be able to obtain or maintain orphan drug designation or exclusivity for our product candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have been granted orphan drug designation in the United States and in the European Union for lenabasum for the treatment of CF,
SSc and DM. Upon receipt of regulatory approval, orphan drug status will provide us with seven years of market exclusivity in
the United States under the Orphan Drug Act. However, there is no guarantee that the FDA will grant orphan drug designation for
any of our drug candidates for any future indication, which would make us ineligible for the additional exclusivity and other
benefits of orphan drug designation. <FONT STYLE="background-color: white">Moreover, there can be no assurance that another company
also holding orphan drug designation for the same indication or which may receive orphan drug designation in the future will not
receive approval prior to us, in which case our competitor would have the benefit of the seven years of market exclusivity, and
we would be unable to commercialize our product for the same indication until the expiration of such seven-year period. Even if
we are the first to obtain approval for the orphan drug indication, there are circumstances under which a competing product may
be approved for the same indication during our seven-year period of exclusivity.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
the Orphan Drug Act, the FDA may grant orphan drug designation to a drug intended to treat a rare disease or condition, which
is generally a disease or condition that affects fewer than 200,000 individuals in the United States and for which there is no
reasonable expectation that the cost of developing and making a drug available in the Unites States for this type of disease or
condition will be recovered from sales of the product. Orphan drug designation must be requested before submitting an NDA. After
the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly
by the FDA. Orphan designation does not convey any advantage in or shorten the duration of regulatory review and approval process.
In addition to the potential period of exclusivity, orphan designation makes a company eligible for grant funding of up to $400,000
per year for four years to defray costs of clinical trial expenses, tax credits for clinical research expenses and potential exemption
from the FDA application user fee.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has
such designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other applications
to market the same drug for the same indication for seven years, except in limited circumstances, such as (i) the drug&rsquo;s
orphan designation is revoked; (ii) its marketing approval is withdrawn; (iii) the orphan exclusivity holder consents to the approval
of another applicant&rsquo;s product; (iv) the orphan exclusivity holder is unable to assure the availability of a sufficient
quantity of drug; or (v) a showing of clinical superiority to the product with orphan exclusivity by a competitor product. If
a drug designated as an orphan product receives marketing approval for an indication broader than what is designated, it may not
be entitled to orphan drug exclusivity. There can be no assurance that we will receive orphan drug designation for any of our
drug candidates for any additional indications, if we elect to seek such designation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
fast track designation or grant of priority review status by the FDA may not actually lead to a faster development or regulatory
review or approval process, nor will it assure FDA approval of our product candidates. Additionally, our product candidates may
treat indications that do not qualify for priority review vouchers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have received fast track designation for lenabasum for the treatment of cystic fibrosis and systemic sclerosis in the United States
and European Union and may seek fast track designation or priority review of applications for approval of our product candidate
for future indications. If a drug is intended for the treatment of a serious or life-threatening condition and the drug demonstrates
the potential to address unmet medical needs for this condition, the drug sponsor may apply for FDA fast track designation. If
a product candidate offers major advances in treatment, the FDA may designate it eligible for priority review. The FDA has broad
discretion whether or not to grant these designations, so even if we believe a particular product candidate is eligible for these
designations, we cannot assure you that the FDA would decide to grant them. Even if we do receive fast track designation or priority
review, we may not experience a faster development process, review or approval compared to conventional FDA procedures. The FDA
may withdraw fast track designation if it believes that the designation is no longer supported by data from our clinical development
program.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 55; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->53<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Any
breakthrough therapy designation granted by the FDA for our product candidate may not lead to a faster development or regulatory
review or approval process, and it does not increase the likelihood that our product candidate will receive marketing approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have applied for, and may in the future apply for, a breakthrough therapy designation of our product candidates for future indications.
A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a
serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial
improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed
early in clinical development. For drugs and biologics that have been designated as breakthrough therapies, interaction and communication
between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing
the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also
be eligible for accelerated approval if the relevant criteria are met.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designation
of a product candidate as a breakthrough therapy is within the discretion of the FDA. Accordingly, even if we believe our product
candidate meets the criteria for designation as a breakthrough therapy, the FDA may disagree and instead determine not to make
such designation. In any event, the receipt of a breakthrough therapy designation for a product candidate may not result in a
faster development process, review or approval compared to drugs considered for approval under conventional FDA procedures and
does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough
therapies, the FDA may later decide that the products no longer meet the conditions for qualification or decide that the time
period for FDA review or approval will not be shortened.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Third-party
coverage and reimbursement and health care cost containment initiatives and treatment guidelines may constrain our future revenues.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to successfully market our drug candidates will depend in part on the level of reimbursement that government health administration
authorities, private health coverage insurers and other organizations provide for the cost of our products and related treatments.
Countries in which our drug candidates are expected to be sold through reimbursement schemes under national health insurance programs
frequently require that manufacturers and sellers of pharmaceutical products obtain governmental approval of initial prices and
any subsequent price increases. In certain countries, including the United States, government-funded and private medical care
plans can exert significant indirect pressure on prices. We may not be able to sell our drug candidates profitably if adequate
prices are not approved or coverage and reimbursement is unavailable or limited in scope. Increasingly, third-party payors attempt
to contain health care costs in ways that are likely to impact our development of products including:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
failing to approve or challenging the prices charged for health care products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
introducing reimportation schemes from lower priced jurisdictions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
limiting both coverage and the amount of reimbursement for new therapeutic products;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
denying or limiting coverage for products that are approved by the regulatory agencies but are considered to be experimental or
investigational by third-party payors; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
refusing to provide coverage when an approved product is used in a way that has not received regulatory marketing approval.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Relating to Our Intellectual Property Rights</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>It
is difficult and costly to protect our intellectual property rights, and we cannot ensure the protection of these rights.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
commercial success will depend, in part, on maintaining and obtaining additional patent protection for our technologies, products
and processes, successfully defending these patents against third-party challenges and successfully enforcing these patents against
third party competitors. The patent positions of pharmaceutical companies can be highly uncertain and involve complex legal, scientific
and factual questions for which important legal principles remain unresolved. Changes in either the patent laws or in interpretations
of patent laws may diminish the value of our intellectual property. Accordingly, we cannot predict the breadth of claims that
may be allowable in our pending applications or, the enforceability of our existing and future patents. Our pending patent applications
for lenabasum and its uses may never be approved by United States or foreign patent offices and the existing patents and patent
applications relating to lenabasum and related technologies may be challenged, invalidated or circumvented by third parties and
may not protect us against competitors with similar products or technologies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 56; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->54<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
degree of our current and future protection for our proprietary rights is uncertain, because legal means afford only limited protection
and may not adequately protect our rights, permit us to gain or keep our competitive advantage, or provide us with any competitive
advantage at all. For example, others have filed, and in the future are likely to file, patent applications covering products
and technologies that are similar, identical or competitive to lenabasum, or important to our business. We cannot be certain that
any patents or patent application owned by a third party will not have priority over patents and patent applications filed by
us, or that we will not be involved in interference, opposition or invalidity proceedings before United States or foreign patent
offices.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
also rely on trade secrets to protect technology, especially in cases when we believe patent protection is not appropriate or
obtainable. However, trade secrets are difficult to protect. While we require employees, academic collaborators, consultants and
other contractors to enter into confidentiality agreements, we may not be able to adequately protect our trade secrets or other
proprietary or licensed information. Typically, research collaborators and scientific advisors have rights to publish data and
information in which we may have rights. If we cannot maintain the confidentiality of our proprietary technology and other confidential
information, our ability to receive patent protection and our ability to protect valuable information owned by us may be imperiled.
Enforcing a claim that a third-party entity illegally obtained and is using any of our trade secrets is expensive and time consuming,
and the outcome is unpredictable. In addition, courts are sometimes less willing to protect trade secrets than patents. Moreover,
our competitors may independently develop equivalent knowledge, methods and know-how.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we fail to maintain or obtain additional patent protection or trade secret protection for lenabasum or our technologies, third
parties could use our proprietary information, which could impair our ability to compete in the market and adversely affect our
ability to generate revenues and attain profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may also rely on the trademarks we may develop to distinguish our products from the products of our competitors. We cannot guarantee
that any trademark applications filed by us or our business partners will be approved. Third parties may also oppose such trademark
applications, or otherwise challenge our use of the trademarks. In the event that the trademarks we use are successfully challenged,
we could be forced to rebrand our products, which could result in loss of brand recognition, and could require us to devote resources
to advertising and marketing new brands. Further, we cannot provide assurance that competitors will not infringe the trademarks
we use, or that we will have adequate resources to enforce these trademarks.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
have in-licensed a portion of our intellectual property, and if we fail to comply with our obligations under these arrangements,
we could lose such intellectual property rights or owe damages to the licensor of such intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a party to a license agreement with Jenrin pursuant to which we licensed the exclusive worldwide rights to develop, manufacture
and market drug candidates from Jenrin. This agreement is important to our business, and we may enter into additional license
agreements in the future. Certain of our in-licensed intellectual property covers, or may cover, CRB-4001 and other potential
developmental candidates. Our existing license agreement imposes, and we expect that future license agreements will impose, various
diligence, milestone payment, royalty and other obligations on us. If there is any conflict, dispute, disagreement or issue of
non-performance between us and our licensing partners regarding our rights or obligations under the license agreements, including
any such conflict, dispute or disagreement arising from our failure to satisfy payment obligations under any such agreement, we
may owe damages, our licensor may have a right to terminate the affected license, and our ability to utilize the affected intellectual
property in our product discovery and development efforts and our ability to enter into collaboration or marketing agreements
for an affected product candidate may be adversely affected.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 57; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->55<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Lenabasum
and our other product candidates may infringe the intellectual property rights of others, which could increase our costs and delay
or prevent our development and commercialization efforts.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
success depends in part on avoiding infringement of the proprietary technologies of others. The pharmaceutical industry has been
characterized by frequent litigation regarding patent and other intellectual property rights. Identification of third party patent
rights that may be relevant to our proprietary technology is difficult because patent searching is imperfect due to differences
in terminology among patents, incomplete databases and the difficulty in assessing the meaning of patent claims. Additionally,
because patent applications are maintained in secrecy until the application is published, we may be unaware of third-party patents
that may be infringed by commercialization of lenabasum or any of our other product candidates. There may be certain issued patents
and patent applications claiming subject matter that we may be required to license in order to research, develop or commercialize
lenabasum or our other product candidates, and we do not know if such patents and patent applications would be available to license
on commercially reasonable terms, or at all. Any claims of patent infringement asserted by third parties would be time-consuming
and may:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
result in costly litigation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
divert the time and attention of our technical personnel and management;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
prevent us from commercializing a product until the asserted patent expires or is held finally invalid or not infringed in a court
of law;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
require us to cease or modify our use of the technology and/or develop non-infringing technology; or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
require us to enter into royalty or licensing agreements.</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
no third party has asserted a claim of infringement against us, others may hold proprietary rights that could prevent our product
candidates from being marketed. Any patent-related legal action against us claiming damages and seeking to enjoin commercial activities
relating to our product candidates or our processes could subject us to potential liability for damages and require us to obtain
a license to continue to manufacture or market lenabasum or any other product candidates. We cannot predict whether we would prevail
in any such actions or that any license required under any of these patents would be made available on commercially acceptable
terms, if at all. In addition, we cannot be sure that we could redesign lenabasum or any other product candidates or processes
to avoid infringement, if necessary. Accordingly, an adverse determination in a judicial or administrative proceeding, or the
failure to obtain necessary licenses, could prevent us from developing and commercializing lenabasum or another product candidate,
which could harm our business, financial condition and operating results.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
number of companies, including several major pharmaceutical companies, have conducted research on anti-inflammatory and anti-fibrosis
therapies which resulted in the filing of many patent applications related to this research. If we were to challenge the validity
of these or any issued United States patent in court, we would need to overcome a statutory presumption of validity that attaches
to every issued United States patent. This means that, in order to prevail, we would have to present clear and convincing evidence
as to the invalidity of the patent&rsquo;s claims.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we were to challenge the validity of these or any issued United States patent in an administrative trial before the Patent Trial
and Appeal Board in the United States Patent and Trademark Office, we would have to prove that the claims are unpatentable by
a preponderance of the evidence. There is no assurance that a jury and/or court would find in our favor on questions of infringement,
validity or enforceability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees have wrongfully
used or disclosed alleged confidential information or trade secrets of their former employers.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
is commonplace in our industry, we employ individuals who were previously employed at other pharmaceutical companies, including
our competitors or potential competitors. Although no claims against us are currently pending, we may be subject in the future
to claims that our employees or prospective employees are subject to a continuing obligation to their former employers (such as
non-competition or non-solicitation obligations) or claims that our employees or we have inadvertently or otherwise used or disclosed
trade secrets or other proprietary information of their former employers. Litigation may be necessary to defend against these
claims. Even if we are successful in defending against these claims, litigation could result in substantial costs and be a distraction
to management.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 58; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->56<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be subject to claims challenging the inventorship of our patents and other intellectual property.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
we are not aware of any asserted third-party claims challenging inventorship on our patents or ownership of our intellectual property,
we may in the future be subject to claims that former employees, strategic partners, commercial counterparties or other third
parties associated with us or one of our predecessors in ownership of lenabasum have an interest in our patents or other intellectual
property as an inventor or co-inventor. While it is our policy to require our employees and contractors who may be involved in
the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we cannot
fully control the enforcement of these policies by third parties with which we contract, nor can we be certain that assignment
agreements between us and our employees, between us and our counterparties, or between our counterparties and their employees
or between our predecessors of ownership and their employees and counterparties, will effectively protect our interests as to
any party who conceives or develops intellectual property that we regard as our own. Among other issues, the assignment of intellectual
property rights may not be self-executing, the assignment agreements may be breached, or we may have disputes arise from conflicting
obligations of consultants or others who are involved in developing our product candidates. As we approach potential commercialization
of our product candidates, we are more closely analyzing all facts that we believe might be used to assert an inventorship claim
against us. Determinations like these involve complex sets of fact and applications of sometimes-unsettled patent law, resulting
in inherent uncertainties regarding ownership rights. Determining the history of development of certain of our intellectual property
is made more difficult by the fact that certain of our intellectual property was developed by other companies for other indications
before being acquired by us. Consequently, we cannot be sure that we have all of the documentary records relevant to such an analysis.
In the course of our analysis we identified a potential issue regarding incomplete inventorship on certain aspects of our lenabasum
portfolio that were developed prior to our acquisition of lenabasum. Since identifying this potential issue, we reached agreement
with the relevant third-party co-inventors and received assignments of such co-inventors&rsquo; rights in and to the relevant
patents.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
claims challenging inventorship are made against us, we may need to resort to litigation to resolve those claims. If we fail in
defending against any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights,
such as exclusive ownership of valuable intellectual property rights or the right to assert those rights against third-parties
marketing competing products. Even if we are successful in defending against such claims, litigation could result in substantial
costs and be a distraction to management and other employees.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
Company-Related Risks</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
will need to grow the size of our organization, and we may experience difficulties in managing this growth.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2018, we had 77 full-time employees. As our development and commercialization plans and strategies develop, we
will need to expand the size of our employee base for managerial, operational, sales, marketing, financial and other resources.
Future growth would impose significant added responsibilities on members of management, including the need to identify, recruit,
maintain, motivate and integrate additional employees. In addition, our management may have to divert a disproportionate amount
of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities.
Our future financial performance and our ability to commercialize our drug candidates and our ability to compete effectively will
depend, in part, on our ability to effectively manage our future growth.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
capital raises may dilute our existing stockholders&rsquo; ownership and/or have other adverse effects on our operations.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we raise additional capital by issuing equity securities, our existing stockholders&rsquo; percentage ownership will be reduced
and these stockholders may experience substantial dilution. We may also issue equity securities that provide for rights, preferences
and privileges senior to those of our common stock. If we raise additional funds by issuing debt securities, these debt securities
would have rights senior to those of our common stock and the terms of the debt securities issued could impose significant restrictions
on our operations, including liens on our assets. If we raise additional funds through collaborations and licensing arrangements,
we may be required to relinquish some rights to our technologies or candidate products, or to grant licenses on terms that are
not favorable to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 59; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->57<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
we are not successful in attracting and retaining highly qualified personnel, we may not be able to successfully implement our
business strategy. In addition, the loss of the services of certain key employees, including Yuval Cohen, our Chief Executive
Officer, Barbara White, our Chief Medical Officer, Craig Millian, our Chief Commercial Officer and Sean Moran, our Chief Financial
Officer would adversely impact our business prospects.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
ability to compete in the highly competitive pharmaceuticals industry depends in large part upon our ability to attract highly
qualified managerial, scientific and medical personnel. In order to induce valuable employees to remain with us, we intend to
provide employees with stock options that vest over time. The value to employees of stock options that vest over time will be
significantly affected by movements in the price of our common stock that we will not be able to control and may at any time be
insufficient to counteract more lucrative offers from other companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management team has expertise in many different aspects of drug development and commercialization. However, we will need to hire
additional personnel as we further develop our drug candidates. Competition for skilled personnel in our market is intense and
competition for experienced scientists may limit our ability to hire and retain highly qualified personnel on acceptable terms.
Despite our efforts to retain valuable employees, members of our management, scientific and medical teams may terminate their
employment with us on short notice. In connection with the merger in April 2014 with Corbus Pharmaceuticals, Inc., our wholly-owned
subsidiary, we entered into employment agreements with certain of our executive officers. However, these employment arrangements
provide for at-will employment, which means that any of our employees could leave our employment at any time, with or without
notice. The loss of the services of any of our executive officers or other key employees could potentially harm our business,
operating results or financial condition. In particular, we believe that the loss of the services of Yuval Cohen, Ph.D., our Chief
Executive Officer, Barbara White, M.D., our Chief Medical Officer, Craig Millian, our Chief Commercial Officer and Sean Moran,
C.P.A., M.B.A., our Chief Financial Officer, would have a material adverse effect on our business. Our success also depends on
our ability to continue to attract, retain and motivate highly skilled junior, mid-level, and senior managers as well as junior,
mid-level, and senior scientific and medical personnel.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk
profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances
for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer.
If we are unable to continue to attract and retain high-quality personnel, the rate and success at which we can develop and commercialize
product candidates would be limited.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>If
product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization
of our drug candidates.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
face a potential risk of product liability as a result of the clinical testing of our drug candidates and will face an even greater
risk if we commercialize our drug candidates. For example, we may be sued if any product we develop or any materials that we use
in our products allegedly causes injury or is found to be otherwise unsuitable during product testing, manufacturing, marketing
or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to
warn of dangers inherent in the product, negligence, strict liability and a breach of warranties. Claims could also be asserted
under state consumer protection acts. If we cannot successfully defend ourselves against product liability claims, we may incur
substantial liabilities or be required to limit commercialization of our drug candidates. Even successful defense would require
significant financial and management resources. Regardless of the merits or eventual outcome, liability claims may result in:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
decreased demand for our drug candidates;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
injury to our reputation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
withdrawal of clinical trial participants;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 60; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->58<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
costs to defend the related litigation;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a diversion of management&rsquo;s time and our resources;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
substantial monetary awards to trial participants or patients;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
product recalls, withdrawals or labeling, marketing or promotional restrictions;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the inability to commercialize our drug candidates; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a decline in the value of our stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product
liability claims could prevent or inhibit the commercialization of products we develop. We intend to obtain product liability
insurance covering our clinical trials. Although we will maintain such insurance, any claim that may be brought against us could
result in a court judgment or settlement in an amount that is not covered, in whole or in part, by our insurance or that is in
excess of the limits of our insurance coverage. Our insurance policies also have various exclusions, and we may be subject to
a product liability claim for which we have no coverage. We may have to pay any amounts awarded by a court or negotiated in a
settlement that exceed our coverage limitations or that are not covered by our insurance, and we may not have, or be able to obtain,
sufficient capital to pay such amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may acquire businesses, assets or products, or form strategic alliances, in the future, and we may not realize the benefits of
such acquisitions.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may acquire additional businesses, assets or products, form strategic alliances or create joint ventures with third parties that
we believe will complement or augment our existing business. If we acquire businesses with promising markets or technologies,
we may not be able to realize the benefit of acquiring such businesses if we are unable to successfully integrate them with our
existing operations and company culture. We may encounter numerous difficulties in developing, manufacturing and marketing any
new delay or prevent us from realizing their expected benefits or enhancing our business. We cannot assure you that, following
any such acquisition, we will achieve the expected synergies to justify the transaction.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Risks
Related to our Common Stock</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
affiliates may control our company for the foreseeable future, including the outcome of matters requiring stockholder approval.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
officers, directors, and five percent stockholders collectively owned approximately 33.4% of our outstanding shares of common
stock as of December 31, 2018. This concentration of voting power and control could have a significant effect in delaying, deferring
or preventing an action that might otherwise be beneficial to our other stockholders and be disadvantageous to our stockholders
with interests different from those entities and individuals. Certain of these individuals also have significant control over
our business, policies and affairs as officers or directors of our company. Therefore, you should not invest in reliance on your
ability to have any control over our company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>An
active, liquid trading market for our common stock may not be sustained.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Presently,
our common stock is traded on the Nasdaq Global Market, or Nasdaq, and as we are in our early stages, an investment in our company
may require a long-term commitment, with no certainty of return. If we are unable to maintain an active, liquid active trading
market:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
investors may have difficulty buying and selling or obtaining market quotations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
market visibility for shares of our common stock may be limited; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
a lack of visibility for shares of our common stock may have a depressive effect on the market price for shares of our common
stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 61; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->59<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lack of an active market could impair your ability to sell your shares at the time you wish to sell them or at a price that you
consider reasonable. The lack of an active market may also reduce the fair market value of your shares. An inactive market may
also impair our ability to raise capital to continue to fund operations by selling shares and may impair our ability to acquire
additional intellectual property assets by using our shares as consideration.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are currently listed on the Nasdaq Global Market. If we are unable to maintain listing of our securities on the Nasdaq Global
Market or any stock exchange, our stock price could be adversely affected and the liquidity of our stock and our ability to obtain
financing could be impaired and it may be more difficult for our stockholders to sell their securities.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Although
our common stock is currently listed on the Nasdaq Global Market, we may not be able to continue to meet the exchange&rsquo;s
minimum listing requirements or those of any other national exchange. If we are unable to maintain listing on Nasdaq or if a liquid
market for our common stock does not develop or is sustained, our common stock may remain thinly traded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Listing Rules of Nasdaq require listing issuers to comply with certain standards in order to remain listed on its exchange. If,
for any reason, we should fail to maintain compliance with these listing standards and Nasdaq should delist our securities from
trading on its exchange and we are unable to obtain listing on another national securities exchange, a reduction in some or all
of the following may occur, each of which could have a material adverse effect on our stockholders:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the liquidity of our common stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the market price of our common stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
our ability to obtain financing for the continuation of our operations;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the number of institutional and general investors that will consider investing in our common stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the number of investors in general that will consider investing in our common stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the number of market makers in our common stock;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the availability of information concerning the trading prices and volume of our common stock; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
the number of broker-dealers willing to execute trades in shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
market price of our common stock may be significantly volatile.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
market price for our common stock may be volatile and subject to wide fluctuations in response to factors including the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
actual or anticipated fluctuations in our quarterly or annual operating results;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in financial or operational estimates or projections;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
conditions in markets generally;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in the economic performance or market valuations of companies similar to ours; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
general economic or political conditions in the United States or elsewhere.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36.8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 62; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->60<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36.8pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
particular, the market prices of biotechnology companies like ours have been highly volatile due to factors, including, but not
limited to:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
any delay or failure to conduct a clinical trial for our product or receive approval from the FDA and other regulatory agencies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
developments or disputes concerning a company&rsquo;s intellectual property rights;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
technological innovations of such companies or their competitors;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
changes in market valuations of similar companies;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
announcements by such companies or their competitors of significant contracts, acquisitions, strategic partnerships, joint ventures,
capital commitments, new technologies, or patents; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;
failure to complete significant transactions or collaborate with vendors in manufacturing a product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
securities market has from time to time experienced significant price and volume fluctuations that are not related to the operating
performance of particular companies. These market fluctuations may also materially and adversely affect the market price of shares
of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Future
sales of shares by existing stockholders could cause our stock price to decline.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2018, we had outstanding options to purchase an aggregate of 9,593,990 shares of our common stock at a weighted
average exercise price of $4.51 per share and warrants to purchase an aggregate of 2,283,500 shares of our common stock at a weighted
average exercise price of $6.34 per share.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2018, pursuant to the terms of the Investment Agreement, we issued a warrant to CFF to purchase an aggregate of 1,000,000
shares of our common stock (the &ldquo;CFF Warrant&rdquo;). The CFF Warrant is exercisable at a price equal to $13.20 per share
and was immediately exercisable for 500,000 shares of our common stock. Upon completion of the final milestone set forth in the
Investment Agreement and receipt of the final payment from CFF to us pursuant to the Investment Agreement, the CFF Warrant will
be exercisable for the remaining 500,000 shares of our common stock. The CFF Warrant expires on January 26, 2025. Any shares of
our common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
exercise of such outstanding options and warrants will result in dilution of your investment. If our existing stockholders sell
substantial amounts of our common stock in the public market, or if the public perceives that such sales could occur, this could
have an adverse impact on the market price of our common stock, even if there is no relationship between such sales and the performance
of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
do not currently intend to pay dividends on our common stock in the foreseeable future, and consequently, your ability to achieve
a return on your investment will depend on appreciation in the price of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock and do not anticipate paying any cash dividends to holders of our
common stock in the foreseeable future. Consequently, investors must rely on sales of their common stock after price appreciation,
which may never occur, as the only way to realize any future gains on their investments. There is no guarantee that shares of
our common stock will appreciate in value or even maintain the price at which our investors have purchased their shares.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 63; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->61<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
are an &ldquo;emerging growth company,&rdquo; and will be able take advantage of reduced disclosure requirements applicable to
&ldquo;emerging growth companies,&rdquo; which could make our common stock less attractive to investors.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are an &ldquo;emerging growth company,&rdquo; as defined in the Jumpstart Our Business Startups Act of 2012, or JOBS Act, and,
for as long as we continue to be an &ldquo;emerging growth company,&rdquo; we intend to take advantage of certain exemptions from
various reporting requirements applicable to other public companies but not to &ldquo;emerging growth companies,&rdquo; including,
but not limited to, not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements, and exemptions
from the requirements of holding a nonbinding advisory vote on executive compensation and stockholder approval of any golden parachute
payments not previously approved. We will remain an emerging growth company until the earlier of (1) December 31, 2019, (2) the
last day of the first fiscal year in which our annual gross revenues exceed $1.07 billion, (3) the date on which we become a &ldquo;large
accelerated filer&rdquo; as defined in Rule 12b-2 under the Securities Exchange Act of 1934, as amended, which would occur if
the market value of our common stock that is held by non-affiliates exceeds $700 million as of the last business day of our most
recently completed second fiscal quarter or (4) the date on which we have issued more than $1 billion in non-convertible debt
during the preceding three-year period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
intend to take advantage of these reporting exemptions described above until we are no longer an &ldquo;emerging growth company.&rdquo;
Under the JOBS Act, &ldquo;emerging growth companies&rdquo; can also delay adopting new or revised accounting standards until
such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption
from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as
other public companies that are not &ldquo;emerging growth companies.&rdquo;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict if investors will find our common stock less attractive if we choose to rely on these exemptions. If some investors
find our common stock less attractive as a result of any choices to reduce future disclosure, there may be a less active trading
market for our common stock and our stock price may be more volatile.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
incur significant costs and devote substantial management time as a result of operating as a public company, and we expect those
costs to increase, particularly after we are no longer an &ldquo;emerging growth company.&rdquo;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. For example,
we are required to comply with certain of the requirements of the Sarbanes-Oxley Act and the Dodd-Frank Wall Street Reform and
Consumer Protection Act, as well as rules and regulations subsequently implemented by the SEC, including the establishment and
maintenance of effective disclosure and financial controls and changes in corporate governance practices. We expect that compliance
with these requirements will increase our legal and financial compliance costs and will make some activities more time consuming
and costly. In addition, we expect that our management and other personnel will need to divert attention from operational and
other business matters to devote substantial time to these public company requirements. In particular, we expect to incur significant
expenses and devote substantial management effort toward ensuring compliance with the requirements of Section 404 of the Sarbanes-Oxley
Act. In addition, after we are no longer qualify as an &ldquo;emerging growth company,&rdquo; we expect to incur additional management
time and cost to comply with the more stringent reporting requirements applicable to companies that are deemed accelerated filers
or large accelerated filers, including complying with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley
Act. We currently do not have an internal audit function, and we will need to hire or contract for additional accounting and financial
staff with appropriate public company experience and technical accounting knowledge.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
cannot predict or estimate the amount of additional costs we may incur as a result of becoming a public company or the timing
of such costs.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>There
may be limitations on the effectiveness of our internal controls, and a failure of our control systems to prevent error or fraud
may materially harm our company.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Proper
systems of internal controls over financial accounting and disclosure are critical to the operation of a public company. We
may be unable to effectively establish such systems, especially in light of the fact that we expect to operate as a publicly reporting
company. This would leave us without the ability to reliably assimilate and compile financial information about our company and
significantly impair our ability to prevent error and detect fraud, all of which would have a negative impact on our company from
many perspectives.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 64; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->62<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Moreover,
we do not expect that disclosure controls or internal control over financial reporting will prevent all error and all fraud. A
control system, no matter how well designed and operated, can provide only reasonable, not absolute, assurance that the control
system&rsquo;s objectives will be met. Further, the design of a control system must reflect the fact that there are resource constraints
and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems,
no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, have been detected.
Failure of our control systems to detect or prevent error or fraud could materially adversely impact us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>We
may be unable to complete our analysis of our internal controls over financial reporting in a timely manner, or these internal
controls may not be determined to be effective, which may adversely affect investor confidence in our company and, as a result,
the value of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are required, pursuant to Section 404 of the Sarbanes-Oxley Act, to furnish a report by our management on, among other things,
the effectiveness of our internal control over financial reporting. This assessment will need to include disclosure of any material
weaknesses identified by our management in our internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may not be able to complete our evaluation, testing and any required remediation in a timely fashion. During the evaluation and
testing process, if we identify one or more material weaknesses in our internal control over financial reporting, we will be unable
to assert that our internal controls are effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
we are unable to assert that our internal control over financial reporting is effective, or, if applicable, our independent registered
public accounting firm is unable to express an opinion on the effectiveness of our internal controls, we could lose investor confidence
in the accuracy and completeness of our financial reports, which would cause the price of our common stock to decline, and we
may be subject to investigation or sanctions by the SEC. We will also be required to disclose changes made in our internal control
and procedures on a quarterly basis.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
remediation efforts may not enable us to avoid a material weakness in our internal control over financial reporting in the future.
Any of the foregoing occurrences, should they come to pass, could negatively impact the public perception of our company, which
could have a negative impact on our stock price.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Upon
dissolution of our company, you may not recoup all or any portion of your investment.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
the event of a liquidation, dissolution or winding-up of our company, whether voluntary or involuntary, the proceeds and/or assets
of our company remaining after giving effect to such transaction, and the payment of all of our debts and liabilities and distributions
required to be made to holders of any outstanding preferred stock will then be distributed to the stockholders of common stock
on a pro rata basis. There can be no assurance that we will have available assets to pay to the holders of common stock, or any
amounts, upon such a liquidation, dissolution or winding-up of our Company. In this event, you could lose some or all of your
investment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
ability to use our net operating loss carryforwards and certain other tax attributes may be limited.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a result of our merger in April 2014 with Corbus Pharmaceuticals, Inc., our wholly-owned subsidiary, our ability to utilize our
federal net operating loss, carryforwards and federal tax credit prior to that date may be limited under Sections 382 of the Internal
Revenue Code. The limitations apply if an &ldquo;ownership change,&rdquo; as defined by Section 382, occurs. Generally, an ownership
change occurs if the percentage of the value of the stock that is owned by one or more direct or indirect &ldquo;five percent
shareholders&rdquo; increases by more than 50 percentage points over their lowest ownership percentage at any time during the
applicable testing period (typically three years). In addition, future changes in our stock ownership, which may be outside of
our control, may trigger an &ldquo;ownership change&rdquo; and, consequently, Section 382 limitations. As a result, if we earn
net taxable income, our ability to use our pre-change net operating loss carryforwards and other tax attributes to offset United
States federal taxable income may be subject to limitations, which could potentially result in increased future tax liability
to us.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></P>

<!-- Field: Page; Sequence: 65; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->63<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"></p><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>The
2017 comprehensive tax reform bill could adversely affect our business and financial condition.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, President Trump signed into law new tax legislation, or the Tax Act, which significantly reforms the Internal
Revenue Code of 1986, as amended. The Tax Act, among other things, contains significant changes to corporate taxation, including
reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for
interest expense to 30% of adjusted earnings (except for certain small businesses); limitation of the deduction of net operating
losses generated in tax years beginning after December 31, 2017 to 80% of taxable income, indefinite carryforward of net operating
losses generated in tax years after 2018 and elimination of net operating loss carrybacks; changes in the treatment of offshore
earnings regardless of whether they are repatriated; current inclusion in U.S. federal taxable income of certain earnings of controlled
foreign corporations, mandatory capitalization of research and development expenses beginning in 2022; immediate deductions for
certain new investments instead of deductions for depreciation expense over time; further deduction limits on executive compensation;
and modifying, repealing and creating many other business deductions and credits, including the reduction in the orphan drug credit
from 50% to 25% of qualifying expenditures. We continue to examine the impact this tax reform legislation may have on our business.
Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain and our business
and financial condition could be adversely affected. The impact of this tax reform on holders of our common stock is also uncertain
and could be adverse. This periodic report does not discuss any such tax legislation or the manner in which it might affect us
or our stockholders in the future. We urge our stockholders to consult with their legal and tax advisors with respect to such
legislation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Our
certificate of incorporation, as amended, allows for our board to create new series of preferred stock without further approval
by our stockholders, which could adversely affect the rights of the holders of our common stock.</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
board of directors has the authority to fix and determine the relative rights and preferences of preferred stock. We anticipate
that our board of directors will have the authority to issue up to 10,000,000 shares of our preferred stock without further stockholder
approval. As a result, our board of directors could authorize the issuance of a series of preferred stock that would grant to
holders the preferred right to our assets upon liquidation and the right to receive dividend payments before dividends are distributed
to the holders of common stock. In addition, our board of directors could authorize the issuance of a series of preferred stock
that has greater voting power than our common stock or that is convertible into our common stock, which could decrease the relative
voting power of our common stock or result in dilution to our existing stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_004"></A><FONT STYLE="font-size: 10pt"><B>Item
    1B.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>UNRESOLVED
    STAFF COMMENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_005"></A><FONT STYLE="font-size: 10pt"><B>Item
    2.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPERTIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
principal offices are located at 500 River Ridge Drive, Norwood, MA 02062 and consisted of 32,733 square feet of leased office
space at December 31. 2018. The initial term of the lease agreement for this office space was for a period of seven years and
commenced in February 2018. The base rent under this lease agreement ranged from approximately $470,000 for the first year to
approximately $908,000 for the seventh year. On February 26, 2019 we amended our lease (&ldquo;February 2019 Lease Agreement&rdquo;)
pursuant to which an additional 30,023 square feet of office space (&ldquo;New Premises&rdquo;) will be leased by us in the same
building for an aggregate total of 62,756 square feet of leased office space (&ldquo;Total Premises&rdquo;). The commencement
date for the New Premises is expected to occur no later than August 1, 2019 and the lease term for the Total Premises is until
October 31, 2026. The future minimum rent commitments for the Total Premises are estimated to be approximately as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" ALIGN="CENTER" STYLE="font: 10pt Times New Roman, Times, Serif; width: 80%; border-collapse: collapse">
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 80%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2019</FONT></TD>
    <TD STYLE="width: 2%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">$</FONT></TD>
    <TD STYLE="width: 16%; text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">678,000</FONT></TD>
    <TD STYLE="width: 1%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2020</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,288,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2021</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,592,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2022</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,640,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2023</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: right; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1,687,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: white; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Thereafter</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5,036,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: #CCEEFF; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$<FONT STYLE="font-size: 10pt">&nbsp;</FONT></FONT></TD>
    <TD STYLE="border-bottom: black 2.25pt double; font: 10pt Times New Roman, Times, Serif; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11,921,000</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 66; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->64<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_006"></A><FONT STYLE="font-size: 10pt"><B>Item
    3.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LEGAL
    PROCEEDINGS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are not currently subject to any material legal proceedings. However, we may from time to time become a party to various legal
proceedings arising in the ordinary course of our business.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_007"></A><FONT STYLE="font-size: 10pt"><B>Item
    4.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MINE
    SAFETY DISCLOSURES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 67; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->65<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_008"></A><FONT STYLE="font-size: 10pt"><B>PART
II</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_009"></A><FONT STYLE="font-size: 10pt"><B>Item
    5.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MARKET
    FOR REGISTRANT&rsquo;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Market
Information</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
common stock is currently listed on the <FONT STYLE="background-color: white">Nasdaq Global Market </FONT>under the symbol &ldquo;CRBP.&rdquo;
Our shares of common stock began trading on the <FONT STYLE="background-color: white">Nasdaq Capital Market under the symbol &ldquo;CRBP&rdquo;
effective April 16, 2015</FONT>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Dividends</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have never declared or paid cash dividends on our common stock. We do not intend to declare or pay cash dividends on our common
stock for the foreseeable future, but currently intend to retain any future earnings to fund the development and growth of our
business. The payment of cash dividends if any, on the common stock will rest solely within the discretion of our board of directors
and will depend, among other things, upon our earnings, capital requirements, financial condition, and other relevant factors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Record
Holders</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of March 6, 2019, there are approximately 92 record holders of shares of common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 68; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->66<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_010"></A><FONT STYLE="font-size: 10pt"><B>Item
    6.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SELECTED
                                         FINANCIAL DATA </B></FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 60pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Not
applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_011"></A><FONT STYLE="font-size: 10pt"><B>Item
    7.</B></FONT></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>MANAGEMENT&rsquo;S
    DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
following discussion and analysis of our financial condition and results of operations should be read together with our financial
statements and the related notes and the other financial information included elsewhere in this Annual Report. This discussion
contains forward-looking statements that involve risks and uncertainties. Our actual results could differ materially from those
anticipated in these forward-looking statements as a result of various factors, including those discussed below and elsewhere
in this Annual Report, particularly those under &ldquo;Risk Factors.&rdquo;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Overview
</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a Phase 3, clinical stage pharmaceutical company, focused on the development and commercialization of novel therapeutics to
treat rare, chronic and serious inflammatory and fibrotic diseases with clear unmet medical needs. Our lead product candidate,
lenabasum, is a novel synthetic, oral, endocannabinoid drug designed to resolve chronic inflammation and fibrotic processes. We
are currently developing lenabasum to treat four life-threatening diseases: systemic sclerosis (SSc), cystic fibrosis (CF), dermatomyositis
(DM) and systemic lupus erythematosus (SLE).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
is a synthetic, rationally-designed oral small-molecule drug that selectively binds to the cannabinoid receptor type 2, or CB2,
found on activated immune cells, fibroblasts and other cell types including muscle and bone cells. Lenabasum stimulates the production
of Specialized Pro-Resolving Lipid Mediators (SPMs) that act to resolve inflammation and halt fibrosis by activating endogenous
pathways. These pathways are activated in healthy individuals during the course of normal immune responses but are dysfunctional
in patients with chronic inflammatory and fibrotic diseases. By its binding to CB2, lenabasum drives innate immune responses from
the activation phase into the resolution phase. CB2 plays a central role in modulating and resolving inflammation by, in effect,
turning heightened inflammation &ldquo;off&rdquo; and restoring homeostasis. This has been demonstrated in animal models lacking
CB2 as well as humans with genetic polymorphism in the CB2 gene, as these exhibit excessive inflammation and fibrosis in response
to activators of the innate immune system.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lenabasum
has generated positive clinical data in three consecutive Phase 2 studies in diffuse cutaneous SSc, CF and skin-predominant DM.
Lenabasum is currently being evaluated in a Phase 3 SSc study that is expected to enroll 354 patients, a Phase 2b CF study that
is expected to enroll 415 patients (that is being supported by a development award for up to $25 million (the &ldquo;2018 CFF
Award&rdquo;) from the Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;)), and a Phase 2 SLE study that is expected to enroll 100
patients and is being funded by a grant through the National Institutes of Health (&ldquo;NIH&rdquo;). In DM, we received guidance
from the FDA on the protocol design for the next clinical study, and announced the commencement of an international Phase 3 study
on December 17, 2018. This trial is a 1-year, double-blind, randomized, placebo-controlled study testing efficacy and safety of
lenabasum in approximately 150 adults with DM. Subjects are randomized to receive lenabasum 20 mg twice per day, lenabasum 5 mg
twice per day, or placebo twice per day in a 2:1:2 ratio. The primary efficacy outcome is American College of Rheumatology/European
League Against Rheumatism 2016 Total Improvement Score (&ldquo;TIS&rdquo;) in adult dermatomyositis and polymyositis, a composite
measure of improvement from baseline in six endpoints: Physician Global Assessment of Disease Activity, Physician Global Assessment
of Extramuscular Disease Activity, Patient Global Assessment of Disease Activity, Health Assessment Questionnaire (patient-reported
disability), Manual Muscle Testing, and muscle enzymes. Change in the Cutaneous Dermatomyositis Activity and Severity Index
(&ldquo;CDASI&rdquo;) activity score is a secondary efficacy outcome. Open-label extension studies are ongoing in SSc and
DM following the completion of the Phase 2 studies in these indications.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
U.S. Food and Drug Administration, or the FDA, has granted lenabasum Orphan Designation as well as Fast Track Status for SSc and
CF, and Orphan Drug Designation for DM. The European Medicines Authority, or the EMA, has granted lenabasum Orphan Designation
for SSc, CF and DM.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 69; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->67<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
our inception, we have devoted substantially all of our efforts to business planning, research and development, recruiting management
and technical staff, acquiring operating assets and raising capital. Our research and development activities have included conducting
pre-clinical studies, developing manufacturing methods and the manufacturing of our drug lenabasum for clinical trials and conducting
clinical studies in patients. Two of the four clinical programs for lenabasum are being supported by non-dilutive awards and grants.
The National Institutes of Health, or NIH, has funded the majority of the clinical development costs for the DM Phase 2 clinical
trial and is funding the SLE Phase 2 clinical trials. In cystic fibrosis, the Phase 2b clinical trial is being supported by the
2018 CFF Award and the Phase 2 clinical trial was partially funded by a $5 million award (the &ldquo;2015 CFFT Award Agreement&rdquo;)
from the Cystic Fibrosis Foundation Therapeutics, Inc., or CFFT, a non-profit drug discovery and development affiliate of the
Cystic Fibrosis Foundation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2018, we acquired an exclusive worldwide license (the &ldquo;Jenrin Agreement&rdquo;) to develop, manufacture and market
drug candidates from more than 600 compounds targeting the endocannabinoid system from Jenrin Discovery LLC (&ldquo;Jenrin&rdquo;).
The pipeline includes CRB-4001, Jenrin&rsquo;s 2nd generation, peripherally-restricted, CB1 inverse agonist targeting liver, lung,
heart and kidney fibrotic diseases. The current portfolio for CRB-4001 includes multiple issued and pending patent applications.
CRB-4001 was developed in collaboration with and with financial support from the NIH. CRB-4001 was specifically designed to eliminate
blood-brain barrier penetration and brain CB1 receptor occupancy that mediate the neuropsychiatric issues associated with first-generation
CB1 inverse agonists such as rimonabant. Potential indications for CRB-4001 include NASH, primary biliary cholangitis, idiopathic
pulmonary fibrosis, radiation-induced pulmonary fibrosis, myocardial fibrosis after myocardial infarction, and acute interstitial
nephritis, among others.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, we entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (&ldquo;Kaken&rdquo;) for the development
and commercialization in Japan of our investigational drug lenabasum for the treatment of systemic sclerosis (&ldquo;SSc&rdquo;)
and dermatomyositis (&ldquo;DM&rdquo;), two rare and serious autoimmune diseases. Under the terms of the agreement, Kaken receives
an exclusive license to commercialize and market lenabasum in Japan for SSc and DM. Kaken will make an upfront payment to us of
$27 million. Corbus will be eligible to receive in addition up to $173 million upon achievement of certain regulatory, development
and sales milestones as well as double- digit royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2019, we consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold
an aggregate of 6,198,500 shares of its common stock at a purchase price of $6.50 per share with gross proceeds to the Company
totaling $40,290,250, less estimated issuance costs incurred of approximately $2,667,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Financial
Operations Overview</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
are a clinical stage pharmaceutical company and have not generated any revenues from the sale of products. We have never been
profitable and at December 31, 2018, we had an accumulated deficit of approximately $121.4 million. Our net losses for the years
ended December 31, 2018 and 2017 were approximately $55,672,000 and $32,422,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 70; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->68<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for the foreseeable future. We expect our expenses
to increase significantly in connection with our ongoing activities to develop, seek regulatory approval of and commercialize
lenabasum. Accordingly, we will need additional financing to support our continuing operations. We will seek to fund our operations
through public or private equity or debt financings or other sources, which may include government grants and collaborations with
third parties. Adequate additional financing may not be available to us on acceptable terms, or at all. Our failure to raise capital
as and when needed would have a negative impact on our financial condition and our ability to pursue our business strategy. We
will need to generate significant revenues to achieve profitability, and we may never do so.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect to continue to incur significant expenses and increasing operating losses for at least the next several years. We expect
our expenses will increase substantially in 2019 and in the future in connection with our ongoing activities, as we:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">conduct
    clinical trials for lenabasum in scleroderma, cystic fibrosis, DM, systemic lupus erythematosus and other indications;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">continue
    our research and development efforts;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">manufacture
    clinical study materials and develop commercial scale manufacturing capabilities;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">seek
    regulatory approval for our product candidates;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">add
    personnel to support development of our product candidates; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">operate
    as a public company.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in
the United States of America. The preparation of these financial statements requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date
of the financial statements and the reported amounts of revenues and expenses during the reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
an ongoing basis, we evaluate our estimates and judgments for all assets and liabilities, including those related to stock-based
compensation expense. We base our estimates and judgments on historical experience, current economic and industry conditions and
on various other factors that are believed to be reasonable under the circumstances. This forms the basis for making judgments
about the carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ
from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue
Recognition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued guidance codified in <I>Accounting Standards Codification (ASC) 606, Revenue Recognition &mdash; Revenue
from Contracts with Customers</I> (&ldquo;ASC 606&rdquo;) which amends the guidance in former <I>ASC 605, Revenue Recognition
</I>(&ldquo;ASC 605&rdquo;), and is effective for public companies for annual and interim periods beginning after December 15,
2017. Specifically, the new standard differs from ASC 605 in many respects, such as in the accounting for variable consideration
received, including milestone payments or contingent payments. Under our accounting policy prior to the adoption of ASC 606 in
the first quarter of 2018, milestone payments were initially recognized only in the period that the payment-triggering event occurred
or was achieved. ASC 606, however, may require a company to recognize such payments before the payment-triggering event is completely
achieved based on the company&rsquo;s estimate of the amount of consideration to which it will be entitled in exchange for transferring
the services, subject to management&rsquo;s assessment of whether it is probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect
of initially applying ASC 606 is recognized at the date of initial application, and elected to utilize a practical expedient and
did not restate contracts that were completed as of the date of adoption. Since we have concluded our performance obligations
and have completed recognizing revenue under the 2015 CFFT Award discussed in the third quarter of 2017, there was no cumulative
effect to record at the date of our adoption of ASC 606 and no revenue to recognize for the first quarter of 2018 related to the
2015 CFFT Award. Revenue for the year ended December 31, 2018 was $4,822,272 recognized in accordance with ASC 606 and pertains
only to the 2018 CFF Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 71; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->69<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will assess any new agreements we enter into under ASC 606, including whether such agreements fall under the scope of such standard.
This standard applies to all contracts with customers, except for contracts that are within the scope of other standards, such
as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its
customer obtains control of promised goods or services, in an amount that reflects the consideration which the entity expects
to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity determines
are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii)
identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price
to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation.
The five-step model is applied to contracts when it is probable that the entity will collect the consideration it is entitled
to in exchange for the goods or services it transfers to the customer. At contract inception, once the contract is determined
to be within the scope of ASC 606, we assess the goods or services promised within each contract and determine those that are
performance obligations, and assess whether each promised good or service is distinct. We then recognize as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is
satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
associated with the performance obligation is being recognized as revenue as the research and development services are provided
using an input method, according to the costs incurred as related to the research and development activities and the costs expected
to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and,
in management&rsquo;s judgment, is the best measure of progress towards satisfying the performance obligation. The research and
development services related to this performance obligation are expected to be performed over an approximately two and a half-year
period expected to be completed in the second quarter of 2020. Amounts received prior to revenue recognition are recorded as deferred
revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet date are classified as
current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as
revenue within the 12 months following the balance sheet date are classified as deferred revenue, net of current portion. Amounts
recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that full consideration has been given to all relevant circumstances that we may be subject to, and the consolidated financial
statements accurately reflect our best estimate of the results of operations, financial position and cash flows for the periods
presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not generated any revenues from the sales of products. We do not expect to generate revenue from product sales unless
and until we successfully complete development and obtain regulatory approval for the marketing of lenabasum, which we expect
will take a number of years and is subject to significant uncertainty.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognized $4,822,272 and $2,440,195 of revenue from awards in the years ended December 31, 2018 and December 31, 2017, respectively.
Amounts recognized in revenue in 2017 were recognized in accordance with ASC 605 and were related to an award agreement (the &ldquo;2015
CFFT Award Agreement) we entered into in fiscal 2015 with the CFFT, pursuant to which we received a development award (the &ldquo;2015
CFFT Award&rdquo;) for up to $5 million in funding. We received a total of $5 million in payments under the 2015 CFFT Award. The
payments received under the 2015 CFFT Award were recorded as deferred revenue when the triggering event to receive those amounts
occurred and were amortized on a straight-line basis over the expected duration of the remaining performance period under the
2015 CFFT Award, which concluded in the third quarter of 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
recognized in revenue for the year ended December 31, 2018 were recognized in accordance with ASC 605 and were in connection with
our entry on January 26, 2018 into the Cystic Fibrosis Program Related Investment Agreement (&ldquo;Investment Agreement) with
the Cystic Fibrosis Foundation (&ldquo;CFF&rdquo;), a non-profit drug discovery and development corporation, pursuant to which
we received a development award for up to $25 million in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b Clinical
Trial (the &ldquo;Phase 2b Clinical Trial&rdquo;) of lenabasum in patients with cystic fibrosis of which we received an aggregate
$12.5 million during the year ended December 31, 2018 upon our achievement of a milestones related to the progress of the Phase
2b Clinical Trial, as set forth in the Investment Agreement. The remainder of the 2018 CFF Award is payable to us incrementally
upon the achievement of the remaining milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
assessed the 2018 CFF Award for accounting under ASC 606, which we adopted in the first quarter of 2018. To determine revenue
recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue
when (or as) the entity satisfies a performance obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"></P>

<!-- Field: Page; Sequence: 72; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->70<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, we are obligated to make certain royalty payments to CFF, including a royalty payment
of one and one-half times the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval
of lenabasum in the United States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon
approval in another major market, as set forth in the Investment Agreement (the &ldquo;Approval Royalty&rdquo;). At our election,
we may satisfy the first of the two Approval Royalties in registered shares of our common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.1in; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are obligated to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty
days after any quarter in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments
to CFF of one percent of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any
quarter in which such net sales occur, and (iii) royalty payments to CFF of ten percent of any amount that we and our stockholders
receive in connection with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment
or prevention of CF, or a change of control transaction, except that such payment shall not exceed five times the amount of the
2018 CFF Award, with such payments to be credited against any other net sales royalty payments due. Either CFF or we may terminate
the Investment Agreement for cause, which includes our material failure to achieve certain commercialization and development milestones.
Our payment obligations survive the termination of the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Research
and development expenses are incurred for the development of lenabasum and consist primarily of payroll and payments to contract
research and development companies. To date, these costs are related to generating pre-clinical data and the cost of manufacturing
lenabasum for clinical trials and conducting clinical trials. These costs are expected to increase significantly in the future
as lenabasum is continued to be evaluated in additional later stage clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">General
and administrative expenses consist primarily of payroll, rent and professional services such as accounting and legal services.
We anticipate that our general and administrative expenses will increase significantly during 2019 and in the future as we increase
our headcount to support our continued research and development and the potential commercialization of our product candidates.
We also anticipate increased expenses related to audit, legal, and tax-related services associated with maintaining compliance
with NASDAQ exchange listing and SEC requirements, director and officer insurance, and investor relations costs associated with
being a public company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income, Net</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Other
income, net consists primarily of interest income we earn on interest-bearing accounts, interest expense incurred on our outstanding
debt, and foreign currency exchange transaction losses and gains.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Critical
Accounting Policies and Estimates</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United
States of America. The preparation of these financial statements requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the reporting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
an ongoing basis, we evaluate our estimates and judgments for all assets and liabilities, including those related to stock-based
compensation expense and accrued research and development expense. We base our estimates and judgments on historical experience,
current economic and industry conditions and on various other factors that are believed to be reasonable under the circumstances.
This forms the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from
other sources. Actual results may differ from these estimates under different assumptions or conditions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 73; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->71<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
believe that full consideration has been given to all relevant circumstances that we may be subject to, and the consolidated financial
statements accurately reflect our best estimate of the results of operations, financial position and cash flows for the periods
presented.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Accrued
Research and Development Expenses</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing financial statements, we are required to estimate and accrue expenses, the largest of which are
research and development expenses. This process involves: communicating with our applicable personnel to identify services that
have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service
when we have not yet been invoiced or otherwise notified of actual cost; estimating and accruing expenses in our financial statements
as of each balance sheet date based on facts and circumstances known to us at the time; and periodically confirming the accuracy
of our estimates with selected service providers and making adjustments, if necessary.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Examples
of estimated research and development expenses that we accrue include:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    paid to CROs in connection with nonclinical studies;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    paid to contract manufacturers in connection with the production of lenabasum for clinical trials;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">fees
    paid to CRO and research institutions in connection with conducting of clinical studies; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9679;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">professional
    service fees for consulting and related services.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 48.95pt; text-align: justify; text-indent: -0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
base our expense accruals related to clinical studies on our estimates of the services performed pursuant to contracts with multiple
research institutions and clinical research organizations that conduct and manage clinical studies on our behalf. The financial
terms of these agreements vary from contract to contract and may result in uneven payment flows. Payments under some of these
contracts depend on factors, such as the successful enrollment of patients and the completion of clinical study milestones. Our
service providers invoice us monthly in arrears for services performed. In accruing service fees, we estimate the time period
over which services will be performed and the level of effort to be expended in each period. If we do not identify costs that
we have begun to incur or if we underestimate or overestimate the level of services performed or the costs of these services,
our actual expenses could differ from our estimates.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
date, we have not experienced significant changes in our estimates of accrued research and development expenses following each
applicable reporting period. However, due to the nature of estimates, we cannot assure you that we will not make changes to our
estimates in the future as we become aware of additional information regarding the status or conduct of our clinical studies and
other research activities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Stock-Based
Compensation</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Stock
options are granted with an exercise price at no less than fair market value at the date of the grant. The stock options normally
expire ten years from the date of grant. Stock option awards vest upon terms determined by our board of directors.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
recognize compensation costs resulting from the issuance of stock-based awards to employees, members of our Board of directors
and consultants. The fair value of each option grant was estimated as of the date of grant using the Black-Scholes option-pricing
model. The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards,
which is generally the vesting period. Due to our limited operating history, we estimated our volatility in consideration of a
number of factors, including the volatility of comparable public companies and, commencing in 2015, we also included the volatility
of our own common stock. We use historical data, as well as subsequent events occurring prior to the issuance of the consolidated
financial statements, to estimate option exercise and employee forfeitures within the valuation model. The expected term of options
granted to employees under our stock plans is based on the average of the contractual term (generally 10 years) and the vesting
period (generally 48 months). The expected term of options granted under the 2014 Plan, all of which qualify as &ldquo;plain vanilla&rdquo;
per SEC Staff Accounting Bulletin 107, is based on the average of the 6.25 years. For non-employee options, the expected term
is the contractual term and stock options granted to non-employee consultants are revalued at the end of each reporting period
until vested and changes in their fair value are recorded as adjustments to expense over the related vesting period. The risk-free
rate is based on the yield of a U.S. Treasury security with a term consistent with the option. We estimate the forfeiture rate
at the time of grant and revise it, if necessary, in subsequent periods if actual forfeitures differ from those estimates. Forfeitures
were estimated based on management&rsquo;s expectation through industry knowledge and historical data. We have never paid dividends
on our common stock and do not anticipate paying dividends on our common stock in the foreseeable future. Accordingly, we have
assumed no dividend yield for purposes of estimating the fair value of our share-based compensation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 74; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->72<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following assumptions were used to estimate the fair value of stock options granted using the Black-Scholes option pricing model
for the years ended December 31, 2018 and 2017 is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 64%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk
    free interest rate</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.53</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 14%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.17</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    term in years</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.23</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">87.70</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">86.36</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Estimated
    forfeiture rate</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Emerging
Growth Company Status</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Under
Section 107(b) of the Jumpstart Our Business Startups Act of 2012, emerging growth companies can delay adopting new or revised
accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves
of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting
standards as other public companies that are not emerging growth companies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Results
of Operations </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Comparison
of Year Ended 2018 to 2017</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Revenue
from Awards. </B>We have recognized approximately $4,822,000 and $2,440,000 of revenue from awards in the years ended December
31, 2018 and 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Amounts
recognized in 2018 were related to the 2018 CFF Award. We received an aggregate of $12.5 million during the year ended December
31, 2018 upon our achievement of milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment
Agreement. The remainder of the 2018 CFF Award is payable to us incrementally upon the achievement of the remaining milestones
related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement. We assessed the 2018 CFF Award
for accounting under ASC 606, which we adopted in the first quarter of 2018. To determine revenue recognition for arrangements
that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate
the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies
a performance obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
amounts recognized in 2017 were related to the 2015 CFFT Award. The payments received under the 2015 CFFT Award were recorded
as deferred revenue when the triggering event to receive those amounts occurred and were amortized on a straight-line basis over
the expected duration of the remaining performance period under the 2015 CFFT Award, which concluded in the third quarter of 2017.We
received a total of $5 million in payments under the 2015 CFFT Award since its inception. Revenue was recognized for the 2015
CFFT Award under ASC 605 during 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Research
and Development. </B>Research and Development expenses for the year ended December 31, 2018 totaled approximately $48,614,000,
an increase of $22,575,000 over the $26,039,000 recorded for the year ended December 31, 2017. The increase in fiscal 2018 as
compared to fiscal 2017 was primarily attributable to increases of $17,526,000 in clinical trial costs, $4,004,000
in compensation costs, and $1,045,000 in stock-based compensation expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
2018, the Company formed a subsidiary in each of the United Kingdom and Australia and approximately 33% of research and development
expenses recorded for the year ended December 31, 2018 was recorded in these entities.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>General
and Administrative.</B> General and Administrative expense for the year ended December 31, 2018 totaled approximately $12,956,000,
an increase of $3,992,000 over the $8,964,000 recorded for the year ended December 31, 2017. The increase in 2018 as compared
to 2017 was primarily attributable to increases of approximately $1,357,000 in compensation costs, $870,000 in stock-based compensation
expense, $799,000 in legal costs, $438,000 in consulting costs, $165,000 in travel, meals, and conventions and $150,000 in facilities
costs due to increased headcount, and an aggregate net increase of approximately $213,000 for other general and administrative
expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Other
Income, Net.</B> Other income, net for 2018 was approximately $1,076,000 as compared to approximately $141,000 recorded for 2017.
The increase in 2018 as compared to 2017 was primarily attributable to an increase in net interest income of approximately $800,000
due to increased cash balances in 2018 as compared to 2017, plus increases in foreign currency exchange transaction gains of approximately
$135,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 75; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->73<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Liquidity
and Capital Resources</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Since
inception, we have experienced negative cash flows from operations. We have financed our operations primarily through sales of
equity-related securities. In addition, the majority of the costs of the Phase 2 DM and SLE clinical trials have been or are expected
to be funded by NIH grants, and our Phase 2 cystic fibrosis clinical trial was partially funded by the 2015 CFFT Award. Our Phase
2b cystic fibrosis trial is being supported by the 2018 CFF Award. At December 31, 2018, our accumulated deficit since inception
was approximately $121,370,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2018, we had total current assets of approximately $44,240,000 and current liabilities of approximately $18,089,000
resulting in working capital of approximately $26,151,000. <FONT STYLE="background-color: white">Of our total cash and cash equivalents
of $41.7 million at December 31, 2018, $41.0 million was held within the United States.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net
cash used in operating activities for the year ended December 31, 2018 was approximately $30,067,000, which includes a net loss
of approximately $55,672,000, adjusted for non-cash expenses of approximately $8,596,000 principally related to stock-based compensation
expense of $7,610,000, depreciation expense of $494,000 and deferred rent of $422,000, and approximately $17,009,000 of cash provided
by net working capital items, principally related to the receipt of $12,500,000 under the 2018 CFF Award during 2018 and increases
in accounts payable and accrued expenses.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
used in investing activities for the year ended December 31, 2018 totaled approximately $2,300,000, which was largely related
to the construction costs and purchases of furniture and fixtures for our office space that we began occupying in February 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash
provided by financing activities for the year ended December 31, 2018 totaled approximately $11,420,000. On January 5, 2018, we
entered into a Controlled Equity Offering<SUP>SM</SUP> Sales Agreement (&ldquo;January 2018 Sales Agreement&rdquo;) with Cantor
Fitzgerald pursuant to which Cantor Fitzgerald served as our sales agent to sell up to $50 million of shares of our common stock
through an &ldquo;at the market offering,&rdquo; of which we sold 1,500,000 shares for net proceeds of approximately $11.2 million
in the first quarter of 2018. We did not sell any shares under the January 2018 Sales Agreement in the remainder of 2018 and through
February 8, 2019, the effective date of our termination of the January 2018 Sales Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 76; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->74<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2018, we also received proceeds of approximately $347,645 from the issuance of 139,069 shares
of our common stock upon the exercise of stock options to purchase common stock, and issued 5,000 shares of common stock upon
the exercise of stock warrants and we received proceeds of $5,000. Cash provided by financing activities for the year ended December
31, 2018 included proceeds from issuances of notes payable of $491,629, partially offset by principal payments on notes payable
of $430,184 in connection with our loan agreements with financing companies. The terms of the loan that we entered into in November
2017 stipulated equal monthly payments of principal and interest payments of $41,975 over a ten-month period. Interest accrued
on this loan at an annual rate of 2.35%. This loan was paid in full in August 2018. In November 2018, we entered into a loan agreement
with a financing company for $491,629 to finance one of our insurance policies. The terms of the loan stipulate equal monthly
payments of principal and interest payments of $49,857 over a ten-month period. Interest accrues on this loan at an annual rate
of 3.07%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, we entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (&ldquo;Kaken&rdquo;) for the development
and commercialization in Japan of our investigational drug lenabasum for the treatment of systemic sclerosis (&ldquo;SSc&rdquo;)
and dermatomyositis (&ldquo;DM&rdquo;), two rare and serious autoimmune diseases. Under the terms of the agreement, Kaken receives
an exclusive license to commercialize and market lenabasum in Japan for SSc and DM. Kaken will make an upfront payment to us of
$27 million. We will be eligible to receive in addition up to $173 million upon achievement of certain regulatory, development
and sales milestones as well as double- digit royalties.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2019, we consummated an underwritten public offering of shares of our common stock pursuant to which we sold an aggregate
of 6,198,500 shares of our common stock at a purchase price of $6.50 per share with gross proceeds to us totaling $40,290,250,
less estimated issuance costs incurred of approximately $2,667,000. (&ldquo;January 2019 Offering&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
expect our cash and cash equivalents of approximately $41.7 million at December 31, 2018 together with the $27 million upfront
payment to be received from Kaken, less the $2.7 million royalty (which is 10% of such upfront payment) that we will owe to CFF
pursuant to the Investment Agreement, and the approximately $37.6 million of net proceeds from the January 2019 Offering, to be
sufficient to meet our operating and capital requirements into the fourth quarter of 2020, based on current planned expenditures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 77; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->75<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
will need to raise significant additional capital to continue to fund operations and the clinical trials for lenabasum. We may
seek to sell common stock, preferred stock or convertible debt securities, enter into a credit facility or another form of third-party
funding or seek other debt financing. In addition, we may seek to raise cash through collaborative agreements or from government
grants. The sale of equity and convertible debt securities may result in dilution to our stockholders and certain of those securities
may have rights senior to those of our common shares. If we raise additional funds through the issuance of preferred stock, convertible
debt securities or other debt financing, these securities or other debt could contain covenants that would restrict our operations.
Any other third-party funding arrangement could require us to relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically,
on the progress of our clinical development programs. Funding may not be available when needed, at all, or on terms acceptable
to us. Lack of necessary funds may require us, among other things, to delay, scale back or eliminate expenses including some or
all of our planned clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contractual
Obligations and Commitments</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
following table presents information about our known contractual obligations as of December 31, 2018. It does not reflect contractual
obligations that may have arisen or may arise after that date. Except for historical facts, the information in this section is
forward-looking information.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="18" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Payments
    due by period</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Contractual
    Obligations</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2019</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fiscal
                                         2020-</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2021</FONT></P></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fiscal
                                         2022-</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">2023</FONT></P></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">After</FONT></P>
                                                                                <P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Fiscal
                                         2023</FONT></P></TD><TD STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 28%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Operating
    lease obligations (1)</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">5,029,289</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">623,958</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">1,614,843</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">1,734,849</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="width: 10%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">1,055,639</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Capital
    lease obligations (2)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">378</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">378</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&mdash;</FONT></TD><TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">5,029,667</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 9pt">624</FONT></FONT><FONT STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-size: 9pt">,336</FONT></FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">1,614,843</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">1,734,849</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">$</FONT></TD><TD STYLE="text-align: right; border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">1,055,639</FONT></TD><TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 9pt">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 12pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.3in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
                                         August 21, 2017, we entered into a lease agreement (&ldquo;the August 2017 Lease Agreement&rdquo;)
                                         with the initial term of a period of seven years which commenced in February 2018. The
                                         base rent pursuant to the August 2017 Lease Agreement ranges from approximately $470,000
                                         for the first year to approximately $908,000 for the seventh year. Additionally, the
                                         August 2017 Lease Agreement required us to provide a standby irrevocable letter of credit
                                         of $400,000, which may be reduced, if we are not in default under the August 2017 Lease
                                         Agreement, to $300,000 and $200,000 on the third and fourth anniversary of the commencement
                                         date, respectively. We entered into an unsecured letter of credit with a commercial bank
                                         for $400,000 in connection with the August 2017 Lease Agreement. On February 26, 2019
                                         we amended our lease (&ldquo;February 2019 Lease Agreement&rdquo;) pursuant to which
                                         an additional 30,023 square feet of office space (&ldquo;New Premises&rdquo;) will be
                                         leased by us in the same building for an aggregate total of 62,756 square feet of leased
                                         office space (&ldquo;Total Premises&rdquo;). The commencement date for the New Premises
                                         is expected to occur no later than August 1, 2019 and the lease term for the Total Premises
                                         is until October 31, 2026.</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
        future minimum rent commitments for the Total Premises are estimated to be approximately as follows:</FONT></P></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif; margin-left: 0.5in">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">678,000</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,288,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,592,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,640,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,687,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,036,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,921,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; width: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
    December 30, 2015, we entered into a lease agreement for a copier machine. The machine was placed in service in January 2016.
    The lease is for a three-year term and includes a bargain purchase option at the end of the term.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
may enter into contracts in the normal course of business with clinical research organizations for clinical trials and clinical
supply manufacturing and with vendors for pre-clinical research studies, research supplies and other services and products for
operating purposes. These contracts generally provide for termination on notice, and therefore, we believe that our non-cancelable
obligations under these agreements are not material. As of December 31, 2018, other than our leases in the table above, we had
no material Contractual Obligations or Commitments that will affect our future liquidity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 78; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->76<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Off-Balance
Sheet Arrangements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
do not have any off-balance sheet arrangements that have or are reasonably likely to have a current or future effect on our financial
condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital
resources that is material to investors, other than future payments under development award agreements discussed as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2015
CFFT Award </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the 2015 CFFT Award agreement, we are obligated to make royalty payments to CFFT contingent upon commercialization
of lenabasum in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five
times the amount we receive under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments
following the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale
of lenabasum, (ii) a royalty payment to CFFT equal to the amount we receive under the 2015 CFFT Award Agreement, up to $5 million,
due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million,
and (iii) royalty payment(s) to CFFT of up to approximately $15 million if we transfer, sell or license lenabasum in the Field
of Use other than for certain clinical or development purposes, or if we enter into a change of control transaction, with such
payment(s) to be credited against the royalty payments due upon commercialization. The Field of Use is defined in the CFFT Award
Agreement as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD hypersensitivity pneumonitis,
pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or we may terminate the 2015 CFFT Award Agreement
for cause, which includes our material failure to achieve certain commercialization and development milestones. Our payment obligations,
if any, would survive the termination of the 2015 CFFT Award Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2018
CFF Award </I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, we are obligated to make certain royalty payments to CFF, including a royalty payment
of one and one-half times the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval
of lenabasum in the United States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon
approval in another major market, as set forth in the Investment Agreement (the &ldquo;Approval Royalty&rdquo;). At our election,
we may satisfy the first of the two Approval Royalties in registered shares of our common stock. Additionally, we will owe to
CFF a royalty payment equal to 10% of any amounts we receive as payment under the collaboration agreement with Kaken, provided
that the total royalties that we will be required to pay under the Investment Agreement resulting from income from licenses or
sales subject to the Investment Agreement are capped at five times the total amount of the 2018 CFF Award, and we may credit such
royalties against any royalties on net sales otherwise owed to CFF under the Investment Agreement. Accordingly, we will be required
to pay CFF $2,700,000 within 60 days of our receipt of the $27,000,000 upfront cash payment from Kaken described above.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 79; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->77<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
we are obligated to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty
days after any quarter in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments
to CFF of one percent of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any
quarter in which such net sales occur, and (iii) royalty payments to CFF of ten percent of any amount that we and our stockholders
receive in connection with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment
or prevention of CF, or a change of control transaction, except that such payment shall not exceed five times the amount of the
2018 CFF Award, with such payments to be credited against any other net sales royalty payments due. Either CFF or we may terminate
the Investment Agreement for cause, which includes our material failure to achieve certain commercialization and development milestones.
Our payment obligations survive the termination of the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>License
Agreement with Jenrin</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.3in; text-align: justify; text-indent: 0.3in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Jenrin Agreement, we are obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million
for each compound we elect to develop based upon the achievement of specified development and regulatory milestones. In addition,
we are obligated to pay Jenrin royalties in the mid, single digits based on net sales of any Licensed Products, as defined in
the Jenrin Agreement, subject to specified reductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Jenrin Agreement terminates on a country-by-country basis and product-by-product basis upon the expiration of the royalty term
for such product in such country. Each royalty term begins on the date of the first commercial sale of the licensed product in
the applicable country and ends on the later of seven years from such first commercial sale or the expiration of the last to expire
of the applicable patents in that country. The Jenrin Agreement may be terminated earlier in specified situations, including termination
for uncured material breach of the Jenrin Agreement by either party, termination by Jenrin in specified circumstances, termination
by Corbus with advance notice and termination upon a party&rsquo;s insolvency or bankruptcy.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Collaboration
Agreement with Kaken</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Kaken Agreement, we will bear the cost of, and be responsible for, among other things, conducting the clinical
studies and other developmental activities for the Licensed Products in the Initial Indications in the Territory, and Kaken will
bear the cost of, and be responsible for, among other things, preparing and filing applications for regulatory approval in the
Territory and for commercializing Licensed Products in the Territory, and will use commercially reasonable efforts to commercialize
Licensed Products and obtain pricing approval for Licensed Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the license and other rights granted by us, Kaken will pay us, a $27,000,000 upfront cash payment and is obligated
to pay potential milestone payments to us totaling up to approximately $173,000,000 for the achievement of certain development,
sales and regulatory milestones. In addition, during the Royalty Term (as defined below), Kaken is obligated to pay us royalties
on sales of Licensed Products in the Territory, under certain conditions, in the double digits, which royalty shall be reduced
in certain circumstances. In particular, for so long as we supply Licensed Products to Kaken pursuant to a supply agreement to
be entered into by the parties, royalty payments shall be payable for each unit of Licensed Product that we supply as a percentage
of the Japanese National Health Insurance price of the Licensed Product. During any time in which a supply agreement is not in
effect, royalty payments shall be changed to a rate to be agreed upon by the parties in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agreement will remain in effect on a Licensed Product-by-Licensed product basis and will expire upon the expiration of the Royalty
Term for the final Licensed Product. The &ldquo;Royalty Term&rdquo; means the period beginning on the date of the first commercial
sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents
covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial
Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication
in Japan. The Agreement may be terminated by either party for material breach, upon a party&rsquo;s insolvency or bankruptcy or
upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for
a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a
Licensed Product in either of the Initial Indications in the Territory, with 180 days&rsquo; notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 80; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->78<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_012"></A><FONT STYLE="font-size: 10pt"><B>Item
    7A.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>QUANTITATIVE
    AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
exposure to market risk is limited to our cash and cash equivalents, all of which have maturities of three months or less. The
primary objectives of our investment activities are to preserve principal, provide liquidity and maximize income without significantly
increasing risk. Our primary exposure to market risk is interest income sensitivity, which is affected by changes in the general
level of U.S. interest rates. However, because of the short-term nature of the instruments in our portfolio, a sudden change in
market interest rates would not be expected to have a material impact on our financial condition and/or results of operation.
We do not have other derivative financial instruments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Foreign
Exchange Risk</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
majority of our operations are based in the United States and, accordingly our transactions are denominated in U.S. Dollars. However,
we have foreign currency exposures related to our cash valued in the United Kingdom in British Pounds and Euros because our functional
currency is the U.S. Dollar in our foreign-based subsidiaries. Our foreign denominated assets and liabilities are remeasured each
reporting period with any exchange gains and losses recorded in our consolidated statements of operations.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_013"></A><FONT STYLE="font-size: 10pt"><B>Item
    8.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FINANCIAL
    STATEMENTS AND SUPPLEMENTARY DATA</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">See
pages F-1 through F-20 following the Exhibit Index of this Annual Report on Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_014"></A><FONT STYLE="font-size: 10pt"><B>Item
    9.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CHANGES
    IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_015"></A><FONT STYLE="font-size: 10pt"><B>Item
    9A.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CONTROLS
    AND PROCEDURES </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Evaluation
of Our Disclosure Controls</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
maintain disclosure controls and procedures that are designed to provide reasonable assurance that material information required
to be disclosed in our periodic reports filed under the Exchange Act is recorded, processed, summarized, and reported within the
time periods specified in the SEC&rsquo;s rules and forms and to provide reasonable assurance that such information is accumulated
and communicated to our management, our chief executive officer and our chief financial officer, to allow timely decisions regarding
required disclosure. We carried out an evaluation, under the supervision and with the participation of our management, including
our principal executive and principal financial officer, of the effectiveness of the design and operation of our disclosure controls
and procedures, as defined in Rule 13(a)-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer
and principal financial officer concluded that, as of December 31, 2018, our disclosure controls and procedures were effective.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Management&rsquo;s
Report on Internal Control Over Financial Reporting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules
13a-15(f) and 15d-15(f) under the Exchange Act. Under the supervision and with the participation of our management, including
our Chief Executive Officer and Chief Financial Officer, we conducted an evaluation of the effectiveness of our internal control
over financial reporting based on criteria established in the framework in <I>Internal Control &mdash; Integrated Framework (2013)
issued by the Committee of Sponsoring Organizations of the Treadway Commission</I>. Based on this evaluation, our management concluded
that our internal control over financial reporting was effective as of December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 81; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->79<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Because
of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections
of any evaluation of effectiveness to future periods are subject to the risks that controls may become inadequate because of changes
in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Annual Report does not include an attestation report of our independent registered public accounting firm because we are an &ldquo;emerging
growth company,&rdquo; and may take advantage of certain exemptions from various reporting requirements that are applicable to
public companies that are not &ldquo;emerging growth companies&rdquo; including, but not limited to, not being required to comply
with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Changes
in Internal Controls over Financial Reporting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2018, there have been no changes in our internal control over financial reporting that have materially
affected or are reasonably likely to materially affect our internal controls over financial reporting. From time to time, we make
changes to our internal control over financial reporting that are intended to enhance its effectiveness and which do not have
a material effect on our overall internal control over financial reporting.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_016"></A><FONT STYLE="font-size: 10pt"><B>Item
    9B.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>OTHER
    INFORMATION </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>None</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 82; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->80<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_017"></A><FONT STYLE="font-size: 10pt"><B>PART
III</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_018"></A><FONT STYLE="font-size: 10pt"><B>Item
    10.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DIRECTORS,
    EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2019 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_019"></A><FONT STYLE="font-size: 10pt"><B>Item
    11.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXECUTIVE
    COMPENSATION</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated herein by reference to our Proxy Statement for the 2019 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_020"></A><FONT STYLE="font-size: 10pt"><B>Item
    12.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SECURITY
    OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2019 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_021"></A><FONT STYLE="font-size: 10pt"><B>Item
    13.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTAIN
    RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2019 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_022"></A><FONT STYLE="font-size: 10pt"><B>Item
    14.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PRINCIPAL
    ACCOUNTING FEES AND SERVICES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Information
required by this item is incorporated by reference to our Proxy Statement for the 2019 Annual Meeting of Stockholders.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 83; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->81<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_023"></A><FONT STYLE="font-size: 10pt"><B>PART
IV</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_024"></A><FONT STYLE="font-size: 10pt"><B>Item
    15.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>EXHIBITS,
    FINANCIAL STATEMENT SCHEDULES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(a)
List of Documents filed as part of this Report</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(1)
Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
financial statements and related notes, together with the report of EisnerAmper LLP appear at pages F-1 through F-19 following
the Exhibit List as required by Part II, Item 8 &ldquo;Financial Statements and Supplementary Data&rdquo; of this Form 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(2)
Financial Statement Schedules.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Schedules
are omitted because they are either not required, not applicable, or the information is otherwise included.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(3)
Exhibits </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has filed with this report or incorporated by reference herein certain exhibits as specified below pursuant to Rule 12b-32
under the Exchange Act. See Exhibit Index following the signature page to this report for a complete list of documents filed with
this report.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.75in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.1in; padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217005930/ex3-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Certificate of Incorporation of the Company (incorporated by reference to Exhibit 3.1 of the Company&rsquo;s
    Current Report on Form 8-K filed with the SEC on May 26, 2017).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217005930/ex3-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Bylaws of the Company (incorporated by reference to Exhibit 3.2 of the Company&rsquo;s Current Report on Form
    8-K filed with the SEC on May 26, 2017).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Merger Warrant (incorporated by reference to Exhibit 4.1 of the Company&rsquo;s Registration Statement on Form S-1 filed
    with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Replacement Warrant (incorporated by reference to Exhibit 4.2 of the Company&rsquo;s Registration Statement on Form S-1
    filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Investor Warrant (incorporated by reference to Exhibit 4.3 of the Company&rsquo;s Registration Statement on Form S-1 filed
    with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Additional Replacement Warrant (incorporated by reference to Exhibit 4.4 of the Company&rsquo;s Registration Statement
    on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Placement Agent Warrant (incorporated by reference to Exhibit 4.5 of the Company&rsquo;s Registration Statement on Form
    S-1 filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex4-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Registration
    Rights Agreement (incorporated by reference to Exhibit 4.6 of the Company&rsquo;s Registration Statement on Form S-1 filed
    with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312514416997/d823238dex44.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Specimen
    Common Stock Certificate, $0.0001 par value (incorporated herein by reference to Exhibit 4.1 of the Company&rsquo;s Registration
    Statement on Form S-3 filed with the SEC on November 10, 2015).</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218003208/ex4-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Warrant
    to Purchase Common Stock, dated as of January 26, 2018, issued to the Cystic Fibrosis Foundation (incorporated herein by reference
    to Exhibit 4.8 of the Company&rsquo;s Annual Report on Form 10-K filed with the SEC on March 12, 2018).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Placement
    Agency Agreement, dated March 27, 2014, between the Company and Aegis Capital Corporation (incorporated by reference to Exhibit
    10.1 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consulting
    Agreement, dated March 21, 2014, between the Company and Orchestra Medical Ventures (incorporated by reference to Exhibit
    10.2 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 84; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->82<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.75in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.1in; padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.3</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Subscription Agreement for the Company&rsquo;s 2014 Private Placement (incorporated by reference to Exhibit 10.3 of the
    Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.4</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Voting Agreement, dated April 11, 2014, by and among the Company and the stockholders named therein (incorporated by reference
    to Exhibit 10.4 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.5</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">2014
    Equity Compensation Plan (incorporated by reference to Exhibit 10.5 of the Company&rsquo;s Registration Statement on Form
    S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.6</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-6.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Incentive Stock Option Agreement (incorporated by reference to Exhibit 10.6 of the Company&rsquo;s Registration Statement
    on Form S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.7</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-7.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Non-Qualified Stock Option Agreement (incorporated by reference to Exhibit 10.7 of the Company&rsquo;s Registration Statement
    on Form S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.8</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-8.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Restricted Stock Agreement (incorporated by reference to Exhibit 10.8 of the Company&rsquo;s Registration Statement on
    Form S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.9</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-9.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated April 11, 2014, between the Company and Yuval Cohen (incorporated by reference to Exhibit 10.9 of the Company&rsquo;s
    Registration Statement on Form S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.10</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-10.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated April 11, 2014, between the Company and Mark Tepper (incorporated by reference to Exhibit 10.10 of the Company&rsquo;s
    Registration Statement on Form S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.11</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Employment Agreement, dated June 19, 2014, between the Company and Sean Moran (incorporated by reference to Exhibit
    10.11 of the Company&rsquo;s Registration Statement on Form S-1 filed with the SEC on September 3, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.12</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-12.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Agreement
    and Plan of Merger, dated March 27, 2014, by and among the Company, Corbus Pharmaceuticals Acquisition, Inc. and JB Therapeutics,
    Inc. (incorporated by reference to Exhibit 10.12 of the Company&rsquo;s Registration Statement on Form S-1 filed with the
    SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.13</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-13.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Subscription
    Agreement, dated April 2009, between Sumner Burstein and JB Therapeutics, Inc. (which is now known as Corbus Pharmaceuticals,
    Inc.) (incorporated by reference to Exhibit 10.13 of the Company&rsquo;s Registration Statement on Form S-1 filed with the
    SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.14</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414054047/v388165_ex10-14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Letter
    Agreement, dated April 29, 2009, between JB Therapeutics, Inc. (which is now known as Corbus Pharmaceuticals, Inc.) and Sumner
    Burstein (incorporated by reference to Exhibit 10.14 of the Company&rsquo;s Registration Statement on Form S-1 filed with
    the SEC on September 3, 2014).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.15</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000114420414058605/v390155_ex10-15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Form
    of Indemnification Agreement (incorporated by reference to Exhibit 10.15 of the Company&rsquo;s Registration Statement on
    Amendment No. 1 to Form S-1 filed with the SEC on September 30, 2014). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.16</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312515114246/d900328dex1015.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Letter
    Agreement, dated August 18, 2014, between the Company and Barbara White (incorporated herein by reference to Exhibit 10.15
    of the Company&rsquo;s Post-Effective Amendment No. 1 to Form S-1 filed with the SEC on March 31, 2015). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.17</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312515184856/d908885dex101.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Award
    Agreement, dated April 9, 2015, between Cystic Fibrosis Foundation Therapeutics, Inc. and the Company (incorporated herein
    by reference to Exhibit 10.1 of the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on May 13, 2015).#</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.18</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex101_14.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment
    No.1 to Employment Agreement, dated April 11, 2016, between the Company and Yuval Cohen (incorporated by reference to Exhibit
    10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.19</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex102_15.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment
    No.1 to Employment Agreement, dated April 11, 2016, between the Company and Mark Tepper (incorporated by reference to Exhibit
    10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.20</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex103_16.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amendment
    No.1 to Amended and Restated Employment Agreement, dated April 11, 2016, between the Company and Sean Moran (incorporated
    by reference to Exhibit 10.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 15, 2016). &dagger;</FONT></A></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 85; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->83<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; vertical-align: top; width: 0.75in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.1in; padding-bottom: 1.5pt; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.21</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016016297/crbp-ex104_17.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Employment
    Agreement, dated April 11, 2016, between the Company and Barbara White (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s
    Current Report on Form 8-K filed with the SEC on April 15, 2016). &dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.22</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000156459016020500/crbp-ex101_39.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Securities
    Purchase Agreement, dated June 10, 2016, between Company and each purchaser identified on the signature pages thereto (incorporated
    by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on June 10, 2016).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.23</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216013495/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Consulting
    Agreement, dated September 20, 2016, between Company and Orchestra Medical Ventures, LLC (incorporated by reference to Exhibit
    10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on September 21, 2016).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.24</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Lease,
    dated May 30, 2014, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated by reference to
    Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.25</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">First
    Amendment to Lease, dated August 27, 2015, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated
    by reference to Exhibit 10.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.26</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Second
    Amendment to Lease, dated March 30, 2016, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated
    by reference to Exhibit 10.4 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.27</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315216014751/ex10-5.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Third
    Amendment to Lease, dated September 13, 2016, between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated
    by reference to Exhibit 10.5 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on November 10, 2016).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.28</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000119312516776585/d302766dex11.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Controlled
    Equity Offering<SUP>SM </SUP>Sales Agreement, dated November 23, 2016, by and between Corbus Pharmaceuticals Holdings, Inc.
    and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.1 of the Company&rsquo;s Current Report on Form 8-K
    filed with the SEC on November 23, 2016.)</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.29</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217001977/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Securities
    Purchase Agreement, dated February 28, 2017, between Company and each purchaser identified on the signature pages thereto
    (incorporated by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on February
    28, 2017).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.30</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217009730/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Lease
    Agreement, dated August 21, 2017, by and between Corbus Pharmaceuticals, Inc. and River Ridge Limited Partnership (incorporated
    by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on August 22, 2017).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.31</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315217009730/ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Guarantee,
    dated August 21, 2017, by Corbus Pharmaceuticals Holdings, Inc. (incorporated by reference to Exhibit 10.2 of the Company&rsquo;s
    Current Report on Form 8-K filed with the SEC on August 22, 2017).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.32</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218000239/ex1-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Controlled
    Equity OfferingSM Sales Agreement, dated January 5, 2018, by and between Corbus Pharmaceuticals Holdings, Inc. and Cantor
    Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 of the Company&rsquo;s Registration Statement on Form S-3 filed
    with the SEC on January 5, 2018).</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.33</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218003208/ex10-33.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Cystic
    Fibrosis Program Related Investment Agreement, dated January 26, 2018, between Cystic Fibrosis Foundation Therapeutics, Inc.
    and the Company (incorporated herein by reference to Exhibit 10.33 of the Company&rsquo;s Annual Report on Form 10-K filed
    with the SEC on March 12, 2018).#</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.34</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218005115/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Yuval Cohen, dated April 11, 2018 (incorporated
    by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 13, 2018).&dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.35</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218005115/ex10-2.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Mark Tepper, dated April 11, 2018 (incorporated
    by reference to Exhibit 10.2 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 13, 2018).&dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.36</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218005115/ex10-3.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Amended
    and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Barbara White, dated April 11, 2018 (incorporated
    by reference to Exhibit 10.3 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 13, 2018).&dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.37</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218005115/ex10-4.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Second
    Amended and Restated Employment Agreement between Corbus Pharmaceuticals Holdings, Inc. and Sean Moran, dated April 11, 2018
    (incorporated by reference to Exhibit 10.4 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on April 13,
    2018).&dagger;</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.38</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315218015417/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">License
    Agreement, dated as of September 20, 2018, between Corbus Pharmaceuticals, Inc. and Jenrin Discovery, LLC (incorporated by
    reference to Exhibit 10.1 of the Company&rsquo;s Quarterly Report on Form 10-Q filed with the SEC on November 8, 2018).#</FONT></A></FONT></TD></TR>
</TABLE>

<P STYLE="margin-top: 0; margin-bottom: 0; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<!-- Field: Page; Sequence: 86; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->84<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; width: 0.75in; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.39</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="http://www.sec.gov/Archives/edgar/data/1595097/000149315219000082/ex10-1.htm" STYLE="-sec-extract: exhibit"><FONT STYLE="font-size: 10pt">Collaboration
    and License Agreement, dated January 3, 2019, between Corbus Pharmaceuticals, Inc. and Kaken Pharmaceutical Co., Ltd. (incorporated
    by reference to Exhibit 10.1 of the Company&rsquo;s Current Report on Form 8-K filed with the SEC on January 3, 2019).#</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.40</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex10-40.htm"><FONT STYLE="font-size: 10pt">Lease
    Amendment No. 1, dated as of February 26, 2019, among River Ridge Limited Partnership, Corbus Pharmaceuticals, Inc. and Corbus
    Pharmaceuticals Holdings, Inc.*</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.41</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex10-41.htm"><FONT STYLE="font-size: 10pt">Offer
    Letter, dated as of February 19, 2019, between Craig Millian and Corbus Pharmaceuticals, Inc.*</FONT></A></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">21.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex21-1.htm"><FONT STYLE="font-size: 10pt">List
    of Subsidiaries of the Company.*</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">23.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex23-1.htm"><FONT STYLE="font-size: 10pt">Consent
    of EisnerAmper LLP.*</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex31-1.htm"><FONT STYLE="font-size: 10pt">Certification
    of Chief Executive Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).*</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">31.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex31-2.htm"><FONT STYLE="font-size: 10pt">Certification
    of Chief Financial Officer pursuant to Rule 13a-14(a) or Rule 15d-14(a).*</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex32-1.htm"><FONT STYLE="font-size: 10pt">Certification
    of Chief Executive Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).**</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">32.2</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="ex32-2.htm"><FONT STYLE="font-size: 10pt">Certification
    of Chief Financial Officer pursuant to Rule 13a-14(b) or Rule 15d-14(b).**</FONT></A></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.INS</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Instance Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.SCH</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Schema Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.CAL</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Calculation Linkbase Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.DEF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Definition Linkbase Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.LAB</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Label Linkbase Document.*</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="white-space: nowrap; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: top"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">101.PRE</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">XBRL
    Taxonomy Extension Presentation Linkbase Document.*</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">*</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Filed
    herewith.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">**</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Furnished,
    not filed.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">#</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Confidential
    treatment has been granted with respect to certain portions of this exhibit. Omitted portions have been submitted separately
    to the SEC.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&dagger;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicates
    a management contract or compensation plan, contract or arrangement.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.75in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_025"></A><FONT STYLE="font-size: 10pt"><B>Item
    16.</B></FONT></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>FORM
    10-K SUMMARY</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 55.45pt; text-align: justify; text-indent: -55.45pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">None.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 87; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->85<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report
to be signed on its behalf by the undersigned, thereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
    PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 12, 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    YUVAL COHEN</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 45%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf
of the registrant and in the capacities and on the dates indicated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; width: 38%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Signature</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 38%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Title</B></FONT></TD>
    <TD STYLE="vertical-align: top; width: 2%; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; width: 20%; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Date</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    YUVAL COHEN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
                                         Executive Officer and Director</FONT></P>
        <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
        Executive Officer)</FONT></P></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="white-space: nowrap; vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    SEAN MORAN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer (Principal Financial and Accounting Officer)</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    ALAN HOLMER</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Alan
    Holmer</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    DAVID HOCHMAN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
    Hochman</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    JOHN JENKINS</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">John
    Jenkins</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    AVERY CATLIN</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD ROWSPAN="2" STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Avery
    Catlin</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    PARIS PANAYIOTOPOULOS</I></FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Director</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
    12, 2019</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paris
    Panayiotopoulos </FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.5in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 88; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->86<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INDEX
TO FINANCIAL STATEMENTS</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; width: 0.1in; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 0.5in; border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Page
    Number</B></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_026"><FONT STYLE="font-size: 10pt">Report
    of Independent Registered Public Accounting Firm</FONT></A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-2</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Corbus
    Pharmaceuticals Holdings, Inc. Financial Statements-December 31, 2018:</B></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_027"><FONT STYLE="font-size: 10pt">Consolidated
    Balance Sheets as of December 31, 2018 and December 31, 2017</FONT></A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-3</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_028"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Operations for the Years Ended December 31, 2018 and 2017</FONT></A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-4</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_029"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Stockholders&rsquo; Equity for the Years Ended December 31,2018 and 2017</FONT></A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-5</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_030"><FONT STYLE="font-size: 10pt">Consolidated
    Statements of Cash Flows for the Years Ended December 31,2018 and 2017</FONT></A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-6</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif; background-color: rgb(204,238,255)">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A HREF="#B_031"><FONT STYLE="font-size: 10pt">Notes
    to Consolidated Financial Statements</FONT></A></FONT></TD>
    <TD STYLE="vertical-align: top; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="white-space: nowrap; vertical-align: bottom; text-align: center; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">F-7</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>


<!-- Field: Page; Sequence: 89; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_026"></A><FONT STYLE="font-size: 10pt"><B>REPORT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Board of Directors and Stockholders of</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">Corbus
Pharmaceuticals Holdings, Inc. and Subsidiaries</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Opinion
on the Financial Statements</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have audited the accompanying consolidated balance sheets of Corbus Pharmaceuticals Holdings, Inc. and Subsidiaries (the
&ldquo;Company&rdquo;) as of December 31, 2018 and 2017, and the related consolidated statements of operations, stockholders&rsquo;
equity, and cash flows for each of the years then ended, and the related notes (collectively referred to as the &ldquo;financial
statements&rdquo;). In our opinion, the financial statements present fairly, in all material respects, the consolidated financial
position of the Company as of December 31, 2018 and 2017, and the consolidated results of their operations and their cash flows
for each of the years then ended, in conformity with accounting principles generally accepted in the United States of America.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Basis
for Opinion</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">These
consolidated financial statements are the responsibility of the Company&rsquo;s management. Our responsibility is to express
an opinion on the Company&rsquo;s consolidated financial statements based on our audits. We are a public accounting firm
registered with the Public Company Accounting Oversight Board (United States) (&ldquo;PCAOB&rdquo;) and are required to be independent
with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the
Securities and Exchange Commission and the PCAOB.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit
to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error
or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial
reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not
for the purpose of expressing an opinion on the effectiveness of the Company&rsquo;s internal control over financial reporting.
Accordingly, we express no such opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Our
audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to
error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence
regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles
used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements.
We believe that our audits provide a reasonable basis for our opinion.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
EisnerAmper LLP</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
have served as the Company&rsquo;s auditor since 2014.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">EISNERAMPER
LLP</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
Pennsylvania</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">March
12, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 90; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_027"></A><FONT STYLE="font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Balance Sheets</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">ASSETS</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    assets:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,748,468</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,537,495</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted
    cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">158,991</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Prepaid
    expenses and other current assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,491,844</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,808,244</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,240,312</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">65,504,730</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property
    and equipment, net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,705,206</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,432,655</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    assets</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">43,823</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">40,776</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    assets</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,989,341</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,978,161</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">LIABILITIES
    AND STOCKHOLDERS&rsquo; EQUITY</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Current
    liabilities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Notes
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">394,305</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">332,861</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accounts
    payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,345,335</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,130,295</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,851,191</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,741,519</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    revenue, current</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,462,503</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 13.7pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    rent, current</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,996</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    current liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,089,330</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,204,675</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    rent, noncurrent</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,375,891</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">989,550</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    liabilities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">375</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">19,465,221</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,194,600</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Commitments
    and Contingencies</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stockholders&rsquo;
    equity</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Preferred
    Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at December 31, 2018 and 2017</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2018 and 2017, 57,247,496 and 55,603,427 shares issued
    and outstanding at December 31, 2018 and 2017, respectively</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,725</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,560</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    paid-in capital</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">148,888,635</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">123,476,102</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated
    deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(121,370,240</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(65,698,101</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    stockholders&rsquo; equity</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,524,120</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,783,561</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 30pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    liabilities and stockholders&rsquo; equity</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">46,989,341</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">66,978,161</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 91; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_028"></A><FONT STYLE="font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Operations</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
                                         the Years Ended</B></FONT></P> <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>December
                                         31,</B></FONT></P></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Revenue
    from awards</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,822,272</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,440,195</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    expenses:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Research
    and development</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">48,613,957</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">26,038,965</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">General
    and administrative</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,956,022</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,964,046</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    operating expenses</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">61,569,979</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">35,003,011</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Operating
    loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(56,747,707</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,562,816</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income (expense), net:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Interest
    income, net</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">982,777</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">183,112</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    currency exchange gain (loss)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">92,791</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(41,908</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    income, net</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,075,568</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">141,204</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(55,672,139</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,421,612</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss per share, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.98</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.65</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average number of common shares outstanding, basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,999,741</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,176,953</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 92; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_029"></A><FONT STYLE="font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Statements
of Stockholders&rsquo; Equity</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Common
    Stock</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Additional
    Paid-in</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accumulated</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    Stockholders&rsquo;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Amount</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Capital</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deficit</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Equity</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 35%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2016</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">44,681,745</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,468</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">42,191,256</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(33,276,489</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 9%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8,919,235</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
    compensation expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,694,489</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,694,489</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common stock, net of issuance costs of $2,969,837</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,648,948</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,065</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75,400,894</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">75,401,959</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common stock upon exercise of stock options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">272,734</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">27</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">189,463</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">189,490</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,421,612</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,421,612</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance at
    December 31, 2017</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">55,603,427</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,560</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">123,476,102</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(65,698,101</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,783,561</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
    compensation expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,609,508</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,609,508</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common stock, net of issuance costs of $464,680</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,500,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">150</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,235,170</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,235,320</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common stock upon exercise of stock options</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">139,069</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">14</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">347,631</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">347,645</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    of common stock upon exercise of warrants</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4</FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">,999</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
    value of warrant issued in connection with Investment Agreement</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,215,225</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,215,225</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    Loss</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(55,672,139</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(55,672,139</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Balance
    at December 31, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">57,247,496</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,725</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">148,888,635</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(121,370,240</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">27,524,120</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 93; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_030"></A><FONT STYLE="font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Consolidated
Statements of Cash Flows</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from operating activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(55,672,139</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,421,612</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Adjustments
    to reconcile net loss to net cash used in operating activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock-based
    compensation expense</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,609,508</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,694,489</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Depreciation
    and amortization</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">493,938</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">255,652</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Loss(gain)
    on foreign exchange</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">70,448</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(8,490</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Deferred
    rent</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">422,337</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">913,563</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Changes
    in operating assets and liabilities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decrease
    in customer receivable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,500,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,000,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decrease
    (increase) in prepaid expenses and other current assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">281,625</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,877,983</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    in other assets</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,047</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(40,776</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    (decrease) in accounts payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,904,021</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(885,797</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    in accrued expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,113,551</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,514,521</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Decrease
    in deferred revenue</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,787,497</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,940,195</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in operating activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(30,067,255</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(27,796,628</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from investing activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchases
    of property and equipment</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,300,416</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(707,429</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash used in investing activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,300,416</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(707,429</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    flows from financing activities:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">491,629</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">415,265</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Principal
    payments on notes payable</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(430,184</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(354,161</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Proceeds
    from issuance of common stock</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,052,645</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">78,891,699</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Issuance
    costs paid for common stock financings</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(690,181</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,940,685</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 20pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Principal
    payments under capital lease obligations</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,256</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3,832</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; padding-left: 30pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    cash provided by financing activities</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,419,653</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">76,008,286</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    (decrease) increase in cash, cash equivalents, and restricted cash</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(20,948,018</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">47,504,229</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash,
    cash equivalents, and restricted cash at beginning of the year</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,696,486</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,192,257</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash,
    cash equivalents, and restricted cash at end of the year</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,748,468</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,696,486</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Supplemental
    disclosure of cash flow information and non cash transactions:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    paid during the period for interest</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">10,437</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,377</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair
    value of warrant issued in connection with Investment Agreement</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,215,225</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Purchases
    of property and equipment included in accounts payable or accrued expenses</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,168</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">579,734</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Write
    off of fully amortized leasehold improvements</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">191,244</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Unpaid
    stock issuance costs</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">225,501</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
accompanying notes are an integral part of these Consolidated Financial Statements.</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 94; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->6<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif"><A NAME="B_031"></A><FONT STYLE="font-size: 10pt"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Notes
to Consolidated Financial Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NATURE
    OF OPERATIONS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Business</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
Pharmaceuticals Holdings, Inc. (&ldquo;the Company&rdquo;) is a clinical stage pharmaceutical company, focused on the development
and commercialization of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Since its
inception, the Company has devoted substantially all of its efforts to business planning, research and development, recruiting
management and technical staff, acquiring operating assets and raising capital. The Company&rsquo;s business is subject to significant
risks and uncertainties and the Company will be dependent on raising substantial additional capital before it becomes profitable
and it may never achieve profitability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>2.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LIQUIDITY
    </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company anticipates operating losses to continue for the foreseeable future due to, among other things, costs related to research
funding, development of its product candidates and its preclinical and clinical programs, strategic alliances and the development
of its administrative organization. The Company has incurred recurring losses since inception and as of December 31, 2018, had
an accumulated deficit of $121,370,240.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, the Company entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (&ldquo;Kaken&rdquo;)
(See Note 15).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2019, the Company consummated an underwritten public offering of shares of its common stock (&ldquo;January 2019 Offering&rdquo;)
(See Note 15).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects the cash and cash equivalents of $41,748,468 at December 31, 2018 together with the $27 million of upfront payment
to be received from Kaken, less the $2.7 million royalty (which is 10% of such upfront payment) that the Company will owe to CFF
pursuant to the Investment Agreement (See Note 9), and the approximately $37.6 million of net proceeds from the January 2019 Offering,
to be sufficient to meet its operating and capital requirements at least 12 months from the filing of this 10-K.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Should
the Company be unable to raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including
delaying or discontinuing certain clinical activities. The Company will need to raise significant additional capital to continue
to fund the clinical trials for lenabasum and CRB-4001 (see Note 4). The Company may seek to sell common or preferred equity or
convertible debt securities, enter into a credit facility or another form of third-party funding, or seek other debt financing.
The sale of equity and convertible debt securities may result in dilution to the Company&rsquo;s stockholders and certain of those
securities may have rights senior to those of the Company&rsquo;s common shares. If the Company raises additional funds through
the issuance of preferred stock, convertible debt securities or other debt financing, these securities or other debt could contain
covenants that would restrict the Company&rsquo;s operations. Any other third-party funding arrangement could require the Company
to relinquish valuable rights.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
source, timing and availability of any future financing will depend principally upon market conditions, and, more specifically,
on the progress of the Company&rsquo;s clinical development programs. Funding may not be available when needed, at all, or on
terms acceptable to the Company. Lack of necessary funds may require the Company, among other things, to delay, scale back or
eliminate some or all of the Company&rsquo;s planned clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 95; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->7<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>3.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNIFICANT
    ACCOUNTING POLICIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of the significant accounting policies followed by the Company in the preparation of the financial statements is as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Use
of Estimates</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
process of preparing financial statements in conformity with accounting principles generally accepted in the United States of
America (&ldquo;U.S. GAAP&rdquo;) requires management to make estimates and assumptions that affect the reported amounts of assets
and liabilities and disclosure of assets and liabilities at the date of the financial statements and the reported amounts of revenues
and expenses during the reporting period. Actual results could differ from those estimates and changes in estimates may occur.
The most significant estimates are related to stock-based compensation expense, the accrual of research, product development and
clinical obligations, the recognition of revenue under the Investment Agreement (see Note 9) and the valuation of the CFF Warrant
discussed in Note 9).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Cash
and Cash Equivalents</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company considers only those investments which are highly liquid, readily convertible to cash, and that mature within three months
from date of purchase to be cash equivalents. Marketable investments are those with original maturities in excess of three months.
At December 31, 2018 and 2017, cash equivalents were comprised of money market funds. The Company had no marketable investments
at December 31, 2018 and 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Restricted
cash as of December 31, 2017 in the amount of $108,991 was classified in current assets and included a collateral account for
the Company&rsquo;s corporate credit cards. The collateral account was closed in the first quarter of 2018 and accordingly the
cash became unrestricted. Additionally, as of December 31, 2017, restricted cash included a stand-by letter of credit issued in
favor of a landlord for $50,000 which was classified in current assets as of December 31, 2017. This stand-by letter of credit
was terminated in the first quarter of 2018 in connection with the August 2017 Lease Agreement discussed in Note 6, and accordingly,
the cash became unrestricted.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cash,
cash equivalents, and restricted cash consists of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">808,943</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">206,510</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Money
    market fund</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">40,939,525</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,330,985</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-left: 10pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Cash
    and cash equivalents</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,748,468</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,537,495</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Restricted
    cash</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">158,991</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    cash, cash equivalents, and restricted cash shown in the statement of cash flows</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">41,748,468</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">62,696,486</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
of December 31, 2018, all of the Company&rsquo;s cash was held in the United States, except for approximately $702,000 of cash
which was held in our subsidiary in the United Kingdom. As of December 31, 2017, all of the Company&rsquo;s cash was held in the
United States.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Financial
Instruments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
carrying amounts reported in the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued
expenses approximate their fair value based on the short-term nature of these instruments. The carrying values of the notes payable
approximate their fair value due to the fact that they are at market terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Property
and Equipment</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
estimated life for the Company&rsquo;s property and equipment is as follows: three years for computer hardware and software and
three to five years for office furniture and equipment. The Company&rsquo;s leasehold improvements and assets under capital lease
are amortized over the shorter of their useful lives or the respective leases. See Note 5 for details of property and equipment
and Note 6 for operating and capital lease commitments.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 96; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->8<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Research
and Development Expenses</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Costs
incurred for research and development are expensed as incurred.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Nonrefundable
advance payments for goods or services that have the characteristics that will be used or rendered for future research and development
activities pursuant to executory contractual arrangements with third party research organizations are deferred and recognized
as an expense as the related goods are delivered or the related services are performed.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Accruals
for Research and Development Expenses and Clinical Trials</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
part of the process of preparing its financial statements, the Company is required to estimate its expenses resulting from its
obligations under contracts with vendors, clinical research organizations and consultants and under clinical site agreements in
connection with conducting clinical trials. The financial terms of these contracts are subject to negotiations, which vary from
contract to contract and may result in payment terms that do not match the periods over which materials or services are provided
under such contracts. The Company&rsquo;s objective is to reflect the appropriate expenses in its financial statements by matching
those expenses with the period in which services are performed and efforts are expended. The Company accounts for these expenses
according to the timing of various aspects of the expenses. The Company determines the accrual estimates by taking into account
discussion with applicable personnel and outside service providers as to the progress of clinical trials, or the services completed.
During the course of a clinical trial, the Company adjusts its clinical expense recognition if actual results differ from its
estimates. The Company makes estimates of its accrued expenses as of each balance sheet date based on the facts and circumstances
known to it at that time. The Company&rsquo;s clinical trial accruals are dependent upon the timely and accurate reporting of
contract research organizations and other third-party vendors. Although the Company does not expect its estimates to be materially
different from amounts actually incurred, its understanding of the status and timing of services performed relative to the actual
status and timing of services performed may vary and may result in it reporting amounts that are too high or too low for any particular
period. For the years ended December 31, 2018 and 2017, there were no material adjustments to the Company&rsquo;s prior period
estimates of accrued expenses for clinical trials.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Leases
and Deferred Rent</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company leases its office space. Leases are evaluated and classified as operating or capital leases for financial reporting purposes.
The Company&rsquo;s office space leases qualify as operating leases. For operating leases that contain rent escalations and rent
holidays, the Company records the total rent payable during the lease term on a straight-line basis over the term of the lease
and records the difference between the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement
allowances received from the lessor are recorded as a reduction to rent expense over the term of the lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Concentrations
of Credit Risk</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has no significant off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts
or other hedging arrangements. The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation
insurance limits. However, the Company believes the risk of loss is minimal as these banks are large financial institutions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Segment
Information</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Operating
segments are identified as components of an enterprise about which separate discrete financial information is available for evaluation
by the chief operating decision maker, or decision-making group, in making decisions regarding resource allocation and assessing
performance. To date, the Company has viewed its operations and manages its business as principally one operating segment, which
is developing and commercializing therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December
31, 2018 and 2017, all of the Company&rsquo;s assets were located in the United States, except for approximately $702,000 of cash,
$1,183,000 of prepaid expenses, $28,000 of other assets, and $54,000 of property and equipment, net which were held in our subsidiary
in the United Kingdom as of December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Income
Taxes</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
federal and state income taxes, deferred tax assets and liabilities are recognized based upon temporary differences between the
financial statement and the tax basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted
laws applicable to periods in which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred
tax benefit when it is not more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly,
given the cumulative losses since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax
assets in order to eliminate the deferred tax assets amounts.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 97; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->9<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tax
positions taken or expected to be taken in the course of preparing the Company&rsquo;s tax returns are required to be evaluated
to determine whether the tax positions are &ldquo;more-likely-than-not&rdquo; of being sustained by the applicable tax authority.
Tax positions not deemed to meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be
recorded as a tax expense in the current year. There were no uncertain tax positions that require accrual or disclosure to the
financial statements as of December 31, 2018 or 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, Staff Accounting Bulletin No. 118 (&ldquo;SAB 118&rdquo;) was issued to address the application of U.S. GAAP
in situations when a registrant does not have the necessary information available, prepared, or analyzed (including computations)
in reasonable detail to complete the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, the
Company had recorded a provisional estimate in these financial statements for the effect of the corporate tax rate change. The
Company finalized its estimates during the fourth quarter of 2018, described more fully in Note 10.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Impairment
of Long-lived Assets</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company continually monitors events and changes in circumstances that could indicate that carrying amounts of long-lived assets
may not be recoverable. An impairment loss is recognized when expected undiscounted cash flows of an asset are less than an asset&rsquo;s
carrying value. Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets
in relation to the operating performance and future undiscounted cash flows of the underlying assets. An impairment loss equal
to the excess of the fair value of the asset over its carrying amount, is recorded when it is determined that the carrying value
of the asset may not be recoverable. No impairment charges were recorded for the years ended December 31, 2018 and 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Stock-based
Payments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recognizes compensation costs resulting from the issuance of stock-based awards to employees, non-employees and directors
as an expense in the statement of operations over the service period based on a measurement of fair value for each stock-based
award. The fair value of each option grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing
model, net of estimated forfeitures. The fair value is amortized as compensation cost on a straight-line basis over the requisite
service period of the awards, which is generally the vesting period. Stock options granted to non-employee consultants are revalued
at the end of each reporting period until vested using the Black-Scholes option-pricing model and the changes in their fair value
are recorded as adjustments to expense over the related vesting period.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
March 30, 2016, the FASB issued ASU No. 2016-09, <I>Compensation&mdash;Stock Compensation (Topic 718): Improvements to Employee
Share-Based Payment Accounting </I>(&ldquo;ASU 2016-09&rdquo;)<I>. </I>ASU 2016-09 simplifies several aspects of the accounting
for employee share-based payment transactions including the accounting for income taxes, forfeitures, and statutory tax withholding
requirements, as well as classification in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim
periods within those fiscal years, beginning after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU
2016-09 it did not elect to account for forfeitures as they occur but rather to continue to estimate forfeitures at grant date.
As a result, the adoption of ASU 2016-09 did not have an impact on the Company&rsquo;s consolidated financial statements. ASU
2016-09 also removed the requirement to recognize the excess tax benefits in respect of share based payments only when realized
(See Note 10).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Net
Loss Per Common Share</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>&nbsp;</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Basic
and diluted net loss per share of the Company&rsquo;s common stock has been computed by dividing net loss by the weighted average
number of shares outstanding during the period. For years in which there is a net loss, options and warrants are anti-dilutive
and therefore excluded from diluted loss per share calculations. The following table sets forth the computation of basic and diluted
earnings per share for the years ended December 31, 2018 and 2017:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Years
    Ended December 31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Basic
    and diluted net loss per share of common stock:</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss</FONT></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(55,672,139</FONT></TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="width: 2%; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,421,612</FONT></TD><TD STYLE="width: 1%; padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    average shares of common stock outstanding</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">56,999,741</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">50,176,953</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    loss per share of common stock-basic and diluted</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.98</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(0.65</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 98; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->10<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
impact of the following potentially dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the
computation of dilutive weighted average shares outstanding as the inclusion would be antidilutive.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Warrants</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,283,500</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,288,500</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,593,990</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,844,966</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,877,490</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,133,466</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Recent
Accounting Pronouncements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Revenue
Recognition</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
May 2014, the FASB issued guidance codified in <I>Accounting Standards Codification (ASC) 606, Revenue Recognition &mdash; Revenue
from Contracts with Customers</I> (&ldquo;ASC 606&rdquo;) which amends the guidance in former <I>ASC 605, Revenue Recognition</I>,
and is effective for public companies for annual and interim periods beginning after December 15, 2017. Specifically, the new
standard differs from ASC 605 in many respects, such as in the accounting for variable consideration received, including milestone
payments or contingent payments. Under the Company&rsquo;s accounting policy prior to the adoption of ASC 606 in the first quarter
of 2018, milestone payments were initially recognized only in the period that the payment-triggering event occurred or was achieved
(See Note 9). ASC 606, however, may require a company to recognize such payments before the payment-triggering event is completely
achieved based on the Company&rsquo;s estimate of the amount of consideration to which it will be entitled in exchange for transferring
the services, subject to management&rsquo;s assessment of whether it is probable that a significant reversal in the amount of
cumulative revenue recognized will not occur when the uncertainty associated with the variable consideration is subsequently resolved.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 99; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->11<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative
effect of initially applying ASC 606 is recognized at the date of initial application, and elected to utilize a practical expedient
and did not restate contracts that were completed as of the date of adoption. Since the Company has concluded its performance
obligations and has completed recognizing revenue under the 2015 CFFT Award in the third quarter of 2017 (See Note 9), there was
no cumulative effect to record at the date of the Company&rsquo;s adoption of ASC 606 and no revenue to recognize for the first
quarter of 2018 related to the 2015 CFFT Award.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
for the quarter and the year ended December 31, 2018 was $1,927,306 and $4,822,272, respectively, recognized in
accordance with ASC 606 and pertains only to the 2018 CFF Award discussed in Note 9. The total impact to revenue as a result of
the adoption of ASC 606 was higher revenue of approximately $325,000 for the quarter ended December 31, 2018 and lower revenue
of approximately $201,000 for the year ended December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company will assess any new agreements it enters into under ASC 606, including whether such agreements fall under the scope of
such standard. This standard applies to all contracts with customers, except for contracts that are within the scope of other
standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes
revenue when its customer obtains control of promised goods or services, in an amount that reflects the consideration which the
entity expects to receive in exchange for those goods or services. To determine revenue recognition for arrangements that an entity
determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s) with a
customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate the
transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies
a performance obligation. The Company only applies the five-step model to contracts when it is probable that the entity will collect
the consideration it is entitled to in exchange for the goods or services it transfers to the customer. At contract inception,
once the contract is determined to be within the scope of ASC 606, the Company assesses the goods or services promised within
each contract and determines those that are performance obligations, and assesses whether each promised good or service is distinct.
The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation
when (or as) the performance obligation is satisfied.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revenue
associated with the 2018 CFF Award performance obligation is being recognized as revenue as the research and development services
are provided using an input method, according to the costs incurred as related to the research and development activities and
the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this
time period and, in management&rsquo;s judgment, is the best measure of progress towards satisfying the performance obligation.
The research and development services related to this performance obligation are expected to be performed over an approximately
two and a half-year period expected to be completed in the second quarter of 2020. Amounts received prior to revenue recognition
are recorded as deferred revenue. Amounts expected to be recognized as revenue within the 12 months following the balance sheet
date are classified as current portion of deferred revenue in the accompanying consolidated balance sheets. Amounts not expected
to be recognized as revenue within the 12 months following the balance sheet date would be classified as deferred revenue, net
of current portion. Amounts recognized as revenue, but not yet received or invoiced are generally recognized as contract assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 100; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->12<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Accounting
for Leases</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
February 2016, the FASB issued ASU No<B>. </B>2016-02, <I>Leases (Topic 842), </I>as amended (&ldquo;ASU 2016-02&rdquo;)<I>. </I>Under
ASU 2016-02, a lessee will be required to recognize assets and liabilities for all leases with lease terms of more than 12 months.
Consistent with current US GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from
a lease by a lessee primarily will depend on its classification as a finance or operating lease. However, unlike current US
GAAP, which requires only capital leases to be recognized on the balance sheet, ASU 2016-02 will require both types of leases
to be recognized on the balance sheet. ASU 2016-02 will take effect for fiscal years, and interim periods within those fiscal
years, beginning after December 15, 2018. ASU 2016-02 required a modified retrospective transition approach, which initially required
application of the new guidance for all periods presented in the Company&rsquo;s financial statements (&ldquo;comparative method&rdquo;).
In July 2018, the FASB released ASU 2018-11, offering a second option which provides further relief in the transition to ASC 842.
Companies are allowed to follow the cumulative-effect adjustment transition approach (&ldquo;effective date method&rdquo;), which
releases companies from presenting comparative periods and related disclosures according to ASC 842. Instead, companies electing
to utilize the effective date method will recognize a one-time adjustment to retained earnings on the transition date without
the additional burden of presenting the comparative periods under the new guidance. The Company will adopt ASU 2016-02
using the effective date method as of January 1, 2019 and expects to record a lease liability in the rage of approximately
$3.4-$4.2 million, and a right-to-use asset in the range of approximately $2.1-$2.6 million, and no adjustment
to the accumulated deficit. The Company anticipates that the adoption will not have a material impact on the consolidated
statement of operations or statement of cash flows.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Nonemployee
Share-Based Payment Accounting</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
June 2018, the FASB issued ASU 2018-07, <I>Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based
Payment Accounting</I> (&ldquo;ASU 2018-07&rdquo;). ASU 2018-07 expands the scope of Topic 718 to include share-based payment
transactions for acquiring goods and services from nonemployees. Under ASU 2018-07, consistent with the accounting requirement
for employee share-based payment awards, nonemployee share-based payment awards within the scope of Topic 718 are to be measured
at the grant-date fair value of the equity instruments that an entity is obligated to issue when the good has been delivered or
the service has been rendered and any other conditions necessary to earn the right to benefit from the instruments have been satisfied.
Equity-classified nonemployee share-based payment awards are to be measured at the grant date. The definition of the term grant
date is amended to generally state the date at which a grantor and a grantee reach a mutual understanding of the key terms and
conditions of a share-based payment award. ASU 2018-07 specifies that Topic 718 applies to all share-based payment transactions
in which a grantor acquires goods or services to be used or consumed in its own operations by issuing share-based payment awards.
ASU 2018-07 also clarifies that Topic 718 does not apply to share-based payments used to effectively provide (1) financing to
the issuer or (2) awards granted in conjunction with selling goods or services to customers as part of a contract accounted for
under ASC 606. ASU 2018-07 is effective for public business entities for fiscal years beginning after December 15, 2018, including
interim periods within that fiscal year. The Company expects to adopt ASU 2018-07 on January 1, 2019 and anticipates
that the adoption will not have a material impact on the Company&rsquo;s financial statements and related disclosures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Collaborative
Arrangements</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">In
November 2018, the FASB issued ASU 2018-08, <I>Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic
808 and Topic 606</I></FONT> <FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(&ldquo;ASU 2018-08&rdquo;)<FONT STYLE="background-color: white">.
ASU 2018-08 clarifies the interaction between the accounting guidance for collaborative arrangements and revenue from contracts
with customers. </FONT>ASU 2018-08 is effective for public business entities for fiscal years beginning after December 15, 2019,
including interim periods within that fiscal year<FONT STYLE="background-color: white">. Early adoption, including adoption in
any interim period, is permitted. The Company is currently </FONT>evaluating the timing of the adoption of ASU 2018-08 and the
expected impact it could have on the Company&rsquo;s financial statements and related disclosures<FONT STYLE="background-color: white">.</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 101; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->13<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>4.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>LICENSE
    AGREEMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company, entered into a License Agreement (the &ldquo;Jenrin Agreement&rdquo;) with Jenrin Discovery, LLC, a privately-held Delaware
limited liability company (&ldquo;Jenrin&rdquo;), effective September 20, 2018. Pursuant to the Jenrin Agreement, Jenrin granted
the Company exclusive worldwide rights to develop and commercialize the Licensed Products (as defined in the Jenrin Agreement)
which includes the Jenrin library of over 600 compounds and multiple issued and pending patent filings. The compounds are designed
to treat inflammatory and fibrotic diseases by targeting the endocannabinoid system. The lead product candidate is CRB-4001, a
peripherally-restricted CB-1 inverse agonist targeting fibrotic liver, lung, heart and kidney diseases. The Company plans to commence
a Phase 1 clinical trial of CRB-4001 in 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the license and other rights granted by Jenrin, the Company paid Jenrin a $250,000 upfront cash payment and is
obligated to pay potential milestone payments to Jenrin totaling up to $18.4 million for each compound it elects to develop based
upon the achievement of specified development and regulatory milestones. In addition, Corbus is obligated to pay Jenrin royalties
in the mid, single digits based on net sales of any Licensed Products, subject to specified reductions.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
January 2017, the FASB issued ASU 2017-01, <I>Business Combinations (Topic 805): Clarifying the Definition of a Business </I>(&ldquo;ASU
2017-01&rdquo;) which clarifies the definition of a business and determines when an integrated set of assets and activities is
not a business. ASU 2017-01 requires that if substantially all of the fair value of gross assets acquired or disposed of is concentrated
in a single asset or group of similar identifiable assets, the assets would not represent a business. The Company determined that
substantially all of the fair value of the Jenrin Agreement was attributable to a single in-process research and development asset,
CRB-4001, which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired
in-process research and development asset. Thus, the Company recorded the $250,000 upfront payment to research and development
expenses in the third quarter of 2018. The Company will account for the $18.4 million of development and regulatory milestone
payments in the period that the relevant milestones are achieved as either research and development expense or as an intangible
asset as applicable.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>5.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PROPERTY
    AND EQUIPMENT</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Property
and Equipment consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 68%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Computer
    hardware and software</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">431,637</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 12%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">136,522</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Office
    furniture and equipment</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">914,742</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">287,048</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Leasehold
    improvements</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,025,410</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">191,244</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Construction
    in progress</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,181,730</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property
    and equipment, gross</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,371,789</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,796,544</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    accumulated depreciation</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(666,583</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(363,889</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Property
    and equipment, net</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,705,206</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,432,655</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Depreciation
expense was approximately $494,000 and $256,000 for the years ended December 31, 2018 and 2017, respectively. In the first quarter
of 2018, the Company wrote off $191,244 of fully amortized leasehold improvements related to the termination of the September
2016 Amendment in February 2018 as discussed in Note 6. At December 31, 2017, construction in progress consisted of purchased
property and equipment not placed in service until the Company&rsquo;s relocation into 32,733 square feet of office space in February
2018 (See Note 6).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 102; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->14<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 30, 2015, the Company entered into a lease agreement for a copier machine. The cost of the machine was approximately
$12,000 and is included in office furniture and equipment category in the table above. The lease payments commenced when the machine
was placed in service in January 2016. The machine is being amortized over the life of the lease, which is for a three-year term
and includes a bargain purchase option at the end of the term. See Note 6 for details of this capital lease commitment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>6.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMITMENTS
    AND CONTINGENCIES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Operating
Lease Commitment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
September 2016, the Company amended its commercial lease for office space to expand into an additional 4,088 square feet of office
space within the same building for an aggregate total of 10,414 square feet of leased office space (&ldquo;September 2016 Amendment&rdquo;).
The Company began occupying this space in early November 2016 and the final lease payment was to be due in January 2021. The September
2016 Amendment required an increase in the standby letter of credit to $50,000 (See Note 3). The September 2016 Amendment was
terminated upon the commencement date of the August 2017 Lease Agreement discussed below.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
August 21, 2017, the Company entered into a lease agreement (&ldquo;August 2017 Lease Agreement&rdquo;) with the same landlord,
pursuant to which the Company agreed to lease 32,733 square feet of office space (&ldquo;Leased Premises&rdquo;). The initial
term of the August 2017 Lease Agreement is for a period of seven years which began with the Company&rsquo;s occupancy of the Leased
Premises in February 2018. The base rent for the Leased Premises ranges from approximately $470,000 for the first year to approximately
$908,000 for the seventh year. Per the terms of the August 2017 Lease Agreement, the landlord agreed to reimburse the Company
for $1,080,189 of leasehold improvements. The reimbursements have been deferred and will be recognized as a reduction of rent
expense over the term of the lease. Additionally, the August 2017 Lease Agreement required a standby irrevocable letter of credit
of $400,000, which may be reduced, if the Company is not in default under the August 2017 Lease Agreement, to $300,000 and $200,000
on the third and fourth anniversary of the commencement date, respectively, The Company entered into an unsecured letter of credit
for $400,000 in connection with the August 2017 Lease Agreement for which it incurred interest expense of $7,431 and $9,743 in
year ended December 31, 2018 and 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company records the total rent payable during the lease term on a straight-line basis over the term of the lease and records the
difference between the rents paid and the straight-line rent as deferred rent, which is classified in deferred rent, current and
deferred rent, noncurrent in the Company&rsquo;s balance sheet as of December 31, 2018 and 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Company&rsquo;s non-cancelable lease agreements in effect at December 31, 2018, the future minimum rent commitments
are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">623,958</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">784,243</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">830,600</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">855,150</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">879,699</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,055,639</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,029,289</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Total
rent expense for the years ended December 31, 2018 and 2017 was $587,963 and $356,547, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 103; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->15<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 26, 2019, the Company amended its lease (&ldquo;February 2019 Lease Agreement&rdquo;) pursuant to which
an additional 30,023 square feet of office space (&ldquo;New Premises&rdquo;) will be leased by the Company in the same
building for an aggregate total of 62,756 square feet of leased office space (&ldquo;Total Premises&rdquo;). The commencement
date for the New Premises is expected to occur no later than August 1, 2019 and the lease term for the Total Premises is October
31, 2026. The future minimum rent commitments for the Total Premises are estimated to be approximately as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 76%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2019</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 20%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">678,000</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2020</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,288,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2021</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,592,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2022</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,640,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2023</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,687,000</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Thereafter</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,036,000</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">11,921,000</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Capital
Lease Commitment</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
lease payments commenced when the machine was placed in service in January 2016. The lease is for a three-year term and includes
a bargain purchase option at the end of the term. In the accompanying balance sheet as of December 31, 2017 and 2016, the current
portion of this capital lease obligation is classified in accrued expenses and the long-term portion of the capital lease obligation
is classified in other long-term liabilities. Pursuant to the terms of this capital lease agreement, the future minimum capital
lease commitments are as follows as of December 31, 2018:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 78%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total
    future minimum lease payments &ndash; end in 2019</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 18%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">378</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    interest</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(3</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Future
    capital lease obligations</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">375</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Less:
    current portion</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(375</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Long-term
    portion</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
commitments under the Company&rsquo;s development award agreements- see Note 9.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 104; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->16<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>7.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>NOTES
    PAYABLE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
October 2016, the Company entered into a loan agreement with a financing company for $348,750 to finance one of the Company&rsquo;s
insurance policies. The terms of the loan stipulate equal monthly payments of principal and interest payments of $39,114 over
a nine-month period. Interest on this loan was accrued at an annual rate of 2.25%. This loan was fully repaid in July 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2017, the Company entered into a loan agreement with a financing company for $415,265 to finance one of the Company&rsquo;s
insurance policies. The terms of the loan stipulate equal monthly payments of principal and interest payments of $41,975 over
a ten-month period. Interest accrued on this loan at an annual rate of 2.35%. This loan was fully repaid in August 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
November 2018, the Company entered into a loan agreement with a financing company for $491,629 to finance one of the Company&rsquo;s
insurance policies. The terms of the loan stipulated equal monthly payments of principal and interest payments of $49,857 over
a ten-month period. Interest accrues on this loan was accrued at an annual rate of 3.07%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Prepaid
expenses and other current assets as of December 31, 2018 and 2017 included $441,875 and $368,976, respectively, related to these
insurance policies.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>8.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>ACCRUED
    EXPENSES </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accrued
expenses consisted of the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    clinical operations and trials costs</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,914,881</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,003,799</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    product development costs</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,222,093</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,255,439</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,253,621</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,335,672</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    other</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">460,596</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">146,609</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,851,191</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4,741,519</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>9.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>DEVELOPMENT
    AWARDS AND DEFERRED REVENUE</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2015
CFFT Award</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
April 20, 2015, the Company entered into an award agreement (the &ldquo;2015 CFFT Award Agreement &ldquo;) with the Cystic Fibrosis
Foundation Therapeutics, Inc (&ldquo;CFFT&rdquo;), a non-profit drug discovery and development affiliate of the Cystic Fibrosis
Foundation (&ldquo;CFF&rdquo;) pursuant to which the Company received a development award (the &ldquo;2015 CFFT Award&rdquo;)
for up to $5 million in funding. The funding from the 2015 CFFT Award supported a first-in-patient Phase 2 clinical trial of the
Company&rsquo;s oral anti-inflammatory drug lenabasum in adults with cystic fibrosis (&ldquo;CF&rdquo;). The Company received
$5.0 million in payments under the 2015 CFFT Award as outlined below. The payments received under the 2015 CFFT Award were recorded
as deferred revenue when the triggering event to receive those amounts had occurred and were amortized on a straight-line basis
over the expected duration of the remaining performance period under the 2015 CFFT Award which concluded in the third quarter
of 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Upon
the execution of the 2015 CFFT Award Agreement, the Company received a payment of $1,250,000 in May 2015. In November 2015, the
Company received a second payment of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016,
the Company received a third payment from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related
to dosing the median clinical trial patient. In January 2017, the Company received a fourth payment from the CFFT in the amount
of $1,000,000 for achieving a milestone in December 2016 related to completing the final visit for the final patient, which was
billed by the Company to CFFT in December 2016 and was classified in grants receivable as of December 31, 2016. The Company received
the final payment from CFFT in the amount of $500,000 in November 2017 for achieving the final milestone in September 2017 related
to the issuance to CFFT of the final integrated statistical report for to the Phase 2 CF clinical trial. At that time the Company
had completed all its performance obligations under the contract and therefore the performance period had concluded.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with ASC 605, the Company recorded $2,440,195 of revenue during the year ended December 31, 2017 under the 2015 CFFT
Award Agreement. No revenue was recorded under the 2015 CFFT Award Agreement during the year ended December 31, 2018 as the final
performance period concluded in the third quarter of 2017. Under ASC 605, milestone payments were initially recognized only in
the period that the payment-triggering event occurred or was achieved. Effective January 1, 2018, ASC 605 was superseded by ASC
606 (See Note 3). The Company adopted ASC 606 in the first quarter of 2018 using the modified retrospective method according to
which the cumulative effect of initially applying ASC 606 is recognized at the date of initial application. Since the Company
concluded its performance obligations and completed recognizing revenue under the 2015 CFFT Award Agreement in the third quarter
of 2017, there was no cumulative effect to record at the date of the Company&rsquo;s adoption of ASC 606.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 105; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->17<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the 2015 CFFT Award Agreement, the Company is obligated to make royalty payments to CFFT contingent upon commercialization
of lenabasum in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five
times the amount the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments
following the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale
of lenabasum, (ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up
to $5 million, due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed
$500 million, and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses
lenabasum in the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change
of control transaction, with such payment(s) to be credited against the royalty payments due upon commercialization. The Field
of Use is defined in the 2015 CFFT Award as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD
hypersensitivity pneumonitis, pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or the Company
may terminate the agreement for cause, which includes the Company&rsquo;s material failure to achieve certain commercialization
and development milestones. The Company&rsquo;s payment obligations, if any, would survive the termination of the 2015 CFFT Award
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>2018
CFF Award</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 26, 2018, the Company entered into the Cystic Fibrosis Program Related Investment Agreement with the CFF (&ldquo;Investment
Agreement&rdquo;), a non-profit drug discovery and development corporation, pursuant to which the Company received an award for
up to $25 million in funding (the &ldquo;2018 CFF Award&rdquo;) to support a Phase 2b Clinical Trial (the &ldquo;Phase 2b Clinical
Trial&rdquo;) of lenabasum in patients with cystic fibrosis, of which the Company has received $12.5 million during the year ended
December 31, 2018 upon the Company&rsquo;s achievement of milestones related to the progress of the Phase 2b Clinical Trial, as
set forth in the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company expects that the remainder of the 2018 CFF Award will be paid incrementally upon the Company&rsquo;s achievement of the
remaining milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, the Company is obligated to make certain royalty payments to CFF, including a royalty
payment of one and one-half times the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of
approval of lenabasum in the United States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award
upon approval in another major market, as set forth in the Investment Agreement (the &ldquo;Approval Royalty&rdquo;). At the Company&rsquo;s
election, the Company may satisfy the first of the two Approval Royalties in registered shares of the Company&rsquo;s common stock.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the Company is obligated to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within
sixty days after any quarter in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty
payments to CFF of one percent of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days
after any quarter in which such net sales occur, and (iii) royalty payments to CFF of ten percent of any amount the Company and
its stockholders receive in connection with the license, sale, or other transfer to a third party of lenabasum, if indicated for
the treatment or prevention of CF, or a change of control transaction, except that such payment shall not exceed five times the
amount of the 2018 CFF Award, with such payments to be credited against any other net sales royalty payments due. Accordingly,
we will owe to CFF a royalty payment equal to 10% of any amounts we receive as payment under the collaboration agreement with
Kaken, provided that the total royalties that we will be required to pay under the Investment Agreement resulting from income
from licenses or sales subject to the Investment Agreement are capped at five times the total amount of the 2018 CFF Award, and
we may credit such royalties against any royalties on net sales otherwise owed to CFF under the Investment Agreement. Accordingly,
we will be required to pay CFF $2,700,000 within 60 days of our receipt of the $27,000,000 upfront cash payment from Kaken.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Either
CFF or the Company may terminate the Investment Agreement for cause, which includes the Company&rsquo;s material failure to achieve
certain commercialization and development milestones. The Company&rsquo;s payment obligations survive the termination of the Investment
Agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 106; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->18<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Investment Agreement, the Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of
the Company&rsquo;s common stock (the &ldquo;CFF Warrant&rdquo;). The CFF Warrant is exercisable at a price equal to $13.20 per
share and is immediately exercisable for 500,000 shares of the Company&rsquo;s common stock. Upon completion of the final milestone
set forth in the Investment Agreement and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement,
the CFF Warrant will be exercisable for the remaining 500,000 shares of the Company&rsquo;s common stock. The CFF Warrant expires
on January 26, 2025. Any shares of the Company&rsquo;s common stock issued upon exercise of the CFF Warrant will be unregistered
and subject to a one-year lock-up.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company recorded $4,822,272 of revenue during the year ended December 31, 2018 under the Investment Agreement. The Company assessed
the 2018 CFF Award for accounting under ASC 606, which it adopted in the first quarter of 2018 (Note 3). To determine revenue
recognition for arrangements that an entity determines are within the scope of ASC 606, the entity performs the following five
steps: (i) identify the contract(s) with a customer; (ii) identify the performance obligations in the contract; (iii) determine
the transaction price; (iv) allocate the transaction price to the performance obligations in the contract; and (v) recognize revenue
when (or as) the entity satisfies a performance obligation.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company assessed this arrangement in accordance with ASC 606 and concluded that the contract counterparty, CFF, is a customer.
The Company identified the following material promise under the arrangement: research and development activities and related services
under the Phase 2b Clinical Trial. Based on these assessments, the Company identified one performance obligation at the outset
of the Investment Agreement, which consists of: Phase 2b Clinical Trial research and development activities and related services.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
determine the transaction price, the Company included the total aggregate payments under the Investment Agreement which amount
to $25 million and reduced the revenue to be recognized by the payment to the customer of $6,215,225 in the form of the CFF Warrant
representing its fair value, leaving the remaining $18,784,775 as the transaction price as of the outset of the arrangement, which
will be recognized as revenue over the performance period as discussed below. The $6,215,225 fair value of the warrant was also
recorded as an increase to additional paid in capital. The Company billed and collected $12,500,000 in milestone payments during
the year ended December 31, 2018 which was recorded as an increase to deferred revenue. A roll forward of deferred revenue for
the year ended December 31, 2018 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 70%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-weight: bold; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font-weight: bold; text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31, 2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-weight: bold; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Beginning
    balance</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 71%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Billing
    to CFF upon achievement of milestones</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 25%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">12,500,000</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Fair value
    of CFF Warrant</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(6,215,225</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Recognition
    of revenue</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(4,822,272</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Ending
    balance</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,462,503</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.25in; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
CFF Warrant is accounted for as a payment to the customer under ASC 606. See Note 13 for further information related to the CFF
Warrant. The Company notes that the Investment Agreement contains an initial payment that was received upon contract execution
and subsequent milestone payments, which are a form of variable consideration that require evaluation for constraint considerations.
The Company concluded that the related performance milestones are generally within the Company&rsquo;s control and as result are
considered probable. Revenue associated with the performance obligation is being recognized as revenue as the research and development
services are provided using an input method, according to the costs incurred as related to the research and development activities
on each program and the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control
occurs over this time period and, in management&rsquo;s judgment, is the best measure of progress towards satisfying the performance
obligation. The research and development services related to this performance obligation are expected to be performed over an
approximately two and a half year period expected to be completed in the second quarter of 2020. The amounts received that have
not yet been recognized as revenue are recorded in deferred revenue and the amounts recognized as revenue, but not yet received
or invoiced are generally recognized as contract assets on the Company&rsquo;s condensed consolidated balance sheet.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 107; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->19<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>10.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>INCOME
    TAXES</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">No
provision or benefit for federal or state income taxes has been recorded, as the Company has incurred a net loss for all of the
periods presented, and the Company has provided a full valuation allowance against its deferred tax assets.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2018 and 2017, the Company had federal net operating loss carryforwards of approximately $82,545,000
and $56,536,000, respectively, of which federal carryforwards will expire in varying amounts beginning in 2029. At December 31,
2018 and 2017, the Company had Massachusetts net operating loss carryforwards of approximately $78,152,000 and $53,110,000,
respectively. In the first quarter of 2017, the Company adopted ASU 2016-09, which removed the requirement to recognize the deferred
tax assets on excess tax benefits in respect of share based payments only when realized. As such, during the year ended December
31, 2017, the Company&rsquo;s gross deferred tax assets and corresponding valuation allowance each included a one-time increase
in respect of an additional federal and state net operating losses of $1,432,000. The adoption of ASU 2016-09 did not have an
impact on the Company&rsquo;s balance sheet, results of operations, cash flows or statement of stockholders&rsquo; equity because
the Company has a full valuation allowance on its deferred tax assets. Utilization of net operating losses may be subject to substantial
annual limitations due to the &ldquo;change in ownership&rdquo; provisions of the Internal Revenue Code, and similar state provisions.
The annual limitations may result in the expiration of net operating losses before utilization. The Company has not yet conducted
a study to determine if any such changes have occurred that could limit the Company&rsquo;s ability to use the net operating losses
and tax credit carryforwards. The Company also had research and development tax credit carryforwards at December 31, 2018 and
2017 of approximately $2,926,000 and $1,283,000, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Significant
components of the Company&rsquo;s net deferred tax asset are as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">NOL
    carryforward</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,273,661</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">15,229,127</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    net operating loss carryforward</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3,
                                         616,502</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax
    credits</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,793,247</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,213,347</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Stock
    based compensation</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,381,969</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,724,248</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Accrued
    expenses</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">660,427</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">45,654</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other
    temporary differences</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">186,069</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">116,292</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Subtotal</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">32,911,875</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">18,328,668</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Valuation
    allowance</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(32,911,875</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(18,328,668</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Net
    deferred tax asset</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has maintained a full valuation allowance against its deferred tax assets in all periods presented. A valuation allowance
is required to be recorded when it is not more likely than not that some portion or all of the net deferred tax assets will be
realized. Since the Company cannot determine that it is more likely than not that it will generate taxable income, and thereby
realize the net deferred tax assets, a full valuation allowance has been provided. The valuation allowance increased by $14,583,207
and $5,088,343 in 2018 and 2017, respectively, due to the increase in deferred tax assets, primarily due to net operating
loss carryforwards. The Company has no uncertain tax positions at December 31, 2018 and 2017 that would affect its effective tax
rate. Since the Company is in a loss carryforward position, the Company is generally subject to U.S. federal and state income
tax examinations by tax authorities for all years for which a loss carryforward is available.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 108; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->20<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Income
tax benefits computed using the federal statutory income tax rate differs from the Company&rsquo;s effective tax rate primarily
due to the following:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="6" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">December
    31,</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 57%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax
    provision at statutory rate</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">21.00</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">34.00</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">State
    taxes, net of federal benefit</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.42</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.66</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Permanent
    differences</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-2.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-2.05</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Foreign
    expected tax</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9.85</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Tax
    credits</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.31</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.59</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Income
    tax rate change</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&mdash;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-24.11</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Other</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1.14</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.60</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Increase
    in valuation reserve</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-39.72</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">-15.69</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Total</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.00</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>The
Tax Cut and Jobs Act of 2017</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
December 22, 2017, the legislation commonly referred to as the Tax Cut and Jobs Act (the &ldquo;Tax Act&rdquo;) was enacted
into law. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate
tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense to 30% of
adjusted earnings (except for certain small businesses); limitation of the deduction of net operating losses generated in tax
years beginning after December 31, 2017 to 80% of taxable income, indefinite carryforward of net operating losses generated in
tax years after 2018 and elimination of net operating loss carrybacks; changes in the treatment of offshore earnings regardless
of whether they are repatriated; current inclusion in U.S. federal taxable income of certain earnings of controlled foreign corporations,
mandatory capitalization of research and development expenses beginning in 2022; immediate deductions for certain new investments
instead of deductions for depreciation expense over time; further deduction limits on executive compensation; and modifying, repealing
and creating many other business deductions and credits, including the reduction in the orphan drug credit from 50% to 25% of
qualifying expenditures. As of December 31, 2017, we made a reasonable estimate of the effects of the Tax Act on our existing
deferred taxes and related disclosures by reducing our net federal and state deferred tax assets by $7,815,832 for the reduction
in corporate tax rate. This adjustment to our deferred tax assets was offset against the valuation allowance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Additionally,
the SEC staff has issued SAB 118, which allows to record provisional amounts during a measurement period not to extend beyond
one year of the enactment date. On December 22, 2017, Staff Accounting Bulletin No. 118 (&ldquo;SAB 118&rdquo;) was issued to
address the application of U.S. GAAP in situations when a registrant does not have the necessary information available, prepared,
or analyzed (including computations) in reasonable detail to complete the accounting for certain income tax effects of the Act.
The Company finalized its estimates during the fourth quarter of 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>11.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>COMMON
    STOCK </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company has authorized 150,000,000 shares of common stock, $0.0001 par value per share, of which 57,247,496 shares, and 55,603,427
shares were issued and outstanding as of December 31, 2018, and 2017, respectively.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
February 28, 2017, the Company entered into a securities purchase agreement providing for the issuance and sale by the Company
of 3,887,815 shares of its common stock in a registered direct offering to institutional and accredited investors at a purchase
price of $7.00 per share with gross proceeds to the Company totaling $27,214,705 less issuance costs of $36,291.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 109; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->21<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 26, 2017, the Company consummated an underwritten public offering of shares of its common stock pursuant to which the
Company sold an aggregate of 4,650,000 shares of its common stock at a purchase price of $7.00 per share with gross proceeds to
the Company totaling $32,550,000, less estimated issuance costs incurred of approximately $2,184,000. The Company also granted
the underwriters a 30-day option to purchase up to an additional 697,500 shares of common stock on the same terms as the underwriters
were purchasing the base number of shares, which they exercised in November 2017 with net proceeds to the Company totaling $4,589,550.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 5, 2018, the Company entered into a sales agreement with Cantor Fitzgerald under which the Company had the ability to
direct Cantor Fitzgerald as its sales agent to sell common stock up to an aggregate offering of up to $50 million under an &ldquo;At
the Market Offering&rdquo; (&ldquo;January 2018 Sales Agreement&rdquo;). Sales of common stock under the January 2018 Sales Agreement
were made pursuant to an effective registration statement for an aggregate offering of up to $50 million. During the first quarter
of 2018, the Company sold 1,500,000 shares of its common stock to an institutional investor under the January 2018 Sales Agreement
for which the Company received net proceeds of approximately $11.2 million. The Company did not sell any shares under the January
2018 Sales Agreement in remainder of 2018 and through February 8, 2019, the effective date of the Company&rsquo;s termination
of the January 2018 Sales Agreement (see Note 15). During the year ended December 31, 2017, the Company sold 1,413,633 shares
of its common stock under a sales agreement that the Company entered into in November 2016 with Cantor Fitzgerald (&ldquo;Sales
Agreement&rdquo;) for net proceeds of $13,268,208. The Sales Agreement was terminated in October 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2018, the Company issued 144,069 shares of common stock upon the exercise of stock options and warrants
to purchase common stock and the Company received net proceeds of $352,645 from these exercises. During the year ended December
31, 2017, the Company issued 272,734 shares of common stock upon the exercise of stock options and warrants to purchase common
stock and the Company received net proceeds of $189,490 from these exercises.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2019, the Company consummated an underwritten public offering of shares of its common stock. See Note 15.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>12.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>STOCK
    OPTIONS </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
April 2014, the Company adopted the Corbus Pharmaceuticals Holdings, Inc. 2014 Equity Incentive Plan (the &ldquo;2014 Plan&rdquo;).
Pursuant to the 2014 Plan, the Company&rsquo;s Board of Directors may grant incentive and nonqualified stock options and restricted
stock to employees, officers, directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the
2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically increase on January
1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on December 31st of the
preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may determine that such
increase will provide for a lesser number of shares. On January 1, 2018, pursuant to an annual evergreen provision contained in
the 2014 Plan, the number of shares reserved for future grants was increased by 2,500,000 shares, which was less than seven percent
(7%) of the outstanding shares of common stock on December 31, 2017. As of December 31, 2018, there was a total of 15,543,739
shares reserved for issuance under the 2014 Plan and there were 5,072,241 shares available for future grants. Options issued under
the 2014 Plan generally vest over 4 years from the date of grant in multiple tranches and are exercisable for up to 10 years from
the date of issuance.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
accordance with the terms of the 2014 Plan, effective as of January 1, 2019, the number of shares of common stock available for
issuance under the 2014 Plan increased by 3,000,000 shares, which was less than seven percent (7%) of the outstanding shares of
common stock on December 31, 2018. As of January 1, 2019, the 2014 Plan had a total reserve of 18,543,739 shares and there were
8,072,241 shares available for future grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Share-based
Compensation</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
stock options issued and outstanding for the years ended December 31, 2018 and 2017, the Company recorded non-cash, stock-based
compensation expense of $7,609,508 ($7,500,888 for employees and $108,620 for non-employees) and $5,694,489 ($4,640,646 for employees
and $1,053,843 for non-employees), respectively, net of estimated forfeitures.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
fair value of each option award for employees is estimated on the date of grant and for non-employees is estimated at the end
of each reporting period until vested using the Black-Scholes option pricing model that uses the assumptions noted in the following
table. The Company uses historical data, as well as subsequent events occurring prior to the issuance of the financial statements,
to estimate option exercises and employee terminations in order to estimate its forfeiture rate. The expected term of options
granted under the 2014 Plan, all of which qualify as &ldquo;plain vanilla&rdquo; per SEC Staff Accounting Bulletin 107, is determined
based on the simplified method due to the Company&rsquo;s limited operating history, and is 6.25 years based on the average between
the vesting period and the contractual life of the option. For non-employee options, the expected term is the contractual term.
The risk-free rate is based on the yield of a U.S. Treasury security with a term consistent with the option.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 110; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->22<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average assumptions used principally in determining the fair value of options granted to employees were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2018</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2017</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk
    free interest rate</FONT></TD>
    <TD STYLE="width: 2%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.53</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.12</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    term in years</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.25</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.25</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    volatility</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">87.70</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">86.01</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Estimated
    forfeiture rate</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">%</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
the year ended December 31, 2017, the assumptions used in determining the fair value of options granted to nonemployees included
risk free interest rate ranging from 2.12%-2.38%, no expected dividend yield, expected term ranging from 4.91 years to 9.91 years,
expected volatility ranging from 85.58% to 89.58%, and estimated forfeiture rate of 5%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">A
summary of option activity for years ended December 31, 2018 and 2017 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    <BR> Average <BR> Exercise <BR> Price</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    <BR> Average <BR> Remaining <BR> Contractual <BR> Term in <BR> Years</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Intrinsic
    <BR> Value</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 40%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2016</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6,610,179</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 11%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.54</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 11%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,681,500</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">8.28</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(272,734</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0.67</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(173,979</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.53</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2017</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7,844,966</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.75</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,378,500</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.58</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exercised</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(139,069</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.50</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(490,407</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.85</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Outstanding
    at December 31, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">9,593,990</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.51</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.23</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">22,510,816</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Exerciseable
    </FONT><FONT STYLE="font-family: Times New Roman, Times, Serif">at December 31, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5,967,701</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.87</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.43</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">20,691,512</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
weighted average grant-date fair value of options granted during the years ended December 31, 2018 and 2017 was $5.63 and $6.22
per share, respectively. The aggregate intrinsic value of options exercised during the years ended December 31, 2018 and 2017
was approximately $543,060 and $2,092,964, respectively. As of December 31, 2018, there was approximately $15,400,414 of total
unrecognized compensation expense, related to non-vested share-based compensation arrangements. The unrecognized compensation
expense is estimated to be recognized over a period of 2.55 years at December 31, 2018.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
summary of non-vested stock options for the years ended December 31, 2018 and 2017 is presented below:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; font-family: Times New Roman, Times, Serif">
    <TD STYLE="border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Options</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Shares</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="text-align: center; border-bottom: Black 1.5pt solid; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Weighted
    <BR> Average <BR> Fair <BR> Value</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 60%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-vested
    at December 31, 2016</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,826,274</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="width: 16%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.86</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">1,681,500</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">6.22</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(2,003,806</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.60</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(173,979</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.03</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Nonvested
    at December 31, 2017</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,329,989</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">4.61</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Granted</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2,378,500</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.63</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Vested</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(1,643,772</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3.98</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Forfeited</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">(438,428</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">)</FONT></TD><TD STYLE="padding-bottom: 1.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 1.5pt solid; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 1.5pt solid; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.91</FONT></TD><TD STYLE="padding-bottom: 1.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Non-vested
    at December 31, 2018</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">3,626,289</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: Black 2.5pt double; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">$</FONT></TD><TD STYLE="border-bottom: Black 2.5pt double; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">5.32</FONT></TD><TD STYLE="padding-bottom: 2.5pt; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 111; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->23<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>13.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>WARRANTS
    </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">During
the year ended December 31, 2018, warrants to purchase 5,000 shares of common stock were exercised for proceeds of $5,000. No
warrants were exercised during the year ended December 31, 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">At
December 31, 2018, there were warrants outstanding to purchase 2,283,500 shares of common stock with a weighted average exercise
price of $6.34 and a weighted average remaining life of 2.89 years, including the warrant issued to CFF pursuant to the terms
of the Investment Agreement (Note 8). The Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the
Company&rsquo;s common stock (the &ldquo;CFF Warrant&rdquo;). The CFF Warrant is exercisable at a price equal to $13.20 per share
and is immediately exercisable for 500,000 shares of the Company&rsquo;s common stock. Upon completion of the final milestone
set forth in the Investment Agreement and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement,
the CFF Warrant will be exercisable for the remaining 500,000 shares of the Company&rsquo;s common stock. The CFF Warrant expires
on January 26, 2025. Any shares of the Company&rsquo;s common stock issued upon exercise of the CFF Warrant will be unregistered
and subject to a one-year lock-up. The CFF Warrant is classified as equity as it meets all the conditions under GAAP for equity
classification. In accordance with GAAP, the Company has calculated the fair value of the warrant for initial measurement and
will reassess whether equity classification for the warrant is appropriate upon any changes to the warrants or capital structure,
at each balance sheet date. The weighted average assumptions used in determining the $6,215,225 fair value of the CFF Warrant
were as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLPADDING="0" CELLSPACING="0" ALIGN="CENTER" STYLE="border-collapse: collapse; width: 80%; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="width: 81%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Risk
    free interest rate</FONT></TD><TD STYLE="width: 2%; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="width: 15%; text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">2.60</FONT></TD><TD STYLE="width: 1%; text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    dividend yield</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">0</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255); font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    term in years</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">7.00</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: bottom; background-color: White; font-family: Times New Roman, Times, Serif">
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">Expected
    volatility</FONT></TD><TD STYLE="font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></TD><TD STYLE="text-align: right; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">83.5</FONT></TD><TD STYLE="text-align: left; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">%</FONT></TD></TR>
</TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>14.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RELATED
    PARTY TRANSACTIONS </B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
September 20, 2016, the Company entered into a consulting agreement (the &ldquo;2016 Consulting Agreement&rdquo;) with Orchestra
Medical Ventures, LLC (&ldquo;Orchestra&rdquo;), of which a member of the Company&rsquo;s Board of Directors, David Hochman, is
Managing Partner. Under this agreement, Orchestra rendered a variety of consulting and advisory services relating principally
to identifying and evaluating strategic relationships, licensing opportunities, and business strategies. The term of the 2016
Consulting Agreement commenced on September 20, 2016 and expired on March 20, 2017. Pursuant to the terms of the 2016 Consulting
Agreement, the Company paid to Orchestra cash compensation in an aggregate amount of $100,000. In connection with this agreement,
the Company granted an equity incentive award to Mr. Hochman consisting of options to purchase 50,000 shares (&ldquo;Option Shares&rdquo;)
of common stock (the &ldquo;Option Award&rdquo;) pursuant to the Company&rsquo;s 2014 Equity Compensation Plan, of which fifty
percent (50%) vested on the three (3) month anniversary of the date of grant of the Option Award and the remainder of the Option
Shares vested on the six (6) month anniversary of the date of grant of the Option Award. The Option Shares were granted with an
exercise price of $7.14 per share. The Company recorded stock-based compensation expense of approximately $222,000 during the
year ended December 31, 2016 and $171,000 during the first quarter of 2017 in respect of the Option Award. No stock-based compensation
expense was recorded after the first quarter of 2017 related to the Option Shares as they were fully vested in March 2017.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; border-collapse: collapse; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.35in; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>15.</B></FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUBSEQUENT
    EVENTS</B></FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify; text-indent: -24.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Evergreen
Provision</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of an annual evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under
the 2014 Plan shall automatically increase on January 1 of each year by at least seven percent (7%) of the total number of shares
of common stock outstanding on December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any
year, the Board of Directors may determine that such increase will provide for a lesser number of shares. In accordance with the
terms of the 2014 Plan, effective as of January 1, 2019, the number of shares of common stock available for issuance under the
2014 Plan increased by 3,000,000 shares, such amount being less than seven percent (7%) of the outstanding shares of common stock
on December 31, 2018. As of January 1, 2019, the 2014 Plan had a total reserve of 18,543,739 shares and there were 8,072,2414
shares available for future grants.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 112; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->24<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Collaboration
with Kaken</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 3, 2019, Corbus Pharmaceuticals Holdings, Inc. the Company entered into a Collaboration and License Agreement (the &ldquo;Agreement&rdquo;)
with Kaken Pharmaceutical Co., Ltd., a company organized under the laws of Japan (&ldquo;Kaken&rdquo;). Pursuant to the Agreement,
Corbus granted Kaken an exclusive license to commercialize pharmaceutical preparations containing lenabasum (the &ldquo;Licensed
Products&rdquo;) for the prevention or treatment of dermatomyositis and systemic sclerosis (together, the &ldquo;Initial Indications&rdquo;)
in Japan (the &ldquo;Territory&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the terms of the Agreement, Corbus will bear the cost of, and be responsible for, among other things, conducting the clinical
studies and other developmental activities for the Licensed Products in the Initial Indications in the Territory, and Kaken will
bear the cost of, and be responsible for, among other things, preparing and filing applications for regulatory approval in the
Territory and for commercializing Licensed Products in the Territory, and will use commercially reasonable efforts to commercialize
Licensed Products and obtain pricing approval for Licensed Products in the Territory.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
consideration of the license and other rights granted by Corbus, Kaken will pay Corbus a $27,000,000 upfront cash payment and
is obligated to pay potential milestone payments to Corbus totaling up to approximately $173,000,000 for the achievement of certain
development, sales and regulatory milestones, with part of the milestone payments being calculated in Japanese Yen, and therefore
subject to change based on the conversion rate to U.S. Dollars in effect at the time of payment. In addition, during the Royalty
Term (as defined below), Kaken is obligated to pay Corbus royalties on sales of Licensed Products in the Territory, under certain
conditions, in the double digits, which royalty shall be reduced in certain circumstances. In particular, for so long as Corbus
supplies Licensed Products to Kaken pursuant to a supply agreement to be entered into by the parties, royalty payments shall be
payable for each unit of Licensed Product that Corbus supplies as a percentage of the Japanese National Health Insurance price
of the Licensed Product. During any time in which a supply agreement is not in effect, royalty payments shall be changed to a
rate to be agreed upon by the parties in good faith.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agreement will remain in effect on a Licensed Product-by-Licensed product basis and will expire upon the expiration of the Royalty
Term for the final Licensed Product. The &ldquo;Royalty Term&rdquo; means the period beginning on the date of the first commercial
sale of the Licensed Product in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents
covering such Licensed Product in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial
Indication in Japan, or (iii) ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication
in Japan. The Agreement may be terminated by either party for material breach, upon a party&rsquo;s insolvency or bankruptcy or
upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for
a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a
Licensed Product in either of the Initial Indications in the Territory, with 180 days&rsquo; notice.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the Agreement, the parties agreed to develop a joint steering committee to provide strategic oversight of the parties&rsquo;
activities under the Agreement, as well as a joint development committee to coordinate the development of Licensed Products in
Japan. Additionally, the parties will establish a joint commercialization committee to review and confirm commercialization activities
with respect to Licensed Products in Japan upon regulatory approval of such Licensed Product.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Agreement also contains customary representations, warranties and covenants by both parties, as well as customary provisions relating
to indemnification, confidentiality and other matters.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company is evaluating the terms of the Agreement and believes it is within the scope of ASC 606. Accordingly, the Company expects
that the $27 million upfront payment will be recognized in the first quarter of 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Termination
of January 2018 Sales Agreement</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
January 29, 2019, the Company provided notice of its termination of the January 2018 Sales Agreement. The termination of the January
2018 Sales Agreement was effective on February 8, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Public
Offering</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
January 30, 2019, the Company consummated an underwritten public offering of shares of its common stock pursuant to which the
Company sold an aggregate of 6,198,500 shares of its common stock, including 808,500 shares sold pursuant to the full exercise
of the underwriters&rsquo; option to purchase additional shares, at a purchase price of $6.50 per share with gross proceeds to
the Company totaling $40,290,250, less estimated issuance costs incurred of approximately $2,667,000.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif"><I>Office
Space Lease Amendment</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="margin: 0 0 0 24.5pt; text-align: justify; font-family: Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif">On
February 26, 2019, the Company amended its lease (&ldquo;February 2019 Lease Agreement&rdquo;) pursuant to which an additional
30,023 square feet of office space (&ldquo;New Premises&rdquo;) will be leased by the Company in the same building for an aggregate
total of 62,756 square feet of leased office space (See Note 6).</FONT></P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 113; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">F-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->25<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>figure_001.jpg
<TEXT>
begin 644 figure_001.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" '3!!8# 2(  A$! Q$!_\0
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MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***;)(L4;.[!$499F.
M .I)H =15.SUBPU"0I:WMO<N!DK#*KD#UP#5R@ HHJ*ZNH;&UFN;B5(+>%&D
MDED8*J*!DL2>@ '6@"6BL[3_ !%I6JBS-EJ5I=_;(/M5MY,ZMYT/'[Q,'YEY
M'S#CD5HT %%5[#4+75;5+JRN8;RVDSLF@D#HV#@X(X/-6* "BJ.IZYIVBM9C
M4+ZWLC>3K:VPN)53SIF!*QID_,Q . .>#5Z@ HHHH :S;5)IU1W'^I?Z5)0
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M -"TZBG*M*XQN":>J4]5Q3JD8@7%+112 **** "BBB@ HHHH **** "BBB@
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M'[/?PEF^&O@2&PURRTY]:2_O+G[3;*)#LEN))$^<J#G:PSZ=* /%-6\3^/\
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M%6Q'!#']GP%126QD;F))// !]%4444 %%%% #)O]3)C^Z?Y4Y?NBFS<Q./\
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M&^<",_G0!O\ QJ\:^(/!NGZ6^BWGAW1;>XF9+S7/%%QLM;-0N5 C#HTCN>
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MZE_\D5[312^M8C_GX_O8>RA_*CQ7_ACOX8?] _6__"FU+_Y(I/\ ACGX7_\
M0/UO_P *;4__ )(KVNBCZU7_ .?C^]C]G#^5'B?_  QQ\+_^@?KG_A3ZG_\
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M$E.-E;3]6>[@I2E2O)WU"BBBO/.\**** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH CG.(6/M4E1W
MS"X]JDH **** "BBB@ HHHH **** "BBB@ HHHH **** "HYO]2_TJ2F3?ZE
M_I0 ^BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH :_*,#TQ2TV8XA
M<G^Z?Y4Y>@H 6BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I&^Z?I2TC?
M=/TH 2/_ %:_04ZFQ_ZM/H*=0 445\\_#_X.^&OB-J'CG5=?CU*[O4\4:C;H
MT6KW<"K&LORJ$CE50!GTKJHTH3C*=2325ME??YHQJ3E%J,5=OSM^C/H:BO'-
M6_9U^&&@Z;<:AJ2:A8V%LADFN;CQ%?)'&HZEF,^ *Y#3_"/[/&L7]O8V7BJU
MN[RXD$4-O#XQNF>1SP%4"XR2:Z(X>A-7C*37^!?_ "1#J5%HTOO_ . ?25%>
M2_\ #+7P\/\ RXZM_P"%!J'_ ,?II_97^'1_Y<-7_P#"@U#_ ./UER87_GY+
M_P !7_R9?-5_E7W_ / /7**\A/[*7PY;_EPU?_PH=0_^/TP_LF_#=NMAK'_A
M1:C_ /'Z.3"_SR_\!7_R0[U.R^__ (![#17@FM?L[_!K0;.TNM1?4+:VN[I+
M*"5O$VHE9)G.%C!$_4D$?A6HW[(?PR;KIVM?^%)J7_R10Z=!*_-+_P !7_R0
M<T^R^_\ X![/17BK?L>?#!NNG:U_X4VI?_)%1M^QK\+6ZZ=KG_A3ZG_\D5GR
MT/YW_P" K_Y(=Y]E]_\ P#VZBOE'XG? 7PA\(?$WPIUCPM%J]C?W'C2QLIFG
MUV^N4>%HIV9"DLS*02B]NU?5U14A&*3B[I^5OU8XMNZ84445B6<]M%."EA2@
M4N*V(/-?% _XR&^%O_8/UK_T&UKV>O'/%*_\9"?"_P#[!^M?^@VM>QUT8CX*
M7^'_ -ND13WEZ_H@HHHKA-@HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*^%OVX/BIXG^$/Q\\+:OX4U$:9J$_AJ:UDE-O'-F,W08KB16'55YQGBONFOS
MJ_X*5?\ )7_!W_8"E_\ 2BO<R6$:F-A":NG?1^AQXR3C1;3.!_X;@^,__0W)
M_P""NS_^-5[[^R;\5/$_Q=?Q?K'BO41J>H0&SM8YA;QPXC F8+B-5'5V.<9Y
MKX-K[&_8#_Y WC;_ *^;7_T"2ON\PPF'HX:4Z=-)Z;)+JCYMU:DU:4FSZN9U
MC4L[*BJ,EF. /J:B@OK:Z8K!<P3L!DB*56(_(UQ_QDB-QX#N(EMDO7DN[1%M
M9GV0S$W$?R3-VC/1O;UJK\.?#,NAZE=RR>#?#?AH/#M$^BW7G22?,#M8>6N%
M[]>M?**FG3YV_P O\_T(.WN]2L["2".ZNX+9[AMD*S2!#(V,[5R>3CM5D@C@
MC%<!\7KE)+'1](>QT6Z_M6Z: 3:__P >UN5C9]V."6."  1]:J_#GP+J'A&6
MU%EXSD\0:=N<7EG)(LD$.5RGD#+-'ANQ8@@GTI^S7L^=NS Y#]K+XE>(OA3I
M/A37?"]^--U0W=Q;><8(YOW;1J6&UU8=57G&>*^=_P#AN#XS_P#0W)_X*[/_
M .-5[#^WM_R)'A/_ +"4O_HJOE3X47OA[3?B5X:NO%D0F\.0WT;WR,I9?+!Z
ML!U4'!([@$5]-@<-AZF$52I24FK]$WUT-8U)Q?+&5D>DK^W'\99/N^,(V^FF
M69_]I4O_  W!\9_^AN3_ ,%=G_\ &J[CQMX9U'XA:IX9T#QC_94UAK6N&'0_
M'7AJ.V^SK"\9"6CK&JY)?RR ^&&3C/-<'X;_ &;HM4U+PGIFHZQ<V>JZKI]_
MJ=U8V\"2S+%;R.D<=NNX>9++L)"G'%7!9=R\U2E%>B3[^7D[]CH?M[VC)_>2
M?\-P?&?_ *&Y/_!79_\ QJC_ (;@^,__ $-R?^"NS_\ C5:_@_X9_#O38?B;
M#=:G?ZS'9>&UO;=I]*6.ZT]C(H<.CL-DZ-A>."K$Y[5GW/[+;VOPSG\0/>:P
MNIQ:!_PD6XZ9_P 2HQ;!((!<[LF;RR#C&,Y%.V6WM*E%;+6/=7[!_M%KJ3^\
M@_X;@^,__0W)_P""NS_^-4?\-P?&?_H;E_\ !79__&JU-<_9S\"^'9?$$%]X
MXUB.Y\/Z;:ZQJ$::2C VTP0!8CYGS2!Y$'.!@^QK/\0_!Z\\#Z/X_P!-TG6W
MO=/DM]#N+=);.(/>Q7<I\H.3DPLC9SL//?BG%9;.W+2CTWC;>WEYH/\ :%O)
M_?\ \'R(_P#AN#XS_P#0W)_X*[/_ .-4C?MQ?&5,;O&$:_73+/\ ^-5@_$WX
M4^$_ ]KK=EI_C&:_\4:#=QVFH:=>6BP1SELAVM6#$R!&&"& .#FNX_9^U&:3
MX=R:=X)GT%/'PUCS[[3];C@,NIV'EJ$AMVF4J/FWY7(/S9STJITL"J7M84(M
M><4OF]-O.PHRK<W*YO[_ /@F-_PW!\9_^AN3_P %=G_\:J1OVV/C9'$DK>*2
ML4F=DC:3:!6QUP?)P<>U17'PN\):M<:AXF\37=_\.=*U7Q!/I6G:3#:K<&R=
M,&4SEF79$C,%X!. >*Z*#X63_$3P5\)/"-O?H\276O/+?62^>&AAD5G>%1]\
ML%^4=RPJ)1R^-FZ,;=?=6FC;Z6=K6T&G7=_??W^9SW_#<'QG_P"AN3_P5V?_
M ,:H_P"&X/C/_P!#<G_@KL__ (U6U)^RGIEIJ23ZAK6NZ+H#:#=ZT_\ :6E)
M%J$)MIDC>-X-^/F5]RD'G(SCFN?\,? 3P[KD'ANWNO%5]8:SXO>=O#EM]@5X
MGB5V2%KI@^8S(5/"AL=Z:65M<RIQM_@]?+R8O]IO;F?WDW_#<'QG_P"AN3_P
M5V?_ ,:H_P"&X/C/_P!#<O\ X*[/_P"-50M?@3H\/PHLO%6J^)+RRO+^WN9K
M<Q6!ETZ*6)RHMIYU.8Y7P<#;CD5KQ?"!O'7B/2[/5-:OKF"Q\$V&L)#I6F1/
M>R1LB[;>&)2HD*;\EV.XJI)JG#+E?]U&RO?W>WRU%?$?S/[_ /@E?_AN#XS_
M /0W)_X*[/\ ^-4?\-P?&?\ Z&Y/_!79_P#QJO*O'OA_3?#'BJ]T[2-6.MZ=
M%M,-XT#0N05!*NA^ZZDE6'JIKGZ[(X'!2BI*C'7^ZO\ (R=:LG9S?WGNO_#<
M'QG_ .AN3_P5V?\ \:H_X;@^,_\ T-R?^"NS_P#C5>,:+H6H^([];+2[.:_O
M&4LL,"[F('4XKHO^%.^./^A5U3_OP:F6#P$':5."^2&JM=[2?XGHO_#<'QG_
M .AN3_P5V?\ \:H_X;@^,_\ T-R?^"NS_P#C5>=?\*=\<?\ 0JZI_P!^#1_P
MIWQQ_P!"KJG_ 'X-3]5R[^2'W1'[3$=W^)Z+_P -P?&?_H;D_P#!79__ !JC
M_AN#XS_]#<G_ (*[/_XU7G7_  IWQQ_T*NJ?]^#1_P *=\<?]"KJG_?@T?5<
MN_DA]T0]IB.[_$]%_P"&X/C/_P!#<G_@KL__ (U1_P -P?&?_H;D_P#!79__
M !JO.O\ A3OCC_H5=4_[\&C_ (4[XX_Z%75/^_!H^JY=_)#[HA[3$=W^)Z+_
M ,-P?&?_ *&Y/_!79_\ QJC_ (;@^,__ $-R?^"NS_\ C5>=?\*=\<?]"KJG
M_?@T?\*=\<?]"KJG_?@T?5<N_DA]T0]IB.[_ !/1?^&X/C/_ -#<G_@KL_\
MXU1_PW!\9_\ H;D_\%=G_P#&J\Z_X4[XX_Z%75/^_!H_X4[XX_Z%75/^_!H^
MJY=_)#[HA[3$=W^)Z+_PW!\9_P#H;D_\%=G_ /&J/^&X/C/_ -#<G_@KL_\
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M"NS_ /C5'_#<'QG_ .AN3_P5V?\ \:KSK_A3OCC_ *%75/\ OP:/^%.^./\
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M_E_%'P1Y:?W5_*CRT_NK^5?>_P#P[/T;_H>]2_\  &+_ !I'_P"":.C*I/\
MPG>I<?\ 3C$?ZT?V]E_\_P"#_P @^HU_Y?Q1\$^6G]U?RH\M/[J_E7WO_P .
MS]&_Z'O4O_ &+_&C_AV?HW_0]ZE_X Q?XT?V]E_\_P"#_P @^HU_Y?Q1\$>6
MG]U?RH\M/[J_E7WO_P .S]&_Z'O4O_ &+_&C_AV?HW_0]ZE_X Q?XT?V]E_\
M_P"#_P @^HU_Y?Q1\$>6G]U?RH\M/[J_E7WO_P .S]&_Z'O4O_ &+_&C_AV?
MHW_0]ZE_X Q?XT?V]E_\_P"#_P @^HU_Y?Q1\$>6G]U?RH\M/[J_E7WO_P .
MS]&_Z'O4O_ &+_&C_AV?HW_0]ZE_X Q?XT?V]E_\_P"#_P @^HU_Y?Q1\$>6
MG]U?RH\M/[J_E7WO_P .S]&_Z'O4O_ &+_&C_AV?HW_0]ZE_X Q?XT?V]E_\
M_P"#_P @^HU_Y?Q1\$>6G]U?RH\M/[J_E7WO_P .S]&_Z'O4O_ &+_&C_AV?
MHW_0]ZE_X Q?XT?V]E_\_P"#_P @^HU_Y?Q1\$>6G]U?RH\M/[J_E7WO_P .
MS]&_Z'O4O_ &+_&C_AV?HW_0]ZE_X Q?XT?V]E_\_P"#_P @^HU_Y?Q1\$>6
MG]U?RH\M/[J_E7WO_P .S]&_Z'O4O_ &+_&C_AV?HW_0]ZE_X Q?XT?V]E_\
M_P"#_P @^HU_Y?Q1\$>6G]U?RH\M/[J_E7WLW_!,_1@I/_"=ZE_X Q?XTO\
MP[/T;_H>]2_\ 8O\:/[>R_\ G_!_Y!]1K_R_BCX(\M/[J_E1Y:?W5_*OO?\
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MJMJCE]NTGS1L]/Q/HFQTNSTP2"SM(+42'<_DQA-Q]3@<FK5?+'AG0;G]G/\
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M"ST379I+!(XX1<E@DL'SDOM*@$,!UXXIVRR]O91_\ ]/+S7WB_VG^9_>4/\
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M%;4O^_0_QH_X4]XW_P"A6U+_ +]#_&CZMEW\D/NB'M,1W?XGH?\ PVY\9_\
MH<!_X++/_P"-4?\ #;GQG_Z' ?\ @LL__C5>>?\ "GO&_P#T*VI?]^A_C1_P
MI[QO_P!"MJ7_ 'Z'^-'U;+OY(?=$/:8CN_Q/0_\ AMSXS_\ 0X#_ ,%EG_\
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M%;4O^_0_QH_X4]XW_P"A6U+_ +]#_&CZMEW\D/NB'M,1W?XGH?\ PVY\9_\
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M?4:_\I\"^4G]Q?RH\I/[B_E7WRW_  31T-5)_P"$ZU3_ , HO\:7_AV?H?\
MT/6J?^ <7^-']OX#^?\ !_Y!]1K_ ,I\"^4G]Q?RH\I/[B_E7WU_P[/T/_H>
MM4_\ XO\:/\ AV?H?_0]:I_X!Q?XT?V]@/Y_P?\ D'U&O_*? OE)_<7\J/*3
M^XOY5]]?\.S]#_Z'K5/_  #B_P :/^'9^A_]#UJG_@'%_C1_;V _G_!_Y!]1
MK_RGP+Y2?W%_*CRD_N+^5??7_#L_0_\ H>M4_P# .+_&C_AV?H?_ $/6J?\
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M=GZ'_P!#UJG_ (!Q?XT?V]@/Y_P?^0?4:_\ *? OE)_<7\J/*3^XOY5]]?\
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M  >?^H/)_P"CC7O9)3A5QL835TT_R.+&2<:+:W,'_AXA\4_^?7PY_P" ,O\
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M6H?]^O\ Z]'_  JCQE_T+6H_]^J/J&6_R1_ /;8CNSW+_AXA\4_^?7PY_P"
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MMI?A(>&$\3>-O#UCI>JW-Y97VAJD<NH6\VUC'<)YH5'#*<,"V WY^Z_\.T-
M_P"AYU;_ ,!(:/\ AVAH'_0\ZM_X"0TOK^5<JCSO[GY^5NK#V.)O?E/ O#_Q
MV\/Z;<?"B2Y35)CX7?5&U!VC5WD^TE_+*'>-Y^8;B=O?K4?PZ^.'A[PGX7\"
MZ=>PZ@T^B)KBW1AA1E/VR$)#L)<9P1\V<8[9KZ!_X=H:!_T/.K?^ D-'_#M#
M0/\ H>=6_P# 2&JEF&5233F_N?7F\O[S!4,4M;?UI_DCYEO/&WP]\3>$= FU
M^UUJ;Q)H>A?V+#IT"H+*X9-_D3M+O#KM\S)4*<E0,X-9WP7\;>&O#&D^.M(\
M3S:E:VGB+2X[".YTRV2>2)EF60DJ[H,87'7O7U7_ ,.T- _Z'G5O_ 2&C_AV
MAH'_ $/.K?\ @)#6O]JY;R.'M'9Z[/36^FG<GZMB+I\J/FGPQXH^'&B:3XK\
M*7&H^))_#FJ3:??0:E'80+=">W,A:-HC+M",)3\P8GCI7J^N>+O!7Q(^'?Q%
M\1ZE/KFF^&+OQE82P26MK%)= I9JH5D9PO.UN0W'!]J[_P#X=H:!_P!#SJW_
M ("0U(/^";&BK T(\?:R(6;<8_LT6TMZXZ9]ZYZF89=.7.JSOIT?EY;NR_R+
MC0Q$5;E5OZ_S/$V_:#\(^--4UUO%,6M:;8-XJMO$FG#3(8IY"L,?E""7>Z@9
M4*=PSWXI?"GQZ\&:5XV\3Z]<3^)+6'4M9N+V;3((89[/6+-_NV]S#(^V-@<_
M.NXX;CI7L_\ P[0T#_H>=6_\!(:/^':&@?\ 0\ZM_P" D-'U[*;.*F[/39^7
MEY!['%7ORGRC\$OB!H7@/XH3:YJ\%U:Z--:7UJ8=/C$TD(GB=%"AF7(7<.I[
M5H^&/$7P^^&^IZK<:'JFOZO'J/AW5-)?[=IL-N8YIX0D)&V5LKDMN/48& <U
M]._\.T- _P"AYU;_ ,!(:/\ AVAH'_0\ZM_X"0UTSS;+9R<G4>JL]'TOY>9G
M'#8B*2Y=CP+PSXBU#PE^R3XCAOK-H(]:U06>C7,RX,L+[&O/+]5S;Q@MTSQ2
M^'?C1X1TJ'P[>S#5_P"U+/P7=^%KJW6WC,.]ED$,J/O!()D.[(&,#&:^@)/^
M";.BR11Q/X^UEXH\[(VMHBJ9Y.!VS[5'_P .T- _Z'G5O_ 2&L?[2RR7-S5'
MJV]$^JMV_IE_5\0K6CMYGA?@G]H31?#NA^'=%DEUK3X8_"\NA7VI:6%6YM9S
M<M-'-!\XW@< @E<Y/ISCZU\7="D\,_$32(]9\3>(YM=TRQL[/4->"-*9(K@2
MR;\.?+3&=H!;GZU]&?\ #M#0/^AYU;_P$AH_X=H:!_T/.K?^ D--9AE2DY*;
MU=]GO>_8/88JUK'SOXH^-7A_6=8\<74%O?&+6O"UCHULDL2C]_"]NS[\,<(1
M"^",GD<5O?%/X]^$O&7@/Q3I^G7GB0WFL?V<UKI-[%&-/TP6Y^:&':^0#R=V
MT9XR.]>U?\.T- _Z'G5O_ 2&C_AVAH'_ $/.K?\ @)#2_M#*KQ?._=MT?2WE
MY(/88G56W_K]3PSQ-\:/ WC#7O&D%[_;MKH'B^RL9;F:&VB:XL+ZW(X1"X66
M(@8R2IYZ<5!!\;?"TGCQ[^"]\3>&K33M)L])T76-,$;W2QP !OM$!81R++SE
M2V!QUKWK_AVAH'_0\ZM_X"0T?\.T- _Z'G5O_ 2&DLPRI*WM'M;9^2[=DE_3
M#V&)O?E/#I?C1\//$DOBO3]4L-8T30KSQ);>(;!='MH3([1QA)$D4LJQ[RN_
M*YP6([5;\,_'OP7IOC[Q9XBFN/$EC'JFNW%_)8V\,-Q:ZO9.Q9;:Y@D?:C#)
M&\;B-QQT%>S?\.T- _Z'G5O_  $AH_X=H:!_T/.K?^ D-)X[*FG'VCL_)^7E
MY#]CBKWY4?!^I7$-YJ5W/;VZVEO+,\D=NIR(E+$A!]!@?A5:OOG_ (=H:!_T
M/.K?^ D-'_#M#0/^AYU;_P !(:])9]EZTY_P?^1S?4J_8^!J*^^?^':&@?\
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M^ D-'_#M#0/^AYU;_P !(:/[>R_^?\'_ )!]2K]OQ/@GSI/^>C_]]&CSY?\
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MI5^WXGPA_:M]_P _MS_W^;_&C^UK_P#Y_KK_ +_-_C7W?_P[0T#_ *'G5O\
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MTO<?6H+S4K;3_)^TW,=OYT@BC\QPN]ST4>I/I4]>>^/M7M5N=.U&UU&.TO\
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M'[W_ )!_:-+L_P"OF?JU17Y2_P##:GQF_P"AT?\ \%UI_P#&J/\ AM3XS?\
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M_P!#H_\ X+K3_P"-4?ZLXO\ GC][_P @_M&EV?\ 7S/U:HK\I?\ AM3XS?\
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MK5%?E+_PVI\9O^AT?_P76G_QJC_AM3XS?]#H_P#X+K3_ .-4?ZLXO^>/WO\
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M]"5/_P"#R7_XW1_PD/@[_H2I_P#P>2__ !NCVDOY'^'^8<J[_G_D<E176_\
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M[K_X[3O^&*_@Q_T)47_@==?_ !VE_K-A/Y)?<O\ ,/[.J]U_7R/REHK]6O\
MABOX,?\ 0E1?^!UU_P#':/\ ABOX,?\ 0E1?^!UU_P#':?\ K-A/Y)?<O\P_
MLZKW7]?(_*6BOU:_X8K^#'_0E1?^!UU_\=H_X8K^#'_0E1?^!UU_\=H_UFPG
M\DON7^8?V=5[K^OD?E+17ZM?\,5_!C_H2HO_  .NO_CM'_#%?P8_Z$J+_P #
MKK_X[1_K-A/Y)?<O\P_LZKW7]?(_*6BOU:_X8K^#'_0E1?\ @==?_':/^&*_
M@Q_T)47_ ('77_QVC_6;"?R2^Y?YA_9U7NOZ^1^4M%?JU_PQ7\&/^A*B_P#
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MPHHHK$L**** &3?ZF3_=/\J<OW139N87!Z;3_*G+]T4 +1110 4444 %%%%
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MM'LL/_S]_P#)?^"/VV)_Y]?^3?\  /1J*\W/P3A/_,Z>-/\ P>RTG_"D8?\
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M9_\ QJG[&G_S]7W2_P#D0^LUO^?$OOA_\D>B45YW_P *[\6?]%+UC_P!L_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M#)O]4WTI]1S<Q-]*DH **** "BBB@ HHHH **** "BBB@ HHHH **** "HY_
M]2_TJ2F3<Q-]* 'T444 %%%% !1110 4444 %%%% !1110 4444 %%%% #)O
M]2_^Z?Y4Y>@ILW^I?_=-.7[HH 6BBB@ HHHH **0T 4 +1114@%%%)2 *":3
M=24 %%%% !2-]TTM,D/R-]*8 A_=I]!2DTV/_5I]!_*EHV ****ENX!113<T
MA"[J2BB@ HHHH$%%%-)H 4TVEW49H&)112;J0"T4W-%2%B[11170,\J\=?\
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M5_\ /[_R7_@A_KTO^@;_ ,F_^U/T9HK\X_MUU_S\S?\ ?QO\:/MUU_S\S?\
M?QO\:/\ 55_\_O\ R7_@A_KU'_H&_P#)O_M3]'**_./[==?\_,W_ '\;_&C[
M==?\_,W_ '\;_&C_ %5?_/[_ ,E_X(?Z]1_Z!O\ R;_[4_1RBOSC^W77_/S-
M_P!_&_QH^W77_/S-_P!_&_QH_P!57_S^_P#)?^"'^O4?^@;_ ,F_^U/T<HK\
MX_MUU_S\S?\ ?QO\:/MUU_S\S?\ ?QO\:/\ 55_\_O\ R7_@A_KU'_H&_P#)
MO_M3]'**_./[==?\_,W_ '\;_&C[==?\_,__ '\;_&C_ %5?_/[_ ,E_X(?Z
M]1_Z!O\ R;_[4_1RBOSH9M2CMX[AC>+;R9"3,7"-CKANAQ47VZZ_Y^9O^_C?
MXT?ZJM_\OO\ R7_@@^.DM\-_Y-_]J?HY17YQ_;KK_GYF_P"_C?XT?;KK_GYF
M_P"_C?XT?ZJO_G]_Y+_P0_UZC_T#?^3?_:GZ.45^<?VZZ_Y^9O\ OXW^-'VZ
MZ_Y^9O\ OXW^-'^JK_Y_?^2_\$/]>H_] W_DW_VI^CE%?G']NNO^?F;_ +^-
M_C1]NNO^?F;_ +^-_C1_JJ_^?W_DO_!#_7J/_0-_Y-_]J?HY17YQ_;KK_GYF
M_P"_C?XT?;KK_GYF_P"_C?XT?ZJO_G]_Y+_P0_UZC_T#?^3?_:GZ.45^<?VZ
MZ_Y^9O\ OXW^-'VZZ_Y^9O\ OXW^-'^JK_Y_?^2_\$/]>H_] W_DW_VI^CE%
M?G']NNO^?F;_ +^-_C1]NNO^?F;_ +^-_C1_JJ_^?W_DO_!#_7J/_0-_Y-_]
MJ?HY17YQ_;KK_GYF_P"_C?XT?;KK_GYF_P"_C?XT?ZJO_G]_Y+_P0_UZC_T#
M?^3?_:GZ.45^<?VZZ_Y^9O\ OXW^-'VZZ_Y^9O\ OXW^-'^JK_Y_?^2_\$/]
M>H_] W_DW_VI^C,G,;#VI]?G/:WUS]J@_P!)F_UB_P#+1O[P]Z_19?NK]*\#
M-,J>6<EY\W-?I;:WF^Y]5D>>K.E4M3Y.2W6][W\EV'52UN^;2]%O[U%#O;V\
MDRJW0E5) /Y5=K)\7?\ (J:U_P!>4W_HMJ\2"O))GU$M$V>4>$_&/QG\8^%]
M(UZRT7P/'::G:17D*3ZA>!U21 RA@(B <'G!-:OV[XX?] CP%_X,;W_XS70?
M P8^"_@0?]0.R_\ 1"5L^--/\1ZEI*1>&-8L]$U 2AFN+VR-TACP<KL#I@YQ
MSGMTKTJE:$:TJ:IQ23:U3_S.2G"4J:DY/5>1POV[XY?] CP#_P"#&]_^,TGV
M[XY]M(\ ?^#*]_\ C-9OP%\4^.?%WAN/Q;XJ\2Z.^B?Z7')9V^F&!HS#,\?F
M&4RD8Q&21M[]>*ZKPG\>_!/C:ZO+;2=5DEEMK5K[$UG-")K=>&EB+H!*@]4S
MU'K6E13A*452C+EWLI60XV:3<FK^ABF^^.W;1_A__P"#*]_^,4PWWQY[:/\
M#W_P97W_ ,8J_8?M+?#W4O"MWXDM]9E?2+:6*W,_V&<&660?)'$I3,C=1A 2
M""#6AH?QX\$>(-#U[5[;6#'8:"%_M*2[MI8#;%ER%974'=VVXSDXZU+]M&]\
M.M--G_GYE+DZ3_%'/&_^/G;1OAY_X,[[_P",4QM0_: [:+\.?QU2^_\ C%-\
M5?M.^&;'X<^)?$.A/<7]_I"*#I]UI]S#(LCJ6B,B,@=8V"GYR-OO6CI/Q6M]
M?U;P;?+K3:;9ZGI%W?RZ-/I<HDN/*V;I!(P!C"$GY2/G# BFZ=7EYI44EKT?
M17_(.:-[*?Y&:VH?M"=M$^&_XZI?_P#QBHVU#]HCMH?PU_'5;_\ ^1ZZ/P7^
MT-X$^(&MV6DZ)J\EQ>7L+36OFV<T,<X49=4=T"LRCJH.143?M'^ /^$E&A#6
M9'OFU!-*C9+*<P273.$\I)@FQB&.#AN.]9N%:[C[#5>3'>%K\_XG/-J/[1O;
M0OAF?^XMJ'_R/2> _B9\2D^,UKX&\?:/X7M$O-#N=8M[GP[=W$Y_=3P1%'\U
M$QGSB>,]*]OKQ?6/^3Q/"Q_ZDC4O_2VSKGC)5+IQ6S-&G&SN>T5'-CR7STQW
MQ_6I*CF_U+_2N,U)**\A_:$^*VK_  SM=$31X[?S[YYB\MPN\*L83Y0O'),@
MYSQMZ<\>,?\ #4WCG^]IO_@*?_BJ]_"Y)B\915>G:S[OMH?*8[B; 9?B)8:M
MS<T;7LNZOW[,^Q:*^.O^&IO'/][3?_ 4_P#Q5'_#4WCG^]IO_@*?_BJZ_P#5
MK'?W?O\ ^ <'^N66=I?=_P $^Q:*^.O^&IO'/][3?_ 4_P#Q5'_#4WCG^]IO
M_@*?_BJ/]6L=_=^__@!_KEEG:7W?\$^Q:*^.O^&IO'/][3?_  %/_P 51_PU
M-XY_O:;_ . I_P#BJ/\ 5K'?W?O_ . '^N66=I?=_P $^Q:*^.O^&IO'/][3
M?_ 4_P#Q5'_#4WCG^]IO_@*?_BJ/]6L=_=^__@!_KEEG:7W?\$^Q:*^.O^&I
MO'/][3?_  %/_P 51_PU-XY_O:;_ . I_P#BJ/\ 5K'?W?O_ . '^N66=I?=
M_P $^Q:*^.O^&IO'/][3?_ 4_P#Q5'_#4WCG^]IO_@*?_BJ/]6L=_=^__@!_
MKEEG:7W?\$^Q:*^.O^&IO'/][3?_  %/_P 51_PU-XY_O:;_ . I_P#BJ/\
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M^>IX6K5CSP5UKVULKNRW=D^AR-%7]?T:?P[K=_I=RT;W%G,\$C1$E"RG!()
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MC7%/'2I5)IJZ3_RMTZO3YGHT\LIUZ5.47RMJ[Z][O?I&[^7F> G'0X^E (Z
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M1S9,+8ZXJ2HYO]2^?3V_K7,:'SC^V-_S*/\ V^?^T*^;J^D?VQO^91_[?/\
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M1&S9GMMDK#R68Y8IS\I)Y.*34]6OM:NC=:A>7%]<L #-<RM(Y Z#).:^U/\
MAGWX??\ 0N0_]_I?_BZ/^&??A]_T+D/_ '^E_P#BZ?\ K+@KW]G*_HO\Q?ZF
M9DURNK&WK+_Y$^0M2\6O>V.@2Q&>TUG2XC:B\A?;NB4YB((Y#*"R_0+5"Z\4
M:S?7,UQ<:M?3SSP_9Y99+AV9XB0=C$GE<@<=.*^S/^&??A]_T+D/_?Z7_P"+
MH_X9]^'W_0N0_P#?Z7_XNLX\18".U.7W+U[FLN$,TGO6CTZRZ*W\NY\O6?Q,
MATWP7<Z+;V>H&XN+,V3-/J3R6B*Q!=T@(PK$#UXR:Y^U\::C:Z5JEDTC7!U"
MWALVGFD9GC@C8,(TR>%R ,>@Q7V#_P ,^_#[_H7(?^_TO_Q='_#/OP^_Z%R'
M_O\ 2_\ Q=9QS[+HWM3EJ[]-_P#P(UGPKF\^6]:&BLMUIM_+YGQ7:ZM?64(A
MM[RX@B$RW CCE95$B_=? /WAV/44C:M>LMV#>3D7A#7(\QOWQ!R"_/S8))Y[
MU]J_\,^_#[_H7(?^_P!+_P#%T?\ #/OP^_Z%R'_O]+_\771_K+@M_9R^Y?YG
M+_J7F5K>UC]\O_D3XRM_$FKVFER:;!JEY#ITF=]I'<.L39ZY0'!S5S1O&FHZ
M-<WMRLC7-U<V#:<)[AV9HHB OR\]E&T=@*^P?^&??A]_T+D/_?Z7_P"+H_X9
M]^'W_0N0_P#?Z7_XNHEQ%@))ITY:^2_S-(\'YK%IJM'3;66G_DI\3PWUS;6U
MQ;PW$L5O< +-$CD+( <@,.^#SS5^?Q=KEU9Q6DVLZA+:Q;?+@DNG*)M.5PI.
M!@]/2OLG_AGWX??]"Y#_ -_I?_BZ/^&??A]_T+D/_?Z7_P"+JGQ)@9.[IR^Y
M?YD1X-S.*M&M%?.7_P B?&/]O7TLTK7-Y<W45Q<+<W,;SM^_<'[S'/+=?FZC
M-=]??&IU_LH:=8W;BQO/M^[6-0>\<RA"L85B!A%R2%[GK7TA_P ,^_#[_H7(
M?^_TO_Q='_#/OP^_Z%R'_O\ 2_\ Q=85,^RZJTYTI:>GIW.JCPMG&'35.M!7
M];Z.^[B?%5OJM[:W,]Q!=S03SJZ2R12%6=6^\I(Z@]QWJ2WUW4K.:SF@U"ZA
MELU*6TD<S*T"DDD(0?E&23@>IK[1_P"&??A]_P!"Y#_W^E_^+H_X9]^'W_0N
M0_\ ?Z7_ .+K?_67!/>G+[E_F<BX,S);58_?+_Y$^-E\6ZY'JCZDNLWZZC(N
MQ[L7+B5E_NELY(]JBNO$6JWRW"W.IWEPMP$$RRSLPEV?<W9/.WMGI7V=_P ,
M^_#[_H7(?^_TO_Q='_#/OP^_Z%R'_O\ 2_\ Q=+_ %CP"=U3?W+_ #*?!V:-
M6=:/WRZ_(^0=(\=:KI%A=6BW$EQ%+926,*S2NRVT;L"_EKG )VXK&AU"ZMK6
MXM8;F:*VN=OG0HY"2[3E=P'!P>F:^U_^&??A]_T+D/\ W^E_^+H_X9]^'W_0
MN0_]_I?_ (NA<1X&+;5.6ODO\QRX/S222=:.FBUE_P#(GQA>>(-4U 8NM2N[
MD>8LN)IV;YU4*K<GJ%  /H,5:N/&WB&\E@EGUW4II('$L3R7<C&-P,!E)/!P
M2,CUK[%_X9]^'W_0N0_]_I?_ (NC_AGWX??]"Y#_ -_I?_BZ/]8\!_SZ?W+_
M ##_ %/S37]]'7SE_D?%2ZM>K'$@O+@)%,;B-1*V$E.,N.>&.!SUX%;^B^.I
MX_$UEK.OO>^(I+'Y[=+F\8[9 04)+9RH/51C/K7UM_PS[\/O^A<A_P"_TO\
M\71_PS[\/O\ H7(?^_TO_P 72EQ%@)IITY?<NOS'3X0S2FU*-:&EGNVM-M.6
MQ\B6/BW['IWB*1A))K&L?NGN,C:D+-ODQWW,0!Z8SZUS=?;_ /PS[\/O^A<A
M_P"_TO\ \71_PS[\/O\ H7(?^_TO_P 73CQ)@H-N,):^GIW)J<&YE424JL-/
M-][_ ,OF?$%%?;__  S[\/O^A<A_[_2__%T?\,^_#[_H7(?^_P!+_P#%UI_K
M1A/Y)?<O\S+_ %(Q_P#S\A]\O_D3X@HK[?\ ^&??A]_T+D/_ '^E_P#BZ/\
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M0L]&TNRTBT!S]GL;=(8\^NU0!6E6F,Q;Q4H[VBK:N[?FV31I>S3\PKQW5O\
MD[CPS_V)>I?^EMG7L5>/:M_R=QX9_P"Q,U+_ -+;.L*&\O1_D7/9>J/8:9-D
M1/CKBGU'/S"X]JYC0^<?VQO^91_[?/\ VA7S=7Z"^+/ N@^.(;>+7--BU!;=
MBT1<LK(2,'!4@X.!D=#@>@KF_P#AG_P!_P!"[%_W_E_^+K[G+,^P^#PD*%2+
M;5]K=6WW\S\PSKA;%YECZF*I3BHRMO>^B2[/L?#U%?</_#/_ ( _Z%V+_O\
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M^7_XNC_6C"?R2_#_ ##_ %(Q_P#S\A]\O_D3X>HK[?\ ^% ^ /\ H78O^_\
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M7#TZ<'4BVY*^C2ZM?ROL<G-5G.2BTDG;;R3[KN><?\--?"O_ *'K1_\ O_\
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M^L/_ '['^%+FPW\DO_ E_P#(A:IW7W?\$\I/[77P:'7XC:'_ .!'_P!:F_\
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M&?Q9J'@W]JK0[S36C6:3P9<1-YJ;AM-]&>GX"OJ&OD;]I#_DYGP__P!BC/\
M^EB5\KF-2=' UZE-V:B]2<9)QHMQW.F_X7MXK_Y[6?\ X#__ %Z/^%[>*_\
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MHH **** "BBB@ HHHH **** "HY_]2_TJ2HYO]2_TH DI#Z4M%*X""EI*!2
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M)_UV;_T!J^KJ_5N$?]SJ?XOT1]%EO\*7K^B"BBBONCU@HHHH **** "BBB@
MHHHH **** "BBBE< J*;/E.?:I:CG_U+_3O4@244F:3- "DTVBB@ HHHH *,
MTTFDIO8!2:2BBI; ***,T@"DW4F:*!!1110%QDW^ID_W3_*G+T%-EXB<GIM/
M\J<.@H)%II-!-'&*"A*4&DHH *,TW=25-P%I*0FFY-2,<324FZDW4B6+FFT4
M4A!1110 4C'@TA:FLWRGGM2 2,_NT_W12DTR,_NT^@_E3J+B"DHHW5(@Z4VB
MBD4%(32%J:6I *6IN312;L4KBN+2$TW)HS2$%(32;J*FX!FDHHJ;@%%(6HH
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M[2647$XW;764N-H)X.1P/>K_ ++J*+DY+:^^][VMZVT]4/ZO*U[H\QHKUO\
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M?*":N?V38?\ 0=M/^_$__P ;K*HK6,XQ5G%/[_T92:[&K_9-A_T';3_OQ/\
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M8TOY5]QR'_"I/"/_ $!(/^^F_P :/^%2>$?^@)!_WTW^-=?11_9^#_Y\Q_\
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MC1_PJ3PC_P! 2#_OIO\ &NOHH_L_!_\ /F/_ ("O\@]C2_E7W'(?\*D\(_\
M0$@_[Z;_ !H_X5)X1_Z D'_?3?XUU]%']GX/_GS'_P !7^0>QI?RK[CD/^%2
M>$?^@)!_WTW^-'_"I/"/_0$@_P"^F_QKKZ*/[/P?_/F/_@*_R#V-+^5?<<A_
MPJ3PC_T!(/\ OIO\:/\ A4GA'_H"0?\ ?3?XUU]%']GX/_GS'_P%?Y![&E_*
MON.0_P"%2>$?^@)!_P!]-_C1_P *D\(_] 2#_OIO\:Z^BC^S\'_SYC_X"O\
M(/8TOY5]QR'_  J3PC_T!(/^^F_QH_X5)X1_Z D'_?3?XUU]%']GX/\ Y\Q_
M\!7^0>QI?RK[CD/^%2>$?^@)!_WTW^-'_"I/"/\ T!(/^^F_QKKZ*/[/P?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBBD 4445(!2-113 ;1112 **** "FFBBF@$HH
MHHD 4O:BBH 0TVBB@EA1110 4>E%% A*%HHH'T!J0=:**!"4W)HHJ64A*&HH
MI ,:BBBI$Q#2444@"E[444"&M2444D C4VBBDR6)WI:** &FDHHJ"@IIHHH
M9FBBBD2%-;K114@)33110(*2BBH&%(U%%) -:FT44V2QK4UJ**@0E)WHHJ0#
?I3&)HHK/J(1J2BBGT$!IM%%2(2FT45 #****L#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>figure_002.jpg
<TEXT>
begin 644 figure_002.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %O =L# 2(  A$! Q$!_\0
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M1W6:<QW!B15N8T<!221SP3P/K4]_XJUF*[UI8]2=FCC:2%88E*1*&7.<C<I
M)ZY![470<LNYZM]HE_OFC[1+_?->37GBK6+F2[>QU=U@1[N2)TC4AEC164<C
MIR?SKK/!VHZA>/J<%_=M=&"2(I(R!2 \88CCL"::L)J25[G6_:)?[YH^T2_W
MS45%.R)YGW)?M$O]\T?:)?[YJ*BBR#F?<E^T2_WS1]HE_OFHJ*+(.9]R7[1+
M_?-'VB7^^:BHHL@YGW)?M$O]\T?:)?[YJ*BBR#F?<E^T2_WS4MO+(\P#-D8J
MK4UK_KQ]#2:5AQ;NB_1116)TA1110 4444 %%%(> 3C- "T5QG@C7M0U>[O(
M[VY6=?*2<!4"^2S,X,?'H%'7FLWXJZQJ>DV^G'3[B2V64R(\D;X)X'&/ZU=.
M#G)174BI-0BY/H=[+;&20MN S[4S[$?[X_*OG33/$6M:;?I<V=_<F4N,HSEQ
M)ST(/7->QW7B3Q=9:?+>W'A:S6&&,RN?[3&0 ,GC9U]JVK4I4;:W,*-2%:^A
MU'V(_P!\?E1]B/\ ?'Y5Q,?COQ')I5YJ(\+VZV]FQ68/J(#*0 <8V>A%6M.\
M5>*]4@DFM_"MJ%BE:)Q)J04JR]01LK#G9O[.)UGV1@,>9Q1]D;&/,X]*Y[^V
M/&AZ>%;+_P &@_\ B*7^U_&G_0J67_@T'_Q%'.P]G$Z#[&Q_Y:?I0;-CUDS^
M%<__ &OXT_Z%2R_\&@_^(H_M?QI_T*EE_P"#0?\ Q%'.P]G$Z#[$?[X_*C[$
M?[X_*N?_ +7\:?\ 0J67_@T'_P 11_:_C3_H5++_ ,&@_P#B*.=A[.)T'V(_
MWQ^5/AMC%)N+9X]*YS^U_&G_ $*EE_X-!_\ $4?VOXT_Z%2R_P#!H/\ XBCF
M8*$5J=717*?VOXT_Z%2R_P#!H/\ XBC^U_&G_0J67_@T'_Q%26=717*?VOXT
M_P"A4LO_  :#_P"(H_M?QI_T*EE_X-!_\10!OR6LC2,P*X)S3?LDGJM87]K^
M-/\ H5++_P &@_\ B*/[7\:?]"I9?^#0?_$57.S/V<3=^R2>JT?9)/5:PO[7
M\:?]"I9?^#0?_$4?VOXT_P"A4LO_  :#_P"(I\[#V43=^R2>JT?9)/5:PO[7
M\:?]"I9?^#0?_$4?VOXT_P"A4LO_  :#_P"(HYV'LHF[]DD]5H^R2>JUA?VO
MXT_Z%2R_\&@_^(H_M?QI_P!"I9?^#0?_ !%'.P]E$W?LDGJM'V23U6L+^U_&
MG_0J67_@T'_Q%']K^-/^A4LO_!H/_B*.=A[*)N_9)/5:/LDGJM87]K^-/^A4
MLO\ P:#_ .(H_M?QI_T*EE_X-!_\11SL/91-QK%F*EEC8J<J2,X^E-.G MN,
M<);^\5&?SQ6+_:_C3_H5++_P:#_XBC^U_&G_ $*EE_X-!_\ $4<[#V<3;73]
MF=D<2YZ[5 S^E(-. 5E$4(#?> 08/UXK%_M?QI_T*EE_X-!_\11_:_C3_H5+
M+_P:#_XBESL/9Q-O[!_L1=OX1VZ4G]G#)/E0Y/).P<_I6+_:_C3_ *%2R_\
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M (BCG8>RB;OV23U6C[))ZK6%_:_C3_H5++_P:#_XBC^U_&G_ $*EE_X-!_\
M$4<[#V43=^R2>JT?9)/5:PO[7\:?]"I9?^#0?_$4?VOXT_Z%2R_\&@_^(HYV
M'LHF[]DD]5H^R2>JUA?VOXT_Z%2R_P#!H/\ XBC^U_&G_0J67_@T'_Q%'.P]
ME$W?LDGJM206[QR[FQC':N>_M?QI_P!"I9?^#0?_ !%']K^-/^A4LO\ P:#_
M .(I.;8U32=SJZ*Y3^U_&G_0J67_ (-!_P#$4?VOXT_Z%2R_\&@_^(J2SJZ*
MYRPU/Q5-?PQWOAVUMK5FQ),FH!R@QU"[1GM71T %%%% !1110!C:O-!X<T/4
M=1LK.!90IE8*H42.> 6QUZUQ^IZY/>6=K-?6=I/<QRW-BR,I,+OYD:!L'G'.
M<=:]#NK6"]M9;6YC62"52CHW1@:YBZ\-Z3%JVE:<MK_HKVURC(78Y!*-G.<[
ML\YZT >8:Q8+I4VF:_;6L=O!,[Q2)%DI%-&Y4E<\@'&X?C7L%A<6_BOPLZ2G
MBXB:&;:>02,''\ZCUKPK9ZAX2ET.VB6*-4S;]]CCD')]^I]S7 _#;6KBSNKG
M29% N,&-8Y#@>8N< ^G<?E3K-M1J]M'^C^_1^I6'2M*C_P!O1^7Q+[M5Z,[6
MU\(!-'NM.EU*66.[\S[2QB4&1V"A6'IM"CCO6KHNCC1=-DMS</<RRR/-+,RA
M2[MU.!TK&(O8O%^FW=UYRAK*<W$43L\*,I7&!CKU]S6;"]Y<_$5+A%O/*EPZ
MEE<1_93!T(/ /F=CSFD2=ZG^K7Z"G4U/]6OT%4M:U>WT+2YM0NDF>&(980QE
MV_(=O>@"_163J_B"VT?3H+R6&>;SR%CBA4%V.TL>_8 G\*O6]W'>VEM=6[;H
M9U61#ZJ1D4 6**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'YT .HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT
M.HIN]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN
M]?[P_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P
M_.C>O]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>
MO]X?G0 ZBF[U_O#\Z-Z_WA^= #J*;O7^\/SHWK_>'YT .HIN]?[P_.C>O]X?
MG0 ZBD#*3@,/SI: "BBB@ JO=6-K>M"US;QRM"XDB+KG8PZ$>]6** ,30- E
MT1[QGU&2\^U2F9C+&H;<?4CD\8 '8"GWW_(TZ1_UQN?_ &2MBL>^_P"1IT?_
M *XW/_LE &Q@>E&!Z55U&^&GV,MSY$UPR 8AA7<[DG  'XUE'Q;8)X5_M^5)
M8[?[OEL!OW[MFWKC[W?.* -R2))8WC=0R."K ]P:\U\".WAWQ;K/A6<GRRQF
MML]Q[?52/RKT>UN%NK2&X7 61 X 8-C(]1P?PKR#XE:P-/\ '5G<Z<#%J%G$
M"\I'#9R5&._!/YUT8=.=Z?='/B&H6J=F>Q1 &).!]T5Q>F_\2/QC>::WRV]V
M-\7IGJ/ZBL+P5\2M0U'6;?2M5BB<7!V131+M*MC@$=QQ5[QEJ]M+K%O]D#"Z
MLV^:0C SG('O7GYA!X?EG+=/[^YZN4OZRYTX[26OD]T_O.RU^\L;+2)GOT62
M)AM$1_Y:'L*XK1O!T^H>3=W9^SVDIW",9WD=OH*LZ0[>,->^T:BRB*U4,ELH
M.TFNTO9KB VPM[-K@-*%?;(J^6O][GKCT%81A'%R]I)>ZMO/U_R.F56> A[&
M#]]ZOLNR7GW9+:6=O8VR6]M$L<2#"J*GP/2N%\+ZTC7FL/\ VV][#YPAMTN'
M&]Y1NR54?=4GA1_LYJ?X=ZQ>ZKI]X+]VEGCD5WFWDC<XR4P0-I3&"!7<DDK(
M\IMMW9V>!Z48'I113$&!Z48'I110 8'I1@>E(3@$GH*4'(S0 8'I1@>E%% !
M@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E
M%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110 8'I
M1@>E%% !@>E&!Z444 &!Z48'I110 8'I1@>E%% !@>E&!Z444 &!Z48'I110
M 8'I1110 4444 %%%5;RT>Z: K=3P>5('(B( D_V6R.E $6FZWINKM.MA=QS
MM VV0+GY3_AP>?:JU]_R-.C_ /7&X_\ 9*I>&]'U*QU;5;[4!;H;LH$2%RX^
M7(R"1\J\C"]N:N7X!\4:/G_GC<_^R4 /U;0H]0BNWMI397]Q#Y!O(URZIGH,
MUG2^$I9]"BTJ34E\J!8_)V6J@(Z-D,5SR,8!!Z]:Z78OI1L7TH I:+I<>B:-
M:Z;"[.ENFT,PP3W)QVY/2L/Q7X#T[Q1(MS([VUZB[1-'_$.P8=ZZG8OI2%%P
M>*J,Y0=XLF4%-6DCR3X7Z380>([^&_B8:Q9$B(,?E"]"0/7^AKT77/#UCK,>
M^93'.N,2I]['H?6L";PS%J7C[^TK6[FLWMK5/M#0X#2.V0!S_LCG\*V95N='
MN[5)+N6[LKJ00?O\&2)R,J0P R#C!!Z<4\2XUW[VJ885SP^L'9KJC4T_3;72
M[46]I$$0=3W8^I/>K#]4_P!ZEV+Z4QT7*<?Q5FDHJR+E*4GS2=V.$4:G(C4'
MU IP55SM &3G@4FQ?2C8OI3$.HINQ?2C8OI0 ZBF[%]*-B^E !)_JV^AI5^Z
M/I4-P\$$#/,\<:8^\[8'YFG0F&:)7B9'0CAE.0?QH EHINQ/05FZ;K>E:NUR
MME.)#;']X"C+@'.#R!D'!Y'I0!J45G:3JUAK5NT]B7>('&YHF0-[C(&1[BK^
MQ?2@!U%-V+Z4;%]* '44W8OI1L7TH =13=B^E&Q?2@!U%-V+Z4;%]* '44W8
MOI1L7TH =13=B^E&Q?2@!U%-V+Z4;%]* '44W8OI1L7TH =13=B^E&Q?2@!U
M%-V+Z4;%]* '44W8OI1L7TH =13=B^E&Q?2@!U%-V+Z4;%]* '44W8OI1L7T
MH =13=B^E&Q?2@!U%-V+Z4;%]* '44T(H.0*=0 4444 %%%% !6/??\ (TZ/
M_P!<;G_V2M8.C.R*REE^\ >1]:R;[_D:='_ZXW/_ +)0!L4444 %(>AI:8\L
M2.J/(BL_"J6 +?3UH RI[*\ANTU'3O*:1XECG@E)59 /ND$ X89/;D&N.F\7
MZAJNI7D2:,S7>CN)%T[S1NE.<,^[OM!X ZY!KT7S(HF2$R*'8?*I89;'H*^?
M_$OB:[E\;7>J6 -C/$Q@5H_O$+\N6]S_ (5T4*/M;HYZ];V5F>V>'?$NG^)K
M)Y[)I%>)MD\,JE7B;^ZPK5?JG^]7DWA75-2\;V=YI4U[)97\!6ZCO[10C.PX
M D X:NQTV^\2QQ1Z9J,-E-JJL6$R,1'Y(X$C ="3P%'H>E95*;IRY6:TZBJ1
MYD=716(^JWFDRI_;7V46LF0+N$E51L9PX/0''!S4-AXX\/:IJBZ=I^H+=7+*
MS 1*2.!D_-C%06=#17(Z?XRO]4U.""V\+:HEJ\FV2ZN%$:H/7!Y-)+_PGMUJ
M;",Z196*3?*QW2/)&#^0)% '7U7N;ZTLDW75U# O7,L@7^=<WJO@Z^UC4YYI
M_$^IPV;D%+2V81A!CINZFK=]X(\/ZI?)>:C8"[N$C6+=,Y((7ID9QF@"+3Y=
M.UW7;Y[B2&ZD@V_9HF^95B*@^8!T.XD\^U6/LT.E^)+-+%%BCO4D\^%.%^4
MA\=CDXSWR*DN/#]M$J3:8S:?<0P>3&T &"@Y"E2"" :I>$F^T&ZN+N62?40=
MCRR$9"=0H X49STK.52,9J#W?Z";2=C=O+(7;0$W%Q#Y,@<"&3:']F]1[5SV
MDZ'K-EJ.I7=P]B[7TB+(JER-BA@6&>03D?+G P?6NKHK09SGA+0;O0HKQ+EX
M%2613%!;%S'& N"1N.1NZD=JZ.BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY4?/ZK^5 #J*;\_JOY4?/ZK^5 #J*;\_JOY4?/ZK^5 #J*;\_JOY4?/ZK^5
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M<X]?6G:#H.JZ9XMU&[F?%C<R22'][N$KLP*G;_"5 (/K794Q^J?[U #Z***
M"BBB@ HHHH **** . U3P_J$-]*T<+3QR.65TYZ^M:'@Z,1W=V'?;, %,1X/
M7K762?P?[PK!U[3I89EU>P&+B+F11_&M>5+!1P\_;PUL[M>7EZ&#I\KYD;-Y
M8P7UM+!,IVRH49D8JP'LPY%9<7A33X;!K..6\6)E8,1<,&+%]Y<G^_GO^%:&
MF:C%J=DMQ$<'HR]U/I5RO3C)3BI1V9LG=713TO3+;2-/CLK16$29/S-N8DG)
M)/<DDFKE,3[S_6GU0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MW/UIU% #=S?W/UHW-_<_6G44 -W-_<_6C<W]S]:=10 W<W]S]:-S?W/UIU%
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MP]ZT;BSLKL8N+>.3W*<_G7#AL)B*"=I)^6MC.$)1ZEB.6.5=T;JZ^JG-*_\
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M*6W_ 'W5G^R--_Y\+;_OTO\ A1_9&F_\^%M_WZ7_  K&U?NOQ.F^%[2^^/\
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MVK_='Y4;5_NC\J #</44;AZBC:O]T?E1M7^Z/RH ,CU%+2;5'8?E2T %%%%
M!1110 5CWW_(TZ/_ -<;G_V2I],US3M9:X6PN5F,#;9, C'7D9ZC@\CCBH+[
M_D:='_ZXW/\ [)0!L444R:5((9)I#M2-2S'T Y- #Z*Y/_A97A,_\Q9?^_;_
M .%'_"RO">/^0JO_ '[?_"M?85?Y7]Q//'N=917SWJGQ \0WVJ274&I36L6\
M^5#$0%5>V1W_ !KT?0?B?HTVBV[:Q>I!?@;9D$;8)'<8'?K6D\)4BDUKZ&-/
M$PG)I'>T5R?_  LKPG_T%5_[]O\ X5TEA?6VIV,-[:2>9;S+NC?!&1^-8RIS
M@KR5C=23V98HJ@=09=<:Q95$2VOGE^^=Q&/I6*GCK3Y8C)%;74BC+':JG"
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MN- HIC']ZGT-/H **** "BFHV]-V,=:=0 4444 %%%% !1110 4444 %%%%
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M*S;/0+Z/PK/HQN+=DEM94\P*V1,[,2?]WYN.]=!86[6FGVULS!FAB6,D="0
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MD,W'RE@#A>]=M%)YL*2;2NY0V&ZC/K7(/\-]+:S:W^UW@)<%7WJ2J!2@3IC
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/ 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>figure_003.jpg
<TEXT>
begin 644 figure_003.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" (# >$# 2(  A$! Q$!_\0
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M'Z/_ .@FO2?'G_)-6_W(?Z5YM\-_^1YL?H__ *":='^!+YDUOX\?D=O\8O\
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MH'_(Q:=_U\I_Z$*SPOPS_KN:8KXH?UV/5?C!_P B_9_]?']*YWX0?\C#>?\
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M3_,\1\+?\C3I7_7S'_.O2/C)_P @W2O^NS_^@UYMX7 /BC2@1D?:8_YUZ/\
M&*-$T[2RJ@$S/T_W:JK_ +Q BE_ F9OP<_Y"^I_]<%_]"KGOB)_R/.H_5?\
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M>/J>Q^"_^2?6'_7NW]:\"/\ R$#_ -=?ZU[[X+_Y)]8?]>[?UKP(_P#(0/\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ (!ZC-( !T
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MNE_'G\B:O\"'S/>C_P D\_[AO_M.O!] _P"1BT[_ *^4_P#0A7O!_P"2>?\
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M'Y&H8-+T^UE$MO8VT,@& \<2J?S KIA74:3IVW.:=!RJJ=]CR+XP?\C)9?\
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M*X[4/A)>WNHW5TNJVZB:5I IC/&3FKIUJ:JRDWHR*E&HZ48I:H[4_P#)//\
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M_P#0JY[XB?\ (\ZC]5_]!%=#\'/^0OJ?_7!?_0JY[XB?\CSJ/U7_ -!%$?\
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M &?='3UN_L3:CQY0F_NXSG&>,T =?1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %(WW#]*6D;[A^E 'S!J7_ "%[O_KNW_H5>^:M_P DZG_[
M!X_] %>!ZE_R%[O_ *[M_P"A5[YJW_).I_\ L'C_ - %>GBOL>O^1YN%^WZ?
MYGAWA;_D:=*_Z^8_YUZ1\9/^0;I7_79__0:\W\+?\C3I7_7S'_.O2/C)_P @
MW2O^NS_^@U57_>($4OX$S+^#G_(7U/\ ZX+_ .A5SWQ$_P"1YU'ZK_Z"*Z'X
M.?\ (7U/_K@O_H5<]\1/^1YU'ZK_ .@BB/\ O,O0)?[M'U/6/AQ_R(.E_P"[
M)_Z,:NJKE?AQ_P B#I?^[)_Z,:NJKSJO\27J>C2_AQ] HHHK,T#-%-S10 ZB
MBB@ HHHH *Q]8A\027$#:1>V,%NH_?+<0-(S<_PD$8XK8HH \M&KRZ]XO@GU
M?2]8AT^SG'V&UCL7*.^<>;(V,?053?3=3-M)X5.F7GVE];%X+D1GR/)W!MV_
MIGCIUKUZB@ I&S@[2 ?>EHH BVS_ -]/^^:-L_\ ?3_OFI:* (ML_P#?3_OF
MC;/_ 'T_[YJ6B@"+;/\ WT_[YHVS_P!]/^^:EHH BVS_ -]/^^:-L_\ ?3_O
MFI:* (ML_P#?3_OFC;/_ 'T_[YJ6B@"+;/\ WT_[YHVS_P!]/^^:EHH BVS_
M -]/^^:-L_\ ?3_OFI:* (ML_P#?3_OFC;/_ 'T_[YJ6B@"+;/\ WT_[YHVS
M_P!]/^^:EHH BVS_ -]/^^:-L_\ ?3_OFI:* (ML_P#?3_OFC;/_ 'T_[YJ6
MB@"+;/\ WT_[YHVS_P!]/^^:EHH BVS_ -]/^^:-L_\ ?3_OFI:* (ML_P#?
M3_OFC;/_ 'T_[YJ6B@"+;/\ WT_[YHVS_P!]/^^:EHH BVS_ -]/^^:-L_\
M?3_OFI:* (ML_P#?3_OFC;/_ 'T_[YJ6B@"+;/\ WT_[YHVS_P!]/^^:EHH
MBVS_ -]/^^:-L_\ ?3_OFI:* (ML_P#?3_OFD*SD8WI_WS4U% '"S?"O0YYY
M)G>YWNQ<XD[DY]*ZBYTK[3H[Z6\F+=X?)R!\P7&/SK2HJY5)RM=[$1IPC>RW
M.#L/A9I.G7]O>0W5T9('$BAF&"1Z\5E_&$2#3=+WLI_?/T'^S7J%136T%P )
MX8Y0.0'4-C\ZN->2FIRUL1*A%P<(Z7/(O@[N_MC4L<#R%SD?[5<_\1/^1YU'
MZK_Z"*]\AM+:W),%O%$3P2B!<_E7@?Q$_P"1YU'ZK_Z"*Z\/4]I6<O(Y*]/V
M=%1\SUCX<?\ (@Z7_NR?^C&KJJY7X<?\B#I?^[)_Z,:NJKBJ_P 27J=M+^''
MT"BBBLS02BDQ10 ZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "OGWXB?\ (\ZC]5_]!%?0
M5?/OQ$_Y'G4?JO\ Z"*[,%_$?H<>-^!>IZQ\./\ D0=+_P!V3_T8U=57*_#C
M_D0=+_W9/_1C5U5<]7^)+U.BE_#CZ!11169H)11Q10 M%%% !1110 4444 %
M%>?W'B?Q3I^HV-QJ-I9PV=[??9(]/P3<;><2;@2#ZXQWJ%/&E_>^,;K38=9T
MBS@AN_(C@N(':24#&[# [1GD"@#T:BBB@ HHHH **** "BBB@ HHHH ****
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M]X1\0WTLFDR_V=_93Z@+P7JJ$F500=NQ5 )XQNS7HU%  !@8I",@@''O2T4
M1>4__/9_R%'E/_SV?\A4M% $7E/_ ,]G_(4>4_\ SV?\A4M% $7E/_SV?\A1
MY3_\]G_(5+10!%Y3_P#/9_R%'E/_ ,]G_(5+10!%Y3_\]G_(4>4__/9_R%2T
M4 1>4_\ SV?\A1Y3_P#/9_R%2T4 1>4__/9_R%'E/_SV?\A4M% $7E/_ ,]G
M_(4>4_\ SV?\A4M% $7E/_SV?\A1Y3_\]G_(5+10!%Y3_P#/9_R%'E/_ ,]G
M_(5+10!%Y3_\]G_(4>4__/9_R%2T4 1>4_\ SV?\A1Y3_P#/9_R%2T4 1>4_
M_/9_R%'E/_SV?\A4M% $7E/_ ,]G_(4>4_\ SV?\A4M% $7E/_SV?\A1Y3_\
M]G_(5+10!%Y3_P#/9_R%'E/_ ,]G_(5+10!%Y3_\]G_(4>4__/9_R%2T4 1>
M4_\ SV?\A1Y3_P#/9_R%2T4 1>4__/9_R%'E/_SV?\A4M% $7E/_ ,]G_(4>
M4_\ SV?\A4M% $7E/_SV?\A1Y3_\]G_(5+10!%Y3_P#/9_R%'E/_ ,]G_(5+
M10!&L;!@3*Q]CBO ?B)_R/.H_5?_ $$5]!5\^_$3_D>=1^J_^@BNS!?Q'Z''
MC?@7J>L?#C_D0=+_ -V3_P!&-755ROPX_P"1!TO_ '9/_1C5U5<]7^)+U.BE
M_#CZ!11169H)1110 M%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M:7#=&[BT]@-BR^N[J1GG%*WP_MSJIF_M*Y&F-=_;FT[:NPS>N[KC/.*[&B@
MI",@C)'TI:* (O)_Z:2?]]4>3_TUD_[ZJ6B@"+R?^FLG_?5'D_\ 363_ +ZJ
M6B@"+R?^FLG_ 'U1Y/\ TUD_[ZJ6B@"+R?\ IK)_WU1Y/_363_OJI:* (O)_
MZ:R?]]4>3_TUD_[ZJ6B@"+R?^FLG_?5'D_\ 363_ +ZJ6B@"+R?^FLG_ 'U1
MY/\ TUD_[ZJ6B@"+R?\ IK)_WU1Y/_363_OJI:* (O)_Z:R?]]4>3_TUD_[Z
MJ6B@"+R?^FLG_?5'D_\ 363_ +ZJ6B@"+R?^FLG_ 'U1Y/\ TUD_[ZJ6B@"+
MR?\ IK)_WU1Y/_363_OJI:* (O)_Z:R?]]4>3_TUD_[ZJ6B@"+R?^FLG_?5'
MD_\ 363_ +ZJ6B@"+R?^FLG_ 'U1Y/\ TUD_[ZJ6B@"+R?\ IK)_WU1Y/_36
M3_OJI:* (O)_Z:R?]]4>3_TUD_[ZJ6B@"+R?^FLG_?5'D_\ 363_ +ZJ6B@"
M+R?^FLG_ 'U1Y/\ TUD_[ZJ6B@"+R?\ IK)_WU1Y/_363_OJI:* (O)_Z:R?
M]]4>3_TUD_[ZJ6B@"+R?^FLG_?5'D_\ 363_ +ZJ6B@"-8MI!\QS[$UX#\1/
M^1YU'ZK_ .@BOH*OGWXB?\CSJ/U7_P!!%=F"_B/T./&_ O4]8^''_(@Z7_NR
M?^C&KJJY7X<?\B#I?^[)_P"C&KJJYZO\27J=%+^''T"BBBLS02BBB@!:***
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M9LD#O\_ [CB@#V&B@<CTHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MKS[2=6\<>(+:2^L)=%CM?/DCC6:%RVU6QGAJ /0:*;'O\M?,QOP-V.F>].H
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MG/-='I$,5[\4/$4MTBR26]O!'"'7.Q"#G&?6IK3P-=68AM8_$VH_V5"X>.T
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MX_/G/2I?#_B:]U#6;S1M6TU;"_MXUF"I+YB.C<9!P* .CEEC@3?+(D:=-SL
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M)JWXBNX;;QGX.O+G%I;XF!,N%$9:/A2>@ZXKK6T72GU 7[:;:-> Y$YA7?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
;4444 %%%% !1110 4444 %%%% "4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>figure_004.jpg
<TEXT>
begin 644 figure_004.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $C 9D# 2(  A$! Q$!_\0
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M^TS?W_THY&'M4:%%9_VF;^_^E'VF;^_^E'(P]JC0HK/^TS?W_P!*/M,W]_\
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M*,#TH PO^$<C_P"@UK'_ (&FC_A'(_\ H-:Q_P"!IK=P/2C ]* ,+_A'(_\
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M[QSCH>.N*W_!^E7FC^'HK2^""82.P13D(I;@=3VYZ]36\)<\5*UKE)W5Q?\
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M4Z.*.%-D4:1KDG"K@9/)-/HH H:=_P ?&H_]?/\ [(E7ZH:=_K]1_P"OH_\
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M/UHV+Z?K3J* &[%]/UHV+Z?K3J* &[%]/UHV+Z?K3J* &[%]/UHV+Z?K3J*
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MIHUE]DLD*0AV<*3G!)S^5 #-*Z7G_7U)_.M"L[2U!6\S_P _<G\ZO[![_G0
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M](@U"$!5E&2@;.P^A]Z #2ON7?\ U]2_SK0K.THX2[Z_\?<O;_:K0W#T/Y4
M+12;AZ'\J-P]#^5 "T4FX>A_*C</0_E0 M%)N'H?RHW#T/Y4 +12;AZ'\J-P
M]#^5 "T4FX>A_*C</0_E0 M%)N'H?RHW#T/Y4 -FE6""25_NHI8_A65X;B8:
M8;F3_674C2L?J>*3Q),PTP6T>?,NI%B7CU/-:D*+!!'"@.U%"CCTK#XJW^%?
MB_\ @(C>7H2T4FX>A_*C</0_E6Y8M%)N'H?RHW#T/Y4 +12;AZ'\J-P]#^5
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M M%)M/\ >-&T_P!XT +12;3_ 'C1M/\ >- "T4FT_P!XT;3_ 'C0 M%)M/\
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M48'H*6B@!,#T%&!Z"EHH 3 ]!1@>@I:* $P/048'H*6B@!,#T%&!Z"EHH 3
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
;"BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>figure_005.jpg
<TEXT>
begin 644 figure_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 'B ;0# 2(  A$! Q$!_\0
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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ME_&G\SR'0?\ D8=-_P"OJ/\ ]"%>F?&3_CQTK_KI)_(5YGH/_(PZ;_U]1_\
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M_P"+\CEQG\/YG9?"_P#Y$.X_Z[2_^@BO&K?_ (_HO^NH_G7LOPO_ .1#N/\
MKM+_ .@BO&K?_C^B_P"NH_G771_B5/4Y*W\.GZ'L7Q:_Y%&S_P"OE?\ T$US
M'PA_Y&:Z_P"O8_S%=/\ %K_D4;/_ *^5_P#037,?"'_D9KK_ *]C_,5E3_W5
M_,UJ?[ROD9?Q*_Y'F]_W4_\ 017H/A3_ ))(W_7M-_6O/OB5_P CS>_[J?\
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MO_7H/_0FKI_A%_R+%W_U\'_T$5S'Q>_Y&BU_Z]!_Z$U=/\(O^18N_P#KX/\
MZ"*F?^ZKY%0_WI_,\?F_Y"4G_7<_^A5[)\3?^1 @_P"ND7\J\;F_Y"4G_7<_
M^A5[)\3?^1 @_P"ND7\JVK?Q*?J94?X=0XSX4?\ (Y?]N[_TJ+XI?\CM-_UQ
MC_E4OPH_Y'+_ +=W_I47Q2_Y':;_ *XQ_P J/^8GY"_YAOF=O\/_ /DF,_TN
M/ZUX[I__ "%;3_KNG_H0KV+X?_\ ),9_I<?UKQW3_P#D*VG_ %W3_P!"%*C\
M=3U'6^&GZ'K?QB_Y 6G_ /7R?_036%\'?^0[J'_7L/\ T(5N_&+_ ) 6G_\
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M_GC+_P!\T>>?^>,O_?- $U%0^>?^>,O_ 'S1YY_YXR_]\T 345#YY_YXR_\
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M:U/]Y7R,WXE?\CS>_P"ZG_H(KT'PI_R21O\ KVF_K7GGQ(;=XXO3@CY4X/\
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M!7EL+.:XBN);2"2>'_5R-&"R?0]JL444 %%%% !1110 4444 %%%% !1110
M4444 %<K\0]0N],\)2W-C</!.)4 =#S@FNJKC/BE_P B3-_UV3^=:T5>I%/N
M9UG:G*W8Y#X=^)M;U3Q?#;7VISSP&&0F-SP2!Q6?\6/^1R'_ %[)_6H?A9_R
M/,'_ %PD_E4WQ8_Y'(?]>R?UKT$DL3IV//;;P^O<[+X7_P#(AW'_ %VE_P#0
M17C5O_Q_1?\ 74?SKV7X7_\ (AW'_7:7_P!!%>-6_P#Q_1?]=1_.G1_B5/45
M;^'3]#V+XM?\BC9_]?*_^@FN8^$/_(S77_7L?YBNG^+7_(HV?_7RO_H)KF/A
M#_R,UU_U['^8K*G_ +J_F:U/]Y7R,OXE?\CS>_[J?^@BO0?"G_))&_Z]IOZU
MY]\2O^1YO?\ =3_T$5Z#X4_Y)(W_ %[3?UIU?X,/D*E_&G\SR'0?^1ATW_KZ
MC_\ 0A7IGQD_X\=*_P"NDG\A7F>@_P#(PZ;_ -?4?_H0KTSXR?\ 'CI7_723
M^0K2K_'A\S*E_ G\BA\&_P#D(ZK_ -<4_F:X3Q)_R,6J?]?$G\S7=_!O_D(Z
MK_UQ3^9KA/$G_(Q:I_U\2?S-.'\>7HA3_@1]6>M>*/\ DD,7_7M;_P#LM>??
M#?\ Y'JP_P"!_P#H)KT'Q1_R2&+_ *]K?_V6O/OAO_R/5A_P/_T$UE1_@S^9
MK5_C0^1K?%[_ )&BU_Z]!_Z$U=/\(O\ D6+O_KX/_H(KF/B]_P C1:_]>@_]
M":NG^$7_ "+%W_U\'_T$5,_]U7R*A_O3^9X_-_R$I/\ KN?_ $*O9/B;_P B
M!!_UTB_E7C<W_(2D_P"NY_\ 0J]D^)O_ "($'_72+^5;5OXE/U,J/\.H<9\*
M/^1R_P"W=_Z5%\4O^1VF_P"N,?\ *I?A1_R.7_;N_P#2HOBE_P CM-_UQC_E
M1_S$_(7_ ##?,[?X?_\ ),9_I<?UKQW3_P#D*VG_ %W3_P!"%>Q?#_\ Y)C/
M]+C^M>.Z?_R%;3_KNG_H0I4?CJ>HZWPT_0];^,7_ " M/_Z^3_Z":PO@[_R'
M=0_Z]A_Z$*W?C%_R M/_ .OD_P#H)K"^#O\ R'=0_P"O8?\ H0K*'^ZO^NIK
M/_>E_70Y[XA?\CSJ?^^O_H(KT?1?^2./_P!><O\ 6O./B%_R/.I_[Z_^@BO1
M]%_Y(X__ %YR_P!:NK_"A\B:7\6?S/*/"W_(U:5_U\I_.OI6OFKPM_R-6E?]
M?*?SKZ5K+'?$C3 _"PHHHKA.X**** "BBB@ HHHH ***Y_QE;:0_AZXO-8MO
M/@LD:94\QDRV, 94CKTH Z"BO)(]!;3-'\,Z7=/*L>LWXEOHA*P&-N5BSG.!
MP.O)%266BZCK.BW%K:W"M:Z9?W=M$MQ,P"(0-CAN<["3C/YT >KT5Y[HOB*U
MBU@WVHR7,CW"16]M)M^5("VU7;GK(X)X!XQ7H5 !14;S1HVUG /H:3[3#_ST
M7\Z ):*B^TP_\]%_.C[3#_ST7\Z ):*B^TP_\]%_.C[3#_ST7\Z ):*B^TP_
M\]%_.C[3#_ST7\Z ):*B^TP_\]%_.C[3#_ST7\Z ):*B^TP_\]%_.C[3"?\
MEHOYT ,-]:*2#=0 CJ#(*Y/XHD'P1,0<@RQ\_C7B>JL?[5O2&./.?O[FO8/'
MTL;?#:(*X)Q!_*NWV'LIP=[W9Q>W]K":MLCA_A9_R/,'_7"3^53?%C_D<A_U
M[)_6H/A>ZIXW@+$ >1)U^E3?%9U?QB"I!'V9.GXUT_\ ,3\CG_YAOF=G\+_^
M1#N/^NTO_H(KQJW_ ./Z+_KJ/YU[%\,98U\"7 9P#YTO!_W17CL! OHCV\T?
MSHH_Q*GJ%;^'3]#V+XM?\BC9_P#7RO\ Z":YCX0_\C-=?]>Q_F*Z3XKRH_A*
MT"N"?M*]/]TUS/PD=4\3719@/]&/7ZBLJ?\ NK^9K4_WE?(S?B5_R/-[_NI_
MZ"*]!\*?\DD;_KVF_K7GOQ(96\<7I4@C:G3_ '17?^%98Q\)F4N,_9YN/SIU
M?X,/D*E_&G\SR30?^1ATW_KZC_\ 0A7IGQD_X\=*_P"NDG\A7F6A$#7]-)/'
MVF/_ -"%>E_&*1'L=+VL#^\DZ?05I5_CP^9E2_@3^12^#?\ R$=5_P"N*?S-
M<)XD_P"1BU3_ *^)/YFNY^#KJFHZIN8#,2=?J:X7Q&0?$.ID'(^T2?S-.'\>
M7HA3_@1]6>M^*/\ DD,7_7M;_P#LM>??#?\ Y'JP_P"!_P#H)KOO$\L;?".-
M0X)^S0<?]\UP'PY94\<V!8@#Y^O^Z:RI?P9_,UJ_QH?(U_B]_P C1:_]>@_]
M":NG^$7_ "+%W_U\'_T$5RWQ<=7\3VI5@1]E'3_>:NF^$LL:>&;L,X!^T'K_
M +HJ:G^ZKY%0_P!Z?S/(IO\ D)2?]=S_ .A5[)\3?^1 @_ZZ1?RKQJ8C^T)#
MV\X_^A5[%\2Y8V\!0!7!/F1<#Z5M6_B4_4RH_P .IZ''_"C_ )'+_MW?^E1?
M%+_D=IO^N,?\J?\ "IU3QCEF 'V=^OX5'\4'5_&LQ4@CR8^GTH_YB?D+_F&^
M9W'P_P#^28S_ $N/ZUX[I_\ R%;3_KNG_H0KU_P!+&/AG.I<!O\ 2./P->06
M! U2U.>//3_T(4J/QU/4=;X:?H>M_&+_ ) 6G_\ 7R?_ $$UA?!W_D.ZA_U[
M#_T(5M?%^5'T*PVL#_I)Z?[IK#^$$B1Z[?EV _T8=?\ >%90_P!U?]=36?\
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MG_U\K_Z":YCX0_\ (S77_7L?YBLJ?^ZOYFM3_>5\C+^)7_(\WO\ NI_Z"*]
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M_P")I:?]=T_]"%*C\=3U'6^&GZ'K?QB_Y 6G_P#7R?\ T$UA?!W_ )#NH?\
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M +T_F>.:K_R%KW_KN_\ ,U[)X_\ ^2:1?2#^5>.:K_R%KW_KN_\ ,U['X_\
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MO^1YO?\ =3_T$5Z#X4_Y)(W_ %[3?UIU?X,/D*E_&G\SR'0?^1ATW_KZC_\
M0A7IGQD_X\=*_P"NDG\A7F>@_P#(PZ;_ -?4?_H0KTSXR?\ 'CI7_723^0K2
MK_'A\S*E_ G\BA\&_P#D(ZK_ -<4_F:X3Q)_R,6J?]?$G\S7=_!O_D(ZK_UR
M3^9KA/$G_(Q:I_U\2?S-.'\>7HA3_@1]6>M>*/\ DD,7_7M;_P#LM>??#?\
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MSKEE^ZI[**ZJB@ K \6:9?:C86S:?#9W$]M<+/\ 9[M 4E R",D':>>M;]%
M'F\7@S6H(DU:*&S34DU0WZZ>LA$2J1M*!\=<<YQBMO1M!O\ 3?#=\UQ:VMQJ
MMU<27@@)!CCE;[HW$=L#G%=;10!Y^_@_6+74+ VESN5/+>6X\XJ5EWEIF*_Q
M;\XKT"BB@!C1!FSN<?0TWR!_??\ [ZJ6B@"+R!_??_OJCR!_??\ [ZJ6B@"+
MR!_??_OJCR!_??\ [ZJ6B@",0@'.]_\ OJOF76QC6M0'_3>3^9KZ>KYAUO\
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MNK_KJ:S_ -Z7]=#GOB%_R/.I_P"^O_H(KT?1?^2./_UYR_UKSCXA?\CSJ?\
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M^1VF_P"N,?\ *C_F)^0O^8;YG:> 1+_PK2<AE"_Z1QCZUY!89_M.UQU\]/\
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M .@FO0?%'_)(8O\ KVM__9:\^^&__(]6'_ __0365'^#/YFM7^-#Y&M\7O\
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M%_U[6_\ [+7GWPW_ .1ZL/\ @?\ Z":RI?P9_,UJ_P :'R-3XN;_ /A)[7>
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M_O3^9XYJO_(6O?\ KN_\S7LGC_\ Y)I%](/Y5XWJO_(6O?\ KN_\S7LGC_\
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M -!-<Q\(?^1FNO\ KV/\Q65/_=7\S6I_O*^1E_$K_D>;W_=3_P!!%>@^%/\
MDDC?]>TW]:\^^)7_ "/-[_NI_P"@BO0?"G_))&_Z]IOZTZO\&'R%2_C3^9Y#
MH/\ R,.F_P#7U'_Z$*],^,G_ !XZ5_UTD_D*\ST'_D8=-_Z^H_\ T(5Z9\9/
M^/'2O^NDG\A6E7^/#YF5+^!/Y%#X-_\ (1U7_KBG\S7">)/^1BU3_KXD_F:[
MOX-_\A'5?^N*?S-<)XD_Y&+5/^OB3^9IP_CR]$*?\"/JSUKQ1_R2&+_KVM__
M &6O/OAO_P CU8?\#_\ 037H/BC_ ))#%_U[6_\ [+7GWPW_ .1ZL/\ @?\
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M4UG_ +TOZZ'/?$+_ )'G4_\ ?7_T$5Z/HO\ R1Q_^O.7^M><?$+_ )'G4_\
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M$U=+^!/YDU?X\/D7_BTP;Q5 1G_CU7J/<UUOPEE5?"DP.<_:FZ#V%<G\7/\
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M#?\ R$=5_P"N*?S-<)XD_P"1BU3_ *^)/YFG#^/+T0I_P(^K/6O%'_)(8O\
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M:%5G8M, @Q(2,$MZ\>M '!7VL:QI2W=M'+<!'6##7%Q%)-!O?:7R#@*1T+<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>7
<FILENAME>figure_006.jpg
<TEXT>
begin 644 figure_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $! 5T# 2(  A$! Q$!_\0
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M#R"* %HIDC.J91-[>F<5%YUU_P ^H_[^#_"@"Q15?SKK_GU'_?P?X4>==?\
M/J/^_@_PH X#5?#TU[XH\8W4NE&=9=*2.TE>+=N?8V0A]<@=/:HM%\/7%AJO
M@6>+2G@\FRF6]=8MNQC&.'/J3GKWKT3SKK_GU'_?P?X4>==?\^H_[^#_  H
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MZTN;49_#K0V1N1%JL33$1AML>#DM_L],U0L_#DLWBWQA=-8".66**.PNI(^
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MRU_,NFH7]]NWD5=6\5V.ERQQ -<.PW'RB"%'U_I6C;ZK8W-O',EU$%=0P#.
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MG_A=/@W_ )^+_P#\ )?_ (FNRU7I9_\ 7U'_ %K0H \]_P"%T^#/^?B__P#
M"7_XFC_A=/@S_GXO_P#P E_^)KT*B@#SW_A=/@S_ )^+_P#\ )?_ (FC_A=/
M@S_GXO\ _P  )?\ XFO0J* //?\ A=/@S_GXO_\ P E_^)H_X73X,_Y^+_\
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M^>O_ (Z?\*/[0M?^>O\ XZ?\* +-%5O[0M?^>O\ XZ?\*/[0M?\ GK_XZ?\
M"@"S15;^T+7_ )Z_^.G_  H_M"U_YZ_^.G_"@"S7)>.-;U72?[+ATC)GNY9$
MVK;^<S%8V90%R."0,G/ R:Z3^T+7_GK_ ..G_"HWNK"22.1]C/&248QDE21@
MX...* ,?5/$MWHUKIOVG3XFN;F,&9!*P$;X&0,(V1DGTZ5G>(O%&HZ=XC%I;
M26R10+:L;>1,O=^=*8R$.1C:!G@'GK76_P!H6O\ SU_\=/\ A6==7EF^L69:
MUMI6 8QW#K\\6,9V_+WSV- '/ZSXPN[;Q%Y5G<V?V.%K5?*8;FNA,[*S*P/
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M^>J?]]"CSX?^>J?]]"C[/!_SQC_[Y%'V>#_GC'_WR* #SX?^>J?]]"CSX?\
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MB+#$B'_3(OXA[UI>?#_SU3_OH5E:W9)(+'8WDXNT^XB\_F#6I]G@_P">,?\
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M?\\8_P#OD5N<XHFB8@"1"3V#"GU&((5(*Q(".A"BI* ,KQ+_ ,BY??\ 7/\
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M/_QX_P"-6:* *W]GVO\ SS_\>/\ C1_9]K_SS_\ 'C_C5FB@"M_9]K_SS_\
M'C_C1_9]K_SS_P#'C_C5FB@"M_9]K_SS_P#'C_C1_9]K_P \_P#QX_XU9HH
MK?V?:_\ //\ \>/^-']GVO\ SS_\>/\ C5FB@"M_9]K_ ,\__'C_ (T?V?:_
M\\__ !X_XU9HH K?V?:_\\__ !X_XT?V?:_\\_\ QX_XU9HH K?V?:_\\_\
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ML?\ ?H?XU9HH K>3=?\ /V/^_0_QJC<17/\ ;%B#= G9+@^6/]GWK7JA<_\
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M^^V_PH M5F7<\2Z]8(7PVR08P>^W'\C5G.H?W+;_ +[;_"C.H?W+;_OMO\*
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MR:CV2_F7W_\  #V[_DE]W_!.IIIC0@@HN&.2,=:YC[?XI_Y]+7\FH^W^*?\
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8H **** "BBB@ HHHH **** "BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>8
<FILENAME>figure_007.jpg
<TEXT>
begin 644 figure_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $  30# 2(  A$! Q$!_\0
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M0Z.J2^6/G"OC#8/!QG% '145S\7C'2#<6=I-<;+JX2(D+&[(C2 %5+XP"<\
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M")KAQ?,0%*LRX_=Y/W>?ZUH/XZT.VG%M=W#Q3@1^9B&1D1G0.HW!<<@\>IH
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M0!F?\(MH?_0,M_\ OFC_ (1;0_\ H&6__?-:8GA8 B5"#R"&'-*)8R<!U)]
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MR[ARQ[&8GAW1HXU0:7:84 #,*D_RJ&[\-:?+$GV2WM[.XCD22.>*!<J5(/\
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M:Q_["%M_Z,% &O1110 4444 %9USIK3ZG%>+*JF,#@IDY&[H<\ [N?H*T:*
M,"XTF6U\/7\27?DR.KR-)!&HR-N,;6R!P,<?SK2T;_D!Z?\ ]>T?_H(I^I_\
M@J\_ZX/_ .@FF:-_R ]/_P"O:/\ ]!% %VBBB@ HHHH **** "BBB@ HHHH
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MQ]_.:VK.WFEL;>2'4)%B:-615B0 *1P!\OI0 ^XO+VTMI+B>"U2*-2S,;AN
M/^ 52TWQ!-JLC);6T65C23]Y*5R&&1CY<]^?>K5Y:W*64[O>2SJJ%C$8X_GP
M,XY&*QM!-O/J$T%D9+61+6&1F$,8RK X4?+T&!R.OX4 =#YFI?\ /K:_]_V_
M^(K+U#Q(^FW0M9K>)[@IO$<4I8D9  ^[U.?T-:?V2[_Z"4W_ '[3_"N=\0B"
MUDF:_C>ZV6C2B3R8B6 91L^[D<D'/04 ;\%U?7$$<\5O;&.10ZGSVY!&1_!2
M7-YJ%K;23M9PNJ+N*QS$L?H-M%O;7#VT3Q:A*L;("JB*, #' ^[4&J6LR:5=
M/-=2W$:1,[0[(QOP,XSCCI0!'IVN76J.ZV]B@"QI)O>4A2'&1CY>N.U:'F:E
M_P ^MK_W_;_XBL319/.N[FSM9FMUCCBES&L9# K@ @+P0% QZ8K:^R7?_02F
M_P"_:?X4 9E_XBN-.N'AFT_<Z1>;^[D)#+D XRHR<D<>])K4EZ\%@9K>&-#?
MVQ.V4EA^\';:/YUGZTZ:?>W$TJF:>*W6;S7$2[P'^Z,KU&T$>O J_K$,_P!F
MT^5[V25#?6QV,B#K(OH* .BHHHH @N;2.Z";VD4QMN5HW*D'!'4>QJN^DQ2(
M4>XNF1A@JTQ((J_10!ER:!932"27S9''\3N2?SJ,^&=,*;#$VW 7&[C Z"MB
MB@#,70;-$E1&G19L^8%E(WYX.<=:A3PS911K''<:BJ* JJ+Z7  Z#[U;-% '
M/S^'%-[:F+4+]81O\U#?2Y?CC'/8U9_X1VU_Y^M2_P# Z7_XJI[K33<:E!=^
M8 (\9!7)X)/![9SSZ@5H4 8[>&[-U*M<:@RGJ&O92#_X]0/#=FH 6XU$ # Q
M?2CC_OJMBB@#(_X1VU_Y^M2_\#I?_BJ;_P (Q8ERYFORQ&"WVR7)'UW5LT4
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MM X X'X9/N30!5_X1VU_Y^M2_P# Z7_XJC_A';7_ )^M2_\  Z7_ .*K7HH
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MC9]VT,X!;:,MCZ#FJ5]I#W,44<,RH%@DMG++U1\9( XR-OTIFH:(U]?0W;7
M#(KH8G3<A4HRX'0\[LGGG'TI<WF!:&HP,T2C4F!E^X"2-W8=1W/3UJT1-_S\
MR_G61'I%VLD2O/ ;19?.:W7< &!&T _W1C=C^\?05LYJ6WW%<9B;_GYE_.C]
>_P#\_4OYTZDS2YF%QO[_ /Y^I?SHI<T4<S[@?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>figure_008.jpg
<TEXT>
begin 644 figure_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $+ 5 # 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ IHDC9MH=2?0&G5X3;:?B*PNI;2RLK:XU=T_MI&8S1,)FPK
M#@ -C:#G'K0![M17G$WBR_?QA!:VNH2-:RZD]BZ/'$JKA#PJY+D@\[C@'IBL
M#3]>U33=&MK6#7<M=:E=)<3RF(-;E"2%W/\ *"_WOF],"@#V:BN6M=;U1?AW
M)K$BV]WJ,=K)(OV<[HY2N<$8]0 2![UQUWXAU*ZT;5[1/$,6J0R:*]Y)<0Q(
MIMG[Q_+T# D#/S#% 'K ="F\,NWUSQ0KJ_W6#?0YKA-9M4LO@O/$OEX^P(Q*
M1A <X/0<=^O?K67;Z+JNA0:MK]GIUMHD<6E.J6]M/YWFR_>$A&,#&* /4"0H
MR2 !W-+7D^O^)VUC2=8M8M1BN;5= BGD$>T@3%QN.1WQV[5+J/B'Q!;76J2V
MFK)%;V-_:VD=NUNC*1*J@Y/7C=D<T >IT5YI+XEUJTLKFRGU9%,>M_8)-4D@
M0>3$4#;BOW<Y. 3QS38O$FN7D5E9V^L(V_67L$U%($(N(A&6W!>F0>,CC(H
M]-HKS ^+-472(;:;5)#?+=WD(EBBB0S+#T+,_P B8R"0 2>U6-)UK7?$6HZ%
M;KK'V1;G1Q>7!A@1B[B3;QN!QF@#T>FM)&APSJ#Z$UQ'A77=8UG68K&YF(.E
MPR1ZGB,#S9]Y5.W'RJ6X]16'XKAMI_B)=+<0:',!80D#5[@Q*/F?[N <GUH
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M8W.BW"23N^DPM%%O8?O-W\3\<G))_$U%%X TF.*]@+SM;7,;Q"+*@1AVW'!
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MZ_6J5SX46X\1)K2ZE<I<1QK%&A2-UC4==NY3M)[D<T =#1110 4444 %%%%
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MCRU]/UH =13?+7T_6CRU]/UH =13?+7T_6CRU]/UH =13?+7T_6@(H.<?K0
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M*I+;@5)'. &Z^HZ5L6%O)::?;V\LOFR11JC/_>(&,T 9GB__ )%6_P#]U?\
MT(5Y-7J_BY0/"U^<G[J]_P#:%>45X>9_Q5Z?J?49)_ EZ_H@HHHKSCV3OOAU
M_P >NH?]=$_D:[:N(^'8S:ZAU_UB=#[&NUV#U;\S7T>!_P!WC_74^-S/_>Y_
MUT0ZBF[!ZM^9HV#U;\S74< ZBF[!ZM^9HV#U;\S0 ZBF[!ZM^9HV#U;\S0 Z
MBF[!ZM^9HV#U;\S0 ZBF[!ZM^9HVCU/YF@!U5;?4K*Z:00744AC&7VMT'//T
MX//M5JN:M/#EU%!+;S3Q>6UD;(,@.[;ECN^OS#C]: -^VN[>\B\VVF25,XRI
MSS4U9VCV$VGP2I,Z'?)N549F"#:HQEN>H)_&M J"<Y/YT +13=@]6_,T;!ZM
M^9H =13=@]6_,T;!ZM^9H =13=@]6_,T;!ZM^9H =13=@]6_,T;!ZM^9H =1
M3=@]6_,T;!ZM^9H =13=@]6_,T;!ZM^9H =13=@]6_,T;!ZM^9H =13=@]6_
M,TZ@ KF_$LFJ1ZEI*V&K"T6XF,)B^RB7>VUCDDD8  )/TKI*Y+X@^=)H2Q06
ML-S^\#.CHLC* #@JI(ZD 9'(!- &OX:N7N]!MYI;F6YE9I!))+&(VW!V!&T$
M@8((ZG@5J22)%&TDCJB*,EF. !]:R?"[,?#]LCPPP,@91#$%4(NX[00I(!VX
M)&>N:M:Q9R7^ERV\.SS"48!S@':P;'XXH G-[:BW%P;F$0'@2&0;?SZ5,K!E
M#*05(R".AKGO[(NS8R(\,?F->-=*L=PR;<YXW =1D'I@UN6B3164$=S*)9UC
M422 8#-CDX^M &5XO_Y%6_\ ]U?_ $(5Y-7J_BY<>%K\[B?E7_T(5Y17AYG_
M !5Z?J?49)_ EZ_H@HHHKSCV3OOAU_QZZA_UT3^1KMJXCX=C-KJ')'[Q.GT-
M=KL/]]J^CP/^[Q_KJ?&YG_O<_P"NB'44W8?[[4;#_?:NHX!U%-V'^^U&P_WV
MH =13=A_OM1L/]]J '44W8?[[4;#_?:@!U%-V'^^U&WG[S4 .J&.[MIC((KB
M)S']_:X.WZ^E35S&G:%>VJ/'+';[?L7V0%9#\W+'<>.!R!Z]: .CAN(;F/S(
M)8Y4SC<C!A^8J2L_1[6YM+5X[AN-^8D,AD,:8 V[B!GD$_CBKQ7)^\10 ZBF
M[#_?:C8?[[4 .HINP_WVHV'^^U #J*;L/]]J-A_OM0 ZBF[#_?:C8?[[4 .H
MINP_WVHV'^^U #J*;L/]]J-A_OM0 ZBF[#_?:C8?[[4 .HINP_WVIU !7&^-
MU2:6SMQIDTS.P,UU'I@NC'& V ,@C.[\@2:[*N8\;+;MIULMQ'I[CS20+TR;
M>$8DC9SG /7B@"3P;IT-MHZ7?]GI9W=P-LRK;^07"LP1FC'"L0<GZ_2NA=TB
M1GD9411DLQP *P_!D<47A.R6&5)$^<Y1&4*2[$KAOF&T\<\\5?UFSDO]*EMX
M=AD8HP#G .U@V/QQ0!;2>&2'SDEC:+!.\,"N!UYJ0$$ @Y!KFIM"O;O0[ZR9
MHH#<RR2[!\ZL&S\C=..A)%=!;1O%:PQR,&=$"L0, D"@#)\7_P#(JW_^ZO\
MZ$*\FKU?Q<#_ ,(M?Y8GY5[?[0KRBO#S/^*O3]3ZC)/X$O7]$%%%%><>R=]\
M.O\ CUU#_KHG\C7;5Q'P[!-KJ&#C]XG\C7:[6_OG\A7T6!_W>/\ 74^-S/\
MWN?]=$.HINUO[Y_(4;6_OG\A76< ZBF[6_OG\A1M;^^?R% #J*;M;^^?R%8V
MK>*=%T*Z6VU+4EMYG3S%1HV.5R1G@'T--1<G9"<E%79MT5RO_"P_"G_0<C_[
M]/\ _$T?\+#\*?\ 0<C_ ._3_P#Q-7[*I_*_N(]K#^9'545RA^(GA0 DZY'@
M?],G_P#B:Z>)Q-$DL<FY'4,IQU!J90E'=6*C.,MG<DJ**Y@G9UAFCD9#A@C
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M/_>'Y48?^\/RH =13</_ 'A^5&'_ +P_*@!U%-P_]X?E1A_[P_*@!U%-P_\
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M_-J]'R_]T?G_ /6KS?QSG_A(%R,?N%_FU?:Y=_&^3/S/-_\ =OFOU.:Z]2>
M0.>@/6C))!+,2.F6/'THHKW+(^9YGW$P IQ]:]L@_P"/>/\ W!_*O$ST->UP
M%_L\?RC[H[^U>7F>T?F>WDF\_E^IYW\9/^0#IO\ U]G_ - :O.]*O+.#38UF
MFC5%-R;J$_>F#1@1@#^+G./0\^]>A_&//]A:=D ?Z6>A_P!AJ\=J<-'FHI'7
MB9<M9LZ"QVVFC3!M2TV1]LJ?9C,%#%E WMQF0C^$<8(ZUGZI<Q7,.F>5Y0:.
MS"2+&NW:WF.>??!!_&L^BNA0L[G.YW5CWSX8?\B%8_[\O_HQJ["N.^&);_A
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M7DX:<8U+R9]%B82G3M%'BU%>A?\ "GM=_P"?[3_^^G_^)H_X4]KO_/\ :?\
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MJ$?\?%K^;?X5Z%'O2)%*<J .M>?CZU.HH\CON>OE.'JT7/VD;7M^IYU\9/\
MD Z;_P!?9_\ 0&KQRO?O'GA>^\5Z;:6UG)!"\,WF,9B<$;2., ^M<'_PI[7?
M^?[3_P#OI_\ XFC#5J<::4F;XFC4E4;BCSVBO0O^%/:[_P _VG_]]/\ _$T?
M\*>UW_G^T_\ [Z?_ .)K?ZQ2_F,/J]7^4[KX8?\ (A6/^_+_ .C&KL*P/"&C
M77AWPU;Z9<M'++$SDM$3M.6)[_6M^O)JM.;:/6I)J"3"BBBH+"BBB@ HHHH
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M%XKM=;L[N\"+!;VPW,3,KL%Y.2J\KP.]26WC#0;J98HM07<P)&^-T'"[^I
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MD64RIY@+@J_S;<G<#@DY/3&,5H7WAG3[^".%_-CCBM'LT6-\8C;;GJ#S\@H
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H4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>figure_009.jpg
<TEXT>
begin 644 figure_009.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $R LL# 2(  A$! Q$!_\0
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MI;A)$SC 8<!LD#'OFLZ;7]:O_%GA+[9I\FFPW+RR*L=SO69"@(# 8Y''!]:
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M* "BBB@ HHHH **** "F1_>D_P![^@I],C^])_O?T% #Z*** "BBB@ HHHH
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M44 %%%% !1110 4R'_4K]*?3(?\ 4K]* 'T444 %%%% !1110 4444 %%%%
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M?^_[_P"-6Z* *G]FVWI+_P!_W_QH_LVV])?^_P"_^-6Z* *G]FVWI+_W_?\
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M--?PB%V_\32\Y8#^#_XFCZI+N@]E(Q:1@2C ,5)! 8=O>MW_ (0\?]!6\_\
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M%('*-MV\$,P&#Z4MYX UR74=0L$AT]K"^UI-5_M5I"+F!0RMY:IMZC;M4[L
M&O5** /%?#GAO5];O)1'86,%C;^+9]2DOF<B?]W(?W87;SNX&[=C&>*W-&^'
M^IZ?#X9+Q6:SV&IWEU=.C<LDHD"X..3AE!'M[5Z=10!Y!8?#/6HM+MK2Z@T^
M<1^')--DBDG<(\QN!(!E1D# ^\.A[5J^&M/\6>%+>XDN+=;M;R^MH8K::X\^
M>*+[LCO,L:[\#! ;H%/->E44 <WX[\/W/B;PE<Z;9O$MP7CE19\^7(4=7V-C
ML=N*Y#5O"'B76([75#INEZ?>6VH&Y%C87'EM*IBV;GFV$&0'H=N,<5ZG10!Y
M,/AOK$>E);0QVL9.@W]D4^T,X6:=]R@,5&5ZY..O04EWX!\2+KMI<Z:EM;,4
MLQ<7(NBT;^4BJWFP.A#L I"E2O;->M44 ><VG@C4GU3PW?WL-J6M]2O[_4$9
M]PW3!M@7CG'R#VVUD6/PTU>TT;P];+%8I/96>J0W3(^-S7 (CP<<CD9]*]=H
MH R/"VG3Z/X2T?3+K9]HM+*&"78<KN5 #@^F16O110 4444 %%%% !1110 4
M444 %%<UX]U:]T3PA<WUA.8+A9H$$@B$I4/,BMA3]XX8\5G:/>>)M7\$WKPW
M#_V@+J2.QNYX5MVGA5QMD961@I*Y'W.<9P,T =G+]S\1_,4^N#U.'Q9!\-=7
M2^GEGU;.4:U=6D\K*[@I2-/FV[\8&?>LA+J_3X>:Q9V#:GF6YFDTU2LOGFQ6
M5 VTL-P.UGV@G<1C% 'J=%>(:A'J3:98R0'5I(8;J[;2+26WN'6ZC,J>6DCA
M@Z?*&VE_X<G/&*ZK0Y;U?B#JSV$&IM"\)$\=Z90B3"8<DOE2"A.SR^ J\C.*
M /1:*J^9??\ /K!_W_/_ ,31YE]_SZP?]_S_ /$T 6J*J^9??\^L'_?\_P#Q
M-'F7W_/K!_W_ #_\30!:HJKYE]_SZP?]_P __$T>9??\^L'_ '_/_P 30!:H
MJKYE]_SZP?\ ?\__ !-'F7W_ #ZP?]_S_P#$T 6J9#_J5^E0>9??\^L'_?\
M/_Q-,BDOO*7_ $:#I_SW/_Q- %VBJOF7W_/K!_W_ #_\31YE]_SZP?\ ?\__
M !- %JBJOF7W_/K!_P!_S_\ $T>9??\ /K!_W_/_ ,30!:HJKYE]_P ^L'_?
M\_\ Q-'F7W_/K!_W_/\ \30!:HJKYE]_SZP?]_S_ /$T>9??\^L'_?\ /_Q-
M %JBJOF7W_/K!_W_ #_\31YE]_SZP?\ ?\__ !- %JN3O_$%['KO]FVGDQ[M
M[M)(A?@!>  1ZUT7F7W_ #ZP?]_S_P#$UPMR93XX'FHJ'RY>%;=V7V%732<D
MF3-VBVC;_M+6?^?NT_\  9O_ (NC^TM9_P"?NT_\!F_^+J.BNGDCV.;VDNY)
M_:6L_P#/W:?^ S?_ !=']I:S_P _=I_X#-_\74=%')'L'M)=R3^TM9_Y^[3_
M ,!F_P#BZ/[2UG_G[M/_  &;_P"+J.BCDCV#VDNY)_:6L_\ /W:?^ S?_%T?
MVEK/_/W:?^ S?_%U'11R1[![27<D_M+6?^?NT_\  9O_ (NC^TM9_P"?NT_\
M!F_^+J.BCDCV#VDNY)_:6L_\_=I_X#-_\72?VCK)8-]KM,@$?\>Q_P#BZ911
MR1[![27<D_M+6?\ G[M/_ 9O_BZ/[2UG_G[M/_ 9O_BZCHHY(]@]I+N2?VEK
M/_/W:?\ @,W_ ,71_:6L_P#/W:?^ S?_ !=1T4<D>P>TEW)/[2UG_G[M/_ 9
MO_BZ/[2UG_G[M/\ P&;_ .+K$U34)$M]0C/GZ:D,6Y=2D$?E9XX7+'GG'(K+
M\.^*(IO ^E7US="^U*>U8B&-@9;B9%+,@ _BQCCWJ>6'8KFGW.O_ +2UG_G[
MM/\ P&;_ .+H_M+6?^?NT_\  9O_ (NO+++7_$5Q::]%/J$D5S;W5HS&=%M1
M#&XW211M(,*W.%+=0,]ZZSP1J%]J?AYKF^=Y/]+F2WED*EI(0V$)*@!NXW#@
MXS0E!] <IKJ=/_:6L_\ /W:?^ S?_%T?VEK/_/W:?^ S?_%U'15<D>Q/M)=R
M3^TM9_Y^[3_P&;_XND;4-9;&;NTX.?\ CV/_ ,73**.2/8/:2[DG]I:S_P _
M=I_X#-_\71_:6L_\_=I_X#-_\74=%')'L'M)=R3^TM9_Y^[3_P !F_\ BZ/[
M2UG_ )^[3_P&;_XNHZ*.2/8/:2[DG]I:S_S]VG_@,W_Q=']I:S_S]VG_ (#-
M_P#%U'11R1[![27<D_M+6?\ G[M/_ 9O_BZ/[2UG_G[M/_ 9O_BZCHHY(]@]
MI+N2?VEK/_/W:?\ @,W_ ,71_:6L_P#/W:?^ S?_ !=1T4<D>P>TEW)/[2UG
M_G[M/_ 9O_BZQ_%NH:L_@S75DN;5D.GSA@+<@X\L]#OK4K'\6?\ (FZY_P!>
M$_\ Z :3A&VPU.5]S;^&G_)-/#G_ %X1_P JZ<RQJ2#(H([$US'PT_Y)IX<_
MZ\(_Y5Y5-IME?^//%;W=KX3F"ZGC=K5V\4H&Q>$ X*_UKD.H]_HKR/7?'FM6
M.HZY<6>HV,$6C7D%K!HKPAI;Y'V?,&SN&=QV[1CY>:L67C76A\0FT_4+Z'^S
MIM0FLK>.VBBFB; .U&97\R.0?Q;E(Z].M 'J8(89!!'J*6O$?#7B3Q!<Z)H>
MG:1>6.EQ/H5S?MY=FKJK1S$ *I/ /?KW[U<F^(.NWUE;RKK&G:,T/A^+56\^
M .+V5@<HNYAA05QQ\V6H ]BI 020""1U]J\8U+XB>(6.J72:K8:3]BTFTU*.
MQN8 S3/)'N>+)(.,X''.2O3FH+K7=<T?5/&OB.PNHK5+>YTV2>RE@#F7S(HE
M*%B?E W=AG- 'MN]<XW#.<=>].KQJ6[,_BF$>5!%Y/C:1,Q)MWXM<[F]3[UH
M>"/'>J76N-;^)-3@$<MI+<H8XXC;;4;ETF1SA .H<9]^U 'JM%4M0O\ [-HE
MUJ%L@N3%;//$B'/FX4L "/7^M>3_ /"P];L?"$^L?\)#I.J7EQIT5VMC%;A7
MLF>14).&P43?SNP<CJ!F@#V0D#&2!G@9H!##(((]J\7N-<U;59M#M]5FCG-G
MXKLXX;@&)7=6B=BLB1.RJP/OR"*SM.\3:WH?@W3$TJ[CB@+ZC/<>6(I+CY;A
M\,(Y&7=&!G.TY^E 'O.Y0X0L-Q&0,\D4M>.ZQXJO)C>^*=(GB::UL=.LK>:6
M$A"US(LDI*$Y'RF+C.1ZU*_BOQ=I^HW:SZQ:7-OINN6VG.OV((UPDVW))#?*
M5W<8_'- 'K@(;H0>W%+7$_#+C1M8&<XUR^'_ )%-=M0 4444 %%%% !1110
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M_P"_R?XT>5JG_0)E_P"_R?XUH_\ "8:5_P!/7_@,_P#A1_PF&E?]/7_@,_\
MA1];C_,OO7^8<M/N9WE:I_T"9?\ O\G^-'E:I_T"9?\ O\G^-:/_  F&E?\
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MY\+;_OTO^%7:*+L"E_9&F_\ /A;?]^E_PIATC3O.7_0+;[I_Y9+[>U:%,/\
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M]>$?\JXK6?ACK&I:_<7J-#'%=:VTESB3F2P=82RGCKNBZ>]=K\-/^2:>'/\
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M,XJKH?@37=2\(:#?VUL9HI-,N;*2T:<6^P23NX?YT;Y&4C( #8Q@U[\5###
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MD_[_ /\ ]:@# ?Q)J$^JW-I:);1I;JI+2HS%B2P[$>E2?VKK7_/2P_[\O_\
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MJ.<8P0.35'P-JVMZ5:>'8/MEO+I.J:A?VIMC!\Z;6E</YF>3D'C&,8H ]I#
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M10 4444 %%%% !1110 4R/[TG^]_04^F1_>D_P![^@H ?1110 4444 %%%%
M!1110 4444 %,/\ KD_W3_2GTP_ZY/\ =/\ 2@!]%%% !1110 4444 %%%%
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M\-VUB[>8K8F21F9>#V!'/2O1J** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
>*** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>figure_010.jpg
<TEXT>
begin 644 figure_010.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '. M # 2(  A$! Q$!_\0
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M #/+7W_.CRU]_P Z?2 @D@$$CK0 WRU]_P Z/+7W_.GT9H 9Y:^_YT>6OO\
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MS_<:C>?[C4 /HIF\_P!QJ-Y_N-0 ^BF;S_<:C>?[C4 /HIF\_P!QJ-Y_N-0
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME%9VF:[IFL&06%VDQCP6 R#@]#SV/K6C0 4444 %%%% !1110 4444 %%%%
M!7FOC1=4M/&D4^G0VLLE_I[6*)+.$8DDDE1UXKTJN#\8>%M<OO$4.KZ(UFTI
MM6M2;GK#D_?3WYI,#E_"CZE?>*/#^GW'V$_V(DB.8KH.[9&"2/\ "O9*\ZT7
MP%<:5XFTEXX;6*QTV EKE/\ 774K#YMWL#7HM4]@"BBBD 4444 <_J>CWL'V
M^_TF>6>]N%"BUNIV\C'&0H'W21WKE_"&E:SX?U[[*;*W6.<-+)")]WV6(L<
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M SGU-=]H.H6EYI,26)7;"@1D)PRG'<5PUEX5N;BS@OY[B&&QDC\UYBWW%_\
MU5W'AY-&73V&C30SQ@[7EC8,6;'<UY&$A7]HYU%OWW/=S&IA?8QI47MM;;YE
MS32_]G084?=]:XW6U?P]XP@U-%Q#<'+@=/1A_6NHT/5=/O(/LEM>0S7%N,2Q
MHX+)SW%0^+=,_M+0I0JYFA_>)^'4?E71BJ;E3O'=:KY'%@*JA6Y9?#+1_,UV
MD9H2Z!2"N5(/M4=E)+)90NV&9D!))ZUB>$=3^W^'C$[9EM@8V^F.#_GTK;T[
M_D'6_P#N"MJ515(*:ZG/7I.C4E3?0GR_]U?SKSC6F_X2+Q%)'8Q(J0(?,F ^
M]CJ3_(5TGC'6SI]B+.W;_2[D8&.JKW/]*-%T0:/X<F,B_P"E31EI#Z<<#\*Y
M:W[^HJ*V6K_R.[#?[+1>(?Q/2/ZLT-%T:VTBU46\0+NH+RL?F:M/,G]T?G1#
M_J(_]T?RI]=<8J*M%:'G3G*I)RF[MC,R?W1^=&9/[H_.GT51(S,G]T?G1F3^
MZ/SI]% #,R?W1^=&9/[H_.GT4 ,S)_='YT9D_NC\Z?10 S,G]T?G1F3^Z/SI
M]% #,R?W1^=&9/[H_.GT4 ,S)_='YT9D_NC\Z?10 S,G]T?G1F3^Z/SI]% #
M,R?W1^=&9/[H_.GT4 ,S)_='YT9D_NC\Z?10 S,G]T?G1F3^Z/SI]% #,R?W
M1^=&9/[H_.GT4 ,S)_='YT9D_NC\Z?10 S,G]T?G1F3^Z/SI]% #,R?W1^=&
M9/[H_.GT4 ,S)_='YT9D_NC\Z?10 S,G]T?G1F3^Z/SI]% #,R?W1^=&9/[H
M_.GT4 ,S)_='YT9D_NC\Z?D>M&1ZT ,S)_='YT9D_NC\ZP]:\1C3I_LUO&LD
MP&6+'A:9HWB;[=<BVN8UCD;[C*>"?2N5XRBJGLKZD\ZO8W\R?W1^=&9/[H_.
MGY%&1ZUU%#,R?W1^=&9/[H_.GU4U2]_LW2KJ]V>9Y$32;,XW8&<4 6,R?W1^
M=&9/[H_.LZXUZRLM+M;Z\<Q"X52B*I=B2,X ')P*B_X2O1?ML%H+U6EG"%-J
MDK\_W<G&!GM0!K9D_NC\Z,R?W1^=<_J/C#3[>SU![259KBR0NR," P#!6(..
M<'@XJP?%NC+8B[-TWE^88MOEMO# 9(*XR..?I0!L9D_NC\Z,R?W1^=9G_"2Z
M2;^&R6\5IIE5DV@E3N&5YZ D<@4DWB?2+>W6>2\41M$LRD*3E"VT$#W/% &I
MF3^Z/SHS)_='YUDZ;XJT?5KM;6TNB\Q#$*T;+ROWAR.H[BJ.I^*;FRO+TP:<
M)K'3R@NYC+M8%L'Y%QS@$$T =)F3^Z/SHS)_='YUEVVN"X_M<B# T]RH.[_6
M?(&S[=:;H&KW>KP">:"UBC:-77R;CS&&>Q&.* -;,G]T?G1F3^Z/SI]% #,R
M?W1^=.&<<]:6B@ HHHH **** "BBB@ HHHH *Y7XBM9KX-N1?)</$SH%2!@K
M,VX;1D].:ZJN:\>WUM8>$+N6ZL8[V)BL?DR'"DL0 2>P'7-)C1Y[X1O'7Q=I
ML<BZNF^62+_2=0$B;E7D%1UKV>O(?"FHZ=)XNT^9])TX:I<RS0RR6LS-Y>Q1
MAP.F#TS7KU5T%U"BBBD 4444 %8T/_(XW?\ UY1_^A-6S6(F_P#X2V_\O;O^
MPQ[=W3.YL9H UKBXAM+=[BXE2*&,9=W. H]S5.*XA-W<W F00F%'$I(VXYYS
MZ5POCZ#Q/>>$?L]Y:021@O+=FSDP-BCY1AN3SR?I4&LW1O/ ,MA&LT=REA9O
M<QJA)2(GD\=>.<4 <]XQT._>_?64F34+2[.5N83E3CC'Z5S>BZ+>ZUJHTZSC
MS.02=QP% ZDU[)X+#:QX5DAOD6>SBN72UD\GRA)$I^5MHQBN/TP#2OC#$H&U
M+D< <#YE/]177AJU11<'LEIW^9S8JG3;C-:-O7M\OZL=9J6D:CI_A2[TN61'
MT>*P\O-M&SW);^(@'@CKQZ56\&ZZMMI\\5P\DED]XMK87 M/+:7*_P 2J.QX
MS7<+,YU"2$XV",,/J2:GVC&,#%<K=W=G0E;0\G\ 0EO$UBL5M)')9VUS'?,8
MRHWM+E<G^+BO62 00>0:C@A2WB6-!PHQSUJ2D,\^M?\ BF_&4]JQVVMT"%],
M'D?D>*Z];R'3M!6ZG;$<<0)]_:N9\?\ V1A:D2J+V-ON#KM/KZ<UE3:E<^)F
MTW2(E\E%P)"3PQ'?\J\Q5OJ[G26KOI\^GR/<EAGBU3KRT5O>?IU^:-+PU93:
M_K4VN7RYC1OW2GIGL/H/YUV6H?\ (/N/^N9_E61=:C9:1IMUI6FS1MJ5K9O+
M%;#YG.%)!QWR:S/"VM7>L:+J U"\,MY"B^= UJ8&A)7.,$\_6NVA2]E"SW>_
MJ>9B\1[>I=:16B79'80_ZB/_ '1_*GUPOA+Q'J&H:W+9ZI<M"Y$A@LWM#&61
M6P&#D_-Q7=5L<P4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5/4M.34H%BDEDC
M;=F,X-7**F<5.+C+8&KG/_\ ")VW_/Y=_P#?='_")VW_ #^7?_?==!17/]2P
M_P#+^?\ F3R1['GVMZ/+IEUE?,D@8961N3GT-,T?2I=3NU4!TA7EY!QCZ'UK
MT-E### $>AH55484 #T KD>54_:\U_=[$>R5[F!_PB=M_P _EW_WW1_PB=M_
MS^7?_?==!177]2P_\OY_YE\D>Q3T[3TTVW,,<DD@+;LR')I-8LWU'1KVSB95
M>>%HU+= 2,<U=HKHC%02C'9%)6.+O?#VMZCIVG)<)9+-I[ (D5Q(HE79M.6
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M!)+F.)V&&*CMD=J .AHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Q/$^D:CK.GQP:9J\
MNF3+(&,L0R6'I6W10!QOA_PIX@TK5X[O4/%=SJ%NJL#;R+@$D<'KVJA<^!_%
M4MW-+'XXO(XWD9E0*<*">!U[5Z#10!RGA$G1(YM!U*ZWW\<K2K-(<&Y5CG>/
M4YX(]JE\5SIJ-JNA6DH:^NG7&PY,*@@F0^F,?G6Y?:;9:G$([VUBG0'(#KG'
MT]*;8:58:6C+8VD4 ;[VQ<$_4]30!PS>!/%A8D>.[T G/W3_ (UL>(/#&NZJ
M]F=/\3W.GB&$1RB,9\UO[QYKK:* ,7PSI.HZ-ISV^I:M+J<QD+":08('I6M/
M!%<P203('BD4JZMT(/45)6?KNH/I6A7M_&@=X(BZJW0GWH SD\':/#:3Q/\
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M)(MTP2/WJ=/K5NJ>I?\ 'NG_ %U3^8JY0 4444 %%%% !1110 4444 %%%%
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MR_\ :;\Z/+_VF_.GT4 ,\O\ VF_.CR_]IOSI]% #/+_VF_.CR_\ :;\Z?10
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MW-G;7L1BNK>*:,]5D0,/UK \0>"-*\06-K:R&:U6TS]G^S/L"9]JZ6B@#C]
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M;WTP42R3W,;OG<[#'R\<#^E=K13 **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "N-\:7NF:C-#X5NENC-=KYYF@48ME4Y$C$]
MLBNRKDO%?@RTUV\2^?5;C3I#%]FE:)P!+&3G:<T@.,\(7UIJ7C*QDU#5=6OW
MC$@TZ:ZA5(G(&&((Z\5[!7+V?@NUM-<LK];N5K6P@$-G9_P1'&&;/<FNHJ@"
MBBJFI:=;ZK8R6=V',,F-P1RA_,<T@,W4O$R:=XCT[1VL;AVO6PMQ@"->"<9[
MGCI5#2/&RZKXA.G?8)(K>5IEMKDN")3$0'X[=>*L:CX=EEU/P[)9LJVVF2LS
MB1B6*[-HP>Y^M96@^#=0TSQ-'<SSVYT^T:X:V"9WMYI!(;L,4 =S6-8_\C3J
M_P#US@_D:V:Q;$;O$^L<D?)!T/\ LF@#:HIGEC^\WYT>6/[S?G0 ^BF>6/[S
M?G1Y8_O-^= "B-1(9-HWD8)]J=3/+']YOSH\L?WF_.@!]%,\L?WF_.CRQ_>;
M\Z &W7_'I-_US;^5)9_\>4'_ %S7^5-N8_\ 1)OF;[C=_:DM(_\ 0X.6_P!6
MO?VH LUGZU;6]SIDJSP1R@#@.H..:N^6/[S?G534TQITWS-T'?WH EM-/L[%
M2MI:PP ]?+0+G\JLTSRQ_>;\Z/+']YOSH;N ^BF>6/[S?G1Y8_O-^= #Z*9Y
M8_O-^='EC^\WYT /HIGEC^\WYT>6/[S?G0 ^BF>6/[S?G1Y8_O-^= #Z*9Y8
M_O-^='EC^\WYT /HIGEC^\WYT>6/[S?G0 ^BF>6/[S?G1Y8_O-^= #Z*9Y8_
MO-^='EC^\WYT /HIGEC^\WYT>6/[S?G0!S=W:ZGX<2XN-(:":S=S(;.?(\MB
M>=C#L3S@BH] ^T:]>#5-4EB,MJ2L%K"#LB)'WR3RS8X]JW=10?9DY8CS4[^]
M<[9#^R/%4MJ25AG.%Y]>1_A7-6J2IS@_LO1_H1*3378["BF>6/[S?G1Y8_O-
M^==)8^BF>6/[S?G1Y8_O-^= #Z*9Y8_O-^='EC^\WYT /HIGEC^\WYT>6/[S
M?G0 ^BF>6/[S?G1Y8_O-^= #Z*9Y8_O-^='EC^\WYT /HIGEC^\WYT>6/[S?
MG0 ^BF>6/[S?G1Y8_O-^= #Z*9Y8_O-^='EC^\WYT /HIGEC^\WYT>6/[S?G
M0 ^BF>6/[S?G1Y8_O-^= #Z*9Y8_O-^='EC^\WYT /HIGEC^\WYT>6/[S?G0
M ^BF>6/[S?G1Y8_O-^= #Z*9Y8_O-^='EC^\WYT /HIGEC^\WYT>6/[S?G0
M^BF>6/[S?G1Y8_O-^= #Z*9Y8_O-^='EC^\WYT /HIGEC^\WYTX# Q0 M%%%
M !1110 4444 %%%% !7)_$2:U3PI-#<16\YE=%2&:<Q G<.<CGBNLKSSXC:3
M+J0::[L].-G;QK]GN;BX,;"1F&Y3VP128T<]H^B:_I<\<%OXSMK:ZN-WV6P2
M4W"L0,[23T'O7K>G&\.G6_\ : C%YY8\[R_N[L<X]J\Z\'^';NTURVOH_#VA
M0VX!#7-K=-*R@CL"<5Z=5$A1112&%%%% !6-I_\ R,^L_P"[!_Z":V:QM._Y
M&;6OI!_Z : -FBBB@ HHHH **** "BBB@ HHHH *J:G_ ,@Z;Z#^=6ZJ:G_R
M#IOH/YT 6Z*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* *>I?\ 'NG_ %U3^8K%\76C>5!?Q\/"VUB/3M^M;6I?\>Z?]=4_F*EO+9;R
MSFMWZ2*16.(I>UIN),X\RL,TZ[6^L(;@?QKS]>]2W3M':RNIPRH2#^%<YX3N
M6B>YTZ7AXV+*#^1KH;W_ (\9_P#KFW\J6&J^UI*3WZ^H0E>-R2%B\$;-U*@G
M\J?45M_QZQ?[@_E4M;E!1110 4444 %%%% !1110 4$@=3BBJFH?<M_^NZ?S
MH MT444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %<3X]URU33;W25$;72QI,PN+5I8MA;'0
M#DUVU<1\28=371A>V6LQ:=;0$&?<O,G(Q@]?P[TF-'(> K/0K?Q1;RPZO?27
MLA8B"*T>&#IR#GM7LU>:Z(+]_%FDC5?%7GLUN;FWM4M/)$RL,<G')'7'6O2J
MKH2%%%5K^_M-,LWN[V=(+=/O2.< 4AEFBN2U/Q#J$7B30(K)[5](U%R/,&2[
M_*3QV Z56TK5_$'_  G)TN_GMIH7BDFD@@3_ (]5!Q'E^Y8=J .VK&TW_D9=
M;_[8?^@5LUC:;_R,FM_6#_T"@#9HHR/6C(]: "BC(]:,CUH **,CUHR/6@ H
MHR/6C(]: "BC(]:,CUH *J:G_P @Z;Z#^=6\CUJGJ9']G3<]A_.@"Y129'K2
MY'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%
M&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'K0!4U!6:W0*"3YJ'CZU;HR
M/6C(]: .1U<'2/$L%^@Q'*<M_(UTUV0VGS,#D&,D'\*S_$ED+S2)"HS)%\Z_
MU_2H-'O?MGAJ0,<O%&R-^7'Z5Q4OW5>5/I+5?J9Q]V37<VK;_CUB_P!P?RJ6
MHK<C[+%S_ /Y5+D>M=IH%%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'
MK0 54U#[EO\ ]=T_G5O(]:IZ@1LM^?\ ENG\Z +E%&1ZT9'K0 449'K1D>M
M!11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M&1ZT %%&1ZT9'K0 449'K1
MD>M !11D>M&1ZT %%&1ZT9'K0 449'K1D>M !11D>M% !1110 4444 %%%%
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M;5^M/JG??ZRT_P"NX_D: +E%%% !1110 53O^EM_UW3^=7*J:A]R ^DZ?SH
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MNYKU:JZ %%%%( HHHH *QM'_ .0SK?\ UW3_ - %;-8NC?\ (7UO_KX7_P!
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MK:K$T9L:GK9P?^/H=/\ <6@#;HIGF#T;\J/,'HWY4 /HIGF#T;\J/,'HWY4
M/HIGF#T;\J/,'HWY4 /HIGF#T;\J/,'HWY4 /HIGF#T;\J/,'HWY4 /HIGF#
MT;\J/,'HWY4 /HIGF#T;\J/,'HWY4 /HIGF#T;\J/,'HWY4 /HIGF#T;\J/,
M'HWY4 /HIGF#T;\J/,'HWY4 /HIGF#T;\J/,'HWY4 /HIGF#T;\J/,'HWY4
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MLZ[9:#IKW]^TB0(<$K&6)/H *SKGQC9P2:?''9WMS)?0?:(D@BW$)QR>>.M
M&UJ$,,UC,)XA*@0G:?85YF';;@,P4G.W)Q7H6LZ[9:'IK7M\7$8(545,L['H
MH'<FL2[T*UN;(:A"L]J9%#F!U^Z3V/H:\['86=6TJ?0QJP<M49&FWVI+,EK:
M73J93M 8Y _PK?'AJ]N3F]U21O9<U<TO0[33)/.'F2S8X=AT^@K7\P>C?E1A
M\$^2U;7RN[!"GI[QC0>%-,BY='E/J[?X5;2/2+*)Y%^R1)&=KN2H"GT)[&F3
M2:G+JHM_LL!TIXR'F\TB4,1T"XZ>^:\S2QL(O!^N64UPUG9Q:X )&B:8* 5(
MW#J1ZDUV0H4H?#%(T48K9'K<$\%S")+>6.6,]&C8$?F*SM1@L;QH24AE83JC
MD8)'L:PO!VLVUUX?L[*\6"":\:=($MXC$LR*3EU Z9'-4O!EM#8V^J6UNC)#
M%K;*BDDD# [GDUHXJ2LT-JYW5O:V]JFV"%(Q_LC%34SS!Z-^5'F#T;\J$DE9
M#*>K)JKVZ#2);2.;>-YN49EV]\8[URUW8-:_$M+NQLT%Q-I4S/(%PLDH*A=S
M?A^5=KY@]&_*CS!Z-^5,#RWP6;[PSK'B*XUNSG5ML,D\D>92\C$_=P.1SVZ8
MK/EMKC_A9SR?99P/[2,OEF$A50H!YV_WZ;:]B\P>C?E534Y ;!^&ZCM[B@">
M[M(;VV>WG7<C#\O>N7LKF?PUJ)LKLEK.0Y1_3W_QKK/,'HWY53U.Q@U.T:"5
M6!ZH^WE37-7HN5JE/22_'R9$HWU6Y>5@RAE(((R".]+7)Z-J<VE71TK4<JH.
M(W/;_P"L:ZGS!Z-^571K*K&^SZKLQQES(?59Y7&HQ1 _(8V8CWR*F\P>C?E5
M9SG5H3_TQ;^8K8HN4444 %%%% !1110 4444 %%%% !1110 4444 126T$TL
M4DL,;R1',;,H)0^H/:F1V-I%=R74=K"EQ(,/*L8#M]3U-6** "L71/\ D):W
M_P!?8_\ 0%K:K$T/_D(ZW_U^?^R+0!MT444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !61K&EV4Z":2!?,+J"XX)!-:]4]2_X]E_ZZI_Z$*F4(
MS5I*XFD]SF=<U>'P_P"';C4?#EO979@<)._FY\L9QSCDG/:H=:\<-IOB#3--
M9X;>&2%)[NXE1F #' 5<=,GN>*W=8\,V>HZ!>Z7;)%9+=X+O%&!SD')'<\5F
M:WX%36+R.9=1EMXW@2VNXU0'SXU(8#)^Z<TXQ45:*L"5MB;Q=KU_IC:?::3]
MG^U7C.1)."55$4L>!USTK5\.ZHVM^'K#4GC$;W,(=D!R >]8^K>$+K5(5SK$
MD5Q!</):RB('RHV7:8\=QC/-;VD:9#HVD6NG0%FBMHQ&I;J<=S3&7:J:A]RW
M_P"NZ?SJW5>[A:98@F/EE5SGT!H L4444 <]>Z'=)H.MV\=[=7TUY%)Y23L,
M(2I 5>F!SWKE=?\ #.K7.F:1#;:,DMW'I\=N+M;GRWM)!MYQG!7@]*]+HH X
M;Q3I>KZYIR6TFE?:$T^ZAE"FX"F]0+A\'^$Y/>K_ (?TV^TGP0EIJ&1.&9O+
M+[_+4OE5SWP"!7553U3_ )!TO_ ?YB@"X.E%%% !3/)BVLOEIM?EAM&#]:?1
M0 P11J4(C0;!A<*/E'M56^1$6':JKFX4G QDU=JGJ'W(/^NZ?SH N4444 %%
M%% !535/^0=+^'\Q5NJFJ?\ (-G^G]: +=%%% &7K>CIJMMQA;A.8W_H?:J&
M@:Q)YATR_P K<1_*A;^+V^M='6'K^B_;D%U;?+=Q\C'&X#^M<E:G*,O;4M^J
M[K_,SDFGS1-RJ<G_ "%X?^N+?S%4- UK^T(OL]P=MW&,,#QN'K]:OR?\A>'_
M *XM_,5O2J1J14H[%IIJZ+E%%%:#"BBB@ HHHH **** "BBB@ HHHH ****
M"BJ-SK.G6FHV^GSWD27EP?W4)/S-^%5K/Q/H]_K$VE6UZDEY#G=& >W7!Z''
M>@#7K$T+_D(ZW_U^?^R+6W6)H/\ Q_ZW_P!?I_\ 0%H VZ*** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ JGJ7_'LO_75/_0A5RJ>I?\>R_P#7
M5/\ T(4 7**** "BBB@ HHHH **** "BBB@ JGJG_(/D^J_^A"KE->-)4*.H
M93V- #J*** "BBB@ IK(K@!E!P<C/K3J* "BBB@ HHHH *J:G_R#9_\ =_K5
MNFNBR(4=0RGJ#WH 4=!2T44 %%%% '-:_I$B2C5-/RL\9W.J]_>IM,UB'4;J
M"1V6.58F5U)QSD=*E\3W<]II68"5+N$9QV%<'BO(KUUAJ[Y%ONNASRER2T/5
MJ*YCPA>7$R3V\C,\4>"I;G'M73UZ5"JJM-374VC+F5PHHHK4H**** "BBB@
MHHHH **** "JFI0WD]A)'I]TEK<G&R5X]X7\.]6Z* .,UK2[H^)/"ERT/VBX
MAF87-U'#CC8>3CH,]JY_PKI>I0_$.6>>PNHXUDNF?S(\0Q!V&TQM_$6QS7J=
M% !6'H6?MNM8&?\ 3C_Z"M;E8F@_\?FM?]?S?^@K0!L9?^Z/SHR_]T?G3Z*
M&9?^Z/SHR_\ ='YT^B@!F7_NC\Z,O_='YT^B@!F7_NC\Z,O_ '1^=/HH 9E_
M[H_.C+_W1^=/HH 9E_[H_.C+_P!T?G3Z* &9?^Z/SHR_]T?G3Z* &9?^Z/SH
MR_\ ='YT^B@!F7_NC\Z,O_='YT^B@!F7_NC\Z,O_ '1^=/HH 9E_[H_.C+_W
M1^=/HH 9E_[H_.C+_P!T?G3Z* &9?^Z/SHR_]T?G3Z* &9?^Z/SHR_\ ='YT
M^B@!F7_NC\Z,O_='YT^B@!F7_NC\Z,O_ '1^=/HH 9E_[H_.C+_W1^=/HH 9
ME_[H_.C+_P!T?G3Z* &9?^Z/SHR_]T?G3Z* &9?^Z/SHR_\ ='YT^B@!F7_N
MC\ZJ:B7^S+\H_P!:G?\ VA5ZF2Q),H5QD @_B* #+_W1^=&7_NC\Z?10 S+_
M -T?G1E_[H_.GT4 ,R_]T?G1E_[H_.GT4 ,R_P#='YT9?^Z/SI]% #,O_='Y
MT9?^Z/SI]% #,O\ W1^=&7_NC\Z?10 S+_W1^=&7_NC\Z?10 S+_ -T?G1E_
M[H_.GT4 ,R_]T?G1E_[H_.GT4 ,R_P#='YT9?^Z/SI]% #,O_='YT9?^Z/SI
M]% #,O\ W1^=&7_NC\Z?10 S+_W1^=&7_NC\Z?6?JVF/JEND27]U9E7#[[9@
MK''8Y!XH I1^*[&?6[S2+=)I;RTB,LBJA X[ GJ:9HWBJ/6-4N=.73[RUN;:
M-9)%N$"X#=._>HDTJ]3XA2:KY6;/^SA")-PR7W9QCK571++6-+LM3U6;3Q/J
MVH7F]H/-4;8L[5&[IPO.* -+^W++4M;N= 6WDN'A3-PX'[N,GD*3_>JK)X7L
M?[1CB#2JC(7*ANF"._XUS\7A+58?B"U_':*D+:@;MKY9\;HBF/**>N>]=W)_
MR%X?^N+?S%95*-.I\:N2XI[DEG96]A (;>,(G4^I/O5BBBM$E%616P4444P"
MBBB@ HHHH **** "BBB@ HHHH **** "L70?^/O6?^OYO_05K:K%T'_CYUC_
M *_G_DM &U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]Q?V6JSQW$L$<$RRI'LXD3=MQ[>M=A0 445PVG^,+G4_B1)I-NT?]E1PNH.
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MRQ(?*,@& ^W^]CO6_110 4444 %%%% !5:_T^TU2RDL[Z!)[>08>-QP:LT4
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M7W@"UU*2WDO-3OI9%B6&X8L!]I16W*&X['TKKZ* $4!5"@8 &!2T44 %%%%
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..>BB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>figure_011.jpg
<TEXT>
begin 644 figure_011.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $E 8,# 2(  A$! Q$!_\0
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MJ #</44M)M7T'Y4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO^%J>/\ _HE^H_\ D7_XW1_PM3Q__P!$OU'_ ,B__&Z]BHK8P/'?^%J>/_\
MHE^H_P#D7_XW1_PM3Q__ -$OU'_R+_\ &Z]BHH \=_X6IX__ .B7ZC_Y%_\
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M /1+]1_\B_\ QNO8J* /'?\ A:GC_P#Z)?J/_D7_ .-T?\+4\?\ _1+]1_\
M(O\ \;KV*B@#QW_A:GC_ /Z)?J/_ )%_^-T?\+4\?_\ 1+]1_P#(O_QNO8J*
M /'?^%J>/_\ HE^H_P#D7_XW1_PM3Q__ -$OU'_R+_\ &Z]BHH \=_X6IX__
M .B7ZC_Y%_\ C='_  M3Q_\ ]$OU'_R+_P#&Z]BHH \KT7XD>-M1UNQLKSX=
M7UG;3SI'+<OYF(E)P6.4 X'->J444 %%%% !1110!4U3_D$WO_7!_P#T$U3C
M_P!4G^Z/Y5<U3_D$WO\ UP?_ -!-4X_]4G^Z/Y5G4V1#W(G_ .0IIG_79_\
MT4];E8;_ /(4TS_KL_\ Z*>MRJA\*''J%%-5U?.U@<=<'I3JHH**IKJEB^I-
MIRW*&[5=QB[XXSCUZC\ZN4 4]3TZ'5=/EM)ONN/E8=5;L17-^%]4FL;R30-1
M.V6)ML+'OWQ]".1^5=A7,>,-$>\MEU&S4_;+49(3K(@YP/<=1^([UC5IMM3A
M\2_'R_R[/U.BC4BDZ=3X7^#[_P"?EZ'3T5A>&->36M/&]E^TQ@;\?Q#LP^O\
MZW:NG-5(J43*I3E3DXR"BH/-?[=Y7R^7Y>[ISG.*GJR HHHH **** "BBB@
MHHJ*:;R?+^0MO<)P1QGO0!+1110 4444 5X_^/\ G_ZYI_-JL57C_P"/^?\
MZYI_-JL4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 45'<2F"W
MDE"[MBYQG&:DH **** "BBB@"IJG_()O?^N#_P#H)JG'_JD_W1_*KFJ?\@F]
M_P"N#_\ H)KBO$^JZSH\^G7-M<Z/;Z85V2F^E=6=RO"@*I)Z9&WGKGBHJ*Z1
M#^(Z1_\ D*:9_P!=G_\ 13U;UR-I-&N MJ;H@ ^0,_/@@XX(S],US7AO4)]3
M>RN[B^M+MGO9=OV16$<0\D_("P#'N<D?Q>U=/K4#7.D7$*12R,P&%A*A^HY&
M[@XZX/7I3C\*''J<_H5M!/K"LOAM=-$"R-YOE")L[\1CY6YRF201UKJYXS-"
M\:RO$6& \>-R_3((_2N6T*V-MJBSQZ;J7GR*ZW5S<Q1Q^8S,&+L0W.,8  X!
MKK:HHPX=-U'_ (207MTUO-:Q1&*W8NPDC! W$C;@LQ R<]!P.M;AZ444 -V_
M[34;?]IJ=10!YWKMG/X4UZ+5+'BTN'Y'9'/53_LMU'H?PKN-.O8=3L8[J"1B
MCCD9Y4]P?>GZA86^J6$UE=)NAF7:P[CW'N.M>>Z)J%SX3U^;2]08F+(W-V=/
MX9!_(_\ UJQJ+V;=9;/XO+^]^DOD^YTTW[:/LG\2^'S7\OZQ^:['>X?^V,>8
M=OV?.,=]WK5S;_M-516#ZNK*05-MD$="-U7:V.8;M_VFHV_[34ZB@!NW_::C
M;_M-3JJ:8[2:?$[[MQS]YMQZGO0!9V_[34;?]IJ=10 W;_M-5>[7_4?,W^N6
MK55KO_EA_P!=EH GV_[34;?]IJ=10 W;_M-1M_VFIQ.!DUS>H>)'FN3I^B1?
M:KL\-(.4C]\]_P"59U:L::O+_@OT-:5&=5VC_P !>IK0RQ2:G<QI.&=$3<H8
M$C[W6KFW_::N,B\/:O874EY9WR2:AM#S*R_+)N)R,_A[?A6II_BF&2?[)J<1
ML;P<%9.%;Z'_ #]:QAB;.U9<K>W;[^_D;3PMUS47S);]_N[>9O[?]IJ-O^TU
M.!R,CI174<@W;_M-1M_VFIU% #=O^TU&W_::G44 -V_[34;?]IJ=10 W;_M-
M1M_VFIU% #=O^TU&W_::G44 -V_[34;?]IJ=10 W;_M-1M_VFIU% %:]7_09
M_F;_ %9_E5FJ]]_QX7'_ %S;^56* "BBB@ HHHH J:I_R";W_K@__H)KBO&=
MP+*RTN^BO+FVN[9WEA-K:I.[*(CYGRN0 H7))SZ8YKM=4_Y!-[_UP?\ ]!-<
M5XU2"XTK3[2>WA?[3+Y:3SWK6B0$QMG,B@D;AE<8P<\U$]D2_B-#1;B>:\M8
MKK47O[BWO7C>5[=8<?N-P 5201A@<^_M747QNA8S&Q$1N@A\H2YVENV<=JX_
MPM;+:Q:=&OV,DWDK,]K>M=!V,3?,TC $M_( 5W'054?A"/4R+"+7EU,/J%Q:
M26GD,-EO&4Q)N7&<DYXSWK7KC/#=[?7NIN(M2D%LOS?99X9),KQRLSA2>&4X
MY&"/6NPFFBMXFEFD2.-1EG=@ ![DTRA]%8<?B))_$D6F0)');M&Y,XD'+J%)
M4#N,,.?\*W.@H **;O7UHWKZT .KFO&7AYM9TX7%J -0M<O"?[X[H?K_ #KH
M]Z^M&]?6G&5G<3//?!_B6-)(H;U]D0C,:.__ "S.<[6_'\J]#!#*&4@@\@CO
M7GNL^#[J3Q)=7NE7%MNN$\QK>X0A2>AY'?/.?6J=CJ^O>%Y/*OK*5+;/W6R\
M7_ 7'W:Q=*5!7A[T/+XH^375+NKOR.KGAB'K[L_/X9>:?1OL]/,]/HK+TK7[
M#5XP8)0LN.8G.&'^/X5I;U]:N$XS7-%W1A.$H2Y9*S'53TO_ )!L/X_S-6MZ
M^M4]+=?[-AY]?YFJ)+U%-WKZT;U]: '56N_^6'_79:GWKZU7NW4^1S_RV6@"
MU56_U&UTRV,]W*(T'3U8^@'>LO5O$T5I+]CL(S>7[<"-.0I]R/Y?RJM8>'GN
M+D:AKLPN;GJL/\$?MCO_ "^M<TZ[D^2BKOOT7]=D=4,.HQYZSLNBZOT\O-D&
M=5\5G"[[#23W_CE'^?P^M='I^FVFEVP@M(@B]SW8^I/>K(=   0 *-Z^M52H
M*#YY.\N_^79$U<0YKDBK1[?Y]V0Q_P#'_/\ ]<T_FU1ZAI=GJD'E7<"R#LW1
ME^A[4Z-U^WS\_P "?S:K&]?6MI14E:2NC&,G%WB[,Y4V6M>'#NL'.H6 ZP/]
M]![?_6_*M?2O$%CJPVQ/Y<X^]#)PP_QK3WKZUD:KH&GZJ?-(,%R.5GBX;/OZ
MUR^RJ4M:3NNS_1]/R.KVU.MI65G_ #+]5U^6ILT5R2ZIJ_AYA'J<9O;(<"YB
M'S*/?_Z_YUT5EJ=GJ, FM9UD7OCJOU':M:=>,WR[2[/?_@_(RJX>=-<V\>ZV
M_P"!\RW13=Z^M&]?6MC =13=Z^M12W'ERPH%#"1BI.<8X)_'I0!/13=Z^M&]
M?6@!U%-WKZT;U]: '44W>OK1O7UH =13&EC1"[NJJ.I8X K&O?%NE6AV),;F
M7LD W?KTK.I5A35YNQI3I3J.T%<U;[_CPG_ZYM_*IZXK4KG6]?LVC2Q-C9@[
MV>1R&8#_ #TQ786T1@MHH6D:0H@4NW5L#J:FE6]HW9.W?:Y=6C[)*\E?LM;?
MH2T445L8!1110!4U3_D$WO\ UP?_ -!-</XX\B+3M*O)IK)?LLQD6.\M'N4D
M_=-N_=IR2!EMW\.,UW&J?\@F]_ZX/_Z":XSQM9&[T"%]R1B($/-]L2V9$="C
M!6=2AR"00V/J"*B>R)?Q%OP^"DUG"_\ 9HDAO9$D73K=H8U/DD\J>^"#GT(K
MI=9O)=/T>ZNH4#R1QDJ""1GU(') Z\5QW@RXL;NUT^YL7OY/,O93--?*!)+(
M(2"05^4K@* 5^7 XKOZJ.P1ZG'^&);<Z[*D,T5X3:@_:$LV@,8# ;,="#D8[
M_+SGBNO(!&",CWKG_#FL7NK.TEPZ>6T>Y42SEC"\XXD8[7'TZ]:Z&F44O[)T
M_P#M&/4!9PB[C#!954!OFQG/KT[U=HJ.>4PPM((WDQCY8QDGF@"2BJ_VH[RO
MV:?_ %HCSMXZ9W?[OO31>$A3]EN!N#GE.FWUY[]J +5%5#>D(6^R7)Q&KX"#
M)SVZ]1WIYNB'*_9I^)!'G;QR,[OI[T 1_P#,9'_7O_[-5L@$$$9!Z@UF"Z+:
MHC_9YQF!QM*\C:W?Z]JLF](0M]DN3B-7P$&>?X>O4=Z ,O5?">GZ@A>!%M+@
M<AXA@$^X_P FN3N+SQ5X7G"&?SX,X5;GYT;_ '7ZCZ$UZ&;HB0K]FG.)!'D+
MP<C[WTJ*66.ZA\J>QF>.3>&5XP1\OK]>U8^S<9<])V?7JGZK]59G1&LI1Y*J
MNOQ7H_T=T<Q;?$&*%$_MK3;FQW#Y9D'F1-]&%;OAK4K;5-$AN+5RR LIW#!!
M!Z&L.?1KJP9I=(CE-M(@DELKE-R,#_#CGGV_6L"PEU+PU#<7]NGV2PN2-RRJ
M3'&^>J]QZ?Y%:+$0E%QE3:GV7O)^G_!)>&:?-"HG'ST:]?\ @'J54;O6=.L,
M_:;R)"/X=V6_(<US<6EZGJJ1R:AJ=V\4NXA;90$P.ASTP>W'-7K30](LD\Q=
M)N)7$8DS*N\Y)^[C.-U8>TKR^&%O5_HO\S3V>'A\4[^B_5_Y#7\81SL4TS3[
MJ\?U"[5_K52\@\2ZNT!N#'I\!< *CG=SW..OZ5TZSK$3$EI*JJZH-J #GN/8
M=Z@N+HN;<?9IUS.1DKTV]_Q[4GAYS_B3;\EHO\_Q&L3"G_"@EYO5_P"7X!I.
MB6>CP[;=,R,/GE;EF_'^E:-5/MS>7O\ LES_ *KS-NP9Z_=Z_>]J<UV0[+]F
MG.'5<A>#GOUZ#O71"$8+EBK(YISE.7-)W99HJLMV691]FG&69<E>!M[]>A[4
MW[<?+W_9+G_5>9MV#/7[O7[WM5$CX_\ C_G_ .N:?S:K%9ZW86_N (96($2D
M* 3SGGKT&?TJ=;LEU7[-.,NRY*\#'?KT/:@"S153[<?+W_9+G_5>9MV#/7[O
M7[WM3FNRK,/LUP<,@R%Z[NXYZ#O0!8(# @@$'@@USU]X603F\TB=K&['.$^X
MWU';^7M6R+LEPOV:<9=DR5X&._7H>U-%\3'O^R7/^J,FW8,]?N]?O>U9U*4*
MBM)&M*M.D[P?^7S1AVWB:>PF6TU^V-O(>%N$&4?W_P#U?I721RQS1K)$ZNC#
M(93D&J=TT-U#)!<6$LT>4!5D!!W=QSV[^E<ZVE:CI%P9=!-QY1D96M9QE3CN
M#GH>QZUA>M1W]Z/XK_/\S>U&MM[DO_)7_E^1V-5Y_P#CXM?^NA_] :L>S\56
M\KO;W4$EO>(#F(_Q$=ESCDU?N;LBXM_]%N#MD'1>NY6Z<]N]=$)QFKQ9S3IR
M@[21HT56^U_.%-O,!YA0L5&  ,[NO3WK+G\7:7;[0[OO8?<4 E3G&#@\&G*<
M8:R=@A3G-VBKF[2,P52S$ #J37+2ZWKM]'NTW2S%$3@2S#)ZXSC_ /742^'[
MJ_E4ZS>7MQF4IY<:[8Q@9W?[OOBL'7D_X<6_/9?C_D;K#QCK5FEY;O\ #_,U
M;WQ5I-D2GVCSY.FR ;C^?2J/]J^(=4XT_35M(CTFN3S^7_UC5^PM+#3XU:UT
MF6-O+9\F,%^.V2<Y/85?-X0&/V6X.T(>$Z[O3GMWI>SK3^.5O)?YO4?M:,/X
M<+OO+_):&$OA.6\82:QJ<]T?^>:':@_S^%;=EI5AIXQ:VL<9_O 9;\^M2?:C
MO"_9I_\ 6F/.WCIG=_N^]-%Z2BM]DN1E&?!09&.W7J>U:4\/3@[I:]]W][,Z
MF)JU%:3T[;+[D.OO^/"X_P"N;?RJQ5"ZN2]G<+]GF7]T#EEXY'3\.]7ZV, H
MHHH **** *FJ?\@F]_ZX/_Z":XSQB(_LFDO<-Y%FD^9[T6BW#VW[L[2H96"Y
M; +8./;.:[/5/^03>_\ 7!__ $$UQOBQIDBT:2RN;V+4EF)M4L[=)GE_=D."
M'(4+MY))],<U$]D2_B)O#-]<WYLI)[B6ZA2^ECM;N:'RGN(A$<,5P.Y89 &=
MN<<UV_:N*\.7MS>M8F]NKB>[BO98IEN;58)(F$).PJI(/!!!!.0PKK;UKI;1
MVLHXI+@8*I*Q56&1D9&<<9Y]:J/PA'=G+>$4D349089%#0DR*4F5;=]P_=@N
MQ5^YW*!T]#78US?AC3M0L3_I=M+;Q^5A8S?F9%.<X"[1M_,^E=!.95A<P(CR
M@?*KL54GW(!Q^5,HDHKEK(:F/%\S7-LS*SD;RK[8HO+4C:V=I!?(QC/>NI/3
MB@ HIOS^B_G1\_HOYT .HIOS^B_G1\_HOYT 1_94^V_:MS^9Y?EXS\N,YZ>M
M34WY_1?SH^?T7\Z '44WY_1?SH^?T7\Z '5G6MK#>Z&+:YC62&565T;H02:O
M_/Z+^=5-+W?V;#PO?O[FA.VJ Y71KJ;PCK*^'M1D9]/G).G7+]O^F9/^?UKM
MZR]=T6#7]+DLKE0,_-'(.L;]F%9'A;6[OSY?#^L$+JEH/E=C_P ?$?9AZG'^
M>M=,U[6/M%NM_P#/_/[S*/N/E>W3_+_(ZNJUW_RP_P"NRU/\_HOYU4OWD06V
M%0YN$!R37,:EVBF_/Z+^='S^B_G0 ZBF_/Z+^='S^B_G0 N "3@9/>EJK'YG
MV^?YB1L3"EC@?>[?A5CY_1?SH =13?G]%_.CY_1?SH =13?G]%_.CY_1?SH
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M<O+CQ +=S";:6:X@6-5^>/RL?,3GG.?3NM=*>!5>&PL[>X:XAM88YG4*TBH
MQ Z G\!^56* &[_]EORHW_[+?E3J* &[_P#9;\J-_P#LM^5.HH ;O_V6_*C?
M_LM^5.HH ;O_ -EORHW_ .RWY4ZB@!N__9;\J-_^RWY4ZB@!N_\ V6_*C?\
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M;^]^E.HH ;AO[WZ48;^]^E.HH ;AO[WZ48;^]^E.HH ;AO[WZ48;^]^E.HH
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MNL#"5Y-DGEEV5050-M/)YP.Y% '344V-B\:L5*D@'#=1]:=0 4444 %(0#U
M-<GIFI7DWC2ZMI+F5[<-,JQ\<;=F,ICY ,MAL_/GM76T )M7^Z/RI0 .E%%
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MW$K6U_K\ _L?3/\ H'6G_?A?\*/['TS_ *!UI_WX7_"C[=<?] J\_P"^HO\
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MDD]23U-&H>[V_#_@%K^Q],_Z!UI_WX7_  H_L?3/^@=:?]^%_P */MUQ_P!
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>figure_012.jpg
<TEXT>
begin 644 figure_012.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $M M # 2(  A$! Q$!_\0
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MLQ=6"G"#:?I_F>L45Y/_ ,+ST[_H"W7_ ']6C_A>>G?] 6Z_[^K2^L4NY?\
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MP**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M2UQSPL)2<FSW\/GN(H4HTHQ5EIU_S/F+_A6_C#_H!3_]]I_\51_PK?QA_P!
M*?\ [[3_ .*KZ=HJ?J<.[-?]9,5_+'\?\SYB_P"%;^,/^@%/_P!]I_\ %4?\
M*W\8?] *?_OM/_BJ^G:*/J<.[#_63%?RQ_'_ #/F+_A6_C#_ * 4_P#WVG_Q
M5'_"M_&'_0"G_P"^T_\ BJ^G*Q-:U]]*N[.!+"YF\Z=8V=(BPP58_*<\M\O2
MFL%!NR;!\28E?9C^/^9\_?\ "M_&'_0"N/\ OM/_ (JC_A6_C#_H!3_]]I_\
M57TU$_F1(^UEW ':PP1[$>M/I?4X=V'^LF*_EC^/^9\Q?\*W\8?] *?_ +[3
M_P"*H_X5OXP_Z 4__?:?_%5].T4?4X=V'^LF*_EC^/\ F?,7_"M_&'_0"G_[
M[3_XJC_A6_C#_H!3_P#?:?\ Q5?3M%'U.'=A_K)BOY8_C_F?._AKP#XJLO%&
ME75SHT\<$-W')(Y=,*H8$G[U?1%)BEK:E25-61YF.Q]3&S4ZB2LK:!17-R^,
MK2&:2(V&I,48J2MOD''I3/\ A-K/_H':G_X#_P#UZZO8U.QYGUBGW_K[CIZ*
MYC_A-K3_ *!NJ?\ @/\ _7H_X3:U_P"@9JA_[=__ *]'L*G8/K%+O_7W'3T9
MKDKKQ=;75K+!]@UB+S%*[XX,,ON#FN?L_&6H:/<_9Y_.O+8=!<IY<P']?QJX
MX:I)>9G+%TXM:Z'IM%5=/OEU"RCN5AFB#C[DR;6'X5:KG:MHSI335T<EX7_Y
M&?Q)_P!? _FU=;7)>%_^1G\2?]? _FU=;6U?X_DOR1CA_@^;_-A1116)N%%%
M% !17(Z5XCU"_5I'>V 6.1S&MM*/NYQ\Y^7L*@;Q7J),046Z;K..X/\ H\DF
M689(^4\#ZUM["=[&'UB%KG:YHKC;KQ7=HMBVZUMTGM//D9HWE"G.,?)V^M6X
M-=U2\CT^WBMK>&]NHWE+39V*BG ( YYR#BDZ,TKL%B(-V1T]%<Q+K^IQVUU$
M+2%[VVN%BE:,,Z;6&=X4?,?I1#XBNGMK5F^RO))?+;2&/</E()SM."I]C1[&
M0_;P.GHKE[#Q!J$NJQ6]Y%;P+*[)Y3JZN,9P58_*^?:NHJ)0<79EPJ*:N@HH
MHJ2PHHHH Y+4/^2E:5_UZO\ ^SUUHKDM0_Y*5I7_ %ZO_P"SUUHK:KM'T_5F
M%'>?K^B"BBBL3<**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLO6?$6EZ#:3W%]=*OD1
M&9XD^:39G&0@Y(YZ]!WKC[OQX^IM$ME++IEI#=/;7]V(X[EH&"!H_N%E"MD@
ML<X(QP3F@#L]6UW2]"M7N=3O8K:)%#,6.2%+!=V!SC+ 9Z#-<;=^/+F^URRM
M-*5&LI;DVLDB.A9I?O(-Y.U4>/+*PW$D%< TZ'1]0\8:59:EKDUO:BV$D>XV
MI0W$18JY<,PVQR1@';@%20V?E%5;K6?#/@\2KHUI%?:K]@BN'N,#]_;JQ7SB
MZ#$A3ECM&X@$T 7;K2/$>L:-)X=U156.VN$==;>5=TL:.'1@@_CP-K$X&<D9
MZ5)"GA/PK?0:3IXA%_+;>98K=RNT(5F&U5E(8*&9<A1WR0.:P[V]UO7IVELY
M[^ZEDM L,5A,D2V5T,E'E0.5,<@ZARQ 4C'S5NZ=\-K$-!_:_E7MM!"\4%DR
M9BC5RK[>?O!&#[,_=5L=0#0!G2MK^O3"#4K<7DNFW<J:AI5M*;=9(W4>3)&Y
M8;U !.&(Y+=U%6=$^'$#,E_KA>2\9""GG$O&0Y\MQ*I#>8(]J,P^]M&<XY[R
M&&&TMXX8E"11($49Z*!QR:PK_P 764,YM=/CDU&\Z"*W&0#[M51A*7PHB=2,
M%>3->STZQTX2?8[2"W,AW2&*,*7/JQ'4^YK*U+Q;86DWV:U#W]X>!#;C=S[G
MH*IC1M<UX[M9O/L=J?\ ESM3R1Z,W_ZZWM.TBQTF'R[*V2(=V RS?4]36G+"
M'Q.[\MOO_P C/FJ3^%67GO\ =_F<AJUEJ]]I]QJ&K*EK;*NX6EJ@:1SV#-6G
MX+\/_P!E6/VRYCQ>7 R0>L:=E^OK74XHQ3E7DX<BT0HX:*GSO5G/ZOXX\.Z#
M?FQU/41!<A Y0Q.W!Z'(!':J/_"T?!O_ $&5_P"_$G_Q->3_ !B_Y'^3_KUB
M_K7 5Y53%3C-Q2/L\'D6'KX>%64G=J_3_(^E_P#A:/@W_H,K_P!^)/\ XFC_
M (6CX-_Z#*_]^)/_ (FOFBBH^N3[(Z?]6\-_-+\/\CZ7_P"%H^#?^@RO_?B3
M_P")H_X6CX-_Z#*_]^)/_B:^:**/KD^R#_5O#?S2_#_(^EO^%H^#?^@RO_?B
M3_XFLZ^\<>"+^=99/$5TA7!58O.55//(&W@\]:^>J*%C9KH@?#6%?VI?A_D?
M2D?Q-\&Q1(@UO=M &6AE)/U.VG_\+1\&_P#097_OQ)_\37S111]<GV0?ZMX;
M^:7X?Y'TO_PM'P;_ -!E?^_$G_Q-'_"T?!O_ $&5_P"_$G_Q-?-%%'UR?9!_
MJWAOYI?A_D?2_P#PM'P;_P!!E?\ OQ)_\31_PM'P;_T&5_[\2?\ Q-?-%%'U
MR?9!_JWAOYI?A_D?4&G_ !!\+ZKJ$-C9:H);F9ML:"&09.,]2N.U=+7S%\.?
M^2A:-_UV/_H+5].BNJA5=2+;/G\VP-/!UE3IMM-7U]1:***W/+"BBB@"&Z@>
MXM984G>%G4J)$^\ON*R]+\,:?IC^?M:YNSR;B<[F)]O2MJBJ4Y)63)<(MW:"
MBBBI*.2\+_\ (S^)/^O@?S:NMKDO"_\ R,_B3_KX'\VKK:VK_'\E^2,,/\'S
M?YL****Q-PHHHH J6^G6]KI_V&%2+?:R[2Q)PQ)//XFJ+>&-.)0I]HC*1+"#
M%<.F47H#@\ULT52G);,ATXO=&=!HEA:O$T, 7RX3 JY)&PG)!'?FH3X;TTVD
M5MY4@2%BT++*P://4*P.0/:M>BCGEW#V<-K&5_PCFF?8A:BW(02>;O$C;]_]
M[=G.?QHB\/:=$B*L3DK.+C<TC,S.!@%B3D\5JT4<\NX>SAV,F#PWIEO<I/'"
M^8V+QH96*(Q[JI.!6KBEHI.3>['&*CL@HHHI%!1110!R6H?\E*TK_KU?_P!G
MKK17):A_R4G2O^O5_P#V>NMK6KM'T_5F%'>?K^B"BBBLC<**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** .-3P);CQM<:M*(YM/F#3B!^J7+*8W)XRR,A^Z3@'/'/&WHWAG
M2M"AMTLK1!);P_9XYW4&7RLY"%\9('  ]JUZ* &R1I+&T<B*Z."K*PR"#U!%
M<1HGPNT?1M1^U"6:5(G)MH-Q5(EW;EX]1EE/0,IP0>2>V>1(T+R,J(HR68X
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M'U-7-%>/?V#\6\_\AA?^_P"G_P 373^"--\;66IW#^)[X7%J8<1J)5;#Y'.
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M\$YK_A/-#_YZ7'_?AJ/^$\T/_GI<?]^&KI=B_P!T?E2;%_NC\J.:GV?W_P#
M#EJ_S+[O^"<W_P )YH?_ #TN/^_#4?\ ">:'_P ]+C_OPU:VJW\>EV1G,!F<
MNL<<28R[$X %5&\06_\ 9=I=Q6SRRW;>7%;K@-OYR"3P,8.:I*#5U%_?_P
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M/Q/4ZY+7]+O;OQOX?O8+=GM[;>99!C"9]:Y_PUXAUBRFT_\ MW4RR7:[PLP
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M^$7US_H%S_D/\:]EHK3Z_/LC+^S:?=_@>-?\(OKG_0+G_(?XT?\ "+ZY_P!
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MQ]:634KV6-HWN9&1OO#/6E[*?<KVL-K?U8U+#3H)%MDN+:-6E4MEI3O;W '
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MP]2_Y]3_ -]#_&NVHH^M3[!]3AW9Q/\ 8>I?\^I_[Z'^-']AZE_SZG_OI?\
M&NVHH^M3[(/J<.[.4L/#]TURCW*B.-3DC()..W%=7116-2I*;NS>G2C35HA1
M114&@=:@%E:K T MH1"QR8Q&-I/TJ>B@"M_9]D(C$+.W$9.2GE+@GUQBLZVU
M*UM]??0K>S$)6+SMT8"H<X[#O6U7(Q?\E0F_Z\A_2M*<5*]^B,JLG'EMU:.N
MHHHK,U"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M 2^?OX4E-^W&.3C'YT/"UDF[;7Z]@Y)':^&R?^$CL>3_ *P]_8UZI7E?AO\
MY&.Q_P"NA_D:]4KVLG_@R]?T.G#?"PHHHKUSH"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@"AK,U[;:5/-I\:27,8W*C@D$#KT[XK@5\46Z^)9-95"2UB
M$6+_ *:\?+],UZ8:Y9/!MNGBDZE\OV7_ %HAQTES_+O]:Z:$Z<4U-?UV.3$4
MZDG%P?7^F;ND2WLVEP2ZA&D=TZ[G1!@#T_'%7:!17.W=W.I*RL%%%%(84444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !2;AG&1GTI:\L\0_#>[\5_$'4K^><65D(;
M40W @$DC%=Q;RGW QL..<'J/2@#8\3> K[7?$:ZI:ZO#8_ZL>;':D7,87J%D
M5U!!YX<-C)I[_#>RETO6(I)=]_?-=M#<N79;?S]W(C+;00&P2 ">?6L"#PMX
MEM_$W]IHLBI)J5V5D1SYL:L&$+/ERKPG()4*&&%]ZN>'=)U^SOK"6TTNZM;N
M"S=-4DU"]+0WTY"@$$%R?F#MNVC .,<X !HVO@G5+>VM&&I6JW=A<+<6K;9Y
M4)V-&P=9)6."K<;2N#ZT:IX%U'6F5KW6HP\UL+6[>WMO++)Y_FL$Y(7( 7)S
MW)SFL.+PSXDC\4_VO/;N(GU>1I/L\K><D90!2&+[6A+9!7:& Y%5_#GA_68/
M".H65QIFI0ZE)IPC:6)1%*S9&X"5IG#-W^ZN<'D9H Z&V\"ZKI6H6USIFLPR
M"UN+F6%;^W+D"<)O!V,H^^K,, ?>QCBF77@;6I[F5QJU@]M<7YU"XM);5S%-
M)L15#8<$JI3=M/!.,YQ6+9:)K26EBNLZ+J5[I$1N5%E;W&R3>S*8Y60R\#&\
M!=YVYSWXU/#4/B#1M0EAUW3M3OA=V5M#YL+K*D9!EW!F+@Y"N@+ <X)YH FA
M\!:G'?ZK,^I6K)J3S/)M6=2ADCV$!!+Y9QUY4G]#6MX>\+WVG:E;ZAJ=];W$
MUKIZZ= MM 8U\L%26;<S$L2J^@&#ZUR4?AOQ4UK+#="Z<:5);V6GLMQS<0BZ
M1WF;GKY2HO//#>M5;3PWX[MTMH(I;@*UM?R0RR3_ #6L\F0J-R<J>&4\[2Q]
M!0![#17#>"[&]LM=OBNAW.G:8]O& UU=,\C2CJ"ID93U/SC&>*[F@ HHHH *
M*** "BBB@#S?QI_R,3?]<4_K7#ZMX>MM7FDDFFE0O:M:D)C[I8-GGOQ7<>-/
M^1B;_KBG]:YZODL54E#%3E%V=SSZC:FVC 'A*P6\>Z664.US%<XXP"@.!]#D
MDU"/!.FB-%,TYVP2P!CCD2%B3TZC<<5G:C:ZP]UXJ-FT2021KE98'9I?W7_+
M,@@>W?FFR6T"WEN^O:?>75E]@A6V6.)Y%C<+\X*KT;IR:Z%[6U_:?=:^R?D5
M[W<VY_"\3N3!J-[:E[=+:80LO[Y%&!G(.#CN*?)X8TZ42HP;R9+-+/R\C"*A
MRK ]=P/>N2GL-67^QKEH+LRV45Q<1(^68*K@I&Q]2N1CK5:?3[\V>KS36TYD
MNVM+AU:)G +.688')P" 0*N-&;M^]_+O_3_ I1?\QUR^$8$2Q%MJ-S"UG;FW
M1E2-RREMW(8$9S6LNG[M*-C+=3R J4,ZD(_U!7 !'M7&QVI.A7D=A:X)GB:Y
M2SLY;9I( ?F4;SDGZ&K$-K$]U>'0[#4;73FL9$G54:(O*<;?+5S]X#/-9U*<
MY?%/9]EY?G?0EIO=F_IN@1:?J+:@]Y<7=R8_)#S;1A<YQ\H&3[GFI(-%MX-,
MN;!+B<)/*\ID1]KJ6.[@CI@US7ABQC:]N+1M/9[*6V"S2-!+ K,"/E=&)!8_
MWEJHNDM::7J$-AI3B^N]1FM8F4%2MOD$_,> N 0#[T2I2<VG/73M_6FH.+O:
M_8ZW3-!CT[4)+]KNXN[J2,1&24*,(#GHH //<U%-X9MI=(ET_P"TS(DEV;OS
M %+!RV[ R,8S7/K!>+X;O]&NK*^MTMYU>$1?OB(&;(4D$;P.00#G!%0P07!T
M>>&#3Y8X1J-L\;)%(B.-PW%8WR5 []J?LJC;E[36Z[?)_P# #E>]SIO^$;$D
M(AN=1N+A5GCN &CC7!0Y'W5'![TVP\*V.G7=O<023;H)995#8Y\P $'V '%<
M[';26_BD2Q65Y-<-?%F,L,B2(A/)\T$HR =CVKOSUK'$2JTDESW3]"9N2TN:
MOAO_ )&.Q_ZZ'^1KU2O*_#?_ ",=A_UT/\C7JE>ID_\ !EZ_H=&&^%A1117K
MG0%%%% !1110 4444 %%0W;M':3.APRQL0??%< /$FKX'^F'_OA?\*Y,3C(8
M=I23U(G-1W/1:*\[_P"$DU?_ )^S_P!\+_A1_P ))J__ #]G_OA?\*Y_[5H]
MF1[:)Z)17G?_  DFK_\ /V?^^%_PH_X235_^?L_]\+_A1_:M'LP]M$]$HKSO
M_A)-7_Y^S_WPO^%'_"2:O_S]G_OA?\*/[5H]F'MHGHE%>=_\))J__/V?^^%_
MPH_X235_^?L_]\+_ (4?VK1[,/;1/1**\[_X235_^?L_]\+_ (4?\))J_P#S
M]G_OA?\ "C^U:/9A[:)Z)17G?_"2:O\ \_9_[X7_  H_X235_P#G[/\ WPO^
M%']JT>S#VT3T2BO._P#A)-7_ .?L_P#?"_X4?\))J_\ S]G_ +X7_"C^U:/9
MA[:)Z)17G?\ PDFK_P#/V?\ OA?\*0^)-7P?],/_ 'PO^%']JT>S#VT3T6BH
MX26@C8\DJ"?RJ2O36IL%%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 5QS>+[A=#\6WA6U%QH\]Q';QDG
M#B.)7!89SU)SC%=C6;)X=T2:[>[ET?3WN9,[YFMD+MD8.6QDY'% '"6WCKQ1
M=3:A/!IMO+8V<DZROY#*D:I$7#>9YGS'=@; O0]:?9^/-9F0W\O]EFU2_M;)
MK-4<3R>='$Q9&WD9!EZ;>BGFO0DL;2*&6&.UA2*4DR(L8"N2,'([Y%5X]!T>
M&]6]BTJQ2[4 +.MN@D&!@8;&>G'TH X/Q1X^U;P_XUO+!(X9; 6<<<"B,E_M
MDH?R@3G[I,9'XU1T#X@>)M2^P6TJVQF>U\ZXDAL6F^;[1+$>!*@5<1CGGO7J
M$NFV,TQFELK>24E&+O$I8E"2ASCJI)(],\55F\-:#<>7YVB:;)Y8(3?:(=H)
M).,CCDD_4F@#BW\=:S;[KJ0Z7-;OJ%W8QVT:.)D\H2%9"=Y##]WR,#@]:;:?
M$Z27Q!HUG,EJMI<0VR7CJCY2XGCWJ%;[H4$HI!.<R"NZCT'1X;J6ZBTFQ2XE
M#"25;= [@]03C)SWJ1=*TY+5[5+"U6W=@[1"%0C,,8)&,9&U>?8>E '#:GXO
M\1:5JVK6TDFDO#:36D*.T$D84W#$*\C>8<*F.>.?]FJVI>/];T_4CI06SN9X
MKHQ2W5G9R3JR>0TN%B$@.\;>1N/!!]J]&>PLY?/\RU@?[0H6?=&#YH' #?WA
MR>M1VVD:;9I"EKI]I D#,\2Q0JHC8C!*X'!()!Q0!Y[=?$75[?1-$U)HM+$5
MU;M=7;JQD"1^8%5MJMN12IR2 ^UL*1WKTX'(S6>^A:1(L*OI5BRPN9(@UNA$
M;$Y++QP2><CO6A0 4444 %%%% !1110!YOXT_P"1B;_KBG]:YZO4[_P[IVIW
M7VFZB=I=H7(D(X'TJM_PANB_\\)/^_K?XUX&(RRM4JRG%JS9R3H2E)M'FN32
MY([UZ3_PANB_\\)/^_K?XT?\(;HO_/"3_OZW^-8_V1B.Z_KY$_5YGFOXTN3Z
MFO2?^$-T7_GA)_W];_&C_A#=%_YX2?\ ?UO\:/[(Q'=??_P ^KS/-B2>II"2
M>M>E?\(;HO\ SPD_[^M_C44GA;P_#-#%)&ZR3,5C4RM\Q )/Z FC^Q\1W7W_
M / #ZO,\ZR3U-+DUZ3_PANB_\\)/^_K?XT?\(;HO_/"3_OZW^-']CU^Z_KY!
M]7F>:Y/K2Y/7)KTG_A#=%_YX2?\ ?UO\:/\ A#=%_P">$G_?UO\ &C^Q\1W7
MW_\  #ZO,\UR<8SQ17I7_"&Z+_SPD_[^M_C1_P (;HO_ #PD_P"_K?XT?V1B
M.Z_KY!]7F<5X;_Y&.Q_ZZ'^1KU2L:U\+Z597<=S!"ZRQG*DR$\_2MFO6R_#3
MP]-QGU9T48."LPHHHKO-0HHHH ***8[%8V*KN8 D+G&3Z4FP'T5@VGBBV>?[
M-J$,EA<_W9ONGZ-6Z&5@"I!!Y!'>HIU85%>#N)23V(;W_CPN?^N3?R->6#[H
M^E>IWO\ QX7/_7)OY&O+!]T?2O'S?XH?,PK]!:**Y7Q=#<1SZ9/;ZKJ%K]IO
MH;1XX)]J;&SD@8^]QUKRZ5/VDN6]C%*[L=517 7U]?68UNT36YHEM[NVACFN
M9<':4RR^9M(0M_>(Q42ZW<R^'KB.+6IHGBOTB::>=6!0KGRUN4!7_@1 QTKI
M6#DU=/\ /J5R,]$HKSZ#Q!,NE6TIU*Y,5OK$<5Q/+*DBB(@G:94X=??BFZUK
MUS)#K]S8:F[6D=Y9Q02PSA44$?O K]![FA8*?-RW_JX>S=ST.BN<\(S^>EUO
MO)+A@ZC:^II>;1SSE0-O]<5SESKVNIH6INB2&&/56B%]]J :-?- V!,9QCCK
MWJ%A9.;@GM;\0Y'>QZ-17G,VIW+^*=3AFU2XBABOO+11J\=L$3CI&P)8<GI]
M*FUCQ3=0^)IKNVDO&TW3ID@ECBA9H91SYK,P& 5R,?2K^I3;23Z7#V;/0**Y
MBP\06D7B/7H+[5H(XEE@^RI-.JC:8P3M!/0DYK!N=5UV34!#I]Z[3_VW=1QQ
MNWRNB1JPC/MU ],U,<).3:O;9_>"@[GHM%>=P^);R^LKFX^VW-C93:N()IV&
M7LXC&#MYR%^;C/:MGPIJBW.J:E8Q7M]>0PA622YFCF7J1\KIUSUP>E$\).$7
M)O;^OU!P:1U=(WW32TC?=-<A!ZM;_P#'M%_N#^525';_ /'M%_N#^525]G'9
M'>%%%%, HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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B*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>figure_013.jpg
<TEXT>
begin 644 figure_013.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" $N G(# 2(  A$! Q$!_\0
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M^ES_ -\#_&C_ (6!HOI<_P#? _QKRFBCZA1\_O#^TZ_E]QZM_P + T7TN?\
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M6FA7-W<:9;K+")-0@,\9.<*!GKQUXK*-##2U3?W_ #.B>)QD79I?=YV/0_\
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MB^ES_P!\#_&C_A8&B^ES_P!\#_&N'EM]+TBRT_[;8S7MS>P^>Q6?RQ"A.!C
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MSUMX+>-8XA#$P5?4H"3^=9=:0P5&45)7^\SGF&(A)Q=M/(]6_P"%@:+Z7/\
MWP/\:/\ A8&B^ES_ -\#_&O*:*KZA1\_O(_M.OY?<>K?\+ T7TN?^^!_C1_P
ML#1?2Y_[X'^->4T4?4*/G]X?VG7\ON/5O^%@:+Z7/_? _P :/^%@:+Z7/_?
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MCU;_ (6!HOI<_P#? _QH_P"%@:+Z7/\ WP/\:\IHH^H4?/[P_M.OY?<>K?\
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M,7K+N$.>2.M)R2W8I24=W8N4444QA1110 UT21=KJK#T89IGV6W_ .>$7_?
MJ6B@"+[+;_\ /"+_ +X%'V6W_P">$7_? J6B@"+[+;_\\(O^^!1]EM_^>$7_
M 'P*EHH B^RVX/\ J(O^^!4M%% !1110 4444 %%%% !1110 445XE?>-/$$
M&L^*4^VW*W$0NTAACD1UM8HWC E:'9N3Y&+*Y8ACGC % 'H7Q,_Y)GXB_P"O
M&3^5=)8_\@^V_P"N2_R%>.:WXBU2;X7^([6*VO-=T[==00ZQYT6!"N,,QR-^
M"6&5'.*]CL?^0?;?]<E_D* )Z*** "D(# @@$'@@TM4]6N;JSTNXN+.U-U<1
MKE(0?O'_ #S2DTDVR9248MOH<[H-]IP\1ZK;G3XK*1;@+ [HJ%OE"E5Z==N[
M [-775R&EZ5#K]X=4U:R>"^M[A'$6\C8?+0@$?@#77USX7FY'?:^G3[T<V"Y
MN1WVN[=-+O== HK,L?$.EZCJMWIEI=+)=VAQ-'M(VX.#R1@X/'%:==<H2@[2
M5CME&47:2L%%%%22%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445YG\5;W5=*@
M^V6/BW^SXW@,?]G(8TED?/#QDJ6)YP5&.G!!Z@'HE[?6NFV<MY>W$=O;1#<\
MLC851]:R=,\:>']8O5L[._/VA\^7'-#)"9,?W=ZC=^&:=);KJ7@Y([F>^^:V
M21I9'-K.2 &RQ4#RVR.< 8YKD?A;+<W@N+FZU*[O!)#%(L5PMX1$3G[K7!*M
MUQE.OY4=0Z'=ZMH]MK,%O%=&0+;W45TGEMCYXW#KGCID<UG#P=IDNJ/?Z@T^
MIL5=(HK]EFC@5V#,$!'JJ]<D  # KH** .2^'<<</AZ\BB18XTU:_5$10%4"
MYDP !T%=;7*?#_\ Y =__P!AC4/_ $IDKJZ "BBB@ JJVFV3:BNH-;1F\5=@
MFQ\P%6JQ9()CXDCB%_=B%H6G,09=N0RC'3..3WK.HTK75]3*JTK75]4;5%%%
M:&H4444 %%%% !1110!@>+Y-3M]%:ZTNY,4\3#</EP5) )Y!Z?AWJ?PUJD&J
MZ0DD=VUS+'\LS,,$/C)'0<<\''2N>\:Z!?WTW]I0SK"(56-<3-R"PYV[>#D^
MO:NET2SN;"U%O-;V<0"C+VY/[Q^[$;1R:XH.H\2]&E;^GY'GTY57BY734;?)
M^:[&I1117:>@%%%% !1110 4$X'-%9'BB?3;;PMJD^L0M/IR6SFXB49+ICE1
MR.3]10!I+<P-<-;K/&9U4.8PXW!22 <=<9!Y]JY?7/&5QIFIR65II<%P8L;Y
M+G4X+8$D _*&)8]>X KA?AY8Z-I7Q!D6#1[VU,D+V=LUTD6^&6+#RH61B6.V
M1<.>H&,G&:V?B+IUO+XBTY(=/1I+F":6=[>WLA*Y0QJI:2Y&" &(P.>G84 >
M@:1J$NIZ>ES-8RV<A.#%(Z/^*LA(93G@YJWY,7F-)Y:;W&&;:,D>A-5]*3R]
M'LDVLNVWC&UMF1\HZ[/E_P"^>/3BK=# Y+XDQI%\+_$,<:*B+8R *HP!QZ5T
M5O*L&DQ3/G9' &;:"3@+G@#DUS_Q,_Y)GXB_Z\9/Y5:USPY!XK\'C2+FXF@C
MFCC)DA."",$=>"..E:4E!S2J.T;ZO>R$]M#%/BW7=3\<V%EH>FO+H:@K?W%Q
M;21-$XSE<L!@@;3C!SFN[KEO UC'IFG:C81/))';7\D2O*VYF"J@R3W-=373
MCG3514Z4;**M?J^MWYZBC>UV%,EFB@3?-(D:9QN=@!^M/IDL,4Z;)8TD7KM=
M017"[VT&[VT,C3]0LEO]4)O+<!KA2"95Y_=)[UM=N*Y;0E%UK>M0W&BQ0Q13
MCRW9 0?E P..X ;C^]707]];:7837MY*(K>%=SN1G ^@K+#.4XZ=WW[LPPKE
M./S??N^YAZ-;W2>(=29H=+1E=1/+;VK))-E P).X],^]=+7 P^*YWUMKC1-,
MEU.RU"YB5YTR!$/+4'(QP>O7 XKOJ]#%TYQDG-6NOR[ZZ?,]#$0E&2<NP444
M5RG.%%%% !116)XBUZ;0H(I8],FO%D<)F-@ I/;N<^G%1.<81<I;$5*D:<7.
M6R-NFO(D2[I'5%Z98X%-@D>6!))(6A=ADQL02OUQQ7*?$/3&U30XXI#"MLDT
M;,7D*-N+!1C@@C#'.:Z*$(U:D8MV3-Z,54FHMV3.OHJM812P6$$,PC#QH%/E
ML67 X')Y/&.M6:S:L[$-684444A!1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !7E?Q+F\.VFL@ZJFI65_<V@CM;W3Y
M5+7&'_U+HQP &*G+@+S]X8KU2N5UV^LM/U6??X2U+5);FV6*:XM;2.57CR?W
M;%F&1U.,8YI 7MFJ3^#$%Y=+;:D;16N)1&L@5L OQD*<\C@@<\&N#^'6MQ:?
MJD6EW%CJ\*7<,?V.>ZDF,;*0Q0;))'"9"G!!YQCCBNX\/17%CX"TZ&YMA'<Q
M6"(UO(O1MF-A ]^,"O/?AS9Q:?KD4=]HNJ"29(Y(9[K29H5M9MKAHE8D@1JI
M(4'^\<9S5=0Z'?\ BK7=1T232?L5E#+!=7\%M<32R8\I9)%3Y5'+,=Q]ACOT
MK!T_XAW']I9U*T!L+E;I[=;*WEFGC\BX\G#JNXMNSG( QTYZUW5W96M\D:74
M$<RQRI,@<9VNIRK#W! -06FBZ987]S?6EA;P7=T<S31Q@,_.>3]>?<\T@.>^
M&\Z77AFYN(PX275;YU$B%& -Q(1E3R#['D5U]<K\/_\ D!W_ /V&-0_]*9*=
M)8ZXWCV+4%U^!=#6'RVT[ W%\$?SP<YSQC%:TJ:J7O)*R;UOKY:)ZO[A-V.H
MHHKFI+%3XT35?^$C*PI'Y)T[S!M+8(Z9]>>F<BL)2M8WHTE4YKNUDWLW=]M-
MK]WH=+68_P#R,\/_ %YR?^AI6A,6$+E5+MM.%4X)/H#VKSQ-*UK1[D6VAQ7"
M7,D;R%KR:-\+N7.,' [?6L,14<.72Z\CSL55=/EM%M7Z?Y>?J>C45#:-.]G"
MUR@2<H/,4$'#8YZ5-70G=7.I.ZN%%%%,84444 %%<CXEMM;L-8B\066I;K*W
MC"2:?(S*CDG;G@'/+ \CM6EX9A\0PVMP/$5S;3S&4F$P# "?D/P[UFJEY<MF
M=D\(HT%651._36]^JM;IHWTUT)?$<A&E/"D,\LDC+M$43/T8$YP.*TK>=;F%
M95610>TB%&_(\U2UW57T;3&O$LY;LA@OEQ=>>Y]JNVTQN+6&8QM&9$#E''*Y
M&<'WI)KVC5];+^KGFQ:]LU?6RTM^I+1116IL%%%% !1110 5B^+H8+CPCJL5
MS]E,#6S^8+J5HHB,<[G7E1[CI6U5743*NG3M!9I>3!"4MW<()#V!)! ^M 'E
M/@#^R;OQC;S6FCW>E3I;O<,NK7\\DUP9  7A1SM9>!F0\GC@5?\ B1:0C6;8
MK9_;[B2WFN EY<V_DPK'L#;4G1ASD9"D=,GUK<MU\3ZOXOT>^U'0H],LK%+C
M>1?K,79U 7@*.F#^=9OQ&@EUJ\M+.WM;K4(;5)))(]/6U>2&X^4Q>9YV=JX+
M' '/%#!'2^"=<37?#<,RVBVK08MVB0J4!"J1MV\8PPX[=.U>=Z_XP\1_\)-X
M@2&/5;*./2YEM83:L%C5)D#7 )&&)7>0>WRCKFO2?"&H-J7A^*66S-I<H?+N
M4(C&9@ 7;$;,!DDGKGUK<P,YP,],T/<$>*ZSKFLR_"SQ#!:V=SK>CEKJ*'5I
M;M RP C:QW?-*,EN1U KU=M2CTW2[.26"[E#1J +:W>8CY>X4'%8_P 2P!\,
MO$0   L9, ?2NEL?^0?;?]<E_D*J+2=VKH#@/ _BV>XN=;2^T#5+3?J3M&1:
MR2#YL JV%^4C )S_ 'O:O1JP/"_W]<_["LW\EK?KKQ\X3KMPCR[=6^B[DQO8
M***"0 23@#O7$49VG?\ (1U;_KY7_P!%1U-J5F=0L);42+&)!M8M$L@*]P5/
M!S5/2[JWDU/5%CN(G9KA2H5P2?W2=*UZBC*R3CW?YLSH2]VZ[O\ -G'Z-HU[
M::AJEK9ZH+>*%XE"QVD87_5KT':NO4$* 3DXY/K7+>'](:S\8>(KPWUQ*)9$
M'E.?E7<H;],X'H*ZJNW%RYI[WT72W1'9B)7GO?1=/)!1117*<X4444 %8GBC
M4;73M-A>ZF$8:YAQP3G:ZL>GL":VZYG7]3TB]N5T69HY;Q)X',3H2!\ZYYQC
M.T_D:QQ$N6F]4F]KG/BI\M)ZI-Z*_<Z56#*&4@@C(([US?CG2;75_#OE70?:
MEQ$R[&P<EPA_1C70PS0SQ[X)$D3IN1@1^E<EXUU35[72)1#HGGQ?:(@LBS@D
M@."#M R,D ?C7?@U)UHN#UOWL=V%YG5BX/7U.NAB2"".&,$)&H503G@# I]4
M=/NK^Y#&]T\6G *_OQ(2>XX'&*O5A)-.S,I)IZA1114B"BBB@ HHHH ****
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MY1117.8A1110 4444 %%%% !1110!RGQ,_Y)GXB_Z\9/Y5TEC_R#[;_KDO\
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M/Q4FH6'VY[MIT>$S3"=?L_DB$"160'F0R;N=OH00!BNYHHH ***3(SC(SZ4
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M9_CO_H8M$_\ !3)_\?H_L_QW_P!#%HG_ (*9/_C]=712$<I_9_CO_H8M$_\
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M9_:OQ!_Z%;1__!LW_P :H_M7X@_]"MH__@V;_P"-5V=% '&?VK\0?^A6T?\
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M>MKPWIES#K-B\6F7%G-#-=G4+B1/+6=&=S&O_30Y*L#S@ \C.*[^B@ HHHH
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M% &)X1\)V^GV5E=W,#>=%#BTAG&9;&)PK-;%P?WBJP.-W3 ^M==110 4444
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M_0\BB'2=(M[E+B&SM4F1Y'5U4 AG^^0?4]Z -&BF^9'_ 'U_.CS(_P"^OYT
M.HIOF1_WU_.E#*WW2#]#0 M%%% !1110 4444 %%%% !15#7)+>+0=0>[DN(
MK=;=S(]L2)57:<E-O.[TQSFO$U@LK_PB[Q7MW8:=)JBS_8VL[F[6U40,J))R
M&R[?,V"5#$#/<@'O=%>:V7B3Q=HT'A=-1T32;33=0FMK%88YI3/ 63."K# Q
MM/&2>F:]*H8%2^U*VTX0&Y9QY\RPIM0M\S=,X' ]S6;_ ,)?I @,WF3[!#).
M?]&DSL1MK<8ZY[=36I+?00R&-S)N'7$3$?F!3/[3M?67_OP_^% %I'$D:NOW
M6 (R,4ZJ?]IVOK+_ -^'_P */[3M?67_ +\/_A0!<HJ""\AN'*QE\@9^:-E_
MF*GH **** "BBB@!DTT=O!)/*VV.-2[-CH ,DUDKXKT1D#"^&TK"P.QNDIQ'
MV[G\N]:$M];PR&-S)N'7$3$?F!4?]HV?I)_WX?\ PH ?8ZA:ZE%)+:2B1(Y7
MA8X(PZG##GT-6JIC4K0=/-'_ &P?_"C^T[7UE_[\/_A0!<HJ""\AN'*QE\@9
M^:-E_F*GH **** "BBB@"IJ5U/9:?+<6UG)>3)C;!&P4MSCJ?S_"N5_X3'Q!
M]M,/_"&WNP1[L^;WSZ[<?AUKM:*WI5:<$U*"E\W^AM3J0BK2@G\W^ASWB&YO
M9_ 6H7$4$]M>O9,RPHQ\Q'*] 5YS[BLRVA\0Z3>16<<P:%UN;SR,O<;0OE!(
M!*^#R2YR1WP.!7:45BW=W1D]6>;CQ+K\^D1M/<10I.VV2>.U>1X&\HMY3( ,
M$O@#OVZD&EM=2\0P:'$I#-!';I:BW:V?>?\ 0!+O+YSGS!M_$CK7H]%(1P3^
M(]7MWNH <*B6Y#I;EUM8V**[.#\Q<98XY&.>Q%5DUG65N9;]S( T,4'VO[,V
MP0_:95\_R_4IM/X@]*]&HH X2VUSQ),\<I*_9X3;\?8V4W2/<O%OY/R?NPKX
M[9STXK2\):OJ^JRW)U(0H%4$P!2LD$FY@4(QTP!W)ZGH174T4 >>RS)<1^)K
M5=9N8DCU""199S,PV@1ED!7!"%@R_*0!S6JFHZH?"6D26=N;.YN+B*!@Z/-L
MC+E2^&PW*C<-W(R,UUM% 'G#>*/$EG91O>'>]P(PIBLB&0^<T;!5)^9BHW8/
M3GM7:>'KJ:]\/V-S<7,-S/)$#)+!]PMWQ]#D?A5N]L+348/(O+>.:,,&"N,X
M(Z$>A]ZDM[>&TMT@MXDBAC&U$1<!1["@"2BBB@ HHHH **** "BBB@ HHHH
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MTP^)!K_D'^T!'Y>_<<8QC./7'%7!0UY[[:6[_P"1<.77F_IFM1114$!1110
M4444 %%4=5U%],LO/CL+N^D+!$@M4#.Q/U( 'N2!67IGB+5+F]CMM2\+:CIX
ME.$F\V*>,<9^8QL2OXC'O0!M7\-Q<:?<06EU]EN)(V6.?8'\IB.&VG@XZXKA
MK;X;WMMI=K"GB%5OK2=YX+U+!=S&1&24R@N?,9@V=Q(((';BO0:* /*_$7@S
M0?#,_@F33M/ACNTUJTMFN]H\V5!&X^8]\[03]*]4KBOB'_Q\>#_^QCMO_0)*
M[6@ HHHH **** "BBB@ HHHH **** "BBB@ HHILLBPQ/(YPB LQQG@4 9UW
M_P C!IO_ %RG_P#9*TZXK4=?E/C#3'MWC-@L;AV:)]PSC=VSV7&*Z^UNX;R'
MSH&+)G&2I7]#7/1JQG*27?\ 1'+0K0G.:B^OZ(FHHHKH.H**** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** ,3Q7I
M^L:EH$\.A:J^FZDOSPS!%8,0#\C;@< ^HY'Z5A>'-!\0DV-[J'C*_F= K7-B
M4MV3=CE"R+TSW&*9\6$O9O"MK;VMOJ%Q;S:C E]%8(S2M;9)D "\]A7&V5MI
M5MXS\.3>#_">OZ/(MWY=^\UC-%$]N5((?<2#SCK0MP>QV/Q*M=&L],CUF\\*
MV.M7AEBM%>Y"JL2LQ 9Y"#M0$]?5J3X?6B6]U?%?#6@Z1N1?GTN[69I.3PV%
M& *K_%:;3=1TJ#0I=3TRUO\ [1#=QQ:I,T-O,JL<JS 88'!&W/OZ5;^'NCSZ
M>UW<OI/A:SAF10DVA.S>9@GAB0!CTQ0@9W5%%<C=_$'3;479%G?2_9;M[9P(
MPI(CB$LD@#$955/U/8&@"/5/^2N^'?\ L%WG_H45=E7!W&I6.H?%W0A97MM<
MF+3;Q9!#*KE#NBX.#QWZUWE !1110 4452U'5;72TC:Y+_O"0JHNXG R>!2E
M)15V3*2BKR=D7:*S-'U_3==64V$YD,1 =2I4C/3K]#5C4+X:?;^<8)YQG&V%
M0S8QG."1QQ13:J6<-;CIRC52<'=,MT52TS4DU2T6YCM[B&-L%//3:6! ((Y/
M'-7:J47%V>Y33B[,****0@HHHH **** "N?:&['BJ.#^U;WR&@:X,7[O;D.H
MV_<SMP3WS[UN3S1VT#S2DB-!N8A23CZ#DUS#>(=-/BJ*82R[!9.G_'M)G.]3
MTVYKHP\9OF<5?1]#>C&3O9=&=714<$\=S DT1)C<;E)4@X^AY%25SM6T9AL%
M%%% !7B?BJ'3GU3Q+]JO]6O)1,Q6ZBBN6M-/8HNWS2AVAHOF(*]-WS<]/;*\
MF\7V+^&'U(77B'5[#0=7EDEN)8;2WEBC>7Y60Y!EY&.0#U[4#.T\2Z=8WG@6
M?^T([?4TM;0W"/= E)'2,D.VWL>O'K7,?"W2XK*YO)TM)[=IH$)\S0FL!US@
M,6._Z5U6I6RQ^!A#:7L:6<5D \LT#R"2 1X/",K E>X.:X_X>:YH%OK#:;;K
M/!<7$2B%I)KUDE&"0%6X7"<*2,$YP?2GU8NAZ=.LKV\J02"*9D(21EW!6QP2
M,C./2O&KV\U(>#/)O/%!MVB\0WD4M]>2S1"98S(%0M%C8"0,#('&!GH?:::4
M0J5*+@G)&.II >0:AJ^NZDG@(7WAUM/TXZK9217$M_YTK-Y3?*R$;@>3RQ)X
MYZU[#7%?$/\ X^/!_P#V,=M_Z!)7:T, HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH S+O_D8--_ZY3_\ LE:=<WJ6M6]OXTTJP>.8RM&XW*N1\^,?^@G/
MI725E3DI2DD]G^B,*,XRE-)[/]$%%%%:FX4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 1W&TVTH979=AR$^\1
MCMCO7FGA.S\:QZY!):MJ%IX9!^>W\0S)-<L/2/:-R?1V-:7Q:N9;?PQ8*);R
M*TFU2WCOFM-_F?9\DR8V?-T':N'\ W]EJ>MV,>NZ]K=P]G>/'I&GR6TRQA Q
M,<DK[?G;!XW'@"A;@]CT3XF:Y<:#X5CGMGMHWGO(;8RW<'FP1J[8+2#/"@=^
M?IS7G'ASQ3<Z+\0(]/L1X:OH;N]@LYY]'LO*$JNK-N#JQ4E"#D<\'KZ>B_%#
M6KG0_!_G6[V<2SW45M//=QB5(8W;#/Y9^^1_=^OI7*_#[QEI$/B"]T"XUS1;
MV**2(:==V]HEJTTD@PR*B\''RC(ZY[]A;@]CUVN=U/P7I>K27$EP]TKW$_GR
M&.7;G,0A9.GW610"/U%=%10!P,VDZ=IGQ>T-K#3[6T:?3;QI3!"L9D.^+EL#
MD\GKZUWU<;JG_)7?#O\ V"[S_P!"BKLJ "BBB@ KEO&VE6-QIIU2[2=WL4)1
M8FQNSCK[ X-=363K5Q?)9W:0V*RPF!LR&<+CY3GC%8XB,94VI?YG/BHQG1E&
M2_"_H0>%+2P31X;ZSLA:O=QJ\H[DCC\NIX]:YSXCZ.^H265[8:I#;ZE9\K#+
M<+'E3_$,GKQ^(KJ]&GO9+2V2>R6&(0+MD$P;/ QQBK&HVEM-:SR2V\3N(FPS
MH">A]:Z<OJ^P<9QZ>7??1]SHR^HJ*A*/3RMZZ>9Y_P#"^^O-4OKV]GU(BWV+
M!%8-+NQM"_,!V '' [UZ;65X?MK=-#TV5((ED-I%EP@!^Z.]:M;XVJJM>4HJ
MRV^[0Z,5452JY)6_X 4445RG.%%%% ",RHC.[!549)/0"LU?$.D-8+?#4(!:
MM)Y8D+8&[TY[UH2Q)-$\4BAHW4JRGH0>HKD/^$.T8ZG_ &9Y,OV18!.(_/?&
M_<1GKZ<?2L*TJL6N1)^O?H<U>=:+7LTG?O??I\MSKIVE6VE:!0\H0F-2<!FQ
MP,UXI-K?C'Q'J46EK;S6NI1DP7$\ 9"B%P<G'W0".2.HQ^/MRJJ($4 *HP .
MPK&;3M5.NKJ O++RU0PB/[.V?++!NN_[W'7&/:O6P.(A1YG**;Z7[GJ82O&E
M=N*;Z7[FI:12P6<$4TQFE2-5>4C!=@.3^-3445PMW=SE;N[A1112$%>#Z_XJ
M=OB#=?:=4T:UGCGGLHI[ZQ$C:;%&5*R(?XF?<_!XX]!BO>*3:I[#\J ,;5I;
M=?!-[+/F_MAISM)E]AN$\LY^8?=W#OVS7F?@&YTV[\410:OXEM-6U!5CGLI8
MM2,@X$@$!5@"2H8MGJ>"<8%>KZOISZI8&WBO[FQDR&6:WVY!]"&!5EYY!%8N
MD>$[ZROX[J_\037HB.4BCLX+="<8^;8NX_3('M1U#H=---%;P23S2+'%&I=W
M<X"J!DDGL*Y3_A8VAR:/%J5K'>W<<]U+:P16\!:69HP2[*N1\H52V3CCWXKK
M2 P(8 @\$'O7!S> ]1C@6>PU*VCU&'5+R]A>:!GCV7 =61@&!R V00>H]* #
MQI?6^IVW@:_M)!);7.O6DT3@8W*T<A!_(UWM>2:WX%T;PK<>")[*.5KU-8M+
M62X>9R)%$;@G86*KG:#P*];H8!1110 4A(4$D@ <DFEJMJ"VTFG7$=XX2V>,
MI(Q;;A2,'GMUI-V5Q2=DV48?$-M<7(A@M[N4GD.D>5*Y(W;@<8R#6O7BSQ_8
M)9]&:X#6=Q*OEW%M*'V('/+8ZCG)!QTKU_3A$NFVR0W!N(UC55F+9+X&,YKC
MPF)E6;4MU_7],\_ XN==RC-:K^OZ9:HHHKM/1"BBB@ HHHH **** ,2\_M$Z
MS;W$6F>9';K(@;SU!;=MY /3H:VZP[Z/Q ?$MD]I+"-)"_OU.,D\Y]_3&*W*
MRI[RWWZ_H84?BGOOU_3R"BBBM3<**** ,N\\0Z7837L5S<^6]E;"ZG!1CMC)
M(!''/*G@<]/45+-K>F6R[I[^WC^9$(:0 JS_ '01VS[UA:WI>BWNLR&[UJ&V
MN7C"O 94!*!6P"#SC)5_J@J0>"X!.)/M;,L<GF1*T*G&9%D<,>KY*X&>@- '
M027UG$KM)=0(J'#%I  O0\^G4?F*8VIV2EE%U"[A Y1) 6VG&#C/3D<^]<N/
M EI8V]U(-6GCWA6>67;A2K9+'IU58T)R.(Q[U':>$]$6QL[.'5XI&<9AD#1E
MYE6)8^,?> "9X[T =7>:MI^GK(UW>P0B(*SAW *@D*"1UP20*==ZE96*R&XN
M8T:.)IBFX;]B@DD+U/ /2N5U+P]HKZK=7LVL002WK'RQ*ZDB0;4.W)P1E -N
M.O?H*EUK0-.UGQ%^^UQ8[D1[19JR;P3&ZYQG/W9">0>G7'% '27NHV]A!'+,
M7;S6"1I&A=W;!. HY/ )^@-00:]IUQG;.4"H'8RJ8]@.?O;L8Z&B\TN2ZBMR
MEV8KFVE,D$PC! R"N"IZC:Q';UXK*N?"EO=W(^UZE)-<.H9Q(J9D"GD[<=.0
M/;@4 :UYK=G9Q6SYDN!=,1"+6,RE\ DD;<\8'6DLO$&E7Z2/;WT)$:AWW-M*
MKM#9(.#C##G\*H_\(UIM];V:M*)[:WNI[A50C:S2,^1E>RER/PJO=>$+&Z>=
MK2Z%LPD/^I1<1_NXTV?0",''!Y[<&@#<;5=.10SZA:JI4."9E *GH>O3WIW]
MI6!"D7MMAY/*4^:O+_W1SU]JYRR\%:=9VBNUWYT:MYQED12",2]_3]\3^ JI
M+X+TRX>*P@UGRV$<;FWCV9956-0^!S_RS'/3GZ$ '7G4;$!B;RW 63R23*O#
M_P!WK][VZT^VNHKR$RPL60.Z9((^96*M^H-<E=^%]/BM)$N-9BACA+1%I(X@
M(XY%QM;/\9!X<\^W)SO6,FFZ/:2V9U&#%NS2R>;,H:,.Y8;N>!\V 3UH U:*
M;'(DL:R1NKHX#*RG((/<&G4 %%%% !1110 4444 %%%% !1110!SWB'3_$=Q
M.L^B7^G>6%"O9:E:EXF.3\P=2&4]NXXK/TS2/%TM_!-JMQX?LK>)P[1:;9L[
MRX[%Y/NCZ+GW%=C10 56OM1LM,@6:_NX+6)F"!YI @+'H,GOP:LUS?C+0;W7
M;&U2P:%+F"8R1RR321F%BC*)%*=2N[.UN",CB@"AJG_)7/#O_8+O/_0HJ[.O
M.(M(N-*^+^D-/K-_J/GZ?>.JW;(1#\\7";5&!SWST%>CT %%%9?B*ZU.RT*Y
MN-'M5N;Y /+B89SR,\=\#)Q2;LKETZ;J34%U=M=%\V:E5=3_ .05>?\ 7!__
M $$TW29KVXTBTFU&!8+QXE,T:]%;'(K'\2:EJ,-[9:796>^.^S'+<%"PC!X/
M (Z YY-9U:BC3YG_ %<PQ35&,E+7IIKKM_3-O3?^07:?]<4_]!%)J%E]OMO)
M^TW%N,Y+0,%)&,8.0>.:R/#BZ_%=7EOJRQ?9(=J6KH -P'&1@DXP >:T]9TT
M:QHUWIQF> 7$93S$ZK5X:=^5OW?5;=-AX:?-&+=X^J[:;"Z7IRZ99+;1W$\\
M:@!#,P8JH   P!QQ5VLW0-(&A:':Z8MP]P(%*^8XP6R2>G8<UI5K4=YMWOY]
MS:;O)ZW\PHJGJUQ=VFD7EQ86OVJ[BA9X8,X\QP.%_$UY_IGQ>T^#1=.?Q'$]
MMJUS*8Y;:")OW0W$!V#<@=/4^E=%# U\1!SHQYK.UEOLWMVTWV,G)+<],HJ*
MYD>&UFEBB,LB(66,'!<@<#\:\:L[[Q=K?B.W&FV%WISQ;9I4EN)?+*[CR1(>
MAZ8'7;Q7G5:RIM*U[GIX#+I8N,Y<ZBH[MO\ X-_P9[-.\D<+M%%YL@'RINV[
MOQKGQ>:E_P )$S?V5\_V0#9]H7IO/.:Z*3?Y3^7CS-IV[NF>V:\PA\6:]I^N
MM!>V"W6H@"(JA'W2V1C;QWZUCBJT:;CS-K7HCY_&UXTG#F;2;Z*_],].B9WB
M1I$\MR 63.=I],]Z?0.0,C'M178=Z"BBB@ HHHH **** "BBB@ HHKBOB1>:
MC;Z9I\6G:K;Z<\MT3))->"VWHL;DHKE6 ).#T[4 'Q#_ ./CP?\ ]C';?^@2
M5VM>/ZCXCO=;C\!"30]3MK1M6LYH[^\EC;SB8FX.TYW').=H!P>E>P4, HHH
MH **** ,Q?\ D:)?^O)/_0VK3K V^&O^$A^P^5;_ -J?ZS;L.[/WNO3/?%;]
M94GOJMWL8T7?FU6[V"BBBM38**** "BBB@ HHHH **** "BBB@ HHHH Q-;T
M675))FB>)=^G7-H-V<AI-F#QV&TUCR^%-8748GM=5>.SBE9HHOM#YB4D'N"6
MSR,$C&>#79T4 8T6G7EKX8_L^)+:>YC@"(;J1I$D? RSY!.-V3W_  K(M?"U
M['<0/)]F&^2*6Y<R%WWI(\A*_*!\Y?D<!><9KL** .>M_#K0165J!;K96][-
M=-"@(!!9FC4#&."P)]U%17VA:A=WUXL9M8K>XNHKI;G<3+$41 ,+MQG*==W0
MGBNFHH XK3?"^N6GV4W-^+GRY-S))=R84_)F0;0N3\K_ "GCY^O7.WJ>AR7F
MI->6LR6D[V<ELUPJ9D&YD(Q[ *W?J:VJ* .>TS0[[3O"LNC1W,$4HCE6"X@4
MH(RS,5PO; (YS_C63;>$]7@GWQ7$-NK3^:%CNI6\CYER1D?O"RJ5(; ';N*[
M>B@#&&C/-X8ETJ\6*622V$3L[%UD81A=QR/4?IGO5*VT"^M=3AN!]D>.)EFW
M;F#LXMQ#LZ?=XW9_#'>NFHH YB\\-SB]NKNRCLBTMTMP(I<JKGR6B8L0#S\V
M>AZ8JA'X3U6QB5;-["62W5A!-/G+,YCRS#:0"NP[>N3MSC'/;44 4])LQI^D
MVMH(Q&(8PNT2;\?\"P,_D*N444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% '&ZI_P E=\._]@N\_P#0HJ[*N-U3_DKOAW_L%WG_ *%%794 %4-6U&72
M[)[I+*6ZCC5GD\MU4JH&2?F(S^%7ZR?$5U;IH&J1//$LAM)?E+@'[A[5,W:+
M9MAXJ56,6KIM?FET+MA<RWEJLTUJ]LS=$=U8X['*DBK-5+"Y@FM84BFC=A&N
M0K@D<"K=-;$5%:;TM_7F%%%%,@**** "N;_L^RU#QKJ/VVT@N?(M;22+SHP_
MEL'G^9<]#]*W+T7AM'%@T"W/&PSJ63KSD @],]ZY*U3Q/_PENI[;C1_.^QVV
M\F"7;C=-C W]>N?PKLPL7RSDI).W>SW7D3(["XN$M;=YI!(57J(XR[?@ "37
M-1Z]:#Q3<R^3?[391+C[#-G(>3MMSCGK741[_*3S2IDP-Q48&>^/:LJ+_D;[
MK_KPA_\ 1DE<%1.ZL^O^9VX:4%&?-&^CZV[>3-6-Q+$DBA@& 8!E(//J#R*K
MKIM@LPE6RMA*&W!Q$N<^N<=:M4532>YQRC%[H****8PHHHH **** "BBB@ H
MHHH *@N[*TOX#!>6T-S"2#Y<T8=<CH<&IZR]<\0Z;X<M8[C4IG197V1I%$TK
MN<%CA5!)P 2>. * .>^(0 G\'   #Q%;8 _W)*[6N%\<74%]'X(N[659;>?7
M[62*1#D.ICD((^HKN6947<S!1ZDXH 6BF)-'(<)(C'&<!@:>2 ,DX HV **8
MLL;$!9$)/8-3Z :L4_[*L/[3_M+[+']MV[?.Q\V,8_EQ5RBBDHI;(2BH[(**
M8TT2L0TB CJ"PIX((R#D4[#"BBD9@JEF( '4F@!:*C6>)V"K*C,>@# FI*&K
M %%,$T3' E0GV84^@;36X4444""BF-+&IPSJ#Z$TX$,,@@CU% "T444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M%% !1110 4444 %%%% !1110 57OX9;G3KJ""5H9I(G1)%."C$$ @^H-6**
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
+"BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>figure_014.jpg
<TEXT>
begin 644 figure_014.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" %. L(# 2(  A$! Q$!_\0
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M_O\ R$_^%'_":Z!_S_?^0G_PKQ^BO8_L^EW9X']J5NR_KYGL'_":Z!_S_?\
MD)_\*/\ A-= _P"?[_R$_P#A7C]%']GTN[#^U*W9?U\SV#_A-= _Y_O_ "$_
M^%'_  FN@?\ /]_Y"?\ PKQ^BC^SZ7=A_:E;LOZ^9[!_PFN@?\_W_D)_\*/^
M$UT#_G^_\A/_ (5X_11_9]+NP_M2MV7]?,]@_P"$UT#_ )_O_(3_ .%'_":Z
M!_S_ '_D)_\ "O'Z*/[/I=V']J5NR_KYGL'_  FN@?\ /]_Y"?\ PH_X370/
M^?[_ ,A/_A7C]%']GTN[#^U*W9?U\SV#_A-= _Y_O_(3_P"%'_":Z!_S_?\
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M!HQ5VV5',J\W9)?U\SU#_A-= _Y_O_(3_P"%'_":Z!_S_?\ D)_\*\Q;2O\
MB0VVH([M+/=FU6$+[$@Y_"JQT^[5[I3;N&M!FX'_ #S'O26"H/JQO,,0K>ZM
M?4]7_P"$UT#_ )_O_(3_ .%'_":Z!_S_ '_D)_\ "O,%T'5GA,RZ=<-&$$FX
M)QM(R"/7CTJ*YTK4+)83<V<T0G.(]R_>/H/?VI_4J#=N;\4#S#$I7<?P9ZI_
MPFN@?\_W_D)_\*/^$UT#_G^_\A/_ (5Y;>Z+J>G0+/>64T,3' 9AQGT/I^-.
MDT'5H8)9Y-.N$BBY=BO"C&<_E1]3H?S?B@_M#$[<OX,]0_X370/^?[_R$_\
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M8) Y]>*/JE"[7-MZ!]>Q/*I<JU\F>I?\)KH'_/\ ?^0G_P */^$UT#_G^_\
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M (370/\ G^_\A/\ X4?\)KH'_/\ ?^0G_P *\?HH_L^EW8?VI6[+^OF>P?\
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M?_94?7:/?\&']GXC^7\4>>45Z'_PK2/_ *"C?]^/_LJ/^%:1_P#04;_OQ_\
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M%&_[\?\ V5'UVCW_  8?V?B/Y?Q1YY17H?\ PK2/_H*-_P!^/_LJ/^%:1_\
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MH=[$<'/\.,MZ ]Z -&BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%\0^(ET Z<IL;BY-
M[>16NZ,82+>ZKN=NW+# ZG\R-JJ6IZ5;:O!##=!]L-Q%<IL;!WQN'7\,@4 <
M?<^.IKV/4+>TA>P=4F>RO&7SQ,(IO)?<B@E!OP,D'@Y]JV-!\;:-K%Y%I'VY
M!KB0AKFS,;(\;@#>"",#!/J:MZ9X6TS2-6N=2M5F\Z?> KREDB#OO<(IX4,_
MS'WK@ULO(_:/^U["/M&G.-QQ@[4C']XGO_=7\:%L!ZC<22Q(#% 9FS@J& Q[
M\U7^UWG?39/PE3_&K,TT=O$996VH.IQ57^V+#_GX'_?)_P * $DGGFB>*72Y
M6C=2K+YD?(/4?>IEHS6-I%:VVD3100H$CC1X\*HX 'S52M9H[>[6:77KB>,>
M9F)XP%.Y@5Z+GY1P/8\YK1_MBP_Y^!_WR?\ "@!WVRX[Z;<_]]1__%T?;9AU
MTZZ_./\ ^*I\&H6MS)Y<,H9\9Q@BK- %6.[D>14:QN8P?XFV8'UPQJU110 5
M7N+M;=@IBG?(SF.(L/TJQ4$][:VK!9[B*)B,@.P&: (?[2C_ .?>['_;N_\
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M4 <W]I\:_P#0+T'_ ,&,W_QFM^V,[6L1NDC2X*#S%B8LH;'(!(!(SWP*EHH
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M_P#/I!_W[%'V"S_Y](/^_8JQ10 @ 50J@  8 ':EHHH **** "BBB@ HHHH
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M+B]W*L32QWPM<.8VEP&'S+A$)W#O@=ZV/!FE6=EX9ADMI)YX;\?;,W+%F(D
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M)+1K=+IIN=1145M)-+;(]Q"()2/FC#[MI^O>I:LY&K.P4444""BBB@ HHHH
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M134I+1=/F\R6%(PPN!D?*?R(YSP373T5ST:TZ,N>F[/7\58Y&D]QK95#L7)
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MNCB859.*337?^F6:***W.@*\9\?Z4OACQKI^J^'7N1XCUFX9(VE_>0QY78<
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M%%%00%%%% !7+^+]$N-4N] NK99I'LM4AF>-9=J+&#\SE<X8@=.I&3BNHHH
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M:(\MK+;/T,4I4L,?[I(_6K%%6Y^YR6\R^;W>6P4445! 4444 %%%% !1110
M4444 %%%% !1110 4452O]8T_2Y;2*]NXX9+R806Z,?FD<]  /\ ]0H NUP;
MLA^-]LJZD;AAH\^ZTW*?LWSPXX R-W7YOPK5OO'.EQ66HS:?+'>RZ>?W\?F>
M4 -Q7(9A\WS*5&W.6XZU1;9+\5M&NA;&&2?0[EW#H X_>08#>XZ4 =K1110
M4444 %! (((R#110!BVGA+0;*RDLX=,@-O)+YS1R+O&_L?FSTK:  & , 445
M<ZDYN\FV5*<I.\G<****@D**** "L?6=?MM*M;>X\B2\2681C[. ^#Z_I6LZ
M+)&R-RK @\]JH:+HMGH-D;2R$GE%RYWMN.3_ /J%9SYWI'3S_P" 95%4?NPT
M\^WRZD^HWAL--N;Q8))S#&T@BC&6? S@>]<+HUF?&6L-KIEO],-O=1R_9<XW
M_NTZ^QQU[@]*]$KF=#U6SN/$6KK%*Q-Q+&T68V 8+$H)!(]0:]##3<:<W!:]
M_+JK;'?0DXPFXK7OY'34445QG*%%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %<WXN\/MKB:3+#"LES8ZE;W*%Y"H1%E4N0.A.T'&?PZUTE
M% 'G6D^ [HZY=-J<4<5K']H\NZMYR);AY+GST<X *E!\O)/4XXK0N/AI837\
M-W'KOB"V:W5H[9(+[:MO&V 40;3A<*HQ["NUHH6@''?\*_/_ $-_BS_P9?\
MV-'_  K\_P#0W^+/_!E_]C78T4 <=_PK\_\ 0W^+/_!E_P#8U0U#P%JJWNFB
MP\6>)6MFG(O3)J0W+%L;!7Y>N_;^&:WO$7BJ/19TLK6W^W:HT1N%L%?9)-"I
MPYCR,.XZ[,@G%<WX>U#Q!KWB:PUSRX);/[,8SY,S&V:)SDO&2,B964(Z..0
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M4[&&_9C=I:NF)@T:QX.Y3@;4[8ZFNHHH XZ/P/J$4:QIXX\1A$ 51NM^ /\
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MJ_!7_0#3_P ")?\ XJNQHH X[_A5?@K_ * :?^!$O_Q5'_"J_!7_ $ T_P#
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M-R\20AH;B1U(=X')RD<@8F2(@C=GUR?2J* &10QV\*0PQI'%&H5$10%4#@
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M 4444 %%%% !1110 4444 %%%% !7/>--=OO#GAR;4K"RCNI(V4/YC[4C4D
ML>YZ]!W-=#5:_L+74[*2SO8$GMI0 \;]&P<_S H X34/%FKZAJ^H:/;1^1!)
M)<V=O+:C==))"D;,^&(4Y#M@<$8')S5G1?'EO;:WIO@_5[74(==FBRK2QY21
M<,P;<6)Y"G/7# C/%=7%H6E0:S-K$5A FHS+LDN OS,./\!SWP/2O,_$]H!^
MT1X3O,G+6S18YQPDY_NX_P#'L^U 'K;;MIVXW8XSTS5"1M0AB:66XL41 69F
M1@ !U).[BKLID6-C$BN_96;:#^.#5.;[9/"\,VGVLL4BE71I\JP/4$%.10!
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M[2ZAO;6*Y@;=%(NY3C&1^->:IQ<G%;HZIX:K"E&M)>[*]GZ$U%%%48!1110
M445%/ EPH5VD4 Y_=R,A_,$4 2U6L7O'@8WT,,4OF,%6)RX*9.TY(')&,CM3
M/[-@[R71^MU)_P#%4?V;;GJUP?K<R?\ Q5 %RBJ?]EVWK/\ ^!$G_P 50NF6
MJ,& FR#D9G<_UH N4444 %%%% !1110 4444 %%%07E[;:?:M<WD\<$"$!I)
M&VJ"2 .?<D#\: ."T*T-I\:M<8Z<EEY^F)+N2<R?:,S,/,/'R$XQM]O>O1*X
M73[(V?QGU)C=7-Q]HT6.8"=PPBS.XV)P,+QG'/4UV-Q86UU('FB#L!C.3TH
MCOY-2C:+[!;V\JD/YAFE*;3M.W& <Y; /H/6DT^34Y&D_M"VMX5"IL,,I?)*
M_/G(&,-P/4>E']D6/:$CZ2-_C2_V39]DD'TF?_&@"[15+^R[4=//'_;Q)_\
M%5-!:16Y)C,O/7?*S_S)H GHHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3%HS@BV>%E5!QTWD';T'7K0!TE[KUAI]_!9W3RI),R(K^0YC#,<*"X&T$G@
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M<45YG:>-=8O]2TBS^U6MM)-' TVZ-0LF9)$D.68$'$8VA0>6Q]/3* "BBB@
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M?]"QIO\ WY%=77G7BSX@WMC>26FCV<C""Y-E//)"&!E**V(\-G> V0K "3D
MYQD E?X5>$W\5Q7*:1I8LXK-XY;(1\F1G4I(1[!7'XFM7_A67@C_ *%C3?\
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MU% &3_PB_A[_ * 6F?\ @)'_ (5:LM)T[36<V&GVMJ7P',$*INQTS@<U<HH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY8_="GNP)R.37J%% $5LNVUB7=(V$ W2?>/'4^]2T44 %%%% !1110 4444
+%%%% !1110!__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>figure_015.jpg
<TEXT>
begin 644 figure_015.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "! C@# 2(  A$! Q$!_\0
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M[\K_ (4?8;#_ )\;7_ORO^%<^M]J_P#P@IO;YH[;5EL6FD,&UU5PI88SD$'
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M@B[Z_P#CM'MJ7</8U_Y27S?>CS?>H_[*UW_GPM__  +_ /L:/[*UW_GPM_\
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MLSVS6C1,P\IH6ZJ5QW//7-:W]E:[_P ^%O\ ^!?_ -C1_96N_P#/A;_^!?\
M]C0YT'U!4\0NC,RTT.UL_#IT.*YO#9F,Q*7E#2(AXVAB.F./:H-,\*Z7IDEG
M(GGW#64!M[7[3('$"'J%  &3T).3BMK^RM=_Y\+?_P "_P#[&C^RM=_Y\+?_
M ,"__L:.>A>]P]GB-K&''X3TR'0[G1HI+M+"=&C\H2C]VC')521D ^^>.E2V
M7AK3]/OQ>6\ERLQBCADS(,3",80N,=0.,C&<<UK_ -E:[_SX6_\ X%__ &-'
M]E:[_P ^%O\ ^!?_ -C1ST.X>SQ'8Q!X4TH:3?:2#<_V=>%R]MYWR1ECN.SC
M(YY[XJ9_#UA+J%A>SR7,TU@0T'F29 8+MR>/3L,#/:M7^RM=_P"?"W_\"_\
M[&C^RM=_Y\+?_P "_P#[&CGH=P]GB.S)/-]Z/-]ZC_LK7?\ GPM__ O_ .QH
M_LK7?^?"W_\  O\ ^QJO;4NXO8U_Y23S?>CS?>H_[*UW_GPM_P#P+_\ L:/[
M*UW_ )\+?_P+_P#L:/;4NX>QK_RDGF^]'F^]1_V7KO\ SX6__@7_ /8T?V7K
MO_/A;_\ @7_]C1[:EW#V-?\ E)/-]Z/-]ZC_ +*UW_GPM_\ P+_^QH_LK7?^
M?"W_ / O_P"QH]M2[A[&O_*2>;[T>;[U'_96N_\ /A;_ /@7_P#8T?V5KO\
MSX6__@7_ /8T>VI=P]C7_E)/-]Z/-]ZC_LK7?^?"W_\  O\ ^QH_LK7?^?"W
M_P# O_[&CVU+N'L:_P#*2>;[T>;[U'_96N_\^%O_ .!?_P!C1_96N_\ /A;_
M /@7_P#8T>VI=P]C7_E)/-]Z/-]ZC_LK7?\ GPM__ O_ .QH_LK7?^?"W_\
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M'X5]C^"_$6D:[H-K'I=_%=-:V\4<WEYPC;1P3CKP:\EUS]G@W'C&)])NUM]
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M8[I;2:VW*7 ^:42*0N,(.,$#W/-=1_:"?\^VH?\ @ON/_B*/[03_ )]M0_\
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M_+U^Z. 2>:H2>&;MVN90;(2-JAOHD#.JNI3859E *G'((SS6W_:"?\^VH?\
M@ON/_B*/[03_ )]M0_\ !?<?_$4VH/J+FJ]G]QSFI>&I+:S\VU^S6<,%N1(E
MMO(=1N)C,9!#@EN&.&!)(]*AT_P]>ZCI.F7_ )MM;75O9VL=O$%?:?*8/B4$
M C)XP <=>:ZG^T%'_+MJ/_@ON/\ XBC^T%/6VU'_ ,%]Q_\ $4K0ON/GJV^%
M_<<]=^%;Z:\DO(S8">X:ZDE5BV$::(1C:=N3C;DGC))I?^$3O94,37D5JDMK
MY$_V=W993Y00$HPP&!&=P()'!'>N@_M!/^?;4/\ P7W'_P 11_:"?\^VH?\
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MX9^#=4\)Z#%'K&L75Y=&-4%L9BT%LHZ*B],^I_+W[F@ HHHH **** "BBB@
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MI+S6KZZ%Q(I,6G"8^3;ANI9<X+G]/K0!ZE1110 4444 %%%% !1110 4444
M%%%% !7RG\0/B)XOTSQ_KEE9>(+V"VANF2.)&&%7T'%?4.J:9:ZQIEQI]ZA>
MWG38X#%3]01R#[U\M^,O@UXBTKQ9#9Z9%-J5K?RD6]R>2O<B0]B!SGH0/PH
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M?]!E?_ -?_BJ9:7IGB03HEO=%=SV_G*[(/7(ZCWILFK6,<MK$UY!ONF*0 2
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M\_UK_P!_E_QHY4'.R36G_P")%?\ _7!_Y455NKB'4K:2PM)XYY[A?+58F#$
M\%CCH .<FBN:O9-'=A;N+9O>(>L'XUAT45S':%%%% !1110 4444 %%%% !1
M110 4444 %%%% '96G_'I#_N"IJ** "BBB@#C+G_ (^I?]\U%110 4444 %%
M%% !1110 4444 %%%% !1110!UVF_P#(.@_W:M444 %%%% 'SSXJ_P"1CN_]
M\_S-8U%%:K8YY;A1113$%%%% !1110 4444 %%%% !1110!ZU\)_^0==?4?S
M->BT45D]SHCL%%%%(9S6N_\ (0_X"*S*** "BBB@ HHHH **** "BBB@ HHH
5H **** .@\/?\>\W^\/Y4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.40
<SEQUENCE>17
<FILENAME>ex10-40.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhibit
10.40</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>lease
amendment no. 1</U></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">AGREEMENT
made as of this 26th day of February, 2019 by and among RIVER RIDGE LIMITED PARTNERSHIP (&ldquo;Landlord&rdquo;), CORBUS PHARMACEUTICALS,
INC. (&ldquo;Tenant&rdquo;), and CORBUS PHARMACEUTICALS HOLDINGS, INC. (&ldquo;Guarantor&rdquo;).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">witnesseth
that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; font-weight: normal">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Landlord is the landlord and Tenant is the tenant under a certain lease dated March 21, 2017 (the &ldquo;Lease&rdquo;) with respect
to certain premises in Norwood, Massachusetts; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Landlord and Tenant desire to amend the Lease to add to the premises demised under the Lease a certain additional area; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WHEREAS,
Guarantor is the guarantor of the Tenant&rsquo;s obligations under the Lease under a Guarantee dated August 21, 2017 (the &ldquo;Guarantee&rdquo;),
and Guarantor wishes to consent to this Amendment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">NOW,
THEREFORE, for and in consideration of the premises and the mutual covenants herein contained, the parties hereto hereby agree
as follows:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.
Initially capitalized terms used herein and not otherwise defined shall have the meaning set forth in the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.
As of the earlier of (i) the date Tenant commences operations in the New Premises or (ii) August 1, 2019 (the &ldquo;New Premises
Commencement Date&rdquo;), there is added to the Premises an area of approximately 13,492 rentable square feet of floor area located
on the first floor of the Building and an area of approximately 16,531 rentable square feet of floor area on said first floor,
all as shown on <U>Exhibit A</U> annexed hereto (the &ldquo;New Premises&rdquo;), and as of the New Premises Commencement Date
where the term Premises is used in the Lease the same shall mean and include the premises originally leased of approximately 32,733
rentable square feet of floor area, being the entire second floor of the Building (the &ldquo;Original Premises&rdquo;) and the
New Premises. The Tenant accepts the New Premises in their then AS IS condition; however, Landlord shall perform the work set
forth as Landlord&rsquo;s responsibility on the matrix attached as <U>Exhibit B</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.
As of the New Premises Commencement Date, the term of the Lease is extended to end on October 31, 2026.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.
As of November 1, 2019, the Base Rent is hereby changed by adding the following amounts to the Base Rent set forth in Section
1.1 of the Lease: </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period November 1, 2019 through February 29, 2020, the amount of $27,265.08 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2020 through July 31, 2020, the amount of $27,827.25 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period August 1, 2020 through February 28, 2021, the amount of $61,922.44 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2021 through February 28, 2022, the amount of $63,798.88 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2022 through February 28, 2023, the amount of $65,675.31 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2023 through February 29, 2024, the amount of $67,551.75 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2024 through February 28, 2025, the amount of $69,428.19 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2025 through February 28, 2026, the amount of $71,304.63 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0.81in 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">For
and with respect to the period March 1, 2026 through October 31, 2026, the amount of $73,181.06 per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 1in; text-align: justify; text-indent: 0in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.
As of August 1, 2019, the Tenant&rsquo;s Percentage shall be increased to 62.6%.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">6.
In lieu of constructing a new internal staircase between the New Premises and the Original Premises, Tenant shall have the right
to incorporate the existing staircase in the building lobby which connects the first and second floors of the Building as part
of the Premises thus allowing the Tenant&rsquo;s exclusive use of such staircase. Any modifications to such staircase shall be
subject to the Landlord&rsquo;s approval which the Landlord shall not unreasonably withhold, condition or delay and the cost of
modifying the staircase shall be the Tenant&rsquo;s responsibility. The Tenant Improvement Allowance (as hereinafter set forth)
shall not be allocated to the cost of modifying the staircase, and at the expiration of the Lease or any earlier termination thereof,
at Landlord&rsquo;s option, the modifications to said staircase shall be removed by Tenant at Tenant&rsquo;s expense and the staircase
restored to its original condition at Tenant&rsquo;s expense.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2; Options: NewSection; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">7.
Landlord shall provide to Tenant a special allowance in an amount not to exceed $990,759.00 to be applied by Tenant to the costs
and expenses incurred by Tenant to fit out the New Premises including, without limitation, the costs of the design thereof. All
of such fit out shall be performed in accordance with plans and specifications therefor which have been approved by Landlord,
such approval not to be unreasonably withheld, conditioned or delayed. Upon the satisfaction of the following conditions, Landlord
shall pay to Tenant the lesser of (x) the cost of such fit out as certified by Tenant and evidenced by paid invoices, receipts
and the like, or (y) $990,759.00 (the &ldquo;Tenant Improvement Allowance&rdquo;) in monthly payments to Tenant as the work progresses
as follows: Before commencing the work, Tenant shall submit a budget therefor to Landlord. Tenant shall submit to Landlord its
certificate of such costs and expenses for the preceding month, certified by Tenant, and accompanied by evidence thereof, and
within fifteen (15) days thereafter Landlord shall pay to Tenant an amount equal to 90% of the certified amount. Landlord shall
pay the remainder of the Tenant Improvement Allowance within thirty (30) days after satisfaction of the following: (i) Tenant
shall have completed all of such fit out and shall have obtained all necessary governmental approvals for the use and occupancy
of the New Premises; (ii) Tenant shall have delivered to Landlord lien waivers from all architects, engineers, contractors and
materialmen who might have a lien against the New Premises in connection with the fit out, such waivers to be in form and substance
reasonably acceptable to Landlord; and (iii) there shall not exist any default of Tenant under the Lease or any event which with
notice and/or the passage of time would constitute a default. Within thirty (30) days after the satisfaction of the foregoing
conditions, Landlord shall pay to Tenant the remaining Tenant Improvement Allowance; provided, however, that if the Tenant Improvement
Allowance is not claimed by Tenant within twelve (12) months after the New Premises Commencement Date, then Landlord shall have
no obligation to pay the Tenant Improvements/Allowance to Tenant. If at any time a default of Tenant exists, then no payment shall
be made to Tenant until such default is cured. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">8.
Each of Landlord and Tenant hereby represent and warrant to the other that it has not dealt with any person or firm to whom a
brokerage fee would be due and owing in connection with this Amendment except for Colliers International and CBRE whose fee shall
be paid by Landlord pursuant to separate agreement.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">9.
Within five (5) days after the date hereof, Tenant shall deliver to Landlord a new Letter of Credit (the &ldquo;New Letter of
Credit&rdquo;) in the amount of $369,900.00 in form and substance and issued by a bank or financial institution satisfactory to
Landlord in its sole discretion, and Tenant&rsquo;s failure to provide the same to Landlord which continues for more than five
(5) days after notice thereof, shall constitute a default under the Lease not susceptible of cure for which Landlord shall have
all of the rights and remedies provided under the Lease and at law and in equity.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Provided
that Tenant is not in default under the Lease as of the third anniversary of the New Premises Commencement Date, the amount of
the New Letter of Credit will be reduced to $277,425.00; and then, provided that the Tenant is not in default under the Lease
as of the fourth anniversary of the New Premises Commencement Date, the amount of the New Letter of Credit will be reduced to
$184,950.00; in each case subject to the condition that at the time of any such reduction, Tenant must provide reasonable evidence
to Landlord that it has at least $50,000,000.00 in unencumbered funds in an account in its name at a United States Banking institution
as provided in said Section 1.1 of the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">10.
With respect to electricity, Landlord shall endeavor to check meter the New Premises in which event Tenant shall pay Landlord
monthly for the electricity consumed as shown on said check meter, but if it is not check metered then beginning on the New Premises
Commencement Date electricity will be charged at a rate mutually agreed to by Landlord and Tenant (such rate to be subject to
increase from time to time as utility rates increase) and payable monthly in advance together with monthly installments of Base
Rent at an amount equal to 1/12<SUP>th</SUP> of the annual amount. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->3<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">11.
Guarantor hereby consents to this Amendment to the Lease and agrees that the Guarantee shall remain in full force and effect with
respect to the Lease as amended hereby.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">12.
As amended hereby, the Lease is hereby ratified, confirmed and approved and except as amended hereby, the Lease shall remain in
full force and effect in accordance with its original terms.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">13.
Landlord shall use reasonable efforts to relocate the bank tenant&rsquo;s first floor storage room adjacent to the loading dock
so as to allow Tenant the right to expand the existing shared conference room, such expansion work to be mutually agreed upon
by Landlord and Tenant. Landlord shall be responsible for setting up a secured access system prior to Tenant&rsquo;s occupancy
of the New Premises through a key card system. Landlord and Tenant acknowledge that the use of the conference center is on a non-exclusive
basis and is to be shared only with other tenants of the Building. However, tenants of River Ridge Office Park may reserve use
of the room of up to two (2) days per month by contacting Landlord.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">14.
Tenant hereby confirms that as of the date hereof, there is no default of Landlord under the Lease or any event which with notice
or the passage of time or both would constitute a default of Landlord under the Lease.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.
Prior to occupancy of the New Premises, Landlord shall remove all the shrubs in the front of the Building to the right of the
main entrance around the entire side of the Building. Landlord shall construct a patio outside the entrance to the cafeteria and
relocate the metal picnic bench. Landlord will install a variety of new small shrubs with review and input from Tenant prior to
installation. Landlord will use reasonable efforts to replace the fence surrounding utility banks outside the Building and extend
the fence to enclose the generator. Landlord will have the existing deck on the side of the Building power washed and leveled
prior to occupancy by Tenant of the New Premises. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 4; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->4<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">WITNESS
THE EXECUTION HEREOF, under seal, as of the day and year first above written.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>RIVER
    RIDGE LIMITED PARTNERSHIP</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 5%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 45%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Cornerstone
    Corporation, </FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">its
    managing agent</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Paul J. Tryder</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Paul
    J. Tryder, President</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
    PHARMACEUTICALS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sean Moran</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Its:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hereunto
    Duly Authorized</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CORBUS
    PHARMACEUTICALS HOLDINGS, INC.</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sean Moran</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Hereunto
    Duly Authorized</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 109.8pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 5; Value: 2 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->5<!-- Field: /Sequence --></TD><TD STYLE="width: 33%; text-align: right">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhibit
a</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; color: Red; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="ex10-40_001.jpg" ALT=""></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 6; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">A-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; text-transform: uppercase"><B>&nbsp;</B></FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">exhibit
B</FONT></P>

<P STYLE="font: bold 10pt Times New Roman, Times, Serif; margin: 0; text-transform: uppercase; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>LANDLORD/TENANT
RESPONSIBILITY MATRIX</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tenant:
Corbus Pharmaceuticals</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Landlord:
River Ridge Limited Partnership</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Property:
500 River Ridge Drive, Norwood MA, </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>1<SUP>st
</SUP>Floor</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 33%; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; text-align: left; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Tenant
    Responsibility</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 9%; text-align: center; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Landlord
    Responsibility</B></FONT></TD>
    <TD STYLE="width: 2%; padding-bottom: 1.5pt">&nbsp;</TD>
    <TD STYLE="width: 43%; text-align: center; font: 10pt Times New Roman, Times, Serif; vertical-align: bottom; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Comments</B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Ensuring
    properly functioning HVAC system including VAV boxes</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Landlord
    is responsible for properly functioning HVAC system. Landlord responsible for repairing or replacing any nonfunctioning VAV
    boxes. All repairs, replacement and maintenance of HVAC system including VAV boxes during lease term shall be Landlord&rsquo;s
    responsibility.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Building
    permits for Construction</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant&rsquo;s
    contractor shall be responsible for securing the permit and tenant will pay any out of pocket costs, including mutually agreed
    architectural and engineering fees</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanical,
    HVAC, plumbing and building waste systems all in good working order</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mechanical
    and other drawings required for building permits</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant
    to engage architectural and engineering firms to prepare all required documentation for permitting.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Fire
    Alarm devices within Tenant areas, connected to Base Building system and addressable Fire Command Center</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X
    </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Reconstruction
    and buildout of tenant space including electrical work, lighting, walls, flooring, ceiling and any plumbing to tenant kitchen
    within tenant space</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tenant
    to hire and enter into contract with General Contractor</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Lighting
    in base building areas</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Landlord
    is responsible for common area lighting.</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Base
    Building telecommunications room</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Telephone/data
    system, including service, wiring and distribution</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Modification
    of sprinkler piping and head layout to suit tenant build-out</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X
    </FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif; background-color: White">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Security
    system to enter tenant space</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">X</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD>&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 7; Options: NewSection; Value: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">B-<!-- Field: Sequence; Type: Arabic; Name: PageNo -->1<!-- Field: /Sequence --></TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%; text-align: center">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>



<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>ex10-40_001.jpg
<TEXT>
begin 644 ex10-40_001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" '0 G # 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQP /:@#9;1M!T/3UCDTZ"YFF;:%\A6DG<]0!T _( 467AG1],@DOKVPL(V"
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M!EY7[*H_D.WYF@#.LM&TGPEI-P?)\U[DXFP"S7#'("*"3QR0%S@#\37.^&/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBD9E12S,% ZDG H 6BHA<VYS^_BX_VQ3EE1QE'5@#CY3F@!]%%% !1110
M4C?=/TI:1ONGZ4 <1X5\/VEU!)<W,ES(=L:)'Y[JD8VY.T*1C)-=#_PC>E_\
M\[C_ ,"I?_BJJ>$/^0:_U3_T 5NS3PVZ;YY8XDSC<[!1GTYH S?^$:TO_GG<
M?^!4O_Q5<UY&BV?C34K._N/LUM'9021":]=,DL^X@E_90:[NL/Q$U['$C6FG
MPS(01/<MAG@7^\J$?.>IQGMWH A'A71[N>"]AFN7@V'"1W;M'*#T;.>W;!K
M?PS9ZEXFU;3DMW,426W[]IG)A4JQ(7YLEC[\#K7<:?#;6VFVL-F0;9(E$1'=
M<<&N6L+YH?&_B>UMT$MY*]L8T/11Y0R['LH_7H* ))O"/ARQ:.VL-*7[6Z;4
M19I% 4$G<^&Z D^Y)P*QAH6EV?B:^M+Z*:[@AL+?RQYK;WE9Y/E0 \9QTZ#'
M/K79R26N@V4EQ<RF2:5OGD; :9^P'8#T'0#\37-Z!=6MUXSUS5KFZM99(+.!
M&>/[ML,R$H&[]B3WSZ4 6;+P3HUK#)>ZC;+'+@L56XDV0)_=SNY]SZUA#P[I
MM]X_L+::Q9-.:QEN8('FDW;Q(@$ARW'&,#\_;MHX'U6=+N[5DM(SN@MVXWGM
M(X_D.W7KTYHWUIXC^)"6]A>QO;0::ZW+QGE\RK\BGL#CDCJ.!0!-_P (CI.I
M7L7]GQS6UG;2[Y+B*XDW3MT,:DG[G]XCJ0 /6J6K:9:MXZTO2=..W?:W+W!,
MKMY)^3#=?O<],CKS767=W(TW]EZ4$29%'FR[?DM4[<="V.B_B>.O(S:EI</C
MW0[/1YQ?7$%K=*T<3[R9',?S2-VSAB6]L>E &]=>'M$L(X(X;!YKK+>1&LSA
MF8_>8G/ YY-$GA[2K*Q2YU;?/-&^\,LC\.> J#//7 [FM1$BTJ"2\O)3+<R8
M#N%R6/9$7T]!^-4M-N;;4=2GN+J[MWNK49%JD@86BG/+$<;C@Y/;H/< IP^$
M]-F?^T]5MS&T?SPQF=P+9<<DG/+$=3T[?7$UO0;+6=5T O;LNDRWI7RI'?=<
M8C=E?K\J@J".Y]JZX1-KDJRS!ETQ#F.%AC[0P/#M_L>@[]3VK%\23-J7B/P_
M;VC.L4-^Z374>/E8POE%]\9R<<<=Z );C0-+U2Y^R643A+>0>==>:YV,/X4.
M>7YY/0?6K=WI.GQ/]DLK=GO)%S\TSE8UZ;WYZ>@[_F:T))$L8XM,TR%!,%^1
M/X8E_OM_G)/XFC]SH]M@;[BZG;_MI._]!^@% &-J^@Z;;Z UC-/?RS7$9@CV
M7#^9*Q'9<[?KQ@#K56S\ :!9:4LNL1>=*D?[UWGD"+Q@@#=W_7]*Z%((K 2:
MKJ<R&X"8:0GY(E_N(/R]R?P%-MK>;4ITO[^-HHD^:VM&_@]'<?W_ $'\/UH
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M0 S3KF65'@NL"[@.V7' ;T<>Q_Q%7JS=2C>"1-1@1GEA&)(U',D?<>Y'4?\
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MR#V9UGQUJEK=7EZMO:VMN\,<%R\2JS%\G"D9/ ZUU]<UIW_)0M=_Z\[7^<E
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M<#["NK6J2S D%V\P#:A'IW/X#OCIKJYD61=*TI46<*-S[?DMD[$CN?1?QZ4
M<?\ $G3=-G\,ZG!:6@^U6UH&?RI#&D2+R@8#AC_=4CWX%=#I>G:9X7TRWBT^
MV=[FX10B-(7DD( _B8G"C\A^59_CL6ND?#S5;1-[RS6SX_BDE;^)V_F3V_(5
MMV:QZ5I8O]0F$EPT2"24+],(B]<9Z#J3[T 2[8M+MI[^^E$EPZX=P.OI&@ZX
MSP!U)]ZPO MD9O"NC7]Z1B*U4P0D_+$.['/\?OV[>M:AMI[F*;4]0!C>.)S;
M6^>(!M/S-ZO[]N@[FL7P+!<:KX)T,7"M'IZ6<?[MOO7#8ZM_L>W?OQU -NYL
MX_$OE^>K#38VWQX)5IF_O CD+Z8Z_3KS7@^SN(-0\1Z/:7+M:07P0W6?F2/R
MDQ$OJP'!;MCUKKIYI;^62SL93''&=L]PO\)_N)_M>I[?6N8\/S&TUOQ+INFP
MQBX-^H10OR0IY*?.^/Q]R?Q- '27-R+(1:5I<*&Z*_(G\$*?WW]O;J3^)I52
M#0K,D![F[G;DG_67,F/T_D!03:Z'   \UU<OT',EQ)C_ #[ >E+!#]BCDU+5
M)D-QM^=Q]R)?[B#_ "2?P% #(8DTV.75=5F0W++AW&=L:]HT'7&?Q8_A6'X:
MT_5KC7-5U/6)@;/[49+*S8C,)P,,X'&[;M&"21S700V[WTZ7U]'L2([K>W?_
M )9_[;?[6.W\/UK*TX/KMUJ7S8TG[7D$$@W)V("/9..WWOIU +I9_$$A5"5T
ME3AG'!NB.P_V/4_Q?3K)=74MY<-INFMY8C^6XN5'$(_N+ZOC_OG\A1<7,EW.
MVF:8WE"/"W%P@XA']Q>V_'Y?D*D9HM,AAT_3X5:=@3'&3P!W=SUQGOU)H YS
MQQHUS?>%D\,Z"8XY;IU$L3=&@S\Y9L';D_Q<DGCO3_A_K,UQ:W_A^_ABM]1T
M2;[,\41)3RB,QLN>=N.!]*WV:WT2U::9WGN9F 9@,R3OV51_(= /Q-<1KBWW
MA;Q=I?C*[($-ZPT_4XH@-D,;']TQ/\15NK>^!Q0!Z51110!GW8:UOX;U?]4^
M(;CV'\+?@3CZ-[5H'I3)HDGADAE7='(I5AZ@]:IZ5-(T#6TS$SVKF)R>K ?=
M;\5(/YT 0WK)IFH1Z@?E@G*PW)[ _P #'\?E/U'I6L*BN(([FWD@E&8Y%*L/
M8U4TB61K,V\[%KBV;R9&/\6.C?B,&@#0HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ K#\6?\@B+_KZA_\ 0Q6Y6%XL
M&=(B_P"ON#_T,4 :EA_R#K7_ *XI_(58K,@U73[5;&RN+R&*YE@1HXW;!88
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M']HR<_K6)K_B&SU#QIX9L;9BRPZDP\[8VR1Q$X94;&T[<\\]3CUQZ!0!RS>
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M&GV+F-%N=LMR!Q"NQ/D3L6_1>_/%7+FXENYVTS3&\I8\+<7"#B$?W$_V\?\
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M"]I)LLMLMPK,&;!WD!OE')X4=JW[C2KRRO)-<.IVUO<O"([CS+8RJ #E53#
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M)*QP",<$;:ZFN9L/^2CZS_V#[7_T*2@#IJ**SM1UB/394CDM+V;>N[=;V[2
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M8_A6M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M>9)QGVKCM4CTN#5?#DVE644,[WQ2YN[203%I7C;,2R'EB2>6Z+]:W?#S3_\
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MN-KOB*[CLAMV6UC" Y@7.<YZ;O<YZ=L"NM/]F:!!RP1I#U)+RS-^K,://O\
M4%Q:QFR@S_KITR[#_93M]6_*I[73;>TD,P#2W###3RG<Y'IGL/88% %?=J.H
M$%%-A;_WG ,S?0=%_')]JN6MC;V8;R4^=OOR,<NY]SU-6*JWFHV5@N;N[AA[
M@.X!/T'6@"U5:]O$LH-Y4O(QVQQ+]Z1NP'^>*JMJ<]R-NG6<DN>DTP,<8]^>
M3^ J:TT\QS&ZN93/=D;=Y&%0>B+V'ZGO0 :=:26T3R3X:ZG;S)F'3.,8'L
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM]1MK:&WNA(+:>*1CN9,$JP(&W(R1SV-6)O%,=Q.UKH=I)JMPIPSQ$+!&?\
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M5 "6]NM@LNIZG,C73+\\G\,2]D0>GZD_E3H8)+V5;R^39&GS06[_ ,'^V_\
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MT5<[XZ_Y$Z^^L7_HU* .CJE)QK-L/^F$O\TJ[5*7_D-6O_7"7^:4 7:**.]
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M+5&PE=7DLIWWS08(<\%T/W6^O8^X]ZO4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !61XH!;PU? ?W!_,5KUB>,./!VK_\ 7J_\
MJ (]&\0Z/+I<9&I6JE6=65I0"I#$$$5?_MW2?^@G9_\ ?Y?\:QO".E:;/X2T
MN233[1V, ^9H5)/)[XK:_L72O^@99?\ @.G^% !_;FD_]!.S_P"_R_XTTZ_H
MX.#JME_W_7_&G?V-I7_0,LO_  '7_"D.B:2>NE6/_@.G^% "?V_H_P#T%;+_
M +_K_C2_V]I!Z:I9_P#?]?\ &C^P](_Z!5C_ . Z?X4?V'I'_0*L?_ =/\*
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M7-Z0WDZ)H\>QR;FZ>09X*AB\F3[8Q^8KI!TYH 6BBB@ HHHH **** "BBB@
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MH]6M+>>R@4V[22J,E\[@ZGGH ,=1D]#0 VQM?$-U=&VU/Q!<V5P!E4AAAQ,
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MK=A8W6HS3O*J//(@(0GD,3R![$8/UK=U7Q+IMUI-Q!#)*9)D*)F%@"3QR2,
M>]4X+CP+'&%46L._,AC='5L]"2#]",^U2K>^"S/9I$;9S=-((I(\E047<VYO
MX<#UH YRT;0!I-K;:A/);V<,,<TSQQ2.QF).?F /EXQR!@DFO2--6V72[-;(
MYM!"@@//W-HV]>>F.M</J-IX<>]\S?>R64J "*PGF5D?DD[%(R&!'/M[UV=M
M=Z?;:-:SQRI#8>2GE-(=H"8&T<\],>] '/>%+Z."]UNVG4HL^LW BD/W6;Y<
MJ?0^GK6TV=$)89.FDY8=3;>X_P!C_P!!^G3!\'7&GZM#K]OO2:.;5)YEZ@,A
MVX93[$=1T.*W[>[:PF2QU";<&.V"Y<C][_LMZ/\ SQD=Z .9T;Q'I-MXK\2A
M[K<LMQ"T;0Q/(& B )RH(Z@_E5O7=:MM7TZ"#29I'N?ML)4-;2!25D!(8E>
M._TK-\$F+0M-OKMXXDM9;^Y$SJ 'B5)6"D^L8''^S],XZ^>.2WE.H6)\U),&
M:!6R)1_>3MNQ^?Y4 ._T?6+9D=7BGA?D=)(''0@_R/0BN+LY]6'C+Q+8G3[&
M\FE2V$GF7'EK(!&>0-I]>?3\J[*:);^*/4-.F5;@#Y'_ (7'=''I^H-<]I$:
MZMXG\3B5);:<?9#_ +4,@C/*GH?KT(H DBU?Q-ISQVEUHMNT<K%+>=]0''HC
MG9RWH>^/7JP7GB717DE&A6ITW&YXEOL^2V>2GR<)W([<D5O02?;8Y=+U6%#-
MM^8?P3I_?7^HZ@_@:()YM-G6SO7,D#G;;W+?HCG^]Z'O]>H!YS;FZTSQ!IQ>
M[$8_M."+[+]J29I%=&(?B,=G^]G)&>N*]!UC3'N-1T_4H+N&"YLA((UG7*2!
MP 0>01TZBN2\1^%[72/$NCZS9KM$VJ6ZNID;]V3N'R#IM(/(QQCCK6SXX\.:
M3KJZ?-JFI_83:.YB)*X?< "-K=3P.G- &_I=TE_ UP8$CN$9H90I#893R-W<
M="/J*S?#3!)_$3.0JC59"2>@'EQUB>&?#.FV]H]A_:-]',7:9($NVB<1$X5F
MC4C&>O3N*U/!]O%"NOVJ[WC359$_>N79AY<?4GD]>] '-MXNUK[?81+>R26]
MW ;AIX+!9E@&]A\Q##"@+UZ]:Z+2;74-9R^LW>GWVFLJR06X@ D#=0SD$@''
M8>M>>/-'-/I[6\@^RVEJT<T'V)9EF=9G/EG=C ((Y'K71>#]:\/Z;)?>3H<E
MA??9O/GEP@\X!MN/E.%&XX P!0!L:I<:IH=TD::]IEOIR[4CM_LX\V%,A5P"
M_P P'X'%<)J=W%'J-_I5QJ$RG3K&]9);FPC5)RS*Y6,DL&R22#P0*]!LM!TK
M4M0U#5]6BTB]EN&C  591 %7&W>>YZ]!7&Z[-H=[K^JZ;8Z!';#3-'OI7F>T
M5$F<*FTH1U SG/O[T 7]"U:ZDTV35[;5C;2WTR6PBU"Q6'YD3&<[^%"@\^HX
MZUV>GZ2MQ$M_?26%[J)YBO8;< +Z8Y.<$=<UC^&8O#'BC2(KQO#4%LY.PQ7M
MBD;L0 25!ZCGK6AHTB:+>?V*);22W>>4VX@<!H<DOY;)V &0"/3M0 S2]2U/
M_A+Y])NKR.Z@BMC(7%OY1#Y7@?,<C!K"\7Z@ND_$71+V6WN)8_LQ4"),Y.X\
M9. .HZFM>P#I\0YX7>X?R[%@K3XRP+J<C ''.._2M*^U6]/B*+0[)8(WDM&N
M6N)<G: X7 4=3SGDT 91^($/V)+P:%J_V:1@J3.D:H23@?,7P.>,UDIJ^J_\
M)!J=Y9Z'JR6][L1ITA1VC\L;2%&[:<G/.<#'0U9CU$7?VSPY<:2[V"13@2R8
M.60YW-SP6;)Z#J.M7;._DT?P%X<>T,$?G1VT;R3#*J&3+,>1SGW[T 4X[N72
MV:XTCPYKL<[?-,LD*,MR?5SNX;_:'Y&G^#]37^U+NVO8)K2Y,,"-#.A&USO.
MW/0Y'3UQ6KH?B6[U;6[C3Y=,E@2W64O.R,%+"3:@4G@[DPU5K*.VN_'?B:QN
M0CB2VM#Y9/) #\COP<<]N* *GBZ]O_#L%K8:?<V\-MJTQM8Y+@M_H;LK'*[?
MX>.!_"?;IFVVWP]K!@U"QT4HUJ+B06<!VS#<0,;L_/@$]?F^O-)XZMM3-UX7
MT]A]I9=7C>WG=@OF*JLQ1SV? (SC!_.MR/24TRXFO=6L[6:RN& \LIYGV$#H
M 3U3DYZ!2?3H )=S>$9X$U"WDTZ&6'<4F, V_P"TKC'(]>X^M<;XMU'PM>KI
M%_9RZ=;2V\[)<Q1(H==V/F&%^8 H.W1J] O/#>G1[KFUTRVEA=<36RH,.O\
M>3T;Z=?K@U8&EV4]E!<:6(DEC#&*1ANW9.65\\D$]<\@T >5:;XF\,37\<6K
M&Q:.-P&D^S_*XY)8#;D=ACMBM+Q?XTT.XT&'2X-8BNA]MM'@D8,&V+,A8.2.
MP&=W<#GGKZ((++6[1X7@%M=P."RA1O@D'0@]QZ'H1^-%N+>Y+Z5JMK;&Y,9R
M/+&R=.FY<_J.WY&@#'G\8V5YJX73-<M_LT5NTCD)YD;ON "L0,@8ST/\JC/C
M%9H=-U+[?':6UQ,N^V>/.(B&^9FQU) QCVKHK=WTN1+.<YMF.VWG]/1']_0]
M_KUBD630I&GA#/IC',L0Y-N>[J/[OJO;J.] #QXET,IO75K-A_LS*:K6_B[3
M+I-\ GD& 3M0' /KSQ^-6Y;./<-0TZ.%W=071<;9U[<^N.A_ ^U+^Q-)O[5K
MO3K:WCN&<OO>//S]UD'IV([=J )G\46,;QH\5TK2$A 8L%B.>.>:Y3Q<^@W/
MAZYAM-'B6YE>/#_943'[Q2<MVS@_6K>C:58:OK?B.VO-/6%H9( B8&Z F($E
M".@SSD=>_I6Y#I>F.QTW4=,LFE(RI\A0DX'<#LP[CMU'% &+%XH\&:;J06&T
M@MKM02&6%$*]B"<\'VK1M_%&G:AJMO-:&:>-8958PIY@4Y3KMS5RVM[?13%8
MS0Q?8F(2WE*CY#V1OZ'OT//7#TNTBL/BG?6]J6CMWL3,80,(KEDR5^OY9S0!
MTT>O:7(VTWD<;?W9<QG_ ,>Q6A'(DR!XW5U/1E.139((IAB6-)!Z.H-4FT+3
M6.5M5C/K$Q3_ -!(H -7@EDM5GMUS<6SB:,8Y..J_BN15VWGCNK>.>%MT<BA
ME/M5'^RI(^8-3O8SZ,XD'_CPJM91SZ-=&"ZN5FM;ER87V!/+<\[,#C!Y(]\B
M@#;HHHH **** ,^YT>TN9C<!7@N",&:!RCGZD=?QJ+^RKM0 FM7H4# W*C'\
M25YK5HH RO[!MY&S>3W-Z,YVW$N4S_NC _.M-$"*%4!548"@< 4ZB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LCQ0N[
MPU>K_L#_ -"%:]9/B?\ Y%N]_P!P?^A"@#SLP^5.\[1Q/ N]7WH&V@RR'.2#
M@?IZXZUB+IMG=Q&X2'3\+)<X\[9O( .W;@$'!]\#M7::'HRZQ<7PDN'C6%R
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MG"L>3;>Q_P!CW[?3H 2.B7\46HZ=,GG;?D?^&1?[C^WZ@_B*4-#JUN1\\%S
MW(_C@?\ J/T(K%\507>FZ9<7ND3R0M/+$LT<0RQ+2*"\8_OXXQT/UJ'3+6UU
M749&BU7Q##>0QA6^T*(B4)/JF#R#^M '0(Z7J2:=J,2><5^9/X95_O+_ )R#
M^!I()7LI4L;QB\;_ "P3M_'_ +#?[7_H7UJK-X=%SY3/K.J%HFW(PE3(/KG;
M7.6GAZ\EN-1TRUUF<6WG.9!= REC\I!!!7!YS^7I0!9\-N="CU601_\ $L;5
MKG<J+C[-\V 0!U3CGTZ].G1W$$EO(=0L )-X#30J>)A_>7_:Q^?0]B,&T\)Z
M[903Q0>(T7SI'E+_ &9RP9NIYDP?Q!IZ^%-9ABCBM?$DL,:J04\MF!)[CY_E
MQZ#CF@#9E1=3AAU+2YT%P@^1S]UQGE''7'Z@UR^CS_:?BOJ$S(\<QTY1)"^<
MQG]WQZ>O(ZU8C\(>(HI[B5/%C(9FW,$M2 #C&<;\9X_&M'0/#,VCW\]W->BY
MDFRTCE6W2.=H+'+''W>@XYH Z2BBB@ HHHH **** *5QI=M<2B?:T5P.DT1V
M/^)'7\:B$.JVY^2YANT ^[,NQ_\ OI>/TK2I",C% &;_ &E=Q$B;2KG_ 'HF
M5P?US^E.?6(8_OVUZ#UQ]F8_R%:-% &=%KFGRR+&TYAD;HLZ&,G\Q6AD''O3
M)88YT*2HLB'JKKD5EO9W&E S:<7EMQRUFQR/^ $_=/MT/M0!L45%;W$5U D\
M+AXW&5(J6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH *P?&DAA\'ZE($+E8P=H.-WS#C/;ZUO5SOCQ&D\"ZPB!B[6Y"A!EB21C
M]: ,[PO+=:?X6TW4!&S6<L.^YMURS0L2273U'/(_$=ZWKJ*4LFJZ6R2.R@O$
M"-MRG;GLP['\#QTP_ ]U-9>$=%CO"3!+;H(YR,;6/\#^GL?P//7:\@Z++)/
MK'3Y#NEA7GR#W=1_=/<=NH[T 2D0ZO:QWEI(8ITSY<A7YD;NCCT[$?\ UC2
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M6A56#03"0+(A'?[I'_UN#0!KVTTVEW,=C=R-);R';:W+=<_\\W/KZ'O]>JR
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M_J:UZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MI_>7^HZ@_@: &R_\28F9%)T]CF1%&?()ZL/]GU';J.]23P/'+_:%AAV< R1
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MVSFXLK.%FD;]["ZA%8_WQB0X/\ZKN/%SWD-V--M4G4@-(I&6CYRI&_GMCT-
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M2*7^U=*VRM( TT*L-MRO8@] ^.A[]#[2?N=7MHKZQE\N=,A)"O*GNCCT[$4
M<]ILTND^*M6MM>3*Z@L(@NO*_<SJB;6W'HK<\@\>E;Z2-HSK#,S-I[$+%,QR
M8#V1C_=]&[=#V-</XP'BS5_[1@MVMH--CM_WL#L@DC8*<L&(S@]F'Z'-=!:2
M>*#;PZ?<MHWFM N/-BEQ,NT9[]?4?C0!7\9Z-(NGD6<HBMY[A7FB(R%8!B63
MT)Q@CIW^O9Q',2'_ &17F7B>+Q;IFG6T=Q=6!T])CM\A'9EST1BQSC&[!^F:
M]-CXB0?[(H ?1110 4444 <5XZO+FSU7PX;<N5:Z/FQHFYI%!0[5'KQ71RQ"
M\6/4M-E3S]ORM_#*O]UO\Y!_$5A>.-,U6]DTFYTBW\V>TF9\C:=IP,'#$ C(
MJFEWXNM;Z:>T\.JL<QS)"95VEO[X^?@^N.OZT =.Z6^MV@_UEO=0/P>DEO)_
MG\"*2VN1>"72]4B0707YD_@F3^^GM[=0?P-<_>7?B1I5N[32U^VH,;?*9%E7
MNC$MCZ'M^E0ZE>>+;V#/_"-+YL>7@9)U1XW['=N/X\8- '3PW+Z?<QV-X[/'
M(=MO</\ Q'^XQ_O>A_B^M0LK: YDC5FTICEXU&3;$_Q*/[GJ.W4<5@S:MXKG
ML_(O/"J3%X_GC#KAB.N#N..<8[U9L]5\20V8BDTMYI5SM\R,@D=E+9P3VW=_
M2@#=G@>.7^T-/VNS@&6('Y9U[$'H&QT/?H?9LL,.J1PW]G($NHLB.0C&/5''
M7'J.QYKF;"]\40+<P0:";6,QEHXV(98Y#V4[L8SVZ#]*+.]\46\L$LVCN+EP
M5NL*&63^ZV5. W;([=>V #IB(-:M7M[A&AN(6!9 </"_9E/\CW_,57-W(;:Z
MTO5%0W'D/L?;\ERF#D@=CZK^/2LN[O=;G6"YCTEX+Y "&6,N-I/*-R,@_IUJ
MAJVK^(M2T>:"3PM<I.P8(8V^:-L$!U;(YYH O^$)4TGP[HRS1QK;75G!Y=RJ
M!<,4'R.1[]#[X//7<E5M)9[B)2UD3NFB49,1[NH]/4?B*XOP_?>)[#PS::+J
MGAN6?[/;B!WV[A(H&!D ^F*V-*U?Q!':^7=:3,"I.P/&S,J]@6S\Q]\?GUH
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M&^@R-/ C/I;DM+"HR;<GJZ#^[ZKVZCN*?<VTD4O]JZ5ME:10TT*L-MRO8@]
M^.A[]#[2032Z=,MK=N7MW;;;W#=?9'/KZ'O]>L,B-H+M/"K/IC'=+"HR;<GJ
MZC^[ZKVZCN* ,&UCC\4>)-7G6YD/V+[.+5'^[&2FYD=.^2!D'ICC%=,CQ:M
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** #%%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
2*** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.41
<SEQUENCE>19
<FILENAME>ex10-41.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0; font: 10pt Times New Roman, Times, Serif"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_005.jpg" ALT="" STYLE="height: 134; width: 680">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Feb.
18, 2019</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
Craig S. Millian</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dear
Craig,</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
behalf of Corbus Pharmaceuticals, Inc. (&ldquo;the Company&rdquo;) we are delighted to offer you the position of Chief Commercial
Officer. Your start date will be Feb. 28, 2019 and you will report directly to Dr. Yuval Cohen, Ph. D., Chief Executive Officer.
We look forward to your future success in the position.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
the Chief Commercial Officer, you shall perform the customary duties and responsibilities associated with the title plus any additional
duties that are assigned to you from time to time. The job duties for the Chief Commercial Officer are described and included
in Attachment B to this letter.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
will be paid an annual salary of $400,000. The Company&rsquo;s payroll is paid bi-weekly (every two weeks) and there are twenty-six
payroll (26) periods in a year, so your bi-weekly salary will be $15,384.62, less applicable deductions. You are also eligible
for an annual discretionary target bonus of 40% of your base salary. You can earn more or less than that target amount depending
on your performance, the Company&rsquo;s performance and subject to Board approval. Your bonus, if approved, will be prorated
in your first year.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">In
connection with your employment, you will be awarded a stock option grant to purchase 180,000 shares of the Company&rsquo;s common
stock at an exercise price equal to the fair market value of the stock at the date of grant. The grant of this stock option is
subject to Board approval and will vest over a four-year period, with 25% vested one year after initial date of employment and
then monthly over thirty-six (36) months. During your employment, based upon your annual review, you are also eligible to receive
additional stock options on an annual basis subject to Board approval. Upon a Change of Control of the Company, subject to Board
approval, the vesting of your stock options and all outstanding stock options in the 2014 Equity Compensation Plan will become
accelerated.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an employee you will have the opportunity to participate in the Company&rsquo;s benefit plans which currently includes a 401(k)
plan, medical and dental insurance, long term disability, short term disability and life insurance. In your first year of employment
you will be entitled to fifteen paid vacation days (up to a maximum of five days of which may be carried over from one year to
the next) in addition to the Company&rsquo;s standard paid holidays which may change from time to time. These vacation days will
accrue at a rate of 1.25 days per month.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B STYLE="font: bold 10pt Times New Roman, Times, Serif">Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">500
River Ridge Drive, Second Floor, Norwood, MA 02062 | Tel +1 617 963-0100</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: rgb(21,84,135)"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">www.corbuspharma.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: rgb(21,84,135)"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: rgb(21,84,135)"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: rgb(21,84,135)"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"></FONT></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center; color: rgb(21,84,135)"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_006.jpg" ALT="" STYLE="height: 134; width: 680">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Your
employment with the company will be on an &ldquo;at will&rdquo; basis, meaning that either you or the Company may terminate your
employment at any time for any reason or no reason, without further obligation or liability.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
a condition of employment, you will be required to authorize the Company to conduct a background investigation. This offer is
contingent upon a positive outcome of such an investigation, as well as your ability to provide to the Company documentary evidence
of your identity and eligibility for employment in the United States. Such documentation must be provided to us within three (3)
business days of the Start Date, or our employment relationship with you will be terminated. This is the full and complete agreement
between us on this term.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">As
an employee of the Company, you will have access to certain Company confidential information and you may, during the course of
your employment, develop certain information or inventions, which will become the property of the Company. As a condition of your
employment, you will be required to sign the Company&rsquo;s Confidential Information and Invention Assignment Agreement, a copy
of which is enclosed for your review and execution (the &ldquo;<U>Confidentiality Agreement</U>&rdquo;), prior to or on your Start
Date (as defined below). We wish to impress upon you that we do not wish you to bring with you any confidential and proprietary
material of any former employer or to violate any other obligation to your former employers. Also, by accepting this offer, you
represent that you are not subject to any restrictions that prevent you from working at the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
hereby represent that you are not presently bound by any employment agreement, confidential or proprietary information agreement
or similar agreement with any current or previous employer that would impose any restriction on your acceptance of this offer
or that would interfere with your ability to fulfill the responsibilities of your position with the Company. You agree to abide
by the Company&rsquo;s strict policy that prohibits any new employee from using or bringing with them from any prior employer
any confidential information, trade secrets, proprietary materials or processes of such former employers.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">While
you render services to the Company, you agree that you will not engage in any other employment, consulting or other business activity
without the prior written consent of the Company. While you render services to the Company, you also will not assist any person
or entity in competing with the Company, in preparing to compete with the Company or in hiring any employees or consultants of
the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">500
River Ridge Drive, Second Floor, Norwood, MA 02062 | Tel +1 617 963-0100</FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">www.corbuspharma.com</FONT>&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"></FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_007.jpg" ALT="" STYLE="width: 680">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
terms of this letter agreement and the resolution of any disputes will be governed by Massachusetts law (without reference to
its conflicts of laws provisions).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;<BR></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">You
agree that there were no promises or commitments made to you regarding your employment with the Company except as set forth in
this letter. This letter, together with the Confidentiality Agreement, set forth the terms of your employment with the Company
and supersede any prior representations or agreements whether written or oral. This letter may not be modified or amended except
by a written agreement, signed by the Company and by you.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 36pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">To
indicate your acceptance of the Company&rsquo;s offer and to acknowledge that you have read, understood and agreed to the terms
and conditions of this offer, please sign and date this letter in the space provided below and return it to me, along with a signed
and dated copy of the Confidentiality Agreement. This offer will expire at 5 p.m., Thursday, Feb. 21.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Craig,
we are delighted to be able to extend you this offer. We look forward to a mutually rewarding working relationship and to you
joining the Corbus family!</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 36pt; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sean Moran</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran, CFO</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-right: 5.4pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
    Pharmaceuticals, Inc. </FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">[Signature
Page Follows]</FONT>&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="color: Black"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">500
River Ridge Drive, Second Floor, Norwood, MA 02062 | Tel +1 617 963-0100</FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">www.corbuspharma.com</FONT>&nbsp;</P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font: 10pt Times New Roman, Times, Serif; color: Black"></FONT></P>


<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; text-align: center; margin-bottom: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><IMG SRC="image_008.jpg" ALT="" STYLE="width: 680">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
HAVE READ AND I UNDERSTAND THE TERMS OF THE OFFER SET OUT ABOVE. AS INDICATED BY MY SIGNATURE BELOW, I ACCEPT THE OFFER AS OUTLINED
ABOVE. I FURTHER ACKNOWLEDGE AND AGREE THAT, AS A CONDITION OF MY EMPLOYMENT, FROM TIME TO TIME, I MAY BE REQUIRED TO REVIEW AND
ACKNOWLEDGE OTHER DOCUMENTS WHICH MAY INCLUDE, WITHOUT LIMITATION, THE COMPANY&rsquo;S EMPLOYEE HANDBOOK AND POLICIES GOVERNING
SECURITIES TRADES BY COMPANY PERSONNEL. NO FURTHER COMMITMENTS WERE MADE TO ME AS A CONDITION OF EMPLOYMENT:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="width: 100%; font: 10pt Times New Roman, Times, Serif; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 0pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Mr.
    Craig S. Millian</FONT></TD>
    <TD STYLE="width: 50%; padding-right: 5.4pt; padding-left: 5.4pt; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; border-bottom: Black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Craig S. Millian</I></FONT></TD>
    <TD STYLE="padding-right: 5.4pt; padding-bottom: 1.5pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">February
    19, 2019</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date</FONT></TD>
    <TD STYLE="padding-right: 5.4pt; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>&nbsp;</I></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attachment
A</I>: Confidential Information and Invention Assignment Agreement (includes Exhibit A, Exhibit B and Exhibit C)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>Attachment
B</I>: Initial Job Duties</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">&nbsp;</FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="color: Black"><B>Corbus
Pharmaceuticals Holdings, Inc.</B></FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">500
River Ridge Drive, Second Floor, Norwood, MA 02062 | Tel +1 617 963-0100</FONT></P>

<P STYLE="font: 10pt/110% Times New Roman, Times, Serif; margin: 0; text-align: center; color: #155487"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">www.corbuspharma.com</FONT></P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B></B></FONT></P>


<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 6pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%; text-align: center">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt; margin-bottom: 6pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>image_005.jpg
<TEXT>
begin 644 image_005.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y ZH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUGR.S?8OF5TNYUU%<QX]UF^T'PP][I\BQW E10S(&&#UX-:MKJ"IX=@U*]D
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M5@I-72ZG0XI[GG%N/M7QMN6?D6]M\N>WR#_$UZ*RAU*D9!&#7G>D<_&;5O\
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MGW[]ZI.YA5H2I[ERBBBK.<**** %HHHJ@$I:2EI@% HQGI2%E1"SL%4#)+'
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MF4-)^'D%MJ::EJ^HSZI=1D%/.^ZI'0XR<UV4L:31/%(@>-P596&00>H-4/\
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M1UH]G/L%D=[]GC]#^='V>/T/YUP7_"U((H[F:ZT:YA@CBN'@<2JWGF&7RV4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#(7 &.X]ZJ> _"^I:#<:E<ZE(=UPL,44;7'GLJ1J0,OM7UX&. *[6BCVDK6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>image_006.jpg
<TEXT>
begin 644 image_006.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y ZH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUGR.S?8OF5TNYUU%<QX]UF^T'PP][I\BQW E10S(&&#UX-:MKJ"IX=@U*]D
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M5@I-72ZG0XI[GG%N/M7QMN6?D6]M\N>WR#_$UZ*RAU*D9!&#7G>D<_&;5O\
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MGW[]ZI.YA5H2I[ERBBBK.<**** %HHHJ@$I:2EI@% HQGI2%E1"SL%4#)+'
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MF4-)^'D%MJ::EJ^HSZI=1D%/.^ZI'0XR<UV4L:31/%(@>-P596&00>H-4/\
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M1UH]G/L%D=[]GC]#^='V>/T/YUP7_"U((H[F:ZT:YA@CBN'@<2JWGF&7RV4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#(7 &.X]ZJ> _"^I:#<:E<ZE(=UPL,44;7'GLJ1J0,OM7UX&. *[6BCVDK6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>image_007.jpg
<TEXT>
begin 644 image_007.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y ZH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HJL]_:QWR6
M3W$8N74NL1/S%1WJ.V>]DO9VD:V:Q('DF,DOGOGM^5.PN9%A+F&29XDFC:5/
MOHK LOU':I:S)9[#3]4 ^S>7/= L\ZQX7 _O-VHU/6H=.M6N%B>Z".JR+!AB
M@/<^U'*WL3SI)WZ%B_>^2%#80PRR;P&$KE0%[G@=:2[LY;F:VD2]G@$3;F2/
M&)/8Y[5"-4M[VQGELKA&\L?,2K';^'6JFG7'V*W^QQR37TX<G.22H/3<3TII
M,3:9))!:V=B;#4]3EE^UR%4::38YS_"I&*TK>.&UBCM8FP$7"JS9; ^O)JM#
M,L[A+ZWBCGC?Y V""?52:R-2CC&J->3ZG;6JLRPPRPQYF![H3R,'Z4[7T$WR
MZG2LP52Q!P!GBLNR9M3N$U**XO88-K1_994V G^]@C-/U:6W<1Z?=6MS-'<Y
M#-$AVJ!S\Q'2HM'U9-1^2TLYELHUVI.YQDCC;CK^-))VN-R3E8NV%FUC;>2]
MU/<G<6\R=LMSV^E5=5U&33;FUDDFM(K)FVRM*6WY/0*!3IEE\ZXCO-0BCMK@
M;(%3]W(I[X;/)JG=G1M&NK*2^65I4C\N.YE5G"C_ &FZ9II7>HI.RTT-F:ZM
M[;R_/GCB\QMJ;V W'T%2U!)!;7@B>2**8*0\990<'L1FLN\$^HZH]K:WU]92
M6Z99A"#$^?<]34I7+<FC<HJ%98T=+=YT:;;G:2 S>^*FI%!1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUGR.S?8OF5TNYUU%<QX]UF^T'PP][I\BQW E10S(&&#UX-:MKJ"IX=@U*]D
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M5@I-72ZG0XI[GG%N/M7QMN6?D6]M\N>WR#_$UZ*RAU*D9!&#7G>D<_&;5O\
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MGW[]ZI.YA5H2I[ERBBBK.<**** %HHHJ@$I:2EI@% HQGI2%E1"SL%4#)+'
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MF4-)^'D%MJ::EJ^HSZI=1D%/.^ZI'0XR<UV4L:31/%(@>-P596&00>H-4/\
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M1UH]G/L%D=[]GC]#^='V>/T/YUP7_"U((H[F:ZT:YA@CBN'@<2JWGF&7RV4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#(7 &.X]ZJ> _"^I:#<:E<ZE(=UPL,44;7'GLJ1J0,OM7UX&. *[6BCVDK6
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>image_008.jpg
<TEXT>
begin 644 image_008.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" "Y ZH# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MUGR.S?8OF5TNYUU%<QX]UF^T'PP][I\BQW E10S(&&#UX-:MKJ"IX=@U*]D
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M5@I-72ZG0XI[GG%N/M7QMN6?D6]M\N>WR#_$UZ*RAU*D9!&#7G>D<_&;5O\
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MGW[]ZI.YA5H2I[ERBBBK.<**** %HHHJ@$I:2EI@% HQGI2%E1"SL%4#)+'
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MF4-)^'D%MJ::EJ^HSZI=1D%/.^ZI'0XR<UV4L:31/%(@>-P596&00>H-4/\
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M1UH]G/L%D=[]GC]#^='V>/T/YUP7_"U((H[F:ZT:YA@CBN'@<2JWGF&7RV4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#(7 &.X]ZJ> _"^I:#<:E<ZE(=UPL,44;7'GLJ1J0,OM7UX&. *[6BCVDK6
MY2/X?:1$$59[WRXS=&)#*"(Q<#$@''3DD>A/>I+#P+INEZG!>V5S?0F..-)(
MEE'ES^6NU6<8Y./0C.*Z>BCVDNX'.:CX.M[_ %\ZU'JNJ6-TT20N+2945T4D
M@$%3W)J _#_16(WFY=0;LE&D&&^T#$@/'Y>GO7544N>7<#CH?AOI45I-%]NU
M1YI'AD6Z>X!EB>(80HVWC XZ'BI/^%=Z.L5DD%SJ%LULC1M)!<%7N$9_,82-
MC)RW)QBNMHI^TEW XR7X9Z)+<7<GVB_5+E)D,2S#8@E(+[<KGJ,\DU>'@?2A
MJ0OA)=>:+N.\QY@QO2(Q =.FT_G72T4>TEW XN3X8Z(\%I$MQJ$8MH5ARDRY
MD59/,7=\O.&],5(/AQH_VJZF>YU"03K<@1/,"D1G&)&08X)''>NPHH]I+N!R
MT'@+2+>1'22[)2Y@N0&D&"T,?EJ#QTV]1ZU67X9Z&MO>V_G7YBN83;HK3 _9
MHBXD*1\< L ><UV5%'M)]P.7MO FEVGB!=8BGO1(D[W"6YE'DK(Z[78+CN,=
MZ?K/@C3-;U%[NYGO46;RQ<V\4^V*Y$9RF]<=CZ8KI:*7/*][@<AI7A$C5_$^
MH7J"V;5Y%1/LLQ#K&BX#;AC#$Y;CI4MMX TFU2V*3WAFAO&O#,9!ND=EVN&P
M,;6'!  KJJ*.>7<#DX/A]I<&DS:6+O4&LG:,QQ-,"(0C[PJ?+P,^N3CO5NT\
M&Z99:M#J44ER9XKJXNE#."N^< /D8Z?*,?UKH:*'.3Z@5M08IIURPZB)B/RH
MT^$0:=;1#^&-1^E/ND\VTFC_ +R$?I4H&% K+E]^_D+J+1115C"BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
..HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>24
<FILENAME>ex21-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
21.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SUSIDIARIES
OF CORBUS PHARMACEUTICALS HOLDINGS, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Name
    of Organization</U></B></FONT></TD>
    <TD STYLE="width: 2%; text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 49%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><U>Jurisdiction</U></B></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
    Pharmaceuticals, Inc.</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Delaware</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
    International Limited</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">United
    Kingdom</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Corbus
    Pharmaceuticals Australia Pty Ltd</FONT></TD>
    <TD STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Australia</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>25
<FILENAME>ex23-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin-top: 0; text-align: center; margin-bottom: 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
23.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><B>CONSENT
OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">We
consent to the incorporation by reference in the Registration Statements of Corbus Pharmaceuticals Holdings, Inc. and Subsidiaries
on Form S-3 (No. 333-222447) and Form S-8 (Nos. 333-200350, 333-201898, 333-210428 and 333-216547) of our report dated March
12, 2018, on our audits of the consolidated financial statements as of December 31, 2018 and 2017 and for the years then
ended December 31, 2018, which report is included in this Annual Report on Form 10-K to be filed on or about March 12, 2019.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font: 10pt Times New Roman, Times, Serif"><I>/s/
    EisnerAmper LLP</I></FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">EISNERAMPER
    LLP</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Philadelphia,
    Pennsylvania</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">March
    12, 2019</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->




</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>26
<FILENAME>ex31-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF EXECUTIVE OFFICER PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Yuval Cohen, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K for the period ended December 31, 2018 of Corbus Pharmaceuticals Holdings, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financing reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 12, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yuval Cohen</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>27
<FILENAME>ex31-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
31.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CERTIFICATION
OF CHIEF FINANCIAL OFFICER PURSUANT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>TO
SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I,
Sean M. Moran, certify that:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">I
    have reviewed this annual report on Form 10-K for the period ended December 31, 2018 of Corbus Pharmaceuticals Holdings, Inc.;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">2.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary
    to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect
    to the period covered by this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">3.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Based
    on my knowledge, the financial statements, and other financial information included in this report, fairly present in all
    material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods
    presented in this report;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">4.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls
    and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financing reporting (as
    defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision,
    to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to
    us by others within those entities, particularly during the period in which this report is being prepared;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Designed
    such internal control over financial reporting, or caused such internal control over financial reporting to be designed under
    our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial
    statements for external purposes in accordance with generally accepted accounting principles;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">c.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Evaluated
    the effectiveness of the registrant&rsquo;s disclosure controls and procedures and presented in this report our conclusions
    about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based
    on such evaluation; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">d.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Disclosed
    in this report any change in the registrant&rsquo;s internal control over financial reporting that occurred during the registrant&rsquo;s
    most recent fiscal quarter (the registrant&rsquo;s fourth fiscal quarter in the case of an annual report) that has materially
    affected, or is reasonably likely to materially affect, the registrant&rsquo;s internal control over financial reporting;
    and</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">5.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    registrant&rsquo;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control
    over financial reporting, to the registrant&rsquo;s auditors and the audit committee of the registrant&rsquo;s board of directors
    (or persons performing the equivalent functions):</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 0.5in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 0.25in; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">a.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">All
    significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which
    are reasonably likely to adversely affect the registrant&rsquo;s ability to record, process, summarize and report financial
    information; and</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">b.</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Any
    fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&rsquo;s
    internal control over financial reporting.</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="width: 50%; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date:
    March 12, 2019</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sean Moran</I></FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting and Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>28
<FILENAME>ex32-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
of Chief Executive Officer Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. Section 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Adopted Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Certification is being filed pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.
This Certification is included solely for the purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act
and is not intended to be used for any other purpose. In connection with the accompanying Annual Report on Form 10-K of Corbus
Pharmaceuticals Holdings, Inc. for the year ended December 31, 2018, each of the undersigned hereby certifies in his capacity
as an officer of Corbus Pharmaceuticals Holdings, Inc. that to such officer&rsquo;s knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Annual Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results
of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Yuval Cohen</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 12, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Yuval
    Cohen</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Executive Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Executive Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->


<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>29
<FILENAME>ex32-2.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
32.2</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Certification
of Chief Financial Officer Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>18
U.S.C. Section 1350,</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>as
Adopted Pursuant to</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Section
906 of the Sarbanes-Oxley Act of 2002</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
Certification is being filed pursuant to 18 U.S.C. Section 1350, as adopted by Section 906 of the Sarbanes-Oxley Act of 2002.
This Certification is included solely for the purposes of complying with the provisions of Section 906 of the Sarbanes-Oxley Act
and is not intended to be used for any other purpose. In connection with the accompanying Annual Report on Form 10-K of Corbus
Pharmaceuticals Holdings, Inc. for the year ended December 31, 2018, each of the undersigned hereby certifies in his capacity
as an officer of Corbus Pharmaceuticals Holdings, Inc. that to such officer&rsquo;s knowledge:</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(1)
The Annual Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(2)
The information contained in the Annual Report fairly presents, in all material respects, the financial condition and results
of operations of the Company.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; width: 50%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 3%; font: 10pt Times New Roman, Times, Serif; padding-bottom: 1.5pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="vertical-align: bottom; width: 47%; font: 10pt Times New Roman, Times, Serif; border-bottom: Black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Sean Moran</I></FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
    March 12, 2019</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Sean
    Moran</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief
    Financial Officer</FONT></TD></TR>
<TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="vertical-align: top; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="vertical-align: bottom; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Principal
    Accounting and Financial Officer)</FONT></TD></TR>
</TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="page-break-before: always; margin-top: 6pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 33%">&nbsp;</TD><TD STYLE="width: 34%; text-align: center">&nbsp;</TD><TD STYLE="width: 33%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->



<P STYLE="margin: 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.INS
<SEQUENCE>30
<FILENAME>crbp-20181231.xml
<DESCRIPTION>XBRL INSTANCE FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20181231 10K FY DFN.xfr; Date: 2019%2D03%2D12T12:43:14Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80080001 -->
<xbrli:xbrl xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2017-01-31" xmlns:srt="http://fasb.org/srt/2018-01-31" xmlns:CRBP="http://corbuspharma.com/20181231">
    <link:schemaRef xlink:href="crbp-20181231.xsd" xlink:type="simple" />
    <xbrli:context id="From2017-01-01to2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-01-01to2016-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-01-01</xbrli:startDate>
        <xbrli:endDate>2016-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CRBP:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-12-30_custom_CopierMachineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:CopierMachineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-12-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:OrchestraMedicalVenturesLLCMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandAndSixteenConsultingAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-02-27</xbrli:startDate>
        <xbrli:endDate>2017-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SecuritiesPurchaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalAndAccreditedInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-02-28</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponCommercializationOfTheProductMember_custom_LenabasumMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponCommercializationOfTheProductMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-18</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponReachingTheSalesTargetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-18</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponTransferSaleOrLicensingMember_custom_LenabasumMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponTransferSaleOrLicensingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-18</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_CorporatecreditCardsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:CorporatecreditCardsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_SalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:SalesAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-20</xbrli:startDate>
        <xbrli:endDate>2017-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FirstYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:FirstYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-20</xbrli:startDate>
        <xbrli:endDate>2017-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_SeventhYearMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:SeventhYearMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-08-20</xbrli:startDate>
        <xbrli:endDate>2017-08-21</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_ThirdAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:ThirdAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FourthAnniversaryMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:FourthAnniversaryMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-08-21</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-10-25</xbrli:startDate>
        <xbrli:endDate>2017-10-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:SeptemberTwoThousandAndSixteenAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:SeptemberTwoThousandAndSixteenAmendmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-09-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_InterestExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:InterestExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-12-21</xbrli:startDate>
        <xbrli:endDate>2017-12-22</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_custom_OrphanDrugCreditMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">CRBP:OrphanDrugCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_custom_OrphanDrugCreditMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:TaxCutAndJobsActOfTwoThousandSeventeenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">CRBP:OrphanDrugCreditMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-01-01to2015-12-30_custom_CopierMachineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:CopierMachineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-01-01</xbrli:startDate>
        <xbrli:endDate>2015-12-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-30_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-04to2018-01-05_custom_AtTheMarketOfferingMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:AtTheMarketOfferingMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-04</xbrli:startDate>
        <xbrli:endDate>2018-01-05</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-26_custom_CysticFibrosisProgramRelatedInvestmentAgreementMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:CysticFibrosisProgramRelatedInvestmentAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember_custom_InvestmentagreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationWarrantsMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-01-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-25to2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-25</xbrli:startDate>
        <xbrli:endDate>2018-01-26</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_StandbyLetterOfCreditMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">CRBP:StandbyLetterOfCreditMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-10-26_custom_InstitutionalInvestorsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:InstitutionalInvestorsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-10-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_InsurancePolicyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CRBP:InsurancePolicyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-12-31_custom_MassachusettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:MassachusettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_CommonStockMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_RetainedEarningsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_WarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_StockOptionsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">CRBP:StockOptionsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_ComputerHardwareAndSoftwareMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:ComputerHardwareAndSoftwareMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_OfficeFurnitureAndEquipmentMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:OfficeFurnitureAndEquipmentMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_ConstructionInProgressMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_CopierMachineMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">CRBP:CopierMachineMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_InsurancePolicyMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">CRBP:InsurancePolicyMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponReachingTheSalesTargetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_InvestmentagreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementScenarioAxis">CRBP:UponReachingTheSalesTargetMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:LenabasumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2015-04-18</xbrli:startDate>
        <xbrli:endDate>2015-04-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationwarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:CysticFibrosisFoundationWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31_custom_JanuaryTwoThousandAndEighteenSalesAgreementMember_custom_InstitutionalInvestorMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:JanuaryTwoThousandAndEighteenSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalInvestorMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_ASC606Member_custom_TwoThousandAndEighteenCffAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">CRBP:ASC606Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:TwoThousandAndEighteenCffAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-03-31">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_CapitalLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:CapitalLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_custom_ASC606Member_custom_TwoThousandAndEighteenCffAwardMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">CRBP:ASC606Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:TwoThousandAndEighteenCffAwardMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_EmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:EmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_NonEmployeesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:NonEmployeesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_country_GB">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:GB</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-09-19to2018-09-20_custom_JenrinAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:JenrinAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-09-19</xbrli:startDate>
        <xbrli:endDate>2018-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-10-01to2016-10-31_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-10-01</xbrli:startDate>
        <xbrli:endDate>2016-10-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-10-31_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-10-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-11-01to2017-11-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-11-01</xbrli:startDate>
        <xbrli:endDate>2017-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-11-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-03-06">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-03-06</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-06-30">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-06-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_UpFrontPaymentArrangementMember_custom_KakenPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:KakenPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_InvestmentagreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:CysticFibrosisFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_InvestmentagreementMember_custom_JanuaryTwoThousandAndNineteenOfferingMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:CysticFibrosisFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:JanuaryTwoThousandAndNineteenOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_custom_ASC606Member_custom_HigherRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">CRBP:ASC606Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">CRBP:HigherRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-10-01to2018-12-31_custom_ASC606Member_custom_LowerRevenueMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AdjustmentsForNewAccountingPronouncementsAxis">CRBP:ASC606Member</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:DeferredRevenueArrangementTypeAxis">CRBP:LowerRevenueMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-10-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_JanuaryOneTwoThousandAndNineteenMember_srt_MinimumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:JanuaryOneTwoThousandAndNineteenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_JanuaryOneTwoThousandAndNineteenMember_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:JanuaryOneTwoThousandAndNineteenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-07-01to2018-09-30_us-gaap_ResearchAndDevelopmentExpenseMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-07-01</xbrli:startDate>
        <xbrli:endDate>2018-09-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:AugustTwoThousandSeventeenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:FebruaryTwoThousandAndNineteenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-11-01to2018-11-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-11-01</xbrli:startDate>
        <xbrli:endDate>2018-11-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-11-30_custom_LoanAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:LoanAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_CollaborationAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:CysticFibrosisFoundationMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:CollaborationAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_InvestmentagreementMember_custom_TwoThousandAndEighteenCffAwardMember_custom_KakenPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:TwoThousandAndEighteenCffAwardMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:KakenPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_MassachusettMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:MassachusettMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_FederalMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">CRBP:FederalMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember_custom_FebruaryTwentySixTwoThousandAndNineteenMember_custom_NewPremisesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:FebruaryTwoThousandAndNineteenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:FebruaryTwentySixTwoThousandAndNineteenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">CRBP:NewPremisesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember_custom_FebruaryTwentySixTwoThousandAndNineteenMember_custom_TotalPremisesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:FebruaryTwoThousandAndNineteenLeaseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:FebruaryTwentySixTwoThousandAndNineteenMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">CRBP:TotalPremisesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-02-01to2018-02-28">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-02-01</xbrli:startDate>
        <xbrli:endDate>2018-02-28</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2014-04-01to2014-04-30_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2014-04-01</xbrli:startDate>
        <xbrli:endDate>2014-04-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandandNiniteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CRBP:JanuaryOneTwoThousandandNiniteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandandNiniteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CRBP:JanuaryOneTwoThousandandNiniteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CRBP:CFFWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CRBP:CFFWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_CFFWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CRBP:CFFWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_CFFWarrantMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CRBP:CFFWarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2016-09-01to2016-09-20_custom_TwoThousandFourteenEquityCompensationPlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityCompensationPlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2016-09-01</xbrli:startDate>
        <xbrli:endDate>2016-09-20</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-12-30to2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-12-30</xbrli:startDate>
        <xbrli:endDate>2019-01-01</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:EvergreenProvisionMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">CRBP:TwoThousandFourteenEquityIncentivePlanMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-01</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-02to2019-01-03_us-gaap_SubsequentEventMember_custom_CollaborationandLicenseAgreementMember_custom_KakenPharmaceuticalCoLtdMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:CollaborationandLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="dei:LegalEntityAxis">CRBP:KakenPharmaceuticalCoLtdMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-02</xbrli:startDate>
        <xbrli:endDate>2019-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-29to2019-01-30_us-gaap_SubsequentEventMember_custom_PublicOfferingMember_custom_TerminationofJanuaryTwoThousandAndEighteenSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:PublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-29</xbrli:startDate>
        <xbrli:endDate>2019-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-29to2019-01-30_us-gaap_SubsequentEventMember_us-gaap_IPOMember_custom_UnderwritersOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:IPOMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">CRBP:UnderwritersOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-29</xbrli:startDate>
        <xbrli:endDate>2019-01-30</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-01-30_us-gaap_SubsequentEventMember_custom_PublicOfferingMember_custom_TerminationofJanuaryTwoThousandAndEighteenSalesAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:PublicOfferingMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-01-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_JanuaryTwoThousandAndEighteenSalesAgreementMember_custom_InstitutionalInvestorMember_custom_Remainder2018AndThroughFebruary82019Member">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:JanuaryTwoThousandAndEighteenSalesAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionAxis">CRBP:InstitutionalInvestorMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">CRBP:Remainder2018AndThroughFebruary82019Member</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_StockOptionMember1457987031">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_us-gaap_WarrantMember1458033187">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_StockOptionMember1458043328">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_us-gaap_WarrantMember1458051890">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_OralAntiinflammatoryDrugMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis">CRBP:OralAntiinflammatoryDrugMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-04-20</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-05-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-05-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2015-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2015-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2016-08-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2016-08-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-01-31_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-01-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2017-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:TwoThousandFifteenCFFTAwardArrangementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2017-11-30</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_custom_InvestmentagreementMember_custom_PhaseTwoBClinicalTrialMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:InvestmentagreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:RelatedPartyTransactionsByRelatedPartyAxis">CRBP:PhaseTwoBClinicalTrialMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2018-12-31_srt_MaximumMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2018-12-31</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:FebruaryTwoThousandAndNineteenLeaseAgreementMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-03-31_us-gaap_StockOptionMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityTypeAxis">us-gaap:StockOptionMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-03-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2019-01-02to2019-01-03_us-gaap_SubsequentEventMember_custom_CollaborationandLicenseAgreementMember_custom_FirstQuarterofTwoThousandandNineteenMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">CRBP:CollaborationandLicenseAgreementMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:AwardDateAxis">CRBP:FirstQuarterofTwoThousandandNineteenMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2019-01-02</xbrli:startDate>
        <xbrli:endDate>2019-01-03</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-26_us-gaap_SubsequentEventMember_custom_NewPremisesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">CRBP:NewPremisesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="AsOf2019-02-26_us-gaap_SubsequentEventMember_custom_TotalPremisesMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
          <xbrldi:explicitMember dimension="us-gaap:LeaseArrangementTypeAxis">CRBP:TotalPremisesMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:instant>2019-02-26</xbrli:instant>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2018-01-01to2018-12-31_custom_StockOptionAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CRBP:StockOptionAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2018-01-01</xbrli:startDate>
        <xbrli:endDate>2018-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:context id="From2017-01-01to2017-12-31_custom_StockOptionAndWarrantsMember">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001595097</xbrli:identifier>
        <xbrli:segment>
          <xbrldi:explicitMember dimension="us-gaap:DerivativeInstrumentRiskAxis">CRBP:StockOptionAndWarrantsMember</xbrldi:explicitMember>
        </xbrli:segment>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2017-01-01</xbrli:startDate>
        <xbrli:endDate>2017-12-31</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
    <xbrli:unit id="Percentage">
      <xbrli:measure>xbrli:pure</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Segment">
      <xbrli:measure>CRBP:Segment</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="sqft">
      <xbrli:measure>utr:sqft</xbrli:measure>
    </xbrli:unit>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-32421612</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-32421612</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-55672139</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:NetIncomeLoss contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-55672139</us-gaap:NetIncomeLoss>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">146609</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">460596</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">150000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">55603427</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">57247496</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">55603427</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">57247496</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">5560</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">5725</us-gaap:CommonStockValue>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">8919235</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">57783561</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">4468</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">42191256</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2016-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-33276489</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5560</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">123476102</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-65698101</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">27524120</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">5725</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">148888635</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" decimals="0">-121370240</us-gaap:StockholdersEquity>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">0.0001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2017-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2018-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2017-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2018-12-31" unitRef="Shares" xsi:nil="true" />
    <us-gaap:SharesOutstanding contextRef="AsOf2016-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">44681745</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">55603427</us-gaap:SharesOutstanding>
    <us-gaap:SharesOutstanding contextRef="AsOf2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">57247496</us-gaap:SharesOutstanding>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">75401959</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1065</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">75400894</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">11235320</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">150</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">11235170</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="Shares" decimals="INF">3887815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">10648948</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember" unitRef="Shares" decimals="INF">1413633</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="Shares" decimals="INF">4650000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-01-01to2018-03-31_custom_JanuaryTwoThousandAndEighteenSalesAgreementMember_custom_InstitutionalInvestorMember" unitRef="Shares" decimals="INF">1500000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="From2018-01-01to2018-12-31_custom_JanuaryTwoThousandAndEighteenSalesAgreementMember_custom_InstitutionalInvestorMember_custom_Remainder2018AndThroughFebruary82019Member" unitRef="Shares" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">189490</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">27</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">189463</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">347645</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">14</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">347631</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">272734</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">272734</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">139069</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">139069</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember1457987031" unitRef="Shares" decimals="INF">144069</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember1458043328" unitRef="Shares" decimals="INF">272734</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2969837</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="USD" decimals="0">36291</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="USD" decimals="0">2184000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">464680</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="From2019-01-29to2019-01-30_us-gaap_SubsequentEventMember_custom_PublicOfferingMember_custom_TerminationofJanuaryTwoThousandAndEighteenSalesAgreementMember" unitRef="USD" decimals="0">2667000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">78891699</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-02-27to2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="USD" decimals="0">27214705</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-01-01to2017-12-31_custom_SalesAgreementMember" unitRef="USD" decimals="0">13268208</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="USD" decimals="0">32550000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2017-11-01to2017-11-30_custom_InstitutionalInvestorsMember" unitRef="USD" decimals="0">4589550</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">12052645</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-01-01to2018-03-31_custom_JanuaryTwoThousandAndEighteenSalesAgreementMember_custom_InstitutionalInvestorMember" unitRef="USD" decimals="0">11200000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_InvestmentagreementMember_custom_JanuaryTwoThousandAndNineteenOfferingMember" unitRef="USD" decimals="0">37600000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2019-01-29to2019-01-30_us-gaap_SubsequentEventMember_custom_PublicOfferingMember_custom_TerminationofJanuaryTwoThousandAndEighteenSalesAgreementMember" unitRef="USD" decimals="0">40290250</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="From2018-01-01to2018-12-31_custom_JanuaryTwoThousandAndEighteenSalesAgreementMember_custom_InstitutionalInvestorMember_custom_Remainder2018AndThroughFebruary82019Member" unitRef="USD" xsi:nil="true" />
    <us-gaap:NatureOfOperations contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;1.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;NATURE OF OPERATIONS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Business&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Corbus Pharmaceuticals Holdings,&#13;Inc. (&amp;#8220;the Company&amp;#8221;) is a clinical stage pharmaceutical company, focused on the development and commercialization&#13;of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Since its inception, the Company&#13;has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical&#13;staff, acquiring operating assets and raising capital. The Company&amp;#8217;s business is subject to significant risks and uncertainties&#13;and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve&#13;profitability.&lt;/p&gt;</us-gaap:NatureOfOperations>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;3.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;A summary of the significant accounting&#13;policies followed by the Company in the preparation of the financial statements is as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The process of preparing financial&#13;statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;)&#13;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure&#13;of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the&#13;reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates&#13;are related to stock-based compensation expense, the accrual of research, product development and clinical obligations, the recognition&#13;of revenue under the Investment Agreement (see Note 9) and the valuation of the CFF Warrant discussed in Note 9).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company considers only those&#13;investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to&#13;be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2018&#13;and 2017, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2018&#13;and 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Restricted cash as of December 31,&#13;2017 in the amount of $108,991 was classified in current assets and included a collateral account for the Company&amp;#8217;s corporate&#13;credit cards. The collateral account was closed in the first quarter of 2018 and accordingly the cash became unrestricted. Additionally,&#13;as of December 31, 2017, restricted cash included a stand-by letter of credit issued in favor of a landlord for $50,000 which was&#13;classified in current assets as of December 31, 2017. This stand-by letter of credit was terminated in the first quarter of 2018&#13;in connection with the August 2017 Lease Agreement discussed in Note 6, and accordingly, the cash became unrestricted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Cash, cash equivalents, and restricted&#13;cash consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;808,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;206,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Money market fund&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;40,939,525&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,330,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,748,468&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,537,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,748,468&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,696,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As of December 31, 2018, all of&#13;the Company&amp;#8217;s cash was held in the United States, except for approximately $702,000 of cash which was held in our subsidiary&#13;in the United Kingdom. As of December 31, 2017, all of the Company&amp;#8217;s cash was held in the United States.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The carrying amounts reported in&#13;the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their&#13;fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair&#13;value due to the fact that they are at market terms.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The estimated life for the Company&amp;#8217;s&#13;property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture&#13;and equipment. The Company&amp;#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their&#13;useful lives or the respective leases. See Note 5 for details of property and equipment and Note 6 for operating and capital lease&#13;commitments.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Costs incurred for research and&#13;development are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Nonrefundable advance payments for&#13;goods or services that have the characteristics that will be used or rendered for future research and development activities pursuant&#13;to executory contractual arrangements with third party research organizations are deferred and recognized as an expense as the&#13;related goods are delivered or the related services are performed.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accruals for Research and&#13;Development Expenses and Clinical Trials&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As part of the process of preparing&#13;its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with&#13;vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical&#13;trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result&#13;in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&amp;#8217;s&#13;objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which&#13;services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects&#13;of the expenses. The Company determines the accrual estimates by taking into account discussion with applicable personnel and outside&#13;service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the&#13;Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its&#13;accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&amp;#8217;s&#13;clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party&#13;vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding&#13;of the status and timing of services performed relative to the actual status and timing of services performed may vary and may&#13;result in it reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2018 and&#13;2017, there were no material adjustments to the Company&amp;#8217;s prior period estimates of accrued expenses for clinical trials.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases and Deferred Rent&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company leases its office space.&#13;Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&amp;#8217;s office&#13;space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records&#13;the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between&#13;the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the lessor&#13;are recorded as a reduction to rent expense over the term of the lease.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has no significant off-balance-sheet&#13;concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may&#13;from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company&#13;believes the risk of loss is minimal as these banks are large financial institutions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Operating segments are identified&#13;as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating&#13;decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. To date,&#13;the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing&#13;therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2018 and 2017, all of the Company&amp;#8217;s&#13;assets were located in the United States, except for approximately $702,000 of cash, $1,183,000 of prepaid expenses, $28,000 of&#13;other assets, and $54,000 of property and equipment, net which were held in our subsidiary in the United Kingdom as of December&#13;31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For federal and state income taxes,&#13;deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax&#13;basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in&#13;which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax benefit when it is not&#13;more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses&#13;since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate&#13;the deferred tax assets amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Tax positions taken or expected&#13;to be taken in the course of preparing the Company&amp;#8217;s tax returns are required to be evaluated to determine whether the tax&#13;positions are &amp;#8220;more-likely-than-not&amp;#8221; of being sustained by the applicable tax authority. Tax positions not deemed to&#13;meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense in&#13;the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December&#13;31, 2018 or 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On December 22, 2017, Staff Accounting&#13;Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does&#13;not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the&#13;accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, the Company had recorded a provisional estimate&#13;in these financial statements for the effect of the corporate tax rate change. The Company finalized its estimates during the fourth&#13;quarter of 2018, described more fully in Note 10.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company continually monitors&#13;events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment&#13;loss is recognized when expected undiscounted cash flows of an asset are less than an asset&amp;#8217;s carrying value. Accordingly,&#13;when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating&#13;performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess of the fair value&#13;of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset may not be recoverable.&#13;No impairment charges were recorded for the years ended December 31, 2018 and 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-based Payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company recognizes compensation&#13;costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement&#13;of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option&#13;grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model, net of estimated forfeitures.&#13;The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which&#13;is generally the vesting period. Stock options granted to non-employee consultants are revalued at the end of each reporting period&#13;until vested using the Black-Scholes option-pricing model and the changes in their fair value are recorded as adjustments to expense&#13;over the related vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On March 30, 2016, the FASB issued&#13;ASU No. 2016-09, &lt;i&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&#13;&lt;/i&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;i&gt;. &lt;/i&gt;ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment&#13;transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification&#13;in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures&#13;as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have&#13;an impact on the Company&amp;#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the excess&#13;tax benefits in respect of share based payments only when realized (See Note 10).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Basic and diluted net loss per share&#13;of the Company&amp;#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding&#13;during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted&#13;loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years&#13;ended December 31, 2018 and 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted net loss per share of common stock:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(55,672,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,421,612&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;56,999,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,176,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share of common stock-basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The impact of the following potentially&#13;dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the computation of dilutive weighted average&#13;shares outstanding as the inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,283,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,593,990&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,877,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,133,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In May 2014, the FASB issued guidance&#13;codified in &lt;i&gt;Accounting Standards Codification (ASC) 606, Revenue Recognition &amp;#8212; Revenue from Contracts with Customers&lt;/i&gt;&#13;(&amp;#8220;ASC 606&amp;#8221;) which amends the guidance in former &lt;i&gt;ASC 605, Revenue Recognition&lt;/i&gt;, and is effective for public companies&#13;for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from ASC 605 in many respects,&#13;such as in the accounting for variable consideration received, including milestone payments or contingent payments. Under the Company&amp;#8217;s&#13;accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone payments were initially recognized only&#13;in the period that the payment-triggering event occurred or was achieved (See Note 9). ASC 606, however, may require a company&#13;to recognize such payments before the payment-triggering event is completely achieved based on the Company&amp;#8217;s estimate of&#13;the amount of consideration to which it will be entitled in exchange for transferring the services, subject to management&amp;#8217;s&#13;assessment of whether it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur&#13;when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company adopted ASC 606 in the&#13;first quarter of 2018 using the modified retrospective method according to which the cumulative effect of initially applying ASC&#13;606 is recognized at the date of initial application, and elected to utilize a practical expedient and did not restate contracts&#13;that were completed as of the date of adoption. Since the Company has concluded its performance obligations and has completed recognizing&#13;revenue under the 2015 CFFT Award in the third quarter of 2017 (See Note 9), there was no cumulative effect to record at the date&#13;of the Company&amp;#8217;s adoption of ASC 606 and no revenue to recognize for the first quarter of 2018 related to the 2015 CFFT Award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Revenue for the quarter and the&#13;year ended December 31, 2018 was $1,927,306 and $4,822,272, respectively, recognized in accordance with ASC 606 and pertains only&#13;to the 2018 CFF Award discussed in Note 9. The total impact to revenue as a result of the adoption of ASC 606 was higher revenue&#13;of approximately $325,000 for the quarter ended December 31, 2018 and lower revenue of approximately $201,000 for the year ended&#13;December 31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company will assess any new&#13;agreements it enters into under ASC 606, including whether such agreements fall under the scope of such standard. This standard&#13;applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance,&#13;collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control&#13;of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for&#13;those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC&#13;606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance&#13;obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations&#13;in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies&#13;the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange&#13;for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the&#13;scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance&#13;obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount&#13;of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is&#13;satisfied.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Revenue associated with the 2018&#13;CFF Award performance obligation is being recognized as revenue as the research and development services are provided using an&#13;input method, according to the costs incurred as related to the research and development activities and the costs expected to be&#13;incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&amp;#8217;s&#13;judgment, is the best measure of progress towards satisfying the performance obligation. The research and development services&#13;related to this performance obligation are expected to be performed over an approximately two and a half-year period expected to&#13;be completed in the second quarter of 2020. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts&#13;expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of&#13;deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#13;months following the balance sheet date would be classified as deferred revenue, net of current portion. Amounts recognized as&#13;revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Accounting for Leases&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;ASU No&lt;b&gt;. &lt;/b&gt;2016-02, &lt;i&gt;Leases (Topic 842), &lt;/i&gt;as amended (&amp;#8220;ASU 2016-02&amp;#8221;)&lt;i&gt;. &lt;/i&gt;Under ASU 2016-02, a lessee will&#13;be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current&#13;US GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will&#13;depend on its classification as a finance or operating lease. However, unlike current US GAAP, which requires only capital leases&#13;to be recognized on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU&#13;2016-02 will take effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. ASU&#13;2016-02 required a modified retrospective transition approach, which initially required application of the new guidance for all&#13;periods presented in the Company&amp;#8217;s financial statements (&amp;#8220;comparative method&amp;#8221;). In July 2018, the FASB released&#13;ASU 2018-11, offering a second option which provides further relief in the transition to ASC 842. Companies are allowed to follow&#13;the cumulative-effect adjustment transition approach (&amp;#8220;effective date method&amp;#8221;), which releases companies from presenting&#13;comparative periods and related disclosures according to ASC 842. Instead, companies electing to utilize the effective date method&#13;will recognize a one-time adjustment to retained earnings on the transition date without the additional burden of presenting the&#13;comparative periods under the new guidance. The Company will adopt ASU 2016-02 using the effective date method as of January 1,&#13;2019 and expects to record a lease liability in the rage of approximately $3.4-$4.2 million, and a right-to-use asset in the range&#13;of approximately $2.1-$2.6 million, and no adjustment to the accumulated deficit. The Company anticipates that the adoption will&#13;not have a material impact on the consolidated statement of operations or statement of cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Nonemployee Share-Based Payment&#13;Accounting&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In June 2018, the FASB issued ASU&#13;2018-07, &lt;i&gt;Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt; (&amp;#8220;ASU&#13;2018-07&amp;#8221;). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and&#13;services from nonemployees. Under ASU 2018-07, consistent with the accounting requirement for employee share-based payment awards,&#13;nonemployee share-based payment awards within the scope of Topic 718 are to be measured at the grant-date fair value of the equity&#13;instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other&#13;conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based&#13;payment awards are to be measured at the grant date. The definition of the term grant date is amended to generally state the date&#13;at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. ASU&#13;2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services&#13;to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does&#13;not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction&#13;with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for public&#13;business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company&#13;expects to adopt ASU 2018-07 on January 1, 2019 and anticipates that the adoption will not have a material impact on the Company&amp;#8217;s&#13;financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Collaborative Arrangements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In&#13;November 2018, the FASB issued ASU 2018-08, &lt;i&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic&#13;808 and Topic 606&lt;/i&gt;&lt;/font&gt; (&amp;#8220;ASU 2018-08&amp;#8221;)&lt;font style="background-color: white"&gt;. ASU 2018-08 clarifies the interaction&#13;between the accounting guidance for collaborative arrangements and revenue from contracts with customers. &lt;/font&gt;ASU 2018-08 is&#13;effective for public business entities for fiscal years beginning after December 15, 2019, including interim periods within that&#13;fiscal year&lt;font style="background-color: white"&gt;. Early adoption, including adoption in any interim period, is permitted. The&#13;Company is currently &lt;/font&gt;evaluating the timing of the adoption of ASU 2018-08 and the expected impact it could have on the&#13;Company&amp;#8217;s financial statements and related disclosures&lt;font style="background-color: white"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;5.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;PROPERTY AND EQUIPMENT&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Property and Equipment consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Computer hardware and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;431,637&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;136,522&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Office furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;914,742&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;287,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,025,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;191,244&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Construction in progress&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,181,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Property and equipment, gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,371,789&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,796,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(666,583&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(363,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,705,206&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,432,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Depreciation expense was approximately&#13;$494,000 and $256,000 for the years ended December 31, 2018 and 2017, respectively. In the first quarter of 2018, the Company wrote&#13;off $191,244 of fully amortized leasehold improvements related to the termination of the September 2016 Amendment in February 2018&#13;as discussed in Note 6. At December 31, 2017, construction in progress consisted of purchased property and equipment not placed&#13;in service until the Company&amp;#8217;s relocation into 32,733 square feet of office space in February 2018 (See Note 6).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On December 30, 2015, the Company&#13;entered into a lease agreement for a copier machine. The cost of the machine was approximately $12,000 and is included in office&#13;furniture and equipment category in the table above. The lease payments commenced when the machine was placed in service in January&#13;2016. The machine is being amortized over the life of the lease, which is for a three-year term and includes a bargain purchase&#13;option at the end of the term. See Note 6 for details of this capital lease commitment.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;6.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;COMMITMENTS AND CONTINGENCIES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;Operating Lease Commitment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In September 2016, the Company amended&#13;its commercial lease for office space to expand into an additional 4,088 square feet of office space within the same building for&#13;an aggregate total of 10,414 square feet of leased office space (&amp;#8220;September 2016 Amendment&amp;#8221;). The Company began occupying&#13;this space in early November 2016 and the final lease payment was to be due in January 2021. The September 2016 Amendment required&#13;an increase in the standby letter of credit to $50,000 (See Note 3). The September 2016 Amendment was terminated upon the commencement&#13;date of the August 2017 Lease Agreement discussed below.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On August 21, 2017, the Company&#13;entered into a lease agreement (&amp;#8220;August 2017 Lease Agreement&amp;#8221;) with the same landlord, pursuant to which the Company&#13;agreed to lease 32,733 square feet of office space (&amp;#8220;Leased Premises&amp;#8221;). The initial term of the August 2017 Lease Agreement&#13;is for a period of seven years which began with the Company&amp;#8217;s occupancy of the Leased Premises in February 2018. The base&#13;rent for the Leased Premises ranges from approximately $470,000 for the first year to approximately $908,000 for the seventh year.&#13;Per the terms of the August 2017 Lease Agreement, the landlord agreed to reimburse the Company for $1,080,189 of leasehold improvements.&#13;The reimbursements have been deferred and will be recognized as a reduction of rent expense over the term of the lease. Additionally,&#13;the August 2017 Lease Agreement required a standby irrevocable letter of credit of $400,000, which may be reduced, if the Company&#13;is not in default under the August 2017 Lease Agreement, to $300,000 and $200,000 on the third and fourth anniversary of the commencement&#13;date, respectively, The Company entered into an unsecured letter of credit for $400,000 in connection with the August 2017 Lease&#13;Agreement for which it incurred interest expense of $7,431 and $9,743 in year ended December 31, 2018 and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company records the total rent&#13;payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents&#13;paid and the straight-line rent as deferred rent, which is classified in deferred rent, current and deferred rent, noncurrent in&#13;the Company&amp;#8217;s balance sheet as of December 31, 2018 and 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the Company&amp;#8217;s&#13;non-cancelable lease agreements in effect at December 31, 2018, the future minimum rent commitments are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 77%"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;623,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;784,243&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;830,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;855,150&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;879,699&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,055,639&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,029,289&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Total rent expense for the years&#13;ended December 31, 2018 and 2017 was $587,963 and $356,547, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On February 26, 2019, the Company&#13;amended its lease (&amp;#8220;February 2019 Lease Agreement&amp;#8221;) pursuant to which an additional 30,023 square feet of office space&#13;(&amp;#8220;New Premises&amp;#8221;) will be leased by the Company in the same building for an aggregate total of 62,756 square feet of&#13;leased office space (&amp;#8220;Total Premises&amp;#8221;). The commencement date for the New Premises is expected to occur no later than&#13;August 1, 2019 and the lease term for the Total Premises is October 31, 2026. The future minimum rent commitments for the Total&#13;Premises are estimated to be approximately as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 77%"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;678,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,592,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,687,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,036,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,921,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;b&gt;Capital Lease Commitment&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The lease payments commenced when&#13;the machine was placed in service in January 2016. The lease is for a three-year term and includes a bargain purchase option at&#13;the end of the term. In the accompanying balance sheet as of December 31, 2017 and 2016, the current portion of this capital lease&#13;obligation is classified in accrued expenses and the long-term portion of the capital lease obligation is classified in other long-term&#13;liabilities. Pursuant to the terms of this capital lease agreement, the future minimum capital lease commitments are as follows&#13;as of December 31, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font-size: 10pt"&gt;Total future minimum lease payments &amp;#8211; end in 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;378&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Future capital lease obligations&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Long-term portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For commitments under the Company&amp;#8217;s&#13;development award agreements- see Note 9.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;7.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;NOTES PAYABLE&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In October 2016, the Company entered&#13;into a loan agreement with a financing company for $348,750 to finance one of the Company&amp;#8217;s insurance policies. The terms&#13;of the loan stipulate equal monthly payments of principal and interest payments of $39,114 over a nine-month period. Interest on&#13;this loan was accrued at an annual rate of 2.25%. This loan was fully repaid in July 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In November 2017, the Company entered&#13;into a loan agreement with a financing company for $415,265 to finance one of the Company&amp;#8217;s insurance policies. The terms&#13;of the loan stipulate equal monthly payments of principal and interest payments of $41,975 over a ten-month period. Interest accrued&#13;on this loan at an annual rate of 2.35%. This loan was fully repaid in August 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In November 2018, the Company entered&#13;into a loan agreement with a financing company for $491,629 to finance one of the Company&amp;#8217;s insurance policies. The terms&#13;of the loan stipulated equal monthly payments of principal and interest payments of $49,857 over a ten-month period. Interest accrues&#13;on this loan was accrued at an annual rate of 3.07%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Prepaid expenses and other current&#13;assets as of December 31, 2018 and 2017 included $441,875 and $368,976, respectively, related to these insurance policies.&lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;8.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;ACCRUED EXPENSES &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Accrued expenses consisted of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued clinical operations and trials costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,914,881&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,003,799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued product development costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,222,093&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,255,439&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,253,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,335,672&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;460,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;146,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,851,191&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,741,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;11.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;COMMON STOCK &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has authorized 150,000,000&#13;shares of common stock, $0.0001 par value per share, of which 57,247,496 shares, and 55,603,427 shares were issued and outstanding&#13;as of December 31, 2018, and 2017, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On February 28, 2017, the Company&#13;entered into a securities purchase agreement providing for the issuance and sale by the Company of 3,887,815 shares of its common&#13;stock in a registered direct offering to institutional and accredited investors at a purchase price of $7.00 per share with gross&#13;proceeds to the Company totaling $27,214,705 less issuance costs of $36,291.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On October 26, 2017, the Company&#13;consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 4,650,000&#13;shares of its common stock at a purchase price of $7.00 per share with gross proceeds to the Company totaling $32,550,000, less&#13;estimated issuance costs incurred of approximately $2,184,000. The Company also granted the underwriters a 30-day option to purchase&#13;up to an additional 697,500 shares of common stock on the same terms as the underwriters were purchasing the base number of shares,&#13;which they exercised in November 2017 with net proceeds to the Company totaling $4,589,550.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 5, 2018, the Company&#13;entered into a sales agreement with Cantor Fitzgerald under which the Company had the ability to direct Cantor Fitzgerald as its&#13;sales agent to sell common stock up to an aggregate offering of up to $50 million under an &amp;#8220;At the Market Offering&amp;#8221;&#13;(&amp;#8220;January 2018 Sales Agreement&amp;#8221;). Sales of common stock under the January 2018 Sales Agreement were made pursuant to&#13;an effective registration statement for an aggregate offering of up to $50 million. During the first quarter of 2018, the Company&#13;sold 1,500,000 shares of its common stock to an institutional investor under the January 2018 Sales Agreement for which the Company&#13;received net proceeds of approximately $11.2 million. The Company did not sell any shares under the January 2018 Sales Agreement&#13;in remainder of 2018 and through February 8, 2019, the effective date of the Company&amp;#8217;s termination of the January 2018 Sales&#13;Agreement (see Note 15). During the year ended December 31, 2017, the Company sold 1,413,633 shares of its common stock under a&#13;sales agreement that the Company entered into in November 2016 with Cantor Fitzgerald (&amp;#8220;Sales Agreement&amp;#8221;) for net proceeds&#13;of $13,268,208. The Sales Agreement was terminated in October 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;During the year ended December 31,&#13;2018, the Company issued 144,069 shares of common stock upon the exercise of stock options and warrants to purchase common stock&#13;and the Company received net proceeds of $352,645 from these exercises. During the year ended December 31, 2017, the Company issued&#13;272,734 shares of common stock upon the exercise of stock options and warrants to purchase common stock and the Company received&#13;net proceeds of $189,490 from these exercises.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 30, 2019, the Company&#13;consummated an underwritten public offering of shares of its common stock. See Note 15.&lt;/p&gt;</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;12.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;STOCK OPTIONS &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In April 2014, the Company adopted&#13;the Corbus Pharmaceuticals Holdings, Inc. 2014 Equity Incentive Plan (the &amp;#8220;2014 Plan&amp;#8221;). Pursuant to the 2014 Plan,&#13;the Company&amp;#8217;s Board of Directors may grant incentive and nonqualified stock options and restricted stock to employees, officers,&#13;directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2014 Plan, the number of shares&#13;of common stock available for issuance under the 2014 Plan shall automatically increase on January 1 of each year by at least seven&#13;percent (7%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or, pursuant&#13;to the terms of the 2014 Plan, in any year, the Board of Directors may determine that such increase will provide for a lesser number&#13;of shares. On January 1, 2018, pursuant to an annual evergreen provision contained in the 2014 Plan, the number of shares reserved&#13;for future grants was increased by 2,500,000 shares, which was less than seven percent (7%) of the outstanding shares of common&#13;stock on December 31, 2017. As of December 31, 2018, there was a total of 15,543,739 shares reserved for issuance under the 2014&#13;Plan and there were 5,072,241 shares available for future grants. Options issued under the 2014 Plan generally vest over 4 years&#13;from the date of grant in multiple tranches and are exercisable for up to 10 years from the date of issuance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In accordance with the terms of&#13;the 2014 Plan, effective as of January 1, 2019, the number of shares of common stock available for issuance under the 2014 Plan&#13;increased by 3,000,000 shares, which was less than seven percent (7%) of the outstanding shares of common stock on December 31,&#13;2018. As of January 1, 2019, the 2014 Plan had a total reserve of 18,543,739 shares and there were 8,072,241 shares available for&#13;future grants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Share-based Compensation&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For stock options issued and outstanding&#13;for the years ended December 31, 2018 and 2017, the Company recorded non-cash, stock-based compensation expense of $7,609,508 ($7,500,888&#13;for employees and $108,620 for non-employees) and $5,694,489 ($4,640,646 for employees and $1,053,843 for non-employees), respectively,&#13;net of estimated forfeitures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The fair value of each option award&#13;for employees is estimated on the date of grant and for non-employees is estimated at the end of each reporting period until vested&#13;using the Black-Scholes option pricing model that uses the assumptions noted in the following table. The Company uses historical&#13;data, as well as subsequent events occurring prior to the issuance of the financial statements, to estimate option exercises and&#13;employee terminations in order to estimate its forfeiture rate. The expected term of options granted under the 2014 Plan, all of&#13;which qualify as &amp;#8220;plain vanilla&amp;#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method&#13;due to the Company&amp;#8217;s limited operating history, and is 6.25 years based on the average between the vesting period and the&#13;contractual life of the option. For non-employee options, the expected term is the contractual term. The risk-free rate is based&#13;on the yield of a U.S. Treasury security with a term consistent with the option.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The weighted average assumptions&#13;used principally in determining the fair value of options granted to employees were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;87.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;86.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Estimated forfeiture rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For the year ended December 31,&#13;2017, the assumptions used in determining the fair value of options granted to nonemployees included risk free interest rate ranging&#13;from 2.12%-2.38%, no expected dividend yield, expected term ranging from 4.91 years to 9.91 years, expected volatility ranging&#13;from 85.58% to 89.58%, and estimated forfeiture rate of 5%.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;A summary of option activity for&#13;years ended December 31, 2018 and 2017 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Exercise &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Remaining &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Contractual &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Term in &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Intrinsic &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(272,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,378,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.58&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(139,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(490,407&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,593,990&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22,510,816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exerciseable at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,967,701&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20,691,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The weighted average grant-date&#13;fair value of options granted during the years ended December 31, 2018 and 2017 was $5.63 and $6.22 per share, respectively. The&#13;aggregate intrinsic value of options exercised during the years ended December 31, 2018 and 2017 was approximately $543,060 and&#13;$2,092,964, respectively. As of December 31, 2018, there was approximately $15,400,414 of total unrecognized compensation expense,&#13;related to non-vested share-based compensation arrangements. The unrecognized compensation expense is estimated to be recognized&#13;over a period of 2.55 years at December 31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As summary of non-vested stock options&#13;for the years ended December 31, 2018 and 2017 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Fair &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Non-vested at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,826,274&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,003,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Nonvested at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,329,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,378,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,643,772&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(438,428&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Non-vested at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,626,289&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <CRBP:WarrantsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;13.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;WARRANTS &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;During the year ended December 31,&#13;2018, warrants to purchase 5,000 shares of common stock were exercised for proceeds of $5,000. No warrants were exercised during&#13;the year ended December 31, 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;At December 31, 2018, there were&#13;warrants outstanding to purchase 2,283,500 shares of common stock with a weighted average exercise price of $6.34 and a weighted&#13;average remaining life of 2.89 years, including the warrant issued to CFF pursuant to the terms of the Investment Agreement (Note&#13;8). The Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the Company&amp;#8217;s common stock (the &amp;#8220;CFF&#13;Warrant&amp;#8221;). The CFF Warrant is exercisable at a price equal to $13.20 per share and is immediately exercisable for 500,000&#13;shares of the Company&amp;#8217;s common stock. Upon completion of the final milestone set forth in the Investment Agreement and receipt&#13;of the final payment from CFF to the Company pursuant to the Investment Agreement, the CFF Warrant will be exercisable for the&#13;remaining 500,000 shares of the Company&amp;#8217;s common stock. The CFF Warrant expires on January 26, 2025. Any shares of the Company&amp;#8217;s&#13;common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up. The CFF Warrant is&#13;classified as equity as it meets all the conditions under GAAP for equity classification. In accordance with GAAP, the Company&#13;has calculated the fair value of the warrant for initial measurement and will reassess whether equity classification for the warrant&#13;is appropriate upon any changes to the warrants or capital structure, at each balance sheet date. The weighted average assumptions&#13;used in determining the $6,215,225 fair value of the CFF Warrant were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;83.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</CRBP:WarrantsTextBlock>
    <us-gaap:RelatedPartyTransactionsDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;14.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;RELATED PARTY TRANSACTIONS &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On September 20, 2016, the Company&#13;entered into a consulting agreement (the &amp;#8220;2016 Consulting Agreement&amp;#8221;) with Orchestra Medical Ventures, LLC (&amp;#8220;Orchestra&amp;#8221;),&#13;of which a member of the Company&amp;#8217;s Board of Directors, David Hochman, is Managing Partner. Under this agreement, Orchestra&#13;rendered a variety of consulting and advisory services relating principally to identifying and evaluating strategic relationships,&#13;licensing opportunities, and business strategies. The term of the 2016 Consulting Agreement commenced on September 20, 2016 and&#13;expired on March 20, 2017. Pursuant to the terms of the 2016 Consulting Agreement, the Company paid to Orchestra cash compensation&#13;in an aggregate amount of $100,000. In connection with this agreement, the Company granted an equity incentive award to Mr. Hochman&#13;consisting of options to purchase 50,000 shares (&amp;#8220;Option Shares&amp;#8221;) of common stock (the &amp;#8220;Option Award&amp;#8221;)&#13;pursuant to the Company&amp;#8217;s 2014 Equity Compensation Plan, of which fifty percent (50%) vested on the three (3) month anniversary&#13;of the date of grant of the Option Award and the remainder of the Option Shares vested on the six (6) month anniversary of the&#13;date of grant of the Option Award. The Option Shares were granted with an exercise price of $7.14 per share. The Company recorded&#13;stock-based compensation expense of approximately $222,000 during the year ended December 31, 2016 and $171,000 during the first&#13;quarter of 2017 in respect of the Option Award. No stock-based compensation expense was recorded after the first quarter of 2017&#13;related to the Option Shares as they were fully vested in March 2017.&lt;/p&gt;</us-gaap:RelatedPartyTransactionsDisclosureTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The following table sets forth the&#13;computation of basic and diluted earnings per share for the years ended December 31, 2018 and 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted net loss per share of common stock:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(55,672,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,421,612&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;56,999,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,176,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share of common stock-basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The impact of the following potentially&#13;dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the computation of dilutive weighted average&#13;shares outstanding as the inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,283,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,593,990&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,877,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,133,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Property and Equipment consisted&#13;of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Computer hardware and software&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;431,637&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;136,522&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Office furniture and equipment&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;914,742&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;287,048&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Leasehold improvements&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,025,410&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;191,244&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Construction in progress&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,181,730&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Property and equipment, gross&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,371,789&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,796,544&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: accumulated depreciation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(666,583&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(363,889&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Property and equipment, net&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,705,206&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,432,655&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The weighted average assumptions&#13;used principally in determining the fair value of options granted to employees were as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 61%"&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 2%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.12&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.25&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;87.70&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;86.01&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Estimated forfeiture rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;A summary of option activity for&#13;years ended December 31, 2018 and 2017 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Exercise &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Price&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Remaining &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Contractual &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Term in &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Intrinsic &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 44%"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6,610,179&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.54&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;8.28&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(272,734&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.67&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.53&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.75&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,378,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.58&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Exercised&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(139,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.50&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(490,407&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Outstanding at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,593,990&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.51&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.23&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22,510,816&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Exerciseable at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,967,701&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.87&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.43&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;20,691,512&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">5694489</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">5694489</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2017-01-01to2017-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">7609508</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">7609508</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Cash, cash equivalents, and restricted&#13;cash consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;808,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;206,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Money market fund&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;40,939,525&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,330,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,748,468&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,537,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,748,468&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,696,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:GainContingencyUnrecordedAmount contextRef="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">5000000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:GainContingencyUnrecordedAmount contextRef="AsOf2018-01-26_custom_CysticFibrosisProgramRelatedInvestmentAgreementMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">25000000</us-gaap:GainContingencyUnrecordedAmount>
    <us-gaap:RoyaltyExpense contextRef="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponCommercializationOfTheProductMember_custom_LenabasumMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">25000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">5000000</us-gaap:RoyaltyExpense>
    <us-gaap:RoyaltyExpense contextRef="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponTransferSaleOrLicensingMember_custom_LenabasumMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">15000000</us-gaap:RoyaltyExpense>
    <CRBP:PaymentDuePeriodAfterTheFirstCommercialSale contextRef="From2015-04-18to2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember">P90D</CRBP:PaymentDuePeriodAfterTheFirstCommercialSale>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1335672</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2253621</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">66978161</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">46989341</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">-65698101</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">-121370240</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">123476102</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">148888635</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:PreferredStockValue contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:PreferredStockValue contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:Liabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">9194600</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">19465221</us-gaap:Liabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">375</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRentCreditNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">989550</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:DeferredRentCreditNoncurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">1375891</us-gaap:DeferredRentCreditNoncurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">8204675</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">18089330</us-gaap:LiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">4741519</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">9851191</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">3130295</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">6345335</us-gaap:AccountsPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">332861</us-gaap:NotesPayableCurrent>
    <us-gaap:NotesPayableCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">394305</us-gaap:NotesPayableCurrent>
    <us-gaap:Assets contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">66978161</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">46989341</us-gaap:Assets>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1432655</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2705206</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2018-12-31_country_GB" unitRef="USD" decimals="0">54000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:AssetsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">65504730</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">44240312</us-gaap:AssetsCurrent>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">158991</us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">62537495</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">41748468</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">40776</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">43823</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">50176953</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">56999741</us-gaap:WeightedAverageNumberOfShareOutstandingBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">-0.65</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:EarningsPerShareBasicAndDiluted contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">-0.98</us-gaap:EarningsPerShareBasicAndDiluted>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">141204</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">1075568</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-41908</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionGainLossBeforeTax contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">92791</us-gaap:ForeignCurrencyTransactionGainLossBeforeTax>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">183112</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">982777</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:OperatingIncomeLoss contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-32562816</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-56747707</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">35003011</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">61569979</us-gaap:OperatingExpenses>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">8964046</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">12956022</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">26038965</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">48613957</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:Revenues contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2440195</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">4822272</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-01-01to2018-12-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:Revenues contextRef="From2017-01-01to2017-12-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">2440195</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-01-01to2018-12-31_custom_InvestmentagreementMember" unitRef="USD" decimals="0">4822272</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationwarrantsMember" unitRef="USD" decimals="0">18784775</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-01-01to2018-12-31_custom_ASC606Member_custom_TwoThousandAndEighteenCffAwardMember" unitRef="USD" decimals="0">4822272</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-10-01to2018-12-31_custom_ASC606Member_custom_TwoThousandAndEighteenCffAwardMember" unitRef="USD" decimals="0">1927306</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-10-01to2018-12-31_custom_ASC606Member_custom_HigherRevenueMember" unitRef="USD" decimals="0">325000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="From2018-10-01to2018-12-31_custom_ASC606Member_custom_LowerRevenueMember" unitRef="USD" decimals="0">201000</us-gaap:Revenues>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">579734</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">1168</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">3832</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:RepaymentsOfLongTermCapitalLeaseObligations contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">4256</us-gaap:RepaymentsOfLongTermCapitalLeaseObligations>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">2940685</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:PaymentOfFinancingAndStockIssuanceCosts contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">690181</us-gaap:PaymentOfFinancingAndStockIssuanceCosts>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">354161</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">430184</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">707429</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">2300416</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">1514521</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">5113551</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-885797</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">3904021</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-1000000</us-gaap:IncreaseDecreaseInReceivables>
    <us-gaap:IncreaseDecreaseInReceivables contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-12500000</us-gaap:IncreaseDecreaseInReceivables>
    <CRBP:IncreaseDecreaseInDeferredRent contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">913563</CRBP:IncreaseDecreaseInDeferredRent>
    <CRBP:IncreaseDecreaseInDeferredRent contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">422337</CRBP:IncreaseDecreaseInDeferredRent>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">5694489</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">7609508</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31_custom_EmployeesMember" unitRef="USD" decimals="0">7500888</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2018-01-01to2018-12-31_custom_NonEmployeesMember" unitRef="USD" decimals="0">108620</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_custom_EmployeesMember" unitRef="USD" decimals="0">4640646</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember" unitRef="USD" decimals="0">1053843</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">40776</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssets contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">3047</us-gaap:IncreaseDecreaseInOtherNoncurrentAssets>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-8490</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:ForeignCurrencyTransactionLossBeforeTax contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">70448</us-gaap:ForeignCurrencyTransactionLossBeforeTax>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2016-12-31" unitRef="USD" decimals="0">15192257</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">62696486</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">41748468</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">12377</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">10437</us-gaap:InterestPaidNet>
    <us-gaap:DepreciationAndAmortization contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">255652</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">493938</us-gaap:DepreciationAndAmortization>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember" unitRef="USDPShares" decimals="INF">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember" unitRef="USDPShares" decimals="INF">6.34</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 contextRef="AsOf2018-12-31_custom_CFFWarrantMember" unitRef="USDPShares" decimals="INF">13.20</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Accrued expenses consisted of the&#13;following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Accrued clinical operations and trials costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,914,881&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,003,799&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued product development costs&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,222,093&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,255,439&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,253,621&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,335,672&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Accrued other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;460,596&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;146,609&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,851,191&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4,741,519&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember" unitRef="Shares" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember_custom_InvestmentagreementMember" unitRef="Shares" decimals="INF">500000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">5000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember" unitRef="Shares" decimals="INF">2283500</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights contextRef="AsOf2018-12-31_custom_CFFWarrantMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <dei:EntityRegistrantName contextRef="From2018-01-01to2018-12-31">Corbus Pharmaceuticals Holdings, Inc.</dei:EntityRegistrantName>
    <dei:EntityCentralIndexKey contextRef="From2018-01-01to2018-12-31">0001595097</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="From2018-01-01to2018-12-31">10-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2018-01-01to2018-12-31">2018-12-31</dei:DocumentPeriodEndDate>
    <dei:AmendmentFlag contextRef="From2018-01-01to2018-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="From2018-01-01to2018-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:EntityFilerCategory contextRef="From2018-01-01to2018-12-31">Accelerated Filer</dei:EntityFilerCategory>
    <dei:TradingSymbol contextRef="From2018-01-01to2018-12-31">CRBP</dei:TradingSymbol>
    <dei:DocumentFiscalPeriodFocus contextRef="From2018-01-01to2018-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2808244</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2491844</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">1877983</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <us-gaap:IncreaseDecreaseInPrepaidExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-281625</us-gaap:IncreaseDecreaseInPrepaidExpense>
    <CRBP:WriteOffOfFullyAmortizedLeaseholdImprovements contextRef="From2017-01-01to2017-12-31" unitRef="USD" xsi:nil="true" />
    <CRBP:WriteOffOfFullyAmortizedLeaseholdImprovements contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">191244</CRBP:WriteOffOfFullyAmortizedLeaseholdImprovements>
    <CRBP:WriteOffOfFullyAmortizedLeaseholdImprovements contextRef="From2018-01-01to2018-03-31" unitRef="USD" decimals="0">191244</CRBP:WriteOffOfFullyAmortizedLeaseholdImprovements>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">6215225</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">6215225</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued contextRef="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationwarrantsMember" unitRef="USD" decimals="0">6215225</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <CRBP:DevelopmentAwardsAndDeferredRevenueTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;9.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;DEVELOPMENT AWARDS AND DEFERRED REVENUE&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;i&gt;2015 CFFT Award&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On April 20, 2015, the Company entered&#13;into an award agreement (the &amp;#8220;2015 CFFT Award Agreement &amp;#8220;) with the Cystic Fibrosis Foundation Therapeutics, Inc (&amp;#8220;CFFT&amp;#8221;),&#13;a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation (&amp;#8220;CFF&amp;#8221;) pursuant to which the&#13;Company received a development award (the &amp;#8220;2015 CFFT Award&amp;#8221;) for up to $5 million in funding. The funding from the&#13;2015 CFFT Award supported a first-in-patient Phase 2 clinical trial of the Company&amp;#8217;s oral anti-inflammatory drug lenabasum&#13;in adults with cystic fibrosis (&amp;#8220;CF&amp;#8221;). The Company received $5.0 million in payments under the 2015 CFFT Award as outlined&#13;below. The payments received under the 2015 CFFT Award were recorded as deferred revenue when the triggering event to receive those&#13;amounts had occurred and were amortized on a straight-line basis over the expected duration of the remaining performance period&#13;under the 2015 CFFT Award which concluded in the third quarter of 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Upon the execution of the 2015 CFFT&#13;Award Agreement, the Company received a payment of $1,250,000 in May 2015. In November 2015, the Company received a second payment&#13;of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, the Company received a third payment&#13;from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical trial patient.&#13;In January 2017, the Company received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone in December&#13;2016 related to completing the final visit for the final patient, which was billed by the Company to CFFT in December 2016 and&#13;was classified in grants receivable as of December 31, 2016. The Company received the final payment from CFFT in the amount of&#13;$500,000 in November 2017 for achieving the final milestone in September 2017 related to the issuance to CFFT of the final integrated&#13;statistical report for to the Phase 2 CF clinical trial. At that time the Company had completed all its performance obligations&#13;under the contract and therefore the performance period had concluded.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;In accordance with ASC 605, the&#13;Company recorded $2,440,195 of revenue during the year ended December 31, 2017 under the 2015 CFFT Award Agreement. No revenue&#13;was recorded under the 2015 CFFT Award Agreement during the year ended December 31, 2018 as the final performance period concluded&#13;in the third quarter of 2017. Under ASC 605, milestone payments were initially recognized only in the period that the payment-triggering&#13;event occurred or was achieved. Effective January 1, 2018, ASC 605 was superseded by ASC 606 (See Note 3). The Company adopted&#13;ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect of initially&#13;applying ASC 606 is recognized at the date of initial application. Since the Company concluded its performance obligations and&#13;completed recognizing revenue under the 2015 CFFT Award Agreement in the third quarter of 2017, there was no cumulative effect&#13;to record at the date of the Company&amp;#8217;s adoption of ASC 606.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Pursuant to the terms of the 2015&#13;CFFT Award Agreement, the Company is obligated to make royalty payments to CFFT contingent upon commercialization of lenabasum&#13;in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five times the amount&#13;the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments following&#13;the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale of lenabasum,&#13;(ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up to $5 million,&#13;due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million,&#13;and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses lenabasum in&#13;the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change of control transaction,&#13;with such payment(s) to be credited against the royalty payments due upon commercialization. The Field of Use is defined in the&#13;2015 CFFT Award as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD hypersensitivity&#13;pneumonitis, pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or the Company may terminate the&#13;agreement for cause, which includes the Company&amp;#8217;s material failure to achieve certain commercialization and development milestones.&#13;The Company&amp;#8217;s payment obligations, if any, would survive the termination of the 2015 CFFT Award Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&lt;i&gt;2018 CFF Award&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;On January 26, 2018, the Company&#13;entered into the Cystic Fibrosis Program Related Investment Agreement with the CFF (&amp;#8220;Investment Agreement&amp;#8221;), a non-profit&#13;drug discovery and development corporation, pursuant to which the Company received an award for up to $25 million in funding (the&#13;&amp;#8220;2018 CFF Award&amp;#8221;) to support a Phase 2b Clinical Trial (the &amp;#8220;Phase 2b Clinical Trial&amp;#8221;) of lenabasum in&#13;patients with cystic fibrosis, of which the Company has received $12.5 million during the year ended December 31, 2018 upon the&#13;Company&amp;#8217;s achievement of milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment&#13;Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The Company expects that the remainder&#13;of the 2018 CFF Award will be paid incrementally upon the Company&amp;#8217;s achievement of the remaining milestones related to the&#13;progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Pursuant to the terms of the Investment&#13;Agreement, the Company is obligated to make certain royalty payments to CFF, including a royalty payment of one and one-half times&#13;the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval of lenabasum in the United&#13;States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon approval in another major market,&#13;as set forth in the Investment Agreement (the &amp;#8220;Approval Royalty&amp;#8221;). At the Company&amp;#8217;s election, the Company may&#13;satisfy the first of the two Approval Royalties in registered shares of the Company&amp;#8217;s common stock.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Additionally, the Company is obligated&#13;to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty days after any quarter&#13;in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments to CFF of one percent&#13;of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any quarter in which such&#13;net sales occur, and (iii) royalty payments to CFF of ten percent of any amount the Company and its stockholders receive in connection&#13;with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment or prevention of CF, or&#13;a change of control transaction, except that such payment shall not exceed five times the amount of the 2018 CFF Award, with such&#13;payments to be credited against any other net sales royalty payments due. Accordingly, we will owe to CFF a royalty payment equal&#13;to 10% of any amounts we receive as payment under the collaboration agreement with Kaken, provided that the total royalties that&#13;we will be required to pay under the Investment Agreement resulting from income from licenses or sales subject to the Investment&#13;Agreement are capped at five times the total amount of the 2018 CFF Award, and we may credit such royalties against any royalties&#13;on net sales otherwise owed to CFF under the Investment Agreement. Accordingly, we will be required to pay CFF $2,700,000 within&#13;60 days of our receipt of the $27,000,000 upfront cash payment from Kaken.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.5in"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Either CFF or the Company may terminate&#13;the Investment Agreement for cause, which includes the Company&amp;#8217;s material failure to achieve certain commercialization and&#13;development milestones. The Company&amp;#8217;s payment obligations survive the termination of the Investment Agreement.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Pursuant to the terms of the Investment&#13;Agreement, the Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the Company&amp;#8217;s common stock&#13;(the &amp;#8220;CFF Warrant&amp;#8221;). The CFF Warrant is exercisable at a price equal to $13.20 per share and is immediately exercisable&#13;for 500,000 shares of the Company&amp;#8217;s common stock. Upon completion of the final milestone set forth in the Investment Agreement&#13;and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement, the CFF Warrant will be exercisable&#13;for the remaining 500,000 shares of the Company&amp;#8217;s common stock. The CFF Warrant expires on January 26, 2025. Any shares of&#13;the Company&amp;#8217;s common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The Company recorded $4,822,272&#13;of revenue during the year ended December 31, 2018 under the Investment Agreement. The Company assessed the 2018 CFF Award for&#13;accounting under ASC 606, which it adopted in the first quarter of 2018 (Note 3). To determine revenue recognition for arrangements&#13;that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)&#13;with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate&#13;the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies&#13;a performance obligation.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The Company assessed this arrangement&#13;in accordance with ASC 606 and concluded that the contract counterparty, CFF, is a customer. The Company identified the following&#13;material promise under the arrangement: research and development activities and related services under the Phase 2b Clinical Trial.&#13;Based on these assessments, the Company identified one performance obligation at the outset of the Investment Agreement, which&#13;consists of: Phase 2b Clinical Trial research and development activities and related services.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;To determine the transaction price,&#13;the Company included the total aggregate payments under the Investment Agreement which amount to $25 million and reduced the revenue&#13;to be recognized by the payment to the customer of $6,215,225 in the form of the CFF Warrant representing its fair value, leaving&#13;the remaining $18,784,775 as the transaction price as of the outset of the arrangement, which will be recognized as revenue over&#13;the performance period as discussed below. The $6,215,225 fair value of the warrant was also recorded as an increase to additional&#13;paid in capital. The Company billed and collected $12,500,000 in milestone payments during the year ended December 31, 2018 which&#13;was recorded as an increase to deferred revenue. A roll forward of deferred revenue for the year ended December 31, 2018 is presented&#13;below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Billing to CFF upon achievement of milestones&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Fair value of CFF Warrant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,215,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Recognition of revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,822,272&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,462,503&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;The CFF Warrant is accounted for&#13;as a payment to the customer under ASC 606. See Note 13 for further information related to the CFF Warrant. The Company notes&#13;that the Investment Agreement contains an initial payment that was received upon contract execution and subsequent milestone payments,&#13;which are a form of variable consideration that require evaluation for constraint considerations. The Company concluded that the&#13;related performance milestones are generally within the Company&amp;#8217;s control and as result are considered probable. Revenue&#13;associated with the performance obligation is being recognized as revenue as the research and development services are provided&#13;using an input method, according to the costs incurred as related to the research and development activities on each program and&#13;the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this&#13;time period and, in management&amp;#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.&#13;The research and development services related to this performance obligation are expected to be performed over an approximately&#13;two and a half year period expected to be completed in the second quarter of 2020. The amounts received that have not yet been&#13;recognized as revenue are recorded in deferred revenue and the amounts recognized as revenue, but not yet received or invoiced&#13;are generally recognized as contract assets on the Company&amp;#8217;s condensed consolidated balance sheet.&lt;/p&gt;</CRBP:DevelopmentAwardsAndDeferredRevenueTextBlock>
    <us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable contextRef="From2018-01-25to2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember">2025-01-26</us-gaap:ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable>
    <CRBP:ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses contextRef="From2018-01-01to2018-12-31_custom_InvestmentagreementMember" unitRef="USD" decimals="0">25000000</CRBP:ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses>
    <CRBP:WarrantsIssuanceFairValue contextRef="From2017-01-01to2017-12-31" unitRef="USD" xsi:nil="true" />
    <CRBP:WarrantsIssuanceFairValue contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">6215225</CRBP:WarrantsIssuanceFairValue>
    <dei:DocumentFiscalYearFocus contextRef="From2018-01-01to2018-12-31">2018</dei:DocumentFiscalYearFocus>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-27796628</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-30067255</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-707429</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-2300416</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">76008286</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">11419653</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <CRBP:DeferredRevenueBillingToUponAchievementOfMilestones contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">12500000</CRBP:DeferredRevenueBillingToUponAchievementOfMilestones>
    <CRBP:FairValueOfWarrant contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-6215225</CRBP:FairValueOfWarrant>
    <CRBP:RoyaltyPaymentSalesTarget contextRef="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_UponReachingTheSalesTargetMember_custom_LenabasumMember" unitRef="USD" decimals="0">500000000</CRBP:RoyaltyPaymentSalesTarget>
    <us-gaap:UseOfEstimates contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The process of preparing financial&#13;statements in conformity with accounting principles generally accepted in the United States of America (&amp;#8220;U.S. GAAP&amp;#8221;)&#13;requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure&#13;of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the&#13;reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates&#13;are related to stock-based compensation expense, the accrual of research, product development and clinical obligations, the recognition&#13;of revenue under the Investment Agreement (see Note 9) and the valuation of the CFF Warrant discussed in Note 9).&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company considers only those&#13;investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to&#13;be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2018&#13;and 2017, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2018&#13;and 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Restricted cash as of December 31,&#13;2017 in the amount of $108,991 was classified in current assets and included a collateral account for the Company&amp;#8217;s corporate&#13;credit cards. The collateral account was closed in the first quarter of 2018 and accordingly the cash became unrestricted. Additionally,&#13;as of December 31, 2017, restricted cash included a stand-by letter of credit issued in favor of a landlord for $50,000 which was&#13;classified in current assets as of December 31, 2017. This stand-by letter of credit was terminated in the first quarter of 2018&#13;in connection with the August 2017 Lease Agreement discussed in Note 6, and accordingly, the cash became unrestricted.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Cash, cash equivalents, and restricted&#13;cash consists of the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;808,943&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;206,510&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Money market fund&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;40,939,525&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,330,985&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-left: 10pt"&gt;&lt;font style="font-size: 10pt"&gt;Cash and cash equivalents&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,748,468&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,537,495&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Restricted cash&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;158,991&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total cash, cash equivalents, and restricted cash shown in the statement of cash flows&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;41,748,468&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;62,696,486&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As of December 31, 2018, all of&#13;the Company&amp;#8217;s cash was held in the United States, except for approximately $702,000 of cash which was held in our subsidiary&#13;in the United Kingdom. As of December 31, 2017, all of the Company&amp;#8217;s cash was held in the United States.&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The carrying amounts reported in&#13;the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their&#13;fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair&#13;value due to the fact that they are at market terms.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The estimated life for the Company&amp;#8217;s&#13;property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture&#13;and equipment. The Company&amp;#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their&#13;useful lives or the respective leases. See Note 5 for details of property and equipment and Note 6 for operating and capital lease&#13;commitments.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Research and Development Expenses&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Costs incurred for research and&#13;development are expensed as incurred.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Nonrefundable advance payments&#13;for goods or services that have the characteristics that will be used or rendered for future research and development activities&#13;pursuant to executory contractual arrangements with third party research organizations are deferred and recognized as an expense&#13;as the related goods are delivered or the related services are performed.&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <CRBP:AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Accruals for Research and&#13;Development Expenses and Clinical Trials&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As part of the process of preparing&#13;its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with&#13;vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical&#13;trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result&#13;in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&amp;#8217;s&#13;objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which&#13;services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects&#13;of the expenses. The Company determines the accrual estimates by taking into account discussion with applicable personnel and&#13;outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial,&#13;the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates&#13;of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&amp;#8217;s&#13;clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party&#13;vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding&#13;of the status and timing of services performed relative to the actual status and timing of services performed may vary and may&#13;result in it reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2018 and&#13;2017, there were no material adjustments to the Company&amp;#8217;s prior period estimates of accrued expenses for clinical trials.&lt;/p&gt;</CRBP:AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Concentrations of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has no significant&#13;off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.&#13;The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However,&#13;the Company believes the risk of loss is minimal as these banks are large financial institutions.&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:SegmentReportingPolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Segment Information&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Operating segments are identified&#13;as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating&#13;decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. To date,&#13;the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing&#13;therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2018 and 2017, all of the Company&amp;#8217;s&#13;assets were located in the United States, except for approximately $702,000 of cash, $1,183,000 of prepaid expenses, $28,000 of&#13;other assets, and $54,000 of property and equipment, net which were held in our subsidiary in the United Kingdom as of December&#13;31, 2018.&lt;/p&gt;</us-gaap:SegmentReportingPolicyPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;For federal and state income taxes,&#13;deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax&#13;basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in&#13;which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax benefit when it is not&#13;more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses&#13;since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate&#13;the deferred tax assets amounts.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Tax positions taken or expected&#13;to be taken in the course of preparing the Company&amp;#8217;s tax returns are required to be evaluated to determine whether the tax&#13;positions are &amp;#8220;more-likely-than-not&amp;#8221; of being sustained by the applicable tax authority. Tax positions not deemed to&#13;meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense in&#13;the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December&#13;31, 2018 or 2017.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On December 22, 2017, Staff Accounting&#13;Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does&#13;not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete&#13;the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, the Company had recorded a provisional&#13;estimate in these financial statements for the effect of the corporate tax rate change. The Company finalized its estimates during&#13;the fourth quarter of 2018, described more fully in Note 10.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Impairment of Long-lived Assets&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company continually monitors&#13;events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An&#13;impairment loss is recognized when expected undiscounted cash flows of an asset are less than an asset&amp;#8217;s carrying value.&#13;Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to&#13;the operating performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess&#13;of the fair value of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset&#13;may not be recoverable. No impairment charges were recorded for the years ended December 31, 2018 and 2017.&lt;/p&gt;</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Stock-based Payments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company recognizes compensation&#13;costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement&#13;of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option&#13;grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model, net of estimated forfeitures.&#13;The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which&#13;is generally the vesting period. Stock options granted to non-employee consultants are revalued at the end of each reporting period&#13;until vested using the Black-Scholes option-pricing model and the changes in their fair value are recorded as adjustments to expense&#13;over the related vesting period.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On March 30, 2016, the FASB issued&#13;ASU No. 2016-09, &lt;i&gt;Compensation&amp;#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting&#13;&lt;/i&gt;(&amp;#8220;ASU 2016-09&amp;#8221;)&lt;i&gt;. &lt;/i&gt;ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment&#13;transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification&#13;in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning&#13;after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures&#13;as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have&#13;an impact on the Company&amp;#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the&#13;excess tax benefits in respect of share based payments only when realized (See Note 10).&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Basic and diluted net loss per share&#13;of the Company&amp;#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding&#13;during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted&#13;loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years&#13;ended December 31, 2018 and 2017:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Years Ended December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Basic and diluted net loss per share of common stock:&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(55,672,139&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,421,612&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%; padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Weighted average shares of common stock outstanding&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;56,999,741&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;50,176,953&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net loss per share of common stock-basic and diluted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(0.65&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The impact of the following potentially&#13;dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the computation of dilutive weighted average&#13;shares outstanding as the inclusion would be antidilutive.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Warrants&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,283,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 11%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Stock options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,593,990&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7,844,966&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,877,490&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9,133,466&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;Recent Accounting Pronouncements&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;Revenue Recognition&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In May 2014, the FASB issued guidance&#13;codified in &lt;i&gt;Accounting Standards Codification (ASC) 606, Revenue Recognition &amp;#8212; Revenue from Contracts with Customers&lt;/i&gt;&#13;(&amp;#8220;ASC 606&amp;#8221;) which amends the guidance in former &lt;i&gt;ASC 605, Revenue Recognition&lt;/i&gt;, and is effective for public companies&#13;for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from ASC 605 in many respects,&#13;such as in the accounting for variable consideration received, including milestone payments or contingent payments. Under the Company&amp;#8217;s&#13;accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone payments were initially recognized only&#13;in the period that the payment-triggering event occurred or was achieved (See Note 9). ASC 606, however, may require a company&#13;to recognize such payments before the payment-triggering event is completely achieved based on the Company&amp;#8217;s estimate of&#13;the amount of consideration to which it will be entitled in exchange for transferring the services, subject to management&amp;#8217;s&#13;assessment of whether it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur&#13;when the uncertainty associated with the variable consideration is subsequently resolved.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company adopted ASC 606 in the&#13;first quarter of 2018 using the modified retrospective method according to which the cumulative effect of initially applying ASC&#13;606 is recognized at the date of initial application, and elected to utilize a practical expedient and did not restate contracts&#13;that were completed as of the date of adoption. Since the Company has concluded its performance obligations and has completed recognizing&#13;revenue under the 2015 CFFT Award in the third quarter of 2017 (See Note 9), there was no cumulative effect to record at the date&#13;of the Company&amp;#8217;s adoption of ASC 606 and no revenue to recognize for the first quarter of 2018 related to the 2015 CFFT Award.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Revenue for the quarter and the&#13;year ended December 31, 2018 was $1,927,306 and $4,822,272, respectively, recognized in accordance with ASC 606 and pertains only&#13;to the 2018 CFF Award discussed in Note 9. The total impact to revenue as a result of the adoption of ASC 606 was higher revenue&#13;of approximately $325,000 for the quarter ended December 31, 2018 and lower revenue of approximately $201,000 for the year ended&#13;December 31, 2018.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company will assess any new&#13;agreements it enters into under ASC 606, including whether such agreements fall under the scope of such standard. This standard&#13;applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance,&#13;collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control&#13;of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for&#13;those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC&#13;606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance&#13;obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations&#13;in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies&#13;the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange&#13;for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the&#13;scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance&#13;obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount&#13;of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is&#13;satisfied.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Revenue associated with the 2018&#13;CFF Award performance obligation is being recognized as revenue as the research and development services are provided using an&#13;input method, according to the costs incurred as related to the research and development activities and the costs expected to be&#13;incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&amp;#8217;s&#13;judgment, is the best measure of progress towards satisfying the performance obligation. The research and development services&#13;related to this performance obligation are expected to be performed over an approximately two and a half-year period expected to&#13;be completed in the second quarter of 2020. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts&#13;expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of&#13;deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12&#13;months following the balance sheet date would be classified as deferred revenue, net of current portion. Amounts recognized as&#13;revenue, but not yet received or invoiced are generally recognized as contract assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Accounting for Leases&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In February 2016, the FASB issued&#13;ASU No&lt;b&gt;. &lt;/b&gt;2016-02, &lt;i&gt;Leases (Topic 842), &lt;/i&gt;as amended (&amp;#8220;ASU 2016-02&amp;#8221;)&lt;i&gt;. &lt;/i&gt;Under ASU 2016-02, a lessee will&#13;be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current&#13;US GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will&#13;depend on its classification as a finance or operating lease. However, unlike current US GAAP, which requires only capital leases&#13;to be recognized on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU&#13;2016-02 will take effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. ASU&#13;2016-02 required a modified retrospective transition approach, which initially required application of the new guidance for all&#13;periods presented in the Company&amp;#8217;s financial statements (&amp;#8220;comparative method&amp;#8221;). In July 2018, the FASB released&#13;ASU 2018-11, offering a second option which provides further relief in the transition to ASC 842. Companies are allowed to follow&#13;the cumulative-effect adjustment transition approach (&amp;#8220;effective date method&amp;#8221;), which releases companies from presenting&#13;comparative periods and related disclosures according to ASC 842. Instead, companies electing to utilize the effective date method&#13;will recognize a one-time adjustment to retained earnings on the transition date without the additional burden of presenting the&#13;comparative periods under the new guidance. The Company will adopt ASU 2016-02 using the effective date method as of January 1,&#13;2019 and expects to record a lease liability in the rage of approximately $3.4-$4.2 million, and a right-to-use asset in the range&#13;of approximately $2.1-$2.6 million, and no adjustment to the accumulated deficit. The Company anticipates that the adoption will&#13;not have a material impact on the consolidated statement of operations or statement of cash flows.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Nonemployee Share-Based Payment&#13;Accounting&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In June 2018, the FASB issued ASU&#13;2018-07, &lt;i&gt;Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting&lt;/i&gt; (&amp;#8220;ASU&#13;2018-07&amp;#8221;). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and&#13;services from nonemployees. Under ASU 2018-07, consistent with the accounting requirement for employee share-based payment awards,&#13;nonemployee share-based payment awards within the scope of Topic 718 are to be measured at the grant-date fair value of the equity&#13;instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other&#13;conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based&#13;payment awards are to be measured at the grant date. The definition of the term grant date is amended to generally state the date&#13;at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. ASU&#13;2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services&#13;to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does&#13;not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction&#13;with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for public&#13;business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company&#13;expects to adopt ASU 2018-07 on January 1, 2019 and anticipates that the adoption will not have a material impact on the Company&amp;#8217;s&#13;financial statements and related disclosures.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Collaborative Arrangements&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="background-color: white"&gt;In&#13;November 2018, the FASB issued ASU 2018-08, &lt;i&gt;Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic&#13;808 and Topic 606&lt;/i&gt;&lt;/font&gt; (&amp;#8220;ASU 2018-08&amp;#8221;)&lt;font style="background-color: white"&gt;. ASU 2018-08 clarifies the interaction&#13;between the accounting guidance for collaborative arrangements and revenue from contracts with customers. &lt;/font&gt;ASU 2018-08 is&#13;effective for public business entities for fiscal years beginning after December 15, 2019, including interim periods within that&#13;fiscal year&lt;font style="background-color: white"&gt;. Early adoption, including adoption in any interim period, is permitted. The&#13;Company is currently &lt;/font&gt;evaluating the timing of the adoption of ASU 2018-08 and the expected impact it could have on the&#13;Company&amp;#8217;s financial statements and related disclosures&lt;font style="background-color: white"&gt;.&lt;/font&gt;&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <dei:EntitySmallBusiness contextRef="From2018-01-01to2018-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2018-01-01to2018-12-31">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod contextRef="From2018-01-01to2018-12-31">true</dei:EntityExTransitionPeriod>
    <us-gaap:SubstantialDoubtAboutGoingConcernTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;2.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;LIQUIDITY &lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company anticipates operating&#13;losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its&#13;product candidates and its preclinical and clinical programs, strategic alliances and the development of its administrative organization.&#13;The Company has incurred recurring losses since inception and as of December 31, 2018, had an accumulated deficit of $121,370,240.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 3, 2019, the Company&#13;entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (&amp;#8220;Kaken&amp;#8221;) (See Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 30, 2019, the Company&#13;consummated an underwritten public offering of shares of its common stock (&amp;#8220;January 2019 Offering&amp;#8221;) (See Note 15).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company expects the cash and&#13;cash equivalents of $41,748,468 at December 31, 2018 together with the $27 million of upfront payment to be received from Kaken,&#13;less the $2.7 million royalty (which is 10% of such upfront payment) that the Company will owe to CFF pursuant to the Investment&#13;Agreement (See Note 9), and the approximately $37.6 million of net proceeds from the January 2019 Offering, to be sufficient to&#13;meet its operating and capital requirements at least 12 months from the filing of this 10-K.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Should the Company be unable to&#13;raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing&#13;certain clinical activities. The Company will need to raise significant additional capital to continue to fund the clinical trials&#13;for lenabasum and CRB-4001 (see Note 4). The Company may seek to sell common or preferred equity or convertible debt securities,&#13;enter into a credit facility or another form of third-party funding, or seek other debt financing. The sale of equity and convertible&#13;debt securities may result in dilution to the Company&amp;#8217;s stockholders and certain of those securities may have rights senior&#13;to those of the Company&amp;#8217;s common shares. If the Company raises additional funds through the issuance of preferred stock,&#13;convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict&#13;the Company&amp;#8217;s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The source, timing and availability&#13;of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company&amp;#8217;s&#13;clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of&#13;necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company&amp;#8217;s&#13;planned clinical trials.&lt;/p&gt;</us-gaap:SubstantialDoubtAboutGoingConcernTextBlock>
    <CRBP:CashEquivalentsAndRestrictedCashMaturityPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_MaximumMember">P3M</CRBP:CashEquivalentsAndRestrictedCashMaturityPeriod>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2017-12-31_custom_CorporatecreditCardsMember" unitRef="USD" decimals="0">108991</us-gaap:RestrictedCashAndCashEquivalents>
    <us-gaap:RestrictedCashAndCashEquivalents contextRef="AsOf2017-12-31_custom_StandbyLetterOfCreditMember" unitRef="USD" decimals="0">50000</us-gaap:RestrictedCashAndCashEquivalents>
    <CRBP:CashHeldInSubsidiary contextRef="AsOf2018-12-31_country_GB" unitRef="USD" decimals="0">702000</CRBP:CashHeldInSubsidiary>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_custom_ComputerHardwareAndSoftwareMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MinimumMember">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="From2018-01-01to2018-12-31_custom_OfficeFurnitureAndEquipmentMember_us-gaap_MaximumMember">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:NumberOfOperatingSegments contextRef="From2018-01-01to2018-12-31" unitRef="Segment" decimals="INF">1</us-gaap:NumberOfOperatingSegments>
    <CRBP:DeferredTaxAssetsValuationAllowancePercentage contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">1.00</CRBP:DeferredTaxAssetsValuationAllowancePercentage>
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:LiabilityForUncertainTaxPositionsCurrent contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetImpairmentCharges contextRef="From2017-01-01to2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:AssetImpairmentCharges contextRef="From2018-01-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">5029289</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">11921000</us-gaap:OperatingLeasesFutureMinimumPaymentsDue>
    <us-gaap:Cash contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">206510</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">808943</us-gaap:Cash>
    <us-gaap:Cash contextRef="AsOf2018-12-31_country_GB" unitRef="USD" decimals="0">702000</us-gaap:Cash>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">62330985</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:MoneyMarketFundsAtCarryingValue contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">40939525</us-gaap:MoneyMarketFundsAtCarryingValue>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">9133466</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">1288500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2017-01-01to2017-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">7844966</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">11877490</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember" unitRef="Shares" decimals="INF">2283500</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="From2018-01-01to2018-12-31_custom_StockOptionsMember" unitRef="Shares" decimals="INF">9593990</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="From2018-09-19to2018-09-20_custom_JenrinAgreementMember" unitRef="USD" decimals="0">250000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <us-gaap:BusinessCombinationConsiderationTransferred1 contextRef="From2018-07-01to2018-09-30_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">250000</us-gaap:BusinessCombinationConsiderationTransferred1>
    <CRBP:PotentialMilestonePayments contextRef="From2018-09-19to2018-09-20_custom_JenrinAgreementMember" unitRef="USD" decimals="0">18400000</CRBP:PotentialMilestonePayments>
    <CRBP:PotentialMilestonePayments contextRef="From2018-01-01to2018-12-31_us-gaap_ResearchAndDevelopmentExpenseMember" unitRef="USD" decimals="0">18400000</CRBP:PotentialMilestonePayments>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1796544</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">191244</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_custom_OfficeFurnitureAndEquipmentMember" unitRef="USD" decimals="0">287048</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_custom_ComputerHardwareAndSoftwareMember" unitRef="USD" decimals="0">136522</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2015-12-30_custom_CopierMachineMember" unitRef="USD" decimals="0">12000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2017-12-31_us-gaap_ConstructionInProgressMember" unitRef="USD" decimals="0">1181730</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">3371789</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_custom_ComputerHardwareAndSoftwareMember" unitRef="USD" decimals="0">431637</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_custom_OfficeFurnitureAndEquipmentMember" unitRef="USD" decimals="0">914742</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_us-gaap_LeaseholdImprovementsMember" unitRef="USD" decimals="0">2025410</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2018-12-31_us-gaap_ConstructionInProgressMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">363889</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">666583</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <CRBP:AreaOfOfficeSpace contextRef="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="sqft" decimals="INF">32733</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2016-09-01to2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember" unitRef="sqft" decimals="INF">10414</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2016-09-01to2016-09-30" unitRef="sqft" decimals="INF">4088</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember_custom_FebruaryTwentySixTwoThousandAndNineteenMember_custom_NewPremisesMember" unitRef="sqft" decimals="INF">30023</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember_custom_FebruaryTwentySixTwoThousandAndNineteenMember_custom_TotalPremisesMember" unitRef="sqft" decimals="INF">62756</CRBP:AreaOfOfficeSpace>
    <CRBP:AreaOfOfficeSpace contextRef="From2018-02-01to2018-02-28" unitRef="sqft" decimals="INF">32733</CRBP:AreaOfOfficeSpace>
    <us-gaap:LeaseExpirationDate1 contextRef="From2016-09-01to2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember">2021-01-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LettersOfCreditOutstandingAmount contextRef="AsOf2016-09-30_custom_SeptemberTwoThousandAndSixteenAmendmentMember" unitRef="USD" decimals="0">50000</us-gaap:LettersOfCreditOutstandingAmount>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">356547</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FirstYearMember" unitRef="USD" decimals="0">470000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2017-08-20to2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_SeventhYearMember" unitRef="USD" decimals="0">908000</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LeaseAndRentalExpense contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">587963</us-gaap:LeaseAndRentalExpense>
    <us-gaap:LineOfCredit contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">400000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_ThirdAnniversaryMember" unitRef="USD" decimals="0">300000</us-gaap:LineOfCredit>
    <us-gaap:LineOfCredit contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember_custom_FourthAnniversaryMember" unitRef="USD" decimals="0">200000</us-gaap:LineOfCredit>
    <us-gaap:InterestExpense contextRef="From2017-01-01to2017-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">9743</us-gaap:InterestExpense>
    <us-gaap:InterestExpense contextRef="From2018-01-01to2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">7431</us-gaap:InterestExpense>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">1055639</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">5036000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueThereafter>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsDue contextRef="AsOf2018-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">378</us-gaap:CapitalLeasesFutureMinimumPaymentsDue>
    <us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments contextRef="AsOf2018-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">3</us-gaap:CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments>
    <us-gaap:CapitalLeaseObligations contextRef="AsOf2018-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">375</us-gaap:CapitalLeaseObligations>
    <us-gaap:CapitalLeaseObligationsCurrent contextRef="AsOf2018-12-31_custom_CopierMachineMember" unitRef="USD" decimals="0">375</us-gaap:CapitalLeaseObligationsCurrent>
    <us-gaap:CapitalLeaseObligationsNoncurrent contextRef="AsOf2018-12-31_custom_CopierMachineMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">415265</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">491629</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2016-10-01to2016-10-31_custom_LoanAgreementMember" unitRef="USD" decimals="0">348750</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2017-11-01to2017-11-30_custom_LoanAgreementMember" unitRef="USD" decimals="0">415265</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:ProceedsFromNotesPayable contextRef="From2018-11-01to2018-11-30_custom_LoanAgreementMember" unitRef="USD" decimals="0">491629</us-gaap:ProceedsFromNotesPayable>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2016-10-01to2016-10-31_custom_LoanAgreementMember" unitRef="USD" decimals="0">39114</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2017-11-01to2017-11-30_custom_LoanAgreementMember" unitRef="USD" decimals="0">41975</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentPeriodicPayment contextRef="From2018-11-01to2018-11-30_custom_LoanAgreementMember" unitRef="USD" decimals="0">49857</us-gaap:DebtInstrumentPeriodicPayment>
    <us-gaap:DebtInstrumentTerm contextRef="From2016-10-01to2016-10-31_custom_LoanAgreementMember">P9M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="From2017-11-01to2017-11-30_custom_LoanAgreementMember">P10M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentTerm contextRef="From2018-11-01to2018-11-30_custom_LoanAgreementMember">P10M</us-gaap:DebtInstrumentTerm>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2016-10-31_custom_LoanAgreementMember" unitRef="Percentage" decimals="INF">0.0225</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2017-11-30_custom_LoanAgreementMember" unitRef="Percentage" decimals="INF">0.0235</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="AsOf2018-11-30_custom_LoanAgreementMember" unitRef="Percentage" decimals="INF">0.0307</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:PrepaidExpenseCurrentAndNoncurrent contextRef="AsOf2018-12-31_country_GB" unitRef="USD" decimals="0">1183000</us-gaap:PrepaidExpenseCurrentAndNoncurrent>
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:CommitmentsAndContingencies contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">5000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="USD" decimals="0">1</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2018-01-01to2018-12-31_us-gaap_AdditionalPaidInCapitalMember" unitRef="USD" decimals="0">4999</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="From2018-01-01to2018-12-31_us-gaap_RetainedEarningsMember" unitRef="USD" xsi:nil="true" />
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="From2018-01-01to2018-12-31_us-gaap_CommonStockMember" unitRef="Shares" decimals="INF">5000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <dei:EntityWellKnownSeasonedIssuer contextRef="From2018-01-01to2018-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="From2018-01-01to2018-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="From2018-01-01to2018-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityPublicFloat contextRef="AsOf2018-06-30" unitRef="USD" decimals="0">271269436</dei:EntityPublicFloat>
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredRentCreditCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">35996</us-gaap:DeferredRentCreditCurrent>
    <us-gaap:StockIssued1 contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">225501</us-gaap:StockIssued1>
    <us-gaap:StockIssued1 contextRef="From2018-01-01to2018-12-31" unitRef="USD" xsi:nil="true" />
    <CRBP:MarketableSecuritiesMaturityPeriod contextRef="From2018-01-01to2018-12-31_us-gaap_MinimumMember">P3M</CRBP:MarketableSecuritiesMaturityPeriod>
    <us-gaap:MarketableSecurities contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:MarketableSecurities contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">56536000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2017-12-31_custom_MassachusettMember" unitRef="USD" decimals="0">53110000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">82545000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="AsOf2018-12-31_custom_MassachusettMember" unitRef="USD" decimals="0">78152000</us-gaap:OperatingLossCarryforwards>
    <CRBP:DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear contextRef="From2018-01-01to2018-12-31_custom_FederalMember">2029</CRBP:DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1432000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">5088343</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">14583207</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2017-01-01to2017-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember" unitRef="Percentage" decimals="INF">0.80</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.00</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit contextRef="From2017-01-01to2017-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember" unitRef="USD" decimals="0">7815832</us-gaap:DeferredFederalStateAndLocalTaxExpenseBenefit>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">15229127</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">22273661</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1213347</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2793247</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1724248</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">3381969</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">45654</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">660427</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">116292</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">186069</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">18328668</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">32911875</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">18328668</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">32911875</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsNet contextRef="AsOf2018-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.3400</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2017-12-21to2017-12-22_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_us-gaap_InterestExpenseMember" unitRef="Percentage" decimals="INF">0.30</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_custom_OrphanDrugCreditMember_srt_MaximumMember" unitRef="Percentage" decimals="INF">0.50</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31_custom_TaxCutAndJobsActOfTwoThousandSeventeenMember_custom_OrphanDrugCreditMember_srt_MinimumMember" unitRef="Percentage" decimals="INF">0.25</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.2100</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0566</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.0542</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">-0.0205</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">-0.0200</us-gaap:EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0159</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.0431</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCredits>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">-0.2411</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">0.0060</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.0114</us-gaap:EffectiveIncomeTaxRateReconciliationOtherAdjustments>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" decimals="INF">-0.1569</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">-0.3972</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2019-03-06" unitRef="Shares" decimals="INF">64395221</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">1462503</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2015-04-20_custom_TwoThousandFifteenCFFTAwardArrangementMember_custom_OralAntiinflammatoryDrugMember" unitRef="USD" decimals="0">5000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2015-05-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1250000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2015-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1250000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2016-08-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2017-01-31_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">1000000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2017-11-30_custom_TwoThousandFifteenCFFTAwardArrangementMember" unitRef="USD" decimals="0">500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2018-12-31_custom_InvestmentagreementMember_custom_PhaseTwoBClinicalTrialMember" unitRef="USD" decimals="0">12500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2018-12-31_srt_MaximumMember" unitRef="USD" decimals="0">12500000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">47504229</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-20948018</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <dei:EntityShellCompany contextRef="From2018-01-01to2018-12-31">false</dei:EntityShellCompany>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="From2017-01-01to2017-12-31" unitRef="USD" decimals="0">-1940195</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-4787497</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <CRBP:LicenseAgreementTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;4.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;LICENSE AGREEMENT&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company, entered into a License&#13;Agreement (the &amp;#8220;Jenrin Agreement&amp;#8221;) with Jenrin Discovery, LLC, a privately-held Delaware limited liability company&#13;(&amp;#8220;Jenrin&amp;#8221;), effective September 20, 2018. Pursuant to the Jenrin Agreement, Jenrin granted the Company exclusive worldwide&#13;rights to develop and commercialize the Licensed Products (as defined in the Jenrin Agreement) which includes the Jenrin library&#13;of over 600 compounds and multiple issued and pending patent filings. The compounds are designed to treat inflammatory and fibrotic&#13;diseases by targeting the endocannabinoid system. The lead product candidate is CRB-4001, a peripherally-restricted CB-1 inverse&#13;agonist targeting fibrotic liver, lung, heart and kidney diseases. The Company plans to commence a Phase 1 clinical trial of CRB-4001&#13;in 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In consideration of the license&#13;and other rights granted by Jenrin, the Company paid Jenrin a $250,000 upfront cash payment and is obligated to pay potential milestone&#13;payments to Jenrin totaling up to $18.4 million for each compound it elects to develop based upon the achievement of specified&#13;development and regulatory milestones. In addition, Corbus is obligated to pay Jenrin royalties in the mid, single digits based&#13;on net sales of any Licensed Products, subject to specified reductions.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In January 2017, the FASB issued&#13;ASU 2017-01, &lt;i&gt;Business Combinations (Topic 805): Clarifying the Definition of a Business &lt;/i&gt;(&amp;#8220;ASU 2017-01&amp;#8221;) which&#13;clarifies the definition of a business and determines when an integrated set of assets and activities is not a business. ASU 2017-01&#13;requires that if substantially all of the fair value of gross assets acquired or disposed of is concentrated in a single asset&#13;or group of similar identifiable assets, the assets would not represent a business. The Company determined that substantially&#13;all of the fair value of the Jenrin Agreement was attributable to a single in-process research and development asset, CRB-4001,&#13;which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process&#13;research and development asset. Thus, the Company recorded the $250,000 upfront payment to research and development expenses in&#13;the third quarter of 2018. The Company will account for the $18.4 million of development and regulatory milestone payments in&#13;the period that the relevant milestones are achieved as either research and development expense or as an intangible asset as applicable.&lt;/p&gt;</CRBP:LicenseAgreementTextBlock>
    <us-gaap:RevenueFromRelatedParties contextRef="From2018-01-01to2018-12-31_us-gaap_UpFrontPaymentArrangementMember_custom_KakenPharmaceuticalCoLtdMember" unitRef="USD" decimals="0">27000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties contextRef="From2018-01-01to2018-12-31_custom_InvestmentagreementMember_custom_TwoThousandAndEighteenCffAwardMember_custom_KakenPharmaceuticalCoLtdMember" unitRef="USD" decimals="0">27000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties contextRef="From2019-01-02to2019-01-03_us-gaap_SubsequentEventMember_custom_CollaborationandLicenseAgreementMember_custom_KakenPharmaceuticalCoLtdMember" unitRef="USD" decimals="0">27000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:RevenueFromRelatedParties contextRef="From2019-01-02to2019-01-03_us-gaap_SubsequentEventMember_custom_CollaborationandLicenseAgreementMember_custom_FirstQuarterofTwoThousandandNineteenMember" unitRef="USD" decimals="0">27000000</us-gaap:RevenueFromRelatedParties>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_InvestmentagreementMember" unitRef="USD" decimals="0">2700000</us-gaap:ProceedsFromRoyaltiesReceived>
    <us-gaap:ProceedsFromRoyaltiesReceived contextRef="From2018-01-01to2018-12-31_custom_InvestmentagreementMember_custom_TwoThousandAndEighteenCffAwardMember_custom_KakenPharmaceuticalCoLtdMember" unitRef="USD" decimals="0">2700000</us-gaap:ProceedsFromRoyaltiesReceived>
    <CRBP:UpfrontPaymentPercentage contextRef="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_InvestmentagreementMember" unitRef="Percentage" decimals="INF">0.10</CRBP:UpfrontPaymentPercentage>
    <us-gaap:OtherAssets contextRef="AsOf2018-12-31_country_GB" unitRef="USD" decimals="0">28000</us-gaap:OtherAssets>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2018-12-31_custom_JanuaryOneTwoThousandAndNineteenMember_srt_MinimumMember" unitRef="USD" decimals="0">3400000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2018-12-31_custom_JanuaryOneTwoThousandAndNineteenMember_srt_MaximumMember" unitRef="USD" decimals="0">4200000</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2018-12-31_custom_JanuaryOneTwoThousandAndNineteenMember_srt_MinimumMember" unitRef="USD" decimals="0">2100000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2018-12-31_custom_JanuaryOneTwoThousandAndNineteenMember_srt_MaximumMember" unitRef="USD" decimals="0">2600000</us-gaap:OperatingLeaseRightOfUseAsset>
    <CRBP:LeaseTerm contextRef="From2015-01-01to2015-12-30_custom_CopierMachineMember">P3Y</CRBP:LeaseTerm>
    <us-gaap:UnsecuredDebt contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">400000</us-gaap:UnsecuredDebt>
    <us-gaap:LeaseholdImprovementsGross contextRef="AsOf2017-08-21_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">1080189</us-gaap:LeaseholdImprovementsGross>
    <CRBP:CapitalLeaseTerm contextRef="From2018-01-01to2018-12-31_custom_CapitalLeaseAgreementMember">P3Y</CRBP:CapitalLeaseTerm>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2017-12-31_custom_InsurancePolicyMember" unitRef="USD" decimals="0">368976</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="AsOf2018-12-31_custom_InsurancePolicyMember" unitRef="USD" decimals="0">441875</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <CRBP:RoyaltyPaymentPercentage contextRef="From2018-01-01to2018-12-31_custom_CysticFibrosisFoundationMember_custom_CollaborationAgreementMember" unitRef="Percentage" decimals="INF">0.10</CRBP:RoyaltyPaymentPercentage>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">3616502</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsForeign>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign contextRef="From2017-01-01to2017-12-31" unitRef="Percentage" xsi:nil="true" />
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign contextRef="From2018-01-01to2018-12-31" unitRef="Percentage" decimals="INF">0.0985</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsForeign>
    <CRBP:ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 82%"&gt;&lt;font style="font-size: 10pt"&gt;Risk free interest rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected dividend yield&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected term in years&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;7.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Expected volatility&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;83.5&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</CRBP:ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock>
    <CRBP:SummaryOfNonvestedStockOptionsTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;As summary of non-vested stock options&#13;for the years ended December 31, 2018 and 2017 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;Options&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Shares&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;Weighted &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Average &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Fair &lt;/font&gt;&lt;br /&gt;&#13;&lt;font style="font-size: 10pt"&gt;Value&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;Non-vested at December 31, 2016&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,826,274&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.86&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,681,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;6.22&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(2,003,806&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(173,979&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.03&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Nonvested at December 31, 2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,329,989&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.61&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Granted&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,378,500&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.63&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Vested&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(1,643,772&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3.98&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Forfeited&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(438,428&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.91&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Non-vested at December 31, 2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,626,289&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.32&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</CRBP:SummaryOfNonvestedStockOptionsTableTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Significant components of the Company&amp;#8217;s&#13;net deferred tax asset are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;NOL carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22,273,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,229,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Foreign net operating loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3, 616,502&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,793,247&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,213,347&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,381,969&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,724,248&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;660,427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;45,654&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Other temporary differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;186,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;116,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Subtotal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,911,875&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,911,875&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="From2017-01-01to2017-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Income tax benefits computed using&#13;the federal statutory income tax rate differs from the Company&amp;#8217;s effective tax rate primarily due to the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%"&gt;&lt;font style="font-size: 10pt"&gt;Tax provision at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-2.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Foreign expected tax&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Income tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-24.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Increase in valuation reserve&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-39.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-15.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <CRBP:LeasesAndDeferredRentPolicyTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;Leases and Deferred Rent&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;b&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company leases its office space.&#13;Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&amp;#8217;s office&#13;space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records&#13;the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between&#13;the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the&#13;lessor are recorded as a reduction to rent expense over the term of the lease.&lt;/p&gt;</CRBP:LeasesAndDeferredRentPolicyTextBlock>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;10.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;INCOME TAXES&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;No provision or benefit for federal&#13;or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and the Company&#13;has provided a full valuation allowance against its deferred tax assets.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;At December 31, 2018 and 2017, the&#13;Company had federal net operating loss carryforwards of approximately $82,545,000 and $56,536,000, respectively, of which federal&#13;carryforwards will expire in varying amounts beginning in 2029. At December 31, 2018 and 2017, the Company had Massachusetts net&#13;operating loss carryforwards of approximately $78,152,000 and $53,110,000, respectively. In the first quarter of 2017, the Company&#13;adopted ASU 2016-09, which removed the requirement to recognize the deferred tax assets on excess tax benefits in respect of share&#13;based payments only when realized. As such, during the year ended December 31, 2017, the Company&amp;#8217;s gross deferred tax assets&#13;and corresponding valuation allowance each included a one-time increase in respect of an additional federal and state net operating&#13;losses of $1,432,000. The adoption of ASU 2016-09 did not have an impact on the Company&amp;#8217;s balance sheet, results of operations,&#13;cash flows or statement of stockholders&amp;#8217; equity because the Company has a full valuation allowance on its deferred tax assets.&#13;Utilization of net operating losses may be subject to substantial annual limitations due to the &amp;#8220;change in ownership&amp;#8221;&#13;provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in the expiration of net&#13;operating losses before utilization. The Company has not yet conducted a study to determine if any such changes have occurred that&#13;could limit the Company&amp;#8217;s ability to use the net operating losses and tax credit carryforwards. The Company also had research&#13;and development tax credit carryforwards at December 31, 2018 and 2017 of approximately $2,926,000 and $1,283,000, respectively.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Significant components of the Company&amp;#8217;s&#13;net deferred tax asset are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 62%"&gt;&lt;font style="font-size: 10pt"&gt;NOL carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;22,273,661&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 16%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;15,229,127&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Foreign net operating loss carryforward&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3, 616,502&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;2,793,247&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,213,347&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Stock based compensation&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;3,381,969&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,724,248&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Accrued expenses&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;660,427&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;45,654&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Other temporary differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;186,069&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;116,292&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Subtotal&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;32,911,875&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Valuation allowance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(32,911,875&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(18,328,668&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Net deferred tax asset&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company has maintained a full&#13;valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded&#13;when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company&#13;cannot determine that it is more likely than not that it will generate taxable income, and thereby realize the net deferred tax&#13;assets, a full valuation allowance has been provided. The valuation allowance increased by $14,583,207 and $5,088,343 in 2018 and&#13;2017, respectively, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards. The Company&#13;has no uncertain tax positions at December 31, 2018 and 2017 that would affect its effective tax rate. Since the Company is in&#13;a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities&#13;for all years for which a loss carryforward is available.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Income tax benefits computed using&#13;the federal statutory income tax rate differs from the Company&amp;#8217;s effective tax rate primarily due to the following:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;December 31,&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="text-align: center"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2018&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;2017&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 60%"&gt;&lt;font style="font-size: 10pt"&gt;Tax provision at statutory rate&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;21.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 15%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;34.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;State taxes, net of federal benefit&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.42&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5.66&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Permanent differences&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-2.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-2.05&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Foreign expected tax&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;9.85&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Tax credits&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;4.31&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.59&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Income tax rate change&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-24.11&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Other&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1.14&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.60&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Increase in valuation reserve&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-39.72&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;-15.69&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;0.00&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;%&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;The Tax Cut and Jobs Act of 2017&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On December 22, 2017, the legislation&#13;commonly referred to as the Tax Cut and Jobs Act (the &amp;#8220;Tax Act&amp;#8221;) was enacted into law. The Tax Act, among other things,&#13;contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35%&#13;to a flat rate of 21%; limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small&#13;businesses); limitation of the deduction of net operating losses generated in tax years beginning after December 31, 2017 to 80%&#13;of taxable income, indefinite carryforward of net operating losses generated in tax years after 2018 and elimination of net operating&#13;loss carrybacks; changes in the treatment of offshore earnings regardless of whether they are repatriated; current inclusion in&#13;U.S. federal taxable income of certain earnings of controlled foreign corporations, mandatory capitalization of research and development&#13;expenses beginning in 2022; immediate deductions for certain new investments instead of deductions for depreciation expense over&#13;time; further deduction limits on executive compensation; and modifying, repealing and creating many other business deductions&#13;and credits, including the reduction in the orphan drug credit from 50% to 25% of qualifying expenditures. As of December 31, 2017,&#13;we made a reasonable estimate of the effects of the Tax Act on our existing deferred taxes and related disclosures by reducing&#13;our net federal and state deferred tax assets by $7,815,832 for the reduction in corporate tax rate. This adjustment to our deferred&#13;tax assets was offset against the valuation allowance.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Additionally, the SEC staff has&#13;issued SAB 118, which allows to record provisional amounts during a measurement period not to extend beyond one year of the enactment&#13;date. On December 22, 2017, Staff Accounting Bulletin No. 118 (&amp;#8220;SAB 118&amp;#8221;) was issued to address the application of&#13;U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including&#13;computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company finalized&#13;its estimates during the fourth quarter of 2018.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <CRBP:LeaseTermDateDescription contextRef="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember_custom_FebruaryTwentySixTwoThousandAndNineteenMember_custom_NewPremisesMember">The commencement date for the New Premises is expected to occur no later than August 1, 2019 </CRBP:LeaseTermDateDescription>
    <CRBP:LeaseTermDateDescription contextRef="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember_custom_FebruaryTwentySixTwoThousandAndNineteenMember_custom_TotalPremisesMember">The lease term for the Total Premises is October 31, 2026.</CRBP:LeaseTermDateDescription>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-02-28_custom_SecuritiesPurchaseAgreementMember_custom_InstitutionalAndAccreditedInvestorsMember_custom_FebruaryTwentyEightTwoThousandSeventeenMember" unitRef="USDPShares" decimals="INF">7.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2017-10-26_custom_InstitutionalInvestorsMember" unitRef="USDPShares" decimals="INF">7.00</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:SaleOfStockPricePerShare contextRef="AsOf2019-01-30_us-gaap_SubsequentEventMember_custom_PublicOfferingMember_custom_TerminationofJanuaryTwoThousandAndEighteenSalesAgreementMember" unitRef="USDPShares" decimals="INF">6.50</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2017-10-25to2017-10-26_custom_InstitutionalInvestorsMember" unitRef="Shares" decimals="INF">697500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward contextRef="From2016-09-01to2016-09-20_custom_TwoThousandFourteenEquityCompensationPlanMember" unitRef="Shares" decimals="INF">50000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="From2017-01-01to2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember" unitRef="Percentage" decimals="INF">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="From2014-04-01to2014-04-30_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Percentage" decimals="INF">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="From2018-01-01to2018-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandandNiniteenMember" unitRef="Percentage" decimals="INF">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="From2018-12-30to2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Percentage" decimals="INF">0.07</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2017-01-01to2017-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandEighteenMember" unitRef="Shares" decimals="INF">2500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2018-01-01to2018-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandandNiniteenMember" unitRef="Shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease contextRef="From2018-12-30to2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">3000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">15543739</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2018-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandandNiniteenMember" unitRef="Shares" decimals="INF">18543739</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance contextRef="AsOf2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">18543739</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember" unitRef="Shares" decimals="INF">5072241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2018-12-31_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember_custom_JanuaryOneTwoThousandandNiniteenMember" unitRef="Shares" decimals="INF">8072241</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant contextRef="AsOf2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Shares" decimals="INF">80722414</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="From2018-01-01to2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="From2018-01-01to2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember">P4Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember">P9Y10M28D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_custom_TwoThousandFourteenEquityIncentivePlanMember_us-gaap_EmployeeStockOptionMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember">P6Y2M30D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember1458033187">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember" unitRef="Percentage" decimals="INF">0.0212</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember" unitRef="Percentage" decimals="INF">0.0238</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0253</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember1458033187" unitRef="Percentage" decimals="INF">0.0260</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.8601</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MinimumMember" unitRef="Percentage" decimals="INF">0.8558</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember_us-gaap_MaximumMember" unitRef="Percentage" decimals="INF">0.8958</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.8770</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember1458033187" unitRef="Percentage" decimals="INF">0.835</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">5.63</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USDPShares" decimals="INF">6.22</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">543060</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="From2017-01-01to2017-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">2092964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="AsOf2018-12-31_us-gaap_StockOptionMember" unitRef="USD" decimals="0">15400414</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2018-01-01to2018-12-31_us-gaap_StockOptionMember">P2Y6M18D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember1458033187" unitRef="Percentage" decimals="INF">0.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="From2017-01-01to2017-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0500</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="From2018-01-01to2018-12-31_us-gaap_EmployeeStockOptionMember" unitRef="Percentage" decimals="INF">0.0500</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate contextRef="From2017-01-01to2017-12-31_custom_NonEmployeesMember" unitRef="Percentage" decimals="INF">0.05</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">6610179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">7844966</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">9593990</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">1681500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">2378500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">173979</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">490407</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">2.54</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">3.75</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">4.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">8.28</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">7.58</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice contextRef="From2016-09-01to2016-09-20_custom_TwoThousandFourteenEquityCompensationPlanMember" unitRef="USDPShares" decimals="INF">7.14</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">0.67</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">2.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">6.53</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">7.85</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="From2018-01-01to2018-12-31">P7Y2M23D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">22510816</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2016-12-31" unitRef="Shares" decimals="INF">3826274</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2017-12-31" unitRef="Shares" decimals="INF">3329989</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">3626289</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">2003806</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">1643772</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2017-01-01to2017-12-31" unitRef="Shares" decimals="INF">173979</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares contextRef="From2018-01-01to2018-12-31" unitRef="Shares" decimals="INF">438428</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2016-12-31" unitRef="USDPShares" decimals="INF">2.86</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2017-12-31" unitRef="USDPShares" decimals="INF">4.61</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">5.32</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">2.60</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">3.98</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2017-01-01to2017-12-31" unitRef="USDPShares" decimals="INF">5.03</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue contextRef="From2018-01-01to2018-12-31" unitRef="USDPShares" decimals="INF">5.91</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue>
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2017-01-01to2017-12-31" unitRef="USD" xsi:nil="true" />
    <us-gaap:ProceedsFromWarrantExercises contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">5000</us-gaap:ProceedsFromWarrantExercises>
    <CRBP:WarrantsWeightedAverageRemainingContractualTerm contextRef="From2018-01-01to2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember">P2Y10M21D</CRBP:WarrantsWeightedAverageRemainingContractualTerm>
    <CRBP:NumberOfWarrantsExercisableForCommonStock contextRef="From2018-01-01to2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember" unitRef="Shares" decimals="INF">500000</CRBP:NumberOfWarrantsExercisableForCommonStock>
    <CRBP:NumberOfWarrantsExercisableForCommonStock contextRef="From2018-01-01to2018-12-31_custom_CFFWarrantMember" unitRef="Shares" decimals="INF">500000</CRBP:NumberOfWarrantsExercisableForCommonStock>
    <us-gaap:FairValueAdjustmentOfWarrants contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">6215225</us-gaap:FairValueAdjustmentOfWarrants>
    <us-gaap:RelatedPartyTransactionDate contextRef="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember">2017-03-20</us-gaap:RelatedPartyTransactionDate>
    <CRBP:CashCompensationAmount contextRef="From2016-09-01to2016-09-20_custom_OrchestraMedicalVenturesLLCMember_custom_TwoThousandAndSixteenConsultingAgreementMember" unitRef="USD" decimals="0">100000</CRBP:CashCompensationAmount>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="From2016-09-01to2016-09-20_custom_TwoThousandFourteenEquityCompensationPlanMember" unitRef="Percentage" decimals="INF">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2016-01-01to2016-12-31" unitRef="USD" decimals="0">222000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-03-31" unitRef="USD" decimals="0">171000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="From2017-01-01to2017-03-31_us-gaap_StockOptionMember" unitRef="USD" xsi:nil="true" />
    <CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear contextRef="From2018-12-30to2019-01-01_us-gaap_SubsequentEventMember_custom_EvergreenProvisionMember_custom_TwoThousandFourteenEquityIncentivePlanMember" unitRef="Percentage" decimals="INF">0.07</CRBP:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2018-01-04to2018-01-05_custom_AtTheMarketOfferingMember_us-gaap_MaximumMember" unitRef="USD" decimals="0">50000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="From2019-01-02to2019-01-03_us-gaap_SubsequentEventMember_custom_CollaborationandLicenseAgreementMember_custom_KakenPharmaceuticalCoLtdMember" unitRef="USD" decimals="0">173000000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <CRBP:RoyaltyTermDescription contextRef="From2019-01-02to2019-01-03_us-gaap_SubsequentEventMember_custom_CollaborationandLicenseAgreementMember_custom_KakenPharmaceuticalCoLtdMember">Ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party's insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days' notice.</CRBP:RoyaltyTermDescription>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2019-01-29to2019-01-30_us-gaap_SubsequentEventMember_custom_PublicOfferingMember_custom_TerminationofJanuaryTwoThousandAndEighteenSalesAgreementMember" unitRef="Shares" decimals="INF">6198500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction contextRef="From2019-01-29to2019-01-30_us-gaap_SubsequentEventMember_us-gaap_IPOMember_custom_UnderwritersOptionMember" unitRef="Shares" decimals="INF">808500</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="From2018-01-01to2018-12-31" unitRef="USD" decimals="0">-4822272</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: top"&gt;&#13;    &lt;td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;15.&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;SUBSEQUENT EVENTS&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"&gt;&lt;b&gt;&amp;#160;&lt;/b&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Evergreen Provision&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of an annual&#13;evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically&#13;increase on January 1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on&#13;December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may&#13;determine that such increase will provide for a lesser number of shares. In accordance with the terms of the 2014 Plan, effective&#13;as of January 1, 2019, the number of shares of common stock available for issuance under the 2014 Plan increased by 3,000,000 shares,&#13;such amount being less than seven percent (7%) of the outstanding shares of common stock on December 31, 2018. As of January 1,&#13;2019, the 2014 Plan had a total reserve of 18,543,739 shares and there were 8,072,2414 shares available for future grants.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Collaboration with Kaken&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 3, 2019, Corbus Pharmaceuticals&#13;Holdings, Inc. the Company entered into a Collaboration and License Agreement (the &amp;#8220;Agreement&amp;#8221;) with Kaken Pharmaceutical&#13;Co., Ltd., a company organized under the laws of Japan (&amp;#8220;Kaken&amp;#8221;). Pursuant to the Agreement, Corbus granted Kaken an&#13;exclusive license to commercialize pharmaceutical preparations containing lenabasum (the &amp;#8220;Licensed Products&amp;#8221;) for the&#13;prevention or treatment of dermatomyositis and systemic sclerosis (together, the &amp;#8220;Initial Indications&amp;#8221;) in Japan (the&#13;&amp;#8220;Territory&amp;#8221;).&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the Agreement,&#13;Corbus will bear the cost of, and be responsible for, among other things, conducting the clinical studies and other developmental&#13;activities for the Licensed Products in the Initial Indications in the Territory, and Kaken will bear the cost of, and be responsible&#13;for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed&#13;Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval&#13;for Licensed Products in the Territory.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;In consideration of the license&#13;and other rights granted by Corbus, Kaken will pay Corbus a $27,000,000 upfront cash payment and is obligated to pay potential&#13;milestone payments to Corbus totaling up to approximately $173,000,000 for the achievement of certain development, sales and regulatory&#13;milestones, with part of the milestone payments being calculated in Japanese Yen, and therefore subject to change based on the&#13;conversion rate to U.S. Dollars in effect at the time of payment. In addition, during the Royalty Term (as defined below), Kaken&#13;is obligated to pay Corbus royalties on sales of Licensed Products in the Territory, under certain conditions, in the double digits,&#13;which royalty shall be reduced in certain circumstances. In particular, for so long as Corbus supplies Licensed Products to Kaken&#13;pursuant to a supply agreement to be entered into by the parties, royalty payments shall be payable for each unit of Licensed Product&#13;that Corbus supplies as a percentage of the Japanese National Health Insurance price of the Licensed Product. During any time in&#13;which a supply agreement is not in effect, royalty payments shall be changed to a rate to be agreed upon by the parties in good&#13;faith.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Agreement will remain in effect&#13;on a Licensed Product-by-Licensed product basis and will expire upon the expiration of the Royalty Term for the final Licensed&#13;Product. The &amp;#8220;Royalty Term&amp;#8221; means the period beginning on the date of the first commercial sale of the Licensed Product&#13;in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product&#13;in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii)&#13;ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may&#13;be terminated by either party for material breach, upon a party&amp;#8217;s insolvency or bankruptcy or upon a challenge by one party&#13;of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical&#13;failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of&#13;the Initial Indications in the Territory, with 180 days&amp;#8217; notice.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the Agreement, the parties&#13;agreed to develop a joint steering committee to provide strategic oversight of the parties&amp;#8217; activities under the Agreement,&#13;as well as a joint development committee to coordinate the development of Licensed Products in Japan. Additionally, the parties&#13;will establish a joint commercialization committee to review and confirm commercialization activities with respect to Licensed&#13;Products in Japan upon regulatory approval of such Licensed Product.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Agreement also contains customary&#13;representations, warranties and covenants by both parties, as well as customary provisions relating to indemnification, confidentiality&#13;and other matters.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The Company is evaluating the terms&#13;of the Agreement and believes it is within the scope of ASC 606. Accordingly, the Company expects that the $27 million upfront&#13;payment will be recognized in the first quarter of 2019.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Termination of January 2018 Sales&#13;Agreement&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;font style="background-color: white"&gt;On&#13;January 29, 2019, the Company provided notice of its termination of the January 2018 Sales Agreement. The termination of the January&#13;2018 Sales Agreement was effective on February 8, 2019.&lt;/font&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;&amp;#160;&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Public Offering&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On January 30, 2019, the Company&#13;consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 6,198,500&#13;shares of its common stock, including 808,500 shares sold pursuant to the full exercise of the underwriters&amp;#8217; option to purchase&#13;additional shares, at a purchase price of $6.50 per share with gross proceeds to the Company totaling $40,290,250, less estimated&#13;issuance costs incurred of approximately $2,667,000.&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&lt;i&gt;Office Space Lease Amendment&lt;/i&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;On February 26, 2019, the Company&#13;amended its lease (&amp;#8220;February 2019 Lease Agreement&amp;#8221;) pursuant to which an additional 30,023 square feet of office space&#13;(&amp;#8220;New Premises&amp;#8221;) will be leased by the Company in the same building for an aggregate total of 62,756 square feet of&#13;leased office space (See Note 6).&lt;/p&gt;</us-gaap:SubsequentEventsTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2018-01-01to2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;Pursuant to the terms of the Company&amp;#8217;s&#13;non-cancelable lease agreements in effect at December 31, 2018, the future minimum rent commitments are as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 77%"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;623,958&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;784,243&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;830,600&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;855,150&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;879,699&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,055,639&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,029,289&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock contextRef="From2018-01-01to2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"&gt;The future minimum rent commitments&#13;for the Total Premises are estimated to be approximately as follows:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 77%"&gt;&lt;font style="font-size: 10pt"&gt;2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 20%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;678,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2020&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,288,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2021&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,592,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2022&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,640,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;2023&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,687,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Thereafter&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;5,036,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Total&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;11,921,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock>
    <us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;Pursuant to the terms of this capital&#13;lease agreement, the future minimum capital lease commitments are as follows as of December 31, 2018:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="width: 79%"&gt;&lt;font style="font-size: 10pt"&gt;Total future minimum lease payments &amp;#8211; end in 2019&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 18%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;378&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: interest&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(3&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Future capital lease obligations&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Less: current portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(375&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Long-term portion&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">623958</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">678000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueCurrent>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">784243</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">1288000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInTwoYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">830600</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">1592000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInThreeYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">855150</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">1640000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFourYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2018-12-31_custom_AugustTwoThousandSeventeenLeaseAgreementMember" unitRef="USD" decimals="0">879699</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears contextRef="AsOf2018-12-31_custom_FebruaryTwoThousandAndNineteenLeaseAgreementMember" unitRef="USD" decimals="0">1687000</us-gaap:OperatingLeasesFutureMinimumPaymentsDueInFiveYears>
    <CRBP:AccruedClinicalOperationsAndTrialsCostsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">2003799</CRBP:AccruedClinicalOperationsAndTrialsCostsCurrent>
    <CRBP:AccruedClinicalOperationsAndTrialsCostsCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">4914881</CRBP:AccruedClinicalOperationsAndTrialsCostsCurrent>
    <CRBP:AccruedProductDevelopmentCostsCurrent contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1255439</CRBP:AccruedProductDevelopmentCostsCurrent>
    <CRBP:AccruedProductDevelopmentCostsCurrent contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2222093</CRBP:AccruedProductDevelopmentCostsCurrent>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight contextRef="AsOf2018-01-26_us-gaap_SubsequentEventMember_custom_CysticFibrosisFoundationwarrantsMember" unitRef="Shares" decimals="INF">1000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2017-12-31" unitRef="USD" decimals="0">1283000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">2926000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2018-12-31_custom_InvestmentagreementMember_custom_CFFWarrantMember">2025-01-26</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2018-01-01to2018-12-31">&lt;p style="margin: 0pt"&gt;&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"&gt;A roll forward of deferred revenue&#13;for the year ended December 31, 2018 is presented below:&lt;/p&gt;&#13;&#13;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&amp;#160;&lt;/p&gt;&#13;&#13;&lt;table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"&gt;&#13;&lt;tr style="vertical-align: bottom"&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"&gt;&lt;font style="font-size: 10pt"&gt;&lt;b&gt;December 31, 2018&lt;/b&gt;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Beginning balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;&amp;#8212;&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="width: 72%"&gt;&lt;font style="font-size: 10pt"&gt;Billing to CFF upon achievement of milestones&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="width: 25%; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;12,500,000&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="width: 1%"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;Fair value of CFF Warrant&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(6,215,225&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: white"&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Recognition of revenue&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 1.5pt solid; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;(4,822,272&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 1.5pt"&gt;&lt;font style="font-size: 10pt"&gt;)&lt;/font&gt;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;tr style="vertical-align: bottom; background-color: #CCEEFF"&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&lt;font style="font-size: 10pt"&gt;Ending balance&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double"&gt;&lt;font style="font-size: 10pt"&gt;$&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="border-bottom: black 2.25pt double; text-align: right"&gt;&lt;font style="font-size: 10pt"&gt;1,462,503&lt;/font&gt;&lt;/td&gt;&#13;    &lt;td style="padding-bottom: 2.5pt"&gt;&amp;#160;&lt;/td&gt;&lt;/tr&gt;&#13;&lt;/table&gt;&#13;&#13;&#13;&lt;p style="margin: 0pt"&gt;&lt;/p&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2018-12-31" unitRef="Shares" decimals="INF">5967701</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice contextRef="AsOf2018-12-31" unitRef="USDPShares" decimals="INF">2.87</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2018-01-01to2018-12-31">P6Y5M5D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="AsOf2018-12-31" unitRef="USD" decimals="0">20691512</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:AreaOfLand contextRef="AsOf2019-02-26_us-gaap_SubsequentEventMember_custom_NewPremisesMember" unitRef="sqft" decimals="INF">30023</us-gaap:AreaOfLand>
    <us-gaap:AreaOfLand contextRef="AsOf2019-02-26_us-gaap_SubsequentEventMember_custom_TotalPremisesMember" unitRef="sqft" decimals="INF">62756</us-gaap:AreaOfLand>
    <us-gaap:IncomeTaxExaminationDescription contextRef="From2018-01-01to2018-12-31">On December 22, 2017, the legislation commonly referred to as the Tax Cut and Jobs Act (the "Tax Act") was enacted into law. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses)</us-gaap:IncomeTaxExaminationDescription>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2018-01-01to2018-12-31_us-gaap_WarrantMember1458033187" unitRef="Shares" decimals="INF">144069</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised contextRef="From2017-01-01to2017-12-31_us-gaap_WarrantMember1458051890" unitRef="Shares" decimals="INF">272734</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2018-01-01to2018-12-31_custom_StockOptionAndWarrantsMember" unitRef="USD" decimals="0">352645</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised contextRef="From2017-01-01to2017-12-31_custom_StockOptionAndWarrantsMember" unitRef="USD" decimals="0">189490</us-gaap:ProceedsFromStockOptionsExercised>
</xbrli:xbrl>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>31
<FILENAME>crbp-20181231.xsd
<DESCRIPTION>XBRL SCHEMA FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20181231 10K FY DFN.xfr; Date: 2019%2D03%2D12T12:43:14Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80080001 -->
    <!-- Field: Doc-Info; Name: Misc; Value: 96Mps7xRiXgen8uDanwsWaeHqbP9z5Z8aekhvWBybVkaTysi5QCIOitI72jmQcII -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2018-01-31" xmlns:us-gaap="http://fasb.org/us-gaap/2018-01-31" xmlns:us-roles="http://fasb.org/us-roles/2018-01-31" xmlns:nonnum="http://www.xbrl.org/dtr/type/non-numeric" xmlns:num="http://www.xbrl.org/dtr/type/numeric" xmlns:us-types="http://fasb.org/us-types/2018-01-31" xmlns:CRBP="http://corbuspharma.com/20181231" elementFormDefault="qualified" targetNamespace="http://corbuspharma.com/20181231">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" id="DocumentAndEntityInformation">
	  <link:definition>00000001 - Document - Document and Entity Information</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/BalanceSheets" id="BalanceSheets">
	  <link:definition>00000002 - Statement - Consolidated Balance Sheets</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" id="BalanceSheetsParenthetical">
	  <link:definition>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfOperations" id="StatementsOfOperations">
	  <link:definition>00000004 - Statement - Consolidated Statements of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" id="StatementsOfStockholdersEquity">
	  <link:definition>00000005 - Statement - Statements of Stockholders' Equity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" id="StatementsOfStockholdersEquityParenthetical">
	  <link:definition>00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" id="StatementsOfCashFlows">
	  <link:definition>00000007 - Statement - Consolidated Statements of Cash Flows</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/NatureOfOperations" id="NatureOfOperations">
	  <link:definition>00000008 - Disclosure - Nature of Operations</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/Liquidity" id="Liquidity">
	  <link:definition>00000009 - Disclosure - Liquidity</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" id="SignificantAccountingPolicies">
	  <link:definition>00000010 - Disclosure - Significant Accounting Policies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/LicenseAgreement" id="LicenseAgreement">
	  <link:definition>00000011 - Disclosure - License Agreement</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipment" id="PropertyAndEquipment">
	  <link:definition>00000012 - Disclosure - Property and Equipment</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" id="CommitmentsAndContingencies">
	  <link:definition>00000013 - Disclosure - Commitments and Contingencies</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/NotesPayable" id="NotesPayable">
	  <link:definition>00000014 - Disclosure - Notes Payable</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/AccruedExpenses" id="AccruedExpenses">
	  <link:definition>00000015 - Disclosure - Accrued Expenses</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" id="DevelopmentAwardsAndDeferredRevenue">
	  <link:definition>00000016 - Disclosure - Development Awards and Deferred Revenue</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxes" id="IncomeTaxes">
	  <link:definition>00000017 - Disclosure - Income Taxes</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommonStock" id="CommonStock">
	  <link:definition>00000018 - Disclosure - Common Stock</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions" id="StockOptions">
	  <link:definition>00000019 - Disclosure - Stock Options</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/Warrants" id="Warrants">
	  <link:definition>00000020 - Disclosure - Warrants</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" id="RelatedPartyTransactions">
	  <link:definition>00000021 - Disclosure - Related Party Transactions</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SubsequentEvents" id="SubsequentEvents">
	  <link:definition>00000022 - Disclosure - Subsequent Events</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" id="SignificantAccountingPoliciesPolicies">
	  <link:definition>00000023 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" id="SignificantAccountingPoliciesTables">
	  <link:definition>00000024 - Disclosure - Significant Accounting Policies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" id="PropertyAndEquipmentTables">
	  <link:definition>00000025 - Disclosure - Property and Equipment (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" id="CommitmentsAndContingenciesTables">
	  <link:definition>00000026 - Disclosure - Commitments and Contingencies (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/AccruedExpensesTables" id="AccruedExpensesTables">
	  <link:definition>00000027 - Disclosure - Accrued Expenses (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" id="DevelopmentAwardsAndDeferredRevenueTables">
	  <link:definition>00000028 - Disclosure - Development Awards and Deferred Revenue (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxesTables" id="IncomeTaxesTables">
	  <link:definition>00000029 - Disclosure - Income Taxes (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptionsTables" id="StockOptionsTables">
	  <link:definition>00000030 - Disclosure - Stock Options (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/WarrantsTables" id="WarrantsTables">
	  <link:definition>00000031 - Disclosure - Warrants (Tables)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" id="LiquidityDetailsNarrative">
	  <link:definition>00000032 - Disclosure - Liquidity (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" id="SignificantAccountingPoliciesDetailsNarrative">
	  <link:definition>00000033 - Disclosure - Significant Accounting Policies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" id="SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails">
	  <link:definition>00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" id="SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails">
	  <link:definition>00000035 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" id="SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails">
	  <link:definition>00000036 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" id="LicenseAgreementDetailsNarrative">
	  <link:definition>00000037 - Disclosure - License Agreement (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" id="PropertyAndEquipmentDetailsNarrative">
	  <link:definition>00000038 - Disclosure - Property and Equipment (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" id="PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails">
	  <link:definition>00000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" id="CommitmentsAndContingenciesDetailsNarrative">
	  <link:definition>00000040 - Disclosure - Commitments and Contingencies (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" id="CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails">
	  <link:definition>00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" id="CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails">
	  <link:definition>00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" id="NotesPayableDetailsNarrative">
	  <link:definition>00000043 - Disclosure - Notes Payable (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" id="AccruedExpenses-ScheduleOfAccruedExpensesDetails">
	  <link:definition>00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" id="DevelopmentAwardsAndDeferredRevenueDetailsNarrative">
	  <link:definition>00000045 - Disclosure - Development Awards and Deferred Revenue (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" id="DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails">
	  <link:definition>00000046 - Disclosure - Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" id="IncomeTaxesDetailsNarrative">
	  <link:definition>00000047 - Disclosure - Income Taxes (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" id="IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails">
	  <link:definition>00000048 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" id="IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails">
	  <link:definition>00000049 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" id="CommonStockDetailsNarrative">
	  <link:definition>00000050 - Disclosure - Common Stock (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" id="StockOptionsDetailsNarrative">
	  <link:definition>00000051 - Disclosure - Stock Options (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" id="StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails">
	  <link:definition>00000052 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" id="StockOptions-SummaryOfOptionActivityDetails">
	  <link:definition>00000053 - Disclosure - Stock Options - Summary of Option Activity (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" id="StockOptions-SummaryOfNon-vestedStockOptionsDetails">
	  <link:definition>00000054 - Disclosure - Stock Options - Summary of Non-Vested Stock Options (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" id="WarrantsDetailsNarrative">
	  <link:definition>00000055 - Disclosure - Warrants (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" id="Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails">
	  <link:definition>00000056 - Disclosure - Warrants - Schedule of Weighted Average Assumption of Warrants (Details)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" id="RelatedPartyTransactionsDetailsNarrative">
	  <link:definition>00000057 - Disclosure - Related Party Transactions (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:roleType roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" id="SubsequentEventsDetailsNarrative">
	  <link:definition>00000058 - Disclosure - Subsequent Events (Details Narrative)</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20181231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20181231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20181231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="crbp-20181231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Definition Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2018-01-31" schemaLocation="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-gaap/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2018-01-31" schemaLocation="http://xbrl.fasb.org/us-gaap/2018/elts/us-types-2018-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/non-numeric" schemaLocation="http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/numeric" schemaLocation="http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2017-01-31" schemaLocation="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd" />
    <import namespace="http://fasb.org/srt/2018-01-31" schemaLocation="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd" />
    <element id="CRBP_WarrantsTextBlock" name="WarrantsTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" name="PaymentDuePeriodAfterTheFirstCommercialSale" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IncreaseDecreaseInDeferredRent" name="IncreaseDecreaseInDeferredRent" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" name="WriteOffOfFullyAmortizedLeaseholdImprovements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock" name="DevelopmentAwardsAndDeferredRevenueTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" name="ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WarrantsIssuanceFairValue" name="WarrantsIssuanceFairValue" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones" name="DeferredRevenueBillingToUponAchievementOfMilestones" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FairValueOfWarrant" name="FairValueOfWarrant" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_RoyaltyPaymentSalesTarget" name="RoyaltyPaymentSalesTarget" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" name="AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" name="CashEquivalentsAndRestrictedCashMaturityPeriod" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CashHeldInSubsidiary" name="CashHeldInSubsidiary" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DeferredTaxAssetsValuationAllowancePercentage" name="DeferredTaxAssetsValuationAllowancePercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_PotentialMilestonePayments" name="PotentialMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AreaOfOfficeSpace" name="AreaOfOfficeSpace" nillable="true" xbrli:periodType="duration" type="num:areaItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_MarketableSecuritiesMaturityPeriod" name="MarketableSecuritiesMaturityPeriod" nillable="true" xbrli:periodType="duration" type="us-types:durationStringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" name="DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" nillable="true" xbrli:periodType="duration" type="xbrli:gYearItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LicenseAgreementTextBlock" name="LicenseAgreementTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UpfrontPaymentPercentage" name="UpfrontPaymentPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LeaseTerm" name="LeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CapitalLeaseTerm" name="CapitalLeaseTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_RoyaltyPaymentPercentage" name="RoyaltyPaymentPercentage" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" name="ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" name="SummaryOfNonvestedStockOptionsTableTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LeasesAndDeferredRentPolicyTextBlock" name="LeasesAndDeferredRentPolicyTextBlock" nillable="true" xbrli:periodType="duration" type="nonnum:textBlockItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LeaseTermDateDescription" name="LeaseTermDateDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WarrantsWeightedAverageRemainingContractualTerm" name="WarrantsWeightedAverageRemainingContractualTerm" nillable="true" xbrli:periodType="duration" type="xbrli:durationItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NumberOfWarrantsExercisableForCommonStock" name="NumberOfWarrantsExercisableForCommonStock" nillable="true" xbrli:periodType="duration" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CashCompensationAmount" name="CashCompensationAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" nillable="true" xbrli:periodType="duration" type="num:percentItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_RoyaltyTermDescription" name="RoyaltyTermDescription" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" name="AccruedClinicalOperationsAndTrialsCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccruedProductDevelopmentCostsCurrent" name="AccruedProductDevelopmentCostsCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CopierMachineMember" name="CopierMachineMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ThreePointTwoFivePercentNotesPayableMember" name="ThreePointTwoFivePercentNotesPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFourteenEquityIncentivePlanMember" name="TwoThousandFourteenEquityIncentivePlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ConditionOneMember" name="ConditionOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ComputerHardwareAndSoftwareMember" name="ComputerHardwareAndSoftwareMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OfficeFurnitureAndEquipmentMember" name="OfficeFurnitureAndEquipmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_StockOptionsMember" name="StockOptionsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" name="TwoThousandFifteenCFFTAwardArrangementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CorporatecreditCardsMember" name="CorporatecreditCardsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OrchestraMedicalVenturesLLCMember" name="OrchestraMedicalVenturesLLCMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandAndSixteenConsultingAgreementMember" name="TwoThousandAndSixteenConsultingAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" name="SeptemberTwoThousandAndSixteenAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoPointTwoFivePercentNotesPayableMember" name="TwoPointTwoFivePercentNotesPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SecuritiesPurchaseAgreementMember" name="SecuritiesPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InstitutionalAndAccreditedInvestorsMember" name="InstitutionalAndAccreditedInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SalesAgreementMember" name="SalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CantorFitzgeraldMember" name="CantorFitzgeraldMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_EvergreenProvisionMember" name="EvergreenProvisionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OralAntiinflammatoryDrugMember" name="OralAntiinflammatoryDrugMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UponCommercializationOfTheProductMember" name="UponCommercializationOfTheProductMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LenabasumMember" name="LenabasumMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UponReachingTheSalesTargetMember" name="UponReachingTheSalesTargetMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UponTransferSaleOrLicensingMember" name="UponTransferSaleOrLicensingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFourteenEquityCompensationPlanMember" name="TwoThousandFourteenEquityCompensationPlanMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InstitutionalInvestorsMember" name="InstitutionalInvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OctoberTwoThousandSeventeenOfferingMember" name="OctoberTwoThousandSeventeenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisFoundationTherapeuticsIncMember" name="CysticFibrosisFoundationTherapeuticsIncMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" name="AugustTwoThousandSeventeenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FirstYearMember" name="FirstYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SeventhYearMember" name="SeventhYearMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ThirdAnniversaryMember" name="ThirdAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FourthAnniversaryMember" name="FourthAnniversaryMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_EmployeesMember" name="EmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NonEmployeesMember" name="NonEmployeesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NonEmployeeStockOptionMember" name="NonEmployeeStockOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InvestorsMember" name="InvestorsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" name="FebruaryTwentyEightTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NorwoodMaMember" name="NorwoodMaMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AugustTwoThousandFifiteenAmendmentMember" name="AugustTwoThousandFifiteenAmendmentMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FederalMember" name="FederalMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_WarrantAgreementMember" name="WarrantAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AegisCapitalCorpAndOtherAffiliatesMember" name="AegisCapitalCorpAndOtherAffiliatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TrustMember" name="TrustMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AegisCapitalCorpMember" name="AegisCapitalCorpMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JBTOneZeroOneMember" name="JBTOneZeroOneMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" name="TaxCutAndJobsActOfTwoThousandSeventeenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_OrphanDrugCreditMember" name="OrphanDrugCreditMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CantorFitzgeraldAndCoMember" name="CantorFitzgeraldAndCoMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryFiveTwoThousandAndEighteenMember" name="JanuaryFiveTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisFoundationMember" name="CysticFibrosisFoundationMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" name="JanuaryTwentySixTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_PhaseTwoBClinicalTrialMember" name="PhaseTwoBClinicalTrialMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FebruaryTwoThousandAndEighteenMember" name="FebruaryTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryTwoThousandAndEighteenMember" name="JanuaryTwoThousandAndEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoPointThreeFivePercentNotesPayableMember" name="TwoPointThreeFivePercentNotesPayableMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AtTheMarketOfferingMember" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" name="CysticFibrosisProgramRelatedInvestmentAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CysticFibrosisFoundationWarrantsMember" name="CysticFibrosisFoundationWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InvestmentagreementMember" name="InvestmentagreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandAndEighteenCffAwardMember" name="TwoThousandAndEighteenCffAwardMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_StandbyLetterOfCreditMember" name="StandbyLetterOfCreditMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InsurancePolicyMember" name="InsurancePolicyMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InsurancePoliciesMember" name="InsurancePoliciesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_MassachusettMember" name="MassachusettMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_MassachusettsMember" name="MassachusettsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" name="JanuaryTwoThousandAndEighteenSalesAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InstitutionalInvestorMember" name="InstitutionalInvestorMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AmendedAndRestatedEmploymentAgreementsMember" name="AmendedAndRestatedEmploymentAgreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DrYuvalCohenMember" name="DrYuvalCohenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DrMarkTepperMember" name="DrMarkTepperMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DrBarbaraWhiteMember" name="DrBarbaraWhiteMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SeanMoranMember" name="SeanMoranMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TwoThousandFifteenCFFTAwardMember" name="TwoThousandFifteenCFFTAwardMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_ASC606Member" name="ASC606Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_AccountingStandardsUpdate605Member" name="AccountingStandardsUpdate605Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_MayTwoThousandEighteenMember" name="MayTwoThousandEighteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CapitalLeaseAgreementMember" name="CapitalLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_InvestmentagreementsMember" name="InvestmentagreementsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UnitedStatesMember" name="UnitedStatesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JenrinAgreementMember" name="JenrinAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LoanAgreementMember" name="LoanAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_KakenPharmaceuticalCoLtdMember" name="KakenPharmaceuticalCoLtdMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryTwoThousandAndNineteenOfferingMember" name="JanuaryTwoThousandAndNineteenOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_HigherRevenueMember" name="HigherRevenueMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LowerRevenueMember" name="LowerRevenueMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryOneTwoThousandAndNineteenMember" name="JanuaryOneTwoThousandAndNineteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" name="FebruaryTwoThousandAndNineteenLeaseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" name="FebruaryTwentySixTwoThousandAndNineteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_NewPremisesMember" name="NewPremisesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_TotalPremisesMember" name="TotalPremisesMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CollaborationAgreementMember" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_JanuaryOneTwoThousandandNiniteenMember" name="JanuaryOneTwoThousandandNiniteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CFFWarrantMember" name="CFFWarrantMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CollaborationandLicenseAgreementMember" name="CollaborationandLicenseAgreementMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_FirstQuarterofTwoThousandandNineteenMember" name="FirstQuarterofTwoThousandandNineteenMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_PublicOfferingMember" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_UnderwritersOptionMember" name="UnderwritersOptionMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_Remainder2018AndThroughFebruary82019Member" name="Remainder2018AndThroughFebruary82019Member" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_StockOptionAndWarrantsMember" name="StockOptionAndWarrantsMember" nillable="true" xbrli:periodType="duration" type="nonnum:domainItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DocumentAndEntityInformationAbstract" name="DocumentAndEntityInformationAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_LicenseAgreementAbstract" name="LicenseAgreementAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" name="DevelopmentAwardsAndDeferredRevenueAbstract" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_SignificantAccountingPoliciesTable" name="SignificantAccountingPoliciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_SignificantAccountingPoliciesLineItems" name="SignificantAccountingPoliciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_CommitmentAndContingenciesTable" name="CommitmentAndContingenciesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_CommitmentAndContingenciesLineItems" name="CommitmentAndContingenciesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_DevelopmentAwardTable" name="DevelopmentAwardTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_DevelopmentAwardLineItems" name="DevelopmentAwardLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
    <element id="CRBP_IncomeTaxesTable" name="IncomeTaxesTable" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" />
    <element id="CRBP_IncomeTaxesLineItems" name="IncomeTaxesLineItems" abstract="true" nillable="true" xbrli:periodType="duration" type="xbrli:stringItemType" substitutionGroup="xbrli:item" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>32
<FILENAME>crbp-20181231_cal.xml
<DESCRIPTION>XBRL CALCULATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20181231 10K FY DFN.xfr; Date: 2019%2D03%2D12T12:43:14Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80080001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:href="crbp-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheets" xlink:href="crbp-20181231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:href="crbp-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfOperations" xlink:href="crbp-20181231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:href="crbp-20181231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="crbp-20181231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:href="crbp-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NatureOfOperations" xlink:href="crbp-20181231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Liquidity" xlink:href="crbp-20181231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LicenseAgreement" xlink:href="crbp-20181231.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment" xlink:href="crbp-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayable" xlink:href="crbp-20181231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses" xlink:href="crbp-20181231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes" xlink:href="crbp-20181231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStock" xlink:href="crbp-20181231.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions" xlink:href="crbp-20181231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants" xlink:href="crbp-20181231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:href="crbp-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEvents" xlink:href="crbp-20181231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:href="crbp-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:href="crbp-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpensesTables" xlink:href="crbp-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesTables" xlink:href="crbp-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsTables" xlink:href="crbp-20181231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsTables" xlink:href="crbp-20181231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:href="crbp-20181231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" xlink:href="crbp-20181231.xsd#LicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="crbp-20181231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:href="crbp-20181231.xsd#PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="crbp-20181231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:href="crbp-20181231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:href="crbp-20181231.xsd#AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="crbp-20181231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:href="crbp-20181231.xsd#IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="crbp-20181231.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:href="crbp-20181231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:href="crbp-20181231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:href="crbp-20181231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:href="crbp-20181231.xsd#Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="crbp-20181231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="crbp-20181231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssetsCurrent" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAssets" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesCurrent" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilities" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapStockholdersEquity" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingExpenses" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapRevenues" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingIncomeLoss" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNonoperatingIncomeExpense" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetIncomeLoss" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Statements of Stockholders' Equity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncreaseDecreaseInDeferredRent" xlink:label="loc_CRBPIncreaseDecreaseInDeferredRent" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_CRBPIncreaseDecreaseInDeferredRent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:calculationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:calculationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:calculationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:calculationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:calculationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" weight="-1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" weight="1" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NatureOfOperations" xlink:title="00000008 - Disclosure - Nature of Operations" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LicenseAgreement" xlink:title="00000011 - Disclosure - License Agreement" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayable" xlink:title="00000014 - Disclosure - Notes Payable" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses" xlink:title="00000015 - Disclosure - Accrued Expenses" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" xlink:title="00000016 - Disclosure - Development Awards and Deferred Revenue" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income Taxes" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStock" xlink:title="00000018 - Disclosure - Common Stock" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions" xlink:title="00000019 - Disclosure - Stock Options" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants" xlink:title="00000020 - Disclosure - Warrants" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:title="00000021 - Disclosure - Related Party Transactions" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpensesTables" xlink:title="00000027 - Disclosure - Accrued Expenses (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" xlink:title="00000028 - Disclosure - Development Awards and Deferred Revenue (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsTables" xlink:title="00000030 - Disclosure - Stock Options (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsTables" xlink:title="00000031 - Disclosure - Warrants (Tables)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Liquidity (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - Significant Accounting Policies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapCash" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" xlink:title="00000037 - Disclosure - License Agreement (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000038 - Disclosure - Property and Equipment (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:title="00000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - Commitments and Contingencies (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:title="00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:title="00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000043 - Disclosure - Notes Payable (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:title="00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" xlink:label="loc_CRBPAccruedClinicalOperationsAndTrialsCostsCurrent" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CRBPAccruedClinicalOperationsAndTrialsCostsCurrent" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccruedProductDevelopmentCostsCurrent" xlink:label="loc_CRBPAccruedProductDevelopmentCostsCurrent" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapAccruedLiabilitiesCurrent" xlink:to="loc_CRBPAccruedProductDevelopmentCostsCurrent" xlink:type="arc" weight="1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:title="00000045 - Disclosure - Development Awards and Deferred Revenue (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:title="00000046 - Disclosure - Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:title="00000048 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:calculationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:calculationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:calculationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:calculationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsGross" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:calculationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" weight="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:calculationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaapDeferredTaxAssetsNet" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" weight="-1" />
    </link:calculationLink>
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000049 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:title="00000050 - Disclosure - Common Stock (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:title="00000051 - Disclosure - Stock Options (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:title="00000052 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:title="00000053 - Disclosure - Stock Options - Summary of Option Activity (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:title="00000054 - Disclosure - Stock Options - Summary of Non-Vested Stock Options (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:title="00000055 - Disclosure - Warrants (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:title="00000056 - Disclosure - Warrants - Schedule of Weighted Average Assumption of Warrants (Details)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000057 - Disclosure - Related Party Transactions (Details Narrative)" />
    <link:calculationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - Subsequent Events (Details Narrative)" />
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>33
<FILENAME>crbp-20181231_def.xml
<DESCRIPTION>XBRL DEFINITION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20181231 10K FY DFN.xfr; Date: 2019%2D03%2D12T12:43:14Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80080001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:href="crbp-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheets" xlink:href="crbp-20181231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:href="crbp-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfOperations" xlink:href="crbp-20181231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:href="crbp-20181231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="crbp-20181231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:href="crbp-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NatureOfOperations" xlink:href="crbp-20181231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Liquidity" xlink:href="crbp-20181231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LicenseAgreement" xlink:href="crbp-20181231.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment" xlink:href="crbp-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayable" xlink:href="crbp-20181231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses" xlink:href="crbp-20181231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes" xlink:href="crbp-20181231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStock" xlink:href="crbp-20181231.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions" xlink:href="crbp-20181231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants" xlink:href="crbp-20181231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:href="crbp-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEvents" xlink:href="crbp-20181231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:href="crbp-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:href="crbp-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpensesTables" xlink:href="crbp-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesTables" xlink:href="crbp-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsTables" xlink:href="crbp-20181231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsTables" xlink:href="crbp-20181231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:href="crbp-20181231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" xlink:href="crbp-20181231.xsd#LicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="crbp-20181231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:href="crbp-20181231.xsd#PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="crbp-20181231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:href="crbp-20181231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:href="crbp-20181231.xsd#AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="crbp-20181231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:href="crbp-20181231.xsd#IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="crbp-20181231.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:href="crbp-20181231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:href="crbp-20181231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:href="crbp-20181231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:href="crbp-20181231.xsd#Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="crbp-20181231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="crbp-20181231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" arcroleURI="http://xbrl.org/int/dim/arcrole/all" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#notAll" arcroleURI="http://xbrl.org/int/dim/arcrole/notAll" />
    <link:arcroleRef xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Statements of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapCommonStockMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapRetainedEarningsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_50" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised_50" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_50" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther_50" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther_50" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_50" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss_50" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NatureOfOperations" xlink:title="00000008 - Disclosure - Nature of Operations" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LicenseAgreement" xlink:title="00000011 - Disclosure - License Agreement" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayable" xlink:title="00000014 - Disclosure - Notes Payable" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses" xlink:title="00000015 - Disclosure - Accrued Expenses" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" xlink:title="00000016 - Disclosure - Development Awards and Deferred Revenue" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income Taxes" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStock" xlink:title="00000018 - Disclosure - Common Stock" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions" xlink:title="00000019 - Disclosure - Stock Options" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants" xlink:title="00000020 - Disclosure - Warrants" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:title="00000021 - Disclosure - Related Party Transactions" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpensesTables" xlink:title="00000027 - Disclosure - Accrued Expenses (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" xlink:title="00000028 - Disclosure - Development Awards and Deferred Revenue (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsTables" xlink:title="00000030 - Disclosure - Stock Options (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsTables" xlink:title="00000031 - Disclosure - Warrants (Tables)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="loc_CRBPKakenPharmaceuticalCoLtdMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPKakenPharmaceuticalCoLtdMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationMember" xlink:label="loc_CRBPCysticFibrosisFoundationMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPCysticFibrosisFoundationMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndNineteenOfferingMember" xlink:label="loc_CRBPJanuaryTwoThousandAndNineteenOfferingMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPJanuaryTwoThousandAndNineteenOfferingMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit_50" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue_50" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties_50" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="loc_us-gaapProceedsFromRoyaltiesReceived_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRoyaltiesReceived_50" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UpfrontPaymentPercentage" xlink:label="loc_CRBPUpfrontPaymentPercentage_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPUpfrontPaymentPercentage_50" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_50" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SignificantAccountingPoliciesLineItems" xlink:label="loc_CRBPSignificantAccountingPoliciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SignificantAccountingPoliciesTable" xlink:label="loc_CRBPSignificantAccountingPoliciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPSignificantAccountingPoliciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CorporatecreditCardsMember" xlink:label="loc_CRBPCorporatecreditCardsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPCorporatecreditCardsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StandbyLetterOfCreditMember" xlink:label="loc_CRBPStandbyLetterOfCreditMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPStandbyLetterOfCreditMember_50" xlink:type="arc" order="51" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_srtStatementGeographicalAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="loc_countryGB_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryGB_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="loc_CRBPTwoThousandAndEighteenCffAwardMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPTwoThousandAndEighteenCffAwardMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryOneTwoThousandAndNineteenMember" xlink:label="loc_CRBPJanuaryOneTwoThousandAndNineteenMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryOneTwoThousandAndNineteenMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ASC606Member" xlink:label="loc_CRBPASC606Member_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_CRBPASC606Member_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_HigherRevenueMember" xlink:label="loc_CRBPHigherRevenueMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:to="loc_CRBPHigherRevenueMember_140" xlink:type="arc" order="142" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LowerRevenueMember" xlink:label="loc_CRBPLowerRevenueMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:to="loc_CRBPLowerRevenueMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod_190" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MarketableSecuritiesMaturityPeriod" xlink:label="loc_CRBPMarketableSecuritiesMaturityPeriod_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPMarketableSecuritiesMaturityPeriod_190" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapMarketableSecurities_190" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents_190" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashHeldInSubsidiary" xlink:label="loc_CRBPCashHeldInSubsidiary_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPCashHeldInSubsidiary_190" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife_190" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments_190" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapCash_190" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent_190" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOtherAssets_190" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_190" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage_190" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_190" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges_190" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapRevenues_190" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability_190" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset_190" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset_190" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StockOptionsMember" xlink:label="loc_CRBPStockOptionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CRBPStockOptionsMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_70" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" xlink:title="00000037 - Disclosure - License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JenrinAgreementMember" xlink:label="loc_CRBPJenrinAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPJenrinAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1_40" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PotentialMilestonePayments" xlink:label="loc_CRBPPotentialMilestonePayments_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPPotentialMilestonePayments_40" xlink:type="arc" order="1" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000038 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization_70" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" xlink:label="loc_CRBPWriteOffOfFullyAmortizedLeaseholdImprovements_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPWriteOffOfFullyAmortizedLeaseholdImprovements_70" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="loc_CRBPAreaOfOfficeSpace_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPAreaOfOfficeSpace_70" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_70" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeaseTerm" xlink:label="loc_CRBPLeaseTerm_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPLeaseTerm_70" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:title="00000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross_110" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_110" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet_110" xlink:type="arc" order="3" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPCommitmentAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:label="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember_130" xlink:type="arc" order="131" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CapitalLeaseAgreementMember" xlink:label="loc_CRBPCapitalLeaseAgreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCapitalLeaseAgreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FirstYearMember" xlink:label="loc_CRBPFirstYearMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFirstYearMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeventhYearMember" xlink:label="loc_CRBPSeventhYearMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPSeventhYearMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ThirdAnniversaryMember" xlink:label="loc_CRBPThirdAnniversaryMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPThirdAnniversaryMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FourthAnniversaryMember" xlink:label="loc_CRBPFourthAnniversaryMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFourthAnniversaryMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" xlink:label="loc_CRBPFebruaryTwentySixTwoThousandAndNineteenMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFebruaryTwentySixTwoThousandAndNineteenMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaapLeaseArrangementTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapLeaseArrangementTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NewPremisesMember" xlink:label="loc_CRBPNewPremisesMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPNewPremisesMember_130" xlink:type="arc" order="133" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TotalPremisesMember" xlink:label="loc_CRBPTotalPremisesMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPTotalPremisesMember_140" xlink:type="arc" order="143" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="loc_CRBPAreaOfOfficeSpace_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPAreaOfOfficeSpace_170" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1_170" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount_170" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense_170" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseholdImprovementsGross_170" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLineOfCredit_170" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapUnsecuredDebt_170" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapInterestExpense_170" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeaseTermDateDescription" xlink:label="loc_CRBPLeaseTermDateDescription_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPLeaseTermDateDescription_170" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CapitalLeaseTerm" xlink:label="loc_CRBPCapitalLeaseTerm_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPCapitalLeaseTerm_170" xlink:type="arc" order="10" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:title="00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears_30" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears_30" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter_30" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue_30" xlink:type="arc" order="7" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:title="00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPCommitmentAndContingenciesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue_20" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaapCapitalLeaseObligations_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligations_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000043 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LoanAgreementMember" xlink:label="loc_CRBPLoanAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPLoanAgreementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InsurancePolicyMember" xlink:label="loc_CRBPInsurancePolicyMember_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CRBPInsurancePolicyMember_60" xlink:type="arc" order="61" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreationDateAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable_90" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment_90" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm_90" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage_90" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent_90" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:title="00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:title="00000045 - Disclosure - Development Awards and Deferred Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardLineItems" xlink:label="loc_CRBPDevelopmentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardTable" xlink:label="loc_CRBPDevelopmentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPDevelopmentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:label="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:label="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CollaborationAgreementMember" xlink:label="loc_CRBPCollaborationAgreementMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCollaborationAgreementMember_160" xlink:type="arc" order="162" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OralAntiinflammatoryDrugMember" xlink:label="loc_CRBPOralAntiinflammatoryDrugMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPOralAntiinflammatoryDrugMember_10" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LenabasumMember" xlink:label="loc_CRBPLenabasumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPLenabasumMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapStatementScenarioAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponCommercializationOfTheProductMember" xlink:label="loc_CRBPUponCommercializationOfTheProductMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponCommercializationOfTheProductMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponReachingTheSalesTargetMember" xlink:label="loc_CRBPUponReachingTheSalesTargetMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponReachingTheSalesTargetMember_100" xlink:type="arc" order="102" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponTransferSaleOrLicensingMember" xlink:label="loc_CRBPUponTransferSaleOrLicensingMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponTransferSaleOrLicensingMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="loc_CRBPPhaseTwoBClinicalTrialMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPPhaseTwoBClinicalTrialMember_150" xlink:type="arc" order="152" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationWarrantsMember" xlink:label="loc_CRBPCysticFibrosisFoundationWarrantsMember_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPCysticFibrosisFoundationWarrantsMember_180" xlink:type="arc" order="181" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationMember" xlink:label="loc_CRBPCysticFibrosisFoundationMember_160" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPCysticFibrosisFoundationMember_160" xlink:type="arc" order="161" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="loc_CRBPKakenPharmaceuticalCoLtdMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPKakenPharmaceuticalCoLtdMember_170" xlink:type="arc" order="173" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="loc_CRBPTwoThousandAndEighteenCffAwardMember_170" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPTwoThousandAndEighteenCffAwardMember_170" xlink:type="arc" order="172" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="loc_us-gaapGainContingencyUnrecordedAmount_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapGainContingencyUnrecordedAmount_260" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_260" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenues_260" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRoyaltyExpense_260" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:label="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale_260" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyPaymentSalesTarget" xlink:label="loc_CRBPRoyaltyPaymentSalesTarget_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPRoyaltyPaymentSalesTarget_260" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyPaymentPercentage" xlink:label="loc_CRBPRoyaltyPaymentPercentage_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPRoyaltyPaymentPercentage_260" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="loc_us-gaapProceedsFromRoyaltiesReceived_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapProceedsFromRoyaltiesReceived_260" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties_260" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_260" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_260" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_260" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_260" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" xlink:label="loc_CRBPReclassifiedToContractAssetAndClassifiedInPrepaidExpenses_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPReclassifiedToContractAssetAndClassifiedInPrepaidExpenses_260" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_260" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued_260" xlink:type="arc" order="14" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:title="00000046 - Disclosure - Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncomeTaxesLineItems" xlink:label="loc_CRBPIncomeTaxesLineItems" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncomeTaxesTable" xlink:label="loc_CRBPIncomeTaxesTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_CRBPIncomeTaxesTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FederalMember" xlink:label="loc_CRBPFederalMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPFederalMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MassachusettMember" xlink:label="loc_CRBPMassachusettMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPMassachusettMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:label="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OrphanDrugCreditMember" xlink:label="loc_CRBPOrphanDrugCreditMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_CRBPOrphanDrugCreditMember_90" xlink:type="arc" order="92" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_100" xlink:type="arc" order="103" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards_120" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:label="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_120" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_120" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch_120" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount_120" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent_120" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription_120" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_120" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations_120" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit_120" xlink:type="arc" order="9" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:title="00000048 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000049 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:title="00000050 - Disclosure - Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_CRBPSecuritiesPurchaseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSecuritiesPurchaseAgreementMember_20" xlink:type="arc" order="21" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" xlink:label="loc_CRBPJanuaryTwoThousandAndEighteenSalesAgreementMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPJanuaryTwoThousandAndEighteenSalesAgreementMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SalesAgreementMember" xlink:label="loc_CRBPSalesAgreementMember_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSalesAgreementMember_100" xlink:type="arc" order="101" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:label="loc_CRBPInstitutionalAndAccreditedInvestorsMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPInstitutionalAndAccreditedInvestorsMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalInvestorMember" xlink:label="loc_CRBPInstitutionalInvestorMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPInstitutionalInvestorMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalInvestorsMember" xlink:label="loc_CRBPInstitutionalInvestorsMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPInstitutionalInvestorsMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AtTheMarketOfferingMember" xlink:label="loc_CRBPAtTheMarketOfferingMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPAtTheMarketOfferingMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_Remainder2018AndThroughFebruary82019Member" xlink:label="loc_CRBPRemainder2018AndThroughFebruary82019Member_90" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPRemainder2018AndThroughFebruary82019Member_90" xlink:type="arc" order="93" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_110" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember_110" xlink:type="arc" order="111" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StockOptionAndWarrantsMember" xlink:label="loc_CRBPStockOptionAndWarrantsMember_150" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CRBPStockOptionAndWarrantsMember_150" xlink:type="arc" order="151" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_120" xlink:type="arc" order="121" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized_180" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised_180" xlink:type="arc" order="12" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:title="00000051 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryOneTwoThousandandNiniteenMember" xlink:label="loc_CRBPJanuaryOneTwoThousandandNiniteenMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CRBPJanuaryOneTwoThousandandNiniteenMember_40" xlink:type="arc" order="43" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EmployeesMember" xlink:label="loc_CRBPEmployeesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPEmployeesMember_70" xlink:type="arc" order="71" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NonEmployeesMember" xlink:label="loc_CRBPNonEmployeesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPNonEmployeesMember_80" xlink:type="arc" order="81" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember_120" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember_120" xlink:type="arc" order="122" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember_130" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember_130" xlink:type="arc" order="132" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_140" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapStockOptionMember_140" xlink:type="arc" order="141" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_180" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_180" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_180" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_180" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_180" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_180" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation_180" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_180" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_180" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_180" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_180" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_180" xlink:type="arc" order="12" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_180" xlink:type="arc" order="13" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_180" xlink:type="arc" order="14" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_180" xlink:type="arc" order="15" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_180" xlink:type="arc" order="16" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:title="00000052 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_30" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_30" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_30" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_30" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_30" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:title="00000053 - Disclosure - Stock Options - Summary of Option Activity (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:title="00000054 - Disclosure - Stock Options - Summary of Non-Vested Stock Options (Details)" />
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:title="00000055 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember_30" xlink:type="arc" order="31" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CFFWarrantMember" xlink:label="loc_CRBPCFFWarrantMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CRBPCFFWarrantMember_30" xlink:type="arc" order="32" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_80" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises_80" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_80" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:label="loc_CRBPWarrantsWeightedAverageRemainingContractualTerm_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CRBPWarrantsWeightedAverageRemainingContractualTerm_80" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NumberOfWarrantsExercisableForCommonStock" xlink:label="loc_CRBPNumberOfWarrantsExercisableForCommonStock_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CRBPNumberOfWarrantsExercisableForCommonStock_80" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate_80" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants_80" xlink:type="arc" order="6" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:title="00000056 - Disclosure - Warrants - Schedule of Weighted Average Assumption of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_20" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_20" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_20" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_20" xlink:type="arc" order="4" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000057 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OrchestraMedicalVenturesLLCMember" xlink:label="loc_CRBPOrchestraMedicalVenturesLLCMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPOrchestraMedicalVenturesLLCMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:label="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember_10" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapStockOptionMember_40" xlink:type="arc" order="41" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate_60" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashCompensationAmount" xlink:label="loc_CRBPCashCompensationAmount_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CRBPCashCompensationAmount_60" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_60" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_60" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_60" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense_60" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense_60" xlink:type="arc" order="5" />
    </link:definitionLink>
    <link:definitionLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStatementTable" xlink:type="arc" order="10" xbrldt:closed="true" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember_0" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember_0" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="loc_CRBPKakenPharmaceuticalCoLtdMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPKakenPharmaceuticalCoLtdMember_20" xlink:type="arc" order="23" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember_0" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CollaborationandLicenseAgreementMember" xlink:label="loc_CRBPCollaborationandLicenseAgreementMember_20" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCollaborationandLicenseAgreementMember_20" xlink:type="arc" order="22" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FirstQuarterofTwoThousandandNineteenMember" xlink:label="loc_CRBPFirstQuarterofTwoThousandandNineteenMember_30" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CRBPFirstQuarterofTwoThousandandNineteenMember_30" xlink:type="arc" order="33" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PublicOfferingMember" xlink:label="loc_CRBPPublicOfferingMember_40" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPPublicOfferingMember_40" xlink:type="arc" order="42" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapIPOMember_50" xlink:type="arc" order="52" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UnderwritersOptionMember" xlink:label="loc_CRBPUnderwritersOptionMember_50" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CRBPUnderwritersOptionMember_50" xlink:type="arc" order="53" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaapLeaseArrangementTypeAxis" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseArrangementTypeAxis" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain" xlink:type="arc" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain_10" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xbrldt:contextElement="segment" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain_10" xlink:type="arc" order="30" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NewPremisesMember" xlink:label="loc_CRBPNewPremisesMember_70" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPNewPremisesMember_70" xlink:type="arc" order="72" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TotalPremisesMember" xlink:label="loc_CRBPTotalPremisesMember_80" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPTotalPremisesMember_80" xlink:type="arc" order="82" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_100" xlink:type="arc" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_100" xlink:type="arc" order="1" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_100" xlink:type="arc" order="2" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance_100" xlink:type="arc" order="3" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_100" xlink:type="arc" order="4" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties_100" xlink:type="arc" order="5" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction_100" xlink:type="arc" order="6" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyTermDescription" xlink:label="loc_CRBPRoyaltyTermDescription_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPRoyaltyTermDescription_100" xlink:type="arc" order="7" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction_100" xlink:type="arc" order="8" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare_100" xlink:type="arc" order="9" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock_100" xlink:type="arc" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_100" xlink:type="arc" order="11" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand_100" />
      <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand_100" xlink:type="arc" order="12" />
    </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>34
<FILENAME>crbp-20181231_lab.xml
<DESCRIPTION>XBRL LABEL FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20181231 10K FY DFN.xfr; Date: 2019%2D03%2D12T12:43:14Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80080001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:to="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OptionIndexedToIssuersEquityTypeAxis_lbl" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US">Employee Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share By Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantMember_lbl" xml:lang="en-US">Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US">Property Plant And Equipment By Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US">Equity Components [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US">Common Stock [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US">Accumulated Deficit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StockOptionsMember" xlink:label="CRBP_StockOptionsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StockOptionsMember" xlink:to="CRBP_StockOptionsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_StockOptionsMember_lbl" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="CRBP_OfficeFurnitureAndEquipmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OfficeFurnitureAndEquipmentMember" xlink:to="CRBP_OfficeFurnitureAndEquipmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OfficeFurnitureAndEquipmentMember_lbl" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="CRBP_ComputerHardwareAndSoftwareMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ComputerHardwareAndSoftwareMember" xlink:to="CRBP_ComputerHardwareAndSoftwareMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ComputerHardwareAndSoftwareMember_lbl" xml:lang="en-US">Computer Hardware and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CopierMachineMember" xlink:label="CRBP_CopierMachineMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CopierMachineMember" xlink:to="CRBP_CopierMachineMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CopierMachineMember_lbl" xml:lang="en-US">Copier Machine [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_lbl" xml:lang="en-US">Related Party Transactions By Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OrchestraMedicalVenturesLLCMember" xlink:label="CRBP_OrchestraMedicalVenturesLLCMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrchestraMedicalVenturesLLCMember" xlink:to="CRBP_OrchestraMedicalVenturesLLCMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OrchestraMedicalVenturesLLCMember_lbl" xml:lang="en-US">Orchestra Medical Ventures LLC [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TypeOfArrangementAxis" xlink:to="us-gaap_TypeOfArrangementAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TypeOfArrangementAxis_lbl" xml:lang="en-US">Type of Arrangement and Non-arrangement Transactions [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:label="CRBP_TwoThousandAndSixteenConsultingAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:to="CRBP_TwoThousandAndSixteenConsultingAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandAndSixteenConsultingAgreementMember_lbl" xml:lang="en-US">2016 Consulting Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SecuritiesPurchaseAgreementMember" xlink:label="CRBP_SecuritiesPurchaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SecuritiesPurchaseAgreementMember" xlink:to="CRBP_SecuritiesPurchaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SecuritiesPurchaseAgreementMember_lbl" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="us-gaap_RelatedPartyTransactionAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionAxis" xlink:to="us-gaap_RelatedPartyTransactionAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionAxis_lbl" xml:lang="en-US">Related Party Transaction [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:label="CRBP_InstitutionalAndAccreditedInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:to="CRBP_InstitutionalAndAccreditedInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InstitutionalAndAccreditedInvestorsMember_lbl" xml:lang="en-US">Institutional and Accredited Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:label="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:to="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_lbl" xml:lang="en-US">2015 CFFT Award Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US">Range [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US">Maximum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="us-gaap_StatementScenarioAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementScenarioAxis" xlink:to="us-gaap_StatementScenarioAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementScenarioAxis_lbl" xml:lang="en-US">Scenario [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponCommercializationOfTheProductMember" xlink:label="CRBP_UponCommercializationOfTheProductMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponCommercializationOfTheProductMember" xlink:to="CRBP_UponCommercializationOfTheProductMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UponCommercializationOfTheProductMember_lbl" xml:lang="en-US">Upon Commercialization of the Product [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_lbl" xml:lang="en-US">Capitalized Costs Of Unproved Properties Excluded From Amortization By Property Or Project [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LenabasumMember" xlink:label="CRBP_LenabasumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LenabasumMember" xlink:to="CRBP_LenabasumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LenabasumMember_lbl" xml:lang="en-US">Lenabasum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponReachingTheSalesTargetMember" xlink:label="CRBP_UponReachingTheSalesTargetMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponReachingTheSalesTargetMember" xlink:to="CRBP_UponReachingTheSalesTargetMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UponReachingTheSalesTargetMember_lbl" xml:lang="en-US">Upon Reaching the Sales Target [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponTransferSaleOrLicensingMember" xlink:label="CRBP_UponTransferSaleOrLicensingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponTransferSaleOrLicensingMember" xlink:to="CRBP_UponTransferSaleOrLicensingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UponTransferSaleOrLicensingMember_lbl" xml:lang="en-US">Upon Transfer Sale or Licensing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="us-gaap_DebtInstrumentAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentAxis" xlink:to="us-gaap_DebtInstrumentAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentAxis_lbl" xml:lang="en-US">Debt Instrument [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CorporatecreditCardsMember" xlink:label="CRBP_CorporatecreditCardsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CorporatecreditCardsMember" xlink:to="CRBP_CorporatecreditCardsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CorporatecreditCardsMember_lbl" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US">Construction in Progress [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SalesAgreementMember" xlink:label="CRBP_SalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SalesAgreementMember" xlink:to="CRBP_SalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SalesAgreementMember_lbl" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:to="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_lbl" xml:lang="en-US">August 2017 Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardTypeAxis_lbl" xml:lang="en-US">Award Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FirstYearMember" xlink:label="CRBP_FirstYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FirstYearMember" xlink:to="CRBP_FirstYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FirstYearMember_lbl" xml:lang="en-US">First Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeventhYearMember" xlink:label="CRBP_SeventhYearMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeventhYearMember" xlink:to="CRBP_SeventhYearMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SeventhYearMember_lbl" xml:lang="en-US">Seventh Year [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ThirdAnniversaryMember" xlink:label="CRBP_ThirdAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThirdAnniversaryMember" xlink:to="CRBP_ThirdAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ThirdAnniversaryMember_lbl" xml:lang="en-US">Third Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FourthAnniversaryMember" xlink:label="CRBP_FourthAnniversaryMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FourthAnniversaryMember" xlink:to="CRBP_FourthAnniversaryMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FourthAnniversaryMember_lbl" xml:lang="en-US">Fourth Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalInvestorsMember" xlink:label="CRBP_InstitutionalInvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalInvestorsMember" xlink:to="CRBP_InstitutionalInvestorsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InstitutionalInvestorsMember_lbl" xml:lang="en-US">Institutional Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:label="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:to="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_lbl" xml:lang="en-US">September 2016 Amendment [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxAuthorityAxis_lbl" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:label="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:to="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_lbl" xml:lang="en-US">The Tax Cut and Jobs Act of 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US">Income Statement Location [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="us-gaap_InterestExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpenseMember" xlink:to="us-gaap_InterestExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpenseMember_lbl" xml:lang="en-US">Interest Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="us-gaap_TaxCreditCarryforwardAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TaxCreditCarryforwardAxis" xlink:to="us-gaap_TaxCreditCarryforwardAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TaxCreditCarryforwardAxis_lbl" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OrphanDrugCreditMember" xlink:label="CRBP_OrphanDrugCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrphanDrugCreditMember" xlink:to="CRBP_OrphanDrugCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OrphanDrugCreditMember_lbl" xml:lang="en-US">Orphan Drug Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US">Minimum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LegalEntityAxis_lbl" xml:lang="en-US">Legal Entity [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EvergreenProvisionMember" xlink:label="CRBP_EvergreenProvisionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EvergreenProvisionMember" xlink:to="CRBP_EvergreenProvisionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_EvergreenProvisionMember_lbl" xml:lang="en-US">Evergreen Provision [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US">Plan Name [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="CRBP_TwoThousandFourteenEquityIncentivePlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="CRBP_TwoThousandFourteenEquityIncentivePlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandFourteenEquityIncentivePlanMember_lbl" xml:lang="en-US">2014 Equity Incentive Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NonEmployeesMember" xlink:label="CRBP_NonEmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NonEmployeesMember" xlink:to="CRBP_NonEmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_NonEmployeesMember_lbl" xml:lang="en-US">Non-Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="us-gaap_StockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockOptionMember_lbl" xml:lang="en-US">Stock Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AtTheMarketOfferingMember" xlink:label="CRBP_AtTheMarketOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AtTheMarketOfferingMember" xlink:to="CRBP_AtTheMarketOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AtTheMarketOfferingMember_lbl" xml:lang="en-US">At the Market Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:label="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:to="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_lbl" xml:lang="en-US">Cystic Fibrosis Program Related Investment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationWarrantsMember" xlink:label="CRBP_CysticFibrosisFoundationWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationWarrantsMember" xlink:to="CRBP_CysticFibrosisFoundationWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CysticFibrosisFoundationWarrantsMember_lbl" xml:lang="en-US">Cystic Fibrosis Foundation Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="CRBP_InvestmentagreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestmentagreementMember" xlink:to="CRBP_InvestmentagreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InvestmentagreementMember_lbl" xml:lang="en-US">Investment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StandbyLetterOfCreditMember" xlink:label="CRBP_StandbyLetterOfCreditMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StandbyLetterOfCreditMember" xlink:to="CRBP_StandbyLetterOfCreditMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_StandbyLetterOfCreditMember_lbl" xml:lang="en-US">Stand-by Letter of Credit [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="srt_ProductOrServiceAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_ProductOrServiceAxis_lbl" xml:lang="en-US">Products and Services [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InsurancePolicyMember" xlink:label="CRBP_InsurancePolicyMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InsurancePolicyMember" xlink:to="CRBP_InsurancePolicyMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InsurancePolicyMember_lbl" xml:lang="en-US">Insurance Policy [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MassachusettMember" xlink:label="CRBP_MassachusettMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MassachusettMember" xlink:to="CRBP_MassachusettMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_MassachusettMember_lbl" xml:lang="en-US">Massachusett [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" xlink:label="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" xlink:to="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember_lbl" xml:lang="en-US">January 2018 Sales Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalInvestorMember" xlink:label="CRBP_InstitutionalInvestorMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalInvestorMember" xlink:to="CRBP_InstitutionalInvestorMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_InstitutionalInvestorMember_lbl" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:to="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_lbl" xml:lang="en-US">Adjustments for New Accounting Pronouncements [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ASC606Member" xlink:label="CRBP_ASC606Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ASC606Member" xlink:to="CRBP_ASC606Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ASC606Member_lbl" xml:lang="en-US">ASC 606 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="CRBP_TwoThousandAndEighteenCffAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndEighteenCffAwardMember" xlink:to="CRBP_TwoThousandAndEighteenCffAwardMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandAndEighteenCffAwardMember_lbl" xml:lang="en-US">2018 CFF Award [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CapitalLeaseAgreementMember" xlink:label="CRBP_CapitalLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CapitalLeaseAgreementMember" xlink:to="CRBP_CapitalLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CapitalLeaseAgreementMember_lbl" xml:lang="en-US">Capital Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EmployeesMember" xlink:label="CRBP_EmployeesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EmployeesMember" xlink:to="CRBP_EmployeesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_EmployeesMember_lbl" xml:lang="en-US">Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="srt_StatementGeographicalAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_StatementGeographicalAxis_lbl" xml:lang="en-US">Statement Geographical [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="country_GB" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="country_GB" xlink:to="country_GB_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="country_GB_lbl" xml:lang="en-US">United Kingdom [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JenrinAgreementMember" xlink:label="CRBP_JenrinAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JenrinAgreementMember" xlink:to="CRBP_JenrinAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JenrinAgreementMember_lbl" xml:lang="en-US">Jenrin Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US">Research and Development Expense [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LoanAgreementMember" xlink:label="CRBP_LoanAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LoanAgreementMember" xlink:to="CRBP_LoanAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LoanAgreementMember_lbl" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="CRBP_KakenPharmaceuticalCoLtdMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_KakenPharmaceuticalCoLtdMember" xlink:to="CRBP_KakenPharmaceuticalCoLtdMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_KakenPharmaceuticalCoLtdMember_lbl" xml:lang="en-US">Kaken Pharmaceutical Co., Ltd. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationMember" xlink:label="CRBP_CysticFibrosisFoundationMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationMember" xlink:to="CRBP_CysticFibrosisFoundationMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CysticFibrosisFoundationMember_lbl" xml:lang="en-US">Cystic Fibrosis Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndNineteenOfferingMember" xlink:label="CRBP_JanuaryTwoThousandAndNineteenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndNineteenOfferingMember" xlink:to="CRBP_JanuaryTwoThousandAndNineteenOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryTwoThousandAndNineteenOfferingMember_lbl" xml:lang="en-US">January 2019 Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRevenueArrangementTypeAxis" xlink:to="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRevenueArrangementTypeAxis_lbl" xml:lang="en-US">Deferred Revenue Arrangement Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_HigherRevenueMember" xlink:label="CRBP_HigherRevenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_HigherRevenueMember" xlink:to="CRBP_HigherRevenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_HigherRevenueMember_lbl" xml:lang="en-US">Higher Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LowerRevenueMember" xlink:label="CRBP_LowerRevenueMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LowerRevenueMember" xlink:to="CRBP_LowerRevenueMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LowerRevenueMember_lbl" xml:lang="en-US">Lower Revenue [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryOneTwoThousandAndNineteenMember" xlink:label="CRBP_JanuaryOneTwoThousandAndNineteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryOneTwoThousandAndNineteenMember" xlink:to="CRBP_JanuaryOneTwoThousandAndNineteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryOneTwoThousandAndNineteenMember_lbl" xml:lang="en-US">January 01, 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:to="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember_lbl" xml:lang="en-US">February 2019 Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CollaborationAgreementMember" xlink:label="CRBP_CollaborationAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CollaborationAgreementMember" xlink:to="CRBP_CollaborationAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CollaborationAgreementMember_lbl" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FederalMember" xlink:label="CRBP_FederalMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FederalMember" xlink:to="CRBP_FederalMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FederalMember_lbl" xml:lang="en-US">Federal [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" xlink:label="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" xlink:to="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember_lbl" xml:lang="en-US">February 26, 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="us-gaap_LeaseArrangementTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseArrangementTypeAxis" xlink:to="us-gaap_LeaseArrangementTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseArrangementTypeAxis_lbl" xml:lang="en-US">Lease Arrangement, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NewPremisesMember" xlink:label="CRBP_NewPremisesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NewPremisesMember" xlink:to="CRBP_NewPremisesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_NewPremisesMember_lbl" xml:lang="en-US">New Premises [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TotalPremisesMember" xlink:label="CRBP_TotalPremisesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TotalPremisesMember" xlink:to="CRBP_TotalPremisesMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TotalPremisesMember_lbl" xml:lang="en-US">Total Premises [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="us-gaap_AwardDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardDateAxis" xlink:to="us-gaap_AwardDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AwardDateAxis_lbl" xml:lang="en-US">Award Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryOneTwoThousandandNiniteenMember" xlink:label="CRBP_JanuaryOneTwoThousandandNiniteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryOneTwoThousandandNiniteenMember" xlink:to="CRBP_JanuaryOneTwoThousandandNiniteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_JanuaryOneTwoThousandandNiniteenMember_lbl" xml:lang="en-US">January 1, 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CFFWarrantMember" xlink:label="CRBP_CFFWarrantMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CFFWarrantMember" xlink:to="CRBP_CFFWarrantMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CFFWarrantMember_lbl" xml:lang="en-US">CFF Warrant [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:label="CRBP_TwoThousandFourteenEquityCompensationPlanMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:to="CRBP_TwoThousandFourteenEquityCompensationPlanMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_TwoThousandFourteenEquityCompensationPlanMember_lbl" xml:lang="en-US">2014 Equity Compensation Plan [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTypeAxis_lbl" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventMember_lbl" xml:lang="en-US">Subsequent Event [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CollaborationandLicenseAgreementMember" xlink:label="CRBP_CollaborationandLicenseAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CollaborationandLicenseAgreementMember" xlink:to="CRBP_CollaborationandLicenseAgreementMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CollaborationandLicenseAgreementMember_lbl" xml:lang="en-US">Collaboration and License Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PublicOfferingMember" xlink:label="CRBP_PublicOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PublicOfferingMember" xlink:to="CRBP_PublicOfferingMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_PublicOfferingMember_lbl" xml:lang="en-US">Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US">Public Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UnderwritersOptionMember" xlink:label="CRBP_UnderwritersOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UnderwritersOptionMember" xlink:to="CRBP_UnderwritersOptionMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UnderwritersOptionMember_lbl" xml:lang="en-US">Underwriters' Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_Remainder2018AndThroughFebruary82019Member" xlink:label="CRBP_Remainder2018AndThroughFebruary82019Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_Remainder2018AndThroughFebruary82019Member" xlink:to="CRBP_Remainder2018AndThroughFebruary82019Member_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_Remainder2018AndThroughFebruary82019Member_lbl" xml:lang="en-US">Remainder of 2018 and Through February 8, 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="us-gaap_DerivativeInstrumentRiskAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentRiskAxis" xlink:to="us-gaap_DerivativeInstrumentRiskAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentRiskAxis_lbl" xml:lang="en-US">Derivative Instrument [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockOptionMember" xlink:to="us-gaap_StockOptionMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockOptionMember_2_lbl" xml:lang="en-US">Equity Option [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OralAntiinflammatoryDrugMember" xlink:label="CRBP_OralAntiinflammatoryDrugMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OralAntiinflammatoryDrugMember" xlink:to="CRBP_OralAntiinflammatoryDrugMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_OralAntiinflammatoryDrugMember_lbl" xml:lang="en-US">Oral Anti-inflammatory Drug [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="CRBP_PhaseTwoBClinicalTrialMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PhaseTwoBClinicalTrialMember" xlink:to="CRBP_PhaseTwoBClinicalTrialMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_PhaseTwoBClinicalTrialMember_lbl" xml:lang="en-US">Phase 2b Clinical Trial [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FirstQuarterofTwoThousandandNineteenMember" xlink:label="CRBP_FirstQuarterofTwoThousandandNineteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FirstQuarterofTwoThousandandNineteenMember" xlink:to="CRBP_FirstQuarterofTwoThousandandNineteenMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FirstQuarterofTwoThousandandNineteenMember_lbl" xml:lang="en-US">First Quarter of 2019 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StockOptionAndWarrantsMember" xlink:label="CRBP_StockOptionAndWarrantsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StockOptionAndWarrantsMember" xlink:to="CRBP_StockOptionAndWarrantsMember_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_StockOptionAndWarrantsMember_lbl" xml:lang="en-US">Stock Option and Warrants [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DocumentAndEntityInformationAbstract" xlink:label="CRBP_DocumentAndEntityInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DocumentAndEntityInformationAbstract" xlink:to="CRBP_DocumentAndEntityInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DocumentAndEntityInformationAbstract_lbl" xml:lang="en-US">Document And Entity Information</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Entity Ex Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US">ASSETS</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US">Current assets:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="us-gaap_PrepaidExpenseCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrent" xlink:to="us-gaap_PrepaidExpenseCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US">Total current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US">Total assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US">LIABILITIES AND STOCKHOLDERS' EQUITY</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US">Current liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="us-gaap_NotesPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NotesPayableCurrent" xlink:to="us-gaap_NotesPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NotesPayableCurrent_lbl" xml:lang="en-US">Notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US">Accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_lbl" xml:lang="en-US">Deferred revenue, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditCurrent_lbl" xml:lang="en-US">Deferred rent, current</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US">Total current liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredRentCreditNoncurrent" xlink:to="us-gaap_DeferredRentCreditNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredRentCreditNoncurrent_lbl" xml:lang="en-US">Deferred rent, noncurrent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US">Other liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US">Total liabilities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingencies_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US">Stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US">Preferred Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at December 31, 2018 and 2017</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2018 and 2017, 57,247,496 and 55,603,427 shares issued and outstanding at December 31, 2018 and 2017, respectively</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock_lbl" xml:lang="en-US">Additional paid-in capital</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US">Accumulated deficit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US">Total stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Preferred stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US">Preferred stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US">Preferred stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US">Preferred stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US">Common stock, par value</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US">Common stock, shares authorized</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US">Common stock, shares issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US">Common stock, shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US">Income Statement [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="us-gaap_Revenues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Revenues_lbl" xml:lang="en-US">Revenue from awards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US">Operating expenses:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US">Research and development</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US">General and administrative</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US">Total operating expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US">Operating loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract_lbl" xml:lang="en-US">Other income (expense), net:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet_lbl" xml:lang="en-US">Interest income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionGainLossBeforeTax_lbl" xml:lang="en-US">Foreign currency exchange gain (loss)</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="us-gaap_NonoperatingIncomeExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NonoperatingIncomeExpense_lbl" xml:lang="en-US">Other income, net</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US">Net loss</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_lbl" xml:lang="en-US">Net loss per share, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_lbl" xml:lang="en-US">Weighted average number of common shares outstanding, basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US">Statement [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US">Statement [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_2_lbl" xml:lang="en-US">Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharesOutstanding_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US">Issuance of common stock, net of issuance costs, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of stock options, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueOther_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesOther_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_lbl" xml:lang="en-US">Fair value of warrant issued in connection with Investment Agreement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_2_lbl" xml:lang="en-US">Net loss</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_3_lbl" xml:lang="en-US">Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharesOutstanding_2_lbl" xml:lang="en-US">Balance, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_lbl" xml:lang="en-US">Stock issuance cost</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationAndAmortization_lbl" xml:lang="en-US">Depreciation and amortization</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:to="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ForeignCurrencyTransactionLossBeforeTax_lbl" xml:lang="en-US">Loss(gain) on foreign exchange</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncreaseDecreaseInDeferredRent" xlink:label="CRBP_IncreaseDecreaseInDeferredRent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncreaseDecreaseInDeferredRent" xlink:to="CRBP_IncreaseDecreaseInDeferredRent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IncreaseDecreaseInDeferredRent_lbl" xml:lang="en-US">Deferred rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInReceivables_lbl" xml:lang="en-US">Decrease in customer receivable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_lbl" xml:lang="en-US">Decrease (increase) in prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_lbl" xml:lang="en-US">Increase in other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US">Increase (decrease) in accounts payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities_lbl" xml:lang="en-US">Increase in accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInContractWithCustomerLiability_lbl" xml:lang="en-US">Decrease in deferred revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US">Net cash used in operating activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from investing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US">Purchases of property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US">Net cash used in investing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US">Cash flows from financing activities:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="us-gaap_ProceedsFromNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromNotesPayable" xlink:to="us-gaap_ProceedsFromNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromNotesPayable_lbl" xml:lang="en-US">Proceeds from issuance of notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="us-gaap_RepaymentsOfNotesPayable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfNotesPayable_lbl" xml:lang="en-US">Principal payments on notes payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_lbl" xml:lang="en-US">Proceeds from issuance of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_lbl" xml:lang="en-US">Issuance costs paid for common stock financings</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_lbl" xml:lang="en-US">Principal payments under capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US">Net cash provided by financing activities</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US">Net (decrease) increase in cash, cash equivalents, and restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at beginning of the year</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2_lbl" xml:lang="en-US">Cash, cash equivalents, and restricted cash at end of the year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US">Supplemental disclosure of cash flow information and non cash transactions:</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US">Cash paid during the period for interest</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsIssuanceFairValue" xlink:label="CRBP_WarrantsIssuanceFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsIssuanceFairValue" xlink:to="CRBP_WarrantsIssuanceFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CRBP_WarrantsIssuanceFairValue_lbl" xml:lang="en-US">Fair value of warrant issued in connection with Investment Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalExpendituresIncurredButNotYetPaid_lbl" xml:lang="en-US">Purchases of property and equipment included in accounts payable or accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" xlink:label="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" xlink:to="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements_lbl" xml:lang="en-US">Write off of fully amortized leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="us-gaap_StockIssued1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssued1" xlink:to="us-gaap_StockIssued1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssued1_lbl" xml:lang="en-US">Unpaid stock issuance costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NatureOfOperations_lbl" xml:lang="en-US">Nature of Operations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:to="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubstantialDoubtAboutGoingConcernTextBlock_lbl" xml:lang="en-US">Liquidity</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US">Significant Accounting Policies</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LicenseAgreementAbstract" xlink:label="CRBP_LicenseAgreementAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LicenseAgreementAbstract" xlink:to="CRBP_LicenseAgreementAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LicenseAgreementAbstract_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LicenseAgreementTextBlock" xlink:label="CRBP_LicenseAgreementTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LicenseAgreementTextBlock" xlink:to="CRBP_LicenseAgreementTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CRBP_LicenseAgreementTextBlock_lbl" xml:lang="en-US">License Agreement</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US">Commitments and Contingencies</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US">Notes Payable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="us-gaap_PayablesAndAccrualsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PayablesAndAccrualsAbstract" xlink:to="us-gaap_PayablesAndAccrualsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PayablesAndAccrualsAbstract_lbl" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US">Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:label="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract_lbl" xml:lang="en-US">Development Awards And Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock" xlink:label="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock" xlink:to="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock_lbl" xml:lang="en-US">Development Awards and Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityAbstract_lbl" xml:lang="en-US">Equity [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock_lbl" xml:lang="en-US">Common Stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US">Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract_lbl" xml:lang="en-US">Derivative Instruments and Hedging Activities Disclosure [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsTextBlock" xlink:label="CRBP_WarrantsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsTextBlock" xlink:to="CRBP_WarrantsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_WarrantsTextBlock_lbl" xml:lang="en-US">Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="us-gaap_RelatedPartyTransactionsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsAbstract" xlink:to="us-gaap_RelatedPartyTransactionsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsAbstract_lbl" xml:lang="en-US">Related Party Transactions [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:to="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionsDisclosureTextBlock_lbl" xml:lang="en-US">Related Party Transactions</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="us-gaap_SubsequentEventsAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsAbstract" xlink:to="us-gaap_SubsequentEventsAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsAbstract_lbl" xml:lang="en-US">Subsequent Events [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="us-gaap_SubsequentEventsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventsTextBlock" xlink:to="us-gaap_SubsequentEventsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventsTextBlock_lbl" xml:lang="en-US">Subsequent Events</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US">Use of Estimates</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US">Cash and Cash Equivalents</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US">Financial Instruments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US">Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US">Research and Development Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:label="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:to="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_lbl" xml:lang="en-US">Accruals for Research and Development Expenses and Clinical Trials</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:label="CRBP_LeasesAndDeferredRentPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:to="CRBP_LeasesAndDeferredRentPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LeasesAndDeferredRentPolicyTextBlock_lbl" xml:lang="en-US">Leases and Deferred Rent</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US">Concentrations of Credit Risk</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:to="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SegmentReportingPolicyPolicyTextBlock_lbl" xml:lang="en-US">Segment Information</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US">Income Taxes</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_lbl" xml:lang="en-US">Impairment of Long-lived Assets</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US">Stock-based Payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US">Net Loss Per Common Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US">Recent Accounting Pronouncements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_lbl" xml:lang="en-US">Schedule of Cash and Cash Equivalents and Restricted Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_lbl" xml:lang="en-US">Schedule of Computation of Basic and Diluted Earnings Per Share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US">Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US">Summary of Property and Equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Rent Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:to="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock_lbl" xml:lang="en-US">Schedule of Future Minimum Capital Lease Commitments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_lbl" xml:lang="en-US">Schedule of Roll Forward Deferred Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US">Components of Net Deferred Tax Asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US">Summary of Assumptions Used Principally in Determining Fair Value of Options Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US">Summary of Option Activity</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:label="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:to="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_lbl" xml:lang="en-US">Summary of Non-Vested Stock Options</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" xlink:label="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" xlink:to="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock_lbl" xml:lang="en-US">Schedule of Weighted Average Assumption of Warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="us-gaap_RevenueFromRelatedParties" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromRelatedParties_lbl" xml:lang="en-US">Upfront payment, recieved from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRoyaltiesReceived" xlink:to="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRoyaltiesReceived_lbl" xml:lang="en-US">Proceeds from Royalty</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UpfrontPaymentPercentage" xlink:label="CRBP_UpfrontPaymentPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UpfrontPaymentPercentage" xlink:to="CRBP_UpfrontPaymentPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_UpfrontPaymentPercentage_lbl" xml:lang="en-US">Upfront payment, percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_2_lbl" xml:lang="en-US">Proceeds from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SignificantAccountingPoliciesTable" xlink:label="CRBP_SignificantAccountingPoliciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesTable" xlink:to="CRBP_SignificantAccountingPoliciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SignificantAccountingPoliciesTable_lbl" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SignificantAccountingPoliciesLineItems" xlink:label="CRBP_SignificantAccountingPoliciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesLineItems" xlink:to="CRBP_SignificantAccountingPoliciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_SignificantAccountingPoliciesLineItems_lbl" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_StatementGeographicalAxis" xlink:to="srt_StatementGeographicalAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_StatementGeographicalAxis_2_lbl" xml:lang="en-US">Geographical [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:to="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_lbl" xml:lang="en-US">Cash equivalents maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MarketableSecuritiesMaturityPeriod" xlink:label="CRBP_MarketableSecuritiesMaturityPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MarketableSecuritiesMaturityPeriod" xlink:to="CRBP_MarketableSecuritiesMaturityPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_MarketableSecuritiesMaturityPeriod_lbl" xml:lang="en-US">Marketable investments maturity period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="us-gaap_MarketableSecurities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecurities" xlink:to="us-gaap_MarketableSecurities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecurities_lbl" xml:lang="en-US">Marketable investments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="us-gaap_RestrictedCashAndCashEquivalents" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US">Restricted cash</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashHeldInSubsidiary" xlink:label="CRBP_CashHeldInSubsidiary" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashHeldInSubsidiary" xlink:to="CRBP_CashHeldInSubsidiary_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CashHeldInSubsidiary_lbl" xml:lang="en-US">Cash held in subsidiary</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife_lbl" xml:lang="en-US">Estimated useful life of all property and equipment</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US">Operating segments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="us-gaap_Cash" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Cash" xlink:to="us-gaap_Cash_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Cash_lbl" xml:lang="en-US">Cash</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:to="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseCurrentAndNoncurrent_lbl" xml:lang="en-US">Prepaid expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="us-gaap_OtherAssets" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherAssets_lbl" xml:lang="en-US">Other assets</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="CRBP_DeferredTaxAssetsValuationAllowancePercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:to="CRBP_DeferredTaxAssetsValuationAllowancePercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DeferredTaxAssetsValuationAllowancePercentage_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:to="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilityForUncertainTaxPositionsCurrent_lbl" xml:lang="en-US">Uncertain tax position</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="us-gaap_AssetImpairmentCharges" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentCharges" xlink:to="us-gaap_AssetImpairmentCharges_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentCharges_lbl" xml:lang="en-US">Impairment charges</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_Revenues_2_lbl" xml:lang="en-US">Revenues</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US">Operating lease liability</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US">Operating lease, right of use asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsAtCarryingValue" xlink:to="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsAtCarryingValue_lbl" xml:lang="en-US">Money market fund</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_2_lbl" xml:lang="en-US">Cash and cash equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3_lbl" xml:lang="en-US">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:to="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_lbl" xml:lang="en-US">Weighted average shares of common stock outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasicAndDiluted" xlink:to="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasicAndDiluted_2_lbl" xml:lang="en-US">Net loss per share of common stock-basic and diluted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_2_lbl" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BusinessCombinationConsiderationTransferred1" xlink:to="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BusinessCombinationConsiderationTransferred1_lbl" xml:lang="en-US">Upfront cash payment</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PotentialMilestonePayments" xlink:label="CRBP_PotentialMilestonePayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PotentialMilestonePayments" xlink:to="CRBP_PotentialMilestonePayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_PotentialMilestonePayments_lbl" xml:lang="en-US">Potential milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationAndAmortization" xlink:to="us-gaap_DepreciationAndAmortization_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DepreciationAndAmortization_2_lbl" xml:lang="en-US">Depreciation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="CRBP_AreaOfOfficeSpace" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AreaOfOfficeSpace" xlink:to="CRBP_AreaOfOfficeSpace_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AreaOfOfficeSpace_lbl" xml:lang="en-US">Area of office space</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US">Cost of machine</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeaseTerm" xlink:label="CRBP_LeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeaseTerm" xlink:to="CRBP_LeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LeaseTerm_lbl" xml:lang="en-US">Lease term</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_2_lbl" xml:lang="en-US">Property and equipment, gross</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US">Less: accumulated depreciation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_2_lbl" xml:lang="en-US">Property and equipment, net</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="CRBP_CommitmentAndContingenciesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesTable" xlink:to="CRBP_CommitmentAndContingenciesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CommitmentAndContingenciesTable_lbl" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="CRBP_CommitmentAndContingenciesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesLineItems" xlink:to="CRBP_CommitmentAndContingenciesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CommitmentAndContingenciesLineItems_lbl" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="us-gaap_LeaseExpirationDate1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseExpirationDate1" xlink:to="us-gaap_LeaseExpirationDate1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseExpirationDate1_lbl" xml:lang="en-US">Operating lease expiration date</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="us-gaap_LettersOfCreditOutstandingAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LettersOfCreditOutstandingAmount" xlink:to="us-gaap_LettersOfCreditOutstandingAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LettersOfCreditOutstandingAmount_lbl" xml:lang="en-US">Standby letters of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="us-gaap_LeaseAndRentalExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseAndRentalExpense" xlink:to="us-gaap_LeaseAndRentalExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseAndRentalExpense_lbl" xml:lang="en-US">Rent expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="us-gaap_LeaseholdImprovementsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsGross" xlink:to="us-gaap_LeaseholdImprovementsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsGross_lbl" xml:lang="en-US">Leasehold improvements</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="us-gaap_LineOfCredit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LineOfCredit" xlink:to="us-gaap_LineOfCredit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LineOfCredit_lbl" xml:lang="en-US">Irrevocable letter of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="us-gaap_UnsecuredDebt" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnsecuredDebt" xlink:to="us-gaap_UnsecuredDebt_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnsecuredDebt_lbl" xml:lang="en-US">Unsecured letter of credit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="us-gaap_InterestExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestExpense" xlink:to="us-gaap_InterestExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestExpense_lbl" xml:lang="en-US">Incurred interest expense</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeaseTermDateDescription" xlink:label="CRBP_LeaseTermDateDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeaseTermDateDescription" xlink:to="CRBP_LeaseTermDateDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LeaseTermDateDescription_lbl" xml:lang="en-US">Lease term, description</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CapitalLeaseTerm" xlink:label="CRBP_CapitalLeaseTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CapitalLeaseTerm" xlink:to="CRBP_CapitalLeaseTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CapitalLeaseTerm_lbl" xml:lang="en-US">Capital lease term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent_lbl" xml:lang="en-US">2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears_lbl" xml:lang="en-US">2020</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears_lbl" xml:lang="en-US">2021</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears_lbl" xml:lang="en-US">2022</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears_lbl" xml:lang="en-US">2023</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter_lbl" xml:lang="en-US">Thereafter</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsDue_lbl" xml:lang="en-US">Total future minimum lease payments - end in 2019</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_lbl" xml:lang="en-US">Less: interest</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="us-gaap_CapitalLeaseObligations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligations" xlink:to="us-gaap_CapitalLeaseObligations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligations_lbl" xml:lang="en-US">Future capital lease obligations</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="us-gaap_CapitalLeaseObligationsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_lbl" xml:lang="en-US">Less: current portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsNoncurrent" xlink:to="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsNoncurrent_lbl" xml:lang="en-US">Long-term portion</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="us-gaap_DebtInstrumentTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTable" xlink:to="us-gaap_DebtInstrumentTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTable_lbl" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="us-gaap_DebtInstrumentLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentLineItems" xlink:to="us-gaap_DebtInstrumentLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentLineItems_lbl" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_ProductOrServiceAxis" xlink:to="srt_ProductOrServiceAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="srt_ProductOrServiceAxis_2_lbl" xml:lang="en-US">Product and Service [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="us-gaap_CreationDateAxis" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CreationDateAxis" xlink:to="us-gaap_CreationDateAxis_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CreationDateAxis_lbl" xml:lang="en-US">Report Date [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="us-gaap_DebtInstrumentPeriodicPayment" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentPeriodicPayment" xlink:to="us-gaap_DebtInstrumentPeriodicPayment_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentPeriodicPayment_lbl" xml:lang="en-US">Monthly principal and interest payments</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="us-gaap_DebtInstrumentTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentTerm" xlink:to="us-gaap_DebtInstrumentTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentTerm_lbl" xml:lang="en-US">Monthly loan payments term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentInterestRateStatedPercentage_lbl" xml:lang="en-US">Annual interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" xlink:label="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" xlink:to="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent_lbl" xml:lang="en-US">Accrued clinical operations and trials costs</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccruedProductDevelopmentCostsCurrent" xlink:label="CRBP_AccruedProductDevelopmentCostsCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedProductDevelopmentCostsCurrent" xlink:to="CRBP_AccruedProductDevelopmentCostsCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_AccruedProductDevelopmentCostsCurrent_lbl" xml:lang="en-US">Accrued product development costs</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent_lbl" xml:lang="en-US">Accrued other</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AccruedLiabilitiesCurrent_2_lbl" xml:lang="en-US">Total</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardTable" xlink:label="CRBP_DevelopmentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardTable" xlink:to="CRBP_DevelopmentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardTable_lbl" xml:lang="en-US">Development Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardLineItems" xlink:label="CRBP_DevelopmentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardLineItems" xlink:to="CRBP_DevelopmentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DevelopmentAwardLineItems_lbl" xml:lang="en-US">Development Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis_2_lbl" xml:lang="en-US">Project [Axis]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:to="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_2_lbl" xml:lang="en-US">Related Party [Axis]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="us-gaap_GainContingencyUnrecordedAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainContingencyUnrecordedAmount" xlink:to="us-gaap_GainContingencyUnrecordedAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainContingencyUnrecordedAmount_lbl" xml:lang="en-US">Development award received</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_2_lbl" xml:lang="en-US">Amount received upon achievement</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Revenues" xlink:to="us-gaap_Revenues_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_Revenues_3_lbl" xml:lang="en-US">Revenue</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="us-gaap_RoyaltyExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RoyaltyExpense" xlink:to="us-gaap_RoyaltyExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RoyaltyExpense_lbl" xml:lang="en-US">Royalty payable</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:label="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:to="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_lbl" xml:lang="en-US">Payment due period after the first commercial sale</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyPaymentSalesTarget" xlink:label="CRBP_RoyaltyPaymentSalesTarget" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyPaymentSalesTarget" xlink:to="CRBP_RoyaltyPaymentSalesTarget_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_RoyaltyPaymentSalesTarget_lbl" xml:lang="en-US">Royalty payment, sales target</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyPaymentPercentage" xlink:label="CRBP_RoyaltyPaymentPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyPaymentPercentage" xlink:to="CRBP_RoyaltyPaymentPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_RoyaltyPaymentPercentage_lbl" xml:lang="en-US">Royalty payment percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromRelatedParties" xlink:to="us-gaap_RevenueFromRelatedParties_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_RevenueFromRelatedParties_2_lbl" xml:lang="en-US">Upfront payment, received from related party</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight_lbl" xml:lang="en-US">Warrant to purchase of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_lbl" xml:lang="en-US">Warrant exercisable price per share</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_lbl" xml:lang="en-US">Warrant exercisable shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:to="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable_lbl" xml:lang="en-US">Warrant expires date</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" xlink:label="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" xlink:to="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses_lbl" xml:lang="en-US">Reclassified to contract asset and classified in prepaid expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued_2_lbl" xml:lang="en-US">Additional paid in capital, fair value of warrant issued</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CRBP_DevelopmentAwardsAndDeferredRevenueAbstract_2_lbl" xml:lang="en-US">Development Awards And Deferred Revenue - Schedule Of Roll Forward Deferred Revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_3_lbl" xml:lang="en-US">Deferred revenue, beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredRevenueBillingToUponAchievementOfMilestones" xlink:label="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones" xlink:to="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones_lbl" xml:lang="en-US">Billing to CFF upon achievement of milestones</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FairValueOfWarrant" xlink:label="CRBP_FairValueOfWarrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FairValueOfWarrant" xlink:to="CRBP_FairValueOfWarrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_FairValueOfWarrant_lbl" xml:lang="en-US">Fair value of CFF Warrant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ContractWithCustomerLiabilityRevenueRecognized_lbl" xml:lang="en-US">Recognition of revenue</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="us-gaap_ContractWithCustomerLiabilityCurrent_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ContractWithCustomerLiabilityCurrent_4_lbl" xml:lang="en-US">Deferred revenue, ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncomeTaxesTable" xlink:label="CRBP_IncomeTaxesTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesTable" xlink:to="CRBP_IncomeTaxesTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IncomeTaxesTable_lbl" xml:lang="en-US">Income Taxes [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncomeTaxesLineItems" xlink:label="CRBP_IncomeTaxesLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesLineItems" xlink:to="CRBP_IncomeTaxesLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_IncomeTaxesLineItems_lbl" xml:lang="en-US">Income Taxes [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLossCarryforwards_lbl" xml:lang="en-US">Net operating loss carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:label="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:to="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_lbl" xml:lang="en-US">Operating loss carryforwards expiration year</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US">Net operating loss carryforwards excess stock-based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US">Research and development tax credit carryforwards</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US">Deferred tax assets valuation allowance increase</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="us-gaap_IncomeTaxExaminationDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExaminationDescription" xlink:to="us-gaap_IncomeTaxExaminationDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxExaminationDescription_lbl" xml:lang="en-US">Income tax description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US">Corporate tax rate percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US">Taxable income percentage</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:to="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit_lbl" xml:lang="en-US">Deferred tax asset</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US">NOL carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign_lbl" xml:lang="en-US">Foreign net operating loss carryforward</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US">Stock based compensation</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_lbl" xml:lang="en-US">Accrued expenses</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="us-gaap_DeferredTaxAssetsOther" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOther" xlink:to="us-gaap_DeferredTaxAssetsOther_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOther_lbl" xml:lang="en-US">Other temporary differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US">Subtotal</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Valuation allowance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US">Net deferred tax asset</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_2_lbl" xml:lang="en-US">Tax provision at statutory rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US">State taxes, net of federal benefit</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential_lbl" xml:lang="en-US">Permanent differences</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign_lbl" xml:lang="en-US">Foreign expected tax</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_lbl" xml:lang="en-US">Tax credits</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate_lbl" xml:lang="en-US">Income tax rate change</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments_lbl" xml:lang="en-US">Other</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US">Increase in valuation reserve</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_2_lbl" xml:lang="en-US">Total</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_2_lbl" xml:lang="en-US">Aggregate common stock sold, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="us-gaap_SaleOfStockPricePerShare" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockPricePerShare_lbl" xml:lang="en-US">Purchase price per share</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock_3_lbl" xml:lang="en-US">Gross proceeds from sale of stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_lbl" xml:lang="en-US">Options to purchase shares of common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_lbl" xml:lang="en-US">Number of common stock value sold</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_lbl" xml:lang="en-US">Issuance of common stock upon exercise of warrants, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US">Proceeds from exercise of stock options</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_lbl" xml:lang="en-US">Percentage of outstanding common shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_lbl" xml:lang="en-US">Increase in number of shares of common stock available for issuance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US">Aggregate common stock available for stock options granted, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_lbl" xml:lang="en-US">Shares available for grant</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US">Stock option vesting term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_lbl" xml:lang="en-US">Stock option expiration period</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US">Option granted expected term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US">Option granted risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend_lbl" xml:lang="en-US">Option granted expected dividend yield</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_lbl" xml:lang="en-US">Option granted expected volatility</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_lbl" xml:lang="en-US">Option granted expected forfeiture rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted average grant-date fair value, options granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US">Average intrinsic value of options exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US">Total unrecognized compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US">Share-based compensation expense, not yet recognized weighted average period of recognition</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_2_lbl" xml:lang="en-US">Risk free interest rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_lbl" xml:lang="en-US">Expected dividend yield</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_2_lbl" xml:lang="en-US">Expected term in years</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_2_lbl" xml:lang="en-US">Expected volatility</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_2_lbl" xml:lang="en-US">Estimated forfeiture rate</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US">Shares, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US">Shares, Granted</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_2_lbl" xml:lang="en-US">Shares, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US">Shares, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2_lbl" xml:lang="en-US">Shares, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_lbl" xml:lang="en-US">Shares, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercised</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Weighted Average Exercise Price, Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US">Weighted Average Exercise Price, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US">Weighted Average Remaining Contractual Term in Years, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US">Average Intrinsic Value, Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_lbl" xml:lang="en-US">Average Intrinsic Value, Exercisable</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_lbl" xml:lang="en-US">Shares Non-vested , Beginning balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_lbl" xml:lang="en-US">Shares, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_lbl" xml:lang="en-US">Shares, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2_lbl" xml:lang="en-US">Shares Outstanding, Ending balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value Non Vested, Beginning Balance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Fair Value, Granted</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value, Vested</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US">Weighted Average Fair Value, Forfeited</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2_lbl" xml:lang="en-US">Weighted Average Fair Value Non Vested, Ending Balance</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="us-gaap_ClassOfWarrantOrRightTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightTable" xlink:to="us-gaap_ClassOfWarrantOrRightTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightTable_lbl" xml:lang="en-US">Class of Warrant or Right [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfWarrantOrRightLineItems_lbl" xml:lang="en-US">Class of Warrant or Right [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_2_lbl" xml:lang="en-US">Warrants outstanding to purchase of common stock shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromWarrantExercises_lbl" xml:lang="en-US">Proceeds from exercise of warrants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_2_lbl" xml:lang="en-US">Weighted average exercise price of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:label="CRBP_WarrantsWeightedAverageRemainingContractualTerm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:to="CRBP_WarrantsWeightedAverageRemainingContractualTerm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_WarrantsWeightedAverageRemainingContractualTerm_lbl" xml:lang="en-US">Weighted average remaining life of warrants</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NumberOfWarrantsExercisableForCommonStock" xlink:label="CRBP_NumberOfWarrantsExercisableForCommonStock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NumberOfWarrantsExercisableForCommonStock" xlink:to="CRBP_NumberOfWarrantsExercisableForCommonStock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_NumberOfWarrantsExercisableForCommonStock_lbl" xml:lang="en-US">Number of warrants exercisable for common stock</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:to="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WarrantsAndRightsOutstandingMaturityDate_lbl" xml:lang="en-US">Warrants expiration term</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="us-gaap_FairValueAdjustmentOfWarrants" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueAdjustmentOfWarrants" xlink:to="us-gaap_FairValueAdjustmentOfWarrants_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueAdjustmentOfWarrants_lbl" xml:lang="en-US">Fair value of warrants issued</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable_lbl" xml:lang="en-US">Schedule of Related Party Transactions, by Related Party [Table]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="us-gaap_RelatedPartyTransactionLineItems" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionLineItems" xlink:to="us-gaap_RelatedPartyTransactionLineItems_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionLineItems_lbl" xml:lang="en-US">Related Party Transaction [Line Items]</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="us-gaap_RelatedPartyTransactionDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RelatedPartyTransactionDate" xlink:to="us-gaap_RelatedPartyTransactionDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RelatedPartyTransactionDate_lbl" xml:lang="en-US">Agreement expiry date</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashCompensationAmount" xlink:label="CRBP_CashCompensationAmount" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashCompensationAmount" xlink:to="CRBP_CashCompensationAmount_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_CashCompensationAmount_lbl" xml:lang="en-US">Cash compensation amount</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward_2_lbl" xml:lang="en-US">Options to purchase, shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_lbl" xml:lang="en-US">Option vested percentage</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Options granted exercise price</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US">Stock-based compensation expense</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_lbl" xml:lang="en-US">Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease_2_lbl" xml:lang="en-US">Increased number of shares of common stock available for issuance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_2_lbl" xml:lang="en-US">Total reserve under the plan</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_2_lbl" xml:lang="en-US">Shares available for future grants</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockConsiderationReceivedOnTransaction_2_lbl" xml:lang="en-US">Consideration received on milestone payments</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyTermDescription" xlink:label="CRBP_RoyaltyTermDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyTermDescription" xlink:to="CRBP_RoyaltyTermDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_RoyaltyTermDescription_lbl" xml:lang="en-US">Royalty term description</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_lbl" xml:lang="en-US">Number of common stock share sold</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockPricePerShare" xlink:to="us-gaap_SaleOfStockPricePerShare_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SaleOfStockPricePerShare_2_lbl" xml:lang="en-US">Purchase price of shares</link:label>
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfLand" xlink:label="us-gaap_AreaOfLand" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AreaOfLand" xlink:to="us-gaap_AreaOfLand_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AreaOfLand_lbl" xml:lang="en-US">Area of land for office space</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccountingStandardsUpdate605Member" xlink:label="CRBP_AccountingStandardsUpdate605Member" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccountingStandardsUpdate605Member" xlink:to="CRBP_AccountingStandardsUpdate605Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccountingStandardsUpdate605Member_doc" xml:lang="en-US">Accounting Standards Update 605 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:to="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock_doc" xml:lang="en-US">Accruals for research and development expenses and clinical trials [Policy Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AegisCapitalCorpAndOtherAffiliatesMember" xlink:label="CRBP_AegisCapitalCorpAndOtherAffiliatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AegisCapitalCorpAndOtherAffiliatesMember" xlink:to="CRBP_AegisCapitalCorpAndOtherAffiliatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AegisCapitalCorpAndOtherAffiliatesMember_doc" xml:lang="en-US">Aegis Capital Corp And Other Affiliates [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AegisCapitalCorpMember" xlink:label="CRBP_AegisCapitalCorpMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AegisCapitalCorpMember" xlink:to="CRBP_AegisCapitalCorpMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AegisCapitalCorpMember_doc" xml:lang="en-US">Aegis Capital Corp [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AmendedAndRestatedEmploymentAgreementsMember" xlink:label="CRBP_AmendedAndRestatedEmploymentAgreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AmendedAndRestatedEmploymentAgreementsMember" xlink:to="CRBP_AmendedAndRestatedEmploymentAgreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AmendedAndRestatedEmploymentAgreementsMember_doc" xml:lang="en-US">Amended and Restated Employment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AtTheMarketOfferingMember" xlink:to="CRBP_AtTheMarketOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AtTheMarketOfferingMember_doc" xml:lang="en-US">At the Market Offering [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandFifiteenAmendmentMember" xlink:label="CRBP_AugustTwoThousandFifiteenAmendmentMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AugustTwoThousandFifiteenAmendmentMember" xlink:to="CRBP_AugustTwoThousandFifiteenAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AugustTwoThousandFifiteenAmendmentMember_doc" xml:lang="en-US">August Two Thousand Fifiteen Amendment [Member].</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:to="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AugustTwoThousandSeventeenLeaseAgreementMember_doc" xml:lang="en-US">August 2017 Lease Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CantorFitzgeraldAndCoMember" xlink:label="CRBP_CantorFitzgeraldAndCoMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CantorFitzgeraldAndCoMember" xlink:to="CRBP_CantorFitzgeraldAndCoMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CantorFitzgeraldAndCoMember_doc" xml:lang="en-US">Cantor Fitzgerald &amp;amp;amp;amp; Co. [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CantorFitzgeraldMember" xlink:label="CRBP_CantorFitzgeraldMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CantorFitzgeraldMember" xlink:to="CRBP_CantorFitzgeraldMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CantorFitzgeraldMember_doc" xml:lang="en-US">Cantor Fitzgerald [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CapitalLeaseAgreementMember" xlink:to="CRBP_CapitalLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CapitalLeaseAgreementMember_doc" xml:lang="en-US">Capital Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ComputerHardwareAndSoftwareMember" xlink:to="CRBP_ComputerHardwareAndSoftwareMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ComputerHardwareAndSoftwareMember_doc" xml:lang="en-US">Computer Hardware and Software [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ConditionOneMember" xlink:label="CRBP_ConditionOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ConditionOneMember" xlink:to="CRBP_ConditionOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ConditionOneMember_doc" xml:lang="en-US">Condition one.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CopierMachineMember" xlink:to="CRBP_CopierMachineMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CopierMachineMember_doc" xml:lang="en-US">Copier machine.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CorporatecreditCardsMember" xlink:to="CRBP_CorporatecreditCardsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CorporatecreditCardsMember_doc" xml:lang="en-US">Corporate Credit Cards [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationMember" xlink:to="CRBP_CysticFibrosisFoundationMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisFoundationMember_doc" xml:lang="en-US">Cystic Fibrosis Foundation [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationTherapeuticsIncMember" xlink:label="CRBP_CysticFibrosisFoundationTherapeuticsIncMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationTherapeuticsIncMember" xlink:to="CRBP_CysticFibrosisFoundationTherapeuticsIncMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisFoundationTherapeuticsIncMember_doc" xml:lang="en-US">Cystic Fibrosis Foundation Therapeutics, Inc. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisFoundationWarrantsMember" xlink:to="CRBP_CysticFibrosisFoundationWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisFoundationWarrantsMember_doc" xml:lang="en-US">Cystic Fibrosis Foundation warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:to="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember_doc" xml:lang="en-US">Cystic Fibrosis Program Related Investment Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardLineItems" xlink:to="CRBP_DevelopmentAwardLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DevelopmentAwardLineItems_doc" xml:lang="en-US">Development Award [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardTable" xlink:to="CRBP_DevelopmentAwardTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DevelopmentAwardTable_doc" xml:lang="en-US">Development Award [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock" xlink:to="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock_doc" xml:lang="en-US">Development awards and deferred revenue [Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DrBarbaraWhiteMember" xlink:label="CRBP_DrBarbaraWhiteMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DrBarbaraWhiteMember" xlink:to="CRBP_DrBarbaraWhiteMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DrBarbaraWhiteMember_doc" xml:lang="en-US">Dr. Barbara White [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DrMarkTepperMember" xlink:label="CRBP_DrMarkTepperMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DrMarkTepperMember" xlink:to="CRBP_DrMarkTepperMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DrMarkTepperMember_doc" xml:lang="en-US">Dr. Mark Tepper [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DrYuvalCohenMember" xlink:label="CRBP_DrYuvalCohenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DrYuvalCohenMember" xlink:to="CRBP_DrYuvalCohenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DrYuvalCohenMember_doc" xml:lang="en-US">Dr. Yuval Cohen [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EmployeesMember" xlink:to="CRBP_EmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_EmployeesMember_doc" xml:lang="en-US">Employees [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_EvergreenProvisionMember" xlink:to="CRBP_EvergreenProvisionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_EvergreenProvisionMember_doc" xml:lang="en-US">Evergreen Provision [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" xlink:label="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember" xlink:to="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FebruaryTwentyEightTwoThousandSeventeenMember_doc" xml:lang="en-US">February 28, 2017 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndEighteenMember" xlink:label="CRBP_FebruaryTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwoThousandAndEighteenMember" xlink:to="CRBP_FebruaryTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FebruaryTwoThousandAndEighteenMember_doc" xml:lang="en-US">February 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FederalMember" xlink:to="CRBP_FederalMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FederalMember_doc" xml:lang="en-US">Federal [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FirstYearMember" xlink:to="CRBP_FirstYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FirstYearMember_doc" xml:lang="en-US">First Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FourthAnniversaryMember" xlink:to="CRBP_FourthAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FourthAnniversaryMember_doc" xml:lang="en-US">Fourth Anniversary [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncreaseDecreaseInDeferredRent" xlink:to="CRBP_IncreaseDecreaseInDeferredRent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IncreaseDecreaseInDeferredRent_doc" xml:lang="en-US">Increase Decrease In Deferred Rent.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:to="CRBP_InstitutionalAndAccreditedInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InstitutionalAndAccreditedInvestorsMember_doc" xml:lang="en-US">Institutional And Accredited Investors [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalInvestorMember" xlink:to="CRBP_InstitutionalInvestorMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InstitutionalInvestorMember_doc" xml:lang="en-US">Institutional Investor [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InstitutionalInvestorsMember" xlink:to="CRBP_InstitutionalInvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InstitutionalInvestorsMember_doc" xml:lang="en-US">Institutional Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InsurancePoliciesMember" xlink:label="CRBP_InsurancePoliciesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InsurancePoliciesMember" xlink:to="CRBP_InsurancePoliciesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InsurancePoliciesMember_doc" xml:lang="en-US">Insurance Policies [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InsurancePolicyMember" xlink:to="CRBP_InsurancePolicyMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InsurancePolicyMember_doc" xml:lang="en-US">Insurance Policy [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestmentagreementMember" xlink:to="CRBP_InvestmentagreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InvestmentagreementMember_doc" xml:lang="en-US">Investment Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestorsMember" xlink:label="CRBP_InvestorsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestorsMember" xlink:to="CRBP_InvestorsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InvestorsMember_doc" xml:lang="en-US">Investors [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JBTOneZeroOneMember" xlink:label="CRBP_JBTOneZeroOneMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JBTOneZeroOneMember" xlink:to="CRBP_JBTOneZeroOneMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JBTOneZeroOneMember_doc" xml:lang="en-US">JBT-101 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:label="CRBP_JanuaryFiveTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryFiveTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryFiveTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryFiveTwoThousandAndEighteenMember_doc" xml:lang="en-US">January 5, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:label="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryTwentySixTwoThousandAndEighteenMember_doc" xml:lang="en-US">January 26, 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndEighteenMember" xlink:label="CRBP_JanuaryTwoThousandAndEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndEighteenMember" xlink:to="CRBP_JanuaryTwoThousandAndEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryTwoThousandAndEighteenMember_doc" xml:lang="en-US">January 2018 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" xlink:to="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember_doc" xml:lang="en-US">January 2018 Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LenabasumMember" xlink:to="CRBP_LenabasumMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LenabasumMember_doc" xml:lang="en-US">Lenabasum [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MassachusettsMember" xlink:label="CRBP_MassachusettsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MassachusettsMember" xlink:to="CRBP_MassachusettsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MassachusettsMember_doc" xml:lang="en-US">Massachusett [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MayTwoThousandEighteenMember" xlink:label="CRBP_MayTwoThousandEighteenMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MayTwoThousandEighteenMember" xlink:to="CRBP_MayTwoThousandEighteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MayTwoThousandEighteenMember_doc" xml:lang="en-US">May 2018 [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NonEmployeeStockOptionMember" xlink:label="CRBP_NonEmployeeStockOptionMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NonEmployeeStockOptionMember" xlink:to="CRBP_NonEmployeeStockOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NonEmployeeStockOptionMember_doc" xml:lang="en-US">Non-Employee Stock Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NonEmployeesMember" xlink:to="CRBP_NonEmployeesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NonEmployeesMember_doc" xml:lang="en-US">Non-Employees [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NorwoodMaMember" xlink:label="CRBP_NorwoodMaMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NorwoodMaMember" xlink:to="CRBP_NorwoodMaMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NorwoodMaMember_doc" xml:lang="en-US">Norwood Ma [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OctoberTwoThousandSeventeenOfferingMember" xlink:label="CRBP_OctoberTwoThousandSeventeenOfferingMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OctoberTwoThousandSeventeenOfferingMember" xlink:to="CRBP_OctoberTwoThousandSeventeenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OctoberTwoThousandSeventeenOfferingMember_doc" xml:lang="en-US">October 2017 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OfficeFurnitureAndEquipmentMember" xlink:to="CRBP_OfficeFurnitureAndEquipmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OfficeFurnitureAndEquipmentMember_doc" xml:lang="en-US">Office Furniture and Equipment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OralAntiinflammatoryDrugMember" xlink:to="CRBP_OralAntiinflammatoryDrugMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OralAntiinflammatoryDrugMember_doc" xml:lang="en-US">Oral Anti-inflammatory Drug [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrchestraMedicalVenturesLLCMember" xlink:to="CRBP_OrchestraMedicalVenturesLLCMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OrchestraMedicalVenturesLLCMember_doc" xml:lang="en-US">Orchestra Medical Ventures LLC.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_OrphanDrugCreditMember" xlink:to="CRBP_OrphanDrugCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_OrphanDrugCreditMember_doc" xml:lang="en-US">Orphan Drug Credit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:to="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_PaymentDuePeriodAfterTheFirstCommercialSale_doc" xml:lang="en-US">Payment due period after the first commercial sale.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PhaseTwoBClinicalTrialMember" xlink:to="CRBP_PhaseTwoBClinicalTrialMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_PhaseTwoBClinicalTrialMember_doc" xml:lang="en-US">Phase 2b Clinical Trial [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" xlink:to="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses_doc" xml:lang="en-US">Reclassified to contract asset and classified in prepaid expenses.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SalesAgreementMember" xlink:to="CRBP_SalesAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SalesAgreementMember_doc" xml:lang="en-US">Sales Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" xlink:to="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock_doc" xml:lang="en-US">Schedule of weighted average assumption of warrants [Table Text Block]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeanMoranMember" xlink:label="CRBP_SeanMoranMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeanMoranMember" xlink:to="CRBP_SeanMoranMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SeanMoranMember_doc" xml:lang="en-US">Sean Moran [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SecuritiesPurchaseAgreementMember" xlink:to="CRBP_SecuritiesPurchaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SecuritiesPurchaseAgreementMember_doc" xml:lang="en-US">Securities Purchase Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:to="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SeptemberTwoThousandAndSixteenAmendmentMember_doc" xml:lang="en-US">September 2016 Amendment [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SeventhYearMember" xlink:to="CRBP_SeventhYearMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SeventhYearMember_doc" xml:lang="en-US">Seventh Year [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StandbyLetterOfCreditMember" xlink:to="CRBP_StandbyLetterOfCreditMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_StandbyLetterOfCreditMember_doc" xml:lang="en-US">Stand-by Letter of Credit [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StockOptionsMember" xlink:to="CRBP_StockOptionsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_StockOptionsMember_doc" xml:lang="en-US">Stock Options [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:to="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember_doc" xml:lang="en-US">The Tax Cut and Jobs Act of 2017 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThirdAnniversaryMember" xlink:to="CRBP_ThirdAnniversaryMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ThirdAnniversaryMember_doc" xml:lang="en-US">Third Anniversary [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:label="CRBP_ThreePointTwoFivePercentNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ThreePointTwoFivePercentNotesPayableMember" xlink:to="CRBP_ThreePointTwoFivePercentNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ThreePointTwoFivePercentNotesPayableMember_doc" xml:lang="en-US">Three point two five percent notes payable.</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TrustMember" xlink:label="CRBP_TrustMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TrustMember" xlink:to="CRBP_TrustMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TrustMember_doc" xml:lang="en-US">Trust [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:label="CRBP_TwoPointThreeFivePercentNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoPointThreeFivePercentNotesPayableMember" xlink:to="CRBP_TwoPointThreeFivePercentNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoPointThreeFivePercentNotesPayableMember_doc" xml:lang="en-US">Two Point Three Five Percent Notes Payable [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:label="CRBP_TwoPointTwoFivePercentNotesPayableMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoPointTwoFivePercentNotesPayableMember" xlink:to="CRBP_TwoPointTwoFivePercentNotesPayableMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoPointTwoFivePercentNotesPayableMember_doc" xml:lang="en-US">Two Point Two Five Percent Notes Payable [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndEighteenCffAwardMember" xlink:to="CRBP_TwoThousandAndEighteenCffAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandAndEighteenCffAwardMember_doc" xml:lang="en-US">2018 CFF Award [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:to="CRBP_TwoThousandAndSixteenConsultingAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandAndSixteenConsultingAgreementMember_doc" xml:lang="en-US">2016 Consulting Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:to="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFifteenCFFTAwardArrangementMember_doc" xml:lang="en-US">2015 CFFT Award Agreement [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFifteenCFFTAwardMember" xlink:label="CRBP_TwoThousandFifteenCFFTAwardMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFifteenCFFTAwardMember" xlink:to="CRBP_TwoThousandFifteenCFFTAwardMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFifteenCFFTAwardMember_doc" xml:lang="en-US">2015 CFFT Award [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:to="CRBP_TwoThousandFourteenEquityCompensationPlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFourteenEquityCompensationPlanMember_doc" xml:lang="en-US">2014 Equity Compensation Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:to="CRBP_TwoThousandFourteenEquityIncentivePlanMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TwoThousandFourteenEquityIncentivePlanMember_doc" xml:lang="en-US">Two Thousand Fourteen Equity Incentive Plan [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponCommercializationOfTheProductMember" xlink:to="CRBP_UponCommercializationOfTheProductMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UponCommercializationOfTheProductMember_doc" xml:lang="en-US">Upon Commercialization Of The Product [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponReachingTheSalesTargetMember" xlink:to="CRBP_UponReachingTheSalesTargetMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UponReachingTheSalesTargetMember_doc" xml:lang="en-US">Upon Reaching The Sales Target [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UponTransferSaleOrLicensingMember" xlink:to="CRBP_UponTransferSaleOrLicensingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UponTransferSaleOrLicensingMember_doc" xml:lang="en-US">Upon Transfer Sale Or Licensing [Member]</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantAgreementMember" xlink:label="CRBP_WarrantAgreementMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantAgreementMember" xlink:to="CRBP_WarrantAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantAgreementMember_doc" xml:lang="en-US">Warrant Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsIssuanceFairValue" xlink:to="CRBP_WarrantsIssuanceFairValue_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantsIssuanceFairValue_doc" xml:lang="en-US">Fair value of warrant issued.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsTextBlock" xlink:to="CRBP_WarrantsTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantsTextBlock_doc" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" xlink:to="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements_doc" xml:lang="en-US">Write off of fully amortized leasehold improvements.</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementsMember" xlink:label="CRBP_InvestmentagreementsMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_InvestmentagreementsMember" xlink:to="CRBP_InvestmentagreementsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_InvestmentagreementsMember_doc" xml:lang="en-US">Investment Agreements [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones" xlink:to="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DeferredRevenueBillingToUponAchievementOfMilestones_doc" xml:lang="en-US">Billing to CFF upon achievement of milestones.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FairValueOfWarrant" xlink:to="CRBP_FairValueOfWarrant_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FairValueOfWarrant_doc" xml:lang="en-US">Fair value of warrant.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyPaymentSalesTarget" xlink:to="CRBP_RoyaltyPaymentSalesTarget_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_RoyaltyPaymentSalesTarget_doc" xml:lang="en-US">Royalty payment, sales target.</link:label>
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UnitedStatesMember" xlink:label="CRBP_UnitedStatesMember" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UnitedStatesMember" xlink:to="CRBP_UnitedStatesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UnitedStatesMember_doc" xml:lang="en-US">United States [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LicenseAgreementTextBlock" xlink:to="CRBP_LicenseAgreementTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LicenseAgreementTextBlock_doc" xml:lang="en-US">License Agreement [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesTable" xlink:to="CRBP_SignificantAccountingPoliciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SignificantAccountingPoliciesTable_doc" xml:lang="en-US">Significant Accounting Policies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SignificantAccountingPoliciesLineItems" xlink:to="CRBP_SignificantAccountingPoliciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SignificantAccountingPoliciesLineItems_doc" xml:lang="en-US">Significant Accounting Policies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:to="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod_doc" xml:lang="en-US">Cash equivalents and restricted cash maturity period.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashHeldInSubsidiary" xlink:to="CRBP_CashHeldInSubsidiary_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CashHeldInSubsidiary_doc" xml:lang="en-US">Cash held in subsidiary.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:to="CRBP_DeferredTaxAssetsValuationAllowancePercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DeferredTaxAssetsValuationAllowancePercentage_doc" xml:lang="en-US">Deferred Tax Assets Valuation Allowance Percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JenrinAgreementMember" xlink:to="CRBP_JenrinAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JenrinAgreementMember_doc" xml:lang="en-US">Jenrin Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PotentialMilestonePayments" xlink:to="CRBP_PotentialMilestonePayments_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_PotentialMilestonePayments_doc" xml:lang="en-US">Potential milestone payments.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeaseTerm" xlink:to="CRBP_LeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LeaseTerm_doc" xml:lang="en-US">Lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesTable" xlink:to="CRBP_CommitmentAndContingenciesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CommitmentAndContingenciesTable_doc" xml:lang="en-US">Commitment And Contingencies [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CommitmentAndContingenciesLineItems" xlink:to="CRBP_CommitmentAndContingenciesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CommitmentAndContingenciesLineItems_doc" xml:lang="en-US">Commitment And Contingencies [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AreaOfOfficeSpace" xlink:to="CRBP_AreaOfOfficeSpace_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AreaOfOfficeSpace_doc" xml:lang="en-US">Area of office space.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LoanAgreementMember" xlink:to="CRBP_LoanAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LoanAgreementMember_doc" xml:lang="en-US">Loan Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MarketableSecuritiesMaturityPeriod" xlink:to="CRBP_MarketableSecuritiesMaturityPeriod_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MarketableSecuritiesMaturityPeriod_doc" xml:lang="en-US">Marketable Securities Maturity Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesTable" xlink:to="CRBP_IncomeTaxesTable_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IncomeTaxesTable_doc" xml:lang="en-US">Income Taxes [Table]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_IncomeTaxesLineItems" xlink:to="CRBP_IncomeTaxesLineItems_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_IncomeTaxesLineItems_doc" xml:lang="en-US">Income Taxes [Line Items]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:to="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear_doc" xml:lang="en-US">Deferred tax assets operating loss carryforwards expiration year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:to="CRBP_LeasesAndDeferredRentPolicyTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LeasesAndDeferredRentPolicyTextBlock_doc" xml:lang="en-US">Leases and Deferred Rent [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:to="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_SummaryOfNonvestedStockOptionsTableTextBlock_doc" xml:lang="en-US">Summary of Non-Vested Stock Options [Table Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_KakenPharmaceuticalCoLtdMember" xlink:to="CRBP_KakenPharmaceuticalCoLtdMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_KakenPharmaceuticalCoLtdMember_doc" xml:lang="en-US">Kaken Pharmaceutical Co., Ltd. [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UpfrontPaymentPercentage" xlink:to="CRBP_UpfrontPaymentPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UpfrontPaymentPercentage_doc" xml:lang="en-US">Upfront payment, percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryTwoThousandAndNineteenOfferingMember" xlink:to="CRBP_JanuaryTwoThousandAndNineteenOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryTwoThousandAndNineteenOfferingMember_doc" xml:lang="en-US">January 2019 Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ASC606Member" xlink:to="CRBP_ASC606Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ASC606Member_doc" xml:lang="en-US">ASC 606 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_HigherRevenueMember" xlink:to="CRBP_HigherRevenueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_HigherRevenueMember_doc" xml:lang="en-US">Higher Revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LowerRevenueMember" xlink:to="CRBP_LowerRevenueMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LowerRevenueMember_doc" xml:lang="en-US">Lower Revenue [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryOneTwoThousandAndNineteenMember" xlink:to="CRBP_JanuaryOneTwoThousandAndNineteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryOneTwoThousandAndNineteenMember_doc" xml:lang="en-US">January 01, 2019 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:to="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember_doc" xml:lang="en-US">February 2019 Lease Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" xlink:to="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FebruaryTwentySixTwoThousandAndNineteenMember_doc" xml:lang="en-US">February 26, 2019 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NewPremisesMember" xlink:to="CRBP_NewPremisesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NewPremisesMember_doc" xml:lang="en-US">New Premises [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_TotalPremisesMember" xlink:to="CRBP_TotalPremisesMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_TotalPremisesMember_doc" xml:lang="en-US">Total Premises [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CapitalLeaseTerm" xlink:to="CRBP_CapitalLeaseTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CapitalLeaseTerm_doc" xml:lang="en-US">Capital lease term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyPaymentPercentage" xlink:to="CRBP_RoyaltyPaymentPercentage_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_RoyaltyPaymentPercentage_doc" xml:lang="en-US">Royalty payment percentage.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CollaborationAgreementMember" xlink:to="CRBP_CollaborationAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CollaborationAgreementMember_doc" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LeaseTermDateDescription" xlink:to="CRBP_LeaseTermDateDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_LeaseTermDateDescription_doc" xml:lang="en-US">Lease term, description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_JanuaryOneTwoThousandandNiniteenMember" xlink:to="CRBP_JanuaryOneTwoThousandandNiniteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_JanuaryOneTwoThousandandNiniteenMember_doc" xml:lang="en-US">January 1, 2019 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate_doc" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CFFWarrantMember" xlink:to="CRBP_CFFWarrantMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CFFWarrantMember_doc" xml:lang="en-US">CFF Warrant [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:to="CRBP_WarrantsWeightedAverageRemainingContractualTerm_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_WarrantsWeightedAverageRemainingContractualTerm_doc" xml:lang="en-US">Warrants weighted average remaining contractual term.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_NumberOfWarrantsExercisableForCommonStock" xlink:to="CRBP_NumberOfWarrantsExercisableForCommonStock_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_NumberOfWarrantsExercisableForCommonStock_doc" xml:lang="en-US">Number of warrants exercisable for common stock.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CashCompensationAmount" xlink:to="CRBP_CashCompensationAmount_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CashCompensationAmount_doc" xml:lang="en-US">Cash compensation amount.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_CollaborationandLicenseAgreementMember" xlink:to="CRBP_CollaborationandLicenseAgreementMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_CollaborationandLicenseAgreementMember_doc" xml:lang="en-US">Collaboration and License Agreement [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_FirstQuarterofTwoThousandandNineteenMember" xlink:to="CRBP_FirstQuarterofTwoThousandandNineteenMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_FirstQuarterofTwoThousandandNineteenMember_doc" xml:lang="en-US">First Quarter of 2019 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_PublicOfferingMember" xlink:to="CRBP_PublicOfferingMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_PublicOfferingMember_doc" xml:lang="en-US">Public Offering [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_UnderwritersOptionMember" xlink:to="CRBP_UnderwritersOptionMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_UnderwritersOptionMember_doc" xml:lang="en-US">Underwriters' Option [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:to="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear_doc" xml:lang="en-US">Share based compensation arrangement by share based payment award options outstanding period increase minimum percentage in each year.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_RoyaltyTermDescription" xlink:to="CRBP_RoyaltyTermDescription_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_RoyaltyTermDescription_doc" xml:lang="en-US">Royalty term description.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_Remainder2018AndThroughFebruary82019Member" xlink:to="CRBP_Remainder2018AndThroughFebruary82019Member_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_Remainder2018AndThroughFebruary82019Member_doc" xml:lang="en-US">Remainder of 2018 and Through February 8, 2019 [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_MassachusettMember" xlink:to="CRBP_MassachusettMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_MassachusettMember_doc" xml:lang="en-US">Massachusett [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" xlink:to="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent_doc" xml:lang="en-US">Accrued clinical operations and trials costs current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_AccruedProductDevelopmentCostsCurrent" xlink:to="CRBP_AccruedProductDevelopmentCostsCurrent_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_AccruedProductDevelopmentCostsCurrent_doc" xml:lang="en-US">Accrued product development costs current.</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_StockOptionAndWarrantsMember" xlink:to="CRBP_StockOptionAndWarrantsMember_doc" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="CRBP_StockOptionAndWarrantsMember_doc" xml:lang="en-US">Stock Option and Warrants [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_2_lbl" xml:lang="en-US">IPO [Member]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_2_lbl" xml:lang="en-US">Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_2_lbl" xml:lang="en-US">Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_2_lbl" xml:lang="en-US">Liabilities, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_2_lbl" xml:lang="en-US">Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_4_lbl" xml:lang="en-US">Stockholders' Equity Attributable to Parent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_2_lbl" xml:lang="en-US">Liabilities and Equity</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_2_lbl" xml:lang="en-US">Operating Expenses</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_2_lbl" xml:lang="en-US">Operating Income (Loss)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpense" xlink:to="us-gaap_NonoperatingIncomeExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NonoperatingIncomeExpense_2_lbl" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharesOutstanding_3_lbl" xml:lang="en-US">Shares, Outstanding</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_2_lbl" xml:lang="en-US">Share-based Compensation</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInReceivables" xlink:to="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInReceivables_2_lbl" xml:lang="en-US">Increase (Decrease) in Receivables</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:to="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidExpense_2_lbl" xml:lang="en-US">Increase (Decrease) in Prepaid Expense</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets_2_lbl" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfNotesPayable" xlink:to="us-gaap_RepaymentsOfNotesPayable_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfNotesPayable_2_lbl" xml:lang="en-US">Repayments of Notes Payable</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:to="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentOfFinancingAndStockIssuanceCosts_2_lbl" xml:lang="en-US">Payment of Financing and Stock Issuance Costs</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:to="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfLongTermCapitalLeaseObligations_2_lbl" xml:lang="en-US">Repayments of Long-term Capital Lease Obligations</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_2_lbl" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_4_lbl" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_WarrantsIssuanceFairValue" xlink:to="CRBP_WarrantsIssuanceFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_WarrantsIssuanceFairValue_3_lbl" xml:lang="en-US">Warrants [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="CRBP_LicenseAgreementTextBlock" xlink:to="CRBP_LicenseAgreementTextBlock_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="CRBP_LicenseAgreementTextBlock_3_lbl" xml:lang="en-US">LicenseAgreementTextBlock</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_2_lbl" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_2_lbl" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_2_lbl" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalents" xlink:to="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalents_2_lbl" xml:lang="en-US">Restricted Cash and Cash Equivalents</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssets" xlink:to="us-gaap_OtherAssets_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssets_2_lbl" xml:lang="en-US">Other Assets</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_2_lbl" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:to="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesFutureMinimumPaymentsDue_2_lbl" xml:lang="en-US">Operating Leases, Future Minimum Payments Due</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:to="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments_2_lbl" xml:lang="en-US">Capital Leases, Future Minimum Payments, Interest Included in Payments</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CapitalLeaseObligationsCurrent" xlink:to="us-gaap_CapitalLeaseObligationsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CapitalLeaseObligationsCurrent_2_lbl" xml:lang="en-US">Capital Lease Obligations, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2_lbl" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities_2_lbl" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals, Accrued Liabilities</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_2_lbl" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_2_lbl" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_2_lbl" xml:lang="en-US">Deferred Tax Assets, Net of Valuation Allowance</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits_2_lbl" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Percent</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Non-Option Equity Instruments, Exercised</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Number</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares_2_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Nonvested Options Forfeited, Number of Shares</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_3_lbl" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Option, Nonvested, Weighted Average Exercise Price</link:label>
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_2_lbl" xml:lang="en-US">Allocated Share-based Compensation Expense</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>35
<FILENAME>crbp-20181231_pre.xml
<DESCRIPTION>XBRL PRESENTATION FILE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 4.25d -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: http://www.novaworks.co -->
    <!-- Field: Doc-Info; Name: Source; Value: CRBP 20181231 10K FY DFN.xfr; Date: 2019%2D03%2D12T12:43:14Z -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x80080001 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:href="crbp-20181231.xsd#DocumentAndEntityInformation" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheets" xlink:href="crbp-20181231.xsd#BalanceSheets" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:href="crbp-20181231.xsd#BalanceSheetsParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfOperations" xlink:href="crbp-20181231.xsd#StatementsOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:href="crbp-20181231.xsd#StatementsOfStockholdersEquity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:href="crbp-20181231.xsd#StatementsOfStockholdersEquityParenthetical" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:href="crbp-20181231.xsd#StatementsOfCashFlows" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NatureOfOperations" xlink:href="crbp-20181231.xsd#NatureOfOperations" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Liquidity" xlink:href="crbp-20181231.xsd#Liquidity" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LicenseAgreement" xlink:href="crbp-20181231.xsd#LicenseAgreement" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment" xlink:href="crbp-20181231.xsd#PropertyAndEquipment" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayable" xlink:href="crbp-20181231.xsd#NotesPayable" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses" xlink:href="crbp-20181231.xsd#AccruedExpenses" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenue" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes" xlink:href="crbp-20181231.xsd#IncomeTaxes" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStock" xlink:href="crbp-20181231.xsd#CommonStock" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions" xlink:href="crbp-20181231.xsd#StockOptions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants" xlink:href="crbp-20181231.xsd#Warrants" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:href="crbp-20181231.xsd#RelatedPartyTransactions" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEvents" xlink:href="crbp-20181231.xsd#SubsequentEvents" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesPolicies" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:href="crbp-20181231.xsd#PropertyAndEquipmentTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:href="crbp-20181231.xsd#CommitmentsAndContingenciesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpensesTables" xlink:href="crbp-20181231.xsd#AccruedExpensesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenueTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesTables" xlink:href="crbp-20181231.xsd#IncomeTaxesTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsTables" xlink:href="crbp-20181231.xsd#StockOptionsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsTables" xlink:href="crbp-20181231.xsd#WarrantsTables" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:href="crbp-20181231.xsd#LiquidityDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:href="crbp-20181231.xsd#SignificantAccountingPoliciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:href="crbp-20181231.xsd#SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" xlink:href="crbp-20181231.xsd#LicenseAgreementDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:href="crbp-20181231.xsd#PropertyAndEquipmentDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:href="crbp-20181231.xsd#PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:href="crbp-20181231.xsd#CommitmentsAndContingenciesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:href="crbp-20181231.xsd#CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:href="crbp-20181231.xsd#NotesPayableDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:href="crbp-20181231.xsd#AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:href="crbp-20181231.xsd#DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:href="crbp-20181231.xsd#IncomeTaxesDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:href="crbp-20181231.xsd#IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:href="crbp-20181231.xsd#IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:href="crbp-20181231.xsd#CommonStockDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:href="crbp-20181231.xsd#StockOptionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfOptionActivityDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:href="crbp-20181231.xsd#StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:href="crbp-20181231.xsd#WarrantsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:href="crbp-20181231.xsd#Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:href="crbp-20181231.xsd#RelatedPartyTransactionsDetailsNarrative" xlink:type="simple" />
    <link:roleRef roleURI="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:href="crbp-20181231.xsd#SubsequentEventsDetailsNarrative" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DocumentAndEntityInformation" xlink:title="00000001 - Document - Document and Entity Information">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DocumentAndEntityInformationAbstract" xlink:label="loc_CRBPDocumentAndEntityInformationAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDocumentAndEntityInformationAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheets" xlink:title="00000002 - Statement - Consolidated Balance Sheets">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsAbstract" xlink:label="loc_us-gaapAssetsAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapAssetsAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="loc_us-gaapAssetsCurrentAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssetsCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapPrepaidExpenseCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="loc_us-gaapAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsCurrentAbstract" xlink:to="loc_us-gaapAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="loc_us-gaapOtherAssetsNoncurrent" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapOtherAssetsNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Assets" xlink:label="loc_us-gaapAssets" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAssetsAbstract" xlink:to="loc_us-gaapAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="loc_us-gaapLiabilitiesCurrentAbstract" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesCurrentAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NotesPayableCurrent" xlink:label="loc_us-gaapNotesPayableCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapNotesPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="loc_us-gaapAccountsPayableCurrent" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccountsPayableCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="loc_us-gaapDeferredRentCreditCurrent" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapDeferredRentCreditCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="loc_us-gaapLiabilitiesCurrent" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesCurrentAbstract" xlink:to="loc_us-gaapLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="loc_us-gaapDeferredRentCreditNoncurrent" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapDeferredRentCreditNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="loc_us-gaapOtherLiabilitiesNoncurrent" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapOtherLiabilitiesNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Liabilities" xlink:label="loc_us-gaapLiabilities" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="loc_us-gaapCommitmentsAndContingencies" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapCommitmentsAndContingencies" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="loc_us-gaapStockholdersEquityAbstract" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="loc_us-gaapPreferredStockValue" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapPreferredStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockValue" xlink:label="loc_us-gaapCommonStockValue" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapCommonStockValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="loc_us-gaapAdditionalPaidInCapitalCommonStock" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapAdditionalPaidInCapitalCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStockholdersEquityAbstract" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="loc_us-gaapLiabilitiesAndStockholdersEquity" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLiabilitiesAndStockholdersEquityAbstract" xlink:to="loc_us-gaapLiabilitiesAndStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/BalanceSheetsParenthetical" xlink:title="00000003 - Statement - Consolidated Balance Sheets (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="loc_us-gaapStatementOfFinancialPositionAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="loc_us-gaapPreferredStockParOrStatedValuePerShare" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="loc_us-gaapPreferredStockSharesAuthorized" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="loc_us-gaapPreferredStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="loc_us-gaapPreferredStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapPreferredStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfFinancialPositionAbstract" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfOperations" xlink:title="00000004 - Statement - Consolidated Statements of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="loc_us-gaapIncomeStatementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapRevenues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="loc_us-gaapOperatingExpensesAbstract" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingExpensesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="loc_us-gaapResearchAndDevelopmentExpense" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="loc_us-gaapGeneralAndAdministrativeExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapGeneralAndAdministrativeExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingExpenses" xlink:label="loc_us-gaapOperatingExpenses" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOperatingExpensesAbstract" xlink:to="loc_us-gaapOperatingExpenses" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="loc_us-gaapOperatingIncomeLoss" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapOperatingIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="loc_us-gaapNonoperatingIncomeExpenseAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="loc_us-gaapInterestIncomeExpenseNonoperatingNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapInterestIncomeExpenseNonoperatingNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionGainLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionGainLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NonoperatingIncomeExpense" xlink:label="loc_us-gaapNonoperatingIncomeExpense" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNonoperatingIncomeExpenseAbstract" xlink:to="loc_us-gaapNonoperatingIncomeExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquity" xlink:title="00000005 - Statement - Statements of Stockholders' Equity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockMember" xlink:label="loc_us-gaapCommonStockMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapCommonStockMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="loc_us-gaapAdditionalPaidInCapitalMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapAdditionalPaidInCapitalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="loc_us-gaapRetainedEarningsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapRetainedEarningsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodValueOther" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodValueOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesOther" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesOther" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="loc_us-gaapStockholdersEquity_2" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockholdersEquity_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="loc_us-gaapSharesOutstanding_2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSharesOutstanding_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical" xlink:title="00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="loc_us-gaapStatementOfStockholdersEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfStockholdersEquityAbstract" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StatementsOfCashFlows" xlink:title="00000007 - Statement - Consolidated Statements of Cash Flows">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="loc_us-gaapStatementOfCashFlowsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ForeignCurrencyTransactionLossBeforeTax" xlink:label="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapForeignCurrencyTransactionLossBeforeTax" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncreaseDecreaseInDeferredRent" xlink:label="loc_CRBPIncreaseDecreaseInDeferredRent" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_CRBPIncreaseDecreaseInDeferredRent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="loc_us-gaapIncreaseDecreaseInReceivables" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInReceivables" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidExpense" xlink:label="loc_us-gaapIncreaseDecreaseInPrepaidExpense" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInPrepaidExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInOtherNoncurrentAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="loc_us-gaapIncreaseDecreaseInAccountsPayable" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccountsPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInAccruedLiabilities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:label="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapIncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncreaseDecreaseInOperatingCapitalAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInOperatingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapPaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInInvestingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfNotesPayable" xlink:label="loc_us-gaapRepaymentsOfNotesPayable" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfNotesPayable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PaymentOfFinancingAndStockIssuanceCosts" xlink:label="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapPaymentOfFinancingAndStockIssuanceCosts" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RepaymentsOfLongTermCapitalLeaseObligations" xlink:label="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapRepaymentsOfLongTermCapitalLeaseObligations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapNetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="loc_us-gaapNetCashProvidedByUsedInFinancingActivities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="loc_us-gaapSupplementalCashFlowInformationAbstract" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementOfCashFlowsAbstract" xlink:to="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestPaidNet" xlink:label="loc_us-gaapInterestPaidNet" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapInterestPaidNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsIssuanceFairValue" xlink:label="loc_CRBPWarrantsIssuanceFairValue" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CRBPWarrantsIssuanceFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:label="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapCapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" xlink:label="loc_CRBPWriteOffOfFullyAmortizedLeaseholdImprovements" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_CRBPWriteOffOfFullyAmortizedLeaseholdImprovements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssued1" xlink:label="loc_us-gaapStockIssued1" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSupplementalCashFlowInformationAbstract" xlink:to="loc_us-gaapStockIssued1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NatureOfOperations" xlink:title="00000008 - Disclosure - Nature of Operations">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="loc_us-gaapNatureOfOperations" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="loc_us-gaapNatureOfOperations" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Liquidity" xlink:title="00000009 - Disclosure - Liquidity">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubstantialDoubtAboutGoingConcernTextBlock" xlink:label="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSubstantialDoubtAboutGoingConcernTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies" xlink:title="00000010 - Disclosure - Significant Accounting Policies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="loc_us-gaapSignificantAccountingPoliciesTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSignificantAccountingPoliciesTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LicenseAgreement" xlink:title="00000011 - Disclosure - License Agreement">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LicenseAgreementAbstract" xlink:label="loc_CRBPLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LicenseAgreementTextBlock" xlink:label="loc_CRBPLicenseAgreementTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPLicenseAgreementAbstract" xlink:to="loc_CRBPLicenseAgreementTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment" xlink:title="00000012 - Disclosure - Property and Equipment">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies" xlink:title="00000013 - Disclosure - Commitments and Contingencies">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapCommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayable" xlink:title="00000014 - Disclosure - Notes Payable">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="loc_us-gaapDebtDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses" xlink:title="00000015 - Disclosure - Accrued Expenses">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue" xlink:title="00000016 - Disclosure - Development Awards and Deferred Revenue">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:label="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock" xlink:label="loc_CRBPDevelopmentAwardsAndDeferredRevenueTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_CRBPDevelopmentAwardsAndDeferredRevenueTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes" xlink:title="00000017 - Disclosure - Income Taxes">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="loc_us-gaapIncomeTaxDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapIncomeTaxDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStock" xlink:title="00000018 - Disclosure - Common Stock">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStockholdersEquityNoteDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions" xlink:title="00000019 - Disclosure - Stock Options">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants" xlink:title="00000020 - Disclosure - Warrants">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsTextBlock" xlink:label="loc_CRBPWarrantsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_CRBPWarrantsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactions" xlink:title="00000021 - Disclosure - Related Party Transactions">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsDisclosureTextBlock" xlink:label="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapRelatedPartyTransactionsDisclosureTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEvents" xlink:title="00000022 - Disclosure - Subsequent Events">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsTextBlock" xlink:label="loc_us-gaapSubsequentEventsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapSubsequentEventsTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies" xlink:title="00000023 - Disclosure - Significant Accounting Policies (Policies)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="loc_us-gaapUseOfEstimates" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapUseOfEstimates" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapFairValueOfFinancialInstrumentsPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="loc_us-gaapResearchAndDevelopmentExpensePolicy" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapResearchAndDevelopmentExpensePolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:label="loc_CRBPAccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPAccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeasesAndDeferredRentPolicyTextBlock" xlink:label="loc_CRBPLeasesAndDeferredRentPolicyTextBlock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPLeasesAndDeferredRentPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="loc_us-gaapConcentrationRiskCreditRisk" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapConcentrationRiskCreditRisk" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SegmentReportingPolicyPolicyTextBlock" xlink:label="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapSegmentReportingPolicyPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="loc_us-gaapIncomeTaxPolicyTextBlock" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapIncomeTaxPolicyTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:label="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="loc_us-gaapEarningsPerSharePolicyTextBlock" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerSharePolicyTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesTables" xlink:title="00000024 - Disclosure - Significant Accounting Policies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:label="loc_us-gaapScheduleOfRestrictedCashAndCashEquivalentsTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:label="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentTables" xlink:title="00000025 - Disclosure - Property and Equipment (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesTables" xlink:title="00000026 - Disclosure - Commitments and Contingencies (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:label="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpensesTables" xlink:title="00000027 - Disclosure - Accrued Expenses (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables" xlink:title="00000028 - Disclosure - Development Awards and Deferred Revenue (Tables)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:label="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:label="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_us-gaapContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesTables" xlink:title="00000029 - Disclosure - Income Taxes (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsTables" xlink:title="00000030 - Disclosure - Stock Options (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SummaryOfNonvestedStockOptionsTableTextBlock" xlink:label="loc_CRBPSummaryOfNonvestedStockOptionsTableTextBlock" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_CRBPSummaryOfNonvestedStockOptionsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsTables" xlink:title="00000031 - Disclosure - Warrants (Tables)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" xlink:label="loc_CRBPScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_CRBPScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LiquidityDetailsNarrative" xlink:title="00000032 - Disclosure - Liquidity (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="loc_CRBPKakenPharmaceuticalCoLtdMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPKakenPharmaceuticalCoLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationMember" xlink:label="loc_CRBPCysticFibrosisFoundationMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPCysticFibrosisFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndNineteenOfferingMember" xlink:label="loc_CRBPJanuaryTwoThousandAndNineteenOfferingMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPJanuaryTwoThousandAndNineteenOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="loc_us-gaapRetainedEarningsAccumulatedDeficit" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRetainedEarningsAccumulatedDeficit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="loc_us-gaapProceedsFromRoyaltiesReceived" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromRoyaltiesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UpfrontPaymentPercentage" xlink:label="loc_CRBPUpfrontPaymentPercentage" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPUpfrontPaymentPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative" xlink:title="00000033 - Disclosure - Significant Accounting Policies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SignificantAccountingPoliciesTable" xlink:label="loc_CRBPSignificantAccountingPoliciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_CRBPSignificantAccountingPoliciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SignificantAccountingPoliciesLineItems" xlink:label="loc_CRBPSignificantAccountingPoliciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_CRBPSignificantAccountingPoliciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_srtRangeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentAxis" xlink:label="loc_us-gaapDebtInstrumentAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapDebtInstrumentAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentNameDomain" xlink:label="loc_us-gaapDebtInstrumentNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentAxis" xlink:to="loc_us-gaapDebtInstrumentNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CorporatecreditCardsMember" xlink:label="loc_CRBPCorporatecreditCardsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPCorporatecreditCardsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StandbyLetterOfCreditMember" xlink:label="loc_CRBPStandbyLetterOfCreditMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentNameDomain" xlink:to="loc_CRBPStandbyLetterOfCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_StatementGeographicalAxis" xlink:label="loc_srtStatementGeographicalAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_srtStatementGeographicalAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_SegmentGeographicalDomain" xlink:label="loc_srtSegmentGeographicalDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtStatementGeographicalAxis" xlink:to="loc_srtSegmentGeographicalDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.sec.gov/country/2017/country-2017-01-31.xsd#country_GB" xlink:label="loc_countryGB" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtSegmentGeographicalDomain" xlink:to="loc_countryGB" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="loc_CRBPTwoThousandAndEighteenCffAwardMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPTwoThousandAndEighteenCffAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryOneTwoThousandAndNineteenMember" xlink:label="loc_CRBPJanuaryOneTwoThousandAndNineteenMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPJanuaryOneTwoThousandAndNineteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="loc_us-gaapTypeOfAdoptionMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAdjustmentsForNewAccountingPronouncementsAxis" xlink:to="loc_us-gaapTypeOfAdoptionMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ASC606Member" xlink:label="loc_CRBPASC606Member" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfAdoptionMember" xlink:to="loc_CRBPASC606Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeAxis" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesTable" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredRevenueArrangementTypeDomain" xlink:label="loc_us-gaapDeferredRevenueArrangementTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeAxis" xlink:to="loc_us-gaapDeferredRevenueArrangementTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_HigherRevenueMember" xlink:label="loc_CRBPHigherRevenueMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:to="loc_CRBPHigherRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LowerRevenueMember" xlink:label="loc_CRBPLowerRevenueMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredRevenueArrangementTypeDomain" xlink:to="loc_CRBPLowerRevenueMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod" xlink:label="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPCashEquivalentsAndRestrictedCashMaturityPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MarketableSecuritiesMaturityPeriod" xlink:label="loc_CRBPMarketableSecuritiesMaturityPeriod" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPMarketableSecuritiesMaturityPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MarketableSecurities" xlink:label="loc_us-gaapMarketableSecurities" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapMarketableSecurities" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalents" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalents" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashHeldInSubsidiary" xlink:label="loc_CRBPCashHeldInSubsidiary" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPCashHeldInSubsidiary" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentUsefulLife" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="loc_us-gaapNumberOfOperatingSegments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapNumberOfOperatingSegments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseCurrentAndNoncurrent" xlink:label="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPrepaidExpenseCurrentAndNoncurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAssets" xlink:label="loc_us-gaapOtherAssets" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOtherAssets" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsValuationAllowancePercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AssetImpairmentCharges" xlink:label="loc_us-gaapAssetImpairmentCharges" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapAssetImpairmentCharges" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseLiability" xlink:label="loc_us-gaapOperatingLeaseLiability" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOperatingLeaseLiability" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="loc_us-gaapOperatingLeaseRightOfUseAsset" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPSignificantAccountingPoliciesLineItems" xlink:to="loc_us-gaapOperatingLeaseRightOfUseAsset" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails" xlink:title="00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Cash" xlink:label="loc_us-gaapCash" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCash" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_MoneyMarketFundsAtCarryingValue" xlink:label="loc_us-gaapMoneyMarketFundsAtCarryingValue" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapMoneyMarketFundsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue" xlink:label="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapRestrictedCashAndCashEquivalentsAtCarryingValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails" xlink:title="00000035 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="loc_us-gaapNetIncomeLoss" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapNetIncomeLoss" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:label="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapWeightedAverageNumberOfShareOutstandingBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EarningsPerShareBasicAndDiluted" xlink:label="loc_us-gaapEarningsPerShareBasicAndDiluted" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapEarningsPerShareBasicAndDiluted" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails" xlink:title="00000036 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="loc_us-gaapAccountingPoliciesAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAccountingPoliciesAbstract" xlink:to="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="loc_us-gaapAntidilutiveSecuritiesNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="loc_us-gaapAntidilutiveSecuritiesNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StockOptionsMember" xlink:label="loc_CRBPStockOptionsMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesNameDomain" xlink:to="loc_CRBPStockOptionsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="loc_us-gaapAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/LicenseAgreementDetailsNarrative" xlink:title="00000037 - Disclosure - License Agreement (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LicenseAgreementAbstract" xlink:label="loc_CRBPLicenseAgreementAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPLicenseAgreementAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JenrinAgreementMember" xlink:label="loc_CRBPJenrinAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPJenrinAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="loc_us-gaapResearchAndDevelopmentExpenseMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapResearchAndDevelopmentExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_BusinessCombinationConsiderationTransferred1" xlink:label="loc_us-gaapBusinessCombinationConsiderationTransferred1" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapBusinessCombinationConsiderationTransferred1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PotentialMilestonePayments" xlink:label="loc_CRBPPotentialMilestonePayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPPotentialMilestonePayments" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative" xlink:title="00000038 - Disclosure - Property and Equipment (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapAwardTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="loc_us-gaapDepreciationAndAmortization" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapDepreciationAndAmortization" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements" xlink:label="loc_CRBPWriteOffOfFullyAmortizedLeaseholdImprovements" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPWriteOffOfFullyAmortizedLeaseholdImprovements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="loc_CRBPAreaOfOfficeSpace" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPAreaOfOfficeSpace" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeaseTerm" xlink:label="loc_CRBPLeaseTerm" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_CRBPLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails" xlink:title="00000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="loc_us-gaapPropertyPlantAndEquipmentAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentAbstract" xlink:to="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="loc_us-gaapPropertyPlantAndEquipmentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfPropertyPlantAndEquipmentTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ComputerHardwareAndSoftwareMember" xlink:label="loc_CRBPComputerHardwareAndSoftwareMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPComputerHardwareAndSoftwareMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OfficeFurnitureAndEquipmentMember" xlink:label="loc_CRBPOfficeFurnitureAndEquipmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPOfficeFurnitureAndEquipmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="loc_us-gaapLeaseholdImprovementsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapLeaseholdImprovementsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ConstructionInProgressMember" xlink:label="loc_us-gaapConstructionInProgressMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_us-gaapConstructionInProgressMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="loc_us-gaapPropertyPlantAndEquipmentGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapAccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="loc_us-gaapPropertyPlantAndEquipmentNet" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentLineItems" xlink:to="loc_us-gaapPropertyPlantAndEquipmentNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative" xlink:title="00000040 - Disclosure - Commitments and Contingencies (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CRBPCommitmentAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_CRBPCommitmentAndContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeptemberTwoThousandAndSixteenAmendmentMember" xlink:label="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPSeptemberTwoThousandAndSixteenAmendmentMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CapitalLeaseAgreementMember" xlink:label="loc_CRBPCapitalLeaseAgreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCapitalLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FirstYearMember" xlink:label="loc_CRBPFirstYearMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFirstYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SeventhYearMember" xlink:label="loc_CRBPSeventhYearMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPSeventhYearMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ThirdAnniversaryMember" xlink:label="loc_CRBPThirdAnniversaryMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPThirdAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FourthAnniversaryMember" xlink:label="loc_CRBPFourthAnniversaryMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFourthAnniversaryMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwentySixTwoThousandAndNineteenMember" xlink:label="loc_CRBPFebruaryTwentySixTwoThousandAndNineteenMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPFebruaryTwentySixTwoThousandAndNineteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaapLeaseArrangementTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapLeaseArrangementTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NewPremisesMember" xlink:label="loc_CRBPNewPremisesMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPNewPremisesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TotalPremisesMember" xlink:label="loc_CRBPTotalPremisesMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPTotalPremisesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AreaOfOfficeSpace" xlink:label="loc_CRBPAreaOfOfficeSpace" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPAreaOfOfficeSpace" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseExpirationDate1" xlink:label="loc_us-gaapLeaseExpirationDate1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseExpirationDate1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LettersOfCreditOutstandingAmount" xlink:label="loc_us-gaapLettersOfCreditOutstandingAmount" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLettersOfCreditOutstandingAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseAndRentalExpense" xlink:label="loc_us-gaapLeaseAndRentalExpense" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseAndRentalExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseholdImprovementsGross" xlink:label="loc_us-gaapLeaseholdImprovementsGross" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLeaseholdImprovementsGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LineOfCredit" xlink:label="loc_us-gaapLineOfCredit" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapLineOfCredit" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_UnsecuredDebt" xlink:label="loc_us-gaapUnsecuredDebt" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapUnsecuredDebt" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpense" xlink:label="loc_us-gaapInterestExpense" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapInterestExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LeaseTermDateDescription" xlink:label="loc_CRBPLeaseTermDateDescription" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPLeaseTermDateDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CapitalLeaseTerm" xlink:label="loc_CRBPCapitalLeaseTerm" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_CRBPCapitalLeaseTerm" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails" xlink:title="00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AugustTwoThousandSeventeenLeaseAgreementMember" xlink:label="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPAugustTwoThousandSeventeenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:label="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPFebruaryTwoThousandAndNineteenLeaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInTwoYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInThreeYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFourYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueInFiveYears" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDueThereafter" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapOperatingLeasesFutureMinimumPaymentsDue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails" xlink:title="00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesTable" xlink:label="loc_CRBPCommitmentAndContingenciesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCommitmentsAndContingenciesDisclosureAbstract" xlink:to="loc_CRBPCommitmentAndContingenciesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CommitmentAndContingenciesLineItems" xlink:label="loc_CRBPCommitmentAndContingenciesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_CRBPCommitmentAndContingenciesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesTable" xlink:to="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentByTypeAxis" xlink:to="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CopierMachineMember" xlink:label="loc_CRBPCopierMachineMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPropertyPlantAndEquipmentTypeDomain" xlink:to="loc_CRBPCopierMachineMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsDue" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsDue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:label="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligations" xlink:label="loc_us-gaapCapitalLeaseObligations" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsCurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalLeaseObligationsNoncurrent" xlink:label="loc_us-gaapCapitalLeaseObligationsNoncurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPCommitmentAndContingenciesLineItems" xlink:to="loc_us-gaapCapitalLeaseObligationsNoncurrent" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/NotesPayableDetailsNarrative" xlink:title="00000043 - Disclosure - Notes Payable (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="loc_us-gaapDebtDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTable" xlink:label="loc_us-gaapDebtInstrumentTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtDisclosureAbstract" xlink:to="loc_us-gaapDebtInstrumentTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentLineItems" xlink:label="loc_us-gaapDebtInstrumentLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapDebtInstrumentLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LoanAgreementMember" xlink:label="loc_CRBPLoanAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPLoanAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductOrServiceAxis" xlink:label="loc_srtProductOrServiceAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_srtProductOrServiceAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_ProductsAndServicesDomain" xlink:label="loc_srtProductsAndServicesDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductOrServiceAxis" xlink:to="loc_srtProductsAndServicesDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InsurancePolicyMember" xlink:label="loc_CRBPInsurancePolicyMember" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtProductsAndServicesDomain" xlink:to="loc_CRBPInsurancePolicyMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CreationDateAxis" xlink:label="loc_us-gaapCreationDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentTable" xlink:to="loc_us-gaapCreationDateAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DefaultFinancialStatementsDateMember" xlink:label="loc_us-gaapDefaultFinancialStatementsDateMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCreationDateAxis" xlink:to="loc_us-gaapDefaultFinancialStatementsDateMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromNotesPayable" xlink:label="loc_us-gaapProceedsFromNotesPayable" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapProceedsFromNotesPayable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentPeriodicPayment" xlink:label="loc_us-gaapDebtInstrumentPeriodicPayment" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentPeriodicPayment" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentTerm" xlink:label="loc_us-gaapDebtInstrumentTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:label="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapDebtInstrumentInterestRateStatedPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDebtInstrumentLineItems" xlink:to="loc_us-gaapPrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails" xlink:title="00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PayablesAndAccrualsAbstract" xlink:label="loc_us-gaapPayablesAndAccrualsAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent" xlink:label="loc_CRBPAccruedClinicalOperationsAndTrialsCostsCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CRBPAccruedClinicalOperationsAndTrialsCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AccruedProductDevelopmentCostsCurrent" xlink:label="loc_CRBPAccruedProductDevelopmentCostsCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_CRBPAccruedProductDevelopmentCostsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapEmployeeRelatedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="loc_us-gaapOtherAccruedLiabilitiesCurrent" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapOtherAccruedLiabilitiesCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="loc_us-gaapAccruedLiabilitiesCurrent" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPayablesAndAccrualsAbstract" xlink:to="loc_us-gaapAccruedLiabilitiesCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative" xlink:title="00000045 - Disclosure - Development Awards and Deferred Revenue (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:label="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardTable" xlink:label="loc_CRBPDevelopmentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_CRBPDevelopmentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardLineItems" xlink:label="loc_CRBPDevelopmentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_CRBPDevelopmentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFifteenCFFTAwardArrangementMember" xlink:label="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandFifteenCFFTAwardArrangementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:label="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCysticFibrosisProgramRelatedInvestmentAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CollaborationAgreementMember" xlink:label="loc_CRBPCollaborationAgreementMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCollaborationAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_srtRangeAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:label="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProjectMember" xlink:label="loc_us-gaapProjectMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapCapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis" xlink:to="loc_us-gaapProjectMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OralAntiinflammatoryDrugMember" xlink:label="loc_CRBPOralAntiinflammatoryDrugMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPOralAntiinflammatoryDrugMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_LenabasumMember" xlink:label="loc_CRBPLenabasumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapProjectMember" xlink:to="loc_CRBPLenabasumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementScenarioAxis" xlink:label="loc_us-gaapStatementScenarioAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapStatementScenarioAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScenarioUnspecifiedDomain" xlink:label="loc_us-gaapScenarioUnspecifiedDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementScenarioAxis" xlink:to="loc_us-gaapScenarioUnspecifiedDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponCommercializationOfTheProductMember" xlink:label="loc_CRBPUponCommercializationOfTheProductMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponCommercializationOfTheProductMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponReachingTheSalesTargetMember" xlink:label="loc_CRBPUponReachingTheSalesTargetMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponReachingTheSalesTargetMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UponTransferSaleOrLicensingMember" xlink:label="loc_CRBPUponTransferSaleOrLicensingMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScenarioUnspecifiedDomain" xlink:to="loc_CRBPUponTransferSaleOrLicensingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PhaseTwoBClinicalTrialMember" xlink:label="loc_CRBPPhaseTwoBClinicalTrialMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPPhaseTwoBClinicalTrialMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationWarrantsMember" xlink:label="loc_CRBPCysticFibrosisFoundationWarrantsMember" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPCysticFibrosisFoundationWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CysticFibrosisFoundationMember" xlink:label="loc_CRBPCysticFibrosisFoundationMember" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPCysticFibrosisFoundationMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="loc_CRBPKakenPharmaceuticalCoLtdMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPKakenPharmaceuticalCoLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndEighteenCffAwardMember" xlink:label="loc_CRBPTwoThousandAndEighteenCffAwardMember" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPTwoThousandAndEighteenCffAwardMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_GainContingencyUnrecordedAmount" xlink:label="loc_us-gaapGainContingencyUnrecordedAmount" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapGainContingencyUnrecordedAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_Revenues" xlink:label="loc_us-gaapRevenues" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RoyaltyExpense" xlink:label="loc_us-gaapRoyaltyExpense" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRoyaltyExpense" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PaymentDuePeriodAfterTheFirstCommercialSale" xlink:label="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPPaymentDuePeriodAfterTheFirstCommercialSale" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyPaymentSalesTarget" xlink:label="loc_CRBPRoyaltyPaymentSalesTarget" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPRoyaltyPaymentSalesTarget" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyPaymentPercentage" xlink:label="loc_CRBPRoyaltyPaymentPercentage" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPRoyaltyPaymentPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromRoyaltiesReceived" xlink:label="loc_us-gaapProceedsFromRoyaltiesReceived" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapProceedsFromRoyaltiesReceived" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:label="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" xlink:label="loc_CRBPReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_CRBPReclassifiedToContractAssetAndClassifiedInPrepaidExpenses" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalWarrantIssued" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails" xlink:title="00000046 - Disclosure - Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)">
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DevelopmentAwardsAndDeferredRevenueAbstract" xlink:label="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredRevenueBillingToUponAchievementOfMilestones" xlink:label="loc_CRBPDeferredRevenueBillingToUponAchievementOfMilestones" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_CRBPDeferredRevenueBillingToUponAchievementOfMilestones" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FairValueOfWarrant" xlink:label="loc_CRBPFairValueOfWarrant" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_CRBPFairValueOfWarrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:label="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ContractWithCustomerLiabilityCurrent" xlink:label="loc_us-gaapContractWithCustomerLiabilityCurrent_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPDevelopmentAwardsAndDeferredRevenueAbstract" xlink:to="loc_us-gaapContractWithCustomerLiabilityCurrent_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxesDetailsNarrative" xlink:title="00000047 - Disclosure - Income Taxes (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncomeTaxesTable" xlink:label="loc_CRBPIncomeTaxesTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_CRBPIncomeTaxesTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_IncomeTaxesLineItems" xlink:label="loc_CRBPIncomeTaxesLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_CRBPIncomeTaxesLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="loc_us-gaapIncomeTaxAuthorityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeTaxAuthorityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="loc_us-gaapIncomeTaxAuthorityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityAxis" xlink:to="loc_us-gaapIncomeTaxAuthorityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FederalMember" xlink:label="loc_CRBPFederalMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPFederalMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_MassachusettMember" xlink:label="loc_CRBPMassachusettMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPMassachusettMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:label="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxAuthorityDomain" xlink:to="loc_CRBPTaxCutAndJobsActOfTwoThousandSeventeenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="loc_us-gaapIncomeStatementLocationAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapIncomeStatementLocationAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="loc_us-gaapIncomeStatementLocationDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationAxis" xlink:to="loc_us-gaapIncomeStatementLocationDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_InterestExpenseMember" xlink:label="loc_us-gaapInterestExpenseMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeStatementLocationDomain" xlink:to="loc_us-gaapInterestExpenseMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardAxis" xlink:label="loc_us-gaapTaxCreditCarryforwardAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_us-gaapTaxCreditCarryforwardAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TaxCreditCarryforwardNameDomain" xlink:label="loc_us-gaapTaxCreditCarryforwardNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardAxis" xlink:to="loc_us-gaapTaxCreditCarryforwardNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OrphanDrugCreditMember" xlink:label="loc_CRBPOrphanDrugCreditMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTaxCreditCarryforwardNameDomain" xlink:to="loc_CRBPOrphanDrugCreditMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesTable" xlink:to="loc_srtRangeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="loc_us-gaapOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:label="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_CRBPDeferredTaxAssetsOperatingLossCarryforwardsExpirationYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LiabilityForUncertainTaxPositionsCurrent" xlink:label="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapLiabilityForUncertainTaxPositionsCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxExaminationDescription" xlink:label="loc_us-gaapIncomeTaxExaminationDescription" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapIncomeTaxExaminationDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit" xlink:label="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_CRBPIncomeTaxesLineItems" xlink:to="loc_us-gaapDeferredFederalStateAndLocalTaxExpenseBenefit" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails" xlink:title="00000048 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="loc_us-gaapDeferredTaxAssetsNetAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:label="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOperatingLossCarryforwardsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:label="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:label="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsOther" xlink:label="loc_us-gaapDeferredTaxAssetsOther" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsOther" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="loc_us-gaapDeferredTaxAssetsGross" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsGross" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsValuationAllowance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="loc_us-gaapDeferredTaxAssetsNet" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDeferredTaxAssetsNetAbstract" xlink:to="loc_us-gaapDeferredTaxAssetsNet" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails" xlink:title="00000049 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="loc_us-gaapIncomeTaxDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsForeign" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCreditsForeign" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationTaxCredits" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationOtherAdjustments" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapIncomeTaxDisclosureAbstract" xlink:to="loc_us-gaapEffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/CommonStockDetailsNarrative" xlink:title="00000050 - Disclosure - Common Stock (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityAbstract" xlink:label="loc_us-gaapEquityAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SecuritiesPurchaseAgreementMember" xlink:label="loc_CRBPSecuritiesPurchaseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSecuritiesPurchaseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember" xlink:label="loc_CRBPJanuaryTwoThousandAndEighteenSalesAgreementMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPJanuaryTwoThousandAndEighteenSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_SalesAgreementMember" xlink:label="loc_CRBPSalesAgreementMember" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPSalesAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionAxis" xlink:label="loc_us-gaapRelatedPartyTransactionAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDomain" xlink:label="loc_us-gaapRelatedPartyTransactionDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionAxis" xlink:to="loc_us-gaapRelatedPartyTransactionDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalAndAccreditedInvestorsMember" xlink:label="loc_CRBPInstitutionalAndAccreditedInvestorsMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPInstitutionalAndAccreditedInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalInvestorMember" xlink:label="loc_CRBPInstitutionalInvestorMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionDomain" xlink:to="loc_CRBPInstitutionalInvestorMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InstitutionalInvestorsMember" xlink:label="loc_CRBPInstitutionalInvestorsMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPInstitutionalInvestorsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_AtTheMarketOfferingMember" xlink:label="loc_CRBPAtTheMarketOfferingMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPAtTheMarketOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_Remainder2018AndThroughFebruary82019Member" xlink:label="loc_CRBPRemainder2018AndThroughFebruary82019Member" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPRemainder2018AndThroughFebruary82019Member" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_srtRangeAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentRiskAxis" xlink:label="loc_us-gaapDerivativeInstrumentRiskAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapDerivativeInstrumentRiskAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeContractTypeDomain" xlink:label="loc_us-gaapDerivativeContractTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentRiskAxis" xlink:to="loc_us-gaapDerivativeContractTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_StockOptionAndWarrantsMember" xlink:label="loc_CRBPStockOptionAndWarrantsMember" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeContractTypeDomain" xlink:to="loc_CRBPStockOptionAndWarrantsMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="loc_us-gaapCommonStockSharesAuthorized" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesAuthorized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="loc_us-gaapCommonStockParOrStatedValuePerShare" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockParOrStatedValuePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="loc_us-gaapCommonStockSharesIssued" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesIssued" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="loc_us-gaapCommonStockSharesOutstanding" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="loc_us-gaapProceedsFromStockOptionsExercised" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromStockOptionsExercised" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptionsDetailsNarrative" xlink:title="00000051 - Disclosure - Stock Options (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_deiLegalEntityAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapPlanNameAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardTypeAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapAwardDateAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_JanuaryOneTwoThousandandNiniteenMember" xlink:label="loc_CRBPJanuaryOneTwoThousandandNiniteenMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CRBPJanuaryOneTwoThousandandNiniteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EmployeesMember" xlink:label="loc_CRBPEmployeesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NonEmployeesMember" xlink:label="loc_CRBPNonEmployeesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPNonEmployeesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeAxis" xlink:label="loc_srtRangeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_srtRangeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_RangeMember" xlink:label="loc_srtRangeMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeAxis" xlink:to="loc_srtRangeMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MinimumMember" xlink:label="loc_srtMinimumMember" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMinimumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/srt/2018/elts/srt-2018-01-31.xsd#srt_MaximumMember" xlink:label="loc_srtMaximumMember" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srtRangeMember" xlink:to="loc_srtMaximumMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="loc_us-gaapShareBasedCompensation" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensation" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapEmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails" xlink:title="00000052 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="loc_us-gaapEmployeeStockOptionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapEmployeeStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails" xlink:title="00000053 - Disclosure - Stock Options - Summary of Option Activity (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapStockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails" xlink:title="00000054 - Disclosure - Stock Options - Summary of Non-Vested Stock Options (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue_2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/WarrantsDetailsNarrative" xlink:title="00000055 - Disclosure - Warrants (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_InvestmentagreementMember" xlink:label="loc_CRBPInvestmentagreementMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPInvestmentagreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CFFWarrantMember" xlink:label="loc_CRBPCFFWarrantMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CRBPCFFWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="loc_us-gaapProceedsFromWarrantExercises" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapProceedsFromWarrantExercises" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_WarrantsWeightedAverageRemainingContractualTerm" xlink:label="loc_CRBPWarrantsWeightedAverageRemainingContractualTerm" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CRBPWarrantsWeightedAverageRemainingContractualTerm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NumberOfWarrantsExercisableForCommonStock" xlink:label="loc_CRBPNumberOfWarrantsExercisableForCommonStock" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_CRBPNumberOfWarrantsExercisableForCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingMaturityDate" xlink:label="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapWarrantsAndRightsOutstandingMaturityDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_FairValueAdjustmentOfWarrants" xlink:label="loc_us-gaapFairValueAdjustmentOfWarrants" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapFairValueAdjustmentOfWarrants" xlink:type="arc" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails" xlink:title="00000056 - Disclosure - Warrants - Schedule of Weighted Average Assumption of Warrants (Details)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:label="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightTable" xlink:label="loc_us-gaapClassOfWarrantOrRightTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapDerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract" xlink:to="loc_us-gaapClassOfWarrantOrRightTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ClassOfWarrantOrRightLineItems" xlink:label="loc_us-gaapClassOfWarrantOrRightLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapClassOfWarrantOrRightLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_WarrantMember" xlink:label="loc_us-gaapWarrantMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_us-gaapWarrantMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapClassOfWarrantOrRightLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative" xlink:title="00000057 - Disclosure - Related Party Transactions (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsAbstract" xlink:label="loc_us-gaapRelatedPartyTransactionsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:label="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsAbstract" xlink:to="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionLineItems" xlink:label="loc_us-gaapRelatedPartyTransactionLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyDomain" xlink:label="loc_us-gaapRelatedPartyDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionsByRelatedPartyAxis" xlink:to="loc_us-gaapRelatedPartyDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_OrchestraMedicalVenturesLLCMember" xlink:label="loc_CRBPOrchestraMedicalVenturesLLCMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyDomain" xlink:to="loc_CRBPOrchestraMedicalVenturesLLCMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandAndSixteenConsultingAgreementMember" xlink:label="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPTwoThousandAndSixteenConsultingAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityCompensationPlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityCompensationPlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeAxis" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapScheduleOfRelatedPartyTransactionsByRelatedPartyTable" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:label="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeAxis" xlink:to="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StockOptionMember" xlink:label="loc_us-gaapStockOptionMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapOptionIndexedToIssuersEquityTypeDomain" xlink:to="loc_us-gaapStockOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RelatedPartyTransactionDate" xlink:label="loc_us-gaapRelatedPartyTransactionDate" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapRelatedPartyTransactionDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CashCompensationAmount" xlink:label="loc_CRBPCashCompensationAmount" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_CRBPCashCompensationAmount" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:label="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapSharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="loc_us-gaapAllocatedShareBasedCompensationExpense" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapRelatedPartyTransactionLineItems" xlink:to="loc_us-gaapAllocatedShareBasedCompensationExpense" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
    </link:presentationLink>
    <link:presentationLink xlink:type="extended" xlink:role="http://corbuspharma.com/role/SubsequentEventsDetailsNarrative" xlink:title="00000058 - Disclosure - Subsequent Events (Details Narrative)">
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventsAbstract" xlink:label="loc_us-gaapSubsequentEventsAbstract" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementTable" xlink:label="loc_us-gaapStatementTable" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventsAbstract" xlink:to="loc_us-gaapStatementTable" order="100" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementLineItems" xlink:label="loc_us-gaapStatementLineItems" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementLineItems" order="200" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="loc_us-gaapSubsequentEventTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapSubsequentEventTypeAxis" order="10" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="loc_us-gaapSubsequentEventTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeAxis" xlink:to="loc_us-gaapSubsequentEventTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="loc_us-gaapSubsequentEventMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapSubsequentEventTypeDomain" xlink:to="loc_us-gaapSubsequentEventMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_LegalEntityAxis" xlink:label="loc_deiLegalEntityAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_deiLegalEntityAxis" order="20" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2018/dei-2018-01-31.xsd#dei_EntityDomain" xlink:label="loc_deiEntityDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiLegalEntityAxis" xlink:to="loc_deiEntityDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_EvergreenProvisionMember" xlink:label="loc_CRBPEvergreenProvisionMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPEvergreenProvisionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_KakenPharmaceuticalCoLtdMember" xlink:label="loc_CRBPKakenPharmaceuticalCoLtdMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiEntityDomain" xlink:to="loc_CRBPKakenPharmaceuticalCoLtdMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="loc_us-gaapPlanNameAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapPlanNameAxis" order="30" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="loc_us-gaapPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameAxis" xlink:to="loc_us-gaapPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TwoThousandFourteenEquityIncentivePlanMember" xlink:label="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapPlanNameDomain" xlink:to="loc_CRBPTwoThousandFourteenEquityIncentivePlanMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="loc_us-gaapTypeOfArrangementAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapTypeOfArrangementAxis" order="40" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapTypeOfArrangementAxis" xlink:to="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_CollaborationandLicenseAgreementMember" xlink:label="loc_CRBPCollaborationandLicenseAgreementMember" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapArrangementsAndNonarrangementTransactionsMember" xlink:to="loc_CRBPCollaborationandLicenseAgreementMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateAxis" xlink:label="loc_us-gaapAwardDateAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardDateAxis" order="50" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardDateDomain" xlink:label="loc_us-gaapAwardDateDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateAxis" xlink:to="loc_us-gaapAwardDateDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_FirstQuarterofTwoThousandandNineteenMember" xlink:label="loc_CRBPFirstQuarterofTwoThousandandNineteenMember" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardDateDomain" xlink:to="loc_CRBPFirstQuarterofTwoThousandandNineteenMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="loc_us-gaapAwardTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapAwardTypeAxis" order="60" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapAwardTypeAxis" xlink:to="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_PublicOfferingMember" xlink:label="loc_CRBPPublicOfferingMember" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_CRBPPublicOfferingMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_IPOMember" xlink:label="loc_us-gaapIPOMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaapIPOMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="loc_us-gaapStatementEquityComponentsAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapStatementEquityComponentsAxis" order="70" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="loc_us-gaapEquityComponentDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementEquityComponentsAxis" xlink:to="loc_us-gaapEquityComponentDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_UnderwritersOptionMember" xlink:label="loc_CRBPUnderwritersOptionMember" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapEquityComponentDomain" xlink:to="loc_CRBPUnderwritersOptionMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeAxis" xlink:label="loc_us-gaapLeaseArrangementTypeAxis" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementTable" xlink:to="loc_us-gaapLeaseArrangementTypeAxis" order="80" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_LeaseArrangementTypeDomain" xlink:label="loc_us-gaapLeaseArrangementTypeDomain" />
      <link:presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeAxis" xlink:to="loc_us-gaapLeaseArrangementTypeDomain" order="0" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_NewPremisesMember" xlink:label="loc_CRBPNewPremisesMember" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPNewPremisesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_TotalPremisesMember" xlink:label="loc_CRBPTotalPremisesMember" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapLeaseArrangementTypeDomain" xlink:to="loc_CRBPTotalPremisesMember" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:label="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapCommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_RevenueFromRelatedParties" xlink:label="loc_us-gaapRevenueFromRelatedParties" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapRevenueFromRelatedParties" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:label="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="crbp-20181231.xsd#CRBP_RoyaltyTermDescription" xlink:label="loc_CRBPRoyaltyTermDescription" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_CRBPRoyaltyTermDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:label="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_SaleOfStockPricePerShare" xlink:label="loc_us-gaapSaleOfStockPricePerShare" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapSaleOfStockPricePerShare" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="loc_us-gaapProceedsFromIssuanceOfCommonStock" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapProceedsFromIssuanceOfCommonStock" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:label="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2018/elts/us-gaap-2018-01-31.xsd#us-gaap_AreaOfLand" xlink:label="loc_us-gaapAreaOfLand" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaapStatementLineItems" xlink:to="loc_us-gaapAreaOfLand" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813874416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Mar. 06, 2019</div></th>
<th class="th"><div>Jun. 30, 2018</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DocumentAndEntityInformationAbstract', window );"><strong>Document And Entity Information</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Corbus Pharmaceuticals Holdings, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001595097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 271,269,436<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">64,395,221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">CRBP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2018<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DocumentAndEntityInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DocumentAndEntityInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>If the value is true, then the document is an amendment to previously-filed/accepted document.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal period of the document report. For a first quarter 2006 quarterly report, which may also provide financial information from prior periods, the first fiscal quarter should be given as the fiscal period focus. Values: FY, Q1, Q2, Q3, Q4, H1, H2, M9, T1, T2, T3, M8, CY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented.  If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: (1) Large Accelerated Filer, (2) Accelerated Filer, (3) Non-accelerated Filer, (4) Smaller Reporting Company (Non-accelerated), (5) Smaller Reporting Accelerated Filer or (6) Smaller Reporting Company and Large Accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>State aggregate market value of voting and non-voting common equity held by non-affiliates computed by reference to price at which the common equity was last sold, or average bid and asked price of such common equity, as of the last business day of registrant's most recently completed second fiscal quarter. The public float should be reported on the cover page of the registrants form 10K.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if company meets the shell company criteria: a company with no or nominal operations, and with no or nominal assets or assets consisting solely of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a smaller reporting company with both a public float and revenues of less than $75 million.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation 12B<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6814570992">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 41,748,468<span></span>
</td>
<td class="nump">$ 62,537,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">158,991<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">2,491,844<span></span>
</td>
<td class="nump">2,808,244<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">44,240,312<span></span>
</td>
<td class="nump">65,504,730<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,705,206<span></span>
</td>
<td class="nump">1,432,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">43,823<span></span>
</td>
<td class="nump">40,776<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">46,989,341<span></span>
</td>
<td class="nump">66,978,161<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NotesPayableCurrent', window );">Notes payable</a></td>
<td class="nump">394,305<span></span>
</td>
<td class="nump">332,861<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">6,345,335<span></span>
</td>
<td class="nump">3,130,295<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">9,851,191<span></span>
</td>
<td class="nump">4,741,519<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, current</a></td>
<td class="nump">1,462,503<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditCurrent', window );">Deferred rent, current</a></td>
<td class="nump">35,996<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">18,089,330<span></span>
</td>
<td class="nump">8,204,675<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredRentCreditNoncurrent', window );">Deferred rent, noncurrent</a></td>
<td class="nump">1,375,891<span></span>
</td>
<td class="nump">989,550<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other liabilities</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">19,465,221<span></span>
</td>
<td class="nump">9,194,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred Stock $0.0001 par value:10,000,000 shares authorized, no shares issued and outstanding at December 31, 2018 and 2017</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.0001 par value; 150,000,000 shares authorized at December 31, 2018 and 2017, 57,247,496 and 55,603,427 shares issued and outstanding at December 31, 2018 and 2017, respectively</a></td>
<td class="nump">5,725<span></span>
</td>
<td class="nump">5,560<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">148,888,635<span></span>
</td>
<td class="nump">123,476,102<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(121,370,240)<span></span>
</td>
<td class="num">(65,698,101)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">27,524,120<span></span>
</td>
<td class="nump">57,783,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 46,989,341<span></span>
</td>
<td class="nump">$ 66,978,161<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6801-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82911808&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference as of the balance sheet date between the payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, within one year of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRentCreditNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For a classified balance sheet, the cumulative difference between the rental income or payments required by a lease agreement and the rental income or expense recognized on a straight-line basis, or other systematic and rational basis more representative of the time pattern in which use or benefit is granted or derived from the leased property, expected to be recognized in income or expense, by the lessor or lessee, respectively, more than one year after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.26(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902458&amp;loc=d3e39927-112707<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRentCreditNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NotesPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of the portions of long-term notes payable due within one year or the operating cycle if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19,20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NotesPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6787-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 340<br> -SubTopic 10<br> -Section 05<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=68074540&amp;loc=d3e5879-108316<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6814061152">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">57,247,496<span></span>
</td>
<td class="nump">55,603,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">57,247,496<span></span>
</td>
<td class="nump">55,603,427<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813944864">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue from awards</a></td>
<td class="nump">$ 4,822,272<span></span>
</td>
<td class="nump">$ 2,440,195<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">48,613,957<span></span>
</td>
<td class="nump">26,038,965<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">12,956,022<span></span>
</td>
<td class="nump">8,964,046<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">61,569,979<span></span>
</td>
<td class="nump">35,003,011<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(56,747,707)<span></span>
</td>
<td class="num">(32,562,816)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense), net:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income, net</a></td>
<td class="nump">982,777<span></span>
</td>
<td class="nump">183,112<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax', window );">Foreign currency exchange gain (loss)</a></td>
<td class="nump">92,791<span></span>
</td>
<td class="num">(41,908)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,075,568<span></span>
</td>
<td class="nump">141,204<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,672,139)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share, basic and diluted</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average number of common shares outstanding, basic and diluted</a></td>
<td class="nump">56,999,741<span></span>
</td>
<td class="nump">50,176,953<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionGainLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized gain (loss) recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionGainLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6814861168">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Statements of Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Accumulated Deficit [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2016</a></td>
<td class="nump">$ 4,468<span></span>
</td>
<td class="nump">$ 42,191,256<span></span>
</td>
<td class="num">$ (33,276,489)<span></span>
</td>
<td class="nump">$ 8,919,235<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2016</a></td>
<td class="nump">44,681,745<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">5,694,489<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">5,694,489<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 1,065<span></span>
</td>
<td class="nump">75,400,894<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">75,401,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">10,648,948<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 27<span></span>
</td>
<td class="nump">189,463<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 189,490<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">272,734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">272,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(32,421,612)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2017</a></td>
<td class="nump">$ 5,560<span></span>
</td>
<td class="nump">123,476,102<span></span>
</td>
<td class="num">(65,698,101)<span></span>
</td>
<td class="nump">57,783,561<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2017</a></td>
<td class="nump">55,603,427<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">7,609,508<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">7,609,508<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">$ 150<span></span>
</td>
<td class="nump">11,235,170<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">11,235,320<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs, shares</a></td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options</a></td>
<td class="nump">$ 14<span></span>
</td>
<td class="nump">347,631<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 347,645<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="nump">139,069<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 1<span></span>
</td>
<td class="nump">4,999<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Fair value of warrant issued in connection with Investment Agreement</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">6,215,225<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">6,215,225<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="num">(55,672,139)<span></span>
</td>
<td class="num">(55,672,139)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at Dec. 31, 2018</a></td>
<td class="nump">$ 5,725<span></span>
</td>
<td class="nump">$ 148,888,635<span></span>
</td>
<td class="num">$ (121,370,240)<span></span>
</td>
<td class="nump">$ 27,524,120<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance, shares at Dec. 31, 2018</a></td>
<td class="nump">57,247,496<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) from recognition of equity-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109196918&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=79507207&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=27010918&amp;loc=d3e74512-122707<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804990144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Statements of Stockholders' Equity (Parenthetical) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 464,680<span></span>
</td>
<td class="nump">$ 2,969,837<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800828544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,672,139)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">7,609,508<span></span>
</td>
<td class="nump">5,694,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">493,938<span></span>
</td>
<td class="nump">255,652<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax', window );">Loss(gain) on foreign exchange</a></td>
<td class="nump">70,448<span></span>
</td>
<td class="num">(8,490)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncreaseDecreaseInDeferredRent', window );">Deferred rent</a></td>
<td class="nump">422,337<span></span>
</td>
<td class="nump">913,563<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInReceivables', window );">Decrease in customer receivable</a></td>
<td class="nump">12,500,000<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidExpense', window );">Decrease (increase) in prepaid expenses and other current assets</a></td>
<td class="nump">281,625<span></span>
</td>
<td class="num">(1,877,983)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets', window );">Increase in other assets</a></td>
<td class="num">(3,047)<span></span>
</td>
<td class="num">(40,776)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Increase (decrease) in accounts payable</a></td>
<td class="nump">3,904,021<span></span>
</td>
<td class="num">(885,797)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Increase in accrued expenses</a></td>
<td class="nump">5,113,551<span></span>
</td>
<td class="nump">1,514,521<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Decrease in deferred revenue</a></td>
<td class="num">(4,787,497)<span></span>
</td>
<td class="num">(1,940,195)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(30,067,255)<span></span>
</td>
<td class="num">(27,796,628)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,300,416)<span></span>
</td>
<td class="num">(707,429)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(2,300,416)<span></span>
</td>
<td class="num">(707,429)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="nump">491,629<span></span>
</td>
<td class="nump">415,265<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfNotesPayable', window );">Principal payments on notes payable</a></td>
<td class="num">(430,184)<span></span>
</td>
<td class="num">(354,161)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">12,052,645<span></span>
</td>
<td class="nump">78,891,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts', window );">Issuance costs paid for common stock financings</a></td>
<td class="num">(690,181)<span></span>
</td>
<td class="num">(2,940,685)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations', window );">Principal payments under capital lease obligations</a></td>
<td class="num">(4,256)<span></span>
</td>
<td class="num">(3,832)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">11,419,653<span></span>
</td>
<td class="nump">76,008,286<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net (decrease) increase in cash, cash equivalents, and restricted cash</a></td>
<td class="num">(20,948,018)<span></span>
</td>
<td class="nump">47,504,229<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at beginning of the year</a></td>
<td class="nump">62,696,486<span></span>
</td>
<td class="nump">15,192,257<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents, and restricted cash at end of the year</a></td>
<td class="nump">41,748,468<span></span>
</td>
<td class="nump">62,696,486<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information and non cash transactions:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid during the period for interest</a></td>
<td class="nump">10,437<span></span>
</td>
<td class="nump">12,377<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WarrantsIssuanceFairValue', window );">Fair value of warrant issued in connection with Investment Agreement</a></td>
<td class="nump">6,215,225<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property and equipment included in accounts payable or accrued expenses</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">579,734<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements', window );">Write off of fully amortized leasehold improvements</a></td>
<td class="nump">191,244<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssued1', window );">Unpaid stock issuance costs</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 225,501<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IncreaseDecreaseInDeferredRent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Increase Decrease In Deferred Rent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IncreaseDecreaseInDeferredRent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WarrantsIssuanceFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WarrantsIssuanceFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of fully amortized leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513438&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ForeignCurrencyTransactionLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before tax of foreign currency transaction realized and unrealized loss recognized in the income statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30690-110894<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109240200&amp;loc=d3e30700-110894<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450222&amp;loc=d3e30840-110895<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ForeignCurrencyTransactionLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the total amount due within one year (or one operating cycle) from all parties, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentOfFinancingAndStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total of the cash outflow during the period which has been paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt and the cost incurred directly for the issuance of equity securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentOfFinancingAndStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermCapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the obligation for a lease meeting the criteria for capitalization (with maturities exceeding one year or beyond the operating cycle of the entity, if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermCapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssued1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The fair value of stock issued in noncash financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4304-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4332-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4313-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssued1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804822240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Operations<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>1.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>NATURE OF OPERATIONS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Business</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Corbus Pharmaceuticals Holdings,
Inc. (&#8220;the Company&#8221;) is a clinical stage pharmaceutical company, focused on the development and commercialization
of novel therapeutics to treat rare, chronic, and serious inflammatory and fibrotic diseases. Since its inception, the Company
has devoted substantially all of its efforts to business planning, research and development, recruiting management and technical
staff, acquiring operating assets and raising capital. The Company&#8217;s business is subject to significant risks and uncertainties
and the Company will be dependent on raising substantial additional capital before it becomes profitable and it may never achieve
profitability.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796434096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock', window );">Liquidity</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>2.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>LIQUIDITY </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company anticipates operating
losses to continue for the foreseeable future due to, among other things, costs related to research funding, development of its
product candidates and its preclinical and clinical programs, strategic alliances and the development of its administrative organization.
The Company has incurred recurring losses since inception and as of December 31, 2018, had an accumulated deficit of $121,370,240.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 3, 2019, the Company
entered into a strategic collaboration with Kaken Pharmaceutical Co., Ltd. (&#8220;Kaken&#8221;) (See Note 15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 30, 2019, the Company
consummated an underwritten public offering of shares of its common stock (&#8220;January 2019 Offering&#8221;) (See Note 15).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company expects the cash and
cash equivalents of $41,748,468 at December 31, 2018 together with the $27 million of upfront payment to be received from Kaken,
less the $2.7 million royalty (which is 10% of such upfront payment) that the Company will owe to CFF pursuant to the Investment
Agreement (See Note 9), and the approximately $37.6 million of net proceeds from the January 2019 Offering, to be sufficient to
meet its operating and capital requirements at least 12 months from the filing of this 10-K.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Should the Company be unable to
raise sufficient additional capital, the Company may be required to undertake cost-cutting measures including delaying or discontinuing
certain clinical activities. The Company will need to raise significant additional capital to continue to fund the clinical trials
for lenabasum and CRB-4001 (see Note 4). The Company may seek to sell common or preferred equity or convertible debt securities,
enter into a credit facility or another form of third-party funding, or seek other debt financing. The sale of equity and convertible
debt securities may result in dilution to the Company&#8217;s stockholders and certain of those securities may have rights senior
to those of the Company&#8217;s common shares. If the Company raises additional funds through the issuance of preferred stock,
convertible debt securities or other debt financing, these securities or other debt could contain covenants that would restrict
the Company&#8217;s operations. Any other third-party funding arrangement could require the Company to relinquish valuable rights.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The source, timing and availability
of any future financing will depend principally upon market conditions, and, more specifically, on the progress of the Company&#8217;s
clinical development programs. Funding may not be available when needed, at all, or on terms acceptable to the Company. Lack of
necessary funds may require the Company, among other things, to delay, scale back or eliminate some or all of the Company&#8217;s
planned clinical trials.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubstantialDoubtAboutGoingConcernTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 40<br> -URI http://asc.fasb.org/subtopic&amp;trid=51888271<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubstantialDoubtAboutGoingConcernTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804787776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>3.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>SIGNIFICANT ACCOUNTING POLICIES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">A summary of the significant accounting
policies followed by the Company in the preparation of the financial statements is as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The process of preparing financial
statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates
are related to stock-based compensation expense, the accrual of research, product development and clinical obligations, the recognition
of revenue under the Investment Agreement (see Note 9) and the valuation of the CFF Warrant discussed in Note 9).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company considers only those
investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to
be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2018
and 2017, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2018
and 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Restricted cash as of December 31,
2017 in the amount of $108,991 was classified in current assets and included a collateral account for the Company&#8217;s corporate
credit cards. The collateral account was closed in the first quarter of 2018 and accordingly the cash became unrestricted. Additionally,
as of December 31, 2017, restricted cash included a stand-by letter of credit issued in favor of a landlord for $50,000 which was
classified in current assets as of December 31, 2017. This stand-by letter of credit was terminated in the first quarter of 2018
in connection with the August 2017 Lease Agreement discussed in Note 6, and accordingly, the cash became unrestricted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Cash, cash equivalents, and restricted
cash consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">808,943</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">206,510</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Money market fund</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">40,939,525</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,330,985</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">41,748,468</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">62,537,495</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,748,468</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">62,696,486</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As of December 31, 2018, all of
the Company&#8217;s cash was held in the United States, except for approximately $702,000 of cash which was held in our subsidiary
in the United Kingdom. As of December 31, 2017, all of the Company&#8217;s cash was held in the United States.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Financial Instruments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The carrying amounts reported in
the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their
fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair
value due to the fact that they are at market terms.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The estimated life for the Company&#8217;s
property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture
and equipment. The Company&#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their
useful lives or the respective leases. See Note 5 for details of property and equipment and Note 6 for operating and capital lease
commitments.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;<b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Costs incurred for research and
development are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Nonrefundable advance payments for
goods or services that have the characteristics that will be used or rendered for future research and development activities pursuant
to executory contractual arrangements with third party research organizations are deferred and recognized as an expense as the
related goods are delivered or the related services are performed.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Accruals for Research and
Development Expenses and Clinical Trials</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As part of the process of preparing
its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with
vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical
trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects
of the expenses. The Company determines the accrual estimates by taking into account discussion with applicable personnel and outside
service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial, the
Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates of its
accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding
of the status and timing of services performed relative to the actual status and timing of services performed may vary and may
result in it reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2018 and
2017, there were no material adjustments to the Company&#8217;s prior period estimates of accrued expenses for clinical trials.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Leases and Deferred Rent</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company leases its office space.
Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&#8217;s office
space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records
the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between
the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the lessor
are recorded as a reduction to rent expense over the term of the lease.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has no significant off-balance-sheet
concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements. The Company may
from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However, the Company
believes the risk of loss is minimal as these banks are large financial institutions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. To date,
the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing
therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2018 and 2017, all of the Company&#8217;s
assets were located in the United States, except for approximately $702,000 of cash, $1,183,000 of prepaid expenses, $28,000 of
other assets, and $54,000 of property and equipment, net which were held in our subsidiary in the United Kingdom as of December
31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For federal and state income taxes,
deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax
basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in
which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax benefit when it is not
more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses
since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate
the deferred tax assets amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Tax positions taken or expected
to be taken in the course of preparing the Company&#8217;s tax returns are required to be evaluated to determine whether the tax
positions are &#8220;more-likely-than-not&#8221; of being sustained by the applicable tax authority. Tax positions not deemed to
meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense in
the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December
31, 2018 or 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On December 22, 2017, Staff Accounting
Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does
not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete the
accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, the Company had recorded a provisional estimate
in these financial statements for the effect of the corporate tax rate change. The Company finalized its estimates during the fourth
quarter of 2018, described more fully in Note 10.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company continually monitors
events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An impairment
loss is recognized when expected undiscounted cash flows of an asset are less than an asset&#8217;s carrying value. Accordingly,
when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to the operating
performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess of the fair value
of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset may not be recoverable.
No impairment charges were recorded for the years ended December 31, 2018 and 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Stock-based Payments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company recognizes compensation
costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement
of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option
grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model, net of estimated forfeitures.
The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which
is generally the vesting period. Stock options granted to non-employee consultants are revalued at the end of each reporting period
until vested using the Black-Scholes option-pricing model and the changes in their fair value are recorded as adjustments to expense
over the related vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On March 30, 2016, the FASB issued
ASU No. 2016-09, <i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
</i>(&#8220;ASU 2016-09&#8221;)<i>. </i>ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment
transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification
in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures
as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have
an impact on the Company&#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the excess
tax benefits in respect of share based payments only when realized (See Note 10).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Basic and diluted net loss per share
of the Company&#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding
during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted
loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years
ended December 31, 2018 and 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Years Ended December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Basic and diluted net loss per share of common stock:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(55,672,139</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(32,421,612</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average shares of common stock outstanding</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">56,999,741</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,176,953</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share of common stock-basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.98</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.65</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The impact of the following potentially
dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the computation of dilutive weighted average
shares outstanding as the inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,283,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">9,593,990</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,877,490</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,133,466</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>Revenue Recognition</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In May 2014, the FASB issued guidance
codified in <i>Accounting Standards Codification (ASC) 606, Revenue Recognition &#8212; Revenue from Contracts with Customers</i>
(&#8220;ASC 606&#8221;) which amends the guidance in former <i>ASC 605, Revenue Recognition</i>, and is effective for public companies
for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from ASC 605 in many respects,
such as in the accounting for variable consideration received, including milestone payments or contingent payments. Under the Company&#8217;s
accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone payments were initially recognized only
in the period that the payment-triggering event occurred or was achieved (See Note 9). ASC 606, however, may require a company
to recognize such payments before the payment-triggering event is completely achieved based on the Company&#8217;s estimate of
the amount of consideration to which it will be entitled in exchange for transferring the services, subject to management&#8217;s
assessment of whether it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company adopted ASC 606 in the
first quarter of 2018 using the modified retrospective method according to which the cumulative effect of initially applying ASC
606 is recognized at the date of initial application, and elected to utilize a practical expedient and did not restate contracts
that were completed as of the date of adoption. Since the Company has concluded its performance obligations and has completed recognizing
revenue under the 2015 CFFT Award in the third quarter of 2017 (See Note 9), there was no cumulative effect to record at the date
of the Company&#8217;s adoption of ASC 606 and no revenue to recognize for the first quarter of 2018 related to the 2015 CFFT Award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Revenue for the quarter and the
year ended December 31, 2018 was $1,927,306 and $4,822,272, respectively, recognized in accordance with ASC 606 and pertains only
to the 2018 CFF Award discussed in Note 9. The total impact to revenue as a result of the adoption of ASC 606 was higher revenue
of approximately $325,000 for the quarter ended December 31, 2018 and lower revenue of approximately $201,000 for the year ended
December 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company will assess any new
agreements it enters into under ASC 606, including whether such agreements fall under the scope of such standard. This standard
applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance,
collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for
those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC
606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange
for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is
satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Revenue associated with the 2018
CFF Award performance obligation is being recognized as revenue as the research and development services are provided using an
input method, according to the costs incurred as related to the research and development activities and the costs expected to be
incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s
judgment, is the best measure of progress towards satisfying the performance obligation. The research and development services
related to this performance obligation are expected to be performed over an approximately two and a half-year period expected to
be completed in the second quarter of 2020. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts
expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of
deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12
months following the balance sheet date would be classified as deferred revenue, net of current portion. Amounts recognized as
revenue, but not yet received or invoiced are generally recognized as contract assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Accounting for Leases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In February 2016, the FASB issued
ASU No<b>. </b>2016-02, <i>Leases (Topic 842), </i>as amended (&#8220;ASU 2016-02&#8221;)<i>. </i>Under ASU 2016-02, a lessee will
be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current
US GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will
depend on its classification as a finance or operating lease. However, unlike current US GAAP, which requires only capital leases
to be recognized on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU
2016-02 will take effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. ASU
2016-02 required a modified retrospective transition approach, which initially required application of the new guidance for all
periods presented in the Company&#8217;s financial statements (&#8220;comparative method&#8221;). In July 2018, the FASB released
ASU 2018-11, offering a second option which provides further relief in the transition to ASC 842. Companies are allowed to follow
the cumulative-effect adjustment transition approach (&#8220;effective date method&#8221;), which releases companies from presenting
comparative periods and related disclosures according to ASC 842. Instead, companies electing to utilize the effective date method
will recognize a one-time adjustment to retained earnings on the transition date without the additional burden of presenting the
comparative periods under the new guidance. The Company will adopt ASU 2016-02 using the effective date method as of January 1,
2019 and expects to record a lease liability in the rage of approximately $3.4-$4.2 million, and a right-to-use asset in the range
of approximately $2.1-$2.6 million, and no adjustment to the accumulated deficit. The Company anticipates that the adoption will
not have a material impact on the consolidated statement of operations or statement of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Nonemployee Share-Based Payment
Accounting</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In June 2018, the FASB issued ASU
2018-07, <i>Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting</i> (&#8220;ASU
2018-07&#8221;). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and
services from nonemployees. Under ASU 2018-07, consistent with the accounting requirement for employee share-based payment awards,
nonemployee share-based payment awards within the scope of Topic 718 are to be measured at the grant-date fair value of the equity
instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other
conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based
payment awards are to be measured at the grant date. The definition of the term grant date is amended to generally state the date
at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. ASU
2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services
to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does
not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction
with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for public
business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company
expects to adopt ASU 2018-07 on January 1, 2019 and anticipates that the adoption will not have a material impact on the Company&#8217;s
financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Collaborative Arrangements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="background-color: white">In
November 2018, the FASB issued ASU 2018-08, <i>Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic
808 and Topic 606</i></font> (&#8220;ASU 2018-08&#8221;)<font style="background-color: white">. ASU 2018-08 clarifies the interaction
between the accounting guidance for collaborative arrangements and revenue from contracts with customers. </font>ASU 2018-08 is
effective for public business entities for fiscal years beginning after December 15, 2019, including interim periods within that
fiscal year<font style="background-color: white">. Early adoption, including adoption in any interim period, is permitted. The
Company is currently </font>evaluating the timing of the adoption of ASU 2018-08 and the expected impact it could have on the
Company&#8217;s financial statements and related disclosures<font style="background-color: white">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6747438480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LicenseAgreementAbstract', window );"><strong>License Agreement</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LicenseAgreementTextBlock', window );">License Agreement</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>4.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif"><font style="font-size: 10pt"><b>LICENSE AGREEMENT</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company, entered into a License
Agreement (the &#8220;Jenrin Agreement&#8221;) with Jenrin Discovery, LLC, a privately-held Delaware limited liability company
(&#8220;Jenrin&#8221;), effective September 20, 2018. Pursuant to the Jenrin Agreement, Jenrin granted the Company exclusive worldwide
rights to develop and commercialize the Licensed Products (as defined in the Jenrin Agreement) which includes the Jenrin library
of over 600 compounds and multiple issued and pending patent filings. The compounds are designed to treat inflammatory and fibrotic
diseases by targeting the endocannabinoid system. The lead product candidate is CRB-4001, a peripherally-restricted CB-1 inverse
agonist targeting fibrotic liver, lung, heart and kidney diseases. The Company plans to commence a Phase 1 clinical trial of CRB-4001
in 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In consideration of the license
and other rights granted by Jenrin, the Company paid Jenrin a $250,000 upfront cash payment and is obligated to pay potential milestone
payments to Jenrin totaling up to $18.4 million for each compound it elects to develop based upon the achievement of specified
development and regulatory milestones. In addition, Corbus is obligated to pay Jenrin royalties in the mid, single digits based
on net sales of any Licensed Products, subject to specified reductions.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In January 2017, the FASB issued
ASU 2017-01, <i>Business Combinations (Topic 805): Clarifying the Definition of a Business </i>(&#8220;ASU 2017-01&#8221;) which
clarifies the definition of a business and determines when an integrated set of assets and activities is not a business. ASU 2017-01
requires that if substantially all of the fair value of gross assets acquired or disposed of is concentrated in a single asset
or group of similar identifiable assets, the assets would not represent a business. The Company determined that substantially
all of the fair value of the Jenrin Agreement was attributable to a single in-process research and development asset, CRB-4001,
which did not constitute a business. The Company concluded that it did not have any alternative future use for the acquired in-process
research and development asset. Thus, the Company recorded the $250,000 upfront payment to research and development expenses in
the third quarter of 2018. The Company will account for the $18.4 million of development and regulatory milestone payments in
the period that the relevant milestones are achieved as either research and development expense or as an intangible asset as applicable.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LicenseAgreementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LicenseAgreementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LicenseAgreementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>License Agreement [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LicenseAgreementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804787776">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>5.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>PROPERTY AND EQUIPMENT</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Property and Equipment consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Computer hardware and software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">431,637</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">136,522</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Office furniture and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">914,742</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">287,048</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,025,410</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">191,244</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Construction in progress</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,181,730</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Property and equipment, gross</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,371,789</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,796,544</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: accumulated depreciation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(666,583</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(363,889</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Property and equipment, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,705,206</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,432,655</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Depreciation expense was approximately
$494,000 and $256,000 for the years ended December 31, 2018 and 2017, respectively. In the first quarter of 2018, the Company wrote
off $191,244 of fully amortized leasehold improvements related to the termination of the September 2016 Amendment in February 2018
as discussed in Note 6. At December 31, 2017, construction in progress consisted of purchased property and equipment not placed
in service until the Company&#8217;s relocation into 32,733 square feet of office space in February 2018 (See Note 6).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On December 30, 2015, the Company
entered into a lease agreement for a copier machine. The cost of the machine was approximately $12,000 and is included in office
furniture and equipment category in the table above. The lease payments commenced when the machine was placed in service in January
2016. The machine is being amortized over the life of the lease, which is for a three-year term and includes a bargain purchase
option at the end of the term. See Note 6 for details of this capital lease commitment.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, accounting policies and methodology, roll forwards, depreciation, depletion and amortization expense, including composite depreciation, accumulated depreciation, depletion and amortization expense, useful lives and method used, income statement disclosures, assets held for sale and public utility disclosures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI http://asc.fasb.org/topic&amp;trid=2155823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6628205248">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>6.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>COMMITMENTS AND CONTINGENCIES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>Operating Lease Commitment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In September 2016, the Company amended
its commercial lease for office space to expand into an additional 4,088 square feet of office space within the same building for
an aggregate total of 10,414 square feet of leased office space (&#8220;September 2016 Amendment&#8221;). The Company began occupying
this space in early November 2016 and the final lease payment was to be due in January 2021. The September 2016 Amendment required
an increase in the standby letter of credit to $50,000 (See Note 3). The September 2016 Amendment was terminated upon the commencement
date of the August 2017 Lease Agreement discussed below.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On August 21, 2017, the Company
entered into a lease agreement (&#8220;August 2017 Lease Agreement&#8221;) with the same landlord, pursuant to which the Company
agreed to lease 32,733 square feet of office space (&#8220;Leased Premises&#8221;). The initial term of the August 2017 Lease Agreement
is for a period of seven years which began with the Company&#8217;s occupancy of the Leased Premises in February 2018. The base
rent for the Leased Premises ranges from approximately $470,000 for the first year to approximately $908,000 for the seventh year.
Per the terms of the August 2017 Lease Agreement, the landlord agreed to reimburse the Company for $1,080,189 of leasehold improvements.
The reimbursements have been deferred and will be recognized as a reduction of rent expense over the term of the lease. Additionally,
the August 2017 Lease Agreement required a standby irrevocable letter of credit of $400,000, which may be reduced, if the Company
is not in default under the August 2017 Lease Agreement, to $300,000 and $200,000 on the third and fourth anniversary of the commencement
date, respectively, The Company entered into an unsecured letter of credit for $400,000 in connection with the August 2017 Lease
Agreement for which it incurred interest expense of $7,431 and $9,743 in year ended December 31, 2018 and 2017, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company records the total rent
payable during the lease term on a straight-line basis over the term of the lease and records the difference between the rents
paid and the straight-line rent as deferred rent, which is classified in deferred rent, current and deferred rent, noncurrent in
the Company&#8217;s balance sheet as of December 31, 2018 and 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the Company&#8217;s
non-cancelable lease agreements in effect at December 31, 2018, the future minimum rent commitments are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 77%"><font style="font-size: 10pt">2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">623,958</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">784,243</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">830,600</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">855,150</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">879,699</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,055,639</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,029,289</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Total rent expense for the years
ended December 31, 2018 and 2017 was $587,963 and $356,547, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On February 26, 2019, the Company
amended its lease (&#8220;February 2019 Lease Agreement&#8221;) pursuant to which an additional 30,023 square feet of office space
(&#8220;New Premises&#8221;) will be leased by the Company in the same building for an aggregate total of 62,756 square feet of
leased office space (&#8220;Total Premises&#8221;). The commencement date for the New Premises is expected to occur no later than
August 1, 2019 and the lease term for the Total Premises is October 31, 2026. The future minimum rent commitments for the Total
Premises are estimated to be approximately as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 77%"><font style="font-size: 10pt">2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">678,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,288,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,592,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,640,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,687,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,036,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,921,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><b>Capital Lease Commitment</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The lease payments commenced when
the machine was placed in service in January 2016. The lease is for a three-year term and includes a bargain purchase option at
the end of the term. In the accompanying balance sheet as of December 31, 2017 and 2016, the current portion of this capital lease
obligation is classified in accrued expenses and the long-term portion of the capital lease obligation is classified in other long-term
liabilities. Pursuant to the terms of this capital lease agreement, the future minimum capital lease commitments are as follows
as of December 31, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font-size: 10pt">Total future minimum lease payments &#8211; end in 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">378</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: interest</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Future capital lease obligations</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">375</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: current portion</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(375</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long-term portion</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For commitments under the Company&#8217;s
development award agreements- see Note 9.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804821952">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Notes Payable</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>7.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>NOTES PAYABLE</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In October 2016, the Company entered
into a loan agreement with a financing company for $348,750 to finance one of the Company&#8217;s insurance policies. The terms
of the loan stipulate equal monthly payments of principal and interest payments of $39,114 over a nine-month period. Interest on
this loan was accrued at an annual rate of 2.25%. This loan was fully repaid in July 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In November 2017, the Company entered
into a loan agreement with a financing company for $415,265 to finance one of the Company&#8217;s insurance policies. The terms
of the loan stipulate equal monthly payments of principal and interest payments of $41,975 over a ten-month period. Interest accrued
on this loan at an annual rate of 2.35%. This loan was fully repaid in August 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In November 2018, the Company entered
into a loan agreement with a financing company for $491,629 to finance one of the Company&#8217;s insurance policies. The terms
of the loan stipulated equal monthly payments of principal and interest payments of $49,857 over a ten-month period. Interest accrues
on this loan was accrued at an annual rate of 3.07%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Prepaid expenses and other current
assets as of December 31, 2018 and 2017 included $441,875 and $368,976, respectively, related to these insurance policies.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI http://asc.fasb.org/topic&amp;trid=2208564<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6644971232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>8.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>ACCRUED EXPENSES </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Accrued expenses consisted of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Accrued clinical operations and trials costs</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">4,914,881</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">2,003,799</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Accrued product development costs</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,222,093</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,255,439</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,253,621</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,335,672</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Accrued other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">460,596</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">146,609</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,851,191</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,741,519</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796284112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Awards and Deferred Revenue<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardsAndDeferredRevenueAbstract', window );"><strong>Development Awards And Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock', window );">Development Awards and Deferred Revenue</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>9.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>DEVELOPMENT AWARDS AND DEFERRED REVENUE</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><i>2015 CFFT Award</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On April 20, 2015, the Company entered
into an award agreement (the &#8220;2015 CFFT Award Agreement &#8220;) with the Cystic Fibrosis Foundation Therapeutics, Inc (&#8220;CFFT&#8221;),
a non-profit drug discovery and development affiliate of the Cystic Fibrosis Foundation (&#8220;CFF&#8221;) pursuant to which the
Company received a development award (the &#8220;2015 CFFT Award&#8221;) for up to $5 million in funding. The funding from the
2015 CFFT Award supported a first-in-patient Phase 2 clinical trial of the Company&#8217;s oral anti-inflammatory drug lenabasum
in adults with cystic fibrosis (&#8220;CF&#8221;). The Company received $5.0 million in payments under the 2015 CFFT Award as outlined
below. The payments received under the 2015 CFFT Award were recorded as deferred revenue when the triggering event to receive those
amounts had occurred and were amortized on a straight-line basis over the expected duration of the remaining performance period
under the 2015 CFFT Award which concluded in the third quarter of 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Upon the execution of the 2015 CFFT
Award Agreement, the Company received a payment of $1,250,000 in May 2015. In November 2015, the Company received a second payment
of $1,250,000 upon the achievement of a milestone for dosing the first patient. In August 2016, the Company received a third payment
from the CFFT in the amount of $1,000,000 for achieving a milestone in July 2016 related to dosing the median clinical trial patient.
In January 2017, the Company received a fourth payment from the CFFT in the amount of $1,000,000 for achieving a milestone in December
2016 related to completing the final visit for the final patient, which was billed by the Company to CFFT in December 2016 and
was classified in grants receivable as of December 31, 2016. The Company received the final payment from CFFT in the amount of
$500,000 in November 2017 for achieving the final milestone in September 2017 related to the issuance to CFFT of the final integrated
statistical report for to the Phase 2 CF clinical trial. At that time the Company had completed all its performance obligations
under the contract and therefore the performance period had concluded.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">In accordance with ASC 605, the
Company recorded $2,440,195 of revenue during the year ended December 31, 2017 under the 2015 CFFT Award Agreement. No revenue
was recorded under the 2015 CFFT Award Agreement during the year ended December 31, 2018 as the final performance period concluded
in the third quarter of 2017. Under ASC 605, milestone payments were initially recognized only in the period that the payment-triggering
event occurred or was achieved. Effective January 1, 2018, ASC 605 was superseded by ASC 606 (See Note 3). The Company adopted
ASC 606 in the first quarter of 2018 using the modified retrospective method according to which the cumulative effect of initially
applying ASC 606 is recognized at the date of initial application. Since the Company concluded its performance obligations and
completed recognizing revenue under the 2015 CFFT Award Agreement in the third quarter of 2017, there was no cumulative effect
to record at the date of the Company&#8217;s adoption of ASC 606.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Pursuant to the terms of the 2015
CFFT Award Agreement, the Company is obligated to make royalty payments to CFFT contingent upon commercialization of lenabasum
in the Field of Use (as defined in the 2015 CFFT Award Agreement) as follows: (i) a royalty payment equal to five times the amount
the Company receives under the 2015 CFFT Award Agreement, up to $25 million, payable in three equal annual installments following
the first commercial sale of lenabasum, the first of which is due within 90 days following the first commercial sale of lenabasum,
(ii) a royalty payment to CFFT equal to the amount the Company receives under the 2015 CFFT Award Agreement, up to $5 million,
due in the first calendar year in which the aggregate cumulative net sales of lenabasum in the Field of Use exceed $500 million,
and (iii) royalty payment(s) to CFFT of up to approximately $15 million if the Company transfers, sells or licenses lenabasum in
the Field of Use other than for certain clinical or development purposes, or if the Company enters into a change of control transaction,
with such payment(s) to be credited against the royalty payments due upon commercialization. The Field of Use is defined in the
2015 CFFT Award as the treatment in humans of CF, asbestosis, bronchiectasis, byssinosis, chronic bronchitis/COPD hypersensitivity
pneumonitis, pneumoconiosis, primary ciliary dyskinesis, sarcoidosis and silicosis. Either CFFT or the Company may terminate the
agreement for cause, which includes the Company&#8217;s material failure to achieve certain commercialization and development milestones.
The Company&#8217;s payment obligations, if any, would survive the termination of the 2015 CFFT Award Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify"><i>2018 CFF Award</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">On January 26, 2018, the Company
entered into the Cystic Fibrosis Program Related Investment Agreement with the CFF (&#8220;Investment Agreement&#8221;), a non-profit
drug discovery and development corporation, pursuant to which the Company received an award for up to $25 million in funding (the
&#8220;2018 CFF Award&#8221;) to support a Phase 2b Clinical Trial (the &#8220;Phase 2b Clinical Trial&#8221;) of lenabasum in
patients with cystic fibrosis, of which the Company has received $12.5 million during the year ended December 31, 2018 upon the
Company&#8217;s achievement of milestones related to the progress of the Phase 2b Clinical Trial, as set forth in the Investment
Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The Company expects that the remainder
of the 2018 CFF Award will be paid incrementally upon the Company&#8217;s achievement of the remaining milestones related to the
progress of the Phase 2b Clinical Trial, as set forth in the Investment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Pursuant to the terms of the Investment
Agreement, the Company is obligated to make certain royalty payments to CFF, including a royalty payment of one and one-half times
the amount of the 2018 CFF Award, payable in cash within sixty days upon the first receipt of approval of lenabasum in the United
States and a second royalty payment of one and one-half times the amount of the 2018 CFF Award upon approval in another major market,
as set forth in the Investment Agreement (the &#8220;Approval Royalty&#8221;). At the Company&#8217;s election, the Company may
satisfy the first of the two Approval Royalties in registered shares of the Company&#8217;s common stock.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Additionally, the Company is obligated
to make (i) royalty payments to CFF of two and one-half percent of net sales from lenabasum due within sixty days after any quarter
in which such net sales occur in the Field, as defined in the Investment Agreement, (ii) royalty payments to CFF of one percent
of net sales of Non-Field Products, as defined in the Investment Agreement due within sixty days after any quarter in which such
net sales occur, and (iii) royalty payments to CFF of ten percent of any amount the Company and its stockholders receive in connection
with the license, sale, or other transfer to a third party of lenabasum, if indicated for the treatment or prevention of CF, or
a change of control transaction, except that such payment shall not exceed five times the amount of the 2018 CFF Award, with such
payments to be credited against any other net sales royalty payments due. Accordingly, we will owe to CFF a royalty payment equal
to 10% of any amounts we receive as payment under the collaboration agreement with Kaken, provided that the total royalties that
we will be required to pay under the Investment Agreement resulting from income from licenses or sales subject to the Investment
Agreement are capped at five times the total amount of the 2018 CFF Award, and we may credit such royalties against any royalties
on net sales otherwise owed to CFF under the Investment Agreement. Accordingly, we will be required to pay CFF $2,700,000 within
60 days of our receipt of the $27,000,000 upfront cash payment from Kaken.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify; text-indent: 0.5in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Either CFF or the Company may terminate
the Investment Agreement for cause, which includes the Company&#8217;s material failure to achieve certain commercialization and
development milestones. The Company&#8217;s payment obligations survive the termination of the Investment Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Pursuant to the terms of the Investment
Agreement, the Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the Company&#8217;s common stock
(the &#8220;CFF Warrant&#8221;). The CFF Warrant is exercisable at a price equal to $13.20 per share and is immediately exercisable
for 500,000 shares of the Company&#8217;s common stock. Upon completion of the final milestone set forth in the Investment Agreement
and receipt of the final payment from CFF to the Company pursuant to the Investment Agreement, the CFF Warrant will be exercisable
for the remaining 500,000 shares of the Company&#8217;s common stock. The CFF Warrant expires on January 26, 2025. Any shares of
the Company&#8217;s common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The Company recorded $4,822,272
of revenue during the year ended December 31, 2018 under the Investment Agreement. The Company assessed the 2018 CFF Award for
accounting under ASC 606, which it adopted in the first quarter of 2018 (Note 3). To determine revenue recognition for arrangements
that an entity determines are within the scope of ASC 606, the entity performs the following five steps: (i) identify the contract(s)
with a customer; (ii) identify the performance obligations in the contract; (iii) determine the transaction price; (iv) allocate
the transaction price to the performance obligations in the contract; and (v) recognize revenue when (or as) the entity satisfies
a performance obligation.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The Company assessed this arrangement
in accordance with ASC 606 and concluded that the contract counterparty, CFF, is a customer. The Company identified the following
material promise under the arrangement: research and development activities and related services under the Phase 2b Clinical Trial.
Based on these assessments, the Company identified one performance obligation at the outset of the Investment Agreement, which
consists of: Phase 2b Clinical Trial research and development activities and related services.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">To determine the transaction price,
the Company included the total aggregate payments under the Investment Agreement which amount to $25 million and reduced the revenue
to be recognized by the payment to the customer of $6,215,225 in the form of the CFF Warrant representing its fair value, leaving
the remaining $18,784,775 as the transaction price as of the outset of the arrangement, which will be recognized as revenue over
the performance period as discussed below. The $6,215,225 fair value of the warrant was also recorded as an increase to additional
paid in capital. The Company billed and collected $12,500,000 in milestone payments during the year ended December 31, 2018 which
was recorded as an increase to deferred revenue. A roll forward of deferred revenue for the year ended December 31, 2018 is presented
below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Beginning balance</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%"><font style="font-size: 10pt">Billing to CFF upon achievement of milestones</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: right"><font style="font-size: 10pt">12,500,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Fair value of CFF Warrant</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(6,215,225</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Recognition of revenue</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(4,822,272</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Ending balance</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,462,503</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">The CFF Warrant is accounted for
as a payment to the customer under ASC 606. See Note 13 for further information related to the CFF Warrant. The Company notes
that the Investment Agreement contains an initial payment that was received upon contract execution and subsequent milestone payments,
which are a form of variable consideration that require evaluation for constraint considerations. The Company concluded that the
related performance milestones are generally within the Company&#8217;s control and as result are considered probable. Revenue
associated with the performance obligation is being recognized as revenue as the research and development services are provided
using an input method, according to the costs incurred as related to the research and development activities on each program and
the costs expected to be incurred in the future to satisfy the performance obligation. The transfer of control occurs over this
time period and, in management&#8217;s judgment, is the best measure of progress towards satisfying the performance obligation.
The research and development services related to this performance obligation are expected to be performed over an approximately
two and a half year period expected to be completed in the second quarter of 2020. The amounts received that have not yet been
recognized as revenue are recorded in deferred revenue and the amounts recognized as revenue, but not yet received or invoiced
are generally recognized as contract assets on the Company&#8217;s condensed consolidated balance sheet.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardsAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardsAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development awards and deferred revenue [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardsAndDeferredRevenueTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6634390272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>10.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>INCOME TAXES</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">No provision or benefit for federal
or state income taxes has been recorded, as the Company has incurred a net loss for all of the periods presented, and the Company
has provided a full valuation allowance against its deferred tax assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">At December 31, 2018 and 2017, the
Company had federal net operating loss carryforwards of approximately $82,545,000 and $56,536,000, respectively, of which federal
carryforwards will expire in varying amounts beginning in 2029. At December 31, 2018 and 2017, the Company had Massachusetts net
operating loss carryforwards of approximately $78,152,000 and $53,110,000, respectively. In the first quarter of 2017, the Company
adopted ASU 2016-09, which removed the requirement to recognize the deferred tax assets on excess tax benefits in respect of share
based payments only when realized. As such, during the year ended December 31, 2017, the Company&#8217;s gross deferred tax assets
and corresponding valuation allowance each included a one-time increase in respect of an additional federal and state net operating
losses of $1,432,000. The adoption of ASU 2016-09 did not have an impact on the Company&#8217;s balance sheet, results of operations,
cash flows or statement of stockholders&#8217; equity because the Company has a full valuation allowance on its deferred tax assets.
Utilization of net operating losses may be subject to substantial annual limitations due to the &#8220;change in ownership&#8221;
provisions of the Internal Revenue Code, and similar state provisions. The annual limitations may result in the expiration of net
operating losses before utilization. The Company has not yet conducted a study to determine if any such changes have occurred that
could limit the Company&#8217;s ability to use the net operating losses and tax credit carryforwards. The Company also had research
and development tax credit carryforwards at December 31, 2018 and 2017 of approximately $2,926,000 and $1,283,000, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Significant components of the Company&#8217;s
net deferred tax asset are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">NOL carryforward</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">22,273,661</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">15,229,127</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Foreign net operating loss carryforward</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3, 616,502</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,793,247</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,213,347</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Stock based compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,381,969</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,724,248</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued expenses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">660,427</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">45,654</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other temporary differences</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">186,069</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">116,292</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Subtotal</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">32,911,875</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18,328,668</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(32,911,875</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(18,328,668</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net deferred tax asset</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has maintained a full
valuation allowance against its deferred tax assets in all periods presented. A valuation allowance is required to be recorded
when it is not more likely than not that some portion or all of the net deferred tax assets will be realized. Since the Company
cannot determine that it is more likely than not that it will generate taxable income, and thereby realize the net deferred tax
assets, a full valuation allowance has been provided. The valuation allowance increased by $14,583,207 and $5,088,343 in 2018 and
2017, respectively, due to the increase in deferred tax assets, primarily due to net operating loss carryforwards. The Company
has no uncertain tax positions at December 31, 2018 and 2017 that would affect its effective tax rate. Since the Company is in
a loss carryforward position, the Company is generally subject to U.S. federal and state income tax examinations by tax authorities
for all years for which a loss carryforward is available.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Income tax benefits computed using
the federal statutory income tax rate differs from the Company&#8217;s effective tax rate primarily due to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 60%"><font style="font-size: 10pt">Tax provision at statutory rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">21.00</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">State taxes, net of federal benefit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.42</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.66</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Permanent differences</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-2.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-2.05</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Foreign expected tax</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.85</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.31</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.59</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Income tax rate change</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-24.11</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.14</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.60</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Increase in valuation reserve</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-39.72</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-15.69</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>The Tax Cut and Jobs Act of 2017</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On December 22, 2017, the legislation
commonly referred to as the Tax Cut and Jobs Act (the &#8220;Tax Act&#8221;) was enacted into law. The Tax Act, among other things,
contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35%
to a flat rate of 21%; limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small
businesses); limitation of the deduction of net operating losses generated in tax years beginning after December 31, 2017 to 80%
of taxable income, indefinite carryforward of net operating losses generated in tax years after 2018 and elimination of net operating
loss carrybacks; changes in the treatment of offshore earnings regardless of whether they are repatriated; current inclusion in
U.S. federal taxable income of certain earnings of controlled foreign corporations, mandatory capitalization of research and development
expenses beginning in 2022; immediate deductions for certain new investments instead of deductions for depreciation expense over
time; further deduction limits on executive compensation; and modifying, repealing and creating many other business deductions
and credits, including the reduction in the orphan drug credit from 50% to 25% of qualifying expenditures. As of December 31, 2017,
we made a reasonable estimate of the effects of the Tax Act on our existing deferred taxes and related disclosures by reducing
our net federal and state deferred tax assets by $7,815,832 for the reduction in corporate tax rate. This adjustment to our deferred
tax assets was offset against the valuation allowance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Additionally, the SEC staff has
issued SAB 118, which allows to record provisional amounts during a measurement period not to extend beyond one year of the enactment
date. On December 22, 2017, Staff Accounting Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application of
U.S. GAAP in situations when a registrant does not have the necessary information available, prepared, or analyzed (including
computations) in reasonable detail to complete the accounting for certain income tax effects of the Act. The Company finalized
its estimates during the fourth quarter of 2018.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804788576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>11.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>COMMON STOCK </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has authorized 150,000,000
shares of common stock, $0.0001 par value per share, of which 57,247,496 shares, and 55,603,427 shares were issued and outstanding
as of December 31, 2018, and 2017, respectively.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On February 28, 2017, the Company
entered into a securities purchase agreement providing for the issuance and sale by the Company of 3,887,815 shares of its common
stock in a registered direct offering to institutional and accredited investors at a purchase price of $7.00 per share with gross
proceeds to the Company totaling $27,214,705 less issuance costs of $36,291.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On October 26, 2017, the Company
consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 4,650,000
shares of its common stock at a purchase price of $7.00 per share with gross proceeds to the Company totaling $32,550,000, less
estimated issuance costs incurred of approximately $2,184,000. The Company also granted the underwriters a 30-day option to purchase
up to an additional 697,500 shares of common stock on the same terms as the underwriters were purchasing the base number of shares,
which they exercised in November 2017 with net proceeds to the Company totaling $4,589,550.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 5, 2018, the Company
entered into a sales agreement with Cantor Fitzgerald under which the Company had the ability to direct Cantor Fitzgerald as its
sales agent to sell common stock up to an aggregate offering of up to $50 million under an &#8220;At the Market Offering&#8221;
(&#8220;January 2018 Sales Agreement&#8221;). Sales of common stock under the January 2018 Sales Agreement were made pursuant to
an effective registration statement for an aggregate offering of up to $50 million. During the first quarter of 2018, the Company
sold 1,500,000 shares of its common stock to an institutional investor under the January 2018 Sales Agreement for which the Company
received net proceeds of approximately $11.2 million. The Company did not sell any shares under the January 2018 Sales Agreement
in remainder of 2018 and through February 8, 2019, the effective date of the Company&#8217;s termination of the January 2018 Sales
Agreement (see Note 15). During the year ended December 31, 2017, the Company sold 1,413,633 shares of its common stock under a
sales agreement that the Company entered into in November 2016 with Cantor Fitzgerald (&#8220;Sales Agreement&#8221;) for net proceeds
of $13,268,208. The Sales Agreement was terminated in October 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">During the year ended December 31,
2018, the Company issued 144,069 shares of common stock upon the exercise of stock options and warrants to purchase common stock
and the Company received net proceeds of $352,645 from these exercises. During the year ended December 31, 2017, the Company issued
272,734 shares of common stock upon the exercise of stock options and warrants to purchase common stock and the Company received
net proceeds of $189,490 from these exercises.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 30, 2019, the Company
consummated an underwritten public offering of shares of its common stock. See Note 15.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6634390272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock Options</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>12.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>STOCK OPTIONS </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In April 2014, the Company adopted
the Corbus Pharmaceuticals Holdings, Inc. 2014 Equity Incentive Plan (the &#8220;2014 Plan&#8221;). Pursuant to the 2014 Plan,
the Company&#8217;s Board of Directors may grant incentive and nonqualified stock options and restricted stock to employees, officers,
directors, consultants and advisors. Pursuant to the terms of an annual evergreen provision in the 2014 Plan, the number of shares
of common stock available for issuance under the 2014 Plan shall automatically increase on January 1 of each year by at least seven
percent (7%) of the total number of shares of common stock outstanding on December 31st of the preceding calendar year, or, pursuant
to the terms of the 2014 Plan, in any year, the Board of Directors may determine that such increase will provide for a lesser number
of shares. On January 1, 2018, pursuant to an annual evergreen provision contained in the 2014 Plan, the number of shares reserved
for future grants was increased by 2,500,000 shares, which was less than seven percent (7%) of the outstanding shares of common
stock on December 31, 2017. As of December 31, 2018, there was a total of 15,543,739 shares reserved for issuance under the 2014
Plan and there were 5,072,241 shares available for future grants. Options issued under the 2014 Plan generally vest over 4 years
from the date of grant in multiple tranches and are exercisable for up to 10 years from the date of issuance.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In accordance with the terms of
the 2014 Plan, effective as of January 1, 2019, the number of shares of common stock available for issuance under the 2014 Plan
increased by 3,000,000 shares, which was less than seven percent (7%) of the outstanding shares of common stock on December 31,
2018. As of January 1, 2019, the 2014 Plan had a total reserve of 18,543,739 shares and there were 8,072,241 shares available for
future grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Share-based Compensation</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For stock options issued and outstanding
for the years ended December 31, 2018 and 2017, the Company recorded non-cash, stock-based compensation expense of $7,609,508 ($7,500,888
for employees and $108,620 for non-employees) and $5,694,489 ($4,640,646 for employees and $1,053,843 for non-employees), respectively,
net of estimated forfeitures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The fair value of each option award
for employees is estimated on the date of grant and for non-employees is estimated at the end of each reporting period until vested
using the Black-Scholes option pricing model that uses the assumptions noted in the following table. The Company uses historical
data, as well as subsequent events occurring prior to the issuance of the financial statements, to estimate option exercises and
employee terminations in order to estimate its forfeiture rate. The expected term of options granted under the 2014 Plan, all of
which qualify as &#8220;plain vanilla&#8221; per SEC Staff Accounting Bulletin 107, is determined based on the simplified method
due to the Company&#8217;s limited operating history, and is 6.25 years based on the average between the vesting period and the
contractual life of the option. For non-employee options, the expected term is the contractual term. The risk-free rate is based
on the yield of a U.S. Treasury security with a term consistent with the option.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The weighted average assumptions
used principally in determining the fair value of options granted to employees were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%"><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">2.53</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">2.12</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected term in years</font></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.25</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">87.70</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">86.01</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Estimated forfeiture rate</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.00</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For the year ended December 31,
2017, the assumptions used in determining the fair value of options granted to nonemployees included risk free interest rate ranging
from 2.12%-2.38%, no expected dividend yield, expected term ranging from 4.91 years to 9.91 years, expected volatility ranging
from 85.58% to 89.58%, and estimated forfeiture rate of 5%.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">A summary of option activity for
years ended December 31, 2018 and 2017 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Exercise </font><br />
<font style="font-size: 10pt">Price</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Remaining </font><br />
<font style="font-size: 10pt">Contractual </font><br />
<font style="font-size: 10pt">Term in </font><br />
<font style="font-size: 10pt">Years</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Intrinsic </font><br />
<font style="font-size: 10pt">Value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 44%"><font style="font-size: 10pt">Outstanding at December 31, 2016</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">6,610,179</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2.54</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,681,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">8.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(272,734</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.67</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(173,979</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6.53</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2017</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,378,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7.58</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(139,069</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(490,407</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7.85</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at December 31, 2018</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,593,990</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.51</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7.23</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,510,816</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exerciseable at December 31, 2018</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,967,701</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2.87</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6.43</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">20,691,512</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The weighted average grant-date
fair value of options granted during the years ended December 31, 2018 and 2017 was $5.63 and $6.22 per share, respectively. The
aggregate intrinsic value of options exercised during the years ended December 31, 2018 and 2017 was approximately $543,060 and
$2,092,964, respectively. As of December 31, 2018, there was approximately $15,400,414 of total unrecognized compensation expense,
related to non-vested share-based compensation arrangements. The unrecognized compensation expense is estimated to be recognized
over a period of 2.55 years at December 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As summary of non-vested stock options
for the years ended December 31, 2018 and 2017 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Fair </font><br />
<font style="font-size: 10pt">Value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Non-vested at December 31, 2016</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">3,826,274</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">2.86</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,681,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6.22</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(2,003,806</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.60</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(173,979</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5.03</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Nonvested at December 31, 2017</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,329,989</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.61</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,378,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5.63</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,643,772</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.98</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(438,428</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5.91</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Non-vested at December 31, 2018</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,626,289</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5.32</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for compensation-related costs for equity-based compensation, which may include disclosure of policies, compensation plan details, allocation of equity compensation, incentive distributions, equity-based arrangements to obtain goods and services, deferred compensation arrangements, employee stock ownership plan details and employee stock purchase plan details.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -URI http://asc.fasb.org/subtopic&amp;trid=2208855<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6634414080">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WarrantsTextBlock', window );">Warrants</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>13.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>WARRANTS </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">During the year ended December 31,
2018, warrants to purchase 5,000 shares of common stock were exercised for proceeds of $5,000. No warrants were exercised during
the year ended December 31, 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">At December 31, 2018, there were
warrants outstanding to purchase 2,283,500 shares of common stock with a weighted average exercise price of $6.34 and a weighted
average remaining life of 2.89 years, including the warrant issued to CFF pursuant to the terms of the Investment Agreement (Note
8). The Company issued a warrant to CFF to purchase an aggregate of 1,000,000 shares of the Company&#8217;s common stock (the &#8220;CFF
Warrant&#8221;). The CFF Warrant is exercisable at a price equal to $13.20 per share and is immediately exercisable for 500,000
shares of the Company&#8217;s common stock. Upon completion of the final milestone set forth in the Investment Agreement and receipt
of the final payment from CFF to the Company pursuant to the Investment Agreement, the CFF Warrant will be exercisable for the
remaining 500,000 shares of the Company&#8217;s common stock. The CFF Warrant expires on January 26, 2025. Any shares of the Company&#8217;s
common stock issued upon exercise of the CFF Warrant will be unregistered and subject to a one-year lock-up. The CFF Warrant is
classified as equity as it meets all the conditions under GAAP for equity classification. In accordance with GAAP, the Company
has calculated the fair value of the warrant for initial measurement and will reassess whether equity classification for the warrant
is appropriate upon any changes to the warrants or capital structure, at each balance sheet date. The weighted average assumptions
used in determining the $6,215,225 fair value of the CFF Warrant were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">2.60</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected term in years</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">83.5</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WarrantsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants [Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WarrantsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6637731440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsAbstract', window );"><strong>Related Party Transactions [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock', window );">Related Party Transactions</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>14.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>RELATED PARTY TRANSACTIONS </b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On September 20, 2016, the Company
entered into a consulting agreement (the &#8220;2016 Consulting Agreement&#8221;) with Orchestra Medical Ventures, LLC (&#8220;Orchestra&#8221;),
of which a member of the Company&#8217;s Board of Directors, David Hochman, is Managing Partner. Under this agreement, Orchestra
rendered a variety of consulting and advisory services relating principally to identifying and evaluating strategic relationships,
licensing opportunities, and business strategies. The term of the 2016 Consulting Agreement commenced on September 20, 2016 and
expired on March 20, 2017. Pursuant to the terms of the 2016 Consulting Agreement, the Company paid to Orchestra cash compensation
in an aggregate amount of $100,000. In connection with this agreement, the Company granted an equity incentive award to Mr. Hochman
consisting of options to purchase 50,000 shares (&#8220;Option Shares&#8221;) of common stock (the &#8220;Option Award&#8221;)
pursuant to the Company&#8217;s 2014 Equity Compensation Plan, of which fifty percent (50%) vested on the three (3) month anniversary
of the date of grant of the Option Award and the remainder of the Option Shares vested on the six (6) month anniversary of the
date of grant of the Option Award. The Option Shares were granted with an exercise price of $7.14 per share. The Company recorded
stock-based compensation expense of approximately $222,000 during the year ended December 31, 2016 and $171,000 during the first
quarter of 2017 in respect of the Option Award. No stock-based compensation expense was recorded after the first quarter of 2017
related to the Option Shares as they were fully vested in March 2017.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 850<br> -URI http://asc.fasb.org/topic&amp;trid=2122745<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804783024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsAbstract', window );"><strong>Subsequent Events [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventsTextBlock', window );">Subsequent Events</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="width: 34px; font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>15.</b></font></td>
    <td style="font: 12pt Times New Roman, Times, Serif; text-align: justify"><font style="font-size: 10pt"><b>SUBSEQUENT EVENTS</b></font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify; text-indent: -24.5pt"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Evergreen Provision</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of an annual
evergreen provision in the 2014 Plan, the number of shares of common stock available for issuance under the 2014 Plan shall automatically
increase on January 1 of each year by at least seven percent (7%) of the total number of shares of common stock outstanding on
December 31st of the preceding calendar year, or, pursuant to the terms of the 2014 Plan, in any year, the Board of Directors may
determine that such increase will provide for a lesser number of shares. In accordance with the terms of the 2014 Plan, effective
as of January 1, 2019, the number of shares of common stock available for issuance under the 2014 Plan increased by 3,000,000 shares,
such amount being less than seven percent (7%) of the outstanding shares of common stock on December 31, 2018. As of January 1,
2019, the 2014 Plan had a total reserve of 18,543,739 shares and there were 8,072,2414 shares available for future grants.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Collaboration with Kaken</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 3, 2019, Corbus Pharmaceuticals
Holdings, Inc. the Company entered into a Collaboration and License Agreement (the &#8220;Agreement&#8221;) with Kaken Pharmaceutical
Co., Ltd., a company organized under the laws of Japan (&#8220;Kaken&#8221;). Pursuant to the Agreement, Corbus granted Kaken an
exclusive license to commercialize pharmaceutical preparations containing lenabasum (the &#8220;Licensed Products&#8221;) for the
prevention or treatment of dermatomyositis and systemic sclerosis (together, the &#8220;Initial Indications&#8221;) in Japan (the
&#8220;Territory&#8221;).</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the Agreement,
Corbus will bear the cost of, and be responsible for, among other things, conducting the clinical studies and other developmental
activities for the Licensed Products in the Initial Indications in the Territory, and Kaken will bear the cost of, and be responsible
for, among other things, preparing and filing applications for regulatory approval in the Territory and for commercializing Licensed
Products in the Territory, and will use commercially reasonable efforts to commercialize Licensed Products and obtain pricing approval
for Licensed Products in the Territory.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In consideration of the license
and other rights granted by Corbus, Kaken will pay Corbus a $27,000,000 upfront cash payment and is obligated to pay potential
milestone payments to Corbus totaling up to approximately $173,000,000 for the achievement of certain development, sales and regulatory
milestones, with part of the milestone payments being calculated in Japanese Yen, and therefore subject to change based on the
conversion rate to U.S. Dollars in effect at the time of payment. In addition, during the Royalty Term (as defined below), Kaken
is obligated to pay Corbus royalties on sales of Licensed Products in the Territory, under certain conditions, in the double digits,
which royalty shall be reduced in certain circumstances. In particular, for so long as Corbus supplies Licensed Products to Kaken
pursuant to a supply agreement to be entered into by the parties, royalty payments shall be payable for each unit of Licensed Product
that Corbus supplies as a percentage of the Japanese National Health Insurance price of the Licensed Product. During any time in
which a supply agreement is not in effect, royalty payments shall be changed to a rate to be agreed upon by the parties in good
faith.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Agreement will remain in effect
on a Licensed Product-by-Licensed product basis and will expire upon the expiration of the Royalty Term for the final Licensed
Product. The &#8220;Royalty Term&#8221; means the period beginning on the date of the first commercial sale of the Licensed Product
in Japan and ends on the latest of (i) the expiration of the last valid claim of the royalty patents covering such Licensed Product
in Japan, (ii) the expiration of regulatory exclusivity for such Licensed Product for such Initial Indication in Japan, or (iii)
ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may
be terminated by either party for material breach, upon a party&#8217;s insolvency or bankruptcy or upon a challenge by one party
of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical
failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of
the Initial Indications in the Territory, with 180 days&#8217; notice.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the Agreement, the parties
agreed to develop a joint steering committee to provide strategic oversight of the parties&#8217; activities under the Agreement,
as well as a joint development committee to coordinate the development of Licensed Products in Japan. Additionally, the parties
will establish a joint commercialization committee to review and confirm commercialization activities with respect to Licensed
Products in Japan upon regulatory approval of such Licensed Product.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Agreement also contains customary
representations, warranties and covenants by both parties, as well as customary provisions relating to indemnification, confidentiality
and other matters.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company is evaluating the terms
of the Agreement and believes it is within the scope of ASC 606. Accordingly, the Company expects that the $27 million upfront
payment will be recognized in the first quarter of 2019.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Termination of January 2018 Sales
Agreement</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="background-color: white">On
January 29, 2019, the Company provided notice of its termination of the January 2018 Sales Agreement. The termination of the January
2018 Sales Agreement was effective on February 8, 2019.</font></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Public Offering</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On January 30, 2019, the Company
consummated an underwritten public offering of shares of its common stock pursuant to which the Company sold an aggregate of 6,198,500
shares of its common stock, including 808,500 shares sold pursuant to the full exercise of the underwriters&#8217; option to purchase
additional shares, at a purchase price of $6.50 per share with gross proceeds to the Company totaling $40,290,250, less estimated
issuance costs incurred of approximately $2,667,000.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Office Space Lease Amendment</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On February 26, 2019, the Company
amended its lease (&#8220;February 2019 Lease Agreement&#8221;) pursuant to which an additional 30,023 square feet of office space
(&#8220;New Premises&#8221;) will be leased by the Company in the same building for an aggregate total of 62,756 square feet of
leased office space (See Note 6).</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 855<br> -URI http://asc.fasb.org/topic&amp;trid=2122774<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815485888">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Use of Estimates</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The process of preparing financial
statements in conformity with accounting principles generally accepted in the United States of America (&#8220;U.S. GAAP&#8221;)
requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure
of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates and changes in estimates may occur. The most significant estimates
are related to stock-based compensation expense, the accrual of research, product development and clinical obligations, the recognition
of revenue under the Investment Agreement (see Note 9) and the valuation of the CFF Warrant discussed in Note 9).</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Cash and Cash Equivalents</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company considers only those
investments which are highly liquid, readily convertible to cash, and that mature within three months from date of purchase to
be cash equivalents. Marketable investments are those with original maturities in excess of three months. At December 31, 2018
and 2017, cash equivalents were comprised of money market funds. The Company had no marketable investments at December 31, 2018
and 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Restricted cash as of December 31,
2017 in the amount of $108,991 was classified in current assets and included a collateral account for the Company&#8217;s corporate
credit cards. The collateral account was closed in the first quarter of 2018 and accordingly the cash became unrestricted. Additionally,
as of December 31, 2017, restricted cash included a stand-by letter of credit issued in favor of a landlord for $50,000 which was
classified in current assets as of December 31, 2017. This stand-by letter of credit was terminated in the first quarter of 2018
in connection with the August 2017 Lease Agreement discussed in Note 6, and accordingly, the cash became unrestricted.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Cash, cash equivalents, and restricted
cash consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">808,943</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">206,510</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Money market fund</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">40,939,525</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,330,985</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">41,748,468</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">62,537,495</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,748,468</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">62,696,486</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As of December 31, 2018, all of
the Company&#8217;s cash was held in the United States, except for approximately $702,000 of cash which was held in our subsidiary
in the United Kingdom. As of December 31, 2017, all of the Company&#8217;s cash was held in the United States.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Financial Instruments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Financial Instruments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The carrying amounts reported in
the consolidated balance sheet for cash and cash equivalents, receivables, accounts payable and accrued expenses approximate their
fair value based on the short-term nature of these instruments. The carrying values of the notes payable approximate their fair
value due to the fact that they are at market terms.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Property and Equipment</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The estimated life for the Company&#8217;s
property and equipment is as follows: three years for computer hardware and software and three to five years for office furniture
and equipment. The Company&#8217;s leasehold improvements and assets under capital lease are amortized over the shorter of their
useful lives or the respective leases. See Note 5 for details of property and equipment and Note 6 for operating and capital lease
commitments.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Research and Development Expenses</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Costs incurred for research and
development are expensed as incurred.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Nonrefundable advance payments
for goods or services that have the characteristics that will be used or rendered for future research and development activities
pursuant to executory contractual arrangements with third party research organizations are deferred and recognized as an expense
as the related goods are delivered or the related services are performed.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock', window );">Accruals for Research and Development Expenses and Clinical Trials</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Accruals for Research and
Development Expenses and Clinical Trials</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As part of the process of preparing
its financial statements, the Company is required to estimate its expenses resulting from its obligations under contracts with
vendors, clinical research organizations and consultants and under clinical site agreements in connection with conducting clinical
trials. The financial terms of these contracts are subject to negotiations, which vary from contract to contract and may result
in payment terms that do not match the periods over which materials or services are provided under such contracts. The Company&#8217;s
objective is to reflect the appropriate expenses in its financial statements by matching those expenses with the period in which
services are performed and efforts are expended. The Company accounts for these expenses according to the timing of various aspects
of the expenses. The Company determines the accrual estimates by taking into account discussion with applicable personnel and
outside service providers as to the progress of clinical trials, or the services completed. During the course of a clinical trial,
the Company adjusts its clinical expense recognition if actual results differ from its estimates. The Company makes estimates
of its accrued expenses as of each balance sheet date based on the facts and circumstances known to it at that time. The Company&#8217;s
clinical trial accruals are dependent upon the timely and accurate reporting of contract research organizations and other third-party
vendors. Although the Company does not expect its estimates to be materially different from amounts actually incurred, its understanding
of the status and timing of services performed relative to the actual status and timing of services performed may vary and may
result in it reporting amounts that are too high or too low for any particular period. For the years ended December 31, 2018 and
2017, there were no material adjustments to the Company&#8217;s prior period estimates of accrued expenses for clinical trials.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LeasesAndDeferredRentPolicyTextBlock', window );">Leases and Deferred Rent</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Leases and Deferred Rent</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company leases its office space.
Leases are evaluated and classified as operating or capital leases for financial reporting purposes. The Company&#8217;s office
space leases qualify as operating leases. For operating leases that contain rent escalations and rent holidays, the Company records
the total rent payable during the lease term on a straight-line basis over the term of the lease and records the difference between
the rents paid and the straight-line rent as deferred rent. Additionally, any tenant improvement allowances received from the
lessor are recorded as a reduction to rent expense over the term of the lease.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Credit Risk</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Concentrations of Credit Risk</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company has no significant
off-balance-sheet concentration of credit risk such as foreign exchange contracts, option contracts or other hedging arrangements.
The Company may from time to time have cash in banks in excess of Federal Deposit Insurance Corporation insurance limits. However,
the Company believes the risk of loss is minimal as these banks are large financial institutions.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SegmentReportingPolicyPolicyTextBlock', window );">Segment Information</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Segment Information</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Operating segments are identified
as components of an enterprise about which separate discrete financial information is available for evaluation by the chief operating
decision maker, or decision-making group, in making decisions regarding resource allocation and assessing performance. To date,
the Company has viewed its operations and manages its business as principally one operating segment, which is developing and commercializing
therapeutics to treat rare life-threatening inflammatory and fibrotic diseases. As of December 31, 2018 and 2017, all of the Company&#8217;s
assets were located in the United States, except for approximately $702,000 of cash, $1,183,000 of prepaid expenses, $28,000 of
other assets, and $54,000 of property and equipment, net which were held in our subsidiary in the United Kingdom as of December
31, 2018.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Income Taxes</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">For federal and state income taxes,
deferred tax assets and liabilities are recognized based upon temporary differences between the financial statement and the tax
basis of assets and liabilities. Deferred income taxes are based upon prescribed rates and enacted laws applicable to periods in
which differences are expected to reverse. A valuation allowance is recorded to reduce a net deferred tax benefit when it is not
more likely than not that the tax benefit from the deferred tax assets will be realized. Accordingly, given the cumulative losses
since inception, the Company has provided a valuation allowance equal to 100% of the deferred tax assets in order to eliminate
the deferred tax assets amounts.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Tax positions taken or expected
to be taken in the course of preparing the Company&#8217;s tax returns are required to be evaluated to determine whether the tax
positions are &#8220;more-likely-than-not&#8221; of being sustained by the applicable tax authority. Tax positions not deemed to
meet a more-likely-than-not threshold, as well as accrued interest and penalties, if any, would be recorded as a tax expense in
the current year. There were no uncertain tax positions that require accrual or disclosure to the financial statements as of December
31, 2018 or 2017.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On December 22, 2017, Staff Accounting
Bulletin No. 118 (&#8220;SAB 118&#8221;) was issued to address the application of U.S. GAAP in situations when a registrant does
not have the necessary information available, prepared, or analyzed (including computations) in reasonable detail to complete
the accounting for certain income tax effects of the Tax Act. In accordance with SAB 118, the Company had recorded a provisional
estimate in these financial statements for the effect of the corporate tax rate change. The Company finalized its estimates during
the fourth quarter of 2018, described more fully in Note 10.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-lived Assets</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Impairment of Long-lived Assets</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company continually monitors
events and changes in circumstances that could indicate that carrying amounts of long-lived assets may not be recoverable. An
impairment loss is recognized when expected undiscounted cash flows of an asset are less than an asset&#8217;s carrying value.
Accordingly, when indicators of impairment are present, the Company evaluates the carrying value of such assets in relation to
the operating performance and future undiscounted cash flows of the underlying assets. An impairment loss equal to the excess
of the fair value of the asset over its carrying amount, is recorded when it is determined that the carrying value of the asset
may not be recoverable. No impairment charges were recorded for the years ended December 31, 2018 and 2017.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock-based Payments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Stock-based Payments</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company recognizes compensation
costs resulting from the issuance of stock-based awards to employees, non-employees and directors as an expense in the statement
of operations over the service period based on a measurement of fair value for each stock-based award. The fair value of each option
grant to employees is estimated as of the date of grant using the Black-Scholes option-pricing model, net of estimated forfeitures.
The fair value is amortized as compensation cost on a straight-line basis over the requisite service period of the awards, which
is generally the vesting period. Stock options granted to non-employee consultants are revalued at the end of each reporting period
until vested using the Black-Scholes option-pricing model and the changes in their fair value are recorded as adjustments to expense
over the related vesting period.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">On March 30, 2016, the FASB issued
ASU No. 2016-09, <i>Compensation&#8212;Stock Compensation (Topic 718): Improvements to Employee Share-Based Payment Accounting
</i>(&#8220;ASU 2016-09&#8221;)<i>. </i>ASU 2016-09 simplifies several aspects of the accounting for employee share-based payment
transactions including the accounting for income taxes, forfeitures, and statutory tax withholding requirements, as well as classification
in the statement of cash flows. ASU 2016-09 took effect for fiscal years, and interim periods within those fiscal years, beginning
after December 15, 2016. In the first quarter of 2017, when the Company adopted ASU 2016-09 it did not elect to account for forfeitures
as they occur but rather to continue to estimate forfeitures at grant date. As a result, the adoption of ASU 2016-09 did not have
an impact on the Company&#8217;s consolidated financial statements. ASU 2016-09 also removed the requirement to recognize the
excess tax benefits in respect of share based payments only when realized (See Note 10).</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss Per Common Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>Net Loss Per Common Share</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b><i>&#160;</i></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Basic and diluted net loss per share
of the Company&#8217;s common stock has been computed by dividing net loss by the weighted average number of shares outstanding
during the period. For years in which there is a net loss, options and warrants are anti-dilutive and therefore excluded from diluted
loss per share calculations. The following table sets forth the computation of basic and diluted earnings per share for the years
ended December 31, 2018 and 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Years Ended December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Basic and diluted net loss per share of common stock:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(55,672,139</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(32,421,612</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average shares of common stock outstanding</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">56,999,741</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,176,953</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share of common stock-basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.98</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.65</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The impact of the following potentially
dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the computation of dilutive weighted average
shares outstanding as the inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,283,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">9,593,990</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,877,490</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,133,466</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recent Accounting Pronouncements</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>Recent Accounting Pronouncements</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><b>&#160;</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>Revenue Recognition</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 49pt; text-align: justify; text-indent: -24.5pt"><i>&#160;</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In May 2014, the FASB issued guidance
codified in <i>Accounting Standards Codification (ASC) 606, Revenue Recognition &#8212; Revenue from Contracts with Customers</i>
(&#8220;ASC 606&#8221;) which amends the guidance in former <i>ASC 605, Revenue Recognition</i>, and is effective for public companies
for annual and interim periods beginning after December 15, 2017. Specifically, the new standard differs from ASC 605 in many respects,
such as in the accounting for variable consideration received, including milestone payments or contingent payments. Under the Company&#8217;s
accounting policy prior to the adoption of ASC 606 in the first quarter of 2018, milestone payments were initially recognized only
in the period that the payment-triggering event occurred or was achieved (See Note 9). ASC 606, however, may require a company
to recognize such payments before the payment-triggering event is completely achieved based on the Company&#8217;s estimate of
the amount of consideration to which it will be entitled in exchange for transferring the services, subject to management&#8217;s
assessment of whether it is probable that a significant reversal in the amount of cumulative revenue recognized will not occur
when the uncertainty associated with the variable consideration is subsequently resolved.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company adopted ASC 606 in the
first quarter of 2018 using the modified retrospective method according to which the cumulative effect of initially applying ASC
606 is recognized at the date of initial application, and elected to utilize a practical expedient and did not restate contracts
that were completed as of the date of adoption. Since the Company has concluded its performance obligations and has completed recognizing
revenue under the 2015 CFFT Award in the third quarter of 2017 (See Note 9), there was no cumulative effect to record at the date
of the Company&#8217;s adoption of ASC 606 and no revenue to recognize for the first quarter of 2018 related to the 2015 CFFT Award.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Revenue for the quarter and the
year ended December 31, 2018 was $1,927,306 and $4,822,272, respectively, recognized in accordance with ASC 606 and pertains only
to the 2018 CFF Award discussed in Note 9. The total impact to revenue as a result of the adoption of ASC 606 was higher revenue
of approximately $325,000 for the quarter ended December 31, 2018 and lower revenue of approximately $201,000 for the year ended
December 31, 2018.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The Company will assess any new
agreements it enters into under ASC 606, including whether such agreements fall under the scope of such standard. This standard
applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance,
collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when its customer obtains control
of promised goods or services, in an amount that reflects the consideration which the entity expects to receive in exchange for
those goods or services. To determine revenue recognition for arrangements that an entity determines are within the scope of ASC
606, the entity performs the following five steps: (i) identify the contract(s) with a customer; (ii) identify the performance
obligations in the contract; (iii) determine the transaction price; (iv) allocate the transaction price to the performance obligations
in the contract; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company only applies
the five-step model to contracts when it is probable that the entity will collect the consideration it is entitled to in exchange
for the goods or services it transfers to the customer. At contract inception, once the contract is determined to be within the
scope of ASC 606, the Company assesses the goods or services promised within each contract and determines those that are performance
obligations, and assesses whether each promised good or service is distinct. The Company then recognizes as revenue the amount
of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is
satisfied.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Revenue associated with the 2018
CFF Award performance obligation is being recognized as revenue as the research and development services are provided using an
input method, according to the costs incurred as related to the research and development activities and the costs expected to be
incurred in the future to satisfy the performance obligation. The transfer of control occurs over this time period and, in management&#8217;s
judgment, is the best measure of progress towards satisfying the performance obligation. The research and development services
related to this performance obligation are expected to be performed over an approximately two and a half-year period expected to
be completed in the second quarter of 2020. Amounts received prior to revenue recognition are recorded as deferred revenue. Amounts
expected to be recognized as revenue within the 12 months following the balance sheet date are classified as current portion of
deferred revenue in the accompanying consolidated balance sheets. Amounts not expected to be recognized as revenue within the 12
months following the balance sheet date would be classified as deferred revenue, net of current portion. Amounts recognized as
revenue, but not yet received or invoiced are generally recognized as contract assets.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Accounting for Leases</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In February 2016, the FASB issued
ASU No<b>. </b>2016-02, <i>Leases (Topic 842), </i>as amended (&#8220;ASU 2016-02&#8221;)<i>. </i>Under ASU 2016-02, a lessee will
be required to recognize assets and liabilities for all leases with lease terms of more than 12 months. Consistent with current
US GAAP, the recognition, measurement, and presentation of expenses and cash flows arising from a lease by a lessee primarily will
depend on its classification as a finance or operating lease. However, unlike current US GAAP, which requires only capital leases
to be recognized on the balance sheet, ASU 2016-02 will require both types of leases to be recognized on the balance sheet. ASU
2016-02 will take effect for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2018. ASU
2016-02 required a modified retrospective transition approach, which initially required application of the new guidance for all
periods presented in the Company&#8217;s financial statements (&#8220;comparative method&#8221;). In July 2018, the FASB released
ASU 2018-11, offering a second option which provides further relief in the transition to ASC 842. Companies are allowed to follow
the cumulative-effect adjustment transition approach (&#8220;effective date method&#8221;), which releases companies from presenting
comparative periods and related disclosures according to ASC 842. Instead, companies electing to utilize the effective date method
will recognize a one-time adjustment to retained earnings on the transition date without the additional burden of presenting the
comparative periods under the new guidance. The Company will adopt ASU 2016-02 using the effective date method as of January 1,
2019 and expects to record a lease liability in the rage of approximately $3.4-$4.2 million, and a right-to-use asset in the range
of approximately $2.1-$2.6 million, and no adjustment to the accumulated deficit. The Company anticipates that the adoption will
not have a material impact on the consolidated statement of operations or statement of cash flows.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Nonemployee Share-Based Payment
Accounting</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">In June 2018, the FASB issued ASU
2018-07, <i>Compensation-Stock Compensation (Topic 718), Improvements to Nonemployee Share-Based Payment Accounting</i> (&#8220;ASU
2018-07&#8221;). ASU 2018-07 expands the scope of Topic 718 to include share-based payment transactions for acquiring goods and
services from nonemployees. Under ASU 2018-07, consistent with the accounting requirement for employee share-based payment awards,
nonemployee share-based payment awards within the scope of Topic 718 are to be measured at the grant-date fair value of the equity
instruments that an entity is obligated to issue when the good has been delivered or the service has been rendered and any other
conditions necessary to earn the right to benefit from the instruments have been satisfied. Equity-classified nonemployee share-based
payment awards are to be measured at the grant date. The definition of the term grant date is amended to generally state the date
at which a grantor and a grantee reach a mutual understanding of the key terms and conditions of a share-based payment award. ASU
2018-07 specifies that Topic 718 applies to all share-based payment transactions in which a grantor acquires goods or services
to be used or consumed in its own operations by issuing share-based payment awards. ASU 2018-07 also clarifies that Topic 718 does
not apply to share-based payments used to effectively provide (1) financing to the issuer or (2) awards granted in conjunction
with selling goods or services to customers as part of a contract accounted for under ASC 606. ASU 2018-07 is effective for public
business entities for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company
expects to adopt ASU 2018-07 on January 1, 2019 and anticipates that the adoption will not have a material impact on the Company&#8217;s
financial statements and related disclosures.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><i>Collaborative Arrangements</i></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify"><font style="background-color: white">In
November 2018, the FASB issued ASU 2018-08, <i>Collaborative Arrangements (Topic 808): Clarifying the Interaction between Topic
808 and Topic 606</i></font> (&#8220;ASU 2018-08&#8221;)<font style="background-color: white">. ASU 2018-08 clarifies the interaction
between the accounting guidance for collaborative arrangements and revenue from contracts with customers. </font>ASU 2018-08 is
effective for public business entities for fiscal years beginning after December 15, 2019, including interim periods within that
fiscal year<font style="background-color: white">. Early adoption, including adoption in any interim period, is permitted. The
Company is currently </font>evaluating the timing of the adoption of ASU 2018-08 and the expected impact it could have on the
Company&#8217;s financial statements and related disclosures<font style="background-color: white">.</font></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accruals for research and development expenses and clinical trials [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AccrualsForResearchAndDevelopmentExpensesAndClinicalTrialsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LeasesAndDeferredRentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Leases and Deferred Rent [Policy Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LeasesAndDeferredRentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 305<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6375392&amp;loc=d3e26790-107797<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=108315417&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109250915&amp;loc=d3e13279-108611<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 05<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226317&amp;loc=d3e202-110218<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -URI http://asc.fasb.org/extlink&amp;oid=27011434&amp;loc=d3e125687-122742<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32847-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 740<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6491622&amp;loc=d3e9504-115650<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32809-109319<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32840-109319<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32247-109318<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32280-109318<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 05<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=65884525&amp;loc=d3e40913-109327<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, basis of assets, depreciation and depletion methods used, including composite deprecation, estimated useful lives, capitalization policy, accounting treatment for costs incurred for repairs and maintenance, capitalized interest and the method it is calculated, disposals and impairments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for segment reporting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for stock option and stock incentive plans. This disclosure may include (1) the types of stock option or incentive plans sponsored by the entity (2) the groups that participate in (or are covered by) each plan (3) significant plan provisions and (4) how stock compensation is measured, and the methodologies and significant assumptions used to determine that measurement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=84158767&amp;loc=d3e18780-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796441520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of Cash and Cash Equivalents and Restricted Cash</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Cash, cash equivalents, and restricted
cash consists of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Cash</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">808,943</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">206,510</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Money market fund</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">40,939,525</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">62,330,985</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-left: 10pt"><font style="font-size: 10pt">Cash and cash equivalents</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">41,748,468</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">62,537,495</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Restricted cash</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">158,991</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">41,748,468</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">62,696,486</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Computation of Basic and Diluted Earnings Per Share</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The following table sets forth the
computation of basic and diluted earnings per share for the years ended December 31, 2018 and 2017:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Years Ended December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Basic and diluted net loss per share of common stock:</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%; padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(55,672,139</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt">&#160;</td>
    <td style="width: 1%; border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(32,421,612</font></td>
    <td style="width: 1%; padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Weighted average shares of common stock outstanding</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">56,999,741</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">50,176,953</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net loss per share of common stock-basic and diluted</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.98</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">(0.65</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">)</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The impact of the following potentially
dilutive securities outstanding as of December 31, 2018 and 2017 have been excluded from the computation of dilutive weighted average
shares outstanding as the inclusion would be antidilutive.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Warrants</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2,283,500</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">1,288,500</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Stock options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">9,593,990</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,877,490</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,133,466</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6783183184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of Property and Equipment</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Property and Equipment consisted
of the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 72%"><font style="font-size: 10pt">Computer hardware and software</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">431,637</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">136,522</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Office furniture and equipment</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">914,742</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">287,048</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Leasehold improvements</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,025,410</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">191,244</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Construction in progress</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,181,730</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Property and equipment, gross</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,371,789</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,796,544</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: accumulated depreciation</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(666,583</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(363,889</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Property and equipment, net</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2,705,206</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,432,655</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6781798624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock', window );">Schedule of Future Minimum Capital Lease Commitments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">Pursuant to the terms of this capital
lease agreement, the future minimum capital lease commitments are as follows as of December 31, 2018:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 79%"><font style="font-size: 10pt">Total future minimum lease payments &#8211; end in 2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 18%; text-align: right"><font style="font-size: 10pt">378</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: interest</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(3</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Future capital lease obligations</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">375</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Less: current portion</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(375</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Long-term portion</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rent Commitments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Pursuant to the terms of the Company&#8217;s
non-cancelable lease agreements in effect at December 31, 2018, the future minimum rent commitments are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 77%"><font style="font-size: 10pt">2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">623,958</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">784,243</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">830,600</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">855,150</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">879,699</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">1,055,639</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,029,289</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"></p><span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember', window );">February 2019 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock', window );">Schedule of Future Minimum Rent Commitments</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The future minimum rent commitments
for the Total Premises are estimated to be approximately as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 77%"><font style="font-size: 10pt">2019</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 20%; text-align: right"><font style="font-size: 10pt">678,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2020</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,288,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2021</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,592,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">2022</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,640,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">2023</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,687,000</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Thereafter</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5,036,000</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">11,921,000</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum lease payments as of the date of the latest balance sheet presented, in aggregate and for each of the five years succeeding fiscal years, with separate deductions from the total for the amount representing executor costs, including any profit thereon, included in the minimum lease payments and for the amount of the imputed interest necessary to reduce the net minimum lease payments to present value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumLeasePaymentsForCapitalLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of future minimum payments required in the aggregate and for each of the five succeeding fiscal years for operating leases having initial or remaining noncancelable lease terms in excess of one year and the total minimum rentals to be received in the future under noncancelable subleases as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFutureMinimumRentalPaymentsForOperatingLeasesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804947600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Expenses (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Accrued expenses consisted of the
following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="padding-bottom: 1.5pt; text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Accrued clinical operations and trials costs</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">4,914,881</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">2,003,799</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Accrued product development costs</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,222,093</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,255,439</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,253,621</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,335,672</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Accrued other</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">460,596</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">146,609</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,851,191</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4,741,519</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804874800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Awards and Deferred Revenue (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardsAndDeferredRevenueAbstract', window );"><strong>Development Awards And Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Roll Forward Deferred Revenue</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.25in; text-align: justify">A roll forward of deferred revenue
for the year ended December 31, 2018 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td>&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt"><b>December 31, 2018</b></font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Beginning balance</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="width: 72%"><font style="font-size: 10pt">Billing to CFF upon achievement of milestones</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 25%; text-align: right"><font style="font-size: 10pt">12,500,000</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Fair value of CFF Warrant</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(6,215,225</font></td>
    <td><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Recognition of revenue</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(4,822,272</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Ending balance</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">1,462,503</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardsAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardsAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of contract balances and changes in contract balances.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130551-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804944992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2017</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Components of Net Deferred Tax Asset</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Significant components of the Company&#8217;s
net deferred tax asset are as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">NOL carryforward</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">22,273,661</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">15,229,127</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Foreign net operating loss carryforward</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3, 616,502</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,793,247</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,213,347</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Stock based compensation</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,381,969</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,724,248</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Accrued expenses</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">660,427</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">45,654</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Other temporary differences</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">186,069</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">116,292</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Subtotal</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">32,911,875</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">18,328,668</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Valuation allowance</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(32,911,875</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(18,328,668</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Net deferred tax asset</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">Income tax benefits computed using
the federal statutory income tax rate differs from the Company&#8217;s effective tax rate primarily due to the following:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="6" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">December 31,</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 60%"><font style="font-size: 10pt">Tax provision at statutory rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">21.00</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">34.00</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">State taxes, net of federal benefit</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.42</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.66</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Permanent differences</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-2.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-2.05</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Foreign expected tax</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">9.85</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Tax credits</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">4.31</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.59</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Income tax rate change</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">&#8212;</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">-24.11</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Other</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1.14</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0.60</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Increase in valuation reserve</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-39.72</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">-15.69</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Total</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">0.00</font></td>
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">%</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6638084432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of Assumptions Used Principally in Determining Fair Value of Options Granted</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">The weighted average assumptions
used principally in determining the fair value of options granted to employees were as follows:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="text-align: center">&#160;</td>
    <td colspan="2" style="text-align: center">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2018</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">2017</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 61%"><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%; text-align: right"><font style="font-size: 10pt">%</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">2.53</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td>
    <td style="width: 2%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">2.12</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected term in years</font></td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.25</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">6.25</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">87.70</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">86.01</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Estimated forfeiture rate</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.00</font></td>
    <td><font style="font-size: 10pt">%</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">5.00</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Option Activity</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">A summary of option activity for
years ended December 31, 2018 and 2017 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Exercise </font><br />
<font style="font-size: 10pt">Price</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Remaining </font><br />
<font style="font-size: 10pt">Contractual </font><br />
<font style="font-size: 10pt">Term in </font><br />
<font style="font-size: 10pt">Years</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Intrinsic </font><br />
<font style="font-size: 10pt">Value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 44%"><font style="font-size: 10pt">Outstanding at December 31, 2016</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">6,610,179</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 11%; text-align: right"><font style="font-size: 10pt">2.54</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 11%; text-align: right">&#160;</td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,681,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">8.28</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(272,734</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">0.67</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(173,979</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">6.53</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Outstanding at December 31, 2017</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7,844,966</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.75</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,378,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">7.58</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Exercised</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(139,069</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.50</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right">&#160;</td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(490,407</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">7.85</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Outstanding at December 31, 2018</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">9,593,990</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">4.51</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">7.23</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">22,510,816</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Exerciseable at December 31, 2018</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5,967,701</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">2.87</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">6.43</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">20,691,512</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SummaryOfNonvestedStockOptionsTableTextBlock', window );">Summary of Non-Vested Stock Options</a></td>
<td class="text"><p style="margin: 0pt"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">As summary of non-vested stock options
for the years ended December 31, 2018 and 2017 is presented below:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 24.5pt; text-align: justify">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom">
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">Options</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Shares</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><font style="font-size: 10pt">Weighted </font><br />
<font style="font-size: 10pt">Average </font><br />
<font style="font-size: 10pt">Fair </font><br />
<font style="font-size: 10pt">Value</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 62%"><font style="font-size: 10pt">Non-vested at December 31, 2016</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">3,826,274</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%"><font style="font-size: 10pt">$</font></td>
    <td style="width: 16%; text-align: right"><font style="font-size: 10pt">2.86</font></td>
    <td style="width: 1%">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">1,681,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">6.22</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(2,003,806</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">2.60</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(173,979</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5.03</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Nonvested at December 31, 2017</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">3,329,989</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">4.61</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Granted</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">2,378,500</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">5.63</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Vested</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">(1,643,772</font></td>
    <td><font style="font-size: 10pt">)</font></td>
    <td>&#160;</td>
    <td><font style="font-size: 10pt">$</font></td>
    <td style="text-align: right"><font style="font-size: 10pt">3.98</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">Forfeited</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid">&#160;</td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">(438,428</font></td>
    <td style="padding-bottom: 1.5pt"><font style="font-size: 10pt">)</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td>
    <td style="border-bottom: black 1.5pt solid"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 1.5pt solid; text-align: right"><font style="font-size: 10pt">5.91</font></td>
    <td style="padding-bottom: 1.5pt">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="padding-bottom: 2.5pt"><font style="font-size: 10pt">Non-vested at December 31, 2018</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double">&#160;</td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">3,626,289</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="padding-bottom: 2.5pt">&#160;</td>
    <td style="border-bottom: black 2.25pt double"><font style="font-size: 10pt">$</font></td>
    <td style="border-bottom: black 2.25pt double; text-align: right"><font style="font-size: 10pt">5.32</font></td>
    <td style="padding-bottom: 2.5pt">&#160;</td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_SummaryOfNonvestedStockOptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Summary of Non-Vested Stock Options [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_SummaryOfNonvestedStockOptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804883600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract', window );"><strong>Derivative Instruments and Hedging Activities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock', window );">Schedule of Weighted Average Assumption of Warrants</a></td>
<td class="text"><p style="margin: 0pt"></p>

<table cellspacing="0" cellpadding="0" style="font: 12pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td style="width: 82%"><font style="font-size: 10pt">Risk free interest rate</font></td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 1%">&#160;</td>
    <td style="width: 15%; text-align: right"><font style="font-size: 10pt">2.60</font></td>
    <td style="width: 1%"><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected dividend yield</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">0</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
<tr style="vertical-align: bottom; background-color: #CCEEFF">
    <td><font style="font-size: 10pt">Expected term in years</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">7.00</font></td>
    <td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: white">
    <td><font style="font-size: 10pt">Expected volatility</font></td>
    <td>&#160;</td>
    <td>&#160;</td>
    <td style="text-align: right"><font style="font-size: 10pt">83.5</font></td>
    <td><font style="font-size: 10pt">%</font></td></tr>
</table>


<p style="margin: 0pt"></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Schedule of weighted average assumption of warrants [Table Text Block]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ScheduleOfWeightedAverageAssumptionOfWarrantsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>nonnum:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentsAndHedgingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815487520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Liquidity (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">$ (121,370,240)<span></span>
</td>
<td class="num">$ (65,698,101)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">41,748,468<span></span>
</td>
<td class="nump">62,537,495<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">12,052,645<span></span>
</td>
<td class="nump">$ 78,891,699<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember', window );">Kaken Pharmaceutical Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Upfront payment, recieved from related party</a></td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_CysticFibrosisFoundationMember', window );">Cystic Fibrosis Foundation [Member] | Investment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from Royalty</a></td>
<td class="nump">$ 2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_UpfrontPaymentPercentage', window );">Upfront payment, percentage</a></td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_CysticFibrosisFoundationMember', window );">Cystic Fibrosis Foundation [Member] | Investment Agreement [Member] | January 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from sale of stock</a></td>
<td class="nump">$ 37,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_UpfrontPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Upfront payment, percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_UpfrontPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_JanuaryTwoThousandAndNineteenOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_JanuaryTwoThousandAndNineteenOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815623872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>Segment</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MarketableSecurities', window );">Marketable investments</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Operating segments | Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">808,943<span></span>
</td>
<td class="nump">$ 808,943<span></span>
</td>
<td class="nump">206,510<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,705,206<span></span>
</td>
<td class="nump">$ 2,705,206<span></span>
</td>
<td class="nump">1,432,655<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DeferredTaxAssetsValuationAllowancePercentage', window );">Valuation allowance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,822,272<span></span>
</td>
<td class="nump">2,440,195<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=CRBP_ASC606Member', window );">ASC 606 [Member] | Higher Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">325,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=CRBP_ASC606Member', window );">ASC 606 [Member] | Lower Revenue [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">201,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember', window );">2018 CFF Award [Member] | ASC 606 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenues</a></td>
<td class="nump">1,927,306<span></span>
</td>
<td class="nump">$ 4,822,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of all property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_GB', window );">United Kingdom [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CashHeldInSubsidiary', window );">Cash held in subsidiary</a></td>
<td class="nump">702,000<span></span>
</td>
<td class="nump">$ 702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">702,000<span></span>
</td>
<td class="nump">702,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent', window );">Prepaid expenses</a></td>
<td class="nump">1,183,000<span></span>
</td>
<td class="nump">1,183,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssets', window );">Other assets</a></td>
<td class="nump">28,000<span></span>
</td>
<td class="nump">28,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">54,000<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CRBP_CorporatecreditCardsMember', window );">Corporate Credit Cards [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">108,991<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=CRBP_StandbyLetterOfCreditMember', window );">Stand-by Letter of Credit [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod', window );">Cash equivalents maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | January 01, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">4,200,000<span></span>
</td>
<td class="nump">$ 4,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use asset</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 2,600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of all property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_MarketableSecuritiesMaturityPeriod', window );">Marketable investments maturity period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | January 01, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Operating lease liability</a></td>
<td class="nump">3,400,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease, right of use asset</a></td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="nump">$ 2,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_SignificantAccountingPoliciesLineItems', window );"><strong>Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Estimated useful life of all property and equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash equivalents and restricted cash maturity period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CashEquivalentsAndRestrictedCashMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CashHeldInSubsidiary">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash held in subsidiary.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CashHeldInSubsidiary</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DeferredTaxAssetsValuationAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets Valuation Allowance Percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DeferredTaxAssetsValuationAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_MarketableSecuritiesMaturityPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Marketable Securities Maturity Period</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_MarketableSecuritiesMaturityPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>us-types:durationStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_SignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Significant Accounting Policies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_SignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109226348&amp;loc=d3e2420-110228<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77888419&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrentAndNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of expenditures made in advance of when the economic benefit of the cost will be realized, and which will be expensed in future periods with the passage of time or when a triggering event occurs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.10)<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrentAndNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=CRBP_ASC606Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=CRBP_ASC606Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=CRBP_HigherRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=CRBP_HigherRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredRevenueArrangementTypeAxis=CRBP_LowerRevenueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredRevenueArrangementTypeAxis=CRBP_LowerRevenueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_GB">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_GB</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_CorporatecreditCardsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_CorporatecreditCardsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=CRBP_StandbyLetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=CRBP_StandbyLetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_JanuaryOneTwoThousandAndNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_JanuaryOneTwoThousandAndNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796452080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Cash', window );">Cash</a></td>
<td class="nump">$ 808,943<span></span>
</td>
<td class="nump">$ 206,510<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_MoneyMarketFundsAtCarryingValue', window );">Money market fund</a></td>
<td class="nump">40,939,525<span></span>
</td>
<td class="nump">62,330,985<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">41,748,468<span></span>
</td>
<td class="nump">62,537,495<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue', window );">Restricted cash</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">158,991<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total cash, cash equivalents, and restricted cash shown in the statement of cash flows</a></td>
<td class="nump">$ 41,748,468<span></span>
</td>
<td class="nump">$ 62,696,486<span></span>
</td>
<td class="nump">$ 15,192,257<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Cash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Cash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MoneyMarketFundsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Investment in short-term money-market instruments (such as commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and so forth) which are highly liquid (that is, readily convertible to known amounts of cash) and so near their maturity that they present an insignificant risk of changes in value because of changes in interest rates. Generally, only investments with original maturities of three months or less qualify as cash equivalents by definition. Original maturity means an original maturity to the entity holding the investment. For example, both a three-month US Treasury bill and a three-year Treasury note purchased three months from maturity qualify as cash equivalents. However, a Treasury note purchased three-years ago does not become a cash equivalent when its remaining maturity is three months.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MoneyMarketFundsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=98513485&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796432576">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (55,672,139)<span></span>
</td>
<td class="num">$ (32,421,612)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted', window );">Weighted average shares of common stock outstanding</a></td>
<td class="nump">56,999,741<span></span>
</td>
<td class="nump">50,176,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasicAndDiluted', window );">Net loss per share of common stock-basic and diluted</a></td>
<td class="num">$ (0.98)<span></span>
</td>
<td class="num">$ (0.65)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income or loss for the period per each share in instances when basic and diluted earnings per share are the same amount and reported as a single line item on the face of the financial statements.  Basic earnings per share is the amount of net income or loss for the period per each share of common stock or unit outstanding during the reporting period.  Diluted earnings per share includes the amount of net income or loss for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109260490&amp;loc=d3e1337-109256<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669619-108580<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=114867106&amp;loc=SL7669625-108580<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873790&amp;loc=SL114874131-224263<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Average number of shares or units issued and outstanding that are used in calculating basic and diluted earnings per share (EPS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfShareOutstandingBasicAndDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796372672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</a></td>
<td class="nump">11,877,490<span></span>
</td>
<td class="nump">9,133,466<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</a></td>
<td class="nump">2,283,500<span></span>
</td>
<td class="nump">1,288,500<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CRBP_StockOptionsMember', window );">Stock Options [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential dilutive securities excluded from computation of dilutive weighted average shares outstanding</a></td>
<td class="nump">9,593,990<span></span>
</td>
<td class="nump">7,844,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6371337&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CRBP_StockOptionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=CRBP_StockOptionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800712352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>License Agreement (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2018</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Upfront cash payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 18,400,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_JenrinAgreementMember', window );">Jenrin Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BusinessCombinationConsiderationTransferred1', window );">Upfront cash payment</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_PotentialMilestonePayments', window );">Potential milestone payments</a></td>
<td class="nump">$ 18,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_PotentialMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Potential milestone payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_PotentialMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessCombinationConsiderationTransferred1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of consideration transferred, consisting of acquisition-date fair value of assets transferred by the acquirer, liabilities incurred by the acquirer, and equity interest issued by the acquirer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6613-128477<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=35744584&amp;loc=d3e6927-128479<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 805<br> -SubTopic 30<br> -Section 30<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109124213&amp;loc=d3e6578-128477<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessCombinationConsiderationTransferred1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_JenrinAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_JenrinAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815486368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment (Details Narrative)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Mar. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 30, 2015 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 493,938<span></span>
</td>
<td class="nump">$ 255,652<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements', window );">Write off of fully amortized leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 191,244<span></span>
</td>
<td class="nump">191,244<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="nump">32,733<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost of machine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3,371,789<span></span>
</td>
<td class="nump">$ 1,796,544<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember', window );">Copier Machine [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Cost of machine</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LeaseTerm', window );">Lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Write off of fully amortized leasehold improvements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WriteOffOfFullyAmortizedLeaseholdImprovements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6800674224">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property and Equipment - Summary of Property and Equipment (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 3,371,789<span></span>
</td>
<td class="nump">$ 1,796,544<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation</a></td>
<td class="num">(666,583)<span></span>
</td>
<td class="num">(363,889)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">2,705,206<span></span>
</td>
<td class="nump">1,432,655<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember', window );">Computer Hardware and Software [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">431,637<span></span>
</td>
<td class="nump">136,522<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember', window );">Office Furniture and Equipment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">914,742<span></span>
</td>
<td class="nump">287,048<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold Improvements [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">2,025,410<span></span>
</td>
<td class="nump">191,244<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in Progress [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 1,181,730<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.14)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_ComputerHardwareAndSoftwareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_OfficeFurnitureAndEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6814112304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 21, 2017 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Feb. 28, 2018 </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Sep. 30, 2016 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">32,733<span></span>
</td>
<td class="nump">4,088<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 587,963<span></span>
</td>
<td class="nump">$ 356,547<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="nump">32,733<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseholdImprovementsGross', window );">Leasehold improvements</a></td>
<td class="nump">$ 1,080,189<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UnsecuredDebt', window );">Unsecured letter of credit</a></td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestExpense', window );">Incurred interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,431<span></span>
</td>
<td class="nump">$ 9,743<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | First Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">470,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | Seventh Year [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseAndRentalExpense', window );">Rent expense</a></td>
<td class="nump">908,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | Third Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member] | Fourth Anniversary [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LineOfCredit', window );">Irrevocable letter of credit</a></td>
<td class="nump">$ 200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember', window );">February 2019 Lease Agreement [Member] | February 26, 2019 [Member] | New Premises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,023<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LeaseTermDateDescription', window );">Lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The commencement date for the New Premises is expected to occur no later than August 1, 2019 <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember', window );">February 2019 Lease Agreement [Member] | February 26, 2019 [Member] | Total Premises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,756<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_LeaseTermDateDescription', window );">Lease term, description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">The lease term for the Total Premises is October 31, 2026.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_CapitalLeaseAgreementMember', window );">Capital Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CapitalLeaseTerm', window );">Capital lease term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementScenarioAxis=CRBP_SeptemberTwoThousandAndSixteenAmendmentMember', window );">September 2016 Amendment [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AreaOfOfficeSpace', window );">Area of office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LeaseExpirationDate1', window );">Operating lease expiration date</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Jan. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LettersOfCreditOutstandingAmount', window );">Standby letters of credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AreaOfOfficeSpace">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of office space.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AreaOfOfficeSpace</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CapitalLeaseTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Capital lease term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CapitalLeaseTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_LeaseTermDateDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Lease term, description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_LeaseTermDateDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6450988&amp;loc=d3e26243-108391<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=114775744&amp;loc=d3e28555-108399<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (210.5-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=114873765&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseAndRentalExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of rent expense incurred for leased assets, including but not limited to, furniture and equipment, that is not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseAndRentalExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseExpirationDate1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date which lease or group of leases is set to expire, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseExpirationDate1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseholdImprovementsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation of additions or improvements to assets held under a lease arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6812-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseholdImprovementsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LettersOfCreditOutstandingAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The total amount of the contingent obligation under letters of credit outstanding as of the reporting date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LettersOfCreditOutstandingAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LineOfCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The carrying value as of the balance sheet date of the current and noncurrent portions of long-term obligations drawn from a line of credit, which is a bank's commitment to make loans up to a specific amount. Examples of items that might be included in the application of this element may consist of letters of credit, standby letters of credit, and revolving credit arrangements, under which borrowings can be made up to a maximum amount as of any point in time conditional on satisfaction of specified terms before, as of and after the date of drawdowns on the line. Includes short-term obligations that would normally be classified as current liabilities but for which (a) postbalance sheet date issuance of a long term obligation to refinance the short term obligation on a long term basis, or (b) the enterprise has entered into a financing agreement that clearly permits the enterprise to refinance the short-term obligation on a long term basis and the following conditions are met (1) the agreement does not expire within 1 year and is not cancelable by the lender except for violation of an objectively determinable provision, (2) no violation exists at the BS date, and (3) the lender has entered into the financing agreement is expected to be financially capable of honoring the agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LineOfCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnsecuredDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Including the current and noncurrent portions, carrying value as of the balance sheet date of uncollateralized debt obligations (with maturities initially due after one year or beyond the operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6876686&amp;loc=d3e534808-122878<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnsecuredDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_FirstYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_FirstYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_SeventhYearMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_SeventhYearMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_ThirdAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_ThirdAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_FourthAnniversaryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_FourthAnniversaryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_FebruaryTwentySixTwoThousandAndNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_FebruaryTwentySixTwoThousandAndNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=CRBP_NewPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=CRBP_NewPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=CRBP_TotalPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=CRBP_TotalPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_CapitalLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_CapitalLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_SeptemberTwoThousandAndSixteenAmendmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_SeptemberTwoThousandAndSixteenAmendmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6817235504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember', window );">August 2017 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">$ 623,958<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">784,243<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">830,600<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">855,150<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">879,699<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">1,055,639<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">5,029,289<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember', window );">February 2019 Lease Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent', window );">2019</a></td>
<td class="nump">678,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears', window );">2020</a></td>
<td class="nump">1,288,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears', window );">2021</a></td>
<td class="nump">1,592,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears', window );">2022</a></td>
<td class="nump">1,640,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears', window );">2023</a></td>
<td class="nump">1,687,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter', window );">Thereafter</a></td>
<td class="nump">5,036,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue', window );">Total</a></td>
<td class="nump">$ 11,921,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for leases having an initial or remaining non-cancelable letter-terms in excess of one year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the next fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFiveYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the fourth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInFourYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the third fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInThreeYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due in the second fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueInTwoYears</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of required minimum rental payments for operating leases having an initial or remaining non-cancelable lease term in excess of one year due after the fifth fiscal year following the latest fiscal year. Excludes interim and annual periods when interim periods are reported on a rolling approach, from latest balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=77902758&amp;loc=d3e41502-112717<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 10<br> -Section 55<br> -Paragraph 40<br> -Subparagraph (Note 3)<br> -URI http://asc.fasb.org/extlink&amp;oid=82846649&amp;loc=d3e38371-112697<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesFutureMinimumPaymentsDueThereafter</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_AugustTwoThousandSeventeenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_FebruaryTwoThousandAndNineteenLeaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6787740000">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details) - Copier Machine [Member]<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CommitmentAndContingenciesLineItems', window );"><strong>Commitment And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue', window );">Total future minimum lease payments - end in 2019</a></td>
<td class="nump">$ 378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments', window );">Less: interest</a></td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligations', window );">Future capital lease obligations</a></td>
<td class="nump">375<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsCurrent', window );">Less: current portion</a></td>
<td class="num">(375)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CapitalLeaseObligationsNoncurrent', window );">Long-term portion</a></td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CommitmentAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commitment And Contingencies [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CommitmentAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal through the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI http://asc.fasb.org/extlink&amp;oid=6879938&amp;loc=d3e572229-122910<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of capital lease obligation due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeaseObligationsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount equal to the present value (the principal) at the beginning of the lease term of minimum lease payments during the lease term (excluding that portion of the payments representing executory costs such as insurance, maintenance, and taxes to be paid by the lessor, together with any profit thereon) net of payments or other amounts applied to the principal, through the balance sheet date and due to be paid more than one year (or one operating cycle, if longer) after the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=84164758&amp;loc=d3e45023-112735<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeaseObligationsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of minimum lease payments for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount necessary to reduce net minimum lease payments to present value for capital leases.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84164817&amp;loc=d3e45280-112737<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalLeasesFutureMinimumPaymentsInterestIncludedInPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=CRBP_CopierMachineMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815685472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Notes Payable (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 30, 2018</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Oct. 31, 2016</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 491,629<span></span>
</td>
<td class="nump">$ 415,265<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_ProductOrServiceAxis=CRBP_InsurancePolicyMember', window );">Insurance Policy [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 441,875<span></span>
</td>
<td class="nump">$ 368,976<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_LoanAgreementMember', window );">Loan Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromNotesPayable', window );">Proceeds from issuance of notes payable</a></td>
<td class="nump">$ 491,629<span></span>
</td>
<td class="nump">$ 415,265<span></span>
</td>
<td class="nump">$ 348,750<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentPeriodicPayment', window );">Monthly principal and interest payments</a></td>
<td class="nump">$ 49,857<span></span>
</td>
<td class="nump">$ 41,975<span></span>
</td>
<td class="nump">$ 39,114<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentTerm', window );">Monthly loan payments term</a></td>
<td class="text">10 months<span></span>
</td>
<td class="text">10 months<span></span>
</td>
<td class="text">9 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Annual interest rate</a></td>
<td class="nump">3.07%<span></span>
</td>
<td class="nump">2.35%<span></span>
</td>
<td class="nump">2.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentPeriodicPayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of the required periodic payments including both interest and principal payments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.22)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=75038535&amp;loc=d3e64711-112823<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentPeriodicPayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period of time between issuance and maturity of debt instrument, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromNotesPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a borrowing supported by a written promise to pay an obligation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromNotesPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=CRBP_InsurancePolicyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=CRBP_InsurancePolicyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_LoanAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_LoanAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6802935936">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Expenses - Schedule of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent', window );">Accrued clinical operations and trials costs</a></td>
<td class="nump">$ 4,914,881<span></span>
</td>
<td class="nump">$ 2,003,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_AccruedProductDevelopmentCostsCurrent', window );">Accrued product development costs</a></td>
<td class="nump">2,222,093<span></span>
</td>
<td class="nump">1,255,439<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Accrued compensation</a></td>
<td class="nump">2,253,621<span></span>
</td>
<td class="nump">1,335,672<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued other</a></td>
<td class="nump">460,596<span></span>
</td>
<td class="nump">146,609<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 9,851,191<span></span>
</td>
<td class="nump">$ 4,741,519<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued clinical operations and trials costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AccruedClinicalOperationsAndTrialsCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_AccruedProductDevelopmentCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Accrued product development costs current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_AccruedProductDevelopmentCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=82887183&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6817854048">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Awards and Deferred Revenue (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Jan. 26, 2018</div></th>
<th class="th"><div>Apr. 20, 2015</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Jan. 31, 2017</div></th>
<th class="th"><div>Aug. 31, 2016</div></th>
<th class="th"><div>Nov. 30, 2015</div></th>
<th class="th"><div>May 31, 2015</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Amount received upon achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,462,503<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,822,272<span></span>
</td>
<td class="nump">2,440,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercisable shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional paid in capital, fair value of warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6,215,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember', window );">Kaken Pharmaceutical Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Upfront payment, received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CysticFibrosisFoundationWarrantsMember', window );">Cystic Fibrosis Foundation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,784,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight', window );">Warrant to purchase of common stock</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercisable price per share</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercisable shares of common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable', window );">Warrant expires date</a></td>
<td class="text">Jan. 26,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued', window );">Additional paid in capital, fair value of warrant issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,215,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Amount received upon achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Amount received upon achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,000,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 1,250,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="nump">$ 2,440,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Oral Anti-inflammatory Drug [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Amount received upon achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_PaymentDuePeriodAfterTheFirstCommercialSale', window );">Payment due period after the first commercial sale</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">90 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_RoyaltyPaymentSalesTarget', window );">Royalty payment, sales target</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 500,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Development award received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Commercialization of the Product [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Reaching the Sales Target [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember', window );">2015 CFFT Award Agreement [Member] | Maximum [Member] | Lenabasum [Member] | Upon Transfer Sale or Licensing [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RoyaltyExpense', window );">Royalty payable</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember', window );">Cystic Fibrosis Program Related Investment Agreement [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainContingencyUnrecordedAmount', window );">Development award received</a></td>
<td class="nump">$ 25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,822,272<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses', window );">Reclassified to contract asset and classified in prepaid expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member] | Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | 2018 CFF Award [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromRoyaltiesReceived', window );">Proceeds from Royalty</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Upfront payment, received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member] | Phase 2b Clinical Trial [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Amount received upon achievement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member] | Cystic Fibrosis Foundation Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrant exercisable shares of common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_CollaborationAgreementMember', window );">Collaboration Agreement [Member] | Cystic Fibrosis Foundation [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardLineItems', window );"><strong>Development Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_RoyaltyPaymentPercentage', window );">Royalty payment percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Development Award [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_PaymentDuePeriodAfterTheFirstCommercialSale">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Payment due period after the first commercial sale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_PaymentDuePeriodAfterTheFirstCommercialSale</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Reclassified to contract asset and classified in prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ReclassifiedToContractAssetAndClassifiedInPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_RoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment percentage.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_RoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_RoyaltyPaymentSalesTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty payment, sales target.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_RoyaltyPaymentSalesTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in additional paid in capital (APIC) resulting from the issuance of warrants. Includes allocation of proceeds of debt securities issued with detachable stock purchase warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 25<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109126253&amp;loc=d3e4724-112606<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalWarrantIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date the warrants or rights are exercisable, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainContingencyUnrecordedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount or range of possible amounts of gain that could be realized upon the resolution of a contingency.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6397426&amp;loc=d3e17499-108355<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainContingencyUnrecordedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRoyaltiesReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRoyaltiesReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115929826&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RoyaltyExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.3)<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RoyaltyExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CysticFibrosisFoundationWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_CysticFibrosisFoundationWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandFifteenCFFTAwardArrangementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_OralAntiinflammatoryDrugMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_OralAntiinflammatoryDrugMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_LenabasumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedCostsOfUnprovedPropertiesExcludedFromAmortizationByPropertyOrProjectAxis=CRBP_LenabasumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_UponReachingTheSalesTargetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_UponReachingTheSalesTargetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_UponCommercializationOfTheProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_UponCommercializationOfTheProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementScenarioAxis=CRBP_UponTransferSaleOrLicensingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementScenarioAxis=CRBP_UponTransferSaleOrLicensingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_CysticFibrosisProgramRelatedInvestmentAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_CysticFibrosisFoundationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_CysticFibrosisFoundationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_TwoThousandAndEighteenCffAwardMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_PhaseTwoBClinicalTrialMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_PhaseTwoBClinicalTrialMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6796372096">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DevelopmentAwardsAndDeferredRevenueAbstract', window );"><strong>Development Awards And Deferred Revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, beginning balance</a></td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DeferredRevenueBillingToUponAchievementOfMilestones', window );">Billing to CFF upon achievement of milestones</a></td>
<td class="nump">12,500,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_FairValueOfWarrant', window );">Fair value of CFF Warrant</a></td>
<td class="num">(6,215,225)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Recognition of revenue</a></td>
<td class="num">(4,822,272)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue, ending balance</a></td>
<td class="nump">$ 1,462,503<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DeferredRevenueBillingToUponAchievementOfMilestones">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Billing to CFF upon achievement of milestones.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DeferredRevenueBillingToUponAchievementOfMilestones</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DevelopmentAwardsAndDeferredRevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DevelopmentAwardsAndDeferredRevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_FairValueOfWarrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of warrant.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_FairValueOfWarrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130532-203044<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=82913815&amp;loc=SL49130531-203044<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 606<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109196051&amp;loc=SL49130549-203045<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813865056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 22, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 82,545,000<span></span>
</td>
<td class="nump">$ 56,536,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">Net operating loss carryforwards excess stock-based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,432,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credit carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,926,000<span></span>
</td>
<td class="nump">1,283,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Deferred tax assets valuation allowance increase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,583,207<span></span>
</td>
<td class="nump">5,088,343<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent', window );">Uncertain tax position</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExaminationDescription', window );">Income tax description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">On December 22, 2017, the legislation commonly referred to as the Tax Cut and Jobs Act (the "Tax Act") was enacted into law. The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%; limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Taxable income percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_FederalMember', window );">Federal [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear', window );">Operating loss carryforwards expiration year</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2029<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_MassachusettMember', window );">Massachusett [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 78,152,000<span></span>
</td>
<td class="nump">$ 53,110,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Taxable income percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit', window );">Deferred tax asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,815,832<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Orphan Drug Credit [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Orphan Drug Credit [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember', window );">The Tax Cut and Jobs Act of 2017 [Member] | Interest Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Corporate tax rate percentage</a></td>
<td class="nump">30.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax assets operating loss carryforwards expiration year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_DeferredTaxAssetsOperatingLossCarryforwardsExpirationYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Income Taxes [Line Items]</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state, local, and federal tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExaminationDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A brief description of status of the tax examination, significant findings to date, and the entity's position with respect to the findings.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExaminationDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilityForUncertainTaxPositionsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount recognized for uncertainty in income taxes classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilityForUncertainTaxPositionsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=84176650&amp;loc=d3e32123-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_FederalMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CRBP_FederalMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_MassachusettMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CRBP_MassachusettMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=CRBP_TaxCutAndJobsActOfTwoThousandSeventeenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=CRBP_OrphanDrugCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=CRBP_OrphanDrugCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_InterestExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6753872896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Components of Net Deferred Tax Asset (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred Tax Assets, Net [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">NOL carryforward</a></td>
<td class="nump">$ 22,273,661<span></span>
</td>
<td class="nump">$ 15,229,127<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign', window );">Foreign net operating loss carryforward</a></td>
<td class="nump">3,616,502<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">2,793,247<span></span>
</td>
<td class="nump">1,213,347<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock based compensation</a></td>
<td class="nump">3,381,969<span></span>
</td>
<td class="nump">1,724,248<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">660,427<span></span>
</td>
<td class="nump">45,654<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other temporary differences</a></td>
<td class="nump">186,069<span></span>
</td>
<td class="nump">116,292<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Subtotal</a></td>
<td class="nump">32,911,875<span></span>
</td>
<td class="nump">18,328,668<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(32,911,875)<span></span>
</td>
<td class="num">(18,328,668)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Net deferred tax asset</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible foreign operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32559-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32621-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 25<br> -Paragraph 20<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=115928272&amp;loc=d3e28680-109314<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6749278976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Tax provision at statutory rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">34.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit</a></td>
<td class="nump">5.42%<span></span>
</td>
<td class="nump">5.66%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential', window );">Permanent differences</a></td>
<td class="num">(2.00%)<span></span>
</td>
<td class="num">(2.05%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign', window );">Foreign expected tax</a></td>
<td class="nump">9.85%<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits', window );">Tax credits</a></td>
<td class="nump">4.31%<span></span>
</td>
<td class="nump">1.59%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate', window );">Income tax rate change</a></td>
<td class="text"> <span></span>
</td>
<td class="num">(24.11%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments', window );">Other</a></td>
<td class="nump">1.14%<span></span>
</td>
<td class="nump">0.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Increase in valuation reserve</a></td>
<td class="num">(39.72%)<span></span>
</td>
<td class="num">(15.69%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to statutory income tax expense (benefit) outside of the country of domicile.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other adjustments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationOtherAdjustments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to tax credits. Including, but not limited to, research credit, foreign tax credit, investment tax credit, and other tax credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign tax credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32698-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=84230637&amp;loc=d3e32687-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I)<br> -URI http://asc.fasb.org/extlink&amp;oid=34349781&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsForeign</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6813619072">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 05, 2018</div></th>
<th class="th"><div>Oct. 26, 2017</div></th>
<th class="th"><div>Feb. 28, 2017</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Mar. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
<td class="nump">150,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
<td class="nump">$ 0.0001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,247,496<span></span>
</td>
<td class="nump">55,603,427<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">57,247,496<span></span>
</td>
<td class="nump">55,603,427<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,052,645<span></span>
</td>
<td class="nump">$ 78,891,699<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 464,680<span></span>
</td>
<td class="nump">$ 2,969,837<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">139,069<span></span>
</td>
<td class="nump">272,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember', window );">Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised', window );">Issuance of common stock upon exercise of warrants, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,069<span></span>
</td>
<td class="nump">272,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember', window );">Equity Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Issuance of common stock upon exercise of stock options, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144,069<span></span>
</td>
<td class="nump">272,734<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DerivativeInstrumentRiskAxis=CRBP_StockOptionAndWarrantsMember', window );">Stock Option and Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 352,645<span></span>
</td>
<td class="nump">$ 189,490<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=CRBP_AtTheMarketOfferingMember', window );">At the Market Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Number of common stock value sold</a></td>
<td class="nump">$ 50,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_InstitutionalInvestorsMember', window );">Institutional Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,650,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 32,550,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4,589,550<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,184,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase shares of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">697,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SecuritiesPurchaseAgreementMember', window );">Securities Purchase Agreement [Member] | Institutional and Accredited Investors [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,887,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price per share</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,214,705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember', window );">January 2018 Sales Agreement [Member] | Institutional Investor [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember', window );">January 2018 Sales Agreement [Member] | Institutional Investor [Member] | Remainder of 2018 and Through February 8, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember', window );">Sales Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Aggregate common stock sold, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,413,633<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Gross proceeds from sale of stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,268,208<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of stock options granted under share-based compensation arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-option equity instruments exercised by participants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DerivativeInstrumentRiskAxis=CRBP_StockOptionAndWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DerivativeInstrumentRiskAxis=CRBP_StockOptionAndWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_InstitutionalInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_InstitutionalInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_SecuritiesPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_SecuritiesPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CRBP_InstitutionalAndAccreditedInvestorsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CRBP_InstitutionalAndAccreditedInvestorsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_JanuaryTwoThousandAndEighteenSalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionAxis=CRBP_InstitutionalInvestorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionAxis=CRBP_InstitutionalInvestorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_Remainder2018AndThroughFebruary82019Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_Remainder2018AndThroughFebruary82019Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_SalesAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6815220544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,609,508<span></span>
</td>
<td class="nump">$ 5,694,489<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant-date fair value, options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.63<span></span>
</td>
<td class="nump">$ 6.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Average intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 543,060<span></span>
</td>
<td class="nump">$ 2,092,964<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Total unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,400,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based compensation expense, not yet recognized weighted average period of recognition</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 6 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_EmployeesMember', window );">Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7,500,888<span></span>
</td>
<td class="nump">4,640,646<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember', window );">Non-Employees [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 108,620<span></span>
</td>
<td class="nump">$ 1,053,843<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate', window );">Option granted expected forfeiture rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember', window );">Non-Employees [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option granted expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Option granted risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Option granted expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Option granted expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember', window );">Non-Employees [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option granted expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">9 years 10 months 28 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Option granted risk free interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.38%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend', window );">Option granted expected dividend yield</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Option granted expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89.58%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember', window );">2014 Equity Incentive Plan [Member] | Employee Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate common stock available for stock options granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,543,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,072,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Stock option vesting term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Stock option expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Option granted expected term</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember', window );">Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common shares</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember', window );">Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member] | January 1, 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increase in number of shares of common stock available for issuance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Aggregate common stock available for stock options granted, shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,543,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for grant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8,072,241<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Unrecognized cost of unvested share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average period over which unrecognized compensation is expected to be recognized for equity-based compensation plans, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of noncash, equity-based employee remuneration. This may include the value of stock or unit options, amortization of restricted stock or units, and adjustment for officers' compensation. As noncash, this element is an add back when calculating net cash generated by operating activities using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer contingent on satisfaction of either a service condition, market condition or a performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of the weighted average expected dividend for an entity using a valuation technique with different dividend rates during the contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageExpectedDividend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_EmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_EmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_NonEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_EvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=CRBP_JanuaryOneTwoThousandandNiniteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=CRBP_JanuaryOneTwoThousandandNiniteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6803161600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details) - Employee Stock Option [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.53%<span></span>
</td>
<td class="nump">2.12%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
<td class="text">6 years 2 months 30 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">87.70%<span></span>
</td>
<td class="nump">86.01%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate', window );">Estimated forfeiture rate</a></td>
<td class="nump">5.00%<span></span>
</td>
<td class="nump">5.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Forfeiture Rate</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardForfeitureRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804067568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Summary of Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Beginning balance</a></td>
<td class="nump">7,844,966<span></span>
</td>
<td class="nump">6,610,179<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">2,378,500<span></span>
</td>
<td class="nump">1,681,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Shares, Exercised</a></td>
<td class="num">(139,069)<span></span>
</td>
<td class="num">(272,734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Shares, Forfeited</a></td>
<td class="num">(490,407)<span></span>
</td>
<td class="num">(173,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Shares, Outstanding, Ending balance</a></td>
<td class="nump">9,593,990<span></span>
</td>
<td class="nump">7,844,966<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Shares, Exercisable</a></td>
<td class="nump">5,967,701<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Beginning balance</a></td>
<td class="nump">$ 3.75<span></span>
</td>
<td class="nump">$ 2.54<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Granted</a></td>
<td class="nump">7.58<span></span>
</td>
<td class="nump">8.28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercised</a></td>
<td class="nump">2.50<span></span>
</td>
<td class="nump">0.67<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Forfeited</a></td>
<td class="nump">7.85<span></span>
</td>
<td class="nump">6.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Outstanding, Ending balance</a></td>
<td class="nump">4.51<span></span>
</td>
<td class="nump">$ 3.75<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Weighted Average Exercise Price, Exercisable</a></td>
<td class="nump">$ 2.87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Weighted Average Remaining Contractual Term in Years, Outstanding</a></td>
<td class="text">7 years 2 months 23 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Weighted Average Remaining Contractual Term in Years, Exercisable</a></td>
<td class="text">6 years 5 months 5 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Average Intrinsic Value, Outstanding</a></td>
<td class="nump">$ 22,510,816<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Average Intrinsic Value, Exercisable</a></td>
<td class="nump">$ 20,691,512<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6692310512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock Options - Summary of Non-Vested Stock Options (Details) - $ / shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares Non-vested , Beginning balance</a></td>
<td class="nump">3,329,989<span></span>
</td>
<td class="nump">3,826,274<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Shares, Granted</a></td>
<td class="nump">2,378,500<span></span>
</td>
<td class="nump">1,681,500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares', window );">Shares, Vested</a></td>
<td class="num">(1,643,772)<span></span>
</td>
<td class="num">(2,003,806)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares', window );">Shares, Forfeited</a></td>
<td class="num">(438,428)<span></span>
</td>
<td class="num">(173,979)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares', window );">Shares Outstanding, Ending balance</a></td>
<td class="nump">3,626,289<span></span>
</td>
<td class="nump">3,329,989<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value Non Vested, Beginning Balance</a></td>
<td class="nump">$ 4.61<span></span>
</td>
<td class="nump">$ 2.86<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Granted</a></td>
<td class="nump">5.63<span></span>
</td>
<td class="nump">6.22<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Vested</a></td>
<td class="nump">3.98<span></span>
</td>
<td class="nump">2.60<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value, Forfeited</a></td>
<td class="nump">5.91<span></span>
</td>
<td class="nump">5.03<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Weighted Average Fair Value Non Vested, Ending Balance</a></td>
<td class="nump">$ 5.32<span></span>
</td>
<td class="nump">$ 4.61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options forfeited.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of non-vested options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average grant-date fair value of options vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6803097024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase of common stock shares</a></td>
<td class="nump">5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from exercise of warrants</a></td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueAdjustmentOfWarrants', window );">Fair value of warrants issued</a></td>
<td class="nump">$ 6,215,225<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=CRBP_CFFWarrantMember', window );">CFF Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase of common stock shares</a></td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price of warrants</a></td>
<td class="nump">$ 13.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_NumberOfWarrantsExercisableForCommonStock', window );">Number of warrants exercisable for common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember', window );">Investment Agreement [Member] | CFF Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants outstanding to purchase of common stock shares</a></td>
<td class="nump">2,283,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Weighted average exercise price of warrants</a></td>
<td class="nump">$ 6.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_WarrantsWeightedAverageRemainingContractualTerm', window );">Weighted average remaining life of warrants</a></td>
<td class="text">2 years 10 months 21 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_NumberOfWarrantsExercisableForCommonStock', window );">Number of warrants exercisable for common stock</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate', window );">Warrants expiration term</a></td>
<td class="text">Jan. 26,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_NumberOfWarrantsExercisableForCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants exercisable for common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_NumberOfWarrantsExercisableForCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_WarrantsWeightedAverageRemainingContractualTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Warrants weighted average remaining contractual term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_WarrantsWeightedAverageRemainingContractualTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08.(i)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=26873400&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAdjustmentOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense (income) related to adjustment to fair value of warrant liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 480<br> -SubTopic 10<br> -Section 25<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=109262497&amp;loc=d3e20148-110875<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAdjustmentOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expiration date of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=99377789&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CRBP_CFFWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CRBP_CFFWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_InvestmentagreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804776752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Warrants - Schedule of Weighted Average Assumption of Warrants (Details) - Warrants [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2018</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightLineItems', window );"><strong>Class of Warrant or Right [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">2.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term in years</a></td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">83.50%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of share-based compensation awards, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6803037456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Related Party Transactions (Details Narrative) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 20, 2016</div></th>
<th class="th"><div>Mar. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
<th class="th"><div>Dec. 31, 2016</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted exercise price</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 7.58<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 171,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 222,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_StockOptionMember', window );">Stock Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text"> <span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityCompensationPlanMember', window );">2014 Equity Compensation Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward', window );">Options to purchase, shares</a></td>
<td class="nump">50,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Option vested percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Options granted exercise price</a></td>
<td class="nump">$ 7.14<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_OrchestraMedicalVenturesLLCMember', window );">Orchestra Medical Ventures LLC [Member] | 2016 Consulting Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionLineItems', window );"><strong>Related Party Transaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RelatedPartyTransactionDate', window );">Agreement expiry date</a></td>
<td class="text">Mar. 20,  2017<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_CashCompensationAmount', window );">Cash compensation amount</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_CashCompensationAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash compensation amount.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_CashCompensationAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the expense recognized during the period arising from equity-based compensation arrangements (for example, shares of stock, unit, stock options or other equity instruments) with employees, directors and certain consultants qualifying for treatment as employees.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=115993241&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Date of maturity or expiration of arrangements with a related party (for example, but not limited to, leasing and debt arrangements between related parties), in CCYY-MM-DD format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares purchased on the open market during the period for issuance to employees under the plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesPurchasedForAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of share-based compensation awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_StockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityTypeAxis=us-gaap_StockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityCompensationPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityCompensationPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_OrchestraMedicalVenturesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=CRBP_OrchestraMedicalVenturesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandAndSixteenConsultingAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_TwoThousandAndSixteenConsultingAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.19.1</span><table class="report" border="0" cellspacing="2" id="idp6804194976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Subsequent Events (Details Narrative)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jan. 30, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 03, 2019 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jan. 01, 2019 </div>
<div>shares</div>
</th>
<th class="th"><div>Apr. 30, 2014</div></th>
<th class="th">
<div>Dec. 31, 2018 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2017 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Feb. 26, 2019 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12,052,645<span></span>
</td>
<td class="nump">$ 78,891,699<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">464,680<span></span>
</td>
<td class="nump">$ 2,969,837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember', window );">Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increased number of shares of common stock available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember', window );">Kaken Pharmaceutical Co., Ltd. [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Upfront payment, received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | New Premises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land for office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">30,023<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Total Premises [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AreaOfLand', window );">Area of land for office space | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,756<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock share sold | shares</a></td>
<td class="nump">6,198,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Purchase price of shares | $ / shares</a></td>
<td class="nump">$ 6.50<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of common stock</a></td>
<td class="nump">$ 40,290,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Stock issuance cost</a></td>
<td class="nump">$ 2,667,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Public Offering [Member] | Underwriters' Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of common stock share sold | shares</a></td>
<td class="nump">808,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Collaboration and License Agreement [Member] | First Quarter of 2019 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Upfront payment, received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Evergreen Provision [Member] | 2014 Equity Incentive Plan [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear', window );">Increases in number of shares of common stock available for issuance, minimum percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease', window );">Increased number of shares of common stock available for issuance | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Percentage of outstanding common shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Total reserve under the plan | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">18,543,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for future grants | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">80,722,414<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember', window );">Subsequent Event [Member] | Kaken Pharmaceutical Co., Ltd. [Member] | Collaboration and License Agreement [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RevenueFromRelatedParties', window );">Upfront payment, received from related party</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Consideration received on milestone payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 173,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_CRBP_RoyaltyTermDescription', window );">Royalty term description</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Ten (10) years after the first commercial sale of such Licensed Product for such Initial Indication in Japan. The Agreement may be terminated by either party for material breach, upon a party's insolvency or bankruptcy or upon a challenge by one party of any patents of the other party, and Kaken may terminate in specified situations, including for a safety concern or clinical failure, or at its convenience following the second anniversary of the first commercial sale of a Licensed Product in either of the Initial Indications in the Territory, with 180 days' notice.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_RoyaltyTermDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Royalty term description.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_RoyaltyTermDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Share based compensation arrangement by share based payment award options outstanding period increase minimum percentage in each year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">CRBP_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseMinimumPercentageInEachYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>CRBP_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109259400&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=27012166&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AreaOfLand">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area of land held.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AreaOfLand</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI http://asc.fasb.org/extlink&amp;oid=6877327&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=109223946&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromRelatedParties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue, fees and commissions earned from transactions between (a) a parent company and its subsidiaries; (b) subsidiaries of a common parent; (c) an entity and trusts for the benefit of employees, for example, but not limited to, pension and profit-sharing trusts that are managed by or under the trusteeship of the entity's management; (d) an entity and its principal, owners, management, or members of their immediate families; and (e) affiliates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07.1(c))<br> -URI http://asc.fasb.org/extlink&amp;oid=114873854&amp;loc=SL114874292-224272<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.1(e))<br> -URI http://asc.fasb.org/extlink&amp;oid=115205541&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromRelatedParties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase or decrease in number of shares reserved for issuance under stock option agreements awarded under the plan that validly exist and are outstanding, including vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=109197908&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>num:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_EvergreenProvisionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_EvergreenProvisionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=CRBP_TwoThousandFourteenEquityIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=CRBP_KakenPharmaceuticalCoLtdMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=CRBP_NewPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=CRBP_NewPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseArrangementTypeAxis=CRBP_TotalPremisesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseArrangementTypeAxis=CRBP_TotalPremisesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=CRBP_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=CRBP_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=CRBP_UnderwritersOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=CRBP_UnderwritersOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=CRBP_CollaborationandLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=CRBP_CollaborationandLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardDateAxis=CRBP_FirstQuarterofTwoThousandandNineteenMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardDateAxis=CRBP_FirstQuarterofTwoThousandandNineteenMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>94
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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MMWF\81AU8\K(XK%T-8943OTJDH\ Q:X831F:3LTXXFBD(3^ G/,6+V2?$9/
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M_>%W%7:#L7O[CXTO@JJ%7W>AO@!02P,$%     @ 44ML3IE<G",0!@  G"<
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M.AQG0GS/]O:1I24RS^_Y"NM./&<?5I:P7<_/Y)Z,<B.[W?98??9/1VXCUZG
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M/;?T?$(OO2,*$3-8H  %BH ^]P1"Q (6*$&!,J!C/\L ))+F&2@Q"_E>GC<
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M:P.&1.O$J6W(]NUK.]DHL2T6+O A_S_S33">HJ?LE5<8"^^M(2W?^I40W08
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MWH^[Y5H(#2;-\,%DV)JYGPT&M;;;)[.7_O5[0XMA&FP\_UV*?U!+ P04
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M@RV&@MJ%XR=_-M.838;#?OY!;/G&Q6]02P,$%     @ 44ML3ICEK$6S 0
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M/9[V(3X&/'4PVM69A$HNB,_!^%SE- F"0$+I H/PVQ4>0,I Y&7\G#GIDC(
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MFB&G6WIU/(NF]<'!BJSC#7P#_[T[6;38S%()!=H)HXF%.J?WV\,Q#?$QX(>
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M;.Q_H[4#+V5SY4>H\Q]L-@0T+AQO_=E,8S893O?I!Y'Y&Y=_ 5!+ P04
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M1YCK^4#)7/P7N(+RX4&)SU&BLG$EY6 =ZIG%2]'B==IE%_=QNDD.,VP;P&<
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M#S8;"FH?C_?A;,<Q&PV/W?2#V/R-BU]02P,$%     @ 44ML3OS;4NMQ @
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M<STQ1G/Q7^$*W,)=)E:CD%S[+RH&;:2866PJ@KU/:]OY=9SY;V'A #H'T$T
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M]I+[JUA):<!:B>[LB37VK5D"#I5QT\3.U=1Q4V!D/S\F9'G1\C]02P,$%
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M_E>(#GPJFQL_0HW_8+.AH'+A>.O/9ARST7#833^(S=\X_P-02P,$%     @
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M>'MC?V?R4C8J. AM[@YWPL]":&Y$P9/1*\PC,085/VO;34Q?]E=E'VC1#J]
M-#Y%Z[]02P,$%     @ 44ML3F'==I(> @  C04  !D   !X;"]W;W)K<VAE
M971S+W-H965T,S4N>&UL?531CILP$/P5Q'L#V."$B"!=4E6MU$JGJ]H^.V03
MT-F8VDZX_GUM0SA*K+[$WF5F=M:QM^B%?%4U@ [>.&O5+JRU[K91I*H:.%4K
MT4%KOIR%Y%2;4%XBU4F@)T?B+$)Q3").FS8L"Y=[EF4AKIHU+3S+0%TYI_+/
M'ICH=V$2WA,OS:76-A&514<O\!WTC^Y9FBB:5$X-AU8UH@TDG'?A4[(]$(MW
M@)\-]&JV#VPG1R%>;?#EM MC:P@85-HJ4+/<X ",62%CX_>H&4XE+7&^OZM_
M<KV;7HY4P4&P7\U)U[MP$P8G.-,KTR^B_PQC/UD8C,U_A1LP [=.3(U*,.5^
M@^JJM."CBK'"Z=NP-JU;^U'_3O,3T$A $R$A_R7@D8#?":EK?G#F6OU(-2T+
M*?I #G]61^V=2+;8'&9ED^[LW#?3K3+96XGCM(AN5FC$[ <,FF&2"1$9]:D$
M\I78HP<Z^K? X1&!<W\%[&T".SZ>&\QBOT#J%4B=0#H3V.2+0Q@@F8.T#O(A
MR\@:)7B!/'B0&*4H(0GR>\J\GK('3SC.%J8&#)F5RDB>Y^LT67CR .-D3?(,
M^RT1KR7BL406E@;,9MY]O,HW"S]>%,D69J+9+>8@+^[!JZ 2UU;;^S++3C/E
M"=E7L,COS:P91L.[S#"HOE%Y:5H5'(4V;\R]A+,0&HS)>&5.K3:S<0H8G+7=
MKLU>#A-B"+3HQN$731.X_ M02P,$%     @ 44ML3B@*=YDY @  E@8  !D
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M%8@?J$F\2#4($KSR[DNRQ/E!DLQQ-P$EUH 22TG^T8BI52!]O"1J,EEOB_=
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M#@-;_3=ZHI6":R<JQX95PCR#S5%(5EL59:4F;]V[;,S[W'W!T-+\!&@)L">
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M<F:.',3^7([O#PG,E .X(R@]:.QN!H01IRJX.)2RF*0SDORU 9!'TIQ7_NH
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M;XD;I1JI7?H7VME6INO#12XW37L:Z?.J?Z'O+QJU&SY6>(<O)HO_4$L#!!0
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M!\>A\S'+T#(+]CZ&S#\W"P[=CUF1+[-@_V-H Y@;!H<[ $4I6V;!>P .-X'
M,T/,=)/&N"0X9"63 \Q=$+YQ=:I:';U(8\]"?V(=I33"JJ('JW>V=Y*Q4XNC
M<<W<ME5_,/<=([OATI&,-Y_M7U!+ P04    " !12VQ.[XW=)-D!  #M!
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M/U;'[)F 6V0V\V0GW=ZY-5.M,K/W'*51!N[6:-3L!TT\T\0?%<5:@=)) @S
M1!%[*6(7CV;QD!*_ ?(:(&> /P# 11F#ACA-ZS0XA7BS6>B*M<Y<"I2D#RK"
M7B#L 5KLVG[0T'DB\XE2M !:ZV!,"'ZTQ<0+1#Q BT1[X@$BB,;+'5KK($*$
M)K$?B'J!J <(+X#H*A&F$4GI@F<M@YC2Z,'^)%Z<9(6S3+-/5@<CW1 (EP>M
M6.MP@B&!2QXPNZ3VT?S!Y+5J57 4VMQW=RLO0FAN/*,G8U>:=WH:U/RB;3<Q
M?3F\5L- BVY\B,'T;Y#_ U!+ P04    " !12VQ.?9.FP]P$  !C'   &0
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M]\U;I;0T"<,[\YCVYNQU&>1RJYO;B;FON@-(-]#JT!^N@LL);_$/4$L#!!0
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MC(2#2-A'RE,':=20FYD0 21+W?H&<J$P2Q9DR0(LCNM-YK' O$00.ZNA\G4
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ML5@23ILV+'(7V\DB%V?-FA9V,E!GSJG\NP4F^DT8A=? 6W.JM0V0(N_H"7Z
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MN7>0WU0A@%SW&NHU70])<%6Q*D@&T#%,<9G#0 4(5,R!:!X %;- F)2LR+(
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M)J43\VVB#=T8(&W)BL()28/&P",.+WNHBFBX-BN46=>'>"11>2%I1JDF+E.
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MHF&,SLWIM$?>OVYW$$] >;*#-+72X2_[<;\/[\]0;NR#=C4<^*^"O'5X<32
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M4V]4]LB5!WS+G189;MQ"E/0*%<@:P67.1MZC$6A,%>CY00,H!M[A237NQQ5
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MYL%F%CXI45:+3?T6"1<#"VJ!*;>BNC%!/+[;5]2$7EBY@M2B;M<O@)+ZJ:9
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M50Y<RHH<.[/?K!RX"<N!1RWEP*/O*0?^U9E)%8V@"T<%4VPA:2R<8EIP6<?
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MM>-&JL"52!M6:UB>+W!I.4N/35A/?-)IAVPZ(U:E"[^I[86U2RR.DP!&USS
M=FK=R>;%,ZY<"N<J=#N(AG7GY#K<$05/-JY_9#--#(A?+,(0.R%<@F5L=#/K
MPK<\IM-2+D89E6I0[K T%?D0:E3I  G)-ZW4PWRCYG[.P%^G"FEI*V+INL0@
MU6(+W\S'J%+E=+$[+?;.-"6F=G%'8DF)%V WY5.V%9.[<;1:N0O@#N$YVIXQ
MU_DBC24R#H33Q!)O_ZF<7GTIN'811C.;0P5T1V_8U#;\P(D1>P^;4(Y^2DK'
M5Y'_[>><WU?N]HM7UANM$83CV]A;9GL/$Q*Y\'SR%7)W>5IX(T;9:O0PMCW\
MQJ,B+@/'*TZZ@,Q5#'6HIB.MM-*7J4I?;>,TUF[R.==U8MJ/9_VQIZ4]:CO:
M0$KO,R!TV,F3:]X ?4@E\[P!).3JKZ-TK3Q42^KSI\\?@UUA2C-JM8-X/,8D
M8E*#9W&O/S$? !=@9<<X9C2(HW$/6&*W[W3TKPZ$F 4]F0WB_G""6="]03P8
M3J3;*E/E(!,:'D][\6Q,-9S[6,QJ:FH9W^-Q-Q[V)Q'PY/%H:#Z32@Q$!&,&
M,<+4U28#]7\*!X"CP0+[L[ZYWS^PN0V(WZS'J?&]:3SH3V'_4_.7!BIRKEZ]
MB,[]V]$%]>9M. M?[\3_5+U': %#7=M)0>872$$4IK1:U>4N--@TC4?Y(-Z!
M_.#E;:/ZHN$=7^?4%N(GZAV$4=7X1XZ;0,'1E=8)Y+]FW"R56<ZRVUJ:B<'V
M!?DNL*-B,P1:4/MB,G%"L32_(XE6HM!0P'7R9Y$^O-KI&Y<JM17B0PS%R<E6
M@&72T@AHX==D83WK#;'*>-SO3D2LPHJX<!,&4I"'R(BI5_N+-4O1(D #D&VH
M=08PDJ^.R;H!931,W2/L7<QN=AQ[FY>9)/@<I'YL'2)JGG!B$J*L;Q*"8^'Y
M-"48425JDS20%CM[+?S,*V^*.W_KW'<:9""OZ@ )2=:N%0 UT0#H[7=/.;>Y
M-E:=X3JKOKICT]K0L/><9"LV[-SZ29PD.L^E!3Q96SAM15:'*]OON)ZV^Y#P
MEZE7J5)BJZ&!-9C6#S[P_[3R J327F/$F^U61<.^B?J]#G"O-]%@2/]R""8K
MC:ZIE-V253??1*/.L$__C,?PS5V*!@L*;5.$^4UTV>>Q\=\1O&?9C3<_P/)F
MG2D\<T3T3<!9WD3#SJ '__0ZHQD\NZV 4H0O]3E,-NSTX!-A&OAI;PC_=#OC
M+H_@KIB_U5*/!#\?S#H3W-ME#W:'<W(A#AR -L/_D'4'5WJ]YZ33?\L?RNB*
M17:Z+KH2//!?I5&LT)&^HHD-^^3)0F&O>VXU\\;A=90'O@!_\X4)$VPMD,QW
M-OI_E8B+0]Z,41$%.F$S:;!C#;:6%9-PJ:44D>@HM9IC]9GR5GLP!;5OV>:G
M7N=CXDK",-86@VP?*1C#E<89O3$40[!<H178%B_JO?E!2;LN A9&7+@)EV3P
MJ51BQ3+^$ARW^/N>JL; 54>=NXS.=8]>(8'E&LB!>9!&(&EYT33O0F^R43RU
MW(EM:+!,)C!>X>?XSGHZ,*QWVGU#L>\5OH9!\=2N) W)TG<N@2=VM#S%W6V:
MU2+C:>!#,O^I_,&A@<W:]/&95#&S?$*V[>"+[LUBL9((>ML&%/[W*H:_;8(9
MX+#$'R)?S)5:05$"APGH>P@/LO7*F;D)O?UWQ;X7HB\JN02(V!K;*Q/)$V><
M4@K;[+/&2:)5BPW0&!?\Y-&B#%!JD[Z@(5*<+U3/:H<=FLBE%GRQ:.HIPC[,
M;)W^X+Q!'O\(-\4R0MZ8YS20KSD2@C*/T?*$PL8VY3Y$9)_  Z0D"!^F:G%?
M+<[(NTB$]65G*\["-^H@EVVQ18&-,GYLU66\\".XAH#=_1'=1@PIDTX\M-$%
M]: HR2S34"9A$AN*RERD5%\[*?,-(8,M!6IO)O-*ITH)H4/X8%1D^C-UF'T,
MI*F*CW_A3+$D,-#V\"[@]W@[ZN)&D_R+,N DGH)R-1WTG:,T@%6=,$IU-B94
MUBR&\]H9C):PR4F^)$U091LVB*9-@?WW-]>X^N4215PCT5_W5^] ;YI:6QT-
M8#MP8Y*U$QU<%*WS0B?61<*YENQ7()D=^T3LL!+E0_J:<SH F]GLB2&'HDNV
M(! T,\I[6JMJH_@.1':L[Q%]RCNX:-_T@3<1<$'9'_ODV7GSE.HL>(R1(V+S
MQZNK.RJX"N@H4B.I28GD5)"'=Y&GI3>2L6Z!9LF$I#OOJ'72(DKJ0.P*-(]3
MZ=]D]8K.AW-WE0R+CCSE!=O\'))SPQ%5UD0Z'X?M-2VYT=)O>!NNJJV5*0X2
MU3-J^F'O4A!:('5;*H%NC:U-8,>DYE>?W; ][X!CH\==33Y_BNZ_?K[^<TUU
M%HD=0=;CHCODW_?!DSJ6,8[.4"CK]C#/0-S_+F)56>Q'$[11Q,/96 (E677$
MHMC= 9D;9'PN5^%;_6%,"I;<QV-K*<P7MQ9S#^I=3T]HBD&E[-FMZ@.$G?^>
M]5*+ J0TVG(M1* PD;U2R :%K'@Z)>JDXD]MVQ>00B4DU&,]K6>1%6R#7G(I
MJEU.G PNBABCR;LX=PD0S/+RHI108KMX#O%!D_0$96<?3$Q^<;*GHZD4<S)<
MSW1?A$>:Z&% >Q\;D($F00*&VS;[F''X 5J >@1R5\=UW 1Q].?MUUQ1FMH'
M (5_*;!-*)9)?@ BX7=M/0P5F$D8[>'4U1*;352#NX?Q>%1%Y]JXWPW!Z#@$
M!_UX))>)0&A\6>T*,)T?L,GBV9L.O5<AL+GJ3I\.IJCI)B"27RZ25UMZ6L6^
M&ZD?$'@YQK,)QO1$S??=^B:HQ#I'XXO&%$Q*MUBF\1V6 9J;/5U==[ V5H7D
M5!L+O:B75B)@HT1P'-1H#)HAM#LZ7WMT-%T[D8222G;.-< 5;ON';/=?CRB+
MV#I 31G$XC[W5G6YQO4QD$_NL),]SRCB!U9E",'M3TBAL;\=MG:%+ZG'BX,/
M;&XD2RH_4GYE]%F^M5X2UW[65Q6;1O>TJ%J2>4<>5#'"QU$>&H51@F1*=6^Q
MZ9*WN%BN3WCJ/5>U OX'(=")WBN&>K1KGR$ZT8OK.0(UNL '$9)A2W=/A8(W
M>NDUN"B* ,/K! !X=]_O4], ZTDD#$I\.L)IRS(D DDJN(NO9]MND>\?GSP;
MG>JN$?[H#M4":LCVJ2]&-V)VY<=[HXO@.$_V&$=RJL/>(!YCCZGV4Y4+8ZJ7
MWX7R!75+++&H$*AQ&ZUP@G+SG2)\T(?.U0X'<7\\C?M=Z1I5NTIA'[$L*)T^
M.05BIEYB6F2NWG!(+IT6\K]7-2-=WHIPAJTO\2N1NV60:15D3%4"5Z+6*W V
M&/7C\7#D3+:EG[S\A=@A#6W[$^Q -ORM]UH-TG%[-;6]]H!S#6?=EKTJ=B;]
M+6>_D6RE8V-'-?V#_8N?&0:ULL8^N@KC@+7[T18]N49!!]1,G/Z2W91W-GCD
M.VM8]_H=46,^WWV]_?SIGLI[2I%C$%D#N-M2<OPWZL!\!VM8PYA[JJ181G_*
MJ6D,%R.F^B_#2%0J^ ,&WP.QPX;#U5J_0_JKYY75S$7W2MR8'_8N%^OB>Y(8
M4)#'&(-'#G)V,R,F;?(-VW,PBZ..CJJYN&-;*2BR^6M*]9BHK4T!@M?"SL0M
M8/>K76)[92:+YZR$)P<2,'V=]?0Y+9 T;92WPQ=*DTVSXEX1_DSUQCD=GLW+
M5C .RGCQ@))1#KIJCOK_G)Q5SH6GDO1Z.!W%_1!Y /4,R#JVW=AQ2SQC,_3/
M)V\NG*F;W [5Y=9E8:^;XI2*Z/BZ$6AC3.F-H(@8FB9\\1W34A#/ H_*9;S*
MA_BL!5TJWET*#W% (4>NN%:E>PUJ(I@K3QLU;J,!I7%*ME:W#I^^.#72Q8EX
M8%U "\-1^!22+#5=7S@TTGM[^Q5131>37;&U"=&#&CHVG:T^M.JY&J?CU!A(
MFZUTJNLF)KZW5&\4CX8#8"^SZB8/X;8AW'9.=1::1W$7&%5_V+,CA=<D@%?'
MDF679-IP=[Q[]YGZBF (\U":C3G'J)7H+ F*UE@\8+OB"/#YDZT54P39MZH^
M5*]K';W5(>WF&\N_ZGM@*LCCY4TV!84X.FO!KE].94R >8-*9OBOB7E1(^89
M[@URU;Y9?ZBH?5K\LRY5Q,-I%0\KV#4]B%VF@EV:9P>\_0,%&VIFU&+$^]YN
M[!7!B:/7N2-@^13SG)<-L4YA=\AQ=P9T8QJ=GY%U(YY.I[02QQDEB*P[C<=]
MKH.-<[C'%S:R9#P;QL/I# 8:4O.R\9#[5%<'BKNC03P=#AJ&J@2A&/'T>XL0
M?+),K8L&%8 P-8ZXF6TDAE[)RDZR4HTE(FQXF[D=:&5=X7=A>VZ:DLM,2U%Z
M=#EP<W>D(2[GA9C3*H$CN9\_Y60NV+I<0_)]Y8MTQ>QI7]KJ+X I:\$:S*/R
MV2F^<BC'@6B5ESY_RE#[1OZ/'HV$(NM?2 <N=9(4%;.1ZCTD_<)R?+5L1P)4
MQ8(-UR:U1HB2.JUZ!]A6<$QD<PHPLI#4"B]Y;Q%GB^#[C'ONR2D[?Y3.,Y$F
MH?8V6?M> Y6*)49,3&GB[$,(B'BZ7244<;$!"2 1$94,F>B8:G?V]+J3F$MB
MBE2QD)A":P/,8,,LAG*&DU'Q,54!EWRG^*WSG//1O<:VKL6XTQ]9S[V>)@'V
ME#R&G5 1YQ0B"DDS-KF$PW5]XWH&8H>(E,9Y"UVQ9@2PEXPD/23WZ,-C*K+R
MI\LE5M0EGV(F2S:RY%=;5#3AJ*FO!?GK7JU_X=6V;**9;(L=7?G1KA@G>TFQ
M@03>28&$NB]P[2@#3KHL<4%O>V#."A:0CRI&:?U 6EB$31TEGND+[#FB/;NX
M#QO'U!D-Z)]>/WIC;EQ3BPQ%33@:!L>;J,O_^3<8T+;Q-B$ _L^_\)QCK Y9
M4]]$TTEG@D-,QYTN!AG=-!!,NZ01!PSQ/QC\=,P:(IQ&DZ)]:?.DOA.<@&**
MJMIT@Z(%?IAE38P1Q22$X9O+?F<P?8-M=U6'D "8<05990P6M8:=64] "HN9
MN=_41PJNP?3346<TI<B!Z0Q_XLO9Q)E<M!#V.;N*R.S ':4M9^(,16I"9DYC
M]D'Z<B3IRU:>O6?IY*_V,ES)9;BQQID[<M34GG]QV?#7ZBI_%<S[&RWL%AYD
M< GG$88HI^:SDM0: C/'T3@>][IQ;X*M'@'[A^:/<OK8PI2,R?!@VNE/S8WS
M:9Q;<],%/.MVQA0"CM#$9[W)()[!</AL#-?IV!(FT02DBV$\&X^QVV1G,G)+
MZ,>#R526,(%#U$OH#69DW;O@=7?U$H:S;CSL3NC9I#,='5O"- *1:@;+GN%,
MP\ZH!Y_U!QSR/@+P3'MC-[>M<E0?9 1[F,23+K7_ZDPGL/TA#0*RU0P;;O6;
MB2#=MTN4:\SA"UG).#H!#;F?<L<V4P:2U-=.[5K#<.-=$YG#I-IZO'?KEZVH
MX@M J;X[IN0'<X9]T/H R&%U=:<HK=7RX3&V;!]B3\JEZ!-8@,@E<39)V;%1
MN;3(85DH9(@U2>>Z& ]SN:-SA/)IM=2&D?:!(A&@#Z,SLO)$$^))3IHC6WK5
M6H_Y3H7E%]$PJIW I.>37T8CY0&EHC^.^Y,A7Y=Q(^5!C#5_X5'.N:?>M#N6
M6S_NMA$>X)8#7$#[_!-,(>G/XMET1G=^W&LD.WAWW/S8Y!D44*SL0*1J-@VH
MSF :#_M3F7_6.P* :82=_,;4.!T_&/1K[?BD/$/=, V8\<SU^6^QKL&>#<YX
M<']*%\0^KWQ6_6E)PH-.]->K+U^N/GV]/]WKTN@P&%6\CX%9@*0R3S^65*!3
MN0U&'!3P*?=C5SYADF..N4F:4V)C92\P;@9MSM [Z5,BUH$0 I%]:Q3=N5E\
MR,6X _R2$^GMZ\:^[LO<6%$?[L/,BCIAW.2+*Q=B8].PD$>UYEQ+=4%==1A=
M(F9::5'SSRHS&%7*#)K_AC*#D2HS:$Y?^J];9C!2909-,- _K<R@#0$S_UUE
M!IL&-__\,H,!LAG5E@WS(=AQ1K$NT3JEWKJKE56K%Y+YQ!8-B@4E.Q9_9$>R
MC9,:+,7X2>C_Q/#%>;*:2UOBNK*F:0%G,' 5'AU/2SY=! DJ[5A'S073-R[-
MQ0+*N"83D6I+T?9200G+Y/BL#O4Z96G;=O#(E>:H7<5X5<GH%B1]1PMG*#IN
M%&C07 ]6VPI0HFH&:%/^^YS9TZ;S']#V,9JN4=&?#CJCZ$V5U5K?\1V5L_[J
MJYC5^'S[FX<X^; 3?;GY>/7UYGUT=_7EZ]^BK\#5[Z^NV:G\.>S;%]=;1U9C
MR<2E2KI36P?=,:JD]JUZ; @A^><"72VPZ.C'=$'5]/X"[^S)_?#QX[4+,''O
M^::Y+O@6X\6M3^0TYW,<O4_@(*,_Y?.G-7D@R^A'K-^#*T7 ;K \XC>Q168J
M;B;V*P;2N.$*30E5GTJY#KF&C/<UOU;*\HB1UIFU,.9&ZF+:+VVU*G2G8-08
M$*^Y? Q3/&7;,C9<V)H<M-1P9+\A\8[M&B[YPGZNFYTK-VSS.7&=Y,V<+95U
M]&";,-%S>N-'2G:1IY/CW=":9PT=(E3J#K[W6$+E'[3Z1!4RM?"A&W\RQR+J
MZNO,6RMD>*QZ6JM:8_0>TT05HD!Y4K"F'P%#!']L@4B).[$:<2#_!KS3837;
MDEAOTNU>6L4B^2)H.&.J7+]Z 7281^#58O.ZNTC+;,E57]FW-^J^N1#WAS56
M<YNU\\%%Q#WLD\T&@%)@MH(55$)7C/Q1+]O%"P4A>>HM42/#F<OLY^A\W#"O
M?&R.SLNX'\Y!C, >-PONFR9!?8*)GDZ&;"Y!;$[QU55#GOM<+N>TLC%C<;Y-
M>M6/*!#45 KI5*J]U.$!"M71-8>U'BG?STU8K=QC*N7=0EAS(/4KPQRSY%_M
M$6>>>@#EJ(5C>3_7#?FYCKYPB!&"G'G_[=W]S;]_P_;RV$D>=-L;%^5QYZ(\
MCH<&F5\>&O0/..V;0H/,+PD-:G3B_Z+0(//+0X/:N,-WA@:9?R@TR&_T:,A&
M=7TN9,/\<T(VHL,A&X8V+BR0"S_^-J$;WL88;-K\)J$;PY,B@ZZ#)B2^]4@0
M5VJ/I3D^TE3B([504!& P]EPY1^YR4A;$Z=F^9=7&"[#7.<=D'YWBTY,DK:D
M6A6/"5N//5JLDA<Y@"V&;,I4-&9[J*:2M00*E@'R8D">27^FQ.EGUXI'\@5=
MWPRXW<&2)2=18@(D0(ZQSW9CTL 04/D&1T' ^([:I?D&/468&[[ DA! _%ZI
MO(?T?GP%1K(&^;B<KU)N17B^RQ])KV5T=&T&62.^Y?Y N%PW-S:P9T#N?(^_
MKVE19.C(;P=H0!L\=(U 5^P/B6V50Q12)'0JX[E%Z5&0NK&,@BV79;F]:TN*
MI;-L77'^0B6: R*I,JI6C:^!WANB:I"QCQP,>-6,)B=OR[1NBY'&ZCO+C%/)
M?28MKQKD>C1XH ZE&ZP%"W,A/QI)<32[75/=;F5/M)N]1+;S %0YPR>'+]%L
M5]8O0AV@=!H/E#]KPX+LPLG;TGH$;DU68U&%C 6]Y#X:?^(%&DK\'7YXE5L=
MZW.B7C^,CLGQ!CYB(@VZ ^((VQRC.&#?IJ&$.!J%>0:7J];<OW?BN99%RDH%
M;IM]K) YMMEK9!FU".'744H;+>QV8&'5L$AFB<J&9N\\IB+\#=M4.1Y$Q>R4
MB5#JP>C8'=3[4 NA,B^4?"]EA-XC<Z FP+;1NFUYE7&U"5D0BQN2G!@4CY16
M?^S(USVZR>5V(8=KFDY)3L%WF4(>;E/;CN->+/S%MTNRILS8OKO(]Y1*GCUF
MOARW[2?&XNE#ZCH(X!AVK*R8[]<H:LQ%UL+SRO P@$0@-I1YM$)" 3N6?6 K
MU15NH[YTV#"#(8C=YB]>=:X3.5,#!NXZ%Q1L+ZEU47/;L(TIR7B+TC3:6)I
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M@)*YX'IZ=NUM9\QN@J#FGHSH(I>P]8AS4%M#2B EJJ GYZW:$;"D:I"#A [
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M#BK5P1[GPCOI;4QB !9::TYN.Q:'G<]->[-Q@9'[T-<-/ZGG>1#.]Y@]RXF
MVK07"9Y[M9HRDQ;BZ98#$JN$QQD<DD8(N-))O2XWNVU;8U#Z5UJ_IJ;M;=$
M.M1'TS<&WU%<,Q)P.2/#VA#_7:Z/UX)]/$Z3[$[-+]/=OMA8- ^ZU7O1F *
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MJT8ME%S*L]81RYBSI-U9@(-2N_44'?7!NBYKG64E76,,OL];*>L&PQP<3Z?
M681Q(%]8X*F.:UA28AE""<J,.:O]/WV:Z(+#S$98G#,'A(Q^P@#5)HJ)=C:R
M)O"@^L?0G0^][B"" Y)[5AACT RC55V^SYA$("QI5*!G'NN  .%2G;J\7<U:
MB_-@GV'9]5&9><E@'$ 4N4OF&FBHK;//OL=A7JH[JXEX- [*,&%$B*FG>+;]
MY8<? %?&VA<<N>A2/B;2AW<HZ&<0C^WMR%B5CNBWP1[SC?0$8'+,MR&S& Q@
M;HM=%-&Z@210*)&4 &9W?*@L+RW8\YQLO0QZEB\M M*21#&@EJB;2"=Y9>A
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M)C.=+4?=?-,LU"$X6ZA10,Z[_J&V6;^"QS!5L.>0_.MRN7K[/U!+ P04
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M_=$*CQ;CK.5(D>#)_@0Y;?FE*SB].M-O4$L#!!0    ( %%+;$XT3^A@G@0
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M4$L! A0#%     @ 44ML3E/770+O    *P(  !$              ( !F0$
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ 44ML3IE<G",0!@  G"<
M !,              ( !MP(  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " !12VQ.N%]P;=$"  "9"P  &               @ 'X"   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ 44ML3F1'&$[4 P  TQ
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M965T-BYX;6Q02P$"% ,4    " !12VQ. V:9!KH$  !,%0  &
M    @ $8'   >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
M44ML3M>19Q>Q 0  T@,  !@              ( !""$  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( %%+;$[,@4WVM $  -(#   8
M          "  >\B  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " !12VQ.XB\DX+,!  #2 P  &0              @ '9)   >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( %%+;$Z8Y:Q%LP$  -(#
M   9              "  <,F  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ 44ML3ATDJ$"T 0  T@,  !D              ( !K2@
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " !12VQ.%9&Y
M^;<!  #0 P  &0              @ &8*@  >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( %%+;$[HM[AUM $  -(#   9
M  "  88L  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
M44ML3G^R9-RT 0  T@,  !D              ( !<2X  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " !12VQ.^<?XL;0!  #2 P  &0
M            @ %<,   >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( %%+;$[-=,*RLP$  -(#   9              "  4<R  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ 44ML3L?8PH2T 0
MT@,  !D              ( !,30  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " !12VQ.2<N6>K4!  #2 P  &0              @ $<
M-@  >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( %%+;$Y.
MA5+&M0$  -(#   9              "  0@X  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ 44ML3F_AKX:T 0  T@,  !D
M     ( !]#D  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( %%+;$Z2<@J^V0$  -T$   9              "
M 69$  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ 44ML
M3E^WX1>V 0  T@,  !D              ( !=D8  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " !12VQ.QBJ(2K<!  #2 P  &0
M        @ %C2   >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( %%+;$[E**%.QP$  #@$   9              "  5%*  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ 44ML3O -/K// 0  G 0
M !D              ( !3TP  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " !12VQ.@A0'O+<!  #2 P  &0              @ %53@
M>&PO=V]R:W-H965T<R]S:&5E=#,Q+GAM;%!+ 0(4 Q0    ( %%+;$Y*K'JC
M=0(  , '   9              "  4-0  !X;"]W;W)K<VAE971S+W-H965T
M,S(N>&UL4$L! A0#%     @ 44ML3N7L8,.:!   0QD  !D
M ( ![U(  'AL+W=O<FMS:&5E=',O<VAE970S,RYX;6Q02P$"% ,4    " !1
M2VQ.IMMC=SL"  "6!@  &0              @ ' 5P  >&PO=V]R:W-H965T
M<R]S:&5E=#,T+GAM;%!+ 0(4 Q0    ( %%+;$YAW7:2'@(  (T%   9
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M970S.2YX;6Q02P$"% ,4    " !12VQ.%]*2UH8#   ]$0  &0
M    @ '#9@  >&PO=V]R:W-H965T<R]S:&5E=#0P+GAM;%!+ 0(4 Q0    (
M %%+;$Y+E"*.A0(   4)   9              "  8!J  !X;"]W;W)K<VAE
M971S+W-H965T-#$N>&UL4$L! A0#%     @ 44ML3N^-W239 0  [00  !D
M             ( !/&T  'AL+W=O<FMS:&5E=',O<VAE970T,BYX;6Q02P$"
M% ,4    " !12VQ.8'#7O[H"   -"@  &0              @ %,;P  >&PO
M=V]R:W-H965T<R]S:&5E=#0S+GAM;%!+ 0(4 Q0    ( %%+;$Z>M5J#)P(
M !D&   9              "  3UR  !X;"]W;W)K<VAE971S+W-H965T-#0N
M>&UL4$L! A0#%     @ 44ML3GV3IL/<!   8QP  !D              ( !
MFW0  'AL+W=O<FMS:&5E=',O<VAE970T-2YX;6Q02P$"% ,4    " !12VQ.
M@^;0:P<"  !Z!0  &0              @ &N>0  >&PO=V]R:W-H965T<R]S
M:&5E=#0V+GAM;%!+ 0(4 Q0    ( %%+;$YW;U7,&P,  .T-   9
M      "  >Q[  !X;"]W;W)K<VAE971S+W-H965T-#<N>&UL4$L! A0#%
M  @ 44ML3G(E@@Y^ @  7 @  !D              ( !/G\  'AL+W=O<FMS
M:&5E=',O<VAE970T."YX;6Q02P$"% ,4    " !12VQ.8<R+-&P"  "T"
M&0              @ 'S@0  >&PO=V]R:W-H965T<R]S:&5E=#0Y+GAM;%!+
M 0(4 Q0    ( %%+;$X_=?DG%@0  (\3   9              "  9:$  !X
M;"]W;W)K<VAE971S+W-H965T-3 N>&UL4$L! A0#%     @ 44ML3JR,&[ J
M!   #!4  !D              ( !XX@  'AL+W=O<FMS:&5E=',O<VAE970U
M,2YX;6Q02P$"% ,4    " !12VQ.!<E@ Q\"  "&!@  &0
M@ %$C0  >&PO=V]R:W-H965T<R]S:&5E=#4R+GAM;%!+ 0(4 Q0    ( %%+
M;$[N!!M;*@,   (,   9              "  9J/  !X;"]W;W)K<VAE971S
M+W-H965T-3,N>&UL4$L! A0#%     @ 44ML3E(^:$_& @  =PD  !D
M         ( !^Y(  'AL+W=O<FMS:&5E=',O<VAE970U-"YX;6Q02P$"% ,4
M    " !12VQ.S+@:%9<"  "'"0  &0              @ 'XE0  >&PO=V]R
M:W-H965T<R]S:&5E=#4U+GAM;%!+ 0(4 Q0    ( %%+;$[FD'04Y0$   $%
M   9              "  <:8  !X;"]W;W)K<VAE971S+W-H965T-38N>&UL
M4$L! A0#%     @ 44ML3C[0AN'& @  1 H  !D              ( !XIH
M 'AL+W=O<FMS:&5E=',O<VAE970U-RYX;6Q02P$"% ,4    " !12VQ.L*4P
MQ* #   Y$   &0              @ '?G0  >&PO=V]R:W-H965T<R]S:&5E
M=#4X+GAM;%!+ 0(4 Q0    ( %%+;$Z*/X2TLGX  )?E 0 4
M  "  ;:A  !X;"]S:&%R9613=')I;F=S+GAM;%!+ 0(4 Q0    ( %%+;$ZX
M89!5/@(  ((*   -              "  9H@ 0!X;"]S='EL97,N>&UL4$L!
M A0#%     @ 44ML3C1/Z&">!   ;B8   \              ( ! R,! 'AL
M+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( %%+;$XU TT!"0(  #,C   :
M          "  <XG 0!X;"]?<F5L<R]W;W)K8F]O:RYX;6PN<F5L<U!+ 0(4
M Q0    ( %%+;$Z;Z.7DWP$  - B   3              "  0\J 0!;0V]N
E=&5N=%]4>7!E<UTN>&UL4$L%!@    !# $, 1Q(  !\L 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.19.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>165</ContextCount>
  <ElementCount>286</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>83</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00000002 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/BalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00000003 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/BalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00000004 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfOperations</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00000005 - Statement - Statements of Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfStockholdersEquity</Role>
      <ShortName>Statements of Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00000006 - Statement - Statements of Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>Statements of Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00000007 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StatementsOfCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>00000008 - Disclosure - Nature of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/NatureOfOperations</Role>
      <ShortName>Nature of Operations</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>00000009 - Disclosure - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/Liquidity</Role>
      <ShortName>Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>00000010 - Disclosure - Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies</Role>
      <ShortName>Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>00000011 - Disclosure - License Agreement</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/LicenseAgreement</Role>
      <ShortName>License Agreement</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>00000012 - Disclosure - Property and Equipment</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipment</Role>
      <ShortName>Property and Equipment</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>00000013 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>00000014 - Disclosure - Notes Payable</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://corbuspharma.com/role/NotesPayable</Role>
      <ShortName>Notes Payable</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>00000015 - Disclosure - Accrued Expenses</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/AccruedExpenses</Role>
      <ShortName>Accrued Expenses</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>00000016 - Disclosure - Development Awards and Deferred Revenue</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue</Role>
      <ShortName>Development Awards and Deferred Revenue</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>00000017 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>00000018 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>00000019 - Disclosure - Stock Options</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions</Role>
      <ShortName>Stock Options</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>00000020 - Disclosure - Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/Warrants</Role>
      <ShortName>Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>00000021 - Disclosure - Related Party Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/RelatedPartyTransactions</Role>
      <ShortName>Related Party Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>00000022 - Disclosure - Subsequent Events</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SubsequentEvents</Role>
      <ShortName>Subsequent Events</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>00000023 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPoliciesPolicies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>00000024 - Disclosure - Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPoliciesTables</Role>
      <ShortName>Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>00000025 - Disclosure - Property and Equipment (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipmentTables</Role>
      <ShortName>Property and Equipment (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/PropertyAndEquipment</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>00000026 - Disclosure - Commitments and Contingencies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingenciesTables</Role>
      <ShortName>Commitments and Contingencies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/CommitmentsAndContingencies</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>00000027 - Disclosure - Accrued Expenses (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/AccruedExpensesTables</Role>
      <ShortName>Accrued Expenses (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/AccruedExpenses</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>00000028 - Disclosure - Development Awards and Deferred Revenue (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables</Role>
      <ShortName>Development Awards and Deferred Revenue (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>00000029 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/IncomeTaxes</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>00000030 - Disclosure - Stock Options (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptionsTables</Role>
      <ShortName>Stock Options (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/StockOptions</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>00000031 - Disclosure - Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/WarrantsTables</Role>
      <ShortName>Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/Warrants</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>00000032 - Disclosure - Liquidity (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/LiquidityDetailsNarrative</Role>
      <ShortName>Liquidity (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/Liquidity</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>00000033 - Disclosure - Significant Accounting Policies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPoliciesDetailsNarrative</Role>
      <ShortName>Significant Accounting Policies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SignificantAccountingPoliciesTables</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>00000034 - Disclosure - Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfCashAndCashEquivalentsAndRestrictedCashDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Cash and Cash Equivalents and Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>00000035 - Disclosure - Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfComputationOfBasicAndDilutedEarningsPerShareDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Computation of Basic and Diluted Earnings Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>00000036 - Disclosure - Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SignificantAccountingPolicies-ScheduleOfPotentiallyDilutiveSecuritiesExcludedFromComputationOfDilutiveWeightedAverageSharesOutstandingDetails</Role>
      <ShortName>Significant Accounting Policies - Schedule of Potentially Dilutive Securities Excluded from Computation of Dilutive Weighted Average Shares Outstanding (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>00000037 - Disclosure - License Agreement (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/LicenseAgreementDetailsNarrative</Role>
      <ShortName>License Agreement (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/LicenseAgreement</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>00000038 - Disclosure - Property and Equipment (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipmentDetailsNarrative</Role>
      <ShortName>Property and Equipment (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/PropertyAndEquipmentTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>00000039 - Disclosure - Property and Equipment - Summary of Property and Equipment (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/PropertyAndEquipment-SummaryOfPropertyAndEquipmentDetails</Role>
      <ShortName>Property and Equipment - Summary of Property and Equipment (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>39</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>00000040 - Disclosure - Commitments and Contingencies (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingenciesDetailsNarrative</Role>
      <ShortName>Commitments and Contingencies (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/CommitmentsAndContingenciesTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>00000041 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumRentCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Rent Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>00000042 - Disclosure - Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommitmentsAndContingencies-ScheduleOfFutureMinimumCapitalLeaseCommitmentsDetails</Role>
      <ShortName>Commitments and Contingencies - Schedule of Future Minimum Capital Lease Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>00000043 - Disclosure - Notes Payable (Details Narrative)</LongName>
      <ReportType>Notes</ReportType>
      <Role>http://corbuspharma.com/role/NotesPayableDetailsNarrative</Role>
      <ShortName>Notes Payable (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/NotesPayable</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>00000044 - Disclosure - Accrued Expenses - Schedule of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/AccruedExpenses-ScheduleOfAccruedExpensesDetails</Role>
      <ShortName>Accrued Expenses - Schedule of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>00000045 - Disclosure - Development Awards and Deferred Revenue (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueDetailsNarrative</Role>
      <ShortName>Development Awards and Deferred Revenue (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenueTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>00000046 - Disclosure - Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/DevelopmentAwardsAndDeferredRevenue-ScheduleOfRollForwardDeferredRevenueDetails</Role>
      <ShortName>Development Awards and Deferred Revenue - Schedule of Roll Forward Deferred Revenue (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>00000047 - Disclosure - Income Taxes (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxesDetailsNarrative</Role>
      <ShortName>Income Taxes (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/IncomeTaxesTables</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>00000048 - Disclosure - Income Taxes - Components of Net Deferred Tax Asset (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxes-ComponentsOfNetDeferredTaxAssetDetails</Role>
      <ShortName>Income Taxes - Components of Net Deferred Tax Asset (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>00000049 - Disclosure - Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/IncomeTaxes-ScheduleOfEffectiveIncomeTaxRateReconciliationDetails</Role>
      <ShortName>Income Taxes - Schedule of Effective Income Tax Rate Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>00000050 - Disclosure - Common Stock (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/CommonStockDetailsNarrative</Role>
      <ShortName>Common Stock (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/CommonStock</ParentRole>
      <Position>50</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>00000051 - Disclosure - Stock Options (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptionsDetailsNarrative</Role>
      <ShortName>Stock Options (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/StockOptionsTables</ParentRole>
      <Position>51</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>00000052 - Disclosure - Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions-SummaryOfAssumptionsUsedPrincipallyInDeterminingFairValueOfOptionsGrantedDetails</Role>
      <ShortName>Stock Options - Summary of Assumptions Used Principally in Determining Fair Value of Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>00000053 - Disclosure - Stock Options - Summary of Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions-SummaryOfOptionActivityDetails</Role>
      <ShortName>Stock Options - Summary of Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>00000054 - Disclosure - Stock Options - Summary of Non-Vested Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/StockOptions-SummaryOfNon-vestedStockOptionsDetails</Role>
      <ShortName>Stock Options - Summary of Non-Vested Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>00000055 - Disclosure - Warrants (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/WarrantsDetailsNarrative</Role>
      <ShortName>Warrants (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/WarrantsTables</ParentRole>
      <Position>55</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>00000056 - Disclosure - Warrants - Schedule of Weighted Average Assumption of Warrants (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/Warrants-ScheduleOfWeightedAverageAssumptionOfWarrantsDetails</Role>
      <ShortName>Warrants - Schedule of Weighted Average Assumption of Warrants (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>00000057 - Disclosure - Related Party Transactions (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/RelatedPartyTransactionsDetailsNarrative</Role>
      <ShortName>Related Party Transactions (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/RelatedPartyTransactions</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="crbp-20181231.xml">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>00000058 - Disclosure - Subsequent Events (Details Narrative)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://corbuspharma.com/role/SubsequentEventsDetailsNarrative</Role>
      <ShortName>Subsequent Events (Details Narrative)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://corbuspharma.com/role/SubsequentEvents</ParentRole>
      <Position>58</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>crbp-20181231.xml</File>
    <File>crbp-20181231.xsd</File>
    <File>crbp-20181231_cal.xml</File>
    <File>crbp-20181231_def.xml</File>
    <File>crbp-20181231_lab.xml</File>
    <File>crbp-20181231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy>http://fasb.org/us-gaap/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/dei/2018-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://xbrl.sec.gov/country/2017-01-31</BaseTaxonomy>
    <BaseTaxonomy>http://fasb.org/srt/2018-01-31</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>99
<FILENAME>0001493152-19-003143-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001493152-19-003143-xbrl.zip
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M<#V9 /3N8WTJ*GLJRH"0D_!48OOK$[J#X*Z_V(]3YM]B=</H1&R[U8KE^L*
M9GTV%BA6SELFP"MG)PY,X96-YRI%X5^]YYK JT#@RQM1TW>!RIGB1KQV6?ZE
M**@]\,/3ZD25%P1;#!>[H>^J-9XZ;/W6,E1X2FVCJDB%A^P2]?K1+3TE>VN
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MY^8!^Z3)3^^267 "7[[]A+U;1I9S9CGV(X 6>O/D440"/3[.3-9JSW_\HDT
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MB*52=J[B-IS=6L0>O##T9NN,8NH>8<5QYN>M?ZV!2JSWC$\&L"?&EB*CP)H
M@^Z?WW5C=(EURP$?'&OT!Q]6"SS''J=)2P6[@*4K=4F4,\6576F.)>Q$]LI\
MG;TB)KW?/3H5//6J1\O P&"1CSX&X" 3\_Q/VO\^/[^XN+PL8*?OF3\57C_>
M*"77+QGM3Z5I(_-F ?#>OQ VXZ<T5?@8>5)XUCY*N>W6H?!R@A@UFUV]8S3W
M@-$=G2X0KT.V[FRM.?4%UO][5J,]"&_>Q$EW/N V)--NZH/60.^8G6.\QXX1
MXUU3;[4 Z_U]8_SU;D0)F<,F8<9G6^1FY-;MC+I5$#E%=[8L!6QQH@R]U^[K
M[6Y1R7#72WB]I0(I=UH]O3TH2LJ'NV JBN0#0%0%R%^?-;U,H,B8<6MQ8F.8
MCK0OFZOC;VIY8J<H-SKD+#@.8:*T F"6.J_4*UCX\S;9;_D#P=1[=J41/HY,
M(',]_CS!H*,M46ONC@;-AHDT,_:B!X?M31G=//56&D=9^6BW>*UW9Y-(UQUT
M]7:_N^?=R6$HKQR%>5Q1$,-<=V-?%W'Q!,A*1R^R,O0[3IF3'X"F4ZS!G/N+
MK?G<]WY0;).ST-[WFB;Y1B5/C'VD\7!>Y%/@N3VV+7\AO9;*)/\-E#'V9@TM
M?Q4]N8K5KNJ-*SB@Q_)82&@9T,LX*"]IDUU'*;TX2FED^?Z"LD1$&&,<UVB[
M\0%%;S'*?.3]?[ <S $%,80Q?OA&JPPBE+["X"_@D2C,\(B,0)M;BSA[P^(]
M,I-P2>4HXY&Q?0)C8MD^1?DQC4<HBBPA$(;\\ R#$S27!T'Q(QE@Z$],'R(X
M1*Z5QHE]WZZ'H9,Q3-GI-9R:8.#3CR.*P"*ON45!J3QT=$$14A2,1<9<A.F0
M1_SP00G+!^'&Q[2DD.=;890AA8I6ZE <U>F5\;P8RCQAZR*G"*ZYBGXFT9])
M5Q"!>PMF^0$_WC!:A"$^4\L?/Q.18QJ=-PGC/_@K<"HF]I/ZJC>9V, J)I$/
M]YZ,P4Y-OCH%S<$((>Q$I=DS /Q)B;\6X4P\4%CFB='S_ S.,, :^Q)Y3R*2
MF-@$CU)*>$H4L$D$+P+,P Q\$9<<S#%N"9;AR"1 &6_<H36-L:*D(\+N<_&)
M?_$0)HZ$)!./>*0"+@_(\68SFX<H5H5=',4!6 ;T5DVC_*+$HE^(RZ5:\!^>
M0_.26;9+<8(\K%!-125 4C']<+K$18VG,'ZS*G1[$!"^>:[/T'7+Y8?Q$XE'
M($]PA@5()5@>/6],;"9@_A-P19':,K6>&(]K!/8*\@1 $/ <9OQ5)L[RQ&C<
M'>1Y8JLF$0D\JY*'0;0"/L8CL^>1CZ4[0B[2>;");!11YC-FKN*\F--!^1*/
M@M&*L$W;'\-:D,G%\WC^H^6*)&P>%SX67<2$O8I2._[#2<2*\T?PKR0)AJ>=
M<*3P(9 /^WR9G!/S1V)TX5/ 2C&%Z8U3W#+G&_*L''[KWF:/<!XKY-D>,C_G
MW@>-JF+L\5CNH6% !T2J$WEI>=R^@,P@)Z4L55$ A3&1*$=)65+"XT4$Y-[Q
M5#'*]\/T#OQ-R;"2@I$XV?PH<PT&V(?GPXQQ8M:J0TT%%UR<Q9)2EQ@U+N9@
M U1QG2>98)@*^H:_,2V,*@Z(US@#(FKCHE^"$5*8$O4M 1\/OE*$P&6/7FC+
M9#)NVGG"1%_"A7R-LF3D9P0?<^,XWJ2U1[!H,3'QV[&'ZB#FM(QXS#K/T0NX
M),GGPNV@!:28.7$G$%-MC.SGJ JBT319QDI)E\#Q:'DH=MI4) )N%$>F/))*
M.H<I0Y:0 ,"_BJ P>YE6P-,.*7=0OA8'X_.%X3"T*@(BG]5RZ5;4KX@E@#%F
M0:BY-[%V+[00==8XB%]JSD#45*1B@CM'Y3@LDKL%,OA)DJ^GYP'YFU(1Z )-
M\A&3)$C,W;;^P.%M%Z:3>2 BPR F3L"J Q2)=S8L-4#2=6BI7A1BPI:*$;FS
M/FE*8@WP'5 _/^GQJ>"DK<M++,8H*E$.H]21+W$^**9Z^CP?VLH,H<=798Q?
M*@(:T*['S\JK54FGU.R)9J4S2M5<4N(C$E=IS&(FKO*C*%W"=;8E*PW]S"R@
M\+1!B%+-4B::"3_$R%%L?Q3-,,\$4?*'BWXL0*8=\NQ;_ ?X\/J#DD:3W'XI
M0\CR(M%<3(X#.@MI:8HP=4A+,G!QYR2/6,,)/2PNPV6A,Y*%5&;:T(8.'++H
M<9KBXV,/EHB\!%$&PZ?P3F5@6,Q) $"^10@Z[9*TQO&-=!:QI*W30,1?9%=.
M]<@@$XA$DG)\Q&(B3(XT"5?(;00M"X(I^CKR4F*Y@K$*F0ZIC3,F!<=R*3R1
M&Y,(/8^R'.F,P&?'>^8V?, :8M<>18[EQ]G1E^(H<:L",9YEGT(LZG#3/.X7
MX_F#E [(T2R.$.>18N%YE@=@M9Z</WT<EHX!V4?29[^63%-"&R5Z!4(C%UK"
M;6WTVT%B,;=/<>&/V]DP;8HU"!J)=KRN>7*\N,B5!$'DX;%MRLM8TCAM)^*%
M4K8@\N=>]EI.'2 .#K] $20YXK^!Q\!*TA-+,]MERE0FWB"F@2S: K9"[)$%
M<-04WDQ?3LD[L<B(TG@I^N,@=F.$%&I!+TAK?U*;0=@/R9, =P?F9OH6^J'/
MX'C3C68'B3V1/S917I2:+TS("TD(A@ZK?V#A,V.).\5GW EBC^/Z!>G)1,YF
MHE;[9"E-Y9P2NPR9BP4.% ,I>B6]9W[!<N<+&@MX$0D$-0B$.8(7?T!XA9X.
M?Y&P[KE<_G3#6+I8O>R:V:6XQKGG8IJ1+!$*F#KG&;2W=O!'I1C)47(\K+3G
MIJO0 :LY$P+H&0F@PJ2N[(.2R(PUZ[A:1@X/G\%(&$9 M50250W$=ZH^H^B@
MR)Q("IRR\2.)-8JM+"M&<WF(GSI8.LD:^+]DZQ,YX,!1W#\R)1,NV9A2U[\
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MV>:\,^]\*RFQ,WDA^2STO;B)X0S(Q!NG&[#$>2(J!215:A+6@!6#J%8"P$-
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MIK()9UA9G@!97UMAG&X]62"5'KN0O.\TNBW>5*#;,,VD/7FZC0 5W"8@DO;
M=IPQMP13TGS[95!E^O!B*Y)FMQG7?G]OZLV!"==G.PMED>9#F1Z_';W=;.IM
MHTUURJD12N1B.XA'%XY"?NL'7AG#Y\T1156+,UZFGV,OKVT$->5\Y$7N>0'S
MC?.D.P; / ],2UXA(*@CD27KL&,?X49'5G'/D\W>=B&*0*U$H6Z:VF.$'[92
MS41>JRS%CA!=EZVHRU:\RAJ/$U.5K%9PB;?_]L.<9&YZURR>M/PMX?I'GIK>
MW2J-NJ7WS:YN]HXPEWH/6M1N<&HV^OL@H'V;!8LN[]@C.^L4Y9QRST45^T.R
M^Z++^1OOE':L]/D!]-HF\.5FJ6R$ @._A2##[O:G>M]\M@YX>^V MSIS\Z@#
MWCJ-YKXS-ZMS>8%BLEHO.=X,NY;>,@?ZH%\J</ZDA:YVHUNJHT"M$^Q3<*BS
MO9:8;K<HTST&MGKL.@$HK>V6WNN5TM-JG0!OGL9@^[3%6B<X-9V@W>KK[<*5
MV6J=H'(ZP6#;B+G#ZP2["<1<[\JHPS +ZB==](,4UD_J\+-7W)Q.HU6!P+/\
M\(TX*$,YL3S8XD\?H^#LT;+FG[[8P<CQ@LAGUY-S)<#GEH<.G7M!&)!?_C/&
M"]U8"XH.N@=\?7:\T1^__L__@0O\T_GMYYM/?Z< (N57;01(@3]NV>3/[RY]
M;X:'_JQIP/^''GTVS+.6\>[7@F!O$2.RV\B/T)L7</JVVO,?OVA(&,6B4U:&
MRQ2@0WSF 3\8+1Y ]1"CKCAEOC*H?Q_>W@Z_W=]I!0 N< B<_48NB2]M=\QP
M[#/^:'I%F0/\L(Y\]QYE]24=V;BF?59?UY[%V<48OGGDCZ9PW+6.WFPV>;P@
MA2V.O-G,<T4LVC/&*R9QE!B.-O>]$6-C>O8]O=S0OGG)V)E7>.@E ;$&2#(N
MONV@P!S1*0X8A7\(DAC)GI+VJ6ZF"2)$"^U(*S?4#J>:M1SD*S<,MM<>413M
M^VZCU:;0PN1Q D*^XL>-2QQ[PGC09W\@FYCQIFJ2-@7@FAT$$8\A/;^\1+"#
M"+^&O_$I;))&(.,?5V2'QIM(&S[ZC")6M0_?/!&&W/^91Z_B?6:Y"SFR%4\E
MYE"Q8[E:$C@,TQA(O1GR#Y,Q.57T3:/W2Y#&X@=\2OYL-G^!B0@H<3G&OQB_
M2"@!DK_'.)#8EJE+EL Z^S<V;@&(WP.#-YM)&#1M [QGSV9L;/.8874,/)<=
MOA2"H]QR&MKW.7S&T%^'4>"O>'%BNP#/S'9@(SR7:0$+<2J@(-M=O4<(JP^D
M;,]# B8UV)P+%[P%GM@?!<8EDLB;@?<!5%'Z;#L.1B5G<1**</&$5#LOVO#E
M360_YC8-X&I_M=P(8WE!?H=3:W8:VA 6LG$" BQ%58*$HSF%7HOS* ?(62T&
M;C_: 78J'!/6@^CA7VQ$N+, ,G9&W!:%M+-HGD>(' ;'"@)[8N,@ =(@]L.#
M3W:HS1@#9F/!= @#"'IC6S1>! [N:[\-AS>$9_&2'&E$TF4#-D^S1B.0PRP7
MJ)M8#[ZBIU""(,#IU$#R&D4BE'VIA:/*0W!"V,S01MID%HJU,=T1:GSX,F !
M7$53A@PT'SQ)(')< L06D?EP'I%'T%8@60+_<!]9(*DRX<,^P#VW,5P_"/UH
MA/T6=3S2S!I-01EW:.7!%/"H808%WX0E[FLE/2T)C%5]+=^#BFAT=-/LY. G
M12)X;0!2)R#S>L]!'06^DRCP[<)#^R7"0V_S.Y&6%/4/&239V3*$L7 @S<NC
M,P_<P+D A!?Y?67WX3-Y%3?2T;7@WDG-0;4%,##U18EF>-7;PE[)1NJ5#ANX
M6.ZT?+0;TV\U2E5,WO7QVMY<F6]?E-9':<P41LL;RP\7]_!H@#V<07!*C)RU
M:?*0ILGVT9@F;R^^#N\OOF@WP]O[?VCWM\-O=\/S^ZOK;[6Q<C_*P+4+[\U#
M;N0RFSS5:5D;I#0Y4H!(D85#'$1.2!7.$D-0Q@*#(\$@\9.QL4"UQ7 5]-H?
M34&@]BWM=S;&4Z7]#9X#O@'+^OKU7/N@#!L_JPZC2[,&W#\CM*;-^(K6&!,^
M>Y9/>=%?;!]N' \M9%\LD.FTOWBC*2$65,_?+==Z1.B1N;G,;VC?2<\.IZB7
M)N:/!"INW,"'R/;U9/DV"Q?<ZI=@#6UXXR<[\/R%%C#_R1[!GE+>./X,NJX[
MLN>@Y2]0OT4Y$W=,OLE0R>1/XI0A>[1'XF688FK/ XX/!T9U WS,F\\]/XQ0
M14><XB /$?R"*KD<@HGD<Q**!.)6[B'98AAHTF.TMRR34)R2SZTR]-3O%B!)
M/M%K:#?K;(TK9];3QBG+)MME0D$C*YBF<N:Y%<%-FQJM&4@M(1E5#6Y_(ML(
M;)'+Z/+BA)G=9G5J65\!QA76#-@TW*@G&/X9B0O@^ATH1M"3L"[!A@2T(J4L
M0LKXG[*&I2B?GM9$NJYZB+(FY>Q1%&\.$2KU10(I:]_+.RRP&VWM@J]2=5=J
M-PX>E/C@3>P)/#%G_H@X0J?YT\^:"$3PN'TRG*(*_:'ULP;@HN';=0%A?F#Y
M"]4T.1;V8$*RI EU&43#^"4W)(Z3PYY"4V;VP/ZA?>CFS"U>)A VSLW/27H>
M,N](DN F?3?/A-]K "9C*W+:8(X5'$ ,X0>'=C*O7(0L 0&C94I6F*9)M#/>
MZ(&*SRB0?\_(OC2Q_8 ;W_X= =OCJ.75#%Q95R,?+]\\;2/<6&M#KE2S)B'S
MDTFUS(2"F\;E-);W%P:#+Q<<_Y,(.:;8<COA."E'5N*$+R&W9D7>.V WX\AA
MUY,+RT=C8'##?.FPMT=#=_S%=B(8_![ECU<2?U^E& VW7Q*ID+0=H#V:NR#D
M <)MCT)+^BT>$"-$;&..$XT)G"GNE')E-?9B/3T]Z^@ZC615&80#5&_HOD[U
MAG\0:5TLN^/+J42O$#1X)/OV2E4W=A"R^":JDY3(!JMN &S1Q7Y>NE1<%FIP
M:ZN72D8N_E1-2V+=160O%N>,Z:UGPKVZ95BUH+"2ARQV@ZV=_R6NP%A0.$2
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M7,W'*S[+RV3D_%EN?&_._'!QXUAN"+(SRLMS5."^L9>K6^V6V>TH.%TWR;8
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M"(;U>2Q.<0\ZB?'@1G#'X:#I=V)!ICBLC\"4QB[Z*XSQ4V8],*B$5^6,T*S
M;@@$?'6"'A%WYO+#?D=:E< $Z1?(1V>&GG-"8Y0P:AU*#76%:",0WO3:BNIU
M0A_D,)D.G,'H+5O$VCL:.O$%5]0?4Y@0IY4/!-(.NR/3-T$2Q8#7B-0<& ?O
M38YW/I2\+<\N<O35,DZ!T]\[\#_@+!G\(XL7NXI$Y<&4@%N=)P=I#;H<8T;-
M,70F,0_S!R&)TN#IIV6F+F823/OGX\MPJIT)7M&$$Q(Y3F_/C'Z;L\N\F,;O
M\C>VV>VV36O40[*0MSG<I9+<GI@3@GB,S^;)?[!"8E!LOP4$+<=5QTU-7V&
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MC BG,?U'X^W78.%.C($U?/>K<:DG),%^G4NRH^OTY(-^E>05^Y1AZQH]@BC
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M29R)(4Y[*F6";[G2*Q,%1&PMRIMJ2E-)>+A:V=R69_?"(3NA]:-'44A;(<,
M0300\,X,O&D*1Q)!DD427"'>).$V#9DU(@OH&[R*/9D^,$/A7IAOE<V:O$9+
M.\'$T=8FR>CXG%VMT?./Q?LY**^C(/PS%>__DT[3^1)I$8A[59WM0/;M6,A_
MW_!T^(7\JRZVRA7/DXS2:_S7BMBINL-UZ>E89W8'M+2V:F7:$N*]L5T%RR^"
MPFH>,E7#?^7\F[0\4(+"2]0ZU-LB[+;NX=M>S^P/;-/JC':"^@H@O#ON^3/O
M><<VN[9E]BU[__9\]]=@,R5W_\@KHE+]S-Z+&75T.P%BMQ5;&QUR&^KL]<W1
M:&0.NMN6=CZ$.KG[@_6V:0T \[VZ?8D:J'^[AP6UOZP5>$^6S"][?;QW<&'M
M^))JMT8-5LK>@1QRW,!U&]C?MM7/#H6*AHMN5_)1O[RW&JW,TF66:]IJ+((8
MG4<8]< -Y]*^';&);,ZM23,EC8!30S(/UR;3?M8F7F#+5G/E[?L$R;)E7^2@
M<^<PKWXC$Q/0-B^'VTEDPM&6O:5(M>>V[*/]^J#LLD?[=34\';[]>MGJ6%U;
M%][;3>T=F]N4-GYSRY:HICWLF+WV+IJB[M^;V^'* EP-=X2KEU)WZ_5[RP2T
MO@@_/:C68R.S-^J8HU%=@MF+J^<0$3XPA]VN.>IOVYQI?^ZPH[%R&X9MF<,!
M]E_=]@ >L5Z+ZUF=CMG=^A VT"&M6)<O#T)- VC71+_F@V5!#4]CYZ_#P ^P
M;('65N>51L_>L$DV;\#(+IX@'.\'K#DJVBU4W5$)3.)+ERKU_FJ<</ 5I*(S
MR /#P/B;M*XQ >KN+\BE4<@OL>67F&OSA,;%[E*6C7&7N%1;@<"9!%.J[8<!
MOFHM&C7?HAV1\OG.Z$E1FN+MZ>W9.Z/?[IM&P5ZIJBZ6_5[]3A;-LT O2F^<
M <S!G(5Z"B="E<VV.<.)LO4S*!39@1,VY>9-N29<!A4I#K75T "]0DC3>47.
M221R4M#$BB'!"[@,W E981U?MN;@Y8K]1%32RB>JJ&P4HS@39= R;A=L0MCT
M,"^<5^IX-"*!;%%T*N(X$_#S*H:4K,F3AGBY+EES5>3>Y-)^L+PZ-Z^"OH(5
MS/GV\>YP5$Y:)0W-78_!;OA,R[P(18[*'?(X^77+^$;U[5=6_$O!6/!$9%Y5
M6=:;SB2NT/[*!10EYPS-(N@H1]O%?:3\0RV['S-&" PQILAC5+GB8HB3&.[U
M.T91[U2P@&?IB*8FCU3LYQZKO.H))Z-W+0FR:=R+\K"BNX HQ2.HA8.0R82A
MS5(+&/,X^)40N6GM>*QC+N')5%@ORAQ0^41:YT^>52^JGFO4 ""*$I-I!QMT
M<,0>YPNJC"_%R&/*&9;ADKD"LCZXJ3=IX-4N*4^MJ!AD%,GT,%DABB?V+\)@
MS,LX4;5PO1ZQ*+9&I4.-W&K2FF6A..)ZJ0=<$69#T>82""K32Y56PM*/411,
M7$I^4ET22HX/0(KE'V&_815$>J"X/?SD?96^%F;.Z6>;\\ZB\ZTE[<[EA12R
M. Q4?[<YD$DPS7:24 DI.@6DA7Q2UH!%E:@V!,!#0!!,F8(@@C/(I&WQKEZ.
MB5\0E/3'<YB3V,5L-*H]A#F8LB'#U)4E#64>'M8)HQI"\O831Q([1B$34]TA
M"M+'):N$.X.*\.4K[V%!;NXRQ'0ZO;J'WA(&H;EWM#X4:NTR^T>>G$3Q=MB8
MGG%V<?'5.,7,;WGN>(^I7/9DAD&J OR\J/CRY@B>&&;03E"LR(4JNC-P67Z@
M3GV&U\J$GF*"DPG:XD+*K?6G/LA*8!,(E*@3V5L$"&9)E19"P7U_8YDC>V!V
MQ":]Z9H@NIGVP#:UKHTH^VAGT%VN_*5O](*SZBB]WM/-&^+F"3H5G5[X@)PD
M>=98'& O1^'5CU.R<=*\6I6(74!LU%W:O</;2KPI2397JKAC]ZBP<!Z!JQ+*
M/) DU+C&\ICP8&;,= ,(B*5!?VH*UJ\BNOZYS$$M1D#.YF*(UKHJYA7,(]XQ
MB'- )>.E$K*45;C(G;X_PQ+8*=^,)L$BK<LD97HD090;Q$<. ]XNO!T,#I'M
MV 5\4RA'F;+8Z4.JHXI*C-?FYN6NY6PDG'$]@3=*-=->!Z;0 SW/&<M&")G.
M@KPRN-ZP0#5W_I9%%2\%[\:9@C*2ID7]IDBM"RXH?IYI28$G3Q/0_=R-5+=!
MK<L657+'TEM<]!,%,*E3EJB-E1'34OE 0,4+?HD&6Z0!Y<5;<3%CA8&EV7GI
M=U7;-"=JTHRD&.JXXWNDT*(UKRK;.$U$,778Q<T>Y6*1J(=O%+-%]*OQUGTG
MJ_4_2700K;R-WHFF5PKY[^'I_..:\,#W0A,@5,E8/B*]#N^GZ"#1("U'@?K>
MA.%C#^]D8?V2AU1#K6+915?DTNF1*-_"T.E]GZ&SM[@1L&H-@5@!(*+B&T[)
M5-GBCE1V0)Q0I4(AND\0W:)^C-9E+M(KE&45&0T*8D=XV&1WMYQF06\KY0N[
M8Z4$JFP/9/%8ZD\*[TKE3/4WDML-.FN<]KK2"CD'4J9,?\S65Z/ROBFA<IN#
M1JR&(E0E_!.S%=7JEL%4QUL,2F5],JWZ,BW>\"@J3K>"0DVM9P.+%*^FT3,<
M10.&UHK]6_U)MK<U@N[K3,Q)^5BJ>^H2:P%5(]"8)^_)E@=B3[2NU<5TN$S"
M)<^YHCJWH.RCV,JEN64]GJ*?$))42BQ%J2@RG6V+JXF*8@N+>_B6](.,>,L.
MP<H622ST67.Y->(DV^.9YO9RY+.N?W!:UHH&TTO6CYD 0HPOK6Z\"B0\P(EI
MZ4)88I.2U:@F>H''+2RJHAAVLL3>3,+Z!C")3BREIJ%_)U/1\L3E>!YC@6U1
MRDWTZ> ]%^. %YD3T&IU*TH!7KMG0@W6D.V6*=1+G0#&>L-,6C^**1D1/GX,
M.(L"1=R;G9  +YO,I2,1$&/=)" %!(;M5+-ZK-T&OBYJI$J3;FIH+1)0\K7,
M5$5]\; :C^#(K;#X2&A"C&5C%=CX/M(+=. V+K>(I+H>HH*4*%DG2J!3?3?2
MO'AP=0Y"W=!-O)H7J=9*%V5FBU(,I=T8ZZR(@*BZ*A5;G5U:?@VJP%]NS9G=
M3 '3[3,FU9#"I3RQ.-UTJO#U$  93PFU:5F^[!+3>Y97<?V9+XPB=Q=*5Y](
M0]H#+]X>X.C2-R[8.$RP@ORZFGW*SRSJW]'?O%J8K97QX^B5-?J&7?N=J=7+
M0UO,G!M*BDONV6M+[DFE5+T!MRR5;F:,Q&_)8O46%JD:X11WO"'-#D1WKCYS
MR8+^3OM6S[DS!QB_XH,M='A&(&'B(1=*/9UX@N';+97V-\6UKKBTJ5<OY7*M
MJ NMTD"8WL9=*]?LA&ZDBK0Z L+Q4XH N!V  ESO*44%;YMK!$([SY3UX[8Q
MKOTS:M6H"DG3V&F'1"/QL8&&8FEJ<5P+%\@6U=PFSL)%6QS'IK3E91FR<&YE
MN*RI;RO7I:37;1R@K/>TX)G%8ILJ#4IE[0B&S,#8*J7Y H4E+N'A,A"*/)TR
MGPB)8.)>1U$#5!W5+$YSB\IALITEI,]9><X%A1,,<D6"[%(II,@P7]A703^\
M=%&'CN;'T<\PE67\1^(]"4^O8C @BN$NIBR&AP59H+2B=YR0*<4B8:WEBQ=R
M-T"&?1?(K.IA^T#IP$C1!O2!*BPPH998FNQN1;V+.&_@M[XR :3NC!-!'6E!
MV*(MR: B#2X@>6$9&^EY$22L(@_XF18[(KTV.FKEIB%I2C$V[063Z\*NEGWI
M W=R0#1/)R(?EWA..KG(A%$(/#E4^4E4/!0[&9Z0\*_C!MFL:-RC"K %2WO"
M!2D7>VK'PA8_I5^ P,8)"*Z^Z%@D\*"L$D6X2*VR.JUG=7UN(4:#?X:[I"[)
MPG4+5]T_')\N1\N4AW?$_8094R.YN@0WEK>*ZAM(11$*O BM[LF;;LO&T =/
M^1\='HMX$@<G220+Z*N!I)&HP'_0LD[@?_WL:'Z0VR A67,21_IA<!.X.>,(
M)@YBR\I8-G'(>$S4O:(:T3AI"^YL%=*,V)ZI&JL7^PZ-LH*R/[-DID2?+W#6
M5I0TYMPS+6M\%&NY6/N/Q&?Y&T<$R&DW\?"D/2@I07VRNO"TN51X>LU&&46;
ME!>"=;BREZBZ(-L#9#Z.C(Q3MEH%&K<J4]! 46%I(U-4FJ2""8H0U$\W$!<,
MMSM*8Q?=3'ZZ/,TSI( RN:5;$X5SX6IZ^>!UQ:]E+7K!9_P*SQ8Z6U*<.-SZ
M-692]E:Q"52!^80X_W(#$X0YEK%FRC&6=_M@E7UN.Q(V?:2SM-XT6:55==<I
MPS8W(@A-"[!*GPA1/R((\4) 5P5*.>(.]*>RV9UJ_87EI>&^Y7<$WAY\I;FV
MD3K\:4)Z:ELVSFFM)YIIHP3S7(3,8G\-?D6%:[QE\,H1UBII6P<-2WN,-SO@
M.B(,F9HZ>)!-)I[$D?U['3Y $(I;E/<BH(:8].L\B3&<D^0%E3LOYO_.GH26
MQ[LN*Q3C-5M.<JT\(S$B'O4IKTV-^K*.X+6G4E7CU98U$0K6DL=%4Z^2B),5
M=5R8<[&>>E4_^OJ5.WXB$J5>BZ4'*LMRJ!HXD$98N+Y,<SJ*QB)3\_+8$0<1
M*58*7=Z3%.B-M]8[J6VD!G,Z3"&NZJW]3I*;;#6!3:<"_]^)/U%%ZHGW1 RD
M(,70=/<4>O2DXYWZ<SMAS#<ZM9U-9*,DY%.9<($L4DJBB;D!0O8 )QXA30RZ
MUKA>:=2#$TJ54=@(;=2,)*<9>3GMZ4(PK0 .82KA&DJZ72\!&NNEO[+8X>)N
ME<5*S5$$Y&*)"MX A)]J 0A'<:\H:6M5VO EYQ)?4'*CUI]E(J(X(\.,>%BV
M#\K<V<:6)&?$)Y77ZA*/KO =RT[9]#A! J\0]?,!,!,BNZ<ROZS(7HKPY>VE
M51&AL[)AAK4SSFR<E*?J_;TUD2YC6YIDD+,4813J:2)ED5#"S"N7K ,H?.&%
MV1L-\-I115XK.)@:N1[&SYW0>U*,5)]2,5>*@'K*@4 .TP4&3<0QXWVLN+M;
M:.RN<J_!\!D4BMZ"DA1C;+E]5QP%F>):NI>5-TTP=E?V<R3&'Z0!(Y7-AB5L
MOA86E[,N<ZF-=7,59:[CE+F_GI-$?SL',>V#I*JJJ8P@7K/_^6O)*,N3G /%
M U'>_2T,'N-[O>7F)I,5CE8PZ8^ORA1WS;W3&\^X--120\-DC+(V6JH_!LDX
M/AT'2?RW * \P[BDT'^F=-%:%:B:K2L5!XL*%5PZW<6/]T;UVE=5+\*B[&7E
MQK-;N331ZIG,SPSII\O_^^WRX^77/XT*$%?(FMZQ3+(FG?3Y<W5KI?9HHK]R
M!A(H6 94*%"!:&RE<C "--<S.F8BU&A*^1HFAM+AA4-^&KQ%[R+3D"TG52B.
MBMV9):29FYD 'LS7$1$KH"E.DPFV$(;GI@0D>>IB\F5-0.>C-!W2X^4'"BIR
MYA@C'6.K[SNL5@KJ(>]2+.^ZY0GA>H3+DOJOD\ 1A'>.[_Z7AQP1-#K>[ATM
MJBO$0H%D41-(BUR>O"KB,D4L8V'90),ZGSM^D9T>7WACV9;9&;1-N]O^J=6C
MJU1W[4@9+LXKORA&D9T U5^- ++Q\"2%_M/Y#B+N];T3SIT)2WC"UUG0,HU/
M,<A<NOA-CV8REK6.9;UWQVT1V](NVQ=NH!(M57UN8WD,4;KUI5"OG,!:1RM^
M+C-EQ?5MD?.2'>-*O'_<IK4\7YF(T&>'[C?I : /: ,'+8*)3NUONI8YZ [-
M;G^()M[E=*<XN..QV<H+\,8>2+\DCI L0 E,$\[3* X>ZT8:(ITP;O\77=EQ
MF%8Z3A@\.5[\9+P5 1$1X.@O*BLG-\6[U(J5\0H'CV2UQJCA11)BNV/E);WT
ML;=KZF&3Z4"Y3$AY?>2=NX/4%8M 83P@/#!A;!JE)OE">C4%/J)DACR?(XA'
M*6(<(IES59 .#P_BP39Z)T_<&71'QWK,IIQVYGI*"22\G?SSISX*M_>DU.K4
M@;9TGR=X<-R'CAME]D2+6A ;D,V2P(H!N2 TXG(4=H0"T,DDB6D/A<-$;_ Z
M!=&(S$<@7Z&:S.4M%13"$R53"2>-#"^(?/"9D+'X"K2,^^4EY+N6HCC&N8*<
M*D9#;UHE [B",P;PYT2)9S<?3KKMMF6\C>09Z;[+@H1H@1^_DW^ 4:X,,7,T
MYH0RC)9[W80C@S0JW(DI&\=:"68SO>#E]3Z!E]'E!3J>)P9P?"YZ8NBVH/AP
M>H)&_Z=4V"3_ ,#$'Z5YE!N"@Q\!_Z.X/ Z9\!-)T$28708\43*"DDYAKW@A
M9AZ25!9H11<:]N4EUP1.(3::X,:@L]SP9(8ACQ]V'/9=F=\6B,<K=)ZDB[5E
M7&:>Y+02Z02"N$(N' ;)W;WRR\CV\.G6T1IDRF'IWE&D80&RZ0AEUYE]DIN?
MD$3I  0/0'_*(<NCLS$9/W0GL0KH*EI^Z@QK&:?2PUI$'+HA4\PN(Q)UA)$.
M V<$.ZS?DPN9F ??FY^:N=+I"9)PPDQI?23EY\%Q/1$HI4*:_">I/:9>0.)A
M(H1U ?<CZJ;H#$X6 >::A-]9K+EL39Z&0J&Z4:8&CW!*J0R3\K/!B5<R/%TO
ME)IDR[@0U(&G$#UA6&Z=K\@3CG]DNUB !P,%/(]X#(+ W<P3U /%]:*#T3(^
M8:4ZD1J1>OCYZ=.+T&@O%>O8<<!O$=!Z)\B\QC1P: "5PB:@(SW"AN$B['D-
M-A:>XV-87^X:*.[,7-GH)\V%<&U<_WH&HN9Y*FF>^M,;<9#9%'_[[,3($IYJ
M&2W_)8#ZUV<'9+-D_IE$U5]^N^Y\_I^_;C!MWL"9?19>S@V7 ?,TNIIA+0T!
M&G=Z_.LL"!>HAC)^>9VA>UN "0*#RU_]=OOQ%]C."<B77H3&RM^L]G TLE*L
MKX-D!Y!3Z;#QTR<&6EMX-3LC^"N WFO#?_4A5]OU=^9-+WTD,W?JXNDH %7N
M/WD!PJ=__>W#2I &;9M@*ITCC[[K$&\0( LX&#' C/ 2C_@6L5GB?7)GK"J)
M*CJ@IL_AWX$ 'N%2AD%O@UF,?Z94^V>*M@H0[![H*Q2'V442^M317A^3 YT>
M0& <F0-XP$O)\9+>=DOY0GV[KV974JF[97?SI2.XPB>2$K9X4R?NRR\7P"PT
MWUC9;)EC]E&(<U^='Z>4+_,[]R(&_BG&RJ/8!PP1*V-B;'-M.--WET%MJ7-8
M"X@\5C_)*.R+(/PFJX#!2-<!=UA%9R*/I9S/Y3G&C\C]U7>]__T%'6&_&']M
M<LIE'%6:DO!R"7>V&^(FGH$T?\<*"6>@;<B&ZZL^V>K=KS29HD^>3G9!8J%@
M(B*@-OJ8L)6\GQ_LT^0._OCZ&'P%-3^"*^N6*N\QYM/0RK!3Z>:R1_9PE)ZF
MBE#N;G$R>4];'G"=+Z[/-EJ@98UL*W,[;[A"O$-K'*T,$':[W[,T$'"LJN.7
M4%MF_"&(3MW.5N/7E2M63?4Y\-G39U)D4*N(3E$&#-'Z\SM%(F^(Q;[=Z;1'
MPUXZ^9J)&H"K"O:[[5%GU+,WA^M4:VMUJ^P$YZ*Q%G*@L[2EUM4L7^>:9V#7
M9Y'T<K1T7XVL3J?;[Z>K:02\EURSDG-$JY@EME&""<L>#GLZL1\^)I2B \KJ
M%>\)4A4;@V&W.SI<NE@C9Y90@#4<#+JC@R6!50:$FH?!MH>= SX,*_2D30[#
MJ <\?^=T(2/MX-4Q6KC@U3.]^-976=F83:V218].K)%8-/QMM^6B_\'\T/7K
M2%)VSLI1![@=+&R0[B8LK--6='TC(F] :OR86CK/>?F!9UHG:7O7LNGF9UD)
M7(J7.]\K:]AMMU/[3SDDVP%<RENVW8/:\*^U5OPM#*)5)L#5X Q&_5ZW6\$H
M0M,T!I3")ZDJZ$?3,S2KX'%DV2\!=U4+U.J#.!RTN\,7 WZ]^7(EYCO]GFT_
M'_ ] KZ= K]P6?@9J^_[E<#-:G7/3=_(4.,PH?2,2_]:>+0JJ?=#:]!Y1LBK
M*(2=SL :Z$:59P*J&<KM=JQ^9_!BP&_',T96=]!]QF.7O_@V9=1VV^YUK>>G
MXXU.X%JS:AKF^Y%A$+-+@A+\[3$R=OM3D'?#6$0>EP*_Z77=Z7>&^O%K"I[G
M7&<5/M/O]WO#SN[62;+7:<B<JQD_E;<+9U+H' %A? @"JS UX-_;&ZNC_\R6
M_3X=>]#I"*EP";+Z</=1T!8R;%_H$5(K9(N80,H:HF_='PC[*6;S5P?;:G>M
M[D[!7@=!MST<-@? "FVZOOU^^4WXZ0D073Q$]J4O[/$Z9%@K>9E9%5-0NVTW
M2$'[@XFOV"NB'B[Z]J#7;Q07MJ:5VR?VL)'SK-R1B#)0(EVN>'\$1E=H'6CL
M5..UC+L+FYIRV2(HEB'%"))(AI!<);&LT%%@H1(<OR'^LS8Z91ULA5BG*"(?
M"$SH\!LZ9+/7= ^4ZD$.L?F)MH&FF2M)'4KLRO,G<\(J,O0@C_.]7AI_Z+[B
MXD;MX0X75\'3GJ7NX6#4[]2%!CBH/ #%4F8S,DR1LS!'&1HDSPJENC8P0OC4
M]UWJ51<^55A#9]_6<!%@V<QZB[!K+(+*7; HKL?\=D ]HX'NYL^!M0'4*Z27
M!J$&H*W*4%<,S_B*_=IXX8MG#9BQVKU>OU,_8":%]SD6W' 03:_=Z6\20U.^
MZ#.>G;-UM%!=.V=GH!F4*P%1'W))X)>BS>&E7^A&:6A!=993#MFJ55YI395V
ML2.]XB5HTU:$;GTTXBZ!%+-7A/5+X$^:!'>=3>Y:I&HBX\<TM@AV7O:)W5:0
M[UH]N]_+V"X+Y]H&IKIB87=D]>W1;F'JGUCM5,^$O],=^Q0XM1RVG>YPT&OO
M%ES82GU;+4W9K ON\^RXI>_X5N!N2 P?V3B^5$5&><*,.Y'5;W=,$2/+TCRW
M*T'9&NY&26.D,\O=PMTHC0Q[@T;@_HK%7[<GCM^N1Y_+X,$I-@.BYD[_=FVU
M=P!%S7W;$@HI]MPX,;O%RFW3DE0/98FK<7)79'ZT6VW;+CT+JZ!J=CVU3O2:
M]73V8#VU3OKJ]73:I6>^SGJN0[9PW*E0:84DB!I7-2FO6NB]90T[N2B-=;,N
M":/!?.Y2"1#,"SVCN@AWS)^XK$YLU#I9L^8L&^;34-CF)14W_9A@F1'.I"G"
M_HH2AYNP+F80OG;*7<&HN>FQR $-6\58L4^@GZK2"]= M)>^4(PJ7<VCT3ZM
MY$;TA)%!O)MI9"5@\8#CQHFC)(ZY$GUK("V7W_R#>=X__>#1OP4--P"L7/+J
MYE7+7WX)] J<):,M3_M[X '3=,*G"]?#XB*;39<;97D:P51O&/4[]._P(DBJ
MS_8GB_3IBD=;GO6:ZH5=>(%3<F^T^UF7?X%Y>V#9_5&WT]?GU\9=OI%Y"#.Z
M3;@1O/ETTEIS5 JTZXU&??W^+AE_Q=$K="#7-8" E-=K%S/;)=?PNKFWR#0E
M+SI/.T-M-DU#V++21#[175::6#_54@9>P1L-$EC5X;?.X VBB#+Z9D'(NS=L
M&*G6Z_=*+>OY.1J!1LK,GYTH<B;W2<3B2@Z CF6UGP7.2NFN=J_;>TYH-L3:
M8&CU[)IP%M<)*'\O#41![WWM""5,8I$B&$:[C,HJ%52%H(SG5QB(E"Q0&#X%
M6(]GTU2-;B>+\DT!R"]DN51#?N2S>RRK=>EOFH];I'T,AQW=XUL7B%TLHJX*
M975[0]B307.K.)<=$R[]23!G\!+JZ&>JI.!5VA>H]B:L-A=H=%4=B)V#KT(Y
MG!]G"1H _A&,H]-)?#4K<GG7LY ,]V#)&Y=>:6K')'D*?IGA$S",,,!\$/W)
MGF73BF\;.&C+G*\2U%OP[8U9=<^V1Y8]V(A7-PQO%49FV_:@T^];NX$7Z4#6
M2VL MS96<5B%VN+Y&@2S$DH'HXZ](S#E=](\JG6]A%,@R#XBVP9UM=0?. NB
MC;-/K('=M?6\Q5T ]U((J);^-K1&_='>(0"3DL,'AC;IT\DD3 !>^I=-99VK
M>MIHUD:)P<RUEEP)G.=<9K64HW9W)<?>U3J7#:)UCB2Z_PMNQNSHF\-020P>
M]MLK#T4U&+;+8P?Y8-COK^)-A>F%U:&HQ!_@UK>&V2"!C:!8UB-VB)CER1J"
MKR&4;0#?%[8+Z^ZZX3<TOA5+[S<,9L#:Z'SIL2;K)G$0/F4>;E@;['37:Q>U
MX'NV)<,R;6W)MKV),J+LP[F [GKZ9><@4;C"IE8+A3+G/5S<._[',+G32P[_
M*PKC7&G6BDCM'9&Z&JD9CT9%I.J1/ >-U,H+MO: OV6L%NJY32K"KK83]?3*
M=ML MNM%;F,,Z^FE,9Y[D1=!R-P[/_/$1Q=;!#&J[=3HCIY@K%J[YHE=!^%S
MK7KC+>:KKGEH=[%J9;5I_)Q:O5&]Y:6@-+^0;<YB)B=N]PN1'I5SW\'&!+N0
MB('Z[*Y5<U7%<.UVA=6WK0FEA/3ZTREVD"FMI;>53ZI?\\#G =K5HK8Y'9G<
MA^=:E*2@NHI\ P?'ZO5K\K4:P+X +K:YPCJC04TQ90-<:$%Y:=2D"'1,*V(4
MV2]&)^W.2;N_/K:RW\6RX+:5B0!<,=ER&+4?A\#+_G#C^S/2:5BH.C(T'YVW
MZ7358@#Z=J^MYZI6F*PI 'LG[:Y63573'"_<&>J-9Q<77T_1KW2:=D;+ZY*.
MAQ5^77_F.=CD%50;U"RK5E_)5,Q_WJ7W=#6ZQM+7N!=[+[FH3/K'ZUA4'^M@
M[&*G7I+\!KQVTFM;U&[(K_>":\J9V]).P4YQP97K>R=BL/(/9Z)]WE?LGE?]
MC+WP,E<95G<&LQ/=Y_K +?6)RWZA/<FCJ4$""K&,P$?&_[V4W77/?TQ( D+)
MB,M+C:3U#WKMKJWG33_O&O8/@W5#'T'J&'6'\.Q+HS 50&_OF>?)'J]5TUAF
ML""FB['Z*,MEA_+@K3PN35#JB37J@F"NF?MJ K&#-=2FE>Y@..B.!ENO@>*W
M/[D3],6IM-BO3'0HK;SGF5:ZJD'N(N9=>$MZ[_(.L!,@CFCA8+-;7!I]7F#G
M9?%9#/KH3N-[;-#;_LM[8QR$4Q:>3 +/<Q81^]60?_V2SH(3A/)M:L0,-\^)
MZ- ;!XOT440$/3[-3=;I+GZ\-T1G8'M=9V"U5GQ!;RM\$KG_9;RWL'IFC']T
M>0/9L4(2/JT^Q-,5$.X.J$^79^=?;L^-T[_=G)]_/O_RM0*,]&>8P?U?:7<S
M7VW3:WGO>SRK9L2,'-Q3V9-=G"T"1ATPXRUV&Y9MANWV>]ZTPU /J)^L]^^,
M1SC AGCBHQMAU^\0)OKTZ<R$"18A,/R8>4\GP&:GQD?F.5B[W< ^QW IP+\I
MW^'=C1&4MTN3ZU/"*J0AQ5"E10V[;1IXZ%O&=1)B\_-8MF_.@V_*;^ZP:1
MH?<*9]CF)L*A'X/0F\)9X]@1C=RI<3-U 1%MYN? MR8@, *]TC@"HU/C.@RF
MR01>>>M$\,X,LVRQUWP11(#%>W=R#S]3,:M(?\ASQZ$3JC;<B%ZCWVX3O@+J
M/(V S!,O=A<>;_P.$^%WV)4;#3\+!UN.&#/ LW\7M0PD".WM$!O 1T VB G
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M,?.QOJH[QUA--J?79)YLA. P8%93E=I!$'@LB@#52!D<7DX)#GR:)A-2F^-
MX)H7$UFQ[);.,"LSN7PJCV*G']UHX@51$CY7F^I:J2+-)H#$P6*5Q"XFZW07
M/]X;@IU42%)9Q>'6&L0E%[3:K1ROJW[%/S.HEU_.KCZ?&U]/___SVPHP5Q 4
M=LS&Q9>N/V4X]@E_-'<+92^?E[URO@1:)#@P#A%[R:\''H])P 1(Z>CX2A/,
M (A[8"UC8'Z*UYC(;'0NC4_ *PDQ.H<B/:G,((X/S$RR&[@9W&"JM68W%?.4
M5Q!"@:,1N,36C%D"(SPL%Q$PG#NX4:*8;L_EM.*H]7*BR-KTMIV#<%K0@("0
MC5D1IKI(T@V<JL#<->4BJ?ZWLX -^N'.@5:\)^/-T#9[W9[9;K=ICC>]OMGK
M]/&SB?;;!9>X\<:#=Q_OW<E]ANRRPS^ZL-]P;;FAL 2'3PB(,P\2O'/'#-#@
MXS?PH]VV1W"IKEVLH2_T,]"',[E/@$A@/%@NI_UZ2QX,3:MG:TONF);57EYR
MR[CT>5JE&P*M@O@4P@V, RX!1V XTV"!<M[I[3=J@'W2'ID"92&;!R@*</GC
M/PD@B,0%NNHGP9T/_)7++<N' >4A]@,DBBB;<DHB&4&+($78DY[ X$7Q0,2:
M\Y+O/JSY\9YX %#;?]D4L!X943*Y-W4![(DYH<%\/+A++?/,TLS4NQ Q7@ U
MQPA*O$&(8 8^WN>%S(#!CB(/\A+.-0*?G<1P@/ [Y570ENK RTH64[2/<W$.
MF#D%7.@"(!F1PAO+['9H[[G\3'M&K'6F[QO(CU/##T"T=1Y0N$09S\'9_5),
MC$$NQM5$]XS%1$B)QRON"UA 9#;%F8G@$&$I?4-R;2(&W$4L:PCB-"PITD8W
MD&3B)]C[B9-$;(F!K^"T\*&4R2(PWV)0G?_K2!PL<Q# V]S!J8%DQO_&+0"B
MA3\!;C]V"?%^@FJ+.P?UA6L&6DJR7(7=?L]#,G S@T<?%GCO+M2O%F>PZJI3
MK0HN,7$,]_F&/3 _P75/&;]\(IC1<^2]E[XJ=G89+%P'WQ<$ D<G7J4OOH"?
M,&1<P$Z8D:2XRFA?M =(+4^,U"44Y(F2HSB9/B$FI@QE=U0NW!FI#GC\1(Q*
MQ(DLF(A+&)4N3B=!XDWY DJICF?KTQR2, JWD"YK%<J699'9M3A>%!"OQ9O>
M"2?WZB1/80>\8,$95\E8A>US%$,O8,:V.;+[*2^V3'O8*6#%/[- <.SE<:P3
ML&J48S+] >[5,>-\W_#T^C+.C[T\]!F.O3SV#JG'7A['7AZ'M-0-8]9?Z#JH
MNJK7D.)T[.7Q8A1X[.5Q[.6Q-P6QC[T\CKT\]I0=-A/.?.SE<>SE<3#H/O;R
M.*P;X]C+X_5>',=>'L=>'J]J:XZ]/(Z]/+:P8+^69A''[=GK[2E@"L\<\KPO
M82SY@*FYXU)BB8H4)E VB!;&8"X,55Z*46X9IX4Q<6XD@S"G&#@U3E,Q" 0*
MEG1C? R#NN88^N6YWS%<*;YW?/J2,F,B#+2FO!P>FZW%2Q='WX@(69I0QF+>
MN@A2/I9TXO@X31HW1A-RH,H!@M]I@COFLU#4[Z4H&QX4KF*V0S9^DB 4@LMC
MO@AD<U5TH8HOET'?/):L$.DBF'-JP-QOK*[9&W9,NST0,;AF>PCW>;?#0X-Y
MS!A!P>-/LZ'(6GRA'B-:@'!SN5'*NB#I;&(5@L##^XP$EA%2*A2.OP@B5^1!
MK0QYHXUYI% ^AQ(8B8R7.[H44 )NMLL3EYQE0!4$9OX=OOV>]Z2';'YKW;8*
M@F6U?C3LAP.D)F(E89,(BTE\'X34#XC@D&D!&"W,DP1X@',1? ")\^"X'E+@
M3QW =VP8= P$?*&@J9<'ZACC>(QQW .@#C8L\1B^60U/KR]\\]@PZ-@PJ.C-
M8\.@?<+GL6&0C.(Z-@QJ&O+G6^&Q85 &&<>&0<>&07N_PF/#H&/#H&/#H+T@
MOF/#H.VS9/;A/!ZS:7Z2N_/8,$B/A3PV##HV#-K[%;[$M;+O.#DV##K(;7O]
MA_78,$B#_-@PZ-@PZ-@P:,_S"8X-@_9R5XX-@XX-@XX-@XZ-:?9N=X_[\N*,
M=+4-:/_TIL-U@?RDD!?0:</)6WN=MX"34.LE3(A!O\99$E/JR#^"<62<\FKL
M*O0R;=+THK#F\/:R4%WY:6J0;>O%]#UVYT:\DQ*!,PGF<RK5'ZHDID#VZBA$
M_=M<=75\"+Y7WUCOWQF/, #S'7(,NSX,Z#F//+U)/&UB;P9L/\6KRMP#LY=%
MZ@-*SHN,2*\^+0J6PTB3(,0*-"+'C*<A\1K^F%65-C,2^7"9Q[G!G1)8'&S$
M(Y"*W:'P!WBET_L+08$X,&: )O6+C1&B:5%W.3Z..E638EZ2BP'$+$K;*,%8
MG?9?J 3Y%/<(2SPY(;:CB(RWV& !-A]?E$E>T=P1.8ECS-%A6$?]7='<4WVQ
MA=7793[>U!#)8SQ]*NV'X<RPL\12WP6$>=CFJ,#)<ME\V,5FYOHN>B_TQ*N:
M8/#)5=8:PQ7ZQ1T!")(TTPNOY.B](@M15#\.F1/+C@;!;!;=8\*BPG7([@!(
M[(/%6XHP07OL273%6CAQZ"*8,#*6Q,<66TA9%-LL\N$RV6Q9O."H<@_5I/@=
M4'08>!YVY!)1$Y(JJ3<#4*$_=2AF6K1BT_HBR&+X1JX0/@$C*X4M-3BQWQON
M?,ZF+B5N23*),F3F Z=Q_0>@5-ZO S-=F4.;F'MCRA8AF_ ^AYGF8/RH )MZ
M;\R2D-"9TB31JV@BPB8))87I5?;>TY+FP11X%D".J98+S Q%JL3V';B9^&&.
MR86<3\CSH %(((CGT?6M,P/>]$3"(X@$,(^IJ],PN9.-!(@A]."( M7;/3JI
MHF4=CD(+AL>2$-O5G=*6+C<J(3@>&4 [9=14S8D"GX@#$$Q-!^2IY2ERJHR^
M8(B(IR )838WHF7K.:5,]KSSZ!!-5;LT2I>D)<HS@F/@R5E.N"S*"L:,V($Y
MM'KFL&/37B_A;)F!(B/'%$MB9K*;#,XK9^!DH>4>.]0;D+H B(SJN#A9]Z?.
MULSV^4,,W9Z?X>;-9ICO3("X480E F]//QB6-91=?@A_D6SJ@QFZ,B4#*4 T
M01(M=QQC#K29B#Y /'6=)W('0'PQD#IPDZ< _@E\T9Q'$BY>Z(KW3(D2BN6,
M6X+Y=#+!F7'2#PFP/_C+^!*T$'#CK29 B,4L"1!BK7@53Z<AM2'"]BJ+A0="
M@>"/*4_^V^GI-=)K!"=5I!)3/CV>19!XXA#EB&G HK2]#D] QP9'#N6[ OW/
M!4'*]&%,XX9[(<2^8YB!# A]^B\ ]59Q&2E$+1+1[>4=[QJDSO^4 ;OUN.@R
M7P :^,1.BAV=*^MIT5E& 4PBVS %FW12+C^G#$SN%JPFTOLKS0)DS;DN4L-,
M!\<J#1F76]I^9>'\(\SVD463T.7=C*IU;?S7!,@^F/_K@HU# .OIZV/P]3Y(
M(F!6I_[T"_#XF#&?)CF]"QF1ZF<BLN4WX:>G6_='\1#9E^"<7@/=NW!C\A]^
M^>TKB8AP50+SH0,Q)0E1,$(\V/(-S"I/@QT#WC8'L_.1)X>\'L)I<@<S&?Q.
M&!EZ:\P"9+T"C)+!MPBG6E=5B4QZ-H/.JTD<I)>HW6]51)CJT.Q@=V:JXGL=
MNA-VS<);[$:6P=EI=#5#KG32MD_LH03\%B027EW@.@'IJAPMEW!; 4?A?!GP
M@$5:46A@TTN2G8(P6H7'<S0(:)B\Q692*1Y_,1*0H@G.;[<?KPGZZ!=@&1,X
MQU[TO[]<?KGXY;=!J]W6^E*7K'H[[%CM$[M?N.C<.O<%Y!$>@D[[7^+=?]TF
MXXC])P'LGC\L[>)U,H9+XPJ3"X MYFB8"IT0[PYF_W#\Y>-#FPA[AN!%.3JI
MAHY^J[<).O#+#UBZY$R3FT_#$+4>!.'#4_K(->^[=XJ*&(="4O;T(@CIZR)>
MPG>^1[QD,RHH6_)HT,O00,.+>0ED88<^R7CI;[NMJ"BEF N\<(%<SJEWG@[-
MM><L'_P2_ 'R#@)]0+R8,^W< 4E?)3%VYT.QB*C[L_/#G2?S8KI+[[!!]@Z#
M\QOB(?.OI12;.[!EJ ;Q!2 !/3/%LWQ'G.LKGVEORW.]M"7IFI:VI=UJ#QK8
ME0I8>^D=ZIZTNW*'Z.].>Q<[=$1[9>'NV0Z&0_*>>SP;Y9N$&].F31KQ#:LF
MB!Q/3H6YKDC:C[1IKLE,(6/W/C(1PW=H]TK)56_37=_$95\5<WNQ5?O.Z4IV
MJ]/^27=KOUC>WN[.&3E4B3&><7<.!_6&QQBC!'Z1H#?A,HH2JE!9H-WFSD,M
M>I>[<CY?>,$38P0*7TU5+%J]7K<SZ(Q2--9>U7.@99_9A#7<3Q3N\=G= <HV
M/OU?$H3Y:L;G.Y7^ )CP;R'OA[UO9[;7'MAVUVJ \ZU9^Q[A>)\9P/!GV(\]
MYB8"_]T#V@#ZW^^, @"XL&'5%)P;9CJ_77?_; !_!>LJQ-EX_=CC_-CG/Q8N
MCZ3A([\TPJQV'F--K*HQ=%TX;H@=>=@IW)AS+N*>"[<F>D(*":Y(J:Z"B_Z?
M]N=.^V,#^%@+]OXA2#J= U^B*,J1T6>X4>;)7#MK5ONS/3SBJPQ?W,ZD\#7Z
M:?#UG SLISFT14@](J@B@OYP<%(AX%G=WK#=Z5C# :!GT,3]MQEF-I%-BF:Z
M<:/O%R"H7HI0[ANJT]+4O5C5;&];=@.R5]7U[2U"Z]ZC1_0VC=[,M5L9O9WA
MSX;>S2Z4R@CM=8X(77\!549GOPDGP5Z@\P]&#L?IZ0,+8;7RGOSH8F<LOR3L
MJTE&^^WVHX[B-B!X1[A=L]17@N82AOMSH%E.]GN 68H>:#(O(GX-^^TF;+?5
M5[C'2-V1"#;L]78E([Q&%&\BA@U'/R>*=RJ*#0>#73'>@T7JEN+8L-,[3(R*
M*!'R T67PEJ?NS[I1\QE4?!5Y I5DPOL)C39S5:RAXA<1::KSOP*%/=:_2:4
MK]>,XB,B&SKTV]+JJV('YS_@UL!\00D!91&"9AVZ?N1.=L$#<BI6K]MI-V(J
MJ+&B?<'B%M29PZ+='MFC?A.Q&%N@40E^+'QP)ZP8!)# ,=.-\:"%B(;5?S\+
MHOA+$/_)8*F3X,['!.Q5D4J;X<OJ==OM3/#*SH!_-BSQ?;H(0O$5/E?;[U3D
MD+/_['^V=#?P\R[A6:1S:7IY&5?4KM4=?75[@<[=FO*/Z&S0D/\2R*0R!9O/
M%H0S1@6%7N8T4UYVDTMX+K3L]E0>+%IJV1.KHV,WR-A!7@X/SRT2POI+NFF9
MTM2W '>CYN33)?!>9/W+=J22]0^&W>ZHWW]MZU^V392L?]0;=4:CW:2-[6;]
M6<7\;R'51JQK52S!AM4?6LT4[R@']H7PL=IR58(/NS,8'AH^4NZKYFF./@:=
M49/,L@#6%T+'1N31';6[C239/Q\Z-/:TY.OGAA6J3%3M3EUAC+1;O0:-/A6A
MWB-DU7+D=%J#)KQ@!XNL6IZ$;JO71'S&CI$5;6->+T?8MB[#8<NN$Q;0W"KV
M#($;^[$&K5IQ%:\6@3NIB+82[[42.O<8[TL.C&<[_.U6OXZPTNA"]@^-&[,
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M#G55_5@2QKO"EWH53NX9]K#\S*;NQ/%^AWG1*O_ITUEI"=U3?WKK_D"W*QR
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M6$.Y+HU@X1/,1]#!78+3J&$$,6K\Y+BL\1PQ9T/-2<GMK1UNB8L#CB_G#,N
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M"2?9\3ZY7A$_<NS(P@U#<7WJ20?_V6ICNEQ%L=C#V17BQ!7S:>)'H,L;Q +
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M1[7/[*^GY(Y)Z'NX"<!L0>-]ET-WU1NA([*E-(C?I;C'8>JR4'G).2[F*7;
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MNV><6MID0]GN)*$>3%(8G+\LF-.T6DE2O#MYSN 3##%WC^-GCP0,C#,X@X3
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ME[:BUDIH.WKIXJ9I >>06^F7':6YQ+%.1U$N;+6KX(?+%!*O2SC3 8B&%KJ
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MJDC3K^97:&G[%TEY.6!II:WV&AFZAM:1"KY=?4HY)0A\9VB3<HN>USF.W#!
M82>+5L=R-7*]:2S[7D\7_F[_0,%-LK5Q4)P$GI_AJ\CE.J#YG7H_/8#F+FY$
M<5_' &>;D#Y_ZCT0''KA%,>!FX2A<R7.[]2[>U]"XA(4&^JC'R,83"L?,D8P
MC!$,8P3#8",8+@-V<P4CQ)8ZWP;;#_@8F\\3^%+J+:!UX]O!M;T6^.3*K<S6
M>W4<F5:W**=1Y(&IMM.CK&HE6B]TP_UA[>1NL@)IC$VO:N%O=@ ']LP6"\0J
M,W 518,1YG74]Z Z@+F/VS,!PJ/72*^6ZCQUG'@=)UE-YU3,CA?!;Y2XK_%5
M#219,/-D![A%/CJC9LZ&<B,HLBC5W7@$Y;GHPN.LX@5,SB/8?>N%9$2/5QP/
M[&(\6'S*S71CW!#L(.2&"=%X8_N,WEOD(.^)5Z.'V\UXH,34JS;" 6OC^R-E
M(HBR , ;NJU(]F)URQIK#S4W5^!"JB%!ZRWP69P@K"(3NYUIMJC)CN>_&;5=
MS06K$0<0<(6*GKV71^)E+\L%Q#7/S%84)@<L$%R6]H"L+!>RG56N:.(,\C;$
M&A,2UT2L^RNAO'"T!,V%)"HLD?2OZO)(OYK?,A<CX'NCOQ=^[M_IUE#&N([J
M7C9#\I(&70TYU9I.A6J%ANM)Z\>UIERF1CK1Y.7>XSU+4J+_9K^PC!>>\$M-
M^KY/"9BU&*;.G*4BRR;BRK;8I/=H&+%P]\@#I:L[X/@AN@Q"JGO%41AU;8>B
M%3DLF.EJ*E,J<V8"]] 5\0W*F@?* $ZQU&%CI%)6A5^O)UUGF#QBNF5%#D&N
MQSS*+AS'D@3/@1UT9=\*WP,L33WH\%,<:'G'+L9ZV%RA*$)DMCA+B.&*G=-#
MERNIB=Q%Y(,.P/ZMJ*V'[%>$E\1^7+&(7'BKRVD^%"7/YZ*7$PLY9-*5MT@B
MJ$ 83W#S_K?)8@%C&<(-VD2K0L-(7:X*L>ZWWWFZ2O*FDPW#[5/^!X/M4P&V
M[.OYKU]K,,I^_/7K_&/_VT+QE,=U5(+'#WIWAWF]4!9A$Q6KCG[=B/.(I3H/
M1;4TX0DTOLS$4B835:JSIN#(!I!(@CF Q.*NT312F?6!>,^;UO5C3#<2?Z7;
MMV>;($K2'5Y$[*-@[RKH-_^D*12SP2N%F_(#H?))\:9VMJ"J 4UC0H45)\1L
MV>"B(NPW_SPH5.3X@5#YK+DD+RM<)392*LT&9H[4,FE:]%%RY=_7ZM77Q7R?
MKYM=FRRN*N%LQU[@RF8.=/,T/:9-/;PU=]1W)%WCK)[A3R63[2I=TZU7DZN<
M W+A+5<L!^1LL4CHX^IWF:[SB:;\R4[7 =Q&".")=^N,2WZ2TRQ ]0D^,OE-
M@L[S2=^^I)YA;2(&$%C-WJK"O;133*[1<\&8(CB@'YTLOYAO$C8;9F@F8QLA
M<>.B]94/<?$CMZI+.<>_TEJ32==*_+6%16JY-\YD.QPJHTVFCN#L]_:+N[./
M;S[R[[8H--%FXG#G/>81"YLBNJ/OCJU,ZX'1>>WKMGXR&,BQ;NM8MW6LVZIC
MM_]7NC]%)".'J^%J6LXGV@(!&[PZ6(('4/^]5[P5O\+/<N+>;SB?: O_:R=M
MB 50V!\4"[M:1B&@+(01\9P()246OME13+QH<X.(A^NRWY.CMT:#S"=?>@;I
ML!3%-MQ!^"E>FK[9Y >*F#5TAQQ&!.5%"C%QQZ&A),L1^&9IM17JJ(=M@[K6
M0\)+R 9HT6FNW%)\[?=KT," B7H.$#PYED ;3;T6^RORW<N W7CON9Y--AQ=
M56TZ)/'S>8#D;6C8X/<0+6+_REMPJE9)=!X2?DVY@A#5&X]Q'3.YS!;;JQNS
MF&7.&@AV&2!Z E[,//!@JP8,#_MU@$CLR#;3J7=#T*/MY5=!GL5TDYB\[]<X
M<-(_>"N?J.\  9-E"H+SLU8X9]$*D=,P1+R5KM!H@ #M40\A\<5,F^(:<5\I
MN-< L1*S VYW%7LB<@?8O?V2SAU6AC.-,_%]_,P*I@EK^34:8TAHM60.Q$ZO
MK^+*LQ\\WXLV4TR^4[()JZA+V;K!82+Y\$RDV&1'&!+&K5B#SY3U!D&Q"7JY
MIGJ:L,7D;&63)<\?5=]^@.CQ& &QTEW/.SD\$%</'B(>9=+A$RB]-F&^"4RN
MJ-\N !S[L+[# /'A<@*?81D$URT+/IXMOH<H>?=E0:MT&SQTM?R  )I:T/;D
MSEDA-_99;=[Z*O'5L[NL5.V6UU+EV_=-*]_2%AD!%EY8;'S+#MST0X&*Y,L=
M'>GO>=7<_RC(5J?\DFS*Q#Z=+;[:H>=0V9U[?ASM[DZ@]FH2-LX5XH<#A;BC
M@_V94)+(+Z/%RHFQ*#560HYIHKS!=.C(LWU_DQ#M/17.NRY>'#^FSV65I4LR
MSYO^CI+T"/?TB;ZO2Y1P&,[B*&1%A.@#N<+_>)CP"Y1;.3W6CG8K)]YBZU(5
MJFV'G ,K8R%%*;0*3!0@TVCU4E9=>8"J;\'>@EMC)RM[@L[\N>W$/I =J/1U
MGK6B^#GZ*V4KGP6UBKT;?.H]2!U7W^[[%?ZZJ1] D.O3Y4/U7=/7S33"_8D.
MG+@&3E&95&)Q3TWI2#V *#-M!I![WAWX)H>"FS=!>BP$WWB._)[<60M7B<G:
ME9KU71B^Z7N(^:2K7JG!0K/8^3%[Y%]/G19HK3;LO3I\2PESJ#?T-.G Q>%T
MS?:PG1EGZ?"Z*F%UO%-0)QN)%[AO1^&5Y[  D]/\%F^YRZX^51TFV3#6=AQE
MUULIVHV#5YC5[*AKVNIT)-1>!,XAV[2-O/3U<<"5YX/84F<)T[N$)OYF&&BN
M;QLK<]L\ET?C-I"%NBUIW)Q=R#:CGT+;X9LX^?+?=" ]VTL^./@PEDS=)VK"
MV.1=9(?SH-=TXK^A@'C!UI[@%Y:J:ZMKL]?RW<(2[)BYTEX&U)I$.RW/GL0D
MS%6 W$YFJT$)?DU+R0-(%GG3!-WT*#H9\4L!9K@3M O,3%9<BG$UV7=YBT)$
MR6&1-^?H"?DX"4;/<CU$MHI$9UUN.+D7;2]!5HH=0_UR7^.0[FK#\ RO'[P@
M8?>,*G?/3<+&<)!H_#2D?0)CVF0475>F26_C&S,#0:O8HMR&Z7SS?!1&.$!9
M#4_H%G2X@[D82-!MH!<R3] IYN;(>2(_5SV1^5!)]-MV,,/<D6!"DH1[4J:O
M$7%/\%4(LA%-HA&,<7'*XPE&(<E):QC.T*%<"-$6A%8W0^BU4X9?SG^\&<*0
MC>GPIY+)V^#CNAEBO!NQ6]UST"6)>GV2XR6)XR6)\HR;O&0?TR6)CQXBWVQG
M1?<M@FL1]UKJ<HJTO@BQG@-(UN]UUZ]_),CQ4DT?N*=K3"+O7\F?\(O%Z63<
MM96BK;*(EYZ\B+\3+Z+:>C%;3&/?WV1D(#?)#UYAW[U</Q+\A'B.Q49C# >H
M=JRIWB]#-V\09,\6Z3V;=X^V U77V6LW+/G7DS\P"_!7@L,V%GW2;SAXR;,#
MZG_%)>792WJ/R!IX-[:_#T?&^V2#^MVLXX^3NWB]9M?$+>I^Y::S?Y$\$SFQ
MLF<D2>S\<Y/QM&0\+1E/2T;OUG"\6WJW:Z-W:_1NC=XMT[Q;+$T/D;_:Q'UF
MF7F!>X<7$?LH\'4)^FD*-6_M^))@IZ==>;I1G<:$BBI.2-DRP85$V$]7"&1+
M3.3X 4'17.FVSK<C"F/E=)IKNO2T!7:2S(!J32]P+"R3FK])/LIE0-E?$A0*
MD>/UFM>MV49#)^0&U$Z&&IB'.<\FIJV;!WK/)MQU4V^4G./$Z]BW(^06SS;H
M9Q_5''* C'("[!0]87BS0BWG W.?'W"UP]!P%G,CX3KOV]U+#?"UE]YDSVKO
MXJ2X* I895&IH/?W;ZH.WL*(:2G=XIC*8M_A;57V\"HW//]LMA,1]U2\ P0>
M"'E9^60:XUF5EF;M=E!&)L/PI6X39.X<%-C$PWSO*="\?W]I$R" HBEU')MF
M\N0T?@_"1ZJ3%QY5SZ+X7[B+'@\H7^#5 PL!O\9Y.E4B9+)74PF*O7HO[]!C
ME%A1]\_X?H7CD"IZYKKSJ &"@E/*BRMTFS4:0Y<+3?S2X$,X,M2)-M0"4NTU
M5\-R4IKO>AK+28WEI,9R4H,M)W4:+^,P*BB).W9G%M,1B>]>KLY4LT%T^<(5
M5*!JP:AR-SD Y!0]D-@FF[*^OZ8[W(9@-A]H/ADNHFVY!:TEU;B>V8]>9/L-
M .3TF$\^#!8I(5L@)!\TGV<,).N_O<4JF>FO]Z;+X:=GCYG^AAC$PY]*)IO6
MQY7I#YEK'@FC?R";\&VQ<BMMY;6Z?+DQGUT(D/=M_1Z@&Y%9\BLA)'OMYII,
MJKY J6<8@N6#8ECN5QXE. B\)T1":J=SL:EOK"LIJR^ .%Q#*'U2C-(4QR1:
MR<($M)Y_/FZ<>&Q#0'U6#=1VNTMYV-QY+_7[7DD'@<08VGP#O:':7!JP[T"O
M+S_=6A?VY<(]*]QC2-M7$=_<G%A#<!)M(GA]].PJA5(7@V3X-E$M3B9OV91A
MV>L>[!H]WQ"T]D+$O\]OKYTVI2;Q$F AW;#Z45PVX1Y'MB\EX9J6\XFFS6XS
M&8.4@U)^KUC*[0NX3/K>&!T0C0E0#TI9_\)_\?+HI87=S^T(<8K<U[4>##9"
M'D#=K!FA***;L-GBC"#7BV9Q%$;48*?\BFX$%?4<'G(R_)AYI),NU8%[2_FV
M_>QN#)%M56D^/+Q )@S>K51S0 7)>'"?0<+%X03TH^K%C'*5KP@<E JM!H?+
M'NT0$A^U(O&=OMU.3%BZW@,'BE*SH6%10SSHN-9\]1A5E2B,A)JFTG!H@-22
M#[JH.ZJUQVS(<Q0ZQ'L$BKF6:MA5F@]&Y&(F(,%_Z2[0C%/KL-IL4(*N)Q[<
M1!88,R@7]F17/6P:LZHHW^ASU_&:682%;KQ2B.\GS3)E3ZS\F:PD8OI4*WNL
MQ9Y;ZF]";<3Q8OOQ8OLQ+VF\V'[,1!HSD<9,I#$3J3Z58[#)$,WY5+UHFYB&
M-%@X6S(+8JI7$\\>DQN-@V5">%C:I.0W[I['Z"PF!/&.6IJ-HRNM4-K:;<&.
MF9:6)".7 9W.+&R88Q8W'NI84*YP9.8IJ3PO]*E(&=3;P8X([#)/9AZG2G/#
M(IE5H;T=ZWC +K-DYJFL/#/>D[(W>SO6$6%=8LG,TUQ)9NY7B"![$?'VS8V'
M.A:D*QR9>5@LR<O!\!X+J%PH/PWJ\*=XLB5["/16X2%0]GPK(4#A:=!86W6L
MK6KX2= QWE/5/IEJO)MJO)O*B+.B\6ZJX[B;ZI";UPVKVL]/)0(8,'.M+-J;
M+38:4MU[O^_HL*A)>9X@2/4NF&+Z\[C0R\#Q8[JEN0SR7PY!&A[UZ": @%7S
M7_79@^\MDQ0O2<@+'0:,9I4+,X]K (J%YZS\?L<!6Y$9,T]? ,*O<>"T!'#7
M]3@PK/ C<;#2M^/N&D<HI$LZVQ_+75GTKNJ#2X:PLC&475&D9HJR_)S+Y%I
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M>('5[WI"(1V&?^NH=']=-J/<*X3;<@2^@HHKU)6HR@F11Z;<0Y?U=Q@6-3R
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M(PH!KK0S)K87ECV4>C[ ,-W*>R3V=(,=]#FWZ\6/Y<@V=#>X3Z[(A\GIHJE
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M3<0^BAI?18L5*K^+Z(<1_S+ZN$<Z49 FDI\#0H(D-TX>'1J?0TJI7G,0M C
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M0^5083[!>IC!30P/DP0&V@>IWT5\*0P%0AI*N#CV[&U8Y%Y(21=@QT1UJ/_
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MMWJE=1!N8Q<&8-E]P$@\D$2-8[75:!B($Q8#U@9:'&E/&5Z/AX>8USHC[B,
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M]81Q@& PHV),:TS3@I"."O$\B0,U'DP /82XR8VV. NV$6V=P\=/+\$ !L^
MAG 8.3VD0A\V_4WI,68*88A+@SQXY$K;/0>)7<!,ZQ!'PS3K"PLW0' [JFP"
M\=BETT=+W>/WCW^.\O79+LO3#2;\ )D&AJ6U>R?4#I+D.=5OJ*F=%,"^8L
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MVDIK-M"(,I]HV9@ X,MP8F7F@.S9M-JJ?5?Q/BG:LHMW4)Y8T]AC??C6@0\
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M;TD4XNK'K/@UTSTH-E#6[,/!U5SK$+ )@@U[1^UU4,>"G;_?L64BV/R-LG5
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MT..^\S.H_6--.]AVD.UL/M'M:D03R#8>,)AU5%1Z2ET'2>>=Y-E!:(A%C1P
MH*>+. WDT %GB"M/GPCFI\$BL-RCY0A/HFK6W&=!MFZ=16_279*KUG@Z2F^K
M:;.JU=)9338['.RZ28=7E)@M>RMJ%'#R8TN%%C<^;HN3%?8V,/_SJ+G.FF_
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ML4/%-GK+7]0[/,/E >KZ4<S0E62WH(%M!@K9J!3.<[2*GP$ I7'J8KB69N8
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MZPV1Q^(-D8*N]8;(";L$\ZZHZE3476AH<((J'8X-K7(I5O% P*@0U7T$0'[
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MG@RAJ_JX3NF8&+8F*_!"ILY95Q X)&G=HF=F4O LY:U/ZJ\QWP9!G5UG=(Q
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M1_'Z1556">";&#FN2Q\&=.KOZU.'^#K&#NS:)S*)K+1])]-P&XDFJ.+P>[7
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M"!MN%%SE^PRG19S:M*Z(08,Y?PC77'L/YQD.T"\\%G%R197KG!;PNM9V=/X
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M@.2 8XSC,<91OF<W?>RUZ!;^:77 (Z3OC%""D(,C%%(]T_-XX]%H*&Q5;QS
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M0%[Q0MK<I1^@JC6O.\>WVB&HD:1C?_L(WJ( R1%:_JRG @1\Q]I>,9(A@.^
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MN\R(FQ><51#F5>2'&3^07$757\:@K!IU;DE?DQ ]] R*K>1\G0O+QY"N<]B
MLM+H,-,D,PT#\"W[VB2UE["Z?C/-,8.QX]4NSILX\@<B7^\ZTZPU,%.0A&G?
MQ"E)^,8ASF"P-QV^;7OL\B$6Y1C(WG 0>3<FWC59>X?+3$SI*G^3"A <W=L8
MQ[E1#45K&?72@20>NCDWE8^MEQ@\KC45KP&HX'.DO:88:3@JQT#I8Z#TI*F+
ML1?!@FA[6[KVE4T0):O@@)435\+2VHKB_]5>3?Q7PK\<9'ZZ9/>$O5!?=BW
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MQ49+T.Z_ZX'@4[2'0F2M2,\$$&G986N%Q2%G=%PX*X$+2=D%"H:U^CI3K!<
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MQY>#03+_2X%)654]RWS.[<R G^,<O*?=_/0L/=<'@P21_AP2*PU^]W["&'?
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M;[FZ]B)%Z<9Z&RA&[CUG7<IZ."XOS%3^1?Q#E+SCO_G_4$L! A0#%     @
M44ML3E14)"4"\@  ]AH) !$              ( !     &-R8G M,C Q.#$R
M,S$N>&UL4$L! A0#%     @ 44ML3AS4#;#[%   0N(  !$
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L &-R8G M,C Q.#$R,S%?<')E+GAM;%!+!08     !@ & (H!  #"$0(    !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
